[	O	O
Autosomal	O	O
dominant	O	O
limb	O	O
-	O	O
girdle	O	O
muscular	O	O
dystrophy	O	O
associated	O	O
with	O	O
conduction	O	O
defects	O	O
(	O	O
LGMD1B	O	O
)	O	O
:	O	O
a	O	O
description	O	O
of	O	O
8	O	O
new	O	O
families	O	O
with	O	O
the	O	O
LMNA	O	O
gene	O	O
mutations	O	O
]	O	O
.	O	O
La	O	O
dystrophie	O	O
musculaire	O	O
des	O	O
ceintures	O	O
autosomique	O	O
dominante	O	O
associée	O	O
à	O	O
des	O	O
troubles	O	O
de	O	O
la	O	O
conduction	O	O
cardiaque	O	O
(	O	O
LGMD1B	O	O
)	O	O
.	O	O
Description	O	O
de	O	O
8	O	O
nouvelles	O	O
familles	O	O
avec	O	O
mutations	O	O
du	O	O
gène	O	O
LMNA	O	O
.	O	O
INTRODUCTION	O	O
:	O	O
Limb	B-Disease	O
girdle	I-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
type	I-Disease	O
1b	I-Disease	O
(	O	O
LGMD1B	O	O
)	O	O
,	O	O
due	B-Reg	O
to	I-Reg	O
LMNA	B-Gene	O
gene	O	O
mutations	B-Var	O
,	O	O
is	O	O
a	O	O
relatively	O	O
rare	O	O
form	O	O
of	O	O
LGMD	O	O
characterized	O	O
by	O	O
proximal	O	O
muscle	O	O
involvement	O	O
associated	O	O
with	O	O
heart	O	O
involvement	O	O
comprising	O	O
atrio	O	O
-	O	O
ventricular	O	O
conduction	O	O
blocks	O	O
and	O	O
dilated	O	O
cardiomyopathy	O	O
.	O	O
Its	O	O
clinical	O	O
and	O	O
genetic	O	O
diagnosis	O	O
is	O	O
crucial	O	O
for	O	O
cardiac	O	O
management	O	O
and	O	O
genetic	O	O
counselling	O	O
.	O	O
Seven	O	O
LMNA	O	O
mutations	O	O
have	O	O
been	O	O
previously	O	O
reported	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
LGMD1B.	O	O
PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
describe	O	O
the	O	O
neurological	O	O
and	O	O
cardiologic	O	O
features	O	O
of	O	O
14	O	O
patients	O	O
belonging	O	O
to	O	O
8	O	O
families	O	O
in	O	O
whom	O	O
we	O	O
identified	O	O
6	O	O
different	O	O
LMNA	O	O
mutations	O	O
,	O	O
4	O	O
of	O	O
them	O	O
having	O	O
never	O	O
been	O	O
reported	O	O
.	O	O
Results	O	O
.	O	O
Eleven	O	O
patients	O	O
had	O	O
an	O	O
LGMD1B	O	O
phenotype	O	O
with	O	O
scapulohumeral	O	O
and	O	O
pelvic	O	O
-	O	O
femoral	O	O
involvement	O	O
.	O	O
Thirteen	O	O
patients	O	O
had	O	O
cardiac	O	O
disease	O	O
associating	O	O
conduction	O	O
defects	O	O
(	O	O
12	O	O
patients	O	O
)	O	O
or	O	O
arrhythmias	O	O
(	O	O
9	O	O
patients	O	O
)	O	O
.	O	O
Seven	O	O
patients	O	O
needed	O	O
cardiac	O	O
device	O	O
(	O	O
pacemaker	O	O
or	O	O
implantable	O	O
cardiac	O	O
defibrillator	O	O
)	O	O
and	O	O
two	O	O
had	O	O
heart	O	O
transplantation	O	O
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
study	O	O
allowed	O	O
us	O	O
to	O	O
specify	O	O
the	O	O
clinical	O	O
characteristics	O	O
of	O	O
this	O	O
entity	O	O
and	O	O
to	O	O
outline	O	O
the	O	O
first	O	O
phenotype	O	O
/	O	O
genotype	O	O
relations	O	O
resulting	O	O
from	O	O
these	O	O
observations	O	O
.	O	O
Genetics	O	O
of	O	O
laminopathies	O	O
.	O	O
Laminopathies	O	O
are	O	O
now	O	O
recognized	O	O
as	O	O
a	O	O
group	O	O
of	O	O
disorders	O	O
due	O	O
to	O	O
mutations	O	O
of	O	O
the	O	O
LMNA	O	O
gene	O	O
,	O	O
which	O	O
encodes	O	O
A	O	O
-	O	O
type	O	O
lamins	O	O
.	O	O
Primarily	O	O
,	O	O
mutations	B-Var	O
in	O	O
LMNA	B-Gene	O
have	O	O
been	O	O
associated	B-Reg	O
to	I-Reg	O
the	O	O
autosomal	O	O
forms	O	O
of	O	O
Emery	B-Disease	O
-	I-Disease	O
Dreifuss	I-Disease	O
muscular	I-Disease	B-Disease
dystrophy	I-Disease	I-CPA
,	O	O
a	O	O
rare	O	O
slowly	O	O
progressive	O	O
humero	O	O
-	O	O
peroneal	O	O
muscular	O	O
dystrophy	O	O
accompanied	O	O
by	O	O
early	O	O
contractures	O	O
and	O	O
dilated	O	O
cardiomyopathy	O	O
with	O	O
conduction	O	O
defects	O	O
.	O	O
LMNA	O	O
mutations	O	O
have	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
up	O	O
to	O	O
10	O	O
distinct	O	O
phenotypes	O	O
that	O	O
affect	O	O
specifically	O	O
either	O	O
the	O	O
skeletal	O	O
and/or	O	O
cardiac	O	O
muscle	O	O
,	O	O
the	O	O
adipose	O	O
tissue	O	O
,	O	O
the	O	O
peripheral	O	O
nervous	O	O
tissue	O	O
,	O	O
the	O	O
bone	O	O
tissue	O	O
or	O	O
more	O	O
recently	O	O
premature	O	O
ageing	O	O
.	O	O
So	O	O
far	O	O
more	O	O
than	O	O
180	O	O
different	O	O
LMNA	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
903	O	O
individuals	O	O
.	O	O
The	O	O
first	O	O
studies	O	O
of	O	O
phenotype	O	O
/	O	O
genotype	O	O
relationships	O	O
revealed	O	O
no	O	O
dear	O	O
relation	O	O
between	O	O
the	O	O
phenotype	O	O
and	O	O
the	O	O
type	O	O
and/or	O	O
the	O	O
localization	O	O
of	O	O
the	O	O
mutation	O	O
,	O	O
except	O	O
perhaps	O	O
for	O	O
the	O	O
globular	O	O
tail	O	O
domain	O	O
of	O	O
lamins	O	O
A	O	O
/	O	O
C.	O	O
Studies	O	O
of	O	O
the	O	O
consequences	O	O
of	O	O
LMNA	O	O
mutations	O	O
in	O	O
the	O	O
skin	O	O
cultured	O	O
fibroblasts	O	O
from	O	O
the	O	O
patients	O	O
reveal	O	O
abnormal	O	O
nuclei	O	O
in	O	O
variable	O	O
proportions	O	O
,	O	O
with	O	O
dysmorphic	O	O
nuclei	O	O
exhibiting	O	O
abnormal	O	O
patterns	O	O
of	O	O
expression	O	O
of	O	O
B	O	O
-	O	O
type	O	O
lamins	O	O
and	O	O
emerin	O	O
.	O	O
Finally	O	O
,	O	O
the	O	O
development	O	O
of	O	O
KO	O	O
and	O	O
KI	O	O
LMNA	O	O
mice	O	O
,	O	O
will	O	O
certainly	O	O
give	O	O
further	O	O
insight	O	O
into	O	O
the	O	O
pathophysiological	O	O
mechanisms	O	O
associated	O	O
with	O	O
LMNA	O	O
mutations	O	O
.	O	O
For	O	O
example	O	O
,	O	O
Lmna(H222P	O	O
/	O	O
H222P	O	O
)	O	O
mice	O	O
harbour	O	O
phenotypes	O	O
reminiscent	O	O
of	O	O
Emery	O	O
-	O	O
Dreifuss	O	O
muscular	O	O
dystrophy	O	O
.	O	O
Mutations	B-Var	B-Var
in	O	O
the	O	O
mouse	O	O
Lmna	B-Gene	O
gene	O	O
causing	B-Reg	B-Disease
progeria	B-Disease	I-Disease
,	O	O
muscular	B-Disease	B-Disease
dystrophy	I-Disease	I-Disease
and	O	O
cardiomyopathy	B-Disease	O
.	O	O
At	O	O
least	O	O
ten	O	O
different	O	O
diseases	O	O
have	O	O
been	O	O
linked	O	O
to	O	O
mutations	O	O
in	O	O
proteins	O	O
associated	O	O
with	O	O
the	O	O
nuclear	O	O
envelope	O	O
(	O	O
NE	O	O
)	O	O
.	O	O
Eight	O	O
of	O	O
these	O	O
diseases	O	O
are	O	O
associated	O	O
with	O	O
mutations	O	O
in	O	O
the	O	O
lamin	O	O
A	O	O
gene	O	O
(	O	O
LMNA	O	O
)	O	O
.	O	O
These	O	O
diseases	O	O
include	O	O
the	O	O
premature	O	O
ageing	O	O
or	O	O
progeric	O	O
diseases	O	O
Hutchinson	O	O
-	O	O
Gilford	O	O
progeria	O	O
and	O	O
atypical	O	O
Werner	O	O
's	O	O
syndrome	O	O
,	O	O
diseases	O	O
affecting	O	O
striated	O	O
and	O	O
cardiac	O	O
muscle	O	O
including	O	O
muscular	O	O
dystrophies	O	O
and	O	O
dilated	O	O
cardiomyopathies	O	O
,	O	O
lipodystrophies	O	O
affecting	O	O
white	O	O
fat	O	O
deposition	O	O
and	O	O
skeletal	O	O
development	O	O
and	O	O
a	O	O
peripheral	O	O
neuropathy	O	O
resulting	O	O
in	O	O
motor	O	O
neuron	O	O
demyelination	O	O
.	O	O
To	O	O
understand	O	O
how	O	O
these	O	O
diseases	O	O
arise	O	O
from	O	O
different	O	O
mutations	O	O
in	O	O
the	O	O
same	O	O
protein	O	O
,	O	O
we	O	O
established	O	O
mouse	O	O
lines	O	O
carrying	O	O
some	O	O
of	O	O
the	O	O
same	O	O
mutations	O	O
found	O	O
in	O	O
the	O	O
human	O	O
LMNA	O	O
gene	O	O
,	O	O
as	O	O
both	O	O
mouse	O	O
and	O	O
human	O	O
lamin	O	O
genes	O	O
show	O	O
a	O	O
very	O	O
high	O	O
degree	O	O
of	O	O
sequence	O	O
conservation	O	O
.	O	O
We	O	O
have	O	O
generated	O	O
mice	O	O
with	O	O
different	O	O
mutations	O	O
resulting	O	O
in	O	O
progeria	O	O
,	O	O
muscular	O	O
dystrophy	O	O
and	O	O
dilated	O	O
cardiomyopathy	O	O
.	O	O
Our	O	O
mouse	O	O
lines	O	O
are	O	O
providing	O	O
novel	O	O
insights	O	O
into	O	O
how	O	O
changes	O	O
to	O	O
the	O	O
nuclear	O	O
lamina	O	O
affect	O	O
the	O	O
mechanical	O	O
integrity	O	O
of	O	O
the	O	O
nucleus	O	O
and	O	O
in	O	O
turn	O	O
intracellular	O	O
signalling	O	O
,	O	O
such	O	O
as	O	O
the	O	O
NF	O	O
-	O	O
kappaB	O	O
pathway	O	O
,	O	O
as	O	O
well	O	O
as	O	O
cell	O	O
proliferation	O	O
and	O	O
survival	O	O
,	O	O
cellular	O	O
functions	O	O
that	O	O
,	O	O
when	O	O
disrupted	O	O
,	O	O
may	O	O
be	O	O
the	O	O
basis	O	O
for	O	O
the	O	O
origin	O	O
of	O	O
such	O	O
diseases	O	O
.	O	O
A	O	O
novel	O	O
mutation	B-Var	O
of	O	O
the	O	O
cathepsin	B-Gene	O
C	I-Gene	O
gene	O	O
in	O	O
a	O	O
thai	O	O
family	O	O
with	B-Reg	O
Papillon	B-Disease	O
-	I-Disease	O
Lefevre	I-Disease	O
syndrome	I-Disease	O
.	O	O
BACKGROUND	O	O
:	O	O
Papillon	O	O
-	O	O
Lefevre	O	O
syndrome	O	O
(	O	O
PLS	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
characterized	O	O
by	O	O
palmar-	O	O
plantar	O	O
hyperkeratosis	O	O
and	O	O
rapid	O	O
periodontal	O	O
destruction	O	O
of	O	O
both	O	O
primary	O	O
and	O	O
permanent	O	O
dentitions	O	O
.	O	O
It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
the	O	O
disease	O	O
is	O	O
caused	O	O
by	O	O
cathepsin	O	O
C	O	O
gene	O	O
(	B-Gene	O
CTSC	I-Gene	O
)	I-Gene	O
mutation	B-Var	O
leading	O	O
to	O	O
the	O	O
deficiency	B-NegReg	O
of	O	O
cathepsin	B-Enzyme	O
C	I-Enzyme	O
enzymatic	I-Enzyme	O
activity	B-MPA	O
.	O	O
This	O	O
study	O	O
demonstrates	O	O
the	O	O
clinical	O	O
manifestations	O	O
and	O	O
CTSC	O	O
mutational	O	O
and	O	O
enzymatic	O	O
activity	O	O
analyses	O	O
in	O	O
a	O	O
5-year	O	O
-	O	O
old	O	O
Thai	O	O
male	O	O
PLS	O	O
patient	O	O
and	O	O
his	O	O
parents	O	O
.	O	O
METHODS	O	O
:	O	O
Peripheral	O	O
blood	O	O
samples	O	O
were	O	O
obtained	O	O
for	O	O
genomic	O	O
DNA	O	O
isolation	O	O
.	O	O
All	O	O
exons	O	O
of	O	O
the	O	O
CTSC	O	O
gene	O	O
were	O	O
amplified	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
using	O	O
specific	O	O
primers	O	O
.	O	O
Mutations	O	O
were	O	O
identified	O	O
by	O	O
DNA	O	O
sequencing	O	O
.	O	O
Verification	O	O
of	O	O
the	O	O
mutation	O	O
was	O	O
performed	O	O
by	O	O
digestion	O	O
of	O	O
PCR	O	O
products	O	O
by	O	O
restriction	O	O
endonucleases	O	O
.	O	O
The	O	O
cathepsin	O	O
C	O	O
enzymatic	O	O
activity	O	O
was	O	O
determined	O	O
using	O	O
the	O	O
synthetic	O	O
substrate	O	O
glycyl-	O	O
L	O	O
-	O	O
arginine-7-amino-4-methylcoumarin	O	O
.	O	O
RESULTS	O	O
:	O	O
The	O	O
patient	O	O
demonstrated	O	O
classical	O	O
characteristics	O	O
of	O	O
PLS	O	O
,	O	O
including	O	O
hyperkeratotic	O	O
skin	O	O
lesions	O	O
.	O	O
By	O	O
the	O	O
age	O	O
of	O	O
5	O	O
,	O	O
all	O	O
of	O	O
his	O	O
primary	O	O
teeth	O	O
were	O	O
extracted	O	O
due	O	O
to	O	O
severe	O	O
periodontal	O	O
infection	O	O
.	O	O
The	O	O
parents	O	O
had	O	O
no	O	O
physical	O	O
abnormalities	O	O
.	O	O
The	O	O
periodontal	O	O
examination	O	O
revealed	O	O
localized	O	O
mild	O	O
periodontal	O	O
destruction	O	O
.	O	O
Sequence	O	O
analysis	O	O
showed	O	O
a	O	O
nucleotide	O	O
change	O	O
at	O	O
position	O	O
90	O	O
from	O	O
C	O	O
>	O	O
A	O	O
(	B-Var	O
c.90C	I-Var	O
>	I-Var	O
A	I-Var	O
)	I-Var	O
which	O	O
resulted	B-Reg	O
in	I-Reg	O
a	O	O
change	O	O
from	O	O
cysteine	O	O
residue	O	O
to	O	O
a	O	O
premature	B-MPA	O
stop	I-MPA	O
codon	I-MPA	O
at	O	O
the	O	O
amino	O	O
acid	O	O
position	O	O
30	O	O
in	O	O
the	O	O
exon	O	O
1	O	O
.	O	O
The	O	O
HpyCH4V	O	O
digestion	O	O
revealed	O	O
that	O	O
the	O	O
patient	O	O
was	O	O
homozygous	O	O
,	O	O
whereas	O	O
both	O	O
the	O	O
father	O	O
and	O	O
mother	O	O
were	O	O
heterozygous	O	O
carriers	O	O
of	O	O
this	O	O
mutation	O	O
.	O	O
The	O	O
cathepsin	O	O
C	O	O
activity	O	O
was	O	O
reduced	O	O
in	O	O
the	O	O
patient	O	O
's	O	O
mother	O	O
,	O	O
and	O	O
the	O	O
activity	O	O
in	O	O
the	O	O
patient	O	O
was	O	O
almost	O	O
completely	O	O
lost	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
to	O	O
demonstrate	O	O
a	O	O
CTSC	B-Gene	O
gene	O	O
mutation	O	O
in	O	O
a	O	O
Thai	O	O
family	O	O
with	O	O
PLS	O	O
.	O	O
The	O	O
identified	O	O
mutation	B-Var	O
is	O	O
novel	O	O
and	O	O
potentially	O	O
leads	O	O
to	O	O
the	O	O
drastic	O	O
reduction	B-NegReg	O
of	O	O
the	O	O
cathepsin	B-Enzyme	O
C	I-Enzyme	O
enzymatic	I-Enzyme	O
activity	B-MPA	O
.	O	O
This	O	O
suggests	O	O
that	O	O
the	O	O
mutation	O	O
is	O	O
pathogenetic	O	O
,	O	O
causing	B-Reg	O
the	O	O
PLS	B-Disease	O
.	O	O
Mutational	O	O
analysis	O	O
in	O	O
more	O	O
members	O	O
of	O	O
the	O	O
family	O	O
is	O	O
warranted	O	O
to	O	O
identify	O	O
whether	O	O
the	O	O
mutation	O	O
is	O	O
inherited	O	O
from	O	O
a	O	O
common	O	O
ancestor	O	O
.	O	O
Mutations	O	O
of	O	O
COL10A1	O	O
in	O	O
Schmid	O	O
metaphyseal	O	O
chondrodysplasia	O	O
.	O	O
Schmid	B-Disease	O
metaphyseal	I-Disease	O
chondrodysplasia	I-Disease	O
(	O	O
SMCD	O	O
)	O	O
is	O	O
a	O	O
dominantly	O	O
inherited	O	O
cartilage	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
gene	O	O
for	O	O
the	O	O
hypertrophic	O	O
cartilage	O	O
extracellular	O	O
matrix	O	O
structural	O	O
protein	O	O
,	O	O
collagen	O	O
X	O	O
(	B-Gene	O
COL10A1	I-Gene	O
)	I-Gene	O
.	O	O
Thirty	O	O
heterozygous	O	O
mutations	O	O
have	O	O
been	O	O
described	O	O
,	O	O
about	O	O
equally	O	O
divided	O	O
into	O	O
two	O	O
mutation	O	O
types	O	O
,	O	O
missense	O	O
mutations	O	O
,	O	O
and	O	O
mutations	O	O
that	O	O
introduce	O	O
premature	O	O
termination	O	O
signals	O	O
.	O	O
The	O	O
COL10A1	O	O
mutations	O	O
are	O	O
clustered	O	O
(	O	O
33/36	O	O
)	O	O
in	O	O
the	O	O
3	O	O
'	O	O
region	O	O
of	O	O
exon	O	O
3	O	O
,	O	O
which	O	O
codes	O	O
for	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
NC1	O	O
trimerization	O	O
domain	O	O
.	O	O
The	O	O
effect	O	O
of	O	O
COL10A1	O	O
missense	O	O
mutations	O	O
have	O	O
been	O	O
examined	O	O
by	O	O
in	O	O
vitro	O	O
expression	O	O
and	O	O
assembly	O	O
assays	O	O
and	O	O
cell	O	O
transfection	O	O
studies	O	O
,	O	O
which	O	O
suggest	O	O
that	O	O
a	O	O
common	O	O
consequence	O	O
is	O	O
the	O	O
disruption	O	O
of	O	O
collagen	O	O
X	O	O
trimerization	O	O
and	O	O
secretion	O	O
,	O	O
with	O	O
consequent	O	O
intracellular	O	O
degradation	O	O
.	O	O
The	O	O
effect	O	O
of	O	O
COL10A1	B-Gene	O
nonsense	B-Var	O
mutations	I-Var	O
in	O	O
cartilage	O	O
tissue	O	O
has	O	O
been	O	O
examined	O	O
in	O	O
two	O	O
patients	O	O
,	O	O
demonstrating	O	O
that	O	O
the	O	O
mutant	B-Var	O
mRNA	B-MPA	O
is	O	O
completely	O	O
removed	B-NegReg	O
by	O	O
nonsense	B-MPA	O
mediated	I-MPA	O
mRNA	I-MPA	O
decay	B-NegReg	O
.	O	O
Thus	O	O
for	O	O
both	O	O
classes	O	O
of	O	O
mutations	O	O
,	O	O
functional	O	O
haploinsufficiency	O	O
is	O	O
the	O	O
most	O	O
probable	O	O
cause	O	O
of	O	O
the	O	O
clinical	O	O
phenotype	O	O
in	O	O
SMCD	O	O
.	O	O
Sjögren	B-Disease	O
-	I-Disease	O
Larsson	I-Disease	O
syndrome	I-Disease	O
:	I-Disease	O
diversity	O	O
of	B-Reg	O
mutations	B-Var	O
and	O	O
polymorphisms	O	O
in	O	O
the	O	O
fatty	O	O
aldehyde	O	O
dehydrogenase	O	O
gene	O	O
(	B-Gene	O
ALDH3A2	I-Gene	O
)	I-Gene	I-Gene
.	O	O
Sjögren	B-Disease	O
-	I-Disease	O
Larsson	I-Disease	O
syndrome	I-Disease	O
(	O	O
SLS	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
characterized	O	O
by	O	O
ichthyosis	O	O
,	O	O
mental	O	O
retardation	O	O
,	O	O
and	O	O
spastic	O	O
diplegia	O	O
or	O	O
tetraplegia	O	O
.	O	O
The	O	O
disease	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
ALDH3A2	B-Gene	O
gene	O	O
(	O	O
also	O	O
known	O	O
as	O	O
FALDH	B-Gene	O
and	O	O
ALDH10	B-Gene	O
)	I-Gene	O
on	O	O
chromosome	O	O
17p11.2	O	O
that	O	O
encodes	O	O
fatty	O	O
aldehyde	O	O
dehydrogenase	O	O
(	O	O
FALDH	O	O
)	O	O
,	O	O
an	O	O
enzyme	O	O
that	O	O
catalyzes	O	O
the	O	O
oxidation	O	O
of	O	O
long	O	O
-	O	O
chain	O	O
aldehydes	O	O
derived	O	O
from	O	O
lipid	O	O
metabolism	O	O
.	O	O
In	O	O
SLS	O	O
patients	O	O
,	O	O
72	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
,	O	O
with	O	O
a	O	O
distribution	O	O
that	O	O
is	O	O
scattered	O	O
throughout	O	O
the	O	O
ALDH3A2	O	O
gene	O	O
.	O	O
Most	O	O
mutations	O	O
are	O	O
private	O	O
but	O	O
several	O	O
common	O	O
mutations	O	O
have	O	O
been	O	O
detected	O	O
,	O	O
which	O	O
probably	O	O
reflect	O	O
founder	O	O
effects	O	O
or	O	O
recurrent	O	O
mutational	O	O
events	O	O
.	O	O
Missense	O	O
mutations	B-Var	O
comprise	O	O
the	O	O
most	O	O
abundant	O	O
class	O	O
(	O	O
38	O	O
%	O	O
)	O	O
and	O	O
expression	O	O
studies	O	O
indicate	O	O
that	O	O
most	O	O
of	O	O
these	O	O
result	O	O
in	O	O
a	O	O
profound	O	O
reduction	B-NegReg	O
in	O	O
enzyme	B-Enzyme	O
activity	B-MPA	O
.	O	O
Deletions	O	O
account	O	O
for	O	O
about	O	O
25	O	O
%	O	O
of	O	O
the	O	O
mutations	O	O
and	O	O
range	O	O
from	O	O
single	O	O
nucleotides	O	O
to	O	O
entire	O	O
exons	O	O
.	O	O
Twelve	O	O
splice	O	O
-	O	O
site	O	O
mutations	B-Var	O
have	O	O
been	O	O
demonstrated	O	O
to	O	O
cause	B-Reg	O
aberrant	B-MPA	O
splicing	I-MPA	O
in	O	O
cultured	O	O
fibroblasts	O	O
.	O	O
To	O	O
date	O	O
,	O	O
more	O	O
than	O	O
a	O	O
dozen	O	O
intragenic	O	O
ALDH3A2	O	O
polymorphisms	O	O
consisting	O	O
of	O	O
SNPs	O	O
and	O	O
one	O	O
microsatellite	O	O
marker	O	O
have	O	O
been	O	O
characterized	O	O
,	O	O
although	O	O
none	O	O
of	O	O
them	O	O
alter	O	O
the	O	O
FALDH	O	O
protein	O	O
sequence	O	O
.	O	O
The	O	O
striking	O	O
mutational	O	O
diversity	O	O
in	O	O
SLS	O	O
offers	O	O
a	O	O
challenge	O	O
for	O	O
DNA	O	O
-	O	O
based	O	O
diagnosis	O	O
,	O	O
but	O	O
promises	O	O
to	O	O
provide	O	O
a	O	O
wealth	O	O
of	O	O
information	O	O
about	O	O
enzyme	O	O
structure	O	O
-	O	O
function	O	O
correlations	O	O
.	O	O
Genetic	O	O
screening	O	O
of	O	O
familial	O	O
Mediterranean	O	O
fever	O	O
mutations	O	O
in	O	O
the	O	O
Palestinian	O	O
population	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
investigate	O	O
the	O	O
spectrum	O	O
of	O	O
mutations	B-Var	O
and	O	O
genotypes	O	O
in	O	O
the	O	O
pyrin	B-Gene	O
gene	O	O
in	B-Reg	O
familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
patients	O	O
.	O	O
METHODS	O	O
:	O	O
Blood	O	O
samples	O	O
of	O	O
511	O	O
suspected	O	O
FMF	O	O
patients	O	O
,	O	O
received	O	O
from	O	O
the	O	O
Molecular	O	O
Genetics	O	O
Laboratory	O	O
,	O	O
Makassed	O	O
Islamic	O	O
Charitable	O	O
Hospital	O	O
,	O	O
Mount	O	O
Olives	O	O
,	O	O
Jerusalem	O	O
during	O	O
the	O	O
period	O	O
from	O	O
June	O	O
1999	O	O
to	O	O
August	O	O
2004	O	O
,	O	O
were	O	O
investigated	O	O
by	O	O
genotyping	O	O
24	O	O
different	O	O
MEFV	O	O
mutations	O	O
.	O	O
RESULTS	O	O
:	O	O
Our	O	O
work	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
14	O	O
different	O	O
mutations	O	O
from	O	O
the	O	O
identified	O	O
24	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
which	O	O
are	O	O
assembled	O	O
in	O	O
6	O	O
homozygous	O	O
,	O	O
9	O	O
heterozygous	O	O
and	O	O
16	O	O
compound	O	O
heterozygous	O	O
genotypes	O	O
.	O	O
The	O	O
homozygous	O	O
genotypes	O	O
represent	O	O
the	O	O
predominant	O	O
format	O	O
among	O	O
our	O	O
patients	O	O
representing	O	O
approximately	O	O
38	O	O
%	O	O
of	O	O
the	O	O
revealed	O	O
genotypes	O	O
.	O	O
Interestingly	O	O
,	O	O
in	O	O
94	O	O
(	O	O
31.4	O	O
%	O	O
)	O	O
of	O	O
the	O	O
tested	O	O
subjects	O	O
,	O	O
only	O	O
one	O	O
mutation	O	O
in	O	O
the	O	O
pyrin	O	O
gene	O	O
could	O	O
be	O	O
identified	O	O
while	O	O
the	O	O
other	O	O
mutant	O	O
allele	O	O
remains	O	O
unidentified	O	O
.	O	O
Moreover	O	O
,	O	O
the	O	O
genotype	O	O
of	O	O
3	O	O
(	O	O
1	O	O
%	O	O
)	O	O
patients	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
triplet	O	O
mutations	O	O
in	O	O
the	O	O
pyrin	O	O
gene	O	O
.	O	O
CONCLUSION	O	O
:	O	O
The	O	O
results	O	O
of	O	O
our	O	O
study	O	O
clearly	O	O
suggest	O	O
that	O	O
the	O	O
origin	O	O
of	O	O
FMF	O	O
among	O	O
the	O	O
Palestinian	O	O
population	O	O
is	O	O
mostly	O	O
homozygous	O	O
.	O	O
The	O	O
identification	O	O
of	O	O
a	O	O
significant	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
one	O	O
known	O	O
mutation	O	O
indicates	O	O
potentially	O	O
the	O	O
presence	O	O
of	O	O
new	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
which	O	O
will	O	O
be	O	O
investigated	O	O
in	O	O
the	O	O
future	O	O
.	O	O
Novel	O	O
CLN3	B-Gene	O
mutation	B-Var	O
predicted	O	O
to	O	O
cause	O	O
complete	O	O
loss	B-NegReg	O
of	O	O
protein	B-Protein	O
function	B-MPA	O
does	O	O
not	O	O
modify	O	O
the	O	O
classical	O	O
JNCL	O	O
phenotype	O	O
.	O	O
Juvenile	B-Disease	O
Neuronal	I-Disease	O
Ceroid	I-Disease	O
Lipofuscinosis	I-Disease	O
(	O	O
JNCL	O	O
)	O	O
,	O	O
or	O	O
Batten	O	O
disease	O	O
,	O	O
is	O	O
a	O	O
childhood	O	O
neurodegenerative	O	O
disease	O	O
that	O	O
is	O	O
characterized	O	O
clinically	O	O
by	O	O
progressive	O	O
visual	O	O
loss	O	O
,	O	O
seizures	O	O
,	O	O
dementia	O	O
,	O	O
and	O	O
motor	O	O
incoordination	O	O
.	O	O
Children	O	O
affected	O	O
with	O	O
this	O	O
disease	O	O
tend	O	O
to	O	O
develop	O	O
normally	O	O
for	O	O
the	O	O
first	O	O
5	O	O
years	O	O
of	O	O
life	O	O
.	O	O
However	O	O
,	O	O
once	O	O
disease	O	O
onset	O	O
occurs	O	O
,	O	O
they	O	O
decline	O	O
rapidly	O	O
and	O	O
die	O	O
in	O	O
their	O	O
late	O	O
20s	O	O
to	O	O
early	O	O
30s	O	O
.	O	O
Though	O	O
this	O	O
represents	O	O
the	O	O
typical	O	O
disease	O	O
course	O	O
,	O	O
the	O	O
onset	O	O
and	O	O
severity	O	O
of	O	O
disease	O	O
symptoms	O	O
can	O	O
vary	O	O
.	O	O
This	O	O
variability	O	O
is	O	O
presumed	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
both	O	O
differences	O	O
in	O	O
the	O	O
causative	O	O
genetic	O	O
mutation	O	O
in	O	O
the	O	O
CLN3	O	O
gene	O	O
as	O	O
well	O	O
as	O	O
environmental	O	O
influences	O	O
.	O	O
Most	O	O
cases	O	O
of	O	O
JNCL	B-Disease	O
are	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
1	O	O
kb	O	O
deletion	B-Var	O
in	O	O
the	O	O
CLN3	B-Gene	O
gene	O	O
,	O	O
resulting	B-Reg	O
in	I-Reg	O
a	O	O
frameshift	B-Var	O
mutation	I-Var	O
predicted	O	O
to	O	O
leave	O	O
the	O	O
first	O	O
153	O	O
amino	O	O
acids	O	O
of	O	O
the	O	O
CLN3	O	O
protein	O	O
intact	O	O
,	O	O
followed	O	O
by	O	O
the	O	O
addition	O	O
of	O	O
28	O	O
novel	O	O
amino	O	O
acids	O	O
.	O	O
Here	O	O
we	O	O
report	O	O
the	O	O
discovery	O	O
of	O	O
a	O	O
novel	O	O
mutation	O	O
identified	O	O
as	O	O
a	O	O
G	O	O
to	O	O
T	O	O
transversion	O	O
at	O	O
nucleotide	O	O
49	O	O
(	B-Var	O
G49	I-Var	O
T	I-Var	O
)	I-Var	O
in	O	O
exon	O	O
2	O	O
of	O	O
CLN3	B-Gene	O
,	O	O
introducing	B-Reg	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
(	B-Var	O
E17X	I-Var	O
)	I-Var	O
near	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
.	O	O
This	O	O
mutation	O	O
represents	O	O
the	O	O
most	O	O
5	O	O
'	O	O
mutation	O	O
described	O	O
to	O	O
date	O	O
.	O	O
The	O	O
patient	O	O
examined	O	O
in	O	O
this	O	O
study	O	O
was	O	O
heterozygous	O	O
for	O	O
the	O	O
common	O	O
1	O	O
kb	O	O
deletion	O	O
and	O	O
E17X.	O	O
She	O	O
had	O	O
classical	O	O
disease	O	O
progression	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
mutation	O	O
in	O	O
CLN3	O	O
mimics	O	O
the	O	O
more	O	O
prevalent	O	O
1	O	O
kb	O	O
deletion	O	O
and	O	O
that	O	O
progression	O	O
of	O	O
JNCL	O	O
is	O	O
predominantly	O	O
the	O	O
result	O	O
of	O	O
loss	O	O
of	O	O
CLN3	O	O
function	O	O
.	O	O
Identification	O	O
of	O	O
a	O	O
novel	O	O
founder	O	O
mutation	O	O
in	O	O
the	O	O
DYSF	O	O
gene	O	O
causing	O	O
clinical	O	O
variability	O	O
in	O	O
the	O	O
Spanish	O	O
population	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Mutations	B-Var	O
in	O	O
the	O	O
dysferlin	O	O
(	B-Gene	O
DYSF	I-Gene	O
)	I-Gene	O
gene	O	O
cause	B-Reg	O
3	O	O
different	O	O
phenotypes	O	O
of	O	O
muscular	O	O
dystrophies	O	O
:	O	O
Miyoshi	B-Disease	O
myopathy	I-Disease	O
,	O	O
limb	B-Disease	O
-	I-Disease	O
girdle	I-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
type	I-Disease	O
2B	I-Disease	O
,	O	O
and	O	O
distal	B-Disease	O
anterior	I-Disease	O
compartment	I-Disease	O
myopathy	I-Disease	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
present	O	O
the	O	O
results	O	O
of	O	O
clinical	O	O
and	O	O
molecular	O	O
analysis	O	O
of	O	O
8	O	O
patients	O	O
with	O	O
dysferlinopathy	O	O
from	O	O
5	O	O
unrelated	O	O
families	O	O
.	O	O
DESIGN	O	O
:	O	O
Clinical	O	O
assessment	O	O
was	O	O
performed	O	O
with	O	O
a	O	O
standardized	O	O
protocol	O	O
.	O	O
A	O	O
muscle	O	O
biopsy	O	O
specimen	O	O
was	O	O
obtained	O	O
and	O	O
studied	O	O
by	O	O
immunohistochemistry	O	O
.	O	O
Genetic	O	O
analysis	O	O
was	O	O
performed	O	O
using	O	O
single	O	O
-	O	O
stranded	O	O
conformation	O	O
polymorphism	O	O
and	O	O
direct	O	O
sequencing	O	O
of	O	O
genomic	O	O
DNA	O	O
.	O	O
RESULTS	O	O
:	O	O
All	O	O
the	O	O
patients	O	O
presented	O	O
the	O	O
R1905X	O	O
mutation	O	O
in	O	O
the	O	O
DYSF	O	O
gene	O	O
in	O	O
homozygosity	O	O
,	O	O
and	O	O
the	O	O
haplotype	O	O
analysis	O	O
at	O	O
the	O	O
DYSF	O	O
locus	O	O
revealed	O	O
that	O	O
it	O	O
was	O	O
a	O	O
novel	O	O
and	O	O
founder	O	O
mutation	O	O
.	O	O
A	O	O
C	B-Var	O
-	I-Var	O
to	I-Var	O
-	I-Var	O
T	I-Var	O
transition	I-Var	O
at	O	O
nucleotide	O	O
position	O	O
6086	O	O
changes	O	O
an	O	O
arginine	O	O
into	O	O
a	O	O
stop	O	O
codon	O	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
premature	B-MPA	O
termination	I-MPA	O
of	I-MPA	O
translation	I-MPA	O
.	O	O
This	O	O
mutation	O	O
was	O	O
expressed	O	O
as	O	O
3	O	O
different	O	O
clinical	O	O
phenotypes	O	O
(	O	O
limb	O	O
-	O	O
girdle	O	O
muscular	O	O
dystrophy	O	O
type	O	O
2B	O	O
,	O	O
Miyoshi	O	O
distal	O	O
myopathy	O	O
,	O	O
and	O	O
distal	O	O
anterior	O	O
dysferlinopathy	O	O
)	O	O
,	O	O
but	O	O
only	O	O
1	O	O
phenotype	O	O
was	O	O
found	O	O
in	O	O
the	O	O
same	O	O
family	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
new	O	O
R1905X	O	O
DYSF	O	O
founder	O	O
mutation	O	O
produced	O	O
the	O	O
3	O	O
possible	O	O
dysferlinopathy	O	O
phenotypes	O	O
without	O	O
intrafamilial	O	O
heterogeneity	O	O
.	O	O
This	O	O
homogeneous	O	O
population	O	O
in	O	O
Sueca	O	O
,	O	O
Spain	O	O
,	O	O
should	O	O
be	O	O
helpful	O	O
in	O	O
studying	O	O
the	O	O
modifying	O	O
factors	O	O
responsible	O	O
for	O	O
the	O	O
phenotypic	O	O
variability	O	O
.	O	O
A	O	O
novel	O	O
frameshift	B-Var	O
mutation	O	O
(	O	O
+	O	O
G	O	O
)	O	O
at	O	O
codons	O	O
15/16	O	O
in	O	O
a	O	O
beta0	B-Gene	O
thalassaemia	I-Gene	O
gene	I-Gene	O
results	O	O
in	O	O
a	O	O
significant	O	O
reduction	B-NegReg	O
of	O	O
beta	B-MPA	O
globin	I-MPA	O
mRNA	I-MPA	O
values	O	O
.	O	O
AIMS	O	O
:	O	O
To	O	O
identify	O	O
a	O	O
novel	O	O
beta	O	O
globin	O	O
gene	O	O
mutation	O	O
found	O	O
in	O	O
a	O	O
Chinese	O	O
family	O	O
,	O	O
and	O	O
also	O	O
to	O	O
assess	O	O
its	O	O
functional	O	O
consequences	O	O
.	O	O
METHODS	O	O
:	O	O
Haematological	O	O
analysis	O	O
was	O	O
performed	O	O
on	O	O
all	O	O
family	O	O
members	O	O
.	O	O
The	O	O
23	O	O
common	O	O
mutations	O	O
of	O	O
beta	O	O
thalassaemia	O	O
found	O	O
in	O	O
Chinese	O	O
populations	O	O
were	O	O
detected	O	O
by	O	O
means	O	O
of	O	O
a	O	O
reverse	O	O
dot	O	O
blot	O	O
method	O	O
.	O	O
Direct	O	O
DNA	O	O
sequencing	O	O
of	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
amplified	O	O
complete	O	O
beta	O	O
globin	O	O
gene	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
identify	O	O
the	O	O
novel	O	O
mutation	O	O
.	O	O
A	O	O
real	O	O
time	O	O
,	O	O
one	O	O
step	O	O
reverse	O	O
transcription	O	O
PCR	O	O
assay	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
beta	O	O
globin	O	O
mRNA	O	O
in	O	O
the	O	O
reticulocytes	O	O
of	O	O
heterozygous	O	O
patients	O	O
.	O	O
RESULTS	O	O
:	O	O
A	O	O
novel	O	O
frameshift	O	O
mutation	O	O
-	O	O
an	O	O
insertion	B-Var	O
of	O	O
G	O	O
between	O	O
codons	O	O
15	O	O
and	O	O
16	O	O
in	O	O
a	O	O
homonucleotide	O	O
run	O	O
of	O	O
four	O	O
guanines	O	O
-	O	O
was	O	O
determined	O	O
,	O	O
which	O	O
generates	B-Reg	O
a	O	O
new	O	O
premature	B-MPA	O
chain	I-MPA	O
terminator	I-MPA	O
at	O	O
the	O	O
22nd	O	O
codon	O	O
.	O	O
Relative	O	O
quantitative	O	O
analysis	O	O
of	O	O
the	O	O
beta	O	O
globin	O	O
mRNA	O	O
in	O	O
heterozygous	O	O
subjects	O	O
demonstrated	O	O
a	O	O
39.83	O	O
%	O	O
reduction	O	O
compared	O	O
normal	O	O
controls	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
significantly	O	O
lower	B-NegReg	O
amounts	B-MPA	O
of	I-MPA	O
beta	I-MPA	O
globin	I-MPA	O
mRNA	I-MPA	B-Gene
found	O	O
in	O	O
mutation	B-Var	O
carriers	O	O
is	O	O
probably	O	O
caused	B-Reg	B-Reg
by	I-Reg	O
the	O	O
rapid	O	O
nonsense	O	O
mediated	O	B-MPA
degradation	B-MPA	I-MPA
of	O	O
the	O	O
mutant	O	B-Var
mRNA	O	B-Protein
.	O	O
These	O	O
data	O	O
,	O	O
combined	O	O
with	O	O
haematological	O	O
analysis	O	O
,	O	O
suggest	O	O
that	O	O
this	O	O
novel	O	O
mutation	B-Var	O
of	O	O
CDs	O	O
15/16	O	O
(	O	O
+	O	O
G	O	O
)	O	O
results	B-Reg	O
in	I-Reg	O
a	O	O
beta(0	B-Disease	O
)	I-Disease	O
thalassaemia	I-Disease	O
phenotype	O	O
.	O	O
Increased	O	O
risk	O	O
of	O	O
idiopathic	O	O
chronic	O	O
pancreatitis	O	O
in	O	O
cystic	O	O
fibrosis	O	O
carriers	O	O
.	O	O
Cystic	B-Disease	O
fibrosis	I-Disease	O
(	O	O
CF	O	O
)	O	O
is	O	O
a	O	O
recessive	O	O
disease	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
of	O	O
the	O	O
CF	O	O
transmembrane	O	O
conductance	O	B-CPA
regulator	O	I-CPA
(	B-Gene	O
CFTR	I-Gene	O
)	I-Gene	I-Gene
gene	O	O
.	O	O
The	O	O
risk	O	O
of	O	O
idiopathic	O	O
chronic	O	O
pancreatitis	O	O
(	O	O
ICP	O	O
)	O	O
is	O	O
increased	O	O
in	O	O
individuals	O	O
who	O	O
have	O	O
CFTR	O	O
genotypes	O	O
containing	O	O
a	O	O
CF	O	O
-	O	O
causing	O	O
mutation	O	O
plus	O	O
a	O	O
second	O	O
pathogenic	O	O
allele	O	O
.	O	O
It	O	O
is	O	O
unknown	O	O
whether	O	O
the	O	O
risk	O	O
of	O	O
ICP	O	O
is	O	O
increased	O	O
in	O	O
CF	O	O
carriers	O	O
who	O	O
have	O	O
one	O	O
CF	O	O
-	O	O
causing	O	O
mutation	O	O
plus	O	O
one	O	O
normal	O	O
allele	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
52	O	O
sporadic	O	O
cases	O	O
of	O	O
ICP	O	O
were	O	O
ascertained	O	O
through	O	O
the	O	O
European	O	O
Registry	O	O
of	O	O
Hereditary	O	O
Pancreatitis	O	O
and	O	O
Familial	O	O
Pancreatic	O	O
Cancer	O	O
.	O	O
Individuals	O	O
with	O	O
pathogenic	O	O
cationic	O	O
trypsinogen	O	O
mutations	O	O
were	O	O
excluded	O	O
.	O	O
DNA	O	O
was	O	O
comprehensively	O	O
tested	O	O
for	O	O
CFTR	O	O
mutations	O	O
using	O	O
a	O	O
robotically	O	O
enhanced	O	O
,	O	O
multiplexed	O	O
,	O	O
and	O	O
highly	O	O
redundant	O	O
form	O	O
of	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
analysis	O	O
followed	O	O
by	O	O
DNA	O	O
sequencing	O	O
.	O	O
Fifteen	O	O
subjects	O	O
had	O	O
a	O	O
total	O	O
of	O	O
18	O	O
pathogenic	O	O
CFTR	O	O
alleles	O	O
.	O	O
Eight	O	O
subjects	O	O
had	O	O
common	O	O
CF	O	O
-	O	O
causing	O	O
mutations	O	O
.	O	O
This	O	O
group	O	O
included	O	O
seven	O	O
CF	O	O
carriers	O	O
in	O	O
whom	O	O
the	O	O
second	O	O
CFTR	O	O
allele	O	O
was	O	O
normal	O	O
(	O	O
4.3	O	O
times	O	O
the	O	O
expected	O	O
frequency	O	O
,	O	O
P=0.0002	O	O
)	O	O
.	O	O
Three	O	O
subjects	O	O
had	O	O
compound	O	O
heterozygotes	O	O
genotypes	O	O
containing	O	O
two	O	O
pathogenic	O	O
alleles	O	O
(	O	O
31	O	O
times	O	O
the	O	O
expected	O	O
frequency	O	O
,	O	O
P<0.0001	O	O
)	O	O
.	O	O
A	O	O
variant	O	O
allele	O	O
of	O	O
uncertain	O	O
significance	O	O
(	O	O
p	O	O
.	O	O
R75Q	O	O
)	O	O
was	O	O
detected	O	O
in	O	O
eight	O	O
of	O	O
the	O	O
52	O	O
ICP	O	O
subjects	O	O
and	O	O
at	O	O
a	O	O
similar	O	O
frequency	O	O
(	O	O
13/96	O	O
)	O	O
in	O	O
random	O	O
donors	O	O
.	O	O
ICP	O	O
differs	O	O
from	O	O
other	O	O
established	O	O
CFTR	O	O
-	O	O
related	O	O
conditions	O	O
in	O	O
that	O	O
ICP	O	O
risk	O	O
is	O	O
increased	O	O
in	O	O
CF	O	O
carriers	O	O
who	O	O
have	O	O
one	O	O
documented	O	O
normal	O	O
CFTR	O	O
allele	O	O
.	O	O
Having	O	O
two	O	O
CFTR	O	O
mutations	O	O
imparts	O	O
a	O	O
higher	O	O
relative	O	O
risk	O	O
,	O	O
while	O	O
having	O	O
only	O	O
one	O	O
mutation	O	O
imparts	O	O
a	O	O
higher	O	O
attributable	O	O
risk	O	O
.	O	O
Mutation	O	O
identification	O	O
in	O	O
a	O	O
canine	O	O
model	O	O
of	O	O
X	O	O
-	O	O
linked	O	O
ectodermal	O	O
dysplasia	O	O
.	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
hypohidrotic	I-Disease	O
ectodermal	I-Disease	O
dysplasia	I-Disease	O
(	O	O
XHED	O	O
)	O	O
,	O	O
an	O	O
inherited	O	O
disease	O	O
recognized	O	O
in	O	O
humans	O	O
,	O	O
mice	O	O
,	O	O
and	O	O
cattle	O	O
,	O	O
is	O	O
characterized	O	O
by	O	O
hypotrichosis	O	O
,	O	O
a	O	O
reduced	O	O
number	O	O
or	O	O
absence	O	O
of	O	O
sweat	O	O
glands	O	O
,	O	O
and	O	O
missing	O	O
or	O	O
malformed	O	O
teeth	O	O
.	O	O
In	O	O
a	O	O
subset	O	O
of	O	O
affected	O	O
individuals	O	O
and	O	O
animals	O	O
,	O	O
mutations	B-Var	O
in	O	O
the	O	O
EDA	B-Gene	O
gene	O	O
(	O	O
formerly	O	O
EDI	O	O
)	O	O
,	O	O
coding	O	O
for	O	O
ectodysplasin	O	O
,	O	O
have	O	O
been	O	O
found	O	O
to	O	O
cause	B-Reg	O
this	O	O
phenotype	O	O
.	O	O
Ectodysplasin	O	O
is	O	O
a	O	O
homotrimeric	O	O
transmembrane	O	O
protein	O	O
with	O	O
an	O	O
extracellular	O	O
TNF	O	O
-	O	O
like	O	O
domain	O	O
,	O	O
which	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
morphogenesis	O	O
of	O	O
hair	O	O
follicles	O	O
and	O	O
tooth	O	O
buds	O	O
during	O	O
fetal	O	O
development	O	O
.	O	O
Some	O	O
human	O	O
XHED	B-Disease	O
patients	O	O
also	O	O
have	O	O
concurrent	O	O
immunodeficiency	O	O
,	O	O
due	B-Reg	O
to	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
NF	O	O
-	O	O
kappaB	O	O
essential	O	O
modulator	O	O
protein	O	O
(	B-Gene	O
IKBKG	I-Gene	O
;	I-Gene	O
formerly	O	O
NEMO	O	O
)	O	O
,	O	O
which	O	O
is	O	O
also	O	O
encoded	O	O
on	O	O
the	O	O
X	O	O
chromosome	O	O
.	O	O
In	O	O
a	O	O
breeding	O	O
colony	O	O
of	O	O
dogs	O	O
with	O	O
XHED	O	O
,	O	O
immune	O	O
system	O	O
defects	O	O
had	O	O
been	O	O
suspected	O	O
because	O	O
of	O	O
frequent	O	O
pulmonary	O	O
infections	O	O
and	O	O
unexpected	O	O
deaths	O	O
resulting	O	O
from	O	O
pneumonia	O	O
.	O	O
To	O	O
determine	O	O
if	O	O
defects	O	O
in	O	O
EDA	O	O
or	O	O
IKBKG	O	O
cause	O	O
XHED	O	O
in	O	O
the	O	O
dogs	O	O
,	O	O
linkage	O	O
analysis	O	O
and	O	O
sequencing	O	O
experiments	O	O
were	O	O
performed	O	O
.	O	O
A	O	O
polymorphic	O	O
marker	O	O
near	O	O
the	O	O
canine	O	O
EDA	O	O
gene	O	O
showed	O	O
significant	O	O
linkage	O	O
to	O	O
XHED	O	O
.	O	O
The	O	O
canine	O	O
EDA	B-Gene	O
gene	O	O
was	O	O
sequenced	O	O
and	O	O
a	O	O
nucleotide	B-Var	O
substitution	I-Var	O
(	O	O
G	O	O
to	O	O
A	O	O
)	O	O
in	O	O
the	O	O
splice	O	O
acceptor	O	O
site	O	O
of	O	O
intron	O	O
8	O	O
was	O	O
detected	O	O
in	O	O
affected	O	O
dogs	O	O
.	O	O
In	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
A	O	O
residue	O	O
,	O	O
a	O	O
cryptic	O	O
acceptor	O	O
site	O	O
within	O	O
exon	O	O
9	O	O
is	O	O
used	O	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
a	O	O
frame	B-MPA	O
shift	I-MPA	O
and	O	O
use	O	O
of	O	O
a	O	O
premature	B-MPA	O
stop	I-MPA	O
codon	I-MPA	O
that	O	O
truncates	B-NegReg	O
the	O	O
translation	B-MPA	O
of	O	O
both	O	O
isoforms	O	O
,	O	O
EDA	O	O
-	O	O
A1	O	O
and	O	O
EDA	O	O
-	O	O
A2	O	O
,	O	O
resulting	O	O
in	O	O
the	O	O
absence	B-NegReg	O
of	O	O
the	O	O
TNF	B-MPA	O
-	I-MPA	O
like	I-MPA	O
homology	I-MPA	O
domain	I-MPA	O
,	O	O
the	O	O
receptor	O	O
-	O	O
binding	O	O
site	O	O
of	O	O
ectodysplasin	O	O
.	O	O
Familial	O	O
Mediterranean	O	O
fever	O	O
(	O	O
FMF	O	O
)	O	O
in	O	O
Lebanon	O	O
and	O	O
Jordan	O	O
:	O	O
a	O	O
population	O	O
genetics	O	O
study	O	O
and	O	O
report	O	O
of	O	O
three	O	O
novel	O	O
mutations	O	O
.	O	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
disease	O	O
mostly	O	O
frequent	O	O
in	O	O
Mediterranean	O	O
populations	O	O
.	O	O
Over	O	O
50	O	O
mutations	B-Var	O
have	O	O
been	O	O
identified	O	O
in	O	O
the	O	O
gene	O	O
responsible	B-Reg	O
for	I-Reg	O
the	O	O
disease	O	O
,	O	O
MEFV	B-Gene	O
.	O	O
The	O	O
present	O	O
study	O	O
reports	O	O
the	O	O
frequencies	O	O
of	O	O
MEFV	B-Gene	O
mutations	B-Var	O
in	B-Reg	O
558	O	O
Lebanese	O	O
and	O	O
55	O	O
Jordanian	O	O
FMF	B-Disease	O
patients	O	O
and	O	O
points	O	O
out	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
M694V	O	O
frequently	O	O
observed	O	O
mutation	O	O
among	O	O
these	O	O
patients	O	O
.	O	O
Three	O	O
novel	O	O
mutations	O	O
,	O	O
T177I	O	O
,	O	O
S108R	O	O
and	O	O
E474	O	O
K	O	O
were	O	O
also	O	O
identified	O	O
in	O	O
the	O	O
Lebanese	O	O
group	O	O
.	O	O
An	O	O
excess	O	O
of	O	O
homozygotes	O	O
and	O	O
a	O	O
deficit	O	O
of	O	O
heterozygotes	O	O
were	O	O
observed	O	O
in	O	O
both	O	O
samples	O	O
when	O	O
compared	O	O
to	O	O
the	O	O
expected	O	O
number	O	O
of	O	O
observed	O	O
genotypes	O	O
under	O	O
the	O	O
Hardy	O	O
-	O	O
Weinberg	O	O
hypothesis	O	O
.	O	O
Homozygotes	O	O
for	O	O
M694V	O	O
and	O	O
M694I	O	O
were	O	O
still	O	O
in	O	O
excess	O	O
in	O	O
the	O	O
Lebanese	O	O
group	O	O
of	O	O
patients	O	O
,	O	O
even	O	O
after	O	O
consanguinous	O	O
homozygotes	O	O
were	O	O
removed	O	O
,	O	O
or	O	O
population	O	O
structure	O	O
was	O	O
considered	O	O
.	O	O
This	O	O
excess	O	O
is	O	O
therefore	O	O
neither	O	O
due	O	O
to	O	O
consanguinity	O	O
nor	O	O
to	O	O
subgroups	O	O
in	O	O
the	O	O
Lebanese	O	O
population	O	O
,	O	O
but	O	O
rather	O	O
to	O	O
more	O	O
remote	O	O
consanguinity	O	O
or	O	O
to	O	O
a	O	O
selection	O	O
bias	O	O
favoring	O	O
the	O	O
census	O	O
of	O	O
these	O	O
genotypes	O	O
.	O	O
The	O	O
fact	O	O
that	O	O
FMF	O	O
female	O	O
patients	O	O
were	O	O
less	O	O
censed	O	O
than	O	O
male	O	O
patients	O	O
may	O	O
be	O	O
due	O	O
to	O	O
the	O	O
greater	O	O
resistance	O	O
of	O	O
females	O	O
to	O	O
pain	O	O
and	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
confusing	O	O
abdominal	O	O
and	O	O
gynecological	O	O
pain	O	O
.	O	O
The	O	O
phenotypic	O	O
heterogeneity	O	O
of	O	O
the	O	O
FMF	O	O
could	O	O
then	O	O
originate	O	O
both	O	O
from	O	O
genetic	O	O
causes	O	O
like	O	O
allelic	O	O
heterogeneity	O	O
or	O	O
modulating	O	O
genes	O	O
,	O	O
and	O	O
cultural	O	O
background	O	O
facing	O	O
the	O	O
physiological	O	O
consequences	O	O
of	O	O
genotypes	O	O
at	O	O
risk	O	O
.	O	O
[	O	O
Mutational	O	O
and	O	O
clinical	O	O
features	O	O
of	O	O
Japanese	O	O
patients	O	O
with	O	O
dysferlinopathy	O	O
(	O	O
Miyoshi	O	O
myopathy	O	O
and	O	O
limb	O	O
girdle	O	O
muscular	O	O
dystrophy	O	O
type	O	O
2B	O	O
)	O	O
]	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
dysferlin	B-Gene	O
gene	O	O
cause	B-Reg	O
both	O	O
Miyoshi	B-Disease	O
myopathy	I-Disease	O
(	O	O
MM	O	O
)	O	I-Gene
and	O	O
limb	B-Disease	B-Disease
girdle	I-Disease	I-Disease
muscular	I-Disease	I-Disease
dystrophy	I-Disease	I-Disease
2B	I-Disease	O
(	O	O
LGMD2B	O	O
)	O	O
.	O	O
We	O	O
examined	O	O
patients	O	O
with	O	O
dysferlinopathy	O	O
in	O	O
Japan	O	O
,	O	O
and	O	O
identified	O	O
28	O	O
and	O	O
12	O	O
different	O	O
mutations	O	O
respectively	O	O
in	O	O
MM	O	O
and	O	O
LGMD2B	O	O
patients	O	O
.	O	O
The	O	O
mean	O	O
age	O	O
at	O	O
onset	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
MM	O	O
was	O	O
22	O	O
+	O	O
/-	O	O
9	O	O
years	O	O
(	O	O
range	O	O
12	O	O
-	O	O
48	O	O
years	O	O
)	O	O
and	O	O
that	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
LGMD2B	O	O
was	O	O
26	O	O
+	O	O
/-	O	O
10	O	O
years	O	O
(	O	O
range	O	O
11	O	O
-	O	O
43	O	O
years	O	O
)	O	O
.	O	O
On	O	O
the	O	O
average	O	O
,	O	O
the	O	O
first	O	O
use	O	O
of	O	O
a	O	O
cane	O	O
was	O	O
at	O	O
33	O	O
years	O	O
(	O	O
14	O	O
years	O	O
after	O	O
the	O	O
onset	O	O
)	O	O
for	O	O
MM	O	O
and	O	O
39	O	O
years	O	O
(	O	O
15	O	O
years	O	O
after	O	O
onset	O	O
)	O	O
for	O	O
LGMD	O	O
2B.	O	O
Patients	O	O
became	O	O
wheelchair	O	O
-	O	O
bound	O	O
at	O	O
41	O	O
years	O	O
(	O	O
21	O	O
years	O	O
after	O	O
onset	O	O
)	O	O
in	O	O
MM	O	O
and	O	O
45	O	O
years	O	O
(	O	O
21	O	O
years	O	O
after	O	O
onset	O	O
)	O	O
for	O	O
LGMD2B.	O	O
The	O	O
mean	O	O
maximum	O	O
serum	O	O
CK	O	O
level	O	O
at	O	O
any	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
5,829	O	O
+	O	O
/-	O	O
4,273	O	O
IU	O	O
/	O	O
l	O	O
(	O	O
range	O	O
1,289	O	O
-	O	O
12,566	O	O
IU	O	O
/	O	O
l	O	O
)	O	O
for	O	O
MM	O	O
and	O	O
3,787	O	O
+	O	O
/-	O	O
2,493	O	O
IU	O	O
/	O	O
l	O	O
(	O	O
627	O	O
-	O	O
10,000	O	O
IU	O	O
/	O	O
l	O	O
)	O	O
for	O	O
LGMD2B	O	O
:	O	O
in	O	O
both	O	O
disorders	O	O
,	O	O
the	O	O
serum	O	O
CK	O	O
level	O	O
fell	O	O
in	O	O
proportion	O	O
to	O	O
the	O	O
duration	O	O
of	O	O
the	O	O
illness	O	O
.	O	O
We	O	O
have	O	O
identified	O	O
four	O	O
common	O	O
four	O	O
mutations	O	O
(	O	O
C1939	O	O
G	O	O
,	O	O
G3370	O	O
T	O	O
,	O	O
3746delG	O	O
,	O	O
and	O	O
4870delT	O	O
)	O	O
in	O	O
Japanese	O	O
patients	O	O
with	O	O
MM	O	O
,	O	O
accounting	O	O
for	O	O
48	O	O
percent	O	O
of	O	O
all	O	O
MM	O	O
mutations	O	O
in	O	O
this	O	O
population	O	O
.	O	O
Two	O	O
of	O	O
the	O	O
four	O	O
mutations	O	O
(	O	O
G3370	O	O
T	O	O
,	O	O
and	O	O
4870delT	O	O
)	O	O
accounted	O	O
for	O	O
52	O	O
percent	O	O
of	O	O
the	O	O
mutations	O	O
in	O	O
LGMD2B	O	O
patients	O	O
,	O	O
while	O	O
the	O	O
3746delG	O	O
mutation	O	O
was	O	O
not	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
LGMD2B.	O	O
The	O	O
G3370	B-Var	O
T	I-Var	O
mutation	O	O
may	O	O
be	O	O
associated	B-Reg	O
with	I-Reg	O
a	O	O
milder	O	O
form	O	O
of	O	O
MM	B-Disease	O
and	O	O
LGMD2B.	B-Disease	O
By	O	O
contrast	O	O
,	O	O
the	O	O
G3510A	B-Var	O
mutation	O	O
appears	O	O
to	O	O
be	O	O
associated	B-Reg	O
with	I-Reg	O
a	O	O
severe	O	O
form	O	O
of	O	O
MM	B-Disease	O
.	O	O
[	O	O
Molecular	O	O
pathomechanism	O	O
of	O	O
distal	O	O
myopathy	O	O
with	O	O
rimmed	O	O
vacuoles	O	O
]	O	O
.	O	O
Distal	B-Disease	O
myopathy	I-Disease	O
with	I-Disease	O
rimmed	I-Disease	O
vacuoles	I-Disease	O
(	O	O
DMRV	O	O
)	O	O
and	O	O
hereditary	B-Disease	O
inclusion	I-Disease	O
body	I-Disease	O
myopathy	I-Disease	O
(	O	O
HIBM	O	O
)	O	O
are	O	O
genetically	O	O
identical	O	O
autosomal	O	O
recessive	O	O
muscle	O	O
disorders	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
GNE	B-Gene	O
gene	O	O
.	O	O
This	O	O
gene	O	O
encodes	O	O
a	O	O
bifunctional	O	O
protein	O	O
with	O	O
UDP	O	O
-	O	O
GlcNAc	O	O
2-epimerase	O	O
and	O	O
ManNAc	O	O
kinase	O	O
activities	O	O
that	O	O
catalyze	O	O
the	O	O
rate	O	O
limiting	O	O
step	O	O
and	O	O
the	O	O
succeeding	O	O
step	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
sialic	O	O
acid	O	O
biosynthetic	O	O
pathway	O	O
.	O	O
V572L	O	O
mutation	O	O
is	O	O
the	O	O
most	O	O
prevalent	O	O
among	O	O
Japanese	O	O
DMRV	O	O
patients	O	O
and	O	O
accounts	O	O
for	O	O
about	O	O
60	O	O
%	O	O
of	O	O
mutant	O	O
alleles	O	O
.	O	O
Clinical	O	O
spectrum	O	O
of	O	O
DMRV	O	O
/	O	O
HIBM	O	O
seems	O	O
to	O	O
be	O	O
wider	O	O
than	O	O
previously	O	O
thought	O	O
in	O	O
terms	O	O
of	O	O
both	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
disease	O	O
and	O	O
the	O	O
range	O	O
of	O	O
affected	O	O
organs	O	O
.	O	O
There	O	O
are	O	O
rare	O	O
asymptomatic	O	O
homozygotes	O	O
with	O	O
missense	O	O
GNE	O	O
mutations	O	O
,	O	O
indicating	O	O
the	O	O
presence	O	O
of	O	O
mitigating	O	O
factors	O	O
.	O	O
Surprisingly	O	O
,	O	O
more	O	O
than	O	O
10	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
variety	O	O
of	O	O
cardiac	O	O
abnormalities	O	O
,	O	O
suggesting	O	O
that	O	O
skeletal	O	O
muscle	O	O
may	O	O
not	O	O
be	O	O
the	O	O
only	O	O
organ	O	O
involved	O	O
.	O	O
Studies	O	O
on	O	O
recombinant	O	O
GNE	B-Gene	O
demonstrate	O	O
a	O	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
nature	O	O
of	O	O
the	O	O
missense	O	O
mutations	B-Var	O
identified	O	O
.	O	O
Patients	O	O
'	O	O
cells	O	O
show	O	O
decreased	B-NegReg	O
sialylation	B-MPA	O
status	I-MPA	O
which	O	O
can	O	O
be	O	O
recovered	O	O
by	O	O
adding	O	O
GNE	O	O
metabolites	O	O
,	O	O
such	O	O
as	O	O
ManNAc	O	O
and	O	O
NeuAc	O	O
.	O	O
This	O	O
indicates	O	O
the	O	O
possibility	O	O
of	O	O
developing	O	O
a	O	O
therapy	O	O
for	O	O
DMRV	O	O
/	O	O
HIBM	O	O
by	O	O
giving	O	O
these	O	O
metabolites	O	O
to	O	O
patients	O	O
although	O	O
we	O	O
have	O	O
to	O	O
await	O	O
the	O	O
model	O	O
mice	O	O
that	O	O
are	O	O
currently	O	O
being	O	O
produced	O	O
at	O	O
several	O	O
laboratories	O	O
.	O	O
X	B-Disease	O
linked	I-Disease	O
cone	I-Disease	O
-	I-Disease	O
rod	I-Disease	O
dystrophy	I-Disease	O
,	O	O
CORDX3	O	O
,	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
mutation	B-Var	O
in	O	O
the	O	O
CACNA1F	B-Gene	O
gene	O	O
.	O	O
BACKGROUND	O	O
:	O	O
X	B-Disease	O
linked	I-Disease	O
cone	I-Disease	O
-	I-Disease	O
rod	I-Disease	O
dystrophy	I-Disease	O
(	O	O
CORDX	O	O
)	O	O
is	O	O
a	O	O
recessive	O	O
retinal	O	O
disease	O	O
characterised	O	O
by	O	O
progressive	O	O
dysfunction	O	O
of	O	O
photoreceptors	O	O
.	O	O
It	O	O
is	O	O
genetically	O	O
heterogeneous	O	O
,	O	O
showing	O	O
linkage	O	O
to	O	O
three	O	O
X	O	O
chromosomal	O	O
loci	O	O
.	O	O
CORDX1	B-Disease	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
RPGR	B-Gene	O
gene	O	O
(	O	O
Xp21.1	O	O
)	O	O
,	O	O
CORDX2	O	O
is	O	O
located	O	O
on	O	O
Xq27.2	O	O
-	O	O
28	O	O
,	O	O
and	O	O
we	O	O
recently	O	O
localised	O	O
CORDX3	O	O
to	O	O
Xp11.4-q13.1	O	O
.	O	O
We	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
causative	O	O
gene	O	O
behind	O	O
the	O	O
CORDX3	O	O
phenotype	O	O
.	O	O
METHODS	O	O
:	O	O
All	O	O
48	O	O
exons	O	O
of	O	O
the	O	O
CACNA1F	O	O
gene	O	O
were	O	O
screened	O	O
for	O	O
mutations	O	O
by	O	O
DNA	O	O
sequencing	O	O
.	O	O
RNA	O	O
from	O	O
cultured	O	O
lymphoblasts	O	O
and	O	O
peripheral	O	O
blood	O	O
activated	O	O
T	O	O
lymphocytes	O	O
was	O	O
analysed	O	O
by	O	O
RT	O	O
-	O	O
PCR	O	O
and	O	O
sequencing	O	O
.	O	O
RESULTS	O	O
:	O	O
A	O	O
novel	O	O
CACNA1F	O	O
mutation	O	O
,	O	O
IVS28	O	O
-	O	O
1	O	O
GCGTC	O	O
>	O	O
TGG	O	O
,	O	O
in	O	O
the	O	O
splice	O	O
acceptor	O	O
site	O	O
of	O	O
intron	O	O
28	O	O
was	O	O
identified	O	O
.	O	O
Messenger	O	O
RNA	O	O
studies	O	O
indicated	O	O
that	O	O
the	O	O
identified	O	O
mutation	B-Var	O
leads	O	O
to	O	O
altered	B-Reg	B-Reg
splicing	B-MPA	O
of	O	O
the	O	O
CACNA1F	B-Gene	O
transcript	B-MPA	O
.	O	O
Aberrant	B-Var	O
splice	I-Var	O
variants	I-Var	O
are	O	O
predicted	O	O
to	O	O
result	B-Reg	O
in	I-Reg	O
premature	B-MPA	O
termination	I-MPA	O
and	O	O
deletions	B-Var	O
of	O	O
the	O	O
encoded	B-Protein	O
protein	I-Protein	O
,	O	O
Ca(v)1.4	O	O
alpha1	O	O
subunit	O	O
.	O	O
CONCLUSION	O	O
:	O	O
CACNA1F	B-Gene	O
mutations	B-Var	O
cause	B-Reg	O
the	O	O
retinal	B-Disease	O
disorder	I-Disease	O
,	O	O
incomplete	O	O
congenital	B-Disease	O
stationary	I-Disease	O
night	I-Disease	O
blindness	I-Disease	O
(	O	O
CSNB2	O	O
)	O	O
,	O	O
although	O	O
mutations	O	O
have	O	O
also	O	O
been	O	O
detected	O	O
in	O	O
patients	O	O
with	O	O
divergent	O	O
diagnoses	O	O
.	O	O
Our	O	O
results	O	O
indicate	O	O
that	O	O
yet	O	O
another	O	O
phenotype	O	O
,	O	O
CORDX3	B-Disease	O
,	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
mutation	B-Var	O
in	O	O
CACNA1F.	B-Gene	O
Clinically	O	O
,	O	O
CORDX3	O	O
shares	O	O
some	O	O
features	O	O
with	O	O
CSNB2	O	O
but	O	O
is	O	O
distinguishable	O	O
from	O	O
CSNB2	O	O
in	O	O
that	O	O
it	O	O
is	O	O
progressive	O	O
,	O	O
can	O	O
begin	O	O
in	O	O
adulthood	O	O
,	O	O
has	O	O
no	O	O
nystagmus	O	O
or	O	O
hyperopic	O	O
refraction	O	O
,	O	O
has	O	O
only	O	O
low	O	O
grade	O	O
astigmatism	O	O
,	O	O
and	O	O
in	O	O
dark	O	O
adaptation	O	O
lacks	O	O
cone	O	O
threshold	O	O
and	O	O
has	O	O
small	O	O
or	O	O
no	O	O
elevation	O	O
of	O	O
rod	O	O
threshold	O	O
.	O	O
Considering	O	O
all	O	O
features	O	O
,	O	O
CORDX3	O	O
is	O	O
more	O	O
similar	O	O
to	O	O
other	O	O
X	O	O
chromosomal	O	O
cone	O	O
-	O	O
rod	O	O
dystrophies	O	O
than	O	O
to	O	O
CSNB2	O	O
.	O	O
Novel	O	O
JARID1C	O	O
/	O	O
SMCX	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
X	O	O
-	O	O
linked	O	O
mental	O	O
retardation	O	O
.	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
mental	I-Disease	O
retardation	I-Disease	O
(	O	O
XLMR	O	O
)	O	O
is	O	O
a	O	O
heterogeneous	O	O
disorder	O	O
that	O	O
affects	O	O
approximately	O	O
2	O	O
in	O	O
1000	O	O
males	O	O
.	O	O
JARID1C	O	O
/	O	O
SMCX	O	O
is	O	O
relatively	O	O
new	O	O
among	O	O
the	O	O
known	O	O
XLMR	O	O
genes	O	O
,	O	O
and	O	O
seven	O	O
different	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
previously	O	O
in	O	O
this	O	O
gene	O	O
[	O	O
Jensen	O	O
LR	O	O
et	O	O
al	O	O
.	O	O
,	O	O
Am	O	O
.	O	O
J.	O	O
Hum	O	O
.	O	O
Genet	O	O
.	O	O
76:227	O	O
-	O	O
236	O	O
,	O	O
2005	O	O
]	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
report	O	O
five	O	O
novel	O	O
JARID1C	B-Gene	O
mutations	O	O
in	B-Reg	O
five	O	O
XLMR	B-Disease	O
families	O	O
.	O	O
The	O	O
changes	O	O
comprise	O	O
one	O	O
nonsense	O	O
mutation	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
Arg332X	I-Var	O
)	I-Var	O
and	O	O
four	O	O
missense	O	O
mutations	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
Asp87Gly	I-Var	O
;	I-Var	O
p	B-Var	O
.	I-Var	O
Phe642Leu	I-Var	O
;	I-Var	O
p	B-Var	O
.	I-Var	O
Arg750Trp	I-Var	O
;	I-Var	O
p	B-Var	O
.	I-Var	O
Tyr751Cys	I-Var	O
)	I-Var	O
affecting	O	O
evolutionarily	O	O
conserved	O	O
amino	O	O
acids	O	O
.	O	O
The	O	O
degree	O	O
of	O	O
mental	O	O
retardation	O	O
in	O	O
the	O	O
affected	O	O
males	O	O
ranged	O	O
from	O	O
mild	O	O
to	O	O
severe	O	O
,	O	O
and	O	O
some	O	O
patients	O	O
suffered	O	O
from	O	O
additional	O	O
disorders	O	O
such	O	O
as	O	O
epilepsy	O	O
,	O	O
short	O	O
stature	O	O
,	O	O
or	O	O
behavioral	O	O
problems	O	O
.	O	O
This	O	O
study	O	O
brings	O	O
the	O	O
total	O	O
number	O	O
of	O	O
reported	O	O
JARID1C	O	O
mutations	O	O
to	O	O
twelve	O	O
.	O	O
In	O	O
contrast	O	O
to	O	O
other	O	O
XLMR	O	O
genes	O	O
in	O	O
which	O	O
mutations	O	O
were	O	O
found	O	O
only	O	O
in	O	O
single	O	O
or	O	O
very	O	O
few	O	O
families	O	O
,	O	O
JARID1C	O	O
appears	O	O
to	O	O
be	O	O
one	O	O
of	O	O
the	O	O
more	O	O
frequently	O	O
mutated	O	O
genes	O	O
in	O	O
this	O	O
disorder	O	O
.	O	O
Missense	B-Var	O
mutations	I-Var	O
in	O	O
SH2D1A	B-Gene	O
identified	O	O
in	O	O
patients	O	O
with	B-Reg	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
lymphoproliferative	I-Disease	O
disease	I-Disease	O
differentially	O	O
affect	O	O
the	O	O
expression	O	O
and	O	O
function	O	O
of	O	O
SAP	O	O
.	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
lymphoproliferative	I-Disease	O
disease	I-Disease	O
(	O	O
XLP	O	O
)	O	O
is	O	O
an	O	O
immunodeficiency	O	O
resulting	B-Reg	O
from	I-Reg	O
mutations	B-Var	O
in	O	O
SH2D1A	B-Gene	O
,	O	O
which	O	O
encodes	O	O
signalling	O	O
lymphocytic	O	O
activation	O	O
molecule	O	O
(	O	O
SLAM)-associated	O	O
protein	O	O
(	O	O
SAP	O	O
)	O	O
.	O	O
In	O	O
addition	O	O
to	O	O
SLAM	O	O
,	O	O
SAP	O	O
associates	O	O
with	O	O
several	O	O
other	O	O
cell	O	O
-	O	O
surface	O	O
receptors	O	O
including	O	O
2B4	O	O
(	O	O
CD244	O	O
)	O	O
,	O	O
Ly9	O	O
(	O	O
CD229	O	O
)	O	O
,	O	O
CD84	O	O
and	O	O
NTB	O	O
-	O	O
A.	O	O
SAP	O	O
contains	O	O
a	O	O
single	O	O
src	O	O
-	O	O
homology-2	O	O
domain	O	O
and	O	O
acts	O	O
as	O	O
an	O	O
intracellular	O	O
adaptor	O	O
protein	O	O
by	O	O
recruiting	O	O
the	O	O
protein	O	O
tyrosine	O	O
kinase	O	O
FynT	O	O
to	O	O
the	O	O
cytoplasmic	O	O
domains	O	O
of	O	O
some	O	O
of	O	O
these	O	O
receptors	O	O
,	O	O
which	O	O
results	O	O
in	O	O
the	O	O
initiation	O	O
of	O	O
specific	O	O
downstream	O	O
signal	O	O
transduction	O	O
pathways	O	O
.	O	O
XLP	O	O
is	O	O
likely	O	O
to	O	O
result	O	O
from	O	O
perturbed	O	O
signalling	O	O
through	O	O
one	O	O
or	O	O
more	O	O
of	O	O
these	O	O
SAP	O	O
-	O	O
associating	O	O
receptors	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
identified	O	O
missense	O	O
(	O	O
Y54C	O	O
,	O	O
I84	O	O
T	O	O
and	O	O
F87S	O	O
)	O	O
and	O	O
insertion	O	O
(	O	O
fs82	O	O
--	O	O
>	O	O
X103	O	O
)	O	O
mutations	O	O
in	O	O
four	O	O
different	O	O
kindreds	O	O
affected	O	O
by	O	O
XLP	O	O
.	O	O
Each	O	O
mutation	B-Var	O
dramatically	O	O
reduced	B-NegReg	O
the	O	O
half	B-MPA	O
-	I-MPA	O
life	I-MPA	O
of	O	O
SAP	B-Protein	O
,	O	O
thus	O	O
diminishing	B-NegReg	O
its	O	O
expression	B-MPA	O
in	O	O
primary	O	O
lymphocytes	O	O
as	O	O
well	O	O
as	O	O
in	O	O
transfected	O	O
cell	O	O
lines	O	O
.	O	O
Interestingly	O	O
,	O	O
although	O	O
the	O	O
Y54C	B-Var	O
and	O	O
F87S	B-Var	O
mutations	O	O
compromised	B-NegReg	O
the	O	O
ability	B-MPA	O
of	O	O
SAP	B-Protein	O
to	O	O
associate	B-Interaction	O
with	O	O
different	O	O
receptors	O	O
,	O	O
the	O	O
I84	O	O
T	O	O
mutation	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
ability	O	O
of	O	O
SAP	O	O
to	O	O
bind	O	O
SLAM	O	O
,	O	O
CD84	O	O
or	O	O
2B4	O	O
.	O	O
However	O	O
,	O	O
signalling	B-MPA	O
downstream	I-MPA	O
of	I-MPA	O
SLAM	I-MPA	O
was	O	O
reduced	B-NegReg	O
in	O	O
the	O	O
presence	O	O
of	O	O
SAP	B-Protein	O
bearing	O	O
the	O	O
I84	B-Var	O
T	I-Var	O
mutation	O	O
.	O	O
These	O	O
findings	O	O
indicate	O	O
that	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
type	O	O
of	O	O
mutation	O	O
,	O	O
signalling	O	O
through	O	O
SAP	O	O
-	O	O
associating	O	O
receptors	O	O
in	O	O
XLP	O	O
can	O	O
be	O	O
impaired	O	O
by	O	O
reducing	O	B-NegReg
the	O	O
expression	O	B-MPA
of	O	O
SAP	O	O
,	O	O
the	O	O
ability	O	O
of	O	O
SAP	O	O
to	O	O
bind	O	O
surface	O	O
receptors	O	B-MPA
and/or	O	O
its	O	O
ability	O	O
to	O	O
activate	O	O
signal	O	O
transduction	O	O
downstream	O	O
of	O	O
the	O	O
SLAM	O	O
-	O	O
SAP	O	O
complex	O	O
.	O	O
The	O	O
R110C	B-Var	O
mutation	O	O
in	O	O
Notch3	B-Gene	O
causes	B-Reg	O
variable	O	O
clinical	O	O
features	O	O
in	O	O
two	O	O
Turkish	O	O
families	O	O
with	O	O
CADASIL	B-Disease	O
syndrome	I-Disease	O
.	O	O
Mutations	B-Var	O
in	O	O
Notch3	B-Gene	O
gene	O	O
are	O	O
responsible	B-Reg	O
for	O	O
the	O	O
cerebral	B-Disease	O
autosomal	I-Disease	O
dominant	I-Disease	O
arteriopathy	I-Disease	O
with	I-Disease	O
subcortical	I-Disease	O
infarcts	I-Disease	O
and	I-Disease	O
leukoencephalopathy	I-Disease	O
(	O	O
CADASIL	O	O
)	O	O
.	O	O
It	O	O
is	O	O
a	O	O
late	O	O
onset	O	O
neurological	O	O
disorder	O	O
recognized	O	O
by	O	O
recurrent	O	O
strokes	O	O
and	O	O
dementia	O	O
.	O	O
We	O	O
describe	O	O
here	O	O
the	O	O
clinical	O	O
and	O	O
molecular	O	O
findings	O	O
of	O	O
three	O	O
unrelated	O	O
Turkish	O	O
families	O	O
with	O	O
CADASIL	O	O
syndrome	O	O
.	O	O
Two	O	O
of	O	O
the	O	O
families	O	O
were	O	O
identified	O	O
to	O	O
have	O	O
the	O	O
same	O	O
mutation	O	O
,	O	O
p	O	O
.	O	O
R110C	O	O
(	O	O
c	O	O
.	O	O
C328	O	O
T	O	O
)	O	O
,	O	O
located	O	O
in	O	O
exon	O	O
3	O	O
of	O	O
the	O	O
Notch3	O	O
gene	O	O
.	O	O
Interestingly	O	O
,	O	O
the	O	O
phenotypic	O	O
expression	O	O
of	O	O
the	O	O
disease	O	O
in	O	O
these	O	O
two	O	O
families	O	O
was	O	O
markedly	O	O
different	O	O
in	O	O
severity	O	O
and	O	O
age	O	O
of	O	O
onset	O	O
implicating	O	O
additional	O	O
genetic	O	O
and/or	O	O
non	O	O
-	O	O
genetic	O	O
modulating	O	O
factors	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
we	O	O
identified	O	O
the	O	O
novel	O	O
p	O	O
.	O	O
C201R	O	O
(	O	O
c	O	O
.	O	O
T601C	O	O
)	O	O
mutation	O	O
in	O	O
exon	O	O
4	O	O
of	O	O
the	O	O
Notch3	O	O
gene	O	O
in	O	O
a	O	O
proband	O	O
of	O	O
the	O	O
third	O	O
family	O	O
with	O	O
two	O	O
consecutive	O	O
stroke	O	O
-	O	O
like	O	O
episodes	O	O
and	O	O
typical	O	O
MRI	O	O
findings	O	O
.	O	O
Mutations	B-Var	O
described	O	O
here	O	O
cause	B-Reg	O
an	O	O
odd	B-MPA	O
number	I-MPA	O
of	I-MPA	O
cysteines	I-MPA	O
in	I-MPA	O
the	I-MPA	O
N	I-MPA	O
-	I-MPA	O
terminal	I-MPA	O
of	I-MPA	O
the	I-MPA	O
EGF	I-MPA	O
domain	I-MPA	O
of	O	O
Notch3	B-Gene	O
protein	B-Protein	O
,	O	O
which	O	O
seems	O	O
to	O	O
have	O	O
an	O	O
important	O	O
functional	O	O
effect	B-Reg	O
in	O	O
the	O	O
pathophysiology	O	O
of	O	O
CADASIL	B-Disease	O
.	O	O
The	O	O
phenotypic	O	O
variability	O	O
in	O	O
families	O	O
carrying	O	O
the	O	O
same	O	O
molecular	O	O
defect	O	O
as	O	O
presented	O	O
here	O	O
makes	O	O
the	O	O
prediction	O	O
of	O	O
prognosis	O	O
inconceivable	O	O
.	O	O
Although	O	O
DNA	O	O
analysis	O	O
is	O	O
effective	O	O
and	O	O
valuable	O	O
in	O	O
diagnosing	O	O
approximately	O	O
90	O	O
%	O	O
of	O	O
the	O	O
CADASIL	O	O
patients	O	O
,	O	O
lack	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
and	O	O
prognostic	O	O
parameters	O	O
makes	O	O
the	O	O
presymptomatic	O	O
genetic	O	O
counseling	O	O
very	O	O
difficult	O	O
.	O	O
Entries	O	O
in	O	O
the	O	O
Leiden	O	O
Duchenne	O	O
muscular	O	O
dystrophy	O	O
mutation	O	O
database	O	O
:	O	O
an	O	O
overview	O	O
of	O	O
mutation	O	O
types	O	O
and	O	O
paradoxical	O	O
cases	O	O
that	O	O
confirm	O	O
the	O	O
reading	O	O
-	O	O
frame	O	O
rule	O	O
.	O	O
The	O	O
severe	O	O
Duchenne	B-Disease	O
and	O	O
milder	O	O
Becker	B-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
are	O	O
both	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
DMD	B-Gene	O
gene	O	O
.	O	O
This	O	O
gene	O	O
codes	O	O
for	O	O
dystrophin	O	O
,	O	O
a	O	O
protein	O	O
important	O	O
for	O	O
maintaining	O	O
the	O	O
stability	O	O
of	O	O
muscle	O	O
-	O	O
fiber	O	O
membranes	O	O
.	O	O
In	O	O
1988	O	O
,	O	O
Monaco	O	O
and	O	O
colleagues	O	O
postulated	O	O
an	O	O
explanation	O	O
for	O	O
the	O	O
phenotypic	O	O
difference	O	O
between	O	O
Duchenne	O	O
and	O	O
Becker	O	O
patients	O	O
in	O	O
the	O	O
reading	O	O
-	O	O
frame	O	O
rule	O	O
:	O	O
In	O	O
Duchenne	B-Disease	O
patients	O	O
,	O	O
mutations	B-Var	O
induce	B-Reg	O
a	B-MPA	O
shift	I-MPA	O
in	I-MPA	O
the	I-MPA	O
reading	I-MPA	O
frame	I-MPA	O
leading	B-Reg	O
to	O	O
prematurely	B-MPA	O
truncated	I-MPA	O
,	O	O
dysfunctional	B-NegReg	O
dystrophins	B-Protein	O
.	O	O
In	O	O
Becker	B-Disease	O
patients	O	O
,	O	O
in	B-Var	O
-	I-Var	O
frame	I-Var	O
mutations	I-Var	O
allow	B-Reg	O
the	O	O
synthesis	B-MPA	O
of	I-MPA	O
internally	I-MPA	O
deleted	I-MPA	O
,	O	O
but	O	O
largely	B-PosReg	O
functional	I-PosReg	O
dystrophins	B-Protein	O
.	O	O
Currently	O	O
,	O	O
over	O	O
4700	O	O
mutations	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
Leiden	O	O
DMD	O	O
mutation	O	O
database	O	O
,	O	O
of	O	O
which	O	O
91	O	O
%	O	O
are	O	O
in	O	O
agreement	O	O
with	O	O
this	O	O
rule	O	O
.	O	O
In	O	O
this	O	O
study	O	O
we	O	O
provide	O	O
an	O	O
update	O	O
of	O	O
the	O	O
mutational	O	O
variability	O	O
in	O	O
the	O	O
DMD	O	O
gene	O	O
,	O	O
particularly	O	O
focusing	O	O
on	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
and	O	O
mutations	O	O
that	O	O
appear	O	O
to	O	O
be	O	O
exceptions	O	O
to	O	O
the	O	O
reading	O	O
-	O	O
frame	O	O
rule	O	O
.	O	O
Prevalence	O	O
of	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
in	O	O
families	O	O
with	O	O
autosomal	O	O
dominant	O	O
retinitis	O	O
pigmentosa	O	O
:	O	O
a	O	O
screen	O	O
of	O	O
known	O	O
genes	O	O
in	O	O
200	O	O
families	O	O
.	O	O
PURPOSE	O	O
:	O	O
To	O	O
survey	O	O
families	O	O
with	O	O
clinical	O	O
evidence	O	O
of	O	O
autosomal	B-Disease	O
dominant	I-Disease	O
retinitis	I-Disease	O
pigmentosa	I-Disease	O
(	O	O
adRP	O	O
)	O	O
for	O	O
mutations	O	O
in	O	O
genes	O	O
known	O	O
to	O	O
cause	O	O
adRP	O	O
.	O	O
METHODS	O	O
:	O	O
Two	O	O
hundred	O	O
adRP	O	O
families	O	O
,	O	O
drawn	O	O
from	O	O
a	O	O
cohort	O	O
of	O	O
more	O	O
than	O	O
400	O	O
potential	O	O
families	O	O
,	O	O
were	O	O
selected	O	O
by	O	O
analysis	O	O
of	O	O
pedigrees	O	O
.	O	O
Minimum	O	O
criteria	O	O
for	O	O
inclusion	O	O
in	O	O
the	O	O
adRP	O	O
cohort	O	O
included	O	O
either	O	O
evidence	O	O
of	O	O
at	O	O
least	O	O
three	O	O
generations	O	O
of	O	O
affected	O	O
individuals	O	O
or	O	O
two	O	O
generations	O	O
with	O	O
evidence	O	O
of	O	O
male	O	O
-	O	O
to	O	O
-	O	O
male	O	O
transmission	O	O
.	O	O
Probands	O	O
from	O	O
each	O	O
family	O	O
were	O	O
screened	O	O
for	O	O
mutations	B-Var	O
in	O	O
13	O	O
genes	O	O
known	O	O
to	O	O
cause	B-Reg	O
adRP	B-Disease	O
:	I-Disease	O
CA4	B-Gene	O
,	O	O
CRX	B-Gene	O
,	O	O
FSCN2	B-Gene	O
,	O	O
IMPDH1	B-Gene	O
,	O	O
NRL	B-Gene	O
,	O	O
PRPF3	B-Gene	O
(	O	O
RP18	O	O
)	O	O
,	O	O
PRPF8	B-Gene	O
(	O	O
RP13	O	O
)	O	O
,	O	O
PRPF31	B-Gene	O
(	O	O
RP11	O	O
)	O	O
,	O	O
RDS	B-Gene	O
,	O	O
RHO	B-Gene	O
,	O	O
ROM1	B-Gene	O
,	O	O
RP1	B-Gene	O
,	O	O
and	O	O
RP9	B-Gene	O
.	O	O
Families	O	O
without	O	O
mutations	O	O
in	O	O
autosomal	O	O
genes	O	O
and	O	O
in	O	O
which	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
mode	O	O
of	O	O
inheritance	O	O
could	O	O
not	O	O
be	O	O
excluded	O	O
were	O	O
tested	O	O
for	O	O
mutations	O	O
in	O	O
ORF	O	O
15	O	B-MPA
of	O	O
X	O	I-MPA
-	O	I-MPA
linked	O	O
RPGR	O	O
.	O	O
Potentially	O	O
pathogenic	O	O
variants	O	O
were	O	O
evaluated	O	O
based	O	O
on	O	O
a	O	O
variety	O	O
of	O	O
genetic	O	O
and	O	O
computational	O	O
criteria	O	O
,	O	O
to	O	O
confirm	O	O
or	O	O
exclude	O	O
pathogenicity	O	O
.	O	O
RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
82	O	O
distinct	O	O
,	O	O
rare	O	O
(	O	O
nonpolymorphic	O	O
)	O	O
variants	O	O
were	O	O
detected	O	O
among	O	O
the	O	O
genes	O	O
tested	O	O
.	O	O
Of	O	O
these	O	O
,	O	O
57	O	O
are	O	O
clearly	O	O
pathogenic	O	O
based	O	O
on	O	O
multiple	O	O
criteria	O	O
,	O	O
10	O	O
are	O	O
probably	O	O
pathogenic	O	O
,	O	O
and	O	O
15	O	O
are	O	O
probably	O	O
benign	O	O
.	O	O
In	O	O
the	O	O
cohort	O	O
of	O	O
200	O	O
families	O	O
,	O	O
94	O	O
(	O	O
47	O	O
%	O	O
)	O	O
have	O	O
one	O	O
of	O	O
the	O	O
clearly	O	O
pathogenic	O	O
variants	O	O
and	O	O
10	O	O
(	O	O
5	O	O
%	O	O
)	O	O
have	O	O
one	O	O
of	O	O
the	O	O
probably	O	O
pathogenic	O	O
variants	O	O
.	O	O
One	O	O
family	O	O
(	O	O
0.5	O	O
%	O	O
)	O	O
has	O	O
digenic	O	O
RDS	O	O
-	O	O
ROM1	O	O
mutations	O	O
.	O	O
Two	O	O
families	O	O
(	O	O
1	O	O
%	O	O
)	O	O
have	O	O
a	O	O
pathogenic	O	O
RPGR	O	O
mutation	O	O
,	O	O
indicating	O	O
that	O	O
families	O	O
with	O	O
apparent	O	O
autosomal	O	O
transmission	O	O
of	O	O
RP	O	O
may	O	O
actually	O	O
have	O	O
X	O	O
-	O	O
linked	O	O
genetic	O	O
disease	O	O
.	O	O
Thus	O	O
,	O	O
107	O	O
families	O	O
(	O	O
53.5	O	O
%	O	O
)	O	O
have	O	O
mutations	O	O
in	O	O
known	O	O
genes	O	O
,	O	O
leaving	O	O
93	O	O
whose	O	O
underlying	O	O
cause	O	O
is	O	O
still	O	O
unknown	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Together	O	O
,	O	O
the	O	O
known	O	O
adRP	O	O
genes	O	O
account	O	O
for	O	O
retinal	O	O
disease	O	O
in	O	O
approximately	O	O
half	O	O
of	O	O
the	O	O
families	O	O
in	O	O
this	O	O
survey	O	O
,	O	O
mostly	O	O
Americans	O	O
of	O	O
European	O	O
origin	O	O
.	O	O
Among	O	O
the	O	O
adRP	O	O
genes	O	O
,	O	O
IMPDH1	O	O
,	O	O
PRPF8	O	O
,	O	O
PRPF31	O	O
,	O	O
RDS	O	O
,	O	O
RHO	O	O
,	O	O
and	O	O
RP1	O	O
each	O	O
accounts	O	O
for	O	O
more	O	O
than	O	O
2	O	O
%	O	O
of	O	O
the	O	O
total	O	O
;	O	O
CRX	O	O
,	O	O
PRPF3	O	O
,	O	O
and	O	O
RPGR	O	O
each	O	O
accounts	O	O
for	O	O
roughly	O	O
1	O	O
%	O	O
.	O	O
Disease	O	O
-	O	O
causing	O	O
mutations	O	O
were	O	O
not	O	O
found	O	O
in	O	O
CA4	O	O
,	O	O
FSCN2	O	O
,	O	O
NRL	O	O
,	O	O
or	O	O
RP9	O	O
.	O	O
Because	O	O
some	O	O
mutations	O	O
are	O	O
frequent	O	O
and	O	O
some	O	O
regions	O	O
are	O	O
more	O	O
likely	O	O
to	O	O
harbor	O	O
mutations	O	O
than	O	O
others	O	O
,	O	O
more	O	O
than	O	O
two	O	O
thirds	O	O
of	O	O
the	O	O
detected	O	O
mutations	O	O
can	O	O
be	O	O
found	O	O
by	O	O
screening	O	O
less	O	O
than	O	O
10	O	O
%	O	O
of	O	O
the	O	O
total	O	O
gene	O	O
sequences	O	O
.	O	O
Among	O	O
the	O	O
remaining	O	O
families	O	O
,	O	O
mutations	O	O
may	O	O
lie	O	O
in	O	O
regions	O	O
of	O	O
known	O	O
genes	O	O
that	O	O
were	O	O
not	O	O
tested	O	O
,	O	O
mutations	O	O
may	O	O
not	O	O
be	O	O
detectable	O	O
by	O	O
PCR	O	O
-	O	O
based	O	O
sequencing	O	O
,	O	O
or	O	O
other	O	O
loci	O	O
may	O	O
be	O	O
involved	O	O
.	O	O
Clinical	O	O
and	O	O
genetic	O	O
analysis	O	O
of	O	O
Korean	O	O
patients	O	O
with	O	O
Miyoshi	O	O
myopathy	O	O
:	O	O
identification	O	O
of	O	O
three	O	O
novel	O	O
mutations	O	O
in	O	O
the	O	O
DYSF	O	O
gene	O	O
.	O	O
Miyoshi	B-Disease	O
myopathy	I-Disease	O
(	O	O
MM	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
distal	O	O
muscular	O	O
dystrophy	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
dysferlin	O	O
gene	O	O
(	B-Gene	O
DYSF	I-Gene	O
)	I-Gene	O
on	O	O
chromosome	O	O
2p13	O	O
.	O	O
Although	O	O
MM	O	O
patients	O	O
and	O	O
their	O	O
mutations	O	O
in	O	O
the	O	O
DYSF	O	O
gene	O	O
have	O	O
been	O	O
found	O	O
from	O	O
all	O	O
over	O	O
the	O	O
world	O	O
,	O	O
there	O	O
is	O	O
only	O	O
one	O	O
report	O	O
of	O	O
genetically	O	O
confirmed	O	O
case	O	O
of	O	O
MM	O	O
in	O	O
Korea	O	O
.	O	O
Recently	O	O
,	O	O
we	O	O
encountered	O	O
three	O	O
unrelated	O	O
Korean	O	O
patients	O	O
with	O	O
MM	O	O
and	O	O
two	O	O
of	O	O
them	O	O
have	O	O
previously	O	O
been	O	O
considered	O	O
as	O	O
having	O	O
a	O	O
type	O	O
of	O	O
inflammatory	O	O
myopathy	O	O
.	O	O
The	O	O
clinical	O	O
and	O	O
laboratory	O	O
evaluation	O	O
showed	O	O
typical	O	O
features	O	O
of	O	O
muscle	O	O
involvement	O	O
in	O	O
MM	O	O
in	O	O
all	O	O
patients	O	O
but	O	O
one	O	O
patient	O	O
initially	O	O
had	O	O
moderate	O	O
proximal	O	O
muscle	O	O
involvement	O	O
and	O	O
another	O	O
showed	O	O
incomplete	O	O
quadriparesis	O	O
with	O	O
rapid	O	O
progression	O	O
.	O	O
Direct	O	O
sequencing	O	O
analysis	O	O
of	O	O
the	O	O
DYSF	O	O
gene	O	O
revealed	O	O
that	O	O
each	O	O
patient	O	O
had	O	O
compound	O	O
heterozygous	O	O
mutations	O	O
(	O	O
Gln832X	O	O
and	O	O
Trp992Arg	O	O
,	O	O
Gln832X	O	O
and	O	O
Trp999Cys	O	O
,	O	O
and	O	O
Lys1103X	O	O
and	O	O
Ile1401HisfsX8	O	O
,	O	O
respectively	O	O
)	O	O
among	O	O
which	O	O
three	O	O
were	O	O
novel	O	O
.	O	O
Although	O	O
MM	O	O
has	O	O
been	O	O
thought	O	O
to	O	O
be	O	O
quite	O	O
rare	O	O
in	O	O
Korea	O	O
,	O	O
it	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
a	O	O
differential	O	O
diagnosis	O	O
of	O	O
patients	O	O
exhibiting	O	O
distal	O	O
myopathy	O	O
.	O	O
UBE2A	B-Gene	O
,	O	O
which	O	O
encodes	O	O
a	O	O
ubiquitin	O	O
-	O	O
conjugating	O	O
enzyme	O	O
,	O	O
is	O	O
mutated	B-Var	O
in	B-Reg	O
a	O	O
novel	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
mental	I-Disease	O
retardation	I-Disease	O
syndrome	I-Disease	O
.	O	O
We	O	O
report	O	O
a	O	O
mutation	B-Var	O
of	O	O
UBE2A	B-Gene	O
/	I-Gene	O
HR6A	I-Gene	O
,	O	O
which	O	O
encodes	O	O
a	O	O
ubiquitin	O	O
-	O	O
conjugating	O	O
enzyme	O	O
(	O	O
E2	O	O
)	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
ubiquitin	O	O
proteasome	O	O
pathway	O	O
,	O	O
as	O	O
the	O	O
cause	B-Reg	O
of	O	O
a	O	O
novel	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
mental	I-Disease	O
retardation	I-Disease	O
(	I-Disease	O
XLMR	I-Disease	O
)	I-Disease	O
syndrome	I-Disease	O
that	O	O
affects	O	O
three	O	O
males	O	O
in	O	O
a	O	O
two	O	O
-	O	O
generation	O	O
family	O	O
.	O	O
A	O	O
single	O	O
-	O	O
nucleotide	O	O
substitution	O	O
,	O	O
c.382C-->T	B-Var	O
in	O	O
UBE2A	B-Gene	O
,	O	O
led	B-Reg	O
to	I-Reg	O
a	O	O
premature	O	O
UAG	O	O
stop	O	O
codon	O	O
(	B-Var	O
Q128X	I-Var	O
)	I-Var	O
.	O	O
As	O	O
a	O	O
consequence	O	O
,	O	O
the	O	O
predicted	O	O
polypeptide	O	O
lacks	O	O
the	O	O
25	O	O
C	O	O
-	O	O
terminal	O	O
amino	O	O
acid	O	O
residues	O	O
.	O	O
The	O	O
importance	O	O
of	O	O
this	O	O
terminal	O	O
sequence	O	O
for	O	O
UBE2	O	O
function	O	O
is	O	O
inferred	O	O
by	O	O
its	O	O
conservation	O	O
in	O	O
vertebrates	O	O
and	O	O
in	O	O
Drosophila	O	O
.	O	O
UBE2A	O	O
mutations	O	O
do	O	O
not	O	O
appear	O	O
to	O	O
significantly	O	O
contribute	O	O
to	O	O
XLMR	O	O
,	O	O
since	O	O
no	O	O
UBE2A	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
15	O	O
families	O	O
with	O	O
nonsyndromic	O	O
and	O	O
4	O	O
families	O	O
with	O	O
syndromic	O	O
idiopathic	O	O
XLMR	O	O
previously	O	O
mapped	O	O
to	O	O
intervals	O	O
encompassing	O	O
this	O	O
gene	O	O
.	O	O
This	O	O
is	O	O
the	O	O
first	O	O
description	O	O
of	O	O
a	O	O
mutation	O	O
in	O	O
a	O	O
ubiquitin	O	O
-	O	O
conjugating	O	O
enzyme	O	O
gene	O	O
as	O	O
the	O	O
cause	O	O
of	O	O
a	O	O
human	O	O
disease	O	O
.	O	O
Twenty	O	O
-	O	O
one	O	O
novel	O	O
mutations	B-Var	O
in	O	O
the	O	O
GLB1	B-Gene	O
gene	O	O
identified	O	O
in	B-Reg	O
a	O	O
large	O	O
group	O	O
of	O	O
GM1-gangliosidosis	B-Disease	O
and	O	O
Morquio	B-Disease	O
B	I-Disease	O
patients	O	O
:	O	O
possible	O	O
common	O	O
origin	O	O
for	O	O
the	O	O
prevalent	O	O
p	O	O
.	O	O
R59H	O	O
mutation	O	O
among	O	O
gypsies	O	O
.	O	O
GM1-gangliosidosis	B-Disease	O
and	O	O
Morquio	B-Disease	O
B	I-Disease	O
disease	O	O
are	O	O
rare	O	O
lysosomal	O	O
storage	O	O
disorders	O	O
caused	B-Reg	O
by	I-Reg	O
beta	B-MPA	O
-	I-MPA	O
galactosidase	I-MPA	O
deficiency	B-NegReg	O
due	O	O
to	O	O
mutations	B-Var	O
in	O	O
the	O	O
GLB1	B-Gene	O
gene	O	O
.	O	O
Three	O	O
major	O	O
clinical	O	O
forms	O	O
of	O	O
GM1-gangliosidosis	O	O
have	O	O
been	O	O
established	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
age	O	O
of	O	O
onset	O	O
and	O	O
severity	O	O
of	O	O
symptoms	O	O
:	O	O
infantile	O	O
,	O	O
late	O	O
infantile	O	O
/	O	O
juvenile	O	O
,	O	O
and	O	O
adult	O	O
.	O	O
We	O	O
performed	O	O
mutation	O	O
analysis	O	O
on	O	O
30	O	O
GM1-gangliosidosis	O	O
and	O	O
five	O	O
Morquio	O	O
B	O	O
patients	O	O
,	O	O
mainly	O	O
of	O	O
Spanish	O	O
origin	O	O
,	O	O
and	O	O
all	O	O
the	O	O
causative	O	O
mutations	O	O
were	O	O
identified	O	O
.	O	O
Thirty	O	O
different	O	O
mutations	O	O
were	O	O
found	O	O
,	O	O
21	O	O
of	O	O
which	O	O
were	O	O
novel	O	O
.	O	O
With	O	O
the	O	O
exception	O	O
of	O	O
two	O	O
adults	O	O
and	O	O
one	O	O
juvenile	O	O
patient	O	O
,	O	O
all	O	O
the	O	O
GM1-gangliosidosis	O	O
patients	O	O
were	O	O
affected	O	O
by	O	O
the	O	O
infantile	O	O
form	O	O
.	O	O
Clinical	O	O
findings	O	O
are	O	O
presented	O	O
for	O	O
all	O	O
patients	O	O
.	O	O
We	O	O
report	O	O
the	O	O
association	O	O
of	O	O
the	O	O
novel	O	O
mutations	O	O
p	O	O
.	O	O
T420	O	O
K	O	O
and	O	O
p	O	O
.	O	O
L264S	O	O
with	O	O
the	O	O
adult	O	O
form	O	O
and	O	O
the	O	O
juvenile	O	O
form	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
the	O	O
novel	O	O
mutation	O	O
p	B-Var	O
.	I-Var	O
Y83C	I-Var	O
was	O	O
associated	B-Reg	O
with	I-Reg	O
Morquio	B-Disease	O
B	I-Disease	O
disease	O	O
.	O	O
Among	O	O
the	O	O
30	O	O
GM1-gangliosidosis	O	O
patients	O	O
,	O	O
6	O	O
were	O	O
of	O	O
Gypsy	O	O
origin	O	O
(	O	O
Roma	O	O
)	O	O
.	O	O
Moreover	O	O
,	O	O
those	O	O
six	O	O
Gypsy	O	O
patients	O	O
shared	O	O
not	O	O
only	O	O
the	O	O
same	O	O
mutation	O	O
(	O	O
p	O	O
.	O	O
R59H	O	O
)	O	O
but	O	O
also	O	O
a	O	O
common	O	O
haplotype	O	O
.	O	O
This	O	O
observation	O	O
indicates	O	O
a	O	O
possible	O	O
founder	O	O
effect	O	O
in	O	O
this	O	O
group	O	O
and	O	O
suggests	O	O
that	O	O
screening	O	O
of	O	O
the	O	O
p	O	O
.	O	O
R59H	O	O
mutation	O	O
may	O	O
be	O	O
appropriate	O	O
in	O	O
GM1-gangliosidosis	O	O
patients	O	O
of	O	O
Gypsy	O	O
origin	O	O
.	O	O
This	O	O
is	O	O
the	O	O
first	O	O
exhaustive	O	O
mutational	O	O
analysis	O	O
performed	O	O
in	O	O
a	O	O
large	O	O
group	O	O
of	O	O
Iberian	O	O
GM1-gangliosidosis	O	O
and	O	O
Morquio	O	O
B	O	O
patients	O	O
.	O	O
Misregulation	O	O
of	O	O
alternative	O	O
splicing	O	O
causes	O	O
pathogenesis	O	O
in	O	O
myotonic	O	O
dystrophy	O	O
.	O	O
Myotonic	B-Disease	O
dystrophy	I-Disease	O
(	O	O
DM	O	O
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
adult	O	O
onset	O	O
muscular	O	O
dystrophy	O	O
,	O	O
affects	O	O
skeletal	O	O
muscle	O	O
,	O	O
heart	O	O
,	O	O
and	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
.	O	O
Mortality	O	O
results	O	O
primarily	O	O
from	O	O
muscle	O	O
wasting	O	O
and	O	O
cardiac	O	O
arrhythmias	O	O
.	O	O
There	O	O
are	O	O
two	O	O
forms	O	O
of	O	O
the	O	O
disease	O	O
:	O	O
DM1	O	O
and	O	O
DM2	O	O
.	O	O
DM1	O	O
,	O	O
which	O	O
constitutes	O	O
98	O	O
%	O	O
of	O	O
cases	O	O
,	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
CTG	O	O
expansion	O	O
in	O	O
the	O	O
3	O	O
'	O	O
untranslated	O	O
region	O	O
(	O	O
UTR	O	O
)	O	O
of	O	O
the	O	O
DMPK	O	O
gene	O	O
.	O	O
DM2	B-Disease	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
CCTG	B-Var	O
expansion	I-Var	O
in	O	O
the	O	O
first	O	O
intron	O	O
of	O	O
the	O	O
ZNF9	B-Gene	O
gene	O	O
.	O	O
RNA	O	O
containing	O	O
CUG-	O	O
or	O	O
CCUG	O	O
-	O	O
expanded	O	O
repeats	O	O
are	O	O
transcribed	O	O
but	O	O
are	O	O
retained	O	O
in	O	O
the	O	O
nucleus	O	O
in	O	O
foci	O	O
.	O	O
Disease	O	O
pathogenesis	O	O
results	O	O
primarily	O	O
from	O	O
a	O	O
gain	B-PosReg	O
of	I-PosReg	O
function	I-PosReg	O
of	O	O
the	O	O
expanded	B-MPA	O
RNAs	I-MPA	O
,	O	O
which	O	O
alter	B-Reg	O
developmentally	B-MPA	O
regulated	I-MPA	O
alternative	I-MPA	O
splicing	I-MPA	O
as	O	O
well	O	O
as	O	O
pathways	B-Pathway	O
of	I-Pathway	O
muscle	I-Pathway	O
differentiation	I-Pathway	O
.	O	O
The	O	O
toxic	O	O
RNA	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
sequestration	O	O
of	O	O
splicing	O	O
regulators	O	O
and	O	O
transcription	O	O
factors	O	O
thereby	O	O
causing	O	O
specific	O	O
symptoms	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
Here	O	O
we	O	O
review	O	O
the	O	O
proposed	O	O
mechanisms	O	O
for	O	O
the	O	O
toxic	O	O
effects	O	O
of	O	O
the	O	O
expanded	O	O
repeats	O	O
and	O	O
discuss	O	O
the	O	O
molecular	O	O
mechanisms	O	O
of	O	O
splicing	O	O
misregulation	O	O
and	O	O
disease	O	O
pathogenesis	O	O
.	O	O
Clinical	O	O
aspects	O	O
and	O	O
physiopathology	O	O
of	O	O
Brugada	O	O
syndrome	O	O
:	O	O
review	O	O
of	O	O
current	O	O
concepts	O	O
.	O	O
Brugada	B-Disease	O
syndrome	I-Disease	O
(	O	O
BS	O	O
)	O	O
is	O	O
an	O	O
inherited	O	O
cardiac	O	O
disorder	O	O
characterized	O	O
by	O	O
typical	O	O
electrocardiographic	O	O
patterns	O	O
of	O	O
ST	O	O
segment	O	O
elevation	O	O
in	O	O
the	O	O
precordial	O	O
leads	O	O
,	O	O
right	O	O
bundle	O	O
branch	O	O
block	O	O
,	O	O
fast	O	O
polymorphic	O	O
ventricular	O	O
tachycardia	O	O
in	O	O
patients	O	O
without	O	O
any	O	O
structural	O	O
heart	O	O
disease	O	O
,	O	O
and	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
sudden	O	O
cardiac	O	O
death	O	O
.	O	O
The	O	O
incidence	O	O
of	O	O
BS	O	O
is	O	O
high	O	O
in	O	O
male	O	O
vs.	O	O
female	O	O
(	O	O
i.e.	O	O
,	O	O
8	O	O
-	O	O
10/1	O	O
:	O	O
male	O	O
/	O	O
female	O	O
)	O	O
.	O	O
The	O	O
disorder	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
SCN5A	O	O
gene	O	O
encoding	O	O
Nav1.5	O	O
,	O	O
the	O	O
cardiac	O	O
sodium	O	O
channel	O	O
,	O	O
which	O	O
is	O	O
the	O	O
only	O	O
gene	O	O
in	O	O
which	O	O
mutations	O	O
were	O	O
found	O	O
to	O	O
cause	O	O
the	O	O
disease	O	O
.	O	O
Mutations	B-Var	O
in	O	O
SCN5A	B-Gene	O
associated	O	O
with	O	O
the	O	O
BS	B-Disease	O
phenotype	O	O
usually	O	O
result	O	O
in	O	O
a	O	O
loss	B-NegReg	O
of	O	O
channel	B-CPA	O
function	I-CPA	O
by	O	O
a	O	O
reduction	B-NegReg	O
in	O	O
Na+	B-CPA	O
currents	I-CPA	O
.	O	O
We	O	O
review	O	O
the	O	O
clinical	O	O
aspects	O	O
,	O	O
risk	O	O
stratification	O	O
,	O	O
and	O	O
therapeutic	O	O
management	O	O
of	O	O
this	O	O
important	O	O
syndrome	O	O
.	O	O
[	O	O
McLeod	O	O
syndrome	O	O
:	O	O
Multisystem	O	O
involvement	O	O
associated	O	O
with	O	O
neuroacanthocytosis	O	O
linked	O	O
to	O	O
X	O	O
chromosome	O	O
.	O	O
report	O	O
of	O	O
two	O	O
related	O	O
cases	O	O
]	O	O
.	O	O
Síndrome	O	O
de	O	O
McLeod	O	O
:	O	O
compromiso	O	O
multisistémico	O	O
asociado	O	O
a	O	O
neuroacantocitosis	O	O
ligada	O	O
al	O	O
cromosoma	O	O
X	O	O
,	O	O
en	O	O
una	O	O
familia	O	O
chilena	O	O
.	O	O
Neurological	O	O
abnormalities	O	O
associated	O	O
with	O	O
spiculated	O	O
,	O	O
"	O	O
acanthocytic	O	O
"	O	O
red	O	O
cells	O	O
in	O	O
blood	O	O
have	O	O
been	O	O
described	O	O
as	O	O
neuroacanthocytosis	O	O
.	O	O
This	O	O
is	O	O
a	O	O
heterogeneous	O	O
group	O	O
of	O	O
conditions	O	O
that	O	O
can	O	O
be	O	O
clearly	O	O
subdivided	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
recent	O	O
genetic	O	O
findings	O	O
.	O	O
The	O	O
McLeod	B-Disease	O
Syndrome	I-Disease	O
,	O	O
one	O	O
of	O	O
the	O	O
core	O	O
neuroacanthocytosis	B-Disease	O
syndromes	I-Disease	O
,	O	O
is	O	O
a	O	O
rare	O	O
X	O	O
-	O	O
linked	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
of	O	O
the	O	O
XK	B-Gene	O
gene	O	O
,	O	O
an	O	O
X	O	O
-	O	O
chromosomal	O	O
gene	O	O
of	O	O
unknown	O	O
function	O	O
characterized	O	O
by	O	O
haemopoietic	O	O
abnormalities	O	O
and	O	O
late	O	O
-	O	O
onset	O	O
neurological	O	O
and	O	O
muscular	O	O
defects	O	O
.	O	O
We	O	O
report	O	O
two	O	O
Chilean	O	O
brothers	O	O
with	O	O
the	O	O
McLeod	O	O
phenotype	O	O
who	O	O
showed	O	O
important	O	O
psychiatric	O	O
features	O	O
.	O	O
The	O	O
diagnosis	O	O
may	O	O
be	O	O
elusive	O	O
if	O	O
the	O	O
presence	O	O
of	O	O
acanthocytosis	O	O
is	O	O
not	O	O
properly	O	O
studied	O	O
.	O	O
We	O	O
describe	O	O
a	O	O
method	O	O
which	O	O
allowed	O	O
the	O	O
diagnosis	O	O
that	O	O
unmasked	O	O
acanthocytosis	O	O
.	O	O
Otherwise	O	O
the	O	O
condition	O	O
could	O	O
have	O	O
remained	O	O
undiagnosed	O	O
as	O	O
it	O	O
had	O	O
been	O	O
for	O	O
decades	O	O
in	O	O
this	O	O
family	O	O
.	O	O
This	O	O
syndrome	O	O
must	O	O
be	O	O
considered	O	O
when	O	O
assessing	O	O
a	O	O
familial	O	O
movement	O	O
disorder	O	O
,	O	O
specially	O	O
affecting	O	O
males	O	O
with	O	O
relevant	O	O
psychiatric	O	O
features	O	O
.	O	O
A	O	O
reliable	O	O
test	O	O
for	O	O
acanthocytosis	O	O
assessment	O	O
is	O	O
available	O	O
.	O	O
A	O	O
new	O	O
variant	O	O
database	O	O
for	O	O
mismatch	O	O
repair	O	O
genes	O	O
associated	O	O
with	O	O
Lynch	O	O
syndrome	O	O
.	O	O
Mutations	B-Var	O
in	O	O
some	O	O
mismatch	O	O
repair	O	O
(	B-Gene	O
MMR	I-Gene	O
)	I-Gene	O
genes	O	O
are	O	O
associated	B-Reg	O
with	I-Reg	O
Lynch	B-Disease	O
syndrome	I-Disease	O
(	O	O
LS	O	O
;	O	O
also	O	O
called	O	O
hereditary	O	O
nonpolyposis	O	O
colorectal	O	O
cancer	O	O
[	O	O
HNPCC	O	O
]	O	O
)	O	O
,	O	O
an	O	O
autosomal	O	O
dominant	O	O
cancer	O	O
susceptibility	O	O
syndrome	O	I-Disease
.	O	O
Colorectal	O	B-Disease
cancer	O	I-Disease
(	O	O
CRC	O	O
)	O	O
is	O	O
the	O	O
most	O	O
frequent	O	O
cancer	O	O
observed	O	O
in	O	O
LS	O	O
.	O	O
However	O	O
,	O	O
tumors	O	O
occur	O	O
at	O	O
a	O	O
variety	O	O
of	O	O
extracolonic	O	O
sites	O	O
and	O	O
individuals	O	O
may	O	O
have	O	O
multiple	O	O
primary	O	O
cancers	O	O
.	O	O
LS	O	O
is	O	O
the	O	O
most	O	O
common	O	O
hereditary	O	O
form	O	O
of	O	O
CRC	O	O
,	O	O
accounting	O	O
for	O	O
approximately	O	O
1	O	O
%	O	O
of	O	O
all	O	O
CRC	O	O
.	O	O
Since	O	O
the	O	O
first	O	O
account	O	O
of	O	O
mutations	B-Var	O
in	O	O
MSH2	B-Gene	O
causing	B-Reg	O
this	O	O
cancer	B-Disease	O
susceptibility	O	O
syndrome	O	O
in	O	O
1993	O	O
,	O	O
mutations	B-Var	O
in	O	O
three	O	O
additional	O	O
MMR	O	O
genes	O	O
,	O	O
MLH1	B-Gene	O
,	O	O
MSH6	B-Gene	O
,	O	O
and	O	O
PMS2	B-Gene	O
,	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
cause	B-Reg	O
LS	B-Disease	O
.	O	O
More	O	O
than	O	O
1,500	O	O
different	O	O
variants	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
these	O	O
four	O	O
genes	O	O
and	O	O
approximately	O	O
80	O	O
%	O	O
of	O	O
the	O	O
alterations	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
MLH1	O	O
and	O	O
MSH2	O	O
.	O	O
There	O	O
have	O	O
been	O	O
a	O	O
few	O	O
previous	O	O
attempts	O	O
to	O	O
systematically	O	O
record	O	O
MMR	O	O
variants	O	O
associated	O	O
with	O	O
LS	O	O
patients	O	O
;	O	O
however	O	O
,	O	O
they	O	O
were	O	O
not	O	O
complete	O	O
nor	O	O
were	O	O
they	O	O
continuously	O	O
updated	O	O
.	O	O
Thus	O	O
,	O	O
it	O	O
was	O	O
our	O	O
goal	O	O
to	O	O
generate	O	O
and	O	O
maintain	O	O
a	O	O
comprehensive	O	O
catalogue	O	O
of	O	O
MMR	O	O
variants	O	O
from	O	O
genes	O	O
known	O	O
to	O	O
be	O	O
mutated	O	O
in	O	O
LS	O	O
(	O	O
http://www.med.mun.ca/MMRvariants	O	O
;	O	O
last	O	O
accessed	O	O
8	O	O
February	O	O
2007	O	O
)	O	O
.	O	O
Providing	O	O
such	O	O
a	O	O
resource	O	O
should	O	O
aid	O	O
investigators	O	O
in	O	O
understanding	O	O
the	O	O
significance	O	O
of	O	O
the	O	O
variants	O	O
.	O	O
Complete	O	O
androgen	O	O
insensitivity	O	O
without	O	O
Wolffian	O	O
duct	O	O
development	O	O
:	O	O
the	O	O
AR	O	O
-	O	O
A	O	O
form	O	O
of	O	O
the	O	O
androgen	O	O
receptor	O	O
is	O	O
not	O	O
sufficient	O	O
for	O	O
male	O	O
genital	O	O
development	O	O
.	O	O
BACKGROUND	O	O
:	O	O
The	O	O
androgen	O	O
receptor	O	O
(	O	O
AR	O	O
)	O	O
is	O	O
essential	O	O
for	O	O
the	O	O
differentiation	O	O
of	O	O
male	O	O
external	O	O
and	O	O
internal	O	O
genitalia	O	O
.	O	O
It	O	O
is	O	O
normally	O	O
present	O	O
in	O	O
two	O	O
forms	O	O
,	O	O
a	O	O
full	O	O
-	O	O
length	O	O
form	O	O
B	O	O
and	O	O
an	O	O
N	O	O
-	O	O
terminal	O	O
truncated	O	O
form	O	O
A	O	O
with	O	O
still	O	O
unknown	O	O
function	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
AR	B-Gene	O
gene	O	O
cause	B-Reg	O
androgen	B-Disease	B-Disease
insensitivity	I-Disease	I-Disease
syndrome	I-Disease	I-Disease
(	O	O
AIS	O	O
)	O	O
,	O	O
which	O	O
is	O	O
divided	O	O
into	O	O
subgroups	O	O
according	O	O
to	O	O
the	O	O
degree	O	O
of	O	O
undermasculinization	O	O
.	O	O
Patients	O	O
with	O	O
completely	O	O
female	O	O
external	O	O
genitalia	O	O
are	O	O
classified	O	O
as	O	O
complete	O	O
AIS	O	O
(	O	O
CAIS	O	O
)	O	O
.	O	O
However	O	O
,	O	O
a	O	O
recent	O	O
study	O	O
has	O	O
shown	O	O
that	O	O
some	O	O
CAIS	O	O
patients	O	O
have	O	O
signs	O	O
of	O	O
internal	O	O
male	O	O
genital	O	O
differentiation	O	O
due	O	O
to	O	O
missense	O	O
mutations	O	O
that	O	O
show	O	O
some	O	O
degree	O	O
of	O	O
residual	O	O
function	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
We	O	O
aimed	O	O
to	O	O
study	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
different	O	O
forms	O	O
of	O	O
the	O	O
AR	O	O
in	O	O
two	O	O
CAIS	O	O
patients	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
development	O	O
of	O	O
male	O	O
internal	O	O
genital	O	O
structures	O	O
.	O	O
One	O	O
patient	O	O
had	O	O
a	O	O
mutation	O	O
(	O	O
L7fsX33	O	O
)	O	O
that	O	O
affects	O	O
only	O	O
the	O	O
full	O	O
-	O	O
length	O	O
AR	O	O
-	O	O
B	O	O
form	O	O
of	O	O
the	O	O
AR	O	O
,	O	O
whereas	O	O
the	O	O
other	O	O
had	O	O
a	O	O
nonsense	O	O
mutation	O	O
(	O	O
Q733X	O	O
)	O	O
affecting	O	O
both	O	O
isoforms	O	O
.	O	O
MEASUREMENTS	O	O
AND	O	O
RESULTS	O	O
:	O	O
We	O	O
thoroughly	O	O
analysed	O	O
internal	O	O
genitalia	O	O
at	O	O
surgery	O	O
and	O	O
by	O	O
histological	O	O
examination	O	O
.	O	O
No	O	O
signs	O	O
of	O	O
Wolffian	O	O
duct	O	O
(	O	O
WD	O	O
)	O	O
development	O	O
were	O	O
present	O	O
in	O	O
any	O	O
of	O	O
the	O	O
patients	O	O
.	O	O
Western	O	O
blotting	O	O
of	O	O
proteins	O	O
from	O	O
gonadal	O	O
and	O	O
genital	O	O
skin	O	O
fibroblasts	O	O
was	O	O
performed	O	O
with	O	O
AR	O	O
antibodies	O	O
directed	O	O
against	O	O
different	O	O
AR	O	O
epitopes	O	O
.	O	O
The	O	O
N	O	O
-	O	O
terminally	O	O
truncated	O	O
A	O	O
form	O	O
was	O	O
expressed	O	O
in	O	O
normal	O	O
amounts	O	O
in	O	O
the	O	O
patient	O	O
with	O	O
the	O	O
L7fsX33	O	O
mutation	O	O
while	O	O
no	O	O
AR	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
other	O	O
patient	O	O
.	O	O
CONCLUSION	O	O
:	O	O
The	O	O
presence	O	O
of	O	O
the	O	O
AR	O	O
-	O	O
A	O	O
form	O	O
does	O	O
not	O	O
seem	O	O
to	O	O
be	O	O
sufficient	O	O
for	O	O
WD	O	O
maintenance	O	O
and	O	O
differentiation	O	O
.	O	O
Comprehensive	O	O
analysis	O	O
of	O	O
the	O	O
gene	O	O
encoding	O	O
filaggrin	O	O
uncovers	O	O
prevalent	O	O
and	O	O
rare	O	O
mutations	O	O
in	O	O
ichthyosis	O	O
vulgaris	O	O
and	O	O
atopic	O	O
eczema	O	O
.	O	O
We	O	O
recently	O	O
reported	O	O
two	O	O
common	O	O
filaggrin	O	O
(	B-Gene	O
FLG	I-Gene	O
)	I-Gene	O
null	O	O
mutations	B-Var	O
that	O	O
cause	B-Reg	O
ichthyosis	B-Disease	O
vulgaris	I-Disease	B-CPA
and	O	O
predispose	B-Disease	B-CPA
to	I-Disease	O
eczema	I-Disease	I-CPA
and	O	O
secondary	B-Disease	O
allergic	I-Disease	O
diseases	I-Disease	O
.	O	O
We	O	O
show	O	O
here	O	O
that	O	O
these	O	O
common	O	O
European	O	O
mutations	O	O
are	O	O
ancestral	O	O
variants	O	O
carried	O	O
on	O	O
conserved	O	O
haplotypes	O	O
.	O	O
To	O	O
facilitate	O	O
comprehensive	O	O
analysis	O	O
of	O	O
other	O	O
populations	O	O
,	O	O
we	O	O
report	O	O
a	O	O
strategy	O	O
for	O	O
full	O	O
sequencing	O	O
of	O	O
this	O	O
large	O	O
,	O	O
highly	O	O
repetitive	O	O
gene	O	O
,	O	O
and	O	O
we	O	O
describe	O	O
15	O	O
variants	O	O
,	O	O
including	O	O
seven	O	O
that	O	O
are	O	O
prevalent	O	O
.	O	O
All	O	O
the	O	O
variants	B-Var	O
are	O	O
either	O	O
nonsense	O	O
or	O	O
frameshift	O	B-Var
mutations	O	I-Var
that	O	O
,	O	O
in	O	O
representative	O	O
cases	O	O
,	O	O
resulted	O	O
in	O	O
loss	B-NegReg	B-NegReg
of	O	O
filaggrin	B-MPA	O
production	I-MPA	B-MPA
in	O	O
the	O	O
epidermis	O	O
.	O	O
In	O	O
an	O	O
Irish	O	O
case	O	O
-	O	O
control	O	O
study	O	O
,	O	O
the	O	O
five	O	O
most	O	O
common	O	O
European	O	O
mutations	O	O
showed	O	O
a	O	O
strong	O	O
association	O	O
with	O	O
moderate	O	O
-	O	O
to	O	O
-	O	O
severe	O	O
childhood	O	O
eczema	O	O
(	O	O
chi2	O	O
test	O	O
:	O	O
P	O	O
=	O	O
2.12	O	O
x	O	O
10(-51	O	O
)	O	O
;	O	O
Fisher	O	O
's	O	O
exact	O	O
test	O	O
:	O	O
heterozygote	O	O
odds	O	O
ratio	O	O
(	O	O
OR	O	O
)	O	O
=	O	O
7.44	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
c.i	O	O
.	O	O
)	O	O
=	O	O
4.9	O	O
-	O	O
11.3	O	O
)	O	O
,	O	O
and	O	O
homozygote	O	O
OR	O	O
=	O	O
151	O	O
(	O	O
95	O	O
%	O	O
c.i	O	O
.	O	O
=	O	O
20	O	O
-	O	O
1,136	O	O
)	O	O
)	O	O
.	O	O
We	O	O
found	O	O
three	O	O
additional	O	O
rare	O	O
null	O	O
mutations	O	O
in	O	O
this	O	O
case	O	O
series	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
genetic	O	O
architecture	O	O
of	O	O
filaggrin	O	O
-	O	O
related	O	O
atopic	O	O
dermatitis	O	O
consists	O	O
of	O	O
both	O	O
prevalent	O	O
and	O	O
rare	O	O
risk	O	O
alleles	O	O
.	O	O
Increased	O	O
chromosome	O	O
instability	O	O
and	O	O
accumulation	O	O
of	O	O
DNA	O	O
double	O	O
-	O	O
strand	O	O
breaks	O	O
in	O	O
Werner	O	O
syndrome	O	O
cells	O	O
.	O	O
Werner	B-Disease	B-Disease
syndrome	I-Disease	I-Disease
(	O	O
WS	O	O
)	O	O
is	O	O
a	O	O
premature	O	O
aging	O	B-Disease
syndrome	O	I-Disease
caused	B-Reg	B-Reg
by	I-Reg	O
mutations	B-Var	B-Var
of	O	O
the	O	O
WRN	B-Gene	B-Gene
gene	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
a	O	O
strain	O	O
of	O	O
WS	O	O
fibroblast	O	O
cells	O	O
shows	O	O
abnormal	O	O
karyotypes	O	O
characterized	O	O
by	O	O
several	O	O
complex	O	O
translocations	O	O
and	O	O
50-fold	O	O
more	O	O
frequency	O	O
of	O	O
abnormal	O	O
metaphases	O	O
including	O	O
dicentric	O	O
chromosomes	O	O
without	O	O
fragments	O	O
than	O	O
normal	O	O
cells	O	O
when	O	O
examined	O	O
at	O	O
a	O	O
similar	O	O
culture	O	O
stage	O	O
.	O	O
Further	O	O
,	O	O
telomere	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
indicates	O	O
that	O	O
the	O	O
abnormal	O	O
signals	O	O
,	O	O
extra	O	O
telomere	O	O
signal	O	O
and	O	O
loss	O	O
of	O	O
telomere	O	O
signal	O	O
,	O	O
emerge	O	O
two-	O	O
to	O	O
three	O	O
-	O	O
fold	O	O
more	O	O
frequently	O	O
in	O	O
WS	O	O
cells	O	O
than	O	O
in	O	O
normal	O	O
cells	O	O
.	O	O
Taken	O	O
together	O	O
,	O	O
these	O	O
results	O	O
indicate	O	O
that	O	O
chromosome	O	O
instability	O	O
including	O	O
dysfunction	O	O
of	O	O
telomere	O	O
maintenance	O	O
is	O	O
more	O	O
prominent	O	O
in	O	O
WS	O	O
cells	O	O
than	O	O
in	O	O
normal	O	O
cells	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
the	O	O
accumulation	O	O
of	O	O
DNA	O	O
double	O	O
-	O	O
strand	O	O
breaks	O	O
(	O	O
DSBs	O	O
)	O	O
at	O	O
the	O	O
G(1	O	O
)	O	O
phase	O	O
,	O	O
including	O	O
those	O	O
at	O	O
telomeres	O	O
,	O	O
detected	O	O
by	O	O
phosphorylated	O	O
ATM	O	O
(	O	O
ataxia	O	O
telangiectasia	O	O
mutated	O	O
)	O	O
foci	O	O
is	O	O
accelerated	O	O
in	O	O
WS	O	O
cells	O	O
even	O	O
at	O	O
a	O	O
low	O	O
senescence	O	O
level	O	O
.	O	O
The	O	O
increased	O	B-PosReg
accumulation	O	B-PosReg
of	O	O
DSBs	O	O
in	O	O
WS	O	O
cells	O	O
is	O	O
reduced	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
anti	O	O
-	O	O
oxidative	O	O
agents	O	O
,	O	O
suggesting	O	O
that	O	O
enhanced	O	B-PosReg
oxidative	O	B-PosReg
stress	O	I-CPA
in	O	O
WS	O	O
cells	O	O
is	O	O
involved	O	O
in	O	O
accelerated	O	O
accumulation	O	O
of	O	O
DSBs	O	O
.	O	O
These	O	O
results	O	O
indicate	O	O
that	O	O
WS	O	O
cells	O	O
are	O	O
prone	O	O
to	O	O
accumulate	B-PosReg	O
DSBs	B-MPA	O
spontaneously	O	O
due	O	O
to	O	O
a	O	O
defect	B-Var	O
of	O	O
WRN	B-Gene	O
,	O	O
which	O	O
leads	O	O
to	O	O
increased	B-PosReg	B-PosReg
chromosome	B-MPA	O
instability	I-MPA	O
that	O	O
could	O	O
activate	B-PosReg	O
checkpoints	B-MPA	O
,	O	O
resulting	O	O
in	O	O
accelerated	B-PosReg	O
senescence	B-CPA	O
.	O	O
A	O	O
novel	O	O
mutation	B-Var	O
in	O	O
TRIM37	B-Gene	O
is	O	O
associated	B-Reg	O
with	I-Reg	O
mulibrey	B-Disease	O
nanism	I-Disease	O
in	O	O
a	O	O
Turkish	O	O
boy	O	O
.	O	O
Mulibrey	O	O
nanism	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
-	O	O
recessive	O	O
disorder	O	O
characterized	O	O
by	O	O
prenatal	O	O
onset	O	O
severe	O	O
growth	O	O
retardation	O	O
and	O	O
pericardial	O	O
constriction	O	O
associated	O	O
with	O	O
abnormalities	O	O
of	O	O
muscle	O	O
,	O	O
liver	O	O
,	O	O
brain	O	O
and	O	O
eye	O	O
.	O	O
More	O	O
than	O	O
80	O	O
%	O	O
of	O	O
previously	O	O
reported	O	O
patients	O	O
are	O	O
of	O	O
Finnish	O	O
origin	O	O
in	O	O
whom	O	O
a	O	O
founder	O	O
mutation	O	O
in	O	O
the	O	O
TRIM37	O	O
gene	O	O
have	O	O
been	O	O
described	O	O
.	O	O
We	O	O
report	O	O
on	O	O
a	O	O
7-year	O	O
-	O	O
old	O	O
Turkish	O	O
boy	O	O
who	O	O
presented	O	O
with	O	O
classical	O	O
phenotypic	O	O
features	O	O
of	O	O
mulibrey	O	O
nanism	O	O
.	O	O
Mutation	O	O
screening	O	O
of	O	O
the	O	O
TRIM37	O	O
gene	O	O
revealed	O	O
that	O	O
the	O	O
proband	O	O
had	O	O
a	O	O
homozygous	O	O
two	O	O
base	O	O
pair	O	O
deletion	O	O
,	O	O
c.1894_1895delGA	B-Var	O
,	O	O
resulting	B-Reg	O
in	I-Reg	O
a	O	O
frame	B-Var	O
-	I-Var	O
shift	I-Var	O
and	O	O
a	O	O
premature	B-MPA	O
termination	I-MPA	O
codon	O	O
.	O	O
Our	O	O
proband	O	O
is	O	O
one	O	O
of	O	O
the	O	O
rare	O	O
examples	O	O
of	O	O
mulibrey	O	O
nanism	O	O
outside	O	O
Finland	O	O
and	O	O
extends	O	O
the	O	O
mutation	O	O
spectrum	O	O
in	O	O
this	O	O
disorder	O	O
.	O	O
Phenotype	O	O
-	O	O
genotype	O	O
correlation	O	O
in	O	O
eight	O	O
Polish	O	O
patients	O	O
with	O	O
inherited	O	O
Factor	O	O
XIII	O	O
deficiency	O	O
:	O	O
identification	O	O
of	O	O
three	O	O
novel	O	O
mutations	O	O
.	O	O
Inherited	B-Disease	O
factor	I-Disease	O
XIII	I-Disease	O
(	O	O
FXIII	O	O
)	O	O
deficiency	O	O
is	O	O
known	O	O
as	O	O
one	O	O
of	O	O
the	O	O
most	O	O
rare	O	O
blood	O	O
coagulation	O	O
disorder	O	O
in	O	O
humans	O	O
.	O	O
In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
phenotype	O	O
and	O	O
genotype	O	O
of	O	O
eight	O	O
FXIII	O	O
deficient	O	O
Polish	O	O
patients	O	O
from	O	O
five	O	O
unrelated	O	O
families	O	O
were	O	O
compared	O	O
.	O	O
The	O	O
patients	O	O
presented	O	O
with	O	O
a	O	O
severe	O	O
phenotype	O	O
demonstrated	O	O
by	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
intracerebral	O	O
haemorrhages	O	O
(	O	O
seven	O	O
of	O	O
eight	O	O
patients	O	O
)	O	O
,	O	O
haemarthrosis	O	O
(	O	O
six	O	O
patients	O	O
)	O	O
and	O	O
bleeding	O	O
due	O	O
to	O	O
trauma	O	O
(	O	O
five	O	O
patients	O	O
)	O	O
.	O	O
Introduction	O	O
of	O	O
regular	O	O
substitution	O	O
with	O	O
FXIII	O	O
concentrate	O	O
prevented	O	O
spontaneous	O	O
bleeding	O	O
in	O	O
seven	O	O
patients	O	O
.	O	O
In	O	O
all	O	O
patients	O	O
,	O	O
mutations	O	O
within	O	O
the	O	O
F13A	B-Gene	O
gene	O	O
have	O	O
been	O	O
identified	O	O
revealing	O	O
four	O	O
missense	O	O
mutations	O	O
(	B-Var	O
Arg77Cys	I-Var	O
,	O	O
Arg260Cys	B-Var	O
,	O	O
Ala378Pro	B-Var	O
,	O	O
Gly420Ser	B-Var	O
)	I-Var	O
,	O	O
one	O	O
nonsense	O	O
mutation	O	O
(	B-Var	O
Arg661X	I-Var	O
)	I-Var	O
,	O	O
one	O	O
splice	O	O
site	O	O
mutation	O	O
(	B-Var	O
IVS5	I-Var	O
-	I-Var	O
1	I-Var	O
G	I-Var	O
>	I-Var	O
A	I-Var	O
)	I-Var	O
and	O	O
one	O	O
small	O	O
deletion	O	O
(	B-Var	O
c.499	I-Var	O
-	I-Var	O
512del	I-Var	O
)	I-Var	O
.	O	O
One	O	O
homozygous	O	O
large	O	O
deletion	O	O
involving	O	O
exon	O	O
15	O	O
was	O	O
detected	O	O
by	O	O
failure	O	O
of	O	O
PCR	O	O
product	O	O
.	O	O
The	O	O
corresponding	O	O
mutations	B-Var	O
resulted	O	O
in	O	O
severely	O	O
reduced	B-NegReg	B-NegReg
FXIII	B-MPA	O
activity	I-MPA	I-MPA
and	O	O
FXIII	B-MPA	O
A	I-MPA	O
-	I-MPA	O
subunit	I-MPA	O
antigen	I-MPA	O
concentration	I-MPA	O
,	O	O
while	O	O
FXIII	O	O
B	O	O
-	O	O
subunit	O	O
antigen	O	O
remained	O	O
normal	O	O
or	O	O
mildly	O	O
decreased	O	O
.	O	O
Structural	O	O
analysis	O	O
demonstrated	O	O
that	O	O
the	O	O
novel	O	O
Ala378Pro	B-Var	O
mutation	O	O
may	O	O
cause	O	O
a	O	O
disruption	B-NegReg	O
of	O	O
the	O	O
FXIII	B-MPA	O
catalytic	I-MPA	O
triad	I-MPA	O
leading	O	O
to	O	O
a	O	O
non	B-NegReg	O
-	I-NegReg	O
functional	I-NegReg	O
protein	B-Protein	O
which	O	O
presumably	O	O
undergoes	O	O
premature	B-MPA	O
degradation	I-MPA	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
the	O	O
severe	O	O
phenotype	O	O
with	O	O
high	O	O
incidence	O	O
of	O	O
intracranial	O	O
bleeding	O	O
and	O	O
haemarthrosis	O	O
was	O	O
in	O	O
accordance	O	O
with	O	O
laboratory	O	O
findings	O	O
on	O	O
FXIII	O	O
and	O	O
with	O	O
severe	O	O
molecular	O	O
defects	O	O
of	O	O
the	O	O
F13A	O	O
gene	O	O
.	O	O
Effects	O	O
of	O	O
prolonged	O	O
dark	O	O
adaptation	O	O
in	O	O
patients	O	O
with	O	O
retinitis	O	O
pigmentosa	O	O
of	O	O
Bothnia	O	O
type	O	O
:	O	O
an	O	O
electrophysiological	O	O
study	O	O
.	O	O
Bothnia	B-Disease	O
dystrophy	I-Disease	O
(	O	O
BD	O	O
)	O	O
is	O	O
a	O	O
variant	O	O
of	O	O
recessive	O	O
retinitis	O	O
punctata	O	O
albescens	O	O
(	O	O
RPA	O	O
)	O	O
,	O	O
caused	B-Reg	O
by	I-Reg	O
the	O	O
missense	O	O
mutation	O	O
R233W	B-Var	O
in	O	O
cellular	O	O
retinaldehyde	O	O
-	O	O
binding	O	O
protein	O	O
(	B-Protein	O
CRALBP	I-Protein	O
)	I-Protein	O
,	O	O
which	O	O
is	O	O
localized	O	O
in	O	O
the	O	O
retinal	O	O
pigment	O	O
epithelium	O	O
(	O	O
RPE	O	O
)	O	O
and	O	O
Müller	O	O
cells	O	O
of	O	O
the	O	O
retina	O	O
.	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
,	O	O
by	O	O
examining	O	O
the	O	O
electrophysiological	O	O
responses	O	O
of	O	O
the	O	O
retina	O	O
,	O	O
to	O	O
evaluate	O	O
the	O	O
capacity	O	O
of	O	O
recovery	O	O
of	O	O
the	O	O
whole	O	O
retinal	O	O
area	O	O
and	O	O
different	O	O
cell	O	O
types	O	O
induced	O	O
by	O	O
extremely	O	O
prolonged	O	O
dark	O	O
adaptation	O	O
(	O	O
DA	O	O
)	O	O
in	O	O
BD	O	O
disease	O	O
and	O	O
to	O	O
gain	O	O
further	O	O
understanding	O	O
of	O	O
the	O	O
pathogenesis	O	O
of	O	O
BD	O	O
.	O	O
Six	O	O
young	O	O
patients	O	O
underwent	O	O
bilateral	O	O
full	O	O
-	O	O
field	O	O
ERGs	O	O
after	O	O
24	O	O
h	O	O
of	O	O
DA	O	O
in	O	O
one	O	O
eye	O	O
and	O	O
standard	O	O
DA	O	O
in	O	O
the	O	O
fellow	O	O
eye	O	O
.	O	O
The	O	O
results	O	O
were	O	O
also	O	O
compared	O	O
with	O	O
the	O	O
effect	O	O
of	O	O
prolonged	O	O
DA	O	O
(	O	O
10	O	O
h	O	O
)	O	O
,	O	O
previously	O	O
studied	O	O
in	O	O
the	O	O
same	O	O
patients	O	O
.	O	O
After	O	O
extremely	O	O
prolonged	O	O
DA	O	O
(	O	O
24	O	O
h	O	O
)	O	O
the	O	O
rod	O	O
b	O	O
-	O	O
wave	O	O
and	O	O
the	O	O
mixed	O	O
rod	O	O
-	O	O
cone	O	O
a	O	O
-	O	O
wave	O	O
responses	O	O
reached	O	O
normal	O	O
though	O	O
delayed	O	O
amplitudes	O	O
.	O	O
An	O	O
increase	O	O
,	O	O
up	O	O
to	O	O
normal	O	O
level	O	O
,	O	O
in	O	O
the	O	O
oscillatory	O	O
response	O	O
was	O	O
found	O	O
.	O	O
There	O	O
was	O	O
no	O	O
obvious	O	O
recovery	O	O
of	O	O
the	O	O
cone	O	O
response	O	O
.	O	O
We	O	O
conclude	O	O
that	O	O
in	O	O
young	O	O
BD	O	O
patients	O	O
during	O	O
extremely	O	O
prolonged	O	O
DA	O	O
there	O	O
is	O	O
a	O	O
significant	O	O
additional	O	O
capacity	O	O
of	O	O
recovery	O	O
of	O	O
rod	O	O
function	O	O
and	O	O
also	O	O
significant	O	O
gain	O	O
of	O	O
activity	O	O
in	O	O
the	O	O
inner	O	O
retinal	O	O
layer	O	O
.	O	O
A	O	O
continuous	O	O
but	O	O
slow	O	O
regeneration	O	O
of	O	O
rod	O	O
photopigment	O	O
seems	O	O
to	O	O
occur	O	O
at	O	O
least	O	O
up	O	O
to	O	O
24	O	O
h.	O	O
The	O	O
visual	O	O
process	O	O
in	O	O
the	O	O
RPE	O	O
is	O	O
retarded	O	O
and	O	O
CRALBP	O	O
acts	O	O
in	O	O
this	O	O
process	O	O
;	O	O
also	O	O
,	O	O
the	O	O
Müller	O	O
cells	O	O
of	O	O
the	O	O
retina	O	O
seem	O	O
to	O	O
be	O	O
involved	O	O
.	O	O
The	O	O
findings	O	O
also	O	O
support	O	O
an	O	O
extremely	O	O
slow	O	O
synthesis	O	O
of	O	O
photopigments	O	O
and	O	O
irreversibly	O	O
disturbed	O	O
cone	O	O
function	O	O
early	O	O
in	O	O
BD	O	O
.	O	O
A	O	O
case	O	O
of	O	O
lethal	O	O
hypophosphatasia	O	O
providing	O	O
new	O	O
insights	O	O
into	O	O
the	O	O
perinatal	O	O
benign	O	O
form	O	O
of	O	O
hypophosphatasia	O	O
and	O	O
expression	O	O
of	O	O
the	O	O
ALPL	O	O
gene	O	O
.	O	O
Hypophosphatasia	B-Disease	O
is	O	O
a	O	O
rare	O	O
inherited	O	O
bone	O	O
disease	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
alkaline	O	O
phosphatase	O	O
liver	O	O
-	O	O
type	O	O
gene	O	O
(	B-Gene	B-Gene
ALPL	I-Gene	O
)	I-Gene	I-Gene
gene	O	O
,	O	O
with	O	O
extensive	O	O
allelic	O	O
heterogeneity	O	O
leading	O	O
to	O	O
a	O	O
range	O	O
of	O	O
clinical	O	O
phenotypes	O	O
.	O	O
We	O	O
report	O	O
here	O	O
a	O	O
patient	O	O
who	O	O
died	O	O
from	O	O
severe	O	O
lethal	O	O
hypophosphatasia	O	O
,	O	O
who	O	O
was	O	O
compound	O	O
heterozygous	O	O
for	O	O
the	O	O
mutation	O	O
c.1133A	O	O
>	O	O
T	O	O
(	O	O
D361V	O	O
)	O	O
and	O	O
the	O	O
newly	O	O
detected	O	O
missense	O	O
mutation	O	O
c791A	O	O
>	O	O
G	O	O
,	O	O
and	O	O
whose	O	O
parents	O	O
were	O	O
both	O	O
healthy	O	O
.	O	O
Because	O	O
the	O	O
c.1133A	O	O
>	O	I-Var
T	O	O
(	O	O
D361V	O	O
)	O	O
mutation	O	O
was	O	O
previously	O	O
reported	O	O
to	O	O
have	O	O
a	O	O
dominant	O	O
-	O	O
negative	O	O
effect	O	O
and	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
uncommon	O	O
perinatal	O	O
benign	O	O
form	O	O
of	O	O
the	O	O
disease	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
ALPL	O	O
gene	O	O
in	O	O
this	O	O
family	O	O
.	O	O
Analysis	O	O
at	O	O
the	O	O
messenger	O	O
RNA	O	O
(	O	O
mRNA	O	O
)	O	O
level	O	O
,	O	O
both	O	O
quantitative	O	O
and	O	O
qualitative	O	O
,	O	O
showed	O	O
that	O	O
the	O	O
paternal	O	O
c.1133A	B-Var	O
>	I-Var	O
T	I-Var	O
(	O	O
D361V	O	O
)	O	O
mutation	O	O
was	O	O
associated	O	O
with	O	O
over	B-MPA	O
-	I-MPA	O
expression	I-MPA	O
of	O	O
the	O	O
ALPL	B-Gene	O
gene	O	O
and	O	O
that	O	O
the	O	O
maternal	O	O
c.791A	B-Var	O
>	I-Var	O
G	I-Var	O
mutation	O	O
lead	B-Reg	O
to	I-Reg	O
complete	O	O
skipping	B-Var	O
of	I-Var	O
exon	I-Var	O
7	I-Var	O
.	O	O
The	O	O
results	O	O
provide	O	O
an	O	O
explanation	O	O
of	O	O
the	O	O
lethal	O	O
phenotype	O	O
in	O	O
the	O	O
patient	O	O
where	O	O
the	O	O
two	O	O
ALPL	O	O
alleles	O	O
are	O	O
non	O	O
-	O	O
functional	O	O
and	O	O
in	O	O
the	O	O
asymptomatic	O	O
father	O	O
where	O	O
over	O	O
-	O	O
expression	O	O
of	O	O
the	O	O
normal	O	O
allele	O	O
could	O	O
counteract	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
c.1133A	O	O
>	O	O
T	O	I-Gene
(	O	O
D361V	O	O
)	O	I-Gene
mutation	O	O
by	O	O
providing	O	O
an	O	O
increased	O	B-PosReg
level	O	O
of	O	O
normal	O	O
mRNA	O	O
.	O	O
This	O	O
may	O	O
also	O	O
explain	O	O
the	O	O
variable	O	O
expression	O	O
of	O	O
hypophosphatasia	O	O
observed	O	O
in	O	O
parents	O	O
of	O	O
patients	O	O
with	O	O
the	O	O
perinatal	O	O
benign	O	O
form	O	O
.	O	O
Choreoacanthocytosis	O	O
in	O	O
a	O	O
Mexican	O	O
family	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Choreoacanthocytosis	B-Disease	O
(	O	O
CHAC	O	O
)	O	O
(	O	O
Online	O	O
Mendelian	O	O
Inheritance	O	O
in	O	O
Man	O	O
accession	O	O
No	O	O
.	O	O
200150	O	O
)	O	O
is	O	O
a	O	O
hereditary	O	O
neurodegenerative	O	O
syndrome	O	O
characterized	O	O
by	O	O
movement	O	O
disorders	O	O
,	O	O
cognitive	O	O
decline	O	O
,	O	O
myopathy	O	O
,	O	O
behavioral	O	O
changes	O	B-CPA
,	O	O
and	O	O
acanthocytosis	O	O
and	O	O
is	O	O
caused	B-Reg	B-Reg
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
VPS13A	B-Gene	O
gene	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
the	O	O
cases	O	O
of	O	O
2	O	O
Mexican	O	O
women	O	O
with	O	O
clinical	O	O
and	O	O
molecular	O	O
characteristics	O	O
compatible	O	O
with	O	O
CHAC	O	O
.	O	O
DESIGN	O	O
:	O	O
Case	O	O
reports	O	O
.	O	O
Patients	O	O
Choreoacanthocytosis	O	O
was	O	O
identified	O	O
in	O	O
2	O	O
Mexican	O	O
mestizo	O	O
sisters	O	O
with	O	O
healthy	O	O
consanguineous	O	O
parents	O	O
.	O	O
Clinical	O	O
manifestations	O	O
began	O	O
at	O	O
different	O	O
ages	O	O
.	O	O
RESULTS	O	O
:	O	O
The	O	O
onset	O	O
of	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
CHAC	O	O
in	O	O
the	O	O
proband	O	O
was	O	O
at	O	O
age	O	O
32	O	O
years	O	O
and	O	O
was	O	O
characterized	O	O
by	O	O
balancing	O	O
problems	O	O
followed	O	O
by	O	O
chorea	O	O
,	O	O
compulsive	O	O
lip	O	O
and	O	O
tongue	O	O
biting	O	O
with	O	O
buccolingual	O	O
self	O	O
-	O	O
mutilation	O	O
,	O	O
dysarthria	O	O
,	O	O
dysphagia	O	O
,	O	O
and	O	O
weight	O	O
loss	O	O
.	O	O
The	O	O
first	O	O
clinical	O	O
manifestations	O	O
in	O	O
the	O	O
proband	O	O
's	O	O
sister	O	O
occurred	O	O
at	O	O
age	O	O
45	O	O
years	O	O
and	O	O
included	O	O
multiple	O	O
motor	O	O
and	O	O
verbal	O	O
tics	O	O
,	O	O
with	O	O
coprolalia	O	O
,	O	O
followed	O	O
by	O	O
lip	O	O
and	O	O
tongue	O	O
biting	O	O
,	O	O
self	O	O
-	O	O
mutilation	O	O
,	O	O
and	O	O
chorea	O	O
.	O	O
The	O	O
clinical	O	O
findings	O	O
in	O	O
both	O	O
sisters	O	O
were	O	O
remarkable	O	O
for	O	O
acanthocytosis	O	O
that	O	O
developed	O	O
late	O	O
,	O	O
when	O	O
neurologic	O	O
changes	O	O
were	O	O
already	O	O
evident	O	O
.	O	O
Mutation	O	O
screening	O	O
of	O	O
the	O	O
VPS13A	O	O
gene	O	O
revealed	O	O
homozygosity	O	O
for	O	O
the	O	O
frameshift	O	O
mutation	O	O
c.3556_3557dupAC	O	O
in	O	O
exon	O	O
33	O	O
.	O	O
Currently	O	O
,	O	O
the	O	O
proband	O	O
's	O	O
sister	O	O
,	O	O
in	O	O
whom	O	O
neurologic	O	O
defects	O	O
developed	O	O
13	O	O
years	O	O
after	O	O
onset	O	O
of	O	O
CHAC	O	O
in	O	O
the	O	O
proband	O	O
,	O	O
is	O	O
the	O	O
least	O	O
affected	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
same	O	O
mutation	O	O
of	O	O
the	O	O
VPS13A	O	O
gene	O	O
can	O	O
be	O	O
expressed	O	O
differently	O	O
in	O	O
the	O	O
same	O	O
family	O	O
.	O	O
This	O	O
observation	O	O
confirms	O	O
the	O	O
notion	O	O
that	O	O
there	O	O
is	O	O
considerable	O	O
heterogeneity	O	O
in	O	O
the	O	O
clinical	O	O
manifestation	O	O
of	O	O
CHAC	O	O
.	O	O
[	O	O
Phenotype	O	O
-	O	O
genotype	O	O
study	O	O
in	O	O
154	O	O
French	O	O
NF2	O	O
mutation	O	O
carriers	O	O
]	O	O
.	O	O
Analyse	O	O
phénotypique	O	O
de	O	O
154	O	O
patients	O	O
porteurs	O	O
d'une	O	O
mutation	O	O
constitutionnelle	O	O
du	O	O
gène	O	O
NF2	O	O
.	O	O
INTRODUCTION	O	O
:	O	O
Germline	B-Var	O
mutations	I-Var	O
in	O	O
the	O	O
NF2	B-Gene	O
gene	O	O
are	O	O
responsible	B-Reg	O
for	O	O
80	O	O
p.cent	O	O
of	O	O
neurofibromatosis	B-Disease	O
type	I-Disease	O
2	I-Disease	O
typical	O	O
cases	O	O
.	O	O
Mutations	O	O
are	O	O
mainly	O	O
truncating	O	O
mutations	O	O
or	O	O
deletions	O	O
,	O	O
missense	O	O
mutations	O	O
having	O	O
been	O	O
reported	O	O
in	O	O
few	O	O
cases	O	O
.	O	O
An	O	O
important	O	O
phenotypic	O	O
variability	O	O
is	O	O
observed	O	O
among	O	O
gene	O	O
carriers	O	O
.	O	O
To	O	O
assess	O	O
whether	O	O
the	O	O
phenotypic	O	O
variability	O	O
of	O	O
neurofibromatosis	O	O
2	O	O
could	O	O
be	O	O
linked	O	O
to	O	O
genotype	O	O
,	O	O
clinical	O	O
data	O	O
of	O	O
154	O	O
patients	O	O
whose	O	O
NF2	O	O
germline	O	O
alteration	O	O
had	O	O
been	O	O
identified	O	O
in	O	O
our	O	O
laboratory	O	O
have	O	O
been	O	O
collected	O	O
.	O	O
METHODS	O	O
:	O	O
A	O	O
retrospective	O	O
questionnaire	O	O
was	O	O
sent	O	O
to	O	O
the	O	O
physicians	O	O
in	O	O
charge	O	O
of	O	O
these	O	O
patients	O	O
.	O	O
Statistical	O	O
analyses	O	O
regarding	O	O
genotypic	O	O
and	O	O
phenotypic	O	O
data	O	O
were	O	O
performed	O	O
by	O	O
comparisons	O	O
of	O	O
average	O	O
values	O	O
and	O	O
correlation	O	O
tests	O	O
.	O	O
RESULTS	O	O
:	O	O
In	O	O
French	O	O
patients	O	O
,	O	O
type	O	O
of	O	O
mutation	O	O
was	O	O
correlated	O	O
neither	O	O
with	O	O
patients	O	O
'	O	O
sex	O	O
,	O	O
nor	O	O
with	O	O
disease	O	O
occurrence	O	O
mode	O	O
(	O	O
de	O	O
novo	O	O
or	O	O
inherited	O	O
mutation	O	O
)	O	O
.	O	O
Disease	O	O
associated	O	O
with	O	O
missense	O	O
mutations	O	O
occurred	O	O
later	O	O
,	O	O
with	O	O
a	O	O
less	O	O
severe	O	O
symptomatology	O	O
.	O	O
Patients	O	O
with	O	O
nonsense	O	O
or	O	O
frameshift	O	O
mutations	O	O
were	O	O
more	O	O
frequently	O	O
affected	O	O
with	O	O
meningiomas	O	O
and	O	O
spinal	O	O
tumours	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
VIII	O	O
nerve	O	O
schwannomas	O	O
,	O	O
an	O	O
observation	O	O
that	O	O
underlies	O	O
the	O	O
genetic	O	O
determination	O	O
of	O	O
the	O	O
number	O	O
and	O	O
type	O	O
of	O	O
NF2-related	O	O
tumours	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Results	O	O
from	O	O
the	O	O
literature	O	O
as	O	O
well	O	O
as	O	O
from	O	O
our	O	O
study	O	O
tend	O	O
to	O	O
show	O	O
that	O	O
only	O	O
few	O	O
correlations	O	O
exist	O	O
between	O	O
genotype	O	O
and	O	O
phenotype	O	O
in	O	O
the	O	O
NF2	O	O
disease	O	O
.	O	O
It	O	O
also	O	O
recognizes	O	O
that	O	O
missense	O	O
mutations	O	O
have	O	O
a	O	O
lower	O	O
level	O	O
of	O	O
evolution	O	O
,	O	O
severity	O	O
and	O	O
mortality	O	O
risk	O	O
.	O	O
Nonsense	O	O
and	O	O
frameshift	O	O
mutations	O	O
seem	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
higher	O	O
number	O	O
of	O	O
meningiomas	O	O
and	O	O
spinal	O	O
tumours	O	O
.	O	O
Therefore	O	O
,	O	O
NF2	O	O
gene	O	O
screening	O	O
keeps	O	O
its	O	O
indications	O	O
in	O	O
both	O	O
typical	O	O
and	O	O
moderate	O	O
forms	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
Mutations	O	O
are	O	O
responsible	O	O
of	O	O
80	O	O
p.cent	O	O
of	O	O
typical	O	O
forms	O	O
;	O	O
in	O	O
moderate	O	O
forms	O	O
,	O	O
identification	O	O
of	O	O
a	O	O
missense	O	B-Var
mutation	O	I-Var
seems	O	O
linked	O	B-Reg
to	O	O
a	O	O
lower	O	O
disease	O	O
evolution	O	O
.	O	O
In	O	O
any	O	B-Gene
case	O	O
,	O	O
assessment	O	O
and	O	O
supervision	O	O
should	O	O
be	O	O
identical	O	O
.	O	O
Finally	O	O
,	O	O
in	O	O
a	O	O
small	O	O
number	O	O
of	O	O
cases	O	O
,	O	O
the	O	O
NF2	O	O
gene	O	O
appears	O	O
to	O	O
be	O	O
implicated	O	O
in	O	O
clinical	O	O
forms	O	O
different	O	O
from	O	O
those	O	O
defined	O	O
by	O	O
NIH	O	O
and	O	O
it	O	O
might	O	O
be	O	O
of	O	O
interest	O	O
to	O	O
enlarge	O	O
the	O	O
clinical	O	O
features	O	O
suggestive	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
Do	O	O
we	O	O
know	O	O
all	O	O
there	O	O
is	O	O
to	O	O
know	O	O
about	O	O
Familial	O	O
Adenomatous	O	O
Polyposis	O	O
?	O	O
Familial	B-Disease	O
Adenomatous	I-Disease	O
Polyposis	I-Disease	O
(	O	O
FAP	O	O
)	O	O
and	O	O
Attenuated	B-Disease	O
FAP	I-Disease	O
(	O	O
AFAP	O	O
)	O	O
are	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
germline	B-Var	O
mutation	I-Var	O
in	O	O
the	O	O
Adenomatous	O	O
polyposis	O	O
coli	O	O
(	B-Gene	O
APC	I-Gene	O
)	I-Gene	O
gene	O	O
.	O	O
Recently	O	O
,	O	O
a	O	O
new	O	O
pathway	O	O
characterized	O	O
by	O	O
a	O	O
biallelic	O	O
mutation	O	O
in	O	O
the	O	O
MYH	O	O
gene	O	O
,	O	O
with	O	O
a	O	O
recessive	O	O
model	O	O
of	O	O
inheritance	O	O
was	O	O
discovered	O	O
for	O	O
this	O	O
inherited	O	O
syndrome	O	O
.	O	O
This	O	O
report	O	O
describes	O	O
a	O	O
Tunisian	O	O
patient	O	O
with	O	O
an	O	O
attenuated	O	O
FAP	O	O
phenotype	O	O
,	O	O
presenting	O	O
seven	O	O
colon	O	O
polyps	O	O
and	O	O
an	O	O
adenocarcinoma	O	O
but	O	O
no	O	O
detectable	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
FAP	O	O
target	O	O
genes	O	O
.	O	O
A	O	O
well	O	O
known	O	O
somatic	O	O
mutation	O	O
was	O	O
found	O	O
in	O	O
the	O	O
APC	O	O
mutation	O	O
cluster	O	O
region	O	O
(	O	O
MCR	O	O
)	O	O
.	O	O
This	O	O
case	O	O
shows	O	O
that	O	O
further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
fully	O	O
understand	O	O
all	O	O
the	O	O
pathways	O	O
of	O	O
the	O	O
FAP	O	O
syndrome	O	O
.	O	O
Mutations	B-Var	O
in	O	O
NALP12	B-Gene	O
cause	B-Reg	B-Reg
hereditary	B-Disease	O
periodic	I-Disease	O
fever	I-Disease	O
syndromes	I-Disease	O
.	O	O
NALP	O	O
proteins	O	O
,	O	O
also	O	O
known	O	O
as	O	O
NLRPs	O	O
,	O	O
belong	O	O
to	O	O
the	O	O
CATERPILLER	O	O
protein	O	O
family	O	O
involved	O	O
,	O	O
like	O	O
Toll	O	O
-	O	O
like	O	O
receptors	O	O
,	O	O
in	O	O
the	O	O
recognition	O	O
of	O	O
microbial	O	O
molecules	O	O
and	O	O
the	O	O
subsequent	O	O
activation	O	O
of	O	O
inflammatory	O	O
and	O	O
immune	O	O
responses	O	B-CPA
.	O	O
Current	O	O
advances	O	O
in	O	O
the	O	O
function	O	O
of	O	O
NALPs	O	O
support	O	O
the	O	O
recently	O	O
proposed	O	O
model	O	O
of	O	O
a	O	O
disease	O	O
continuum	O	O
bridging	O	O
autoimmune	O	O
and	O	O
autoinflammatory	O	O
disorders	O	O
.	O	O
Among	O	O
these	O	O
diseases	O	O
,	O	O
hereditary	O	O
periodic	O	O
fevers	O	O
(	O	O
HPFs	O	O
)	O	O
are	O	O
Mendelian	O	O
disorders	O	O
associated	O	O
with	O	O
sequence	O	O
variations	O	O
in	O	O
very	O	O
few	O	O
genes	O	O
;	O	O
these	O	O
variations	O	O
are	O	O
mostly	O	O
missense	O	O
mutations	O	O
whose	O	O
deleterious	O	O
effect	O	O
,	O	O
which	O	O
is	O	O
particularly	O	O
difficult	O	O
to	O	O
assess	O	O
,	O	O
is	O	O
often	O	O
questionable	O	O
.	O	O
The	O	O
growing	O	O
number	O	O
of	O	O
identified	O	O
sporadic	O	O
cases	O	O
of	O	O
periodic	O	O
fever	O	O
syndrome	O	O
,	O	O
together	O	O
with	O	O
the	O	O
lack	O	O
of	O	O
discriminatory	O	O
clinical	O	O
criteria	O	O
,	O	O
has	O	O
greatly	O	O
hampered	O	O
the	O	O
identification	O	O
of	O	O
new	O	O
disease	O	O
-	O	O
causing	O	O
genes	O	O
,	O	O
a	O	O
step	O	O
that	O	O
is	O	O
,	O	O
however	O	O
,	O	O
essential	O	O
for	O	O
appropriate	O	O
management	O	O
of	O	O
these	O	O
disorders	O	O
.	O	O
Using	O	O
a	O	O
candidate	O	O
gene	O	O
approach	O	O
,	O	O
we	O	O
identified	O	O
nonambiguous	O	O
mutations	O	O
in	O	O
NALP12	O	O
(	O	O
i.e.	O	O
,	O	O
nonsense	O	O
and	O	O
splice	O	O
site	O	O
)	O	O
in	O	O
two	O	O
families	O	O
with	O	O
periodic	O	O
fever	O	O
syndromes	O	O
.	O	O
As	O	O
shown	O	O
by	O	O
means	O	O
of	O	O
functional	O	O
studies	O	O
,	O	O
these	O	O
two	O	O
NALP12	B-Gene	O
mutations	B-Var	O
have	O	O
a	O	O
deleterious	O	O
effect	B-Reg	O
on	O	O
NF	B-Pathway	O
-	I-Pathway	O
kappaB	I-Pathway	O
signaling	I-Pathway	O
.	O	O
Overall	O	O
,	O	O
these	O	O
data	O	O
identify	O	O
a	O	O
group	O	O
of	O	O
HPFs	O	O
defined	O	O
by	O	O
molecular	O	O
defects	O	O
in	O	O
NALP12	O	O
,	O	O
opening	O	O
up	O	O
new	O	O
ways	O	O
to	O	O
manage	O	O
these	O	O
disorders	O	O
.	O	O
The	O	O
identification	O	O
of	O	O
these	O	O
first	O	O
NALP12	B-Gene	O
mutations	B-Var	O
in	O	O
patients	O	O
with	B-Reg	O
autoinflammatory	B-CPA	O
disorder	I-CPA	O
also	O	O
clearly	O	O
demonstrates	O	O
the	O	O
crucial	O	O
role	O	O
of	O	O
NALP12	O	O
in	O	O
inflammatory	O	O
signaling	O	O
pathways	O	O
,	O	O
thereby	O	O
assigning	O	O
a	O	O
precise	O	O
function	O	O
to	O	O
this	O	O
particular	O	O
member	O	O
of	O	O
an	O	O
emerging	O	O
family	O	O
of	O	O
proteins	O	O
whose	O	O
putative	O	O
biological	O	O
properties	O	O
are	O	O
currently	O	O
inferred	O	O
essentially	O	O
through	O	O
in	O	O
vitro	O	O
means	O	O
.	O	O
ABCA4	O	O
gene	O	O
analysis	O	O
in	O	O
patients	O	O
with	O	O
autosomal	O	O
recessive	O	O
cone	O	O
and	O	O
cone	O	O
rod	O	O
dystrophies	O	O
.	O	O
The	O	O
ATP	O	O
-	O	O
binding	O	O
cassette	O	O
(	O	O
ABC	O	O
)	O	O
transporters	O	O
constitute	O	O
a	O	O
family	O	O
of	O	O
large	O	O
membrane	O	O
proteins	O	O
,	O	O
which	O	O
transport	O	O
a	O	O
variety	O	O
of	O	O
substrates	O	O
across	O	O
membranes	O	O
.	O	O
The	O	O
ABCA4	O	O
protein	O	O
is	O	O
expressed	O	O
in	O	O
photoreceptors	O	O
and	O	O
possibly	O	O
functions	O	O
as	O	O
a	O	O
transporter	O	O
for	O	O
N	O	O
-	O	O
retinylidene	O	O
-	O	O
phosphatidylethanolamine	O	O
(	O	O
N	O	O
-	O	O
retinylidene	O	O
-	O	O
PE	O	O
)	O	O
,	O	O
the	O	O
Schiff	O	O
base	O	O
adduct	O	O
of	O	O
all	O	O
-	O	O
trans	O	O
-	O	O
retinal	O	O
with	O	O
PE	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
ABCA4	B-Gene	O
gene	O	O
have	O	O
been	O	O
initially	O	O
associated	B-Reg	O
with	I-Reg	O
autosomal	O	O
recessive	O	O
Stargardt	B-Disease	O
disease	I-Disease	O
.	O	O
Subsequent	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
mutations	B-Var	B-Var
in	O	O
ABCA4	B-Gene	O
can	O	O
also	O	O
cause	B-Reg	O
a	O	O
variety	O	O
of	O	O
other	O	O
retinal	B-Disease	O
dystrophies	I-Disease	O
including	O	O
cone	B-Disease	O
rod	I-Disease	O
dystrophy	I-Disease	O
and	O	O
retinitis	B-Disease	O
pigmentosa	I-Disease	O
.	O	O
To	O	O
determine	O	O
the	O	O
prevalence	O	O
and	O	O
mutation	O	O
spectrum	O	O
of	O	O
ABCA4	O	O
gene	O	O
mutations	O	O
in	O	O
non	O	O
-	O	O
Stargardt	O	O
phenotypes	O	O
,	O	O
we	O	O
have	O	O
screened	O	O
64	O	O
unrelated	O	O
patients	O	O
with	O	O
autosomal	O	O
recessive	O	O
cone	O	O
(	O	O
arCD	O	O
)	O	O
and	O	O
cone	O	O
rod	O	O
dystrophy	O	O
(	O	O
arCRD	O	O
)	O	O
applying	O	O
the	O	O
Asper	O	O
Ophthalmics	O	O
ABCR400	O	O
microarray	O	O
followed	O	O
by	O	O
DNA	O	O
sequencing	O	O
of	O	O
all	O	O
coding	O	O
exons	O	O
of	O	O
the	O	O
ABCA4	O	O
gene	O	O
in	O	O
subjects	O	O
with	O	O
single	O	O
heterozygous	O	O
mutations	O	O
.	O	O
Disease	O	O
-	O	O
associated	O	O
ABCA4	O	O
alleles	O	O
were	O	O
identified	O	O
in	O	O
20	O	O
of	O	O
64	O	O
patients	O	O
with	O	O
arCD	O	O
or	O	O
arCRD	O	O
.	O	O
In	O	O
four	O	O
of	O	O
64	O	O
patients	O	O
(	O	O
6	O	O
%	O	O
)	O	O
only	O	O
one	O	O
mutant	O	O
ABCA4	O	O
allele	O	O
was	O	O
detected	O	O
and	O	O
in	O	O
16	O	O
patients	O	O
(	O	O
25	O	O
%	O	O
)	O	O
,	O	O
mutations	O	O
on	O	O
both	O	O
ABCA4	O	O
alleles	O	O
were	O	O
identified	O	O
.	O	O
Based	O	O
on	O	O
these	O	O
data	O	O
we	O	O
estimate	O	O
a	O	O
prevalence	O	O
of	O	O
31	O	O
%	O	O
for	O	O
ABCA4	O	O
mutations	O	O
in	O	O
arCD	O	O
and	O	O
arCRD	O	O
,	O	O
supporting	O	O
the	O	O
concept	O	O
that	O	O
the	O	O
ABCA4	O	O
gene	O	O
is	O	O
a	O	O
major	O	O
locus	O	O
for	O	O
various	O	O
types	O	O
of	O	O
degenerative	O	O
retinal	O	O
diseases	O	O
with	O	O
abnormalities	O	O
in	O	O
cone	O	O
or	O	O
both	O	O
cone	O	O
and	O	O
rod	O	O
function	O	O
.	O	O
Premature	O	O
termination	O	O
codons	O	O
in	O	O
PRPF31	O	O
cause	O	O
retinitis	O	O
pigmentosa	O	O
via	O	O
haploinsufficiency	O	O
due	O	O
to	O	O
nonsense	O	O
-	O	O
mediated	O	O
mRNA	O	O
decay	O	O
.	O	O
Dominant	B-Var	O
mutations	I-Var	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
the	O	O
mRNA	O	O
splicing	O	O
factor	O	O
PRPF31	B-Gene	O
cause	B-Reg	B-Reg
retinitis	B-Disease	O
pigmentosa	I-Disease	O
,	O	O
a	O	O
hereditary	O	O
form	O	O
of	O	O
retinal	O	B-Disease
degeneration	O	I-Disease
.	O	O
Most	O	O
of	O	O
these	O	O
mutations	O	O
are	O	O
characterized	O	O
by	O	O
DNA	O	O
changes	O	O
that	O	O
lead	O	O
to	O	O
premature	O	O
termination	O	O
codons	O	O
.	O	O
We	O	O
investigated	O	O
6	O	O
different	O	O
PRPF31	O	O
mutations	O	O
,	O	O
represented	O	O
by	O	O
single	O	O
-	O	O
base	O	O
substitutions	O	O
or	O	O
microdeletions	O	O
,	O	O
in	O	O
cell	O	O
lines	O	O
derived	O	O
from	O	O
9	O	O
patients	O	O
with	O	O
dominant	O	O
retinitis	O	O
pigmentosa	O	O
.	O	O
Five	O	O
of	O	O
these	O	O
mutations	B-Var	O
lead	B-Reg	O
to	I-Reg	O
premature	B-MPA	O
termination	I-MPA	O
codons	I-MPA	O
,	O	O
and	O	O
1	O	O
leads	B-Reg	O
to	I-Reg	O
the	O	O
skipping	B-MPA	O
of	I-MPA	O
exon	I-MPA	O
2	I-MPA	O
.	O	O
Allele	O	O
-	O	O
specific	O	O
measurement	O	O
of	O	O
PRPF31	O	O
transcripts	O	O
revealed	O	O
a	O	O
strong	O	O
reduction	B-NegReg	O
in	O	O
the	O	O
expression	B-MPA	O
of	O	O
mutant	B-Var	O
alleles	O	O
.	O	O
As	O	O
a	O	O
consequence	O	O
,	O	O
total	O	O
PRPF31	B-Gene	O
protein	B-Protein	O
abundance	B-MPA	O
was	O	O
decreased	B-NegReg	O
,	O	O
and	O	O
no	O	O
truncated	O	O
proteins	O	O
were	O	O
detected	O	O
.	O	O
Subnuclear	O	O
localization	O	O
of	O	O
the	O	O
full	O	O
-	O	O
length	O	O
PRPF31	O	O
that	O	O
was	O	O
present	O	O
remained	O	O
unaffected	O	O
.	O	O
Blocking	O	O
nonsense	O	O
-	O	O
mediated	O	O
mRNA	O	O
decay	O	O
significantly	O	O
restored	O	O
the	O	O
amount	O	O
of	O	O
mutant	O	O
PRPF31	O	O
mRNA	O	O
but	O	O
did	O	O
not	O	O
restore	O	O
the	O	O
synthesis	O	O
of	O	O
mutant	O	B-Var
proteins	O	B-Protein
,	O	O
even	O	O
in	O	O
conjunction	O	O
with	O	O
inhibitors	O	B-Reg
of	O	O
protein	O	B-Protein
degradation	O	I-Disease
pathways	O	I-Disease
.	O	O
Our	O	O
results	O	O
indicate	O	O
that	O	O
most	O	O
PRPF31	B-Gene	O
mutations	B-Var	O
ultimately	O	O
result	O	O
in	O	O
null	B-NegReg	O
alleles	B-MPA	O
through	O	O
the	O	O
activation	B-PosReg	O
of	O	O
surveillance	B-MPA	O
mechanisms	I-MPA	O
that	O	O
inactivate	B-NegReg	O
mutant	B-Var	B-Var
mRNA	I-Var	O
and	O	O
,	O	O
possibly	O	O
,	O	O
proteins	B-Protein	O
.	O	O
Furthermore	O	O
,	O	O
these	O	O
data	O	O
provide	O	O
compelling	O	O
evidence	O	O
that	O	O
the	O	O
pathogenic	O	O
effect	O	O
of	O	O
PRPF31	O	O
mutations	O	O
is	O	O
likely	O	O
due	O	O
to	O	O
haploinsufficiency	O	O
rather	O	O
than	O	O
to	O	O
gain	O	O
of	O	O
function	O	O
.	O	O
Xeroderma	O	O
pigmentosum	O	O
-	O	O
variant	O	O
patients	O	O
from	O	O
America	O	O
,	O	O
Europe	O	O
,	O	O
and	O	O
Asia	O	O
.	O	O
Xeroderma	B-Disease	O
pigmentosum	I-Disease	O
-	I-Disease	O
variant	I-Disease	O
(	O	O
XP	O	O
-	O	O
V	O	O
)	O	O
patients	O	O
have	O	O
sun	O	O
sensitivity	O	O
and	O	O
increased	O	O
skin	O	O
cancer	O	O
risk	O	O
.	O	O
Their	O	O
cells	O	O
have	O	O
normal	O	O
nucleotide	O	O
excision	O	O
repair	O	O
,	O	O
but	O	O
have	O	O
defects	O	O
in	O	O
the	O	O
POLH	O	O
gene	O	O
encoding	O	O
an	O	O
error	O	O
-	O	O
prone	O	O
polymerase	O	O
,	O	O
DNA	O	O
polymerase	O	O
eta	O	O
(	O	O
pol	O	O
eta	O	O
)	O	O
.	O	O
To	O	O
survey	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
XP	O	O
-	O	O
V	O	O
worldwide	O	O
,	O	O
we	O	O
measured	O	O
pol	O	O
eta	O	O
protein	O	O
in	O	O
skin	O	O
fibroblasts	O	O
from	O	O
putative	O	O
XP	O	O
-	O	O
V	O	O
patients	O	O
(	O	O
aged	O	O
8	O	O
-	O	O
66	O	O
years	O	O
)	O	O
from	O	O
10	O	O
families	O	O
in	O	O
North	O	O
America	O	O
,	O	O
Turkey	O	O
,	O	O
Israel	O	O
,	O	O
Germany	O	O
,	O	O
and	O	O
Korea	O	O
.	O	O
Pol	O	O
eta	O	O
was	O	O
undetectable	O	O
in	O	O
cells	O	O
from	O	O
patients	O	O
in	O	O
eight	O	O
families	O	O
,	O	O
whereas	O	O
two	O	O
showed	O	O
faint	O	O
bands	O	O
.	O	O
DNA	O	O
sequencing	O	O
identified	O	O
10	O	O
different	O	O
POLH	O	O
mutations	O	O
.	O	O
There	O	O
were	O	O
two	O	O
splicing	O	O
,	O	O
one	O	O
nonsense	O	O
,	O	O
five	O	O
frameshift	O	O
(	O	O
3	O	O
deletion	O	O
and	O	O
2	O	O
insertion	O	O
)	O	O
,	O	O
and	O	O
two	O	O
missense	O	O
mutations	O	O
.	O	O
Nine	O	O
of	O	O
these	O	O
mutations	O	O
involved	O	O
the	O	O
catalytic	O	O
domain	O	O
.	O	O
Although	O	O
affected	O	O
siblings	O	O
had	O	O
similar	O	O
clinical	O	O
features	O	O
,	O	O
the	O	O
relation	O	O
between	O	O
the	O	O
clinical	O	O
features	O	O
and	O	O
the	O	O
mutations	O	O
was	O	O
not	O	O
clear	O	O
.	O	O
POLH	O	O
mRNA	O	O
levels	O	O
were	O	O
normal	O	O
or	O	O
reduced	O	O
by	O	O
50	O	O
%	O	O
in	O	O
three	O	O
cell	O	O
strains	O	O
with	O	O
undetectable	O	O
levels	O	O
of	O	O
pol	O	O
eta	O	O
protein	O	O
,	O	O
indicating	O	O
that	O	O
nonsense	O	O
-	O	O
mediated	O	O
message	O	O
decay	O	O
was	O	O
limited	O	O
.	O	O
We	O	O
found	O	O
a	O	O
wide	O	O
spectrum	O	O
of	O	O
mutations	B-Var	O
in	O	O
the	O	O
POLH	B-Gene	O
gene	O	O
among	B-Reg	O
XP	B-Disease	O
-	I-Disease	O
V	I-Disease	O
patients	O	O
in	O	O
different	O	O
countries	O	O
,	O	O
suggesting	O	O
that	O	O
many	O	O
of	O	O
these	O	O
mutations	O	O
arose	O	O
independently	O	O
.	O	O
Four	O	O
novel	O	O
FXI	B-Gene	O
gene	O	O
mutations	B-Var	O
in	B-Reg	O
three	O	O
factor	B-Disease	O
XI-	I-Disease	O
deficient	I-Disease	O
patients	O	O
.	O	O
Hereditary	O	O
factor	O	O
XI	O	O
deficiency	O	O
is	O	O
a	O	O
mild	O	O
bleeding	O	O
disorder	O	O
,	O	O
which	O	O
is	O	O
highly	O	O
prevalent	O	O
among	O	O
Ashkenazi	O	O
Jews	O	O
,	O	O
but	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
all	O	O
populations	O	O
.	O	O
In	O	O
Ashkenazi	O	O
Jews	O	O
,	O	O
two	O	O
factor	O	O
XI	O	O
gene	O	O
mutations	O	O
Glu	O	O
117X	O	O
(	O	O
type	O	O
II	O	O
)	O	O
and	O	O
Phe283Leu	O	O
(	O	O
type	O	O
III	O	O
)	O	O
are	O	O
particularly	O	O
common	O	O
.	O	O
In	O	O
other	O	O
ethnic	O	O
groups	O	O
,	O	O
factor	B-Disease	O
XI	I-Disease	O
deficiency	I-Disease	O
is	O	O
a	O	O
rare	O	O
bleeding	O	O
disorder	O	O
and	O	O
is	O	O
related	B-Reg	O
to	I-Reg	O
a	O	O
variety	O	O
of	O	O
mutations	B-Var	O
throughout	O	O
the	O	O
factor	B-Gene	O
XI	I-Gene	O
gene	O	O
.	O	O
Three	O	O
cases	O	O
of	O	O
quantitative	O	O
factor	O	O
XI	O	O
deficiency	O	O
in	O	O
relation	O	O
with	O	O
four	O	O
novel	O	O
missense	O	O
mutations	O	O
are	O	O
reported	O	O
:	O	O
a	O	O
compound	O	O
heterozygosity	O	O
for	O	O
two	O	O
novel	O	O
mutations	O	O
(	B-Var	O
Ala	I-Var	O
181	I-Var	O
Val	I-Var	O
and	O	O
Ala	B-Var	O
412	I-Var	O
Thr	I-Var	O
)	I-Var	O
with	O	O
a	O	O
severe	O	O
factor	O	O
XI	O	O
deficiency	O	O
and	O	O
two	O	O
missense	O	O
mutations	O	O
(	B-Var	O
His	I-Var	O
388	I-Var	O
Pro	I-Var	O
and	O	O
Trp	B-Var	O
407	I-Var	O
Cys	I-Var	O
)	I-Var	O
in	B-Reg	O
heterozygous	O	O
patients	O	O
with	O	O
partial	O	O
factor	B-Disease	O
XI	I-Disease	O
deficiency	I-Disease	O
.	O	O
[	O	O
A	O	O
novel	O	O
mutation	B-Var	O
in	O	O
the	O	O
SEDL	B-Gene	O
gene	O	O
leading	B-Reg	O
to	I-Reg	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
spondyloepiphyseal	I-Disease	O
dysplasia	I-Disease	O
tarda	I-Disease	O
in	O	O
a	O	O
large	O	O
Chinese	O	O
pedigree	O	O
]	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
identify	O	O
the	O	O
genetic	O	O
defect	O	O
in	O	O
a	O	O
four	O	O
-	O	O
generation	O	O
pedigree	O	O
with	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
spondyloepiphyseal	O	O
dysplasia	O	O
tarda	O	O
(	O	O
SEDT	O	O
)	O	O
from	O	O
Southwest	O	O
China	O	O
.	O	O
METHODS	O	O
:	O	O
Linkage	O	O
analysis	O	O
with	O	O
one	O	O
panel	O	O
of	O	O
fluorescently	O	O
labeled	O	O
microsatellite	O	O
markers	O	O
on	O	O
chromosome	O	O
X	O	O
and	O	O
mutation	O	O
screening	O	O
of	O	O
SEDL	O	O
gene	O	O
by	O	O
direct	O	O
sequencing	O	O
were	O	O
performed	O	O
.	O	O
RESULTS	O	O
:	O	O
Linkage	O	O
between	O	O
SEDT	O	O
and	O	O
Xp22.2-Xp23.1	O	O
was	O	O
established	O	O
with	O	O
maximum	O	O
LOD	O	O
score	O	O
of	O	O
3.82	O	O
(	O	O
theta	O	O
=	O	O
0	O	O
)	O	O
between	O	O
DXS987	O	O
and	O	O
DXS8051	O	O
.	O	O
Upon	O	O
sequence	O	O
analysis	O	O
,	O	O
a	O	O
point	O	O
mutation	O	O
within	O	O
exon	O	O
4	O	O
of	O	O
the	O	O
SEDL	B-Gene	O
gene	O	O
(	B-Var	O
c.239A	I-Var	O
to	I-Var	O
G	I-Var	O
)	I-Var	O
was	O	O
found	O	O
which	O	O
resulted	B-Reg	O
in	I-Reg	O
substitution	O	O
of	O	O
histidine	O	O
with	O	O
arginine	O	O
at	O	O
codon	O	O
80	O	O
(	B-Var	O
His80Arg	I-Var	O
)	I-Var	O
.	O	O
CONCLUSION	O	O
:	O	O
A	O	O
novel	O	O
missense	O	O
mutation	O	O
(	O	O
H80R	O	O
)	O	O
was	O	O
identified	O	O
for	O	O
SEDL	O	O
gene	O	O
in	O	O
the	O	O
large	O	O
Chinese	O	O
SEDT	O	O
pedigree	O	O
.	O	O
MLPA	O	O
analysis	O	O
/	O	O
complete	O	O
sequencing	O	O
of	O	O
the	O	O
DMD	O	O
gene	O	O
in	O	O
a	O	O
group	O	O
of	O	O
Bulgarian	O	O
Duchenne	O	O
/	O	O
Becker	O	O
muscular	O	O
dystrophy	O	O
patients	O	O
.	O	O
Duchenne	B-Disease	O
/	I-Disease	O
Becker	I-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
(	O	O
DMD	O	O
/	O	O
BMD	O	O
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
X	O	O
-	O	O
linked	O	O
muscular	O	O
dystrophy	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
enormously	O	O
large	O	O
DMD	B-Gene	O
gene	O	O
,	O	O
encoding	O	O
the	O	O
protein	O	O
called	O	O
dystrophin	O	O
.	O	O
This	O	O
gene	O	O
was	O	O
screened	O	O
in	O	O
a	O	O
group	O	O
of	O	O
27	O	O
unrelated	O	O
Bulgarian	O	O
DMD	O	O
/	O	O
BMD	O	O
patients	O	O
by	O	O
MLPA	O	O
analysis	O	O
/	O	O
complete	O	O
sequencing	O	O
.	O	O
We	O	O
managed	O	O
to	O	O
clarify	O	O
the	O	O
disease	O	O
-	O	O
causing	O	O
mutation	O	O
in	O	O
96.3	O	O
%	O	O
of	O	O
the	O	O
analyzed	O	O
families	O	O
.	O	O
The	O	O
MLPA	O	O
analysis	O	O
revealed	O	O
17	O	O
deletions	O	O
(	O	O
including	O	O
a	O	O
deletion	O	O
of	O	O
the	O	O
very	O	O
last	O	O
exon	O	O
79	O	O
)	O	O
,	O	O
6	O	O
duplications	O	O
and	O	O
1	O	O
point	O	O
mutation	O	O
.	O	O
Two	O	O
additional	O	O
point	O	O
mutations	O	O
(	O	O
one	O	O
of	O	O
them	O	O
novel	O	O
)	O	O
were	O	O
detected	O	O
after	O	O
complete	O	O
sequencing	O	O
of	O	O
the	O	O
DMD	O	O
gene	O	O
.	O	O
Altogether	O	O
,	O	O
25	O	O
carriers	O	O
and	O	O
11	O	O
noncarriers	O	O
were	O	O
detected	O	O
in	O	O
our	O	O
families	O	O
.	O	O
The	O	O
MLPA	O	O
test	O	O
proved	O	O
to	O	O
be	O	O
a	O	O
powerful	O	O
tool	O	O
in	O	O
detecting	O	O
deletions	O	O
/	O	O
duplications	O	O
and	O	O
in	O	O
some	O	O
cases	O	O
point	O	O
mutations	O	O
/	O	O
polymorphisms	O	O
along	O	O
the	O	O
DMD	O	O
gene	O	O
.	O	O
Using	O	O
this	O	O
approach	O	O
in	O	O
combination	O	O
with	O	O
a	O	O
direct	O	O
gene	O	O
sequencing	O	O
a	O	O
number	O	O
of	O	O
Bulgarian	O	O
DMD	O	O
/	O	O
BMD	O	O
patients	O	O
are	O	O
genetically	O	O
clarified	O	O
and	O	O
prepared	O	O
for	O	O
gene	O	O
therapy	O	O
in	O	O
future	O	O
.	O	O
A	O	O
case	O	O
of	O	O
Bernard	B-Disease	O
-	I-Disease	O
Soulier	I-Disease	O
Syndrome	I-Disease	O
due	B-Reg	O
to	I-Reg	O
a	O	O
homozygous	O	O
four	O	O
bases	O	O
deletion	B-Var	O
(	O	O
TGAG	O	O
)	O	O
of	O	O
GPIbalpha	B-Gene	O
gene	I-Gene	O
:	I-Gene	O
lack	O	O
of	O	O
GPIbalpha	O	O
but	O	O
absence	O	O
of	O	O
bleeding	O	O
.	O	O
More	O	O
than	O	O
20	O	O
DNA	O	O
mutations	O	O
with	O	O
different	O	O
inheritance	O	O
pattern	O	O
have	O	O
been	O	O
described	O	O
in	O	O
patients	O	O
with	O	O
Bernard	O	O
-	O	O
Soulier	O	O
Syndrome	O	O
(	O	O
BSS	O	O
)	O	O
,	O	O
leading	O	O
to	O	O
abnormal	O	O
or	O	O
absent	O	O
synthesis	O	O
and/or	O	O
expression	O	O
of	O	O
GPIbalpha	O	O
.	O	O
Clinical	O	O
phenotype	O	O
shows	O	O
considerable	O	O
variation	O	O
between	O	O
individuals	O	O
,	O	O
such	O	O
as	O	O
bleeding	O	O
,	O	O
platelet	O	O
count	O	O
and	O	O
the	O	O
percentage	O	O
of	O	O
large	O	O
platelets	O	O
.	O	O
We	O	O
describe	O	O
in	O	O
a	O	O
BSS	O	O
patient	O	O
the	O	O
first	O	O
case	O	O
of	O	O
homozygous	O	O
four	O	O
bases	O	O
deletion	O	O
(	O	O
TGAG	O	O
)	O	O
in	O	O
the	O	O
gpIbalpha	O	O
gene	O	O
coding	O	O
sequence	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
.	O	O
In	O	O
the	O	O
propositus	O	O
,	O	O
blood	O	O
smears	O	O
revealed	O	O
giant	O	O
platelets	O	O
(	O	O
30	O	O
x	O	O
10(9	O	O
)	O	O
platelets	O	O
/	O	O
L	O	O
)	O	O
,	O	O
and	O	O
platelet	O	O
agglutination	O	O
to	O	O
ristocetin	O	O
was	O	O
absent	O	O
.	O	O
Propositus	O	O
'	O	O
parents	O	O
are	O	O
consanguineous	O	O
.	O	O
His	O	O
father	O	O
and	O	O
paternal	O	O
grandmother	O	O
showed	O	O
a	O	O
mild	O	O
thrombocytopenia	O	O
(	O	O
108	O	O
x	O	O
10(9)/L	O	O
and	O	O
120	O	O
x	O	O
10(9)/L	O	O
platelets	O	O
respectively	O	O
)	O	O
while	O	O
mothers	O	O
and	O	O
sister	O	O
's	O	O
referred	O	O
normal	O	O
platelet	O	O
counts	O	O
.	O	O
The	O	O
surface	O	O
expression	O	O
of	O	O
GPIbalpha	O	O
was	O	O
practically	O	O
undetectable	O	O
by	O	O
flow	O	O
-	O	O
cytometry	O	O
and	O	O
western	O	O
blot	O	O
in	O	O
the	O	O
patient	O	O
and	O	O
was	O	O
reduced	O	B-NegReg
in	O	O
the	O	O
father	O	O
.	O	O
Proband	O	O
's	O	O
DNA	O	O
analysis	O	O
revealed	O	O
a	O	O
homozygous	O	O
four	O	O
-	O	O
base	O	O
-	O	O
pair	O	O
deletion	B-Var	O
(	O	O
TGAG	O	O
)	O	O
,	O	O
starting	O	O
from	O	O
the	O	O
last	O	O
base	O	O
of	O	O
the	O	O
codon	O	O
for	O	O
Ser39	O	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
a	O	O
coding	O	O
frame	O	O
shift	O	O
with	O	O
a	O	O
new	O	O
termination	B-MPA	O
codon	I-MPA	O
after	O	O
11	O	O
novel	O	O
amino	O	O
acids	O	O
.	O	O
The	O	O
same	O	O
mutation	O	O
was	O	O
seen	O	O
in	O	O
heterozygosis	O	O
in	O	O
both	O	O
parents	O	O
.	O	O
This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
GPIbalpha	O	O
TGAG	O	O
deletion	O	O
in	O	O
homozygous	O	O
state	O	O
even	O	O
if	O	O
the	O	O
defect	O	O
has	O	O
already	O	O
been	O	O
described	O	O
in	O	O
a	O	O
case	O	O
of	O	O
compound	O	O
heterozygosis	O	O
.	O	O
Surprisingly	O	O
,	O	O
the	O	O
propositus	O	O
does	O	O
not	O	O
report	O	O
any	O	O
spontaneous	O	O
bleeding	O	O
tendency	O	O
.	O	O
Common	O	O
mutations	B-Var	O
in	B-Reg	O
Cuban	O	O
cystic	B-Disease	O
fibrosis	I-Disease	O
patients	O	O
.	O	O
So	O	O
far	O	O
,	O	O
more	O	O
than	O	O
1500	O	O
mutations	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
cystic	O	O
fibrosis	O	O
transmembrane	O	O
conductance	O	O
regulator	O	O
(	B-Gene	O
CFTR	I-Gene	O
)	I-Gene	O
gene	O	O
.	O	O
Mutational	O	O
spectrum	O	O
varies	O	O
in	O	O
accordance	O	O
with	O	O
geographic	O	O
and/or	O	O
ethnic	O	O
origin	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
analyzed	O	O
seven	O	O
common	B-Reg	O
CF	B-Disease	O
mutations	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
F508del	I-Var	O
,	O	O
p	B-Var	O
.	I-Var	O
G542X	I-Var	O
,	O	O
p	B-Var	O
.	I-Var	O
R1162X	I-Var	O
,	O	O
p	B-Var	O
.	I-Var	O
N1303	I-Var	O
K	I-Var	O
,	O	O
p	B-Var	O
.	I-Var	O
R334W	I-Var	O
,	O	O
p	B-Var	O
.	I-Var	O
R553X	I-Var	O
and	O	O
c.3120	B-Var	O
+	I-Var	O
1G	I-Var	O
>	I-Var	O
A	I-Var	O
)	I-Var	O
taking	O	O
into	O	O
account	O	O
the	O	O
ethnic	O	O
origin	O	O
of	O	O
the	O	O
Cuban	O	O
population	O	O
which	O	O
is	O	O
mainly	O	O
influenced	O	O
by	O	O
Spanish	O	O
and	O	O
sub	O	O
-	O	O
Sahara	O	O
African	O	O
contribution	O	O
.	O	O
All	O	O
but	O	O
p	O	O
.	O	O
N1303	O	O
K	O	O
have	O	O
been	O	O
detected	O	O
in	O	O
our	O	O
patients	O	O
,	O	O
the	O	O
p	O	O
.	O	O
F508del	O	O
being	O	O
the	O	O
most	O	O
prevalent	O	O
(	O	O
37.9	O	O
%	O	O
)	O	O
.	O	O
Overall	O	O
,	O	O
six	O	O
mutations	O	O
showed	O	O
frequencies	O	O
above	O	O
1	O	O
%	O	O
accounting	O	O
for	O	O
55.5	O	O
%	O	O
of	O	O
the	O	O
Cuban	O	O
CF	O	O
alleles	O	O
.	O	O
Mutation	B-Var	O
in	O	O
BAG3	B-Gene	O
causes	B-Reg	O
severe	O	O
dominant	O	O
childhood	B-Disease	B-Disease
muscular	I-Disease	I-Disease
dystrophy	I-Disease	I-Disease
.	O	O
OBJECTIVE	O	O
:	O	O
Myofibrillar	O	O
myopathies	O	O
(	O	O
MFMs	O	O
)	O	O
are	O	O
morphologically	O	O
distinct	O	O
but	O	O
genetically	O	O
heterogeneous	O	O
muscular	O	O
dystrophies	O	O
in	O	O
which	O	O
disintegration	O	O
of	O	O
Z	O	O
disks	O	O
and	O	O
then	O	O
of	O	O
myofibrils	O	O
is	O	O
followed	O	O
by	O	O
ectopic	O	O
accumulation	O	O
of	O	O
multiple	O	O
proteins	O	O
.	O	O
Cardiomyopathy	O	O
,	O	O
neuropathy	O	O
,	O	O
and	O	O
dominant	O	O
inheritance	O	O
are	O	O
frequent	O	O
associated	O	O
features	O	O
.	O	O
Mutations	O	O
in	O	O
alphaB	O	O
-	O	O
crystallin	O	O
,	O	O
desmin	O	O
,	O	O
myotilin	O	O
,	O	O
Zasp	O	O
,	O	O
or	O	O
filamin	O	O
-	O	O
C	O	O
can	O	O
cause	O	O
MFMs	O	O
and	O	O
were	O	O
detected	O	O
in	O	O
32	O	O
of	O	O
85	O	O
patients	O	O
of	O	O
the	O	O
Mayo	O	O
MFM	O	O
cohort	O	O
.	O	O
Bag3	B-Protein	O
,	O	O
another	O	O
Z	O	O
-	O	O
disk	O	O
-	O	O
associated	O	O
protein	O	O
,	O	O
has	O	O
antiapoptotic	O	O
properties	O	O
,	O	O
and	O	O
its	O	O
targeted	O	O
deletion	B-Var	O
in	O	O
mice	O	O
causes	B-Reg	O
fulminant	B-Disease	O
myopathy	I-Disease	O
with	O	O
early	O	O
lethality	O	O
.	O	O
We	O	O
therefore	O	O
searched	O	O
for	O	O
mutations	O	O
in	O	O
BAG3	O	O
in	O	O
53	O	O
unrelated	O	O
MFM	O	O
patients	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
searched	O	O
for	O	O
mutations	O	O
in	O	O
BAG3	O	O
by	O	O
direct	O	O
sequencing	O	O
.	O	O
We	O	O
analyzed	O	O
structural	O	O
changes	O	O
in	O	O
muscle	O	O
by	O	O
histochemistry	O	O
,	O	O
immunocytochemistry	O	O
,	O	O
and	O	O
electron	O	O
microscopy	O	O
,	O	O
examined	O	O
mobility	O	O
of	O	O
the	O	O
mutant	O	O
Bag3	O	O
by	O	O
nondenaturing	O	O
electrophoresis	O	O
,	O	O
and	O	O
searched	O	O
for	O	O
abnormal	O	O
aggregation	O	O
of	O	O
the	O	O
mutant	O	O
protein	O	O
in	O	O
COS-7	O	O
(	O	O
SV-40	O	O
transformed	O	O
monkey	O	O
kidney	O	O
fibroblast-7	O	O
)	O	O
cells	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
identified	O	O
a	O	O
heterozygous	O	O
p	O	O
.	O	O
Pro209Leu	O	O
mutation	O	O
in	O	O
three	O	O
patients	O	O
.	O	O
All	O	O
presented	O	O
in	O	O
childhood	O	O
,	O	O
had	O	O
progressive	O	O
limb	O	O
and	O	O
axial	O	O
muscle	O	O
weakness	O	O
,	O	O
and	O	O
experienced	O	O
development	O	O
of	O	O
cardiomyopathy	O	O
and	O	O
severe	O	O
respiratory	O	O
insufficiency	O	O
in	O	O
their	O	O
teens	O	O
;	O	O
two	O	O
had	O	O
rigid	O	O
spines	O	O
,	O	O
and	O	O
one	O	O
a	O	O
peripheral	O	O
neuropathy	O	O
.	O	O
Electron	O	O
microscopy	O	O
showed	O	O
disintegration	O	O
of	O	O
Z	O	O
disks	O	O
,	O	O
extensive	O	O
accumulation	O	O
of	O	O
granular	O	O
debris	O	O
and	O	O
larger	O	O
inclusions	O	O
,	O	O
and	O	O
apoptosis	O	O
of	O	O
8	O	O
%	O	O
of	O	O
the	O	O
nuclei	O	O
.	O	O
On	O	O
nondenaturing	O	O
electrophoresis	O	O
of	O	O
muscle	O	O
extracts	O	O
,	O	O
the	O	O
Bag3	O	O
complex	O	O
migrated	O	O
faster	O	O
in	O	O
patient	O	O
than	O	O
control	O	O
extracts	O	O
,	O	O
and	O	O
expression	O	O
of	O	O
FLAG	O	O
-	O	O
labeled	O	O
mutant	O	O
and	O	O
wild	O	O
-	O	O
type	O	O
Bag3	O	O
in	O	O
COS	O	O
cells	O	O
showed	O	O
abnormal	O	O
aggregation	O	O
of	O	O
the	O	O
mutant	O	O
protein	O	O
.	O	O
INTERPRETATION	O	O
:	O	O
We	O	O
conclude	O	O
mutation	O	O
in	O	O
Bag3	O	O
defines	O	O
a	O	O
novel	O	O
severe	O	O
autosomal	O	O
dominant	O	O
childhood	O	O
muscular	O	O
dystrophy	O	O
.	O	O
Network	O	O
analyses	O	O
of	O	O
differentially	O	O
expressed	O	O
proteins	O	O
in	O	O
amniotic	O	O
fluid	O	O
supernatant	O	O
associated	O	O
with	O	O
abnormal	O	O
human	O	O
karyotypes	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
investigate	O	O
the	O	O
functional	O	O
roles	O	O
of	O	O
differentially	O	O
expressed	O	O
proteins	O	O
in	O	O
the	O	O
amniotic	B-Disease	O
fluid	I-Disease	O
supernatant	I-Disease	O
(	O	O
AFS	O	O
)	O	O
with	O	O
abnormal	O	O
karyotypes	O	O
.	O	O
DESIGN	O	O
:	O	O
Basic	O	O
and	O	O
clinical	O	O
research	O	O
.	O	O
SETTING	O	O
:	O	O
University	O	O
hospital	O	O
.	O	O
PATIENT(S	O	O
)	O	O
:	O	O
Samples	O	O
of	O	O
AFS	O	O
from	O	O
34	O	O
fetuses	O	O
with	O	O
normal	O	O
-	O	O
karyotype	O	O
,	O	O
17	O	O
with	O	O
trisomy	O	O
18	O	O
,	O	O
and	O	O
19	O	O
with	O	O
trisomy	O	O
21	O	O
.	O	O
INTERVENTION(S	O	O
)	O	O
:	O	O
Two	O	O
-	O	O
dimensional	O	O
chromatography	O	O
followed	O	O
by	O	O
mass	O	O
spectrometry	O	O
to	O	O
identify	O	O
the	O	O
proteins	O	O
differentially	O	O
expressed	O	O
in	O	O
AFS	O	O
of	O	O
trisomy-18	O	O
or	O	O
trisomy-21	O	O
fetuses	O	O
.	O	O
MAIN	O	O
OUTCOME	O	O
MEASURE(S	O	O
)	O	O
:	O	O
Differentially	O	O
expressed	O	O
proteins	O	O
were	O	O
confirmed	O	O
with	O	O
Western	O	O
blot	O	O
analysis	O	O
and	O	O
ELISA	O	O
.	O	O
The	O	O
roles	O	O
of	O	O
biologic	O	O
networks	O	O
in	O	O
the	O	O
pathophysiology	O	O
of	O	O
aneuploidies	O	O
were	O	O
analyzed	O	O
using	O	O
MetaCore	O	O
mapping	O	O
tools	O	O
.	O	O
RESULT(S	O	O
)	O	O
:	O	O
Levels	B-MPA	O
of	O	O
apolipoprotein	B-Protein	O
A1	I-Protein	O
,	O	O
AP-3mu	B-Protein	O
,	O	O
and	O	O
antitrypsin	B-Protein	O
were	O	O
significantly	O	O
decreased	B-NegReg	O
in	O	O
trisomy-18	B-Var	O
AFS	O	O
,	O	O
whereas	O	O
placental	B-Protein	O
protein-14	I-Protein	O
was	O	O
increased	B-PosReg	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
apolipoprotein	B-Protein	O
A1	I-Protein	O
was	O	O
decreased	B-NegReg	O
in	O	O
trisomy-21	B-Var	O
AFS	O	O
,	O	O
but	O	O
antitrypsin	B-Protein	O
,	O	O
prealbumin	B-Protein	O
,	O	O
and	O	O
transferrin	B-Protein	O
were	O	O
increased	B-PosReg	O
in	O	O
trisomy	B-Var	O
21	I-Var	O
.	O	O
Biologic	O	O
network	O	O
analyses	O	O
revealed	O	O
that	O	O
the	O	O
proteins	O	O
of	O	O
the	O	O
trisomy-18	O	O
AFS	O	O
network	O	O
were	O	O
involved	O	O
in	O	O
immune	O	O
processes	O	O
,	O	O
dysfunction	O	O
of	O	O
skin	O	O
pigmentation	O	O
,	O	O
and	O	O
platelet	O	O
disorders	O	O
,	O	O
whereas	O	O
those	O	O
of	O	O
trisomy	O	O
21	O	O
were	O	O
associated	O	O
with	O	O
dysfunctional	O	O
lipid	O	O
and	O	O
cholesterol	O	O
metabolism	O	O
,	O	O
processes	O	O
of	O	O
metal	O	O
ion	O	O
transport	O	O
,	O	O
adenosine	O	O
triphosphate	O	O
metabolism	O	O
,	O	O
and	O	O
energy	O	O
-	O	O
coupled	O	O
protein	O	O
transport	O	O
.	O	O
CONCLUSION(S	O	O
)	O	O
:	O	O
The	O	O
combined	O	O
use	O	O
of	O	O
quantitative	O	O
proteomics	O	O
and	O	O
functional	O	O
network	O	O
analyses	O	O
may	O	O
integrally	O	O
analyze	O	O
the	O	O
pathophysiology	O	O
of	O	O
abnormal	O	O
karyotypes	O	O
.	O	O
Canonical	O	O
WNT	O	O
signalling	O	O
determines	O	O
lineage	O	O
specificity	O	O
in	O	O
Wilms	O	O
tumour	O	O
.	O	O
Wilms	O	O
tumours	O	O
(	O	O
WTs	O	O
)	O	O
have	O	O
two	O	O
distinct	O	O
types	O	O
of	O	O
histology	O	O
with	O	O
or	O	O
without	O	O
ectopic	O	O
mesenchymal	O	O
elements	O	O
,	O	O
suggesting	O	O
that	O	O
WTs	O	O
arise	O	O
from	O	O
either	O	O
the	O	O
mesenchymal	O	O
or	O	O
epithelial	O	O
nephrogenic	O	O
lineages	O	O
.	O	O
Regardless	O	O
of	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
CTNNB1	O	O
mutations	O	O
,	O	O
nuclear	O	O
accumulation	O	O
of	O	O
beta	O	O
-	O	O
catenin	O	O
is	O	O
often	O	O
observed	O	O
in	O	O
WTs	O	O
with	O	O
ectopic	O	O
mesenchymal	O	O
elements	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
addressed	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
WNT	O	O
-	O	O
signalling	O	O
pathway	O	O
and	O	O
lineage	O	O
in	O	O
WTs	O	O
by	O	O
examining	O	O
CTNNB1	O	O
and	O	O
WT1	O	O
mutations	O	O
,	O	O
nuclear	O	O
accumulation	O	O
of	O	O
beta	O	O
-	O	O
catenin	O	O
,	O	O
tumour	O	O
histology	O	O
and	O	O
gene	O	O
expression	O	O
profiles	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
we	O	O
screened	O	O
for	O	O
mutations	B-Var	O
in	O	O
WTX	B-Gene	O
,	O	O
which	O	O
has	O	O
been	O	O
proposed	O	O
to	O	O
be	O	O
a	O	O
negative	B-NegReg	O
regulator	O	O
of	O	O
the	O	O
canonical	O	O
WNT	B-Pathway	O
-	I-Pathway	O
signalling	I-Pathway	O
pathway	I-Pathway	O
.	O	O
Unsupervised	O	O
clustering	O	O
analysis	O	O
identified	O	O
two	O	O
classes	O	O
of	O	O
tumours	O	O
:	O	O
mesenchymal	O	O
lineage	O	O
WNT	O	O
-	O	O
dependent	O	O
tumours	O	O
,	O	O
and	O	O
epithelial	O	O
lineage	O	O
WNT	O	O
-	O	O
independent	O	O
tumours	O	O
.	O	O
In	O	O
contrast	O	O
to	O	O
the	O	O
mesenchymal	O	O
lineage	O	O
specificity	O	O
of	O	O
CTNNB1	O	O
mutations	O	O
,	O	O
WTX	O	O
mutations	O	O
were	O	O
surprisingly	O	O
observed	O	O
in	O	O
both	O	O
lineages	O	O
.	O	O
WTX	B-Var	O
-	I-Var	O
mutant	I-Var	O
WTs	O	O
with	O	O
ectopic	O	O
mesenchymal	O	O
elements	O	O
had	O	O
nuclear	O	O
accumulation	B-PosReg	O
of	O	O
beta	B-Protein	O
-	I-Protein	O
catenin	I-Protein	O
,	O	O
upregulation	B-PosReg	O
of	O	O
WNT	B-Gene	O
target	I-Gene	O
genes	I-Gene	O
and	O	O
an	O	O
association	B-Reg	O
with	I-Reg	O
CTNNB1	B-Gene	O
mutations	B-Var	O
in	O	O
exon	O	O
7	O	O
or	O	O
8	O	O
.	O	O
However	O	O
,	O	O
epithelial	O	O
lineage	O	O
WTs	O	O
with	O	O
WTX	O	O
mutations	O	O
had	O	O
no	O	O
indications	O	O
of	O	O
active	O	O
WNT	O	O
signalling	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
involvement	O	O
of	O	O
WTX	O	O
in	O	O
the	O	O
WNT	O	O
-	O	O
signalling	O	O
pathway	O	O
may	O	O
be	O	O
lineage	O	O
dependent	O	O
,	O	O
and	O	O
that	O	O
WTX	O	O
may	O	O
have	O	O
an	O	O
alternative	O	O
function	O	O
to	O	O
its	O	O
role	O	O
in	O	O
the	O	O
canonical	O	O
WNT	O	O
-	O	O
signalling	O	O
pathway	O	O
.	O	O
Apparent	B-Disease	O
mineralocorticoid	I-Disease	O
excess	I-Disease	O
syndrome	I-Disease	O
in	O	O
a	O	O
Brazilian	O	O
boy	O	O
caused	B-Reg	O
by	I-Reg	O
the	O	O
homozygous	O	O
missense	O	O
mutation	O	O
p	B-Var	O
.	I-Var	O
R186C	I-Var	O
in	O	O
the	O	O
HSD11B2	B-Gene	O
gene	O	O
.	O	O
The	O	O
apparent	O	O
mineralocorticoid	O	O
excess	O	O
syndrome	O	O
(	O	O
AME	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
due	O	O
to	O	O
the	O	O
deficiency	O	O
of	O	O
11beta	O	O
-	O	O
hydroxysteroid	O	O
dehydrogenase	O	O
type	O	O
2	O	O
enzyme	O	O
(	O	O
11beta	O	O
-	O	O
HSD2	O	O
)	O	O
.	O	O
The	O	O
11beta	O	O
-	O	O
HSD2	O	O
enzyme	O	O
,	O	O
encoded	O	O
by	O	O
HSD11B2	O	O
gene	O	O
,	O	O
metabolizes	O	O
active	O	O
cortisol	O	O
in	O	O
cortisone	O	O
.	O	O
Mutations	B-Var	O
on	O	O
HSD11B2	B-Gene	O
gene	O	O
affect	B-Reg	O
the	O	O
enzyme	B-Enzyme	O
activity	B-MPA	O
by	O	O
leading	O	O
to	O	O
an	O	O
excess	B-PosReg	O
of	O	O
cortisol	B-MPA	O
,	O	O
which	O	O
causes	B-Reg	O
its	O	O
inappropriate	O	O
access	B-MPA	O
to	I-MPA	O
mineralocorticoid	I-MPA	O
receptor	I-MPA	O
.	O	O
Therefore	O	O
,	O	O
cortisol	O	O
will	O	O
bind	O	O
mineralocorticoid	O	O
receptor	O	O
.	O	O
The	O	O
human	O	O
HSD11B2	O	O
gene	O	O
maps	O	O
to	O	O
chromosome	O	O
16q22	O	O
and	O	O
consists	O	O
of	O	O
five	O	O
exons	O	O
encoding	O	O
a	O	O
protein	O	O
of	O	O
405	O	O
amino	O	O
acids	O	O
.	O	O
We	O	O
present	O	O
here	O	O
clinical	O	O
and	O	O
molecular	O	O
studies	O	O
on	O	O
a	O	O
Brazilian	O	O
boy	O	O
who	O	O
was	O	O
born	O	O
pre	O	O
-	O	O
term	O	O
after	O	O
an	O	O
oligodramnious	O	O
pregnancy	O	O
.	O	O
He	O	O
was	O	O
diagnosed	O	O
as	O	O
having	O	O
AME	O	O
at	O	O
the	O	O
age	O	O
of	O	O
26	O	O
months	O	O
.	O	O
His	O	O
parents	O	O
are	O	O
second	O	O
cousins	O	O
.	O	O
Molecular	O	O
characterization	O	O
of	O	O
the	O	O
HSD11B2	O	O
gene	O	O
revealed	O	O
the	O	O
homozygous	O	O
mutation	O	O
p	O	O
.	O	O
R186C.	O	O
The	O	O
patient	O	O
described	O	O
here	O	O
is	O	O
the	O	O
second	O	O
case	O	O
of	O	O
HDS11B2	B-Gene	O
gene	O	O
mutation	B-Var	O
reported	O	O
in	O	O
Brazilian	O	O
patients	O	O
with	B-Reg	O
AME	B-Disease	O
.	O	O
[	O	O
Primary	O	O
hiperoxaluria	O	O
:	O	O
a	O	O
new	O	O
mutation	O	O
in	O	O
gen	O	O
AGXT	B-Gene	O
(	B-Var	O
R197Q	I-Var	O
)	I-Var	O
cause	B-Reg	O
of	I-Reg	O
neonatal	B-Disease	O
convulsions	I-Disease	O
]	I-Disease	O
.	O	O
Hiperoxaluria	O	O
primaria	O	O
:	O	O
una	O	O
nueva	O	O
mutación	O	O
en	O	O
el	O	O
gen	O	O
AGXT	O	O
(	O	O
r197q	O	O
)	O	O
causante	O	O
de	O	O
convulsiones	O	O
neonatales	O	O
.	O	O
Primary	O	O
hyperoxaluria	O	O
is	O	O
a	O	O
congenital	O	O
innate	O	O
error	O	O
of	O	O
the	O	O
metabolism	O	O
of	O	O
the	O	O
amino	O	O
acids	O	O
,	O	O
that	O	O
is	O	O
transmitted	O	O
like	O	O
an	O	O
autosomal	O	O
recessive	O	O
character	O	O
.	O	O
Two	O	O
types	O	O
of	O	O
hyperoxaluria	O	O
exist	O	O
:	O	O
the	O	O
primary	O	O
type	O	O
I	O	O
,	O	O
that	O	O
corresponds	O	O
to	O	O
the	O	O
peroxisomal	O	O
enzymatic	O	O
deficit	O	O
of	O	O
the	O	O
alanine	O	O
glyoxylate	O	O
aminotransferase	O	O
in	O	O
the	O	O
liver	O	O
(	O	O
AGT	O	O
)	O	O
and	O	O
type	O	O
II	O	O
,	O	O
due	O	O
to	O	O
the	O	O
deficit	O	O
of	O	O
the	O	O
glyoxylate	O	O
reductase	O	O
/	O	O
hydroxypyruvate	O	O
reductase	O	O
deficiency	O	O
(	O	O
GRHPR	O	O
)	O	O
.	O	O
The	O	O
primary	O	O
type	O	O
I	O	O
(	O	O
AGT	O	O
)	O	O
is	O	O
the	O	O
most	O	O
frequenty	O	O
.	O	O
We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
female	O	O
infant	O	O
of	O	O
one	O	O
month	O	O
of	O	O
age	O	O
,	O	O
that	O	O
on	O	O
her	O	O
first	O	O
day	O	O
post	O	O
birth	O	O
,	O	O
presented	O	O
myoclonic	O	O
convulsions	O	O
and	O	O
tonic	O	O
spasms	O	O
,	O	O
both	O	O
during	O	O
wakefullness	O	O
and	O	O
sleep	O	O
periods	O	O
,	O	O
that	O	O
became	O	O
more	O	O
frequent	O	O
and	O	O
did	O	O
not	O	O
respond	O	O
to	O	O
the	O	O
use	O	O
of	O	O
anticonvulsants	O	O
.	O	O
The	O	O
ictal	O	O
Electroencephalogram	O	O
presented	O	O
an	O	O
intermittent	O	O
activity	O	O
of	O	O
spikes	O	O
and	O	O
spike	O	O
-	O	O
waves	O	O
of	O	O
high	O	O
voltage	O	O
in	O	O
the	O	O
right	O	O
hemisphere	O	O
.	O	O
Eight	O	O
minutes	O	O
after	O	O
the	O	O
intravenous	O	O
administration	O	O
of	O	O
150	O	O
mg	O	O
of	O	O
pyridoxine	O	O
,	O	O
it	O	O
was	O	O
observed	O	O
a	O	O
diminution	O	O
of	O	O
the	O	O
epileptic	O	O
activity	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
clinical	O	O
manifestations	O	O
.	O	O
The	O	O
determination	O	O
of	O	O
organic	O	O
acids	O	O
in	O	O
urine	O	O
revealed	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
concentration	O	O
levels	O	O
of	O	O
oxalic	O	O
acid	O	O
(	O	O
3064	O	O
mmol	O	O
/	O	O
mol	O	O
of	O	O
creatinine	O	O
)	O	O
.	O	O
The	O	O
molecular	O	O
genetic	O	O
study	O	O
of	O	O
the	O	O
AGXT	O	O
gene	O	O
,	O	O
showed	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
R197Q	O	O
mutation	O	O
in	O	O
exón	O	O
5	O	O
of	O	O
the	O	O
patient	O	O
and	O	O
her	O	O
father	O	O
.	O	O
She	O	O
received	O	O
treatment	O	O
with	O	O
pyridoxine	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
50	O	O
mg	O	O
/	O	O
day	O	O
.	O	O
When	O	O
she	O	O
reached	O	O
the	O	O
age	O	O
of	O	O
three	O	O
months	O	O
both	O	O
a	O	O
normal	O	O
electroencephalogram	O	O
and	O	O
biochemistry	O	O
were	O	O
obtained	O	O
.	O	O
Although	O	O
it	O	O
is	O	O
a	O	O
rare	O	O
cause	O	O
of	O	O
neonatal	O	O
convulsions	O	O
,	O	O
hyperoxaluria	O	O
,	O	O
due	O	O
to	O	O
new	O	O
mutations	O	O
is	O	O
an	O	O
underdiagnosed	O	O
disease	O	O
by	O	O
neonatologists	O	O
and	O	O
paediatricias	O	O
.	O	O
Identification	O	O
of	O	O
the	O	O
CLCN7	B-Gene	O
gene	O	O
mutations	B-Var	O
in	O	O
two	O	O
Chinese	O	O
families	O	O
with	B-Reg	O
autosomal	B-Disease	O
dominant	I-Disease	O
osteopetrosis	I-Disease	O
(	I-Disease	O
type	I-Disease	O
II	I-Disease	O
)	I-Disease	O
.	O	O
Here	O	O
we	O	O
report	O	O
the	O	O
identification	O	O
of	O	O
two	O	O
different	O	O
mutations	O	O
in	O	O
chloride	O	O
channel	O	O
7	O	O
gene	O	O
in	O	O
two	O	O
unrelated	O	O
patients	O	O
with	O	O
autosomal	O	O
dominant	O	O
osteopetrosis	O	O
type	O	O
II	O	O
.	O	O
We	O	O
determined	O	O
that	O	O
one	O	O
patient	O	O
(	O	O
a	O	O
32-year	O	O
-	O	O
old	O	O
woman	O	O
)	O	O
carried	O	O
a	O	O
heterozygous	O	O
gene	O	O
for	O	O
a	O	O
R767W	O	O
mutation	O	O
in	O	O
exon	O	O
24	O	O
,	O	O
and	O	O
another	O	O
patient	O	O
(	O	O
a	O	O
17-year	O	O
-	O	O
old	O	O
boy	O	O
)	O	O
carried	O	O
a	O	O
heterozygous	O	O
gene	O	O
for	O	O
a	O	O
novel	O	O
frameshift	O	O
mutation	O	O
(	O	O
Glu798FS	O	O
)	O	O
in	O	O
exon	O	O
25	O	O
.	O	O
Recent	O	O
studies	O	O
have	O	O
reported	O	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutations	B-Var	O
in	O	O
the	O	O
chloride	O	O
channel	O	O
7	O	O
(	B-Gene	B-Gene
CLCN7	I-Gene	I-Gene
)	I-Gene	I-Gene
gene	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
autosomal	B-Disease	O
dominant	I-Disease	O
osteopetrosis	I-Disease	O
type	I-Disease	O
II	I-Disease	O
(	I-Disease	O
ADO	I-Disease	O
-	I-Disease	O
II	I-Disease	O
)	I-Disease	O
.	O	O
The	O	O
identification	O	O
of	O	O
gene	O	O
mutations	O	O
in	O	O
Chinese	O	O
with	O	O
ADO	O	O
has	O	O
not	O	O
been	O	O
reported	O	O
previously	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
identified	O	O
mutations	O	O
of	O	O
the	O	O
CLCN7	O	O
gene	O	O
in	O	O
two	O	O
unrelated	O	O
Chinese	O	O
families	O	O
with	O	O
ADO	O	O
-	O	O
II	O	O
.	O	O
Two	O	O
probands	O	O
with	O	O
ADO	O	O
-	O	O
II	O	O
were	O	O
diagnosed	O	O
based	O	O
on	O	O
their	O	O
bone	O	O
characteristics	O	O
on	O	O
X	O	O
-	O	O
rays	O	O
and	O	O
their	O	O
laboratory	O	O
results	O	O
.	O	O
All	O	O
25	O	O
exons	O	O
of	O	O
the	O	O
CLCN7	O	O
gene	O	O
,	O	O
including	O	O
the	O	O
exon	O	O
-	O	O
intron	O	O
boundaries	O	O
,	O	O
were	O	O
sequenced	O	O
.	O	O
We	O	O
found	O	O
in	O	O
family	O	O
1	O	O
that	O	O
the	O	O
proband	O	O
(	O	O
a	O	O
32-year	O	O
-	O	O
old	O	O
woman	O	O
)	O	O
was	O	O
heterozygous	O	O
for	O	O
a	O	O
CLCN7	O	O
mutation	O	O
.	O	O
The	O	O
nonsynonymous	O	O
mutation	O	O
consisted	O	O
of	O	O
a	O	O
heterozygous	O	O
C	O	O
/	O	O
T	O	O
transition	O	O
at	O	O
codon	O	O
2327	O	O
in	O	O
exon	O	O
24	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
an	O	O
arginine	O	O
(	O	O
CGG)-to	O	O
tryptophan	O	O
(	O	O
TGG	O	O
)	O	O
substitution	O	O
at	O	O
position	O	O
767	O	O
(	O	O
R767W	O	O
)	O	O
.	O	O
The	O	O
same	O	O
heterozygous	O	O
mutation	O	O
(	O	O
C	O	O
/	O	O
T	O	O
)	O	O
was	O	O
determined	O	O
in	O	O
her	O	O
father	O	O
and	O	O
son	O	O
,	O	O
who	O	O
were	O	O
asymptomatic	O	O
with	O	O
normal	O	O
skeleton	O	O
radiography	O	O
.	O	O
In	O	O
family	O	O
2	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
proband	O	O
(	O	O
a	O	O
17-year	O	O
-	O	O
old	O	O
boy	O	O
)	O	O
carried	O	O
a	O	O
novel	O	O
frameshift	O	O
mutation	O	O
(	O	O
Glu798FS	O	O
)	O	O
resulting	O	O
from	O	O
a	O	O
G	O	O
insertion	O	O
between	O	O
codon	O	O
60	O	O
and	O	O
codon	O	O
61	O	O
in	O	O
exon	O	O
25	O	O
.	O	O
The	O	O
heterozygous	O	O
-/G	O	O
insertion	O	O
is	O	O
predicted	O	O
to	O	O
elongate	O	O
the	O	O
peptide	O	O
of	O	O
CLCN7	O	O
by	O	O
120	O	O
amino	O	O
acids	O	O
after	O	O
position	O	O
797	O	O
amino	O	O
acids	O	O
.	O	O
Similarly	O	O
,	O	O
some	O	O
individuals	O	O
of	O	O
this	O	O
family	O	O
carried	O	O
the	O	O
same	O	O
heterozygous	O	O
mutation	O	O
,	O	O
but	O	O
they	O	O
are	O	O
all	O	O
asymptomatic	O	O
.	O	O
Furthermore	O	O
,	O	O
the	O	O
R767W	O	O
and	O	O
Glu798FS	O	O
mutations	O	O
were	O	O
not	O	O
found	O	O
in	O	O
100	O	O
unrelated	O	O
controls	O	O
.	O	O
Our	O	O
present	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
novel	O	O
Glu798FS	B-Var	O
mutation	O	O
in	O	O
exon	O	O
25	O	O
and	O	O
R767W	B-Var	O
in	O	O
exon	O	O
24	O	O
in	O	O
the	O	O
CLCN7	B-Gene	O
gene	O	O
were	O	O
responsible	B-Reg	O
for	O	O
ADO	B-Disease	O
-	I-Disease	O
II	I-Disease	O
in	O	O
these	O	O
Chinese	O	O
patients	O	O
.	O	O
A	O	O
case	O	O
of	O	O
factor	B-Disease	O
XI	I-Disease	O
deficiency	I-Disease	O
caused	B-Reg	O
by	I-Reg	O
compound	O	O
heterozygous	O	O
F11	B-Gene	B-Gene
gene	O	O
mutation	B-Var	O
.	O	O
Inherited	O	O
factor	O	O
XI	O	O
(	O	O
FXI	O	O
)	O	O
deficiency	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
bleeding	O	O
disorder	O	O
in	O	O
most	O	O
populations	O	O
except	O	O
for	O	O
Ashkenazi	O	O
Jews	O	O
.	O	O
In	O	O
this	O	O
report	O	O
,	O	O
a	O	O
25-year	O	O
-	O	O
old	O	O
Chinese	O	O
female	O	O
FXI	O	O
deficiency	O	O
case	O	O
has	O	O
been	O	O
studied	O	O
.	O	O
Routine	O	O
clotting	O	O
tests	O	O
showed	O	O
significantly	O	O
prolonged	O	O
activated	O	O
partial	O	O
thromboplastin	O	O
time	O	O
(	O	O
69.5	O	O
s	O	O
,	O	O
control	O	O
35	O	O
+	O	O
/-	O	O
10	O	O
s	O	O
)	O	O
while	O	O
prothrombin	O	O
time	O	O
(	O	O
12.3	O	O
s	O	O
,	O	O
control	O	O
13	O	O
+	O	O
/-	O	O
3	O	O
s)was	O	O
normal	O	O
.	O	O
FXI	O	O
:	O	O
C	O	O
and	O	O
FXI	O	O
:	O	O
Ag	O	O
were	O	O
2.6	O	O
%	O	O
and	O	O
2.5	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
indicating	O	O
that	O	O
this	O	O
case	O	O
was	O	O
cross	O	O
-	O	O
reacting	O	O
material	O	O
negative	O	O
.	O	O
The	O	O
activities	O	O
of	O	O
other	O	O
coagulation	O	O
factors	O	O
and	O	O
liver	O	O
function	O	O
were	O	O
in	O	O
normal	O	O
range	O	O
.	O	O
The	O	O
DNA	O	O
sequence	O	O
results	O	O
of	O	O
the	O	O
15	O	O
exons	O	O
and	O	O
their	O	O
boundaries	O	O
of	O	O
F11	O	O
gene	O	O
revealed	O	O
a	O	O
novel	O	O
G3733C	O	O
missense	O	O
mutation	O	O
in	O	O
exon	O	O
2	O	O
,	O	O
and	O	O
a	O	O
recurrent	O	O
C16642	O	O
T	O	O
nonsense	O	O
mutation	O	O
in	O	O
exon	O	O
8	O	O
.	O	O
The	O	O
G3733C	B-Var	O
mutation	O	O
caused	B-Reg	O
G-1R	B-Var	O
substitution	I-Var	O
in	O	O
FXI	B-Protein	O
signal	I-Protein	O
peptide	I-Protein	O
,	O	O
which	O	O
might	O	O
impair	B-NegReg	O
the	O	O
protein	B-MPA	O
's	I-MPA	O
secretion	I-MPA	O
and	O	O
introduced	B-PosReg	O
a	O	O
new	O	O
BssSI	O	O
enzyme	B-Enzyme	O
digestion	B-MPA	O
site	O	O
.	O	O
The	O	O
C16642	B-Var	O
T	I-Var	O
mutation	O	O
led	B-Reg	O
a	O	O
premature	B-MPA	O
stop	I-MPA	O
codon	I-MPA	O
at	O	O
amino	O	O
acid	O	O
position	O	O
263(Q263Term	B-Var	O
)	I-Var	O
.	O	O
G-1R	B-Var	O
and	O	O
Q263Term	B-Var	O
compound	O	O
heterozygous	O	O
mutations	O	O
in	O	O
F11	B-Gene	O
gene	O	O
were	O	O
the	O	O
cause	B-Reg	O
of	O	O
FXI	B-Disease	O
deficiency	I-Disease	O
for	O	O
this	O	O
proband	O	O
.	O	O
G-1R	B-Var	O
mutation	O	O
was	O	O
a	O	O
novel	O	O
F11	B-Gene	O
gene	O	O
mutation	O	O
causing	B-Reg	O
inherited	O	O
FXI	B-Disease	O
deficiency	I-Disease	O
.	O	O
Accelerated	O	O
inactivation	O	O
of	O	O
the	O	O
L	O	O
-	O	O
type	O	O
calcium	O	O
current	O	O
due	O	O
to	O	O
a	O	O
mutation	O	O
in	O	O
CACNB2b	O	O
underlies	O	O
Brugada	O	O
syndrome	O	O
.	O	O
Recent	O	O
studies	O	O
have	O	O
demonstrated	O	O
an	O	O
association	B-Reg	O
between	O	O
mutations	B-Var	O
in	O	O
CACNA1c	B-Gene	O
or	O	O
CACNB2b	B-Gene	O
and	O	O
Brugada	B-Disease	O
syndrome	I-Disease	O
(	O	O
BrS	O	O
)	O	O
.	O	O
Previously	O	O
described	O	O
mutations	O	O
all	O	O
caused	O	O
a	O	O
loss	O	B-NegReg
of	O	O
function	O	O
secondary	O	O
to	O	O
a	O	O
reduction	O	O
of	O	O
peak	O	B-Disease
calcium	O	I-Disease
current	O	I-CPA
(	O	O
I(Ca	O	O
)	O	O
)	O	O
.	O	O
We	O	O
describe	O	O
a	O	O
novel	O	O
CACNB2b	B-Gene	O
mutation	B-Var	O
associated	O	O
with	O	O
BrS	O	O
in	O	O
which	O	O
loss	O	O
of	O	O
function	O	O
is	O	O
caused	O	O
by	O	O
accelerated	O	O
inactivation	B-NegReg	O
of	O	O
I(Ca	B-MPA	O
)	I-MPA	I-CPA
.	O	O
The	O	O
proband	O	O
,	O	O
a	O	O
32	O	O
year	O	O
old	O	O
male	O	O
,	O	O
displayed	O	O
a	O	O
Type	O	O
I	O	O
ST	O	O
segment	O	O
elevation	O	O
in	O	O
two	O	O
right	O	O
precordial	O	O
ECG	O	O
leads	O	O
following	O	O
a	O	O
procainamide	O	O
challenge	O	O
.	O	O
EP	O	O
study	O	O
was	O	O
positive	O	O
with	O	O
induction	O	O
of	O	O
polymorphic	O	O
VT	O	O
/	O	O
VF	O	O
.	O	O
Interrogation	O	O
of	O	O
implanted	O	O
ICD	O	O
revealed	O	O
brief	O	O
episodes	O	O
of	O	O
very	O	O
rapid	O	O
ventricular	O	O
tachycardia	O	O
.	O	O
He	O	O
was	O	O
also	O	O
diagnosed	O	O
with	O	O
vasovagal	O	O
syncope	O	O
.	O	O
Genomic	O	O
DNA	O	O
was	O	O
isolated	O	O
from	O	O
lymphocytes	O	O
.	O	O
All	O	O
exons	O	O
and	O	O
intron	O	O
borders	O	O
of	O	O
15	O	O
ion	O	O
channel	O	O
genes	O	O
were	O	O
amplified	O	O
and	O	O
sequenced	O	O
.	O	O
The	O	O
only	O	O
mutation	O	O
uncovered	O	O
was	O	O
a	O	O
missense	O	O
mutation	O	O
(	O	O
T11I	O	O
)	O	O
in	O	O
CACNB2b	O	O
.	O	O
We	O	O
expressed	O	O
WT	O	O
or	O	O
T11I	O	O
CACNB2b	O	O
in	O	O
TSA201	O	O
cells	O	O
co	O	O
-	O	O
transfected	O	O
with	O	O
WT	O	O
CACNA1c	O	O
and	O	O
CACNA2d	O	O
.	O	O
Patch	O	O
clamp	O	O
analysis	O	O
showed	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
WT	O	O
and	O	O
T11I	O	O
in	O	O
peak	O	O
I(Ca	O	O
)	O	O
density	O	O
,	O	O
steady	O	O
-	O	O
state	O	O
inactivation	O	O
or	O	O
recovery	O	O
from	O	O
inactivation	O	O
.	O	O
However	O	O
,	O	O
both	O	O
fast	O	O
and	O	O
slow	O	O
decays	O	O
of	O	O
I(Ca	O	O
)	O	O
were	O	O
significantly	O	O
faster	O	O
in	O	O
mutant	O	O
channels	O	O
between	O	O
0	O	O
and	O	O
+	O	O
20	O	O
mV.	O	O
Action	O	O
potential	O	O
voltage	O	O
clamp	O	O
experiments	O	O
showed	O	O
that	O	O
total	O	O
charge	O	O
was	O	O
reduced	O	O
by	O	O
almost	O	O
half	O	O
compared	O	O
to	O	O
WT	O	O
.	O	O
We	O	O
report	O	O
the	O	O
first	O	O
BrS	O	O
mutation	O	O
in	O	O
CaCNB2b	O	O
resulting	O	O
in	O	O
accelerated	O	O
inactivation	O	O
of	O	O
L	O	O
-	O	O
type	O	O
calcium	O	O
channel	O	O
current	O	O
.	O	O
Our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
faster	O	O
current	O	O
decay	O	O
results	O	O
in	O	O
a	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
responsible	O	O
for	O	O
the	O	O
Brugada	O	O
phenotype	O	O
Electrophysiological	O	O
studies	O	O
in	O	O
a	O	O
mouse	O	O
model	O	O
of	O	O
Schwartz	O	O
-	O	O
Jampel	O	O
syndrome	O	O
demonstrate	O	O
muscle	O	O
fiber	O	O
hyperactivity	O	O
of	O	O
peripheral	O	O
nerve	O	O
origin	O	O
.	O	O
Schwartz	B-Disease	O
-	I-Disease	O
Jampel	I-Disease	O
syndrome	I-Disease	O
(	O	O
SJS	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
-	O	O
recessive	O	O
condition	O	O
characterized	O	O
by	O	O
muscle	O	O
stiffness	O	O
and	O	O
chondrodysplasia	O	O
.	O	O
It	O	O
is	O	O
due	O	O
to	O	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
hypomorphic	O	O
mutations	B-Var	O
in	O	O
the	O	O
HSPG2	B-Gene	O
gene	O	O
that	O	O
encodes	O	O
for	O	O
perlecan	O	O
,	O	O
a	O	O
proteoglycan	O	O
secreted	O	O
into	O	O
the	O	O
basement	O	O
membrane	O	O
.	O	O
The	O	O
origin	O	O
of	O	O
muscle	O	O
stiffness	O	O
in	O	O
SJS	O	O
is	O	O
debated	O	O
.	O	O
To	O	O
resolve	O	O
this	O	O
issue	O	O
,	O	O
we	O	O
performed	O	O
an	O	O
electrophysiological	O	O
investigation	O	O
of	O	O
an	O	O
SJS	O	O
mouse	O	O
model	O	O
with	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
the	O	O
HSPG2	O	O
gene	O	O
.	O	O
Compound	O	O
muscle	O	O
action	O	O
potential	O	O
amplitudes	O	O
,	O	O
distal	O	O
motor	O	O
latencies	O	O
,	O	O
repetitive	O	O
nerve	O	O
stimulation	O	O
tests	O	O
,	O	O
and	O	O
sensory	O	O
nerve	O	O
conduction	O	O
velocities	O	O
of	O	O
SJS	O	O
mice	O	O
were	O	O
normal	O	O
.	O	O
On	O	O
electromyography	O	O
(	O	O
EMG	O	O
)	O	O
,	O	O
neuromyotonic	O	O
discharges	O	O
,	O	O
that	O	O
is	O	O
,	O	O
bursts	O	O
of	O	O
motor	O	O
unit	O	O
action	O	O
potentials	O	O
firing	O	O
at	O	O
high	O	O
rates	O	O
(	O	O
120	O	O
-	O	O
300	O	O
HZ	O	O
)	O	O
,	O	O
were	O	O
constantly	O	O
observed	O	O
in	O	O
SJS	O	O
mice	O	O
in	O	O
all	O	O
muscles	O	O
,	O	O
except	O	O
in	O	O
the	O	O
diaphragm	O	O
.	O	O
Neuromyotonic	O	O
discharges	O	O
were	O	O
not	O	O
influenced	O	O
by	O	O
general	O	O
anesthesia	O	O
and	O	O
disappeared	O	O
with	O	O
curare	O	O
administration	O	O
.	O	O
They	O	O
persisted	O	O
after	O	O
complete	O	O
motor	O	O
nerve	O	O
section	O	O
,	O	O
terminating	O	O
only	O	O
with	O	O
Wallerian	O	O
degeneration	O	O
.	O	O
These	O	O
results	O	O
demonstrate	O	O
that	O	O
perlecan	O	O
deficiency	O	O
in	O	O
SJS	O	O
provokes	O	O
a	O	O
neuromyotonic	O	O
syndrome	O	O
.	O	O
The	O	O
findings	O	O
further	O	O
suggest	O	O
a	O	O
distal	O	O
axonal	O	O
localization	O	O
of	O	O
the	O	O
generator	O	O
of	O	O
neuromyotonic	O	O
discharges	O	O
.	O	O
SJS	O	O
should	O	O
now	O	O
be	O	O
considered	O	O
as	O	O
an	O	O
inherited	O	O
disorder	O	O
with	O	O
peripheral	O	O
nerve	O	O
hyperexcitability	O	O
.	O	O
MEFV	B-Gene	O
mutation	B-Var	O
carriage	O	O
in	O	O
Israeli	O	O
Jewish	O	O
individuals	O	O
from	O	O
ethnicities	O	O
with	O	O
low	O	O
risk	O	O
for	B-Reg	O
familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
.	O	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
is	O	O
a	O	O
disease	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
MEditerranean	O	O
FeVer	O	O
gene	O	O
(	B-Gene	O
MEFV	I-Gene	O
)	I-Gene	O
,	O	O
and	O	O
in	O	O
Israel	O	O
it	O	O
most	O	O
commonly	O	O
affects	O	O
Jews	O	O
of	O	O
North	O	O
African	O	O
extraction	O	O
,	O	O
in	O	O
whom	O	O
the	O	O
mutation	O	O
carrier	O	O
rate	O	O
is	O	O
as	O	O
high	O	O
as	O	O
1	O	O
in	O	O
5	O	O
.	O	O
To	O	O
assess	O	O
the	O	O
protective	O	O
as	O	O
well	O	O
as	O	O
the	O	O
modulating	O	O
affect	O	O
of	O	O
MEFV	O	O
mutation	O	O
carriage	O	O
on	O	O
various	O	O
inflammatory	O	O
disease	O	O
states	O	O
,	O	O
we	O	O
sought	O	O
to	O	O
define	O	O
the	O	O
frequency	O	O
of	O	O
MEFV	O	O
mutations	O	O
in	O	O
Israeli	O	O
Jewish	O	O
individuals	O	O
of	O	O
various	O	O
ethnicities	O	O
,	O	O
including	O	O
those	O	O
with	O	O
low	O	O
frequency	O	O
of	O	O
FMF	O	O
,	O	O
which	O	O
were	O	O
not	O	O
in	O	O
the	O	O
focus	O	O
of	O	O
our	O	O
attention	O	O
hitherto	O	O
.	O	O
A	O	O
total	O	O
of	O	O
163	O	O
adults	O	O
of	O	O
Bucharian	O	O
,	O	O
Turkish	O	O
,	O	O
Georgian	O	O
,	O	O
Yemenite	O	O
and	O	O
Bulgarian	O	O
origin	O	O
comprised	O	O
the	O	O
study	O	O
group	O	O
.	O	O
The	O	O
prevalence	O	O
of	O	O
the	O	O
most	O	O
frequent	O	O
MEFV	O	O
mutations	O	O
in	O	O
the	O	O
Israeli	O	O
Jewish	O	O
population	O	O
,	O	O
namely	O	O
:	O	O
M694V	O	O
,	O	O
V726A	O	O
and	O	O
E148Q	O	O
,	O	O
was	O	O
assessed	O	O
.	O	O
The	O	O
association	O	O
of	O	O
mutation	O	O
carriage	O	O
with	O	O
a	O	O
personal	O	O
history	O	O
of	O	O
FMF	O	O
-	O	O
like	O	O
phenomena	O	O
,	O	O
as	O	O
well	O	O
as	O	O
various	O	O
inflammatory	O	O
and	O	O
non	O	O
-	O	O
inflammatory	O	O
diseases	O	O
,	O	O
was	O	O
evaluated	O	O
.	O	O
A	O	O
high	O	O
MEFV	O	O
mutation	O	O
frequency	O	O
was	O	O
found	O	O
among	O	O
Jews	O	O
of	O	O
Bucharian	O	O
,	O	O
Georgian	O	O
and	O	O
Bulgarian	O	O
origin	O	O
(	O	O
20	O	O
%	O	O
)	O	O
,	O	O
whereas	O	O
intermediate	O	O
and	O	O
low	O	O
rates	O	O
were	O	O
detected	O	O
in	O	O
Jews	O	O
of	O	O
Turkish	O	O
and	O	O
Yemenite	O	O
extraction	O	O
(	O	O
14	O	O
and	O	O
8	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
FMF	O	O
-	O	O
like	O	O
manifestations	O	O
and	O	O
related	O	O
diseases	O	O
were	O	O
observed	O	O
more	O	O
often	O	O
in	O	O
MEFV	O	O
mutation	O	O
carriers	O	O
than	O	O
in	O	O
their	O	O
counterparts	O	O
.	O	O
MEFV	O	O
mutation	O	O
frequency	O	O
,	O	O
directly	O	O
assessed	O	O
by	O	O
DNA	O	O
analysis	O	O
,	O	O
exceeds	O	O
the	O	O
rate	O	O
calculated	O	O
from	O	O
disease	O	O
prevalence	O	O
in	O	O
Israeli	O	O
Jewish	O	O
individuals	O	O
originated	O	O
from	O	O
ethnicities	O	O
with	O	O
a	O	O
low	O	O
prevalence	O	O
of	O	O
FMF	O	O
.	O	O
MEFV	O	O
mutation	O	O
carriage	O	O
in	O	O
this	O	O
subgroup	O	O
is	O	O
associated	O	O
with	O	O
various	O	O
inflammatory	O	O
disorders	O	O
.	O	O
In	O	O
vivo	O	O
laser	O	O
confocal	O	O
microscopy	O	O
findings	O	O
and	O	O
mutational	O	O
analysis	O	O
for	O	O
Schnyder	O	O
's	O	O
crystalline	O	O
corneal	O	O
dystrophy	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
identify	O	O
any	O	O
mutation	O	O
of	O	O
the	O	O
UbiA	O	O
prenyltransferase	O	O
domain	O	O
-	O	O
containing	O	O
protein	O	O
1	O	O
(	O	O
UBIAD1	O	O
)	O	O
gene	O	O
in	O	O
Japanese	O	O
patients	O	O
with	O	O
Schnyder	B-Disease	O
's	I-Disease	O
crystalline	I-Disease	O
corneal	I-Disease	O
dystrophy	I-Disease	O
(	O	O
SCCD	O	O
)	O	O
and	O	O
to	O	O
investigate	O	O
in	O	O
vivo	O	O
microstructural	O	O
phenotype	O	O
and	O	O
genotype	O	O
correlations	O	O
using	O	O
laser	O	O
scanning	O	O
confocal	O	O
microscopy	O	O
(	O	O
Heidelberg	O	O
Retina	O	O
Tomograph	O	O
2	O	O
Rostock	O	O
Cornea	O	O
Module	O	O
;	O	O
Heidelberg	O	O
Engineering	O	O
GmbH	O	O
,	O	O
Dossenheim	O	O
,	O	O
Germany	O	O
)	O	O
.	O	O
DESIGN	O	O
:	O	O
Small	O	O
,	O	O
comparative	O	O
case	O	O
series	O	O
.	O	O
PARTICIPANTS	O	O
:	O	O
Three	O	O
patients	O	O
from	O	O
3	O	O
pedigrees	O	O
(	O	O
3	O	O
males	O	O
)	O	O
with	O	O
clinically	O	O
diagnosed	O	O
SCCD	O	O
and	O	O
their	O	O
relatives	O	O
(	O	O
2	O	O
males	O	O
,	O	O
1	O	O
female	O	O
)	O	O
participated	O	O
in	O	O
this	O	O
study	O	O
.	O	O
TESTING	O	O
:	O	O
All	O	O
participants	O	O
were	O	O
examined	O	O
genetically	O	O
and	O	O
by	O	O
slit	O	O
-	O	O
lamp	O	O
biomicroscopy	O	O
and	O	O
in	O	O
vivo	O	O
laser	O	O
confocal	O	O
microscopy	O	O
.	O	O
MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
:	O	O
Genomic	O	O
DNA	O	O
from	O	O
the	O	O
patients	O	O
and	O	O
100	O	O
unrelated	O	O
healthy	O	O
volunteers	O	O
(	O	O
200	O	O
chromosomes	O	O
)	O	O
was	O	O
isolated	O	O
from	O	O
blood	O	O
samples	O	O
and	O	O
used	O	O
for	O	O
mutation	O	O
screening	O	O
of	O	O
the	O	O
UBIAD1	O	O
gene	O	O
.	O	O
Selected	O	O
confocal	O	O
images	O	O
of	O	O
corneal	O	O
layers	O	O
were	O	O
evaluated	O	O
qualitatively	O	O
for	O	O
shape	O	O
and	O	O
degree	O	O
of	O	O
light	O	O
reflection	O	O
of	O	O
deposits	O	O
.	O	O
RESULTS	O	O
:	O	O
Novel	O	O
mutations	O	O
in	O	O
the	O	O
UBIAD1	O	O
gene	O	O
(	O	O
Y174C	O	O
,	O	O
K181R	O	O
,	O	O
and	O	O
N233H	O	O
)	O	O
were	O	O
identified	O	O
.	O	O
Additionally	O	O
,	O	O
cosegregation	O	O
of	O	O
the	O	O
mutation	O	O
(	B-Var	O
Y174C	I-Var	O
)	I-Var	O
and	O	O
SCCD	O	O
was	O	O
confirmed	O	O
in	O	O
1	O	O
pedigree	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
mutation	O	O
of	O	O
the	O	O
UBIAD1	B-Gene	O
gene	O	O
is	O	O
causative	B-Reg	O
for	O	O
SCCD	B-Disease	O
.	O	O
The	O	O
3	O	O
mutations	O	O
were	O	O
absent	O	O
in	O	O
all	O	O
200	O	O
control	O	O
chromosomes	O	O
.	O	O
In	O	O
vivo	O	O
laser	O	O
confocal	O	O
microscopy	O	O
demonstrated	O	O
subepithelial	O	O
highly	O	O
reflective	O	O
crystals	O	O
in	O	O
4	O	O
cases	O	O
;	O	O
the	O	O
shapes	O	O
of	O	O
the	O	O
crystals	O	O
were	O	O
needle	O	O
-	O	O
shaped	O	O
(	O	O
3	O	O
cases	O	O
)	O	O
or	O	O
rectangular	O	O
(	O	O
1	O	O
case	O	O
)	O	O
.	O	O
A	O	O
phenotype	O	O
and	O	O
genotype	O	O
correlation	O	O
was	O	O
demonstrated	O	O
in	O	O
1	O	O
pedigree	O	O
,	O	O
and	O	O
phenotypic	O	O
heterogeneity	O	O
(	O	O
SCCD	O	O
with	O	O
or	O	O
without	O	O
crystals	O	O
caused	O	O
by	O	O
a	O	O
same	O	O
mutation	O	O
of	O	O
Y174C	O	O
in	O	O
the	O	O
UBIAD1	O	O
gene	O	O
)	O	O
also	O	O
was	O	O
demonstrated	O	O
in	O	O
1	O	O
pedigree	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Nonsynonymous	O	O
novel	O	O
mutations	O	O
in	O	O
the	O	O
UBIAD1	O	O
gene	O	O
were	O	O
detected	O	O
in	O	O
3	O	O
unrelated	O	O
Japanese	O	O
pedigrees	O	O
with	O	O
SCCD	O	O
,	O	O
confirming	O	O
the	O	O
genetic	O	O
heterogeneity	O	O
of	O	O
this	O	O
disorder	O	O
.	O	O
In	O	O
vivo	O	O
laser	O	O
confocal	O	O
microscopy	O	O
is	O	O
capable	O	O
of	O	O
identifying	O	O
characteristic	O	O
corneal	O	O
microstructural	O	O
changes	O	O
related	O	O
to	O	O
genetically	O	O
mapped	O	O
SCCD	O	O
with	O	O
high	O	O
resolution	O	O
,	O	O
and	O	O
phenotypic	O	O
heterogeneity	O	O
was	O	O
presented	O	O
.	O	O
Further	O	O
confocal	O	O
and	O	O
mutational	O	O
analysis	O	O
using	O	O
a	O	O
larger	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
SCCD	O	O
is	O	O
required	O	O
to	O	O
elucidate	O	O
in	O	O
vivo	O	O
microstructural	O	O
phenotype	O	O
and	O	O
genotype	O	O
correlations	O	O
.	O	O
FINANCIAL	O	O
DISCLOSURE(S	O	O
)	O	O
:	O	O
The	O	O
author(s	O	O
)	O	O
have	O	O
no	O	O
proprietary	O	O
or	O	O
commercial	O	O
interest	O	O
in	O	O
any	O	O
materials	O	O
discussed	O	O
in	O	O
this	O	O
article	O	O
.	O	O
Neutral	B-Disease	O
lipid	I-Disease	O
storage	I-Disease	O
disease	I-Disease	O
:	I-Disease	O
genetic	O	O
disorders	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
adipose	B-Enzyme	O
triglyceride	I-Enzyme	O
lipase	B-Gene	O
/	I-Gene	O
PNPLA2	I-Gene	O
or	O	O
CGI-58	B-Gene	O
/	I-Gene	O
ABHD5	I-Gene	O
.	O	O
Neutral	O	O
lipid	O	O
storage	O	O
disease	O	O
(	O	O
NLSD	O	O
)	O	O
is	O	O
a	O	O
group	O	O
of	O	O
autosomal	O	O
recessive	O	O
disorders	O	O
characterized	O	O
by	O	O
the	O	O
excessive	O	O
accumulation	O	O
of	O	O
neutral	O	O
lipids	O	O
in	O	O
multiple	O	O
tissues	O	O
.	O	O
Recently	O	O
,	O	O
two	O	O
genes	O	O
,	O	O
adipose	O	O
triglyceride	O	O
lipase	O	O
(	O	O
ATGL	O	O
/	O	O
PNPLA2	O	O
)	O	O
and	O	O
comparative	O	O
gene	O	O
identification-58	O	O
(	O	O
CGI-58	O	O
/	O	O
ABHD5	O	O
)	O	O
,	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
cause	O	O
NLSD	O	O
.	O	O
ATGL	O	O
specifically	O	O
hydrolyzes	O	O
the	O	O
first	O	O
fatty	O	O
acid	O	O
from	O	O
triacylglycerols	O	O
(	O	O
TG	O	O
)	O	O
and	O	O
CGI-58	O	O
/	O	O
ABHD5	O	O
stimulates	O	O
ATGL	O	O
activity	O	O
by	O	O
a	O	O
currently	O	O
unknown	O	O
mechanism	O	O
.	O	O
Mutations	B-Var	O
in	O	O
both	O	O
the	O	O
ATGL	B-Gene	O
and	O	O
the	O	O
CGI-58	B-Gene	O
genes	O	O
are	O	O
associated	B-Reg	O
with	I-Reg	O
systemic	B-MPA	O
TG	I-MPA	O
accumulation	I-MPA	O
,	O	O
yet	O	O
the	O	O
resulting	O	O
clinical	O	O
manifestations	O	O
are	O	O
not	O	O
identical	O	O
.	O	O
Patients	O	O
with	O	O
defective	O	O
ATGL	O	O
function	O	O
suffer	O	O
from	O	O
more	O	O
severe	O	O
myopathy	O	O
(	O	O
NLSDM	O	O
)	O	O
than	O	O
patients	O	O
with	O	O
defective	O	O
CGI-58	O	O
function	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
CGI-58	B-Gene	O
mutations	B-Var	O
are	O	O
always	O	O
associated	B-Reg	O
with	I-Reg	O
ichthyosis	O	O
(	B-Disease	O
NLSDI	I-Disease	O
)	I-Disease	O
,	O	O
which	O	O
was	O	O
not	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
defective	O	O
ATGL	O	O
function	O	O
.	O	O
These	O	O
observations	O	O
indicate	O	O
an	O	O
ATGL	O	O
-	O	O
independent	O	O
function	O	O
of	O	O
CGI-58	O	O
.	O	O
This	O	O
review	O	O
summarizes	O	O
recent	O	O
findings	O	O
with	O	O
the	O	O
goal	O	O
of	O	O
relating	O	O
structural	O	O
variants	O	O
of	O	O
ATGL	O	O
and	O	O
CGI-58	O	O
to	O	O
functional	O	O
consequences	O	O
in	O	O
lipid	O	O
metabolism	O	O
.	O	O
A	O	O
heterozygous	B-Var	O
null	I-Var	O
mutation	I-Var	O
combined	O	O
with	O	O
the	O	O
G1258A	B-Var	O
polymorphism	O	O
of	O	O
SPINK5	B-Gene	O
causes	O	O
impaired	B-NegReg	O
LEKTI	B-MPA	O
function	I-MPA	O
and	O	O
abnormal	B-MPA	O
expression	I-MPA	B-MPA
of	I-MPA	O
skin	I-MPA	O
barrier	I-MPA	O
proteins	I-MPA	O
.	O	O
BACKGROUND	O	O
:	O	O
Loss	B-NegReg	B-NegReg
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	I-NegReg
function	I-NegReg	O
mutations	B-Var	B-Var
in	O	O
the	O	O
Kazal	O	O
-	O	O
type	O	O
serine	O	O
protease	O	O
inhibitor	O	O
,	O	O
LEKTI	O	O
,	O	O
encoded	O	O
by	O	O
the	O	O
SPINK5	B-Gene	O
gene	O	O
cause	O	O
the	O	O
rare	O	O
autosomal	O	B-Disease
recessive	O	I-Disease
skin	O	I-Disease
disease	O	I-Disease
Netherton	B-Disease	I-Disease
syndrome	I-Disease	I-Disease
(	O	O
NS	O	O
)	O	O
.	O	O
G1258A	O	O
polymorphism	O	O
in	O	O
SPINK5	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
atopic	O	O
dermatitis	O	O
,	O	O
which	O	O
shares	O	O
several	O	O
clinical	O	O
features	O	O
with	O	O
NS	O	O
.	O	O
OBJECTIVES	O	O
:	O	O
To	O	O
determine	O	O
if	O	O
the	O	O
phenotype	O	O
of	O	O
NS	O	O
can	O	O
be	O	O
caused	O	O
by	O	O
a	O	O
single	O	O
null	O	O
mutation	O	O
in	O	O
SPINK5	O	O
combined	O	O
with	O	O
the	O	O
homozygous	O	O
G1258A	O	O
polymorphism	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
screened	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
SPINK5	O	O
by	O	O
direct	O	O
DNA	O	O
sequencing	O	O
and	O	O
position	O	O
cloning	O	O
and	O	O
examined	O	O
the	O	O
expressions	O	O
of	O	O
the	O	O
SPINK5-encoded	O	O
protein	O	O
LEKTI	O	O
and	O	O
other	O	O
relevant	O	O
proteins	O	O
by	O	O
immunostaining	O	O
and	O	O
immunoblot	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
describe	O	O
here	O	O
a	O	O
patient	O	O
who	O	O
was	O	O
clinically	O	O
diagnosed	O	O
with	O	O
NS	O	O
and	O	O
carried	O	O
a	O	O
single	O	O
null	O	O
mutation	O	O
in	O	O
SPINK5	O	O
combined	O	O
with	O	O
the	O	O
homozygous	O	O
G1258A	O	O
polymorphism	O	O
.	O	O
SPINK5	O	O
mRNA	O	O
was	O	O
present	O	O
at	O	O
normal	O	O
levels	O	O
and	O	O
LEKTI	O	O
was	O	O
expressed	O	O
in	O	O
the	O	O
epidermis	O	O
.	O	O
Nonetheless	O	O
,	O	O
the	O	O
putative	O	O
downstream	O	O
LEKTI	O	O
substrates	O	O
stratum	O	O
corneum	O	O
trypsin	O	O
-	O	O
like	O	O
enzyme	O	O
(	O	O
SCTE	O	O
)	O	O
,	O	O
desmoglein	O	O
1	O	O
and	O	O
protein	O	O
markers	O	O
of	O	O
keratinocyte	O	O
differentiation	O	O
were	O	O
expressed	O	O
abnormally	O	O
,	O	O
similar	O	O
to	O	O
that	O	O
seen	O	O
in	O	O
NS	O	O
if	O	O
two	O	O
null	O	O
mutant	O	O
alleles	O	O
are	O	O
present	O	O
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
finding	O	O
indicates	O	O
that	O	O
haploinsufficiency	O	O
of	O	O
SPINK5	O	O
can	O	O
cause	O	O
the	O	O
NS	O	O
phenotype	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
one	O	O
null	O	O
mutation	O	O
with	O	O
homozygous	O	O
G1258A	O	O
polymorphisms	O	B-PosReg
in	O	O
SPINK5	O	O
,	O	O
and	O	O
this	O	O
could	O	O
impair	O	O
the	O	O
function	O	O
of	O	O
LEKTI	O	O
and	O	O
therefore	O	O
acts	O	O
as	O	O
a	O	O
true	O	O
mutation	O	O
.	O	O
MEFV	B-Gene	O
mutations	B-Var	O
in	O	O
patients	O	O
with	B-Reg	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
Fever	I-Disease	O
from	O	O
the	O	O
Aegean	O	O
region	O	O
of	O	O
Turkey	O	O
.	O	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
Fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
which	O	O
is	O	O
frequently	O	O
present	O	O
in	O	O
Mediterranean	O	O
populations	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
MEFV	B-Gene	O
gene	O	O
.	O	O
According	O	O
to	O	O
recent	O	O
data	O	O
,	O	O
MEFV	O	O
mutations	O	O
are	O	O
not	O	O
the	O	O
only	O	O
cause	O	O
of	O	O
FMF	O	O
,	O	O
but	O	O
these	O	O
are	O	O
major	O	O
genetic	O	O
determinants	O	O
which	O	O
cause	O	O
FMF	O	O
.	O	O
It	O	O
has	O	O
also	O	O
been	O	O
suggested	O	O
that	O	O
there	O	O
may	O	O
be	O	O
a	O	O
number	O	O
of	O	O
other	O	O
genes	O	O
causing	O	O
FMF	O	O
.	O	O
The	O	O
MEFV	O	O
gene	O	O
is	O	O
located	O	O
at	O	O
16p13.3	O	O
and	O	O
encodes	O	O
a	O	O
protein	O	O
,	O	O
pyrin	O	O
/	O	O
marenostrin	O	O
.	O	O
More	O	O
than	O	O
70	O	O
disease	O	O
associated	O	O
mutations	O	O
and	O	O
totally	O	O
186	O	O
mutations	O	O
and	O	O
polymorphisms	O	O
have	O	O
been	O	O
defined	O	O
in	O	O
affected	O	O
individuals	O	O
.	O	O
We	O	O
have	O	O
retrospectively	O	O
evaluated	O	O
the	O	O
molecular	O	O
test	O	O
results	O	O
of	O	O
1,201	O	O
patients	O	O
identified	O	O
as	O	O
having	O	O
FMF	O	O
clinical	O	O
symptoms	O	O
referred	O	O
to	O	O
the	O	O
Molecular	O	O
Genetics	O	O
Laboratory	O	O
of	O	O
the	O	O
Department	O	O
of	O	O
Medical	O	O
Genetics	O	O
,	O	O
Faculty	O	O
of	O	O
Medicine	O	O
,	O	O
Ege	O	O
University	O	O
,	O	O
Izmir	O	O
/	O	O
Turkey	O	O
over	O	O
the	O	O
last	O	O
4	O	O
years	O	O
.	O	O
Patients	O	O
were	O	O
tested	O	O
for	O	O
12	O	O
common	O	O
mutations	O	O
in	O	O
the	O	O
MEFV	O	O
gene	O	O
using	O	O
a	O	O
strip	O	O
assay	O	O
method	O	O
(	O	O
Innogenetics	O	O
,	O	O
Belgium	O	O
)	O	O
.	O	O
Out	O	O
of	O	O
the	O	O
1,201	O	O
patients	O	O
tested	O	O
(	O	O
2,402	O	O
chromosomes	O	O
)	O	O
in	O	O
the	O	O
Aegean	O	O
region	O	O
in	O	O
Turkey	O	O
,	O	O
654	O	O
(	O	O
54.45	O	O
%	O	O
)	O	O
did	O	O
not	O	O
carry	O	O
any	O	O
mutations	O	O
,	O	O
among	O	O
the	O	O
547	O	O
(	O	O
45.55	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
mutations	O	O
246	O	O
patients	O	O
were	O	O
either	O	O
homozygous	O	O
(	O	O
101	O	O
)	O	O
or	O	O
compound	O	O
heterozygous	O	O
(	O	O
145	O	O
)	O	O
,	O	O
296	O	O
carried	O	O
only	O	O
one	O	O
detected	O	O
mutation	O	O
,	O	O
and	O	O
five	O	O
patients	O	O
had	O	O
three	O	O
mutations	O	O
.	O	O
Allelic	O	O
frequencies	O	O
for	O	O
the	O	O
four	O	O
most	O	O
common	O	O
mutations	O	O
in	O	O
the	O	O
mutation	O	O
positive	O	O
groups	O	O
were	O	O
47.60	O	O
%	O	O
(	O	O
M694V	O	O
)	O	O
,	O	O
16.75	O	O
%	O	O
(	O	O
E148Q	O	O
)	O	O
,	O	O
12.95	O	O
%	O	O
(	O	O
V726A	O	O
)	O	O
,	O	O
11.94	O	O
%	O	O
(	O	O
M680I	O	O
G	O	O
/	O	O
C).The	O	O
remaining	O	O
alleles	O	O
(	O	O
10.76	O	O
%	O	O
)	O	O
showed	O	O
rare	O	O
mutations	O	O
which	O	O
were	O	O
R761H	O	O
,	O	O
P369S	O	O
,	O	O
A744S	O	O
,	O	O
K695R	O	O
,	O	O
F479L	O	O
,	O	O
M694I.	O	O
When	O	O
the	O	O
frequencies	O	O
of	O	O
mutations	O	O
detected	O	O
in	O	O
our	O	O
group	O	O
were	O	O
compared	O	O
to	O	O
the	O	O
frequencies	O	O
reported	O	O
in	O	O
the	O	O
other	O	O
regions	O	O
of	O	O
Turkey	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
V726A	O	O
mutation	O	O
frequency	O	O
was	O	O
observed	O	O
.	O	O
No	O	O
patient	O	O
showed	O	O
a	O	O
I692del	O	O
mutation	O	O
which	O	O
is	O	O
sometimes	O	O
evident	O	O
in	O	O
other	O	O
Mediterranean	O	O
populations	O	O
.	O	O
Factor	B-Protein	O
VIII	I-Protein	O
mutations	B-Var	O
in	B-Reg	O
42	O	O
Moldovan	O	O
haemophilia	B-Disease	O
A	I-Disease	O
families	O	O
,	O	O
including	O	O
12	O	O
that	O	O
are	O	O
novel	O	O
.	O	O
Haemophilia	B-Disease	O
A	I-Disease	O
(	O	O
HA	O	O
)	O	O
is	O	O
a	O	O
bleeding	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
within	O	O
the	O	O
X	O	O
-	O	O
linked	O	O
F8	B-Gene	O
gene	O	O
.	O	O
A	O	O
series	O	O
of	O	O
42	O	O
unrelated	O	O
Moldovan	O	O
patients	O	O
with	O	O
HA	O	O
had	O	O
their	O	O
disease	O	O
-	O	O
causative	O	O
mutation	O	O
determined	O	O
to	O	O
provide	O	O
clinically	O	O
valuable	O	O
genotyping	O	O
information	O	O
for	O	O
a	O	O
historically	O	O
underserved	O	O
population	O	O
and	O	O
to	O	O
utilize	O	O
factor	O	O
VIII	O	O
(	O	O
FVIII	O	O
)	O	O
structural	O	O
information	O	O
to	O	O
analyse	O	O
the	O	O
effects	O	O
of	O	O
haemophilic	O	O
missense	O	O
substitutions	O	O
.	O	O
DNA	O	O
samples	O	O
were	O	O
analysed	O	O
to	O	O
detect	O	O
intron	O	O
22	O	O
and	O	O
intron	O	O
1	O	O
inversions	O	O
followed	O	O
by	O	O
heteroduplex	O	O
analysis	O	O
of	O	O
PCR	O	O
-	O	O
amplified	O	O
fragments	O	O
containing	O	O
all	O	O
exonic	O	O
sequences	O	O
.	O	O
Missense	O	O
sites	O	O
identified	O	O
by	O	O
DNA	O	O
sequencing	O	O
were	O	O
visualized	O	O
in	O	O
the	O	O
recently	O	O
described	O	O
crystal	O	O
structures	O	O
of	O	O
human	O	O
FVIII	O	O
.	O	O
Of	O	O
the	O	O
26	O	O
different	O	O
point	O	O
mutations	O	O
,	O	O
12	O	O
were	O	O
novel	O	O
.	O	O
Gel	O	O
electrophoresis	O	O
identified	O	O
samples	O	O
with	O	O
a	O	O
second	O	O
major	O	O
DNA	O	O
band	O	O
that	O	O
migrated	O	O
abnormally	O	O
;	O	O
these	O	O
amplified	O	O
products	O	O
were	O	O
sequenced	O	O
.	O	O
Thirteen	O	O
intron	O	O
22	O	O
inversions	O	O
and	O	O
one	O	O
intron	O	O
1	O	O
inversion	O	O
were	O	O
found	O	O
.	O	O
Two	O	O
patients	O	O
had	O	O
large	O	O
,	O	O
partial	O	O
gene	O	O
deletions	O	O
and	O	O
there	O	O
were	O	O
six	O	O
frameshift	O	O
,	O	O
two	O	O
non	O	O
-	O	O
sense	O	O
,	O	O
two	O	O
splicing	O	O
and	O	O
16	O	O
missense	O	O
genotypes	O	O
.	O	O
Two	O	O
subjects	O	O
with	O	O
an	O	O
intron	O	O
22	O	O
inversion	O	O
and	O	O
one	O	O
with	O	O
a	O	O
large	O	O
,	O	O
partial	O	O
gene	O	O
deletion	O	O
developed	O	O
an	O	O
alloimmune	O	O
inhibitor	O	O
.	O	O
Their	O	O
localization	O	O
suggests	O	O
intra-	O	O
and	O	O
possibly	O	O
inter	O	O
-	O	O
molecular	O	O
interactions	O	O
that	O	O
are	O	O
important	O	O
for	O	O
the	O	O
structural	O	O
integrity	O	O
and/or	O	O
procoagulant	O	O
function	O	O
of	O	O
FVIII	O	O
.	O	O
Investigation	O	O
of	O	O
C5a	O	O
receptor	O	O
gene	O	O
450	O	O
C	O	O
/	O	O
T	O	O
polymorphism	O	O
in	O	O
Turkish	O	O
patients	O	O
with	O	O
familial	O	O
Mediterranean	O	O
fever	O	O
.	O	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
is	O	O
a	O	O
genetic	O	O
disorder	O	O
with	O	O
acute	O	O
inflammatory	O	O
serosal	O	O
attacks	O	O
due	B-Reg	O
to	I-Reg	O
MEFV	B-Gene	O
gene	O	O
mutations	B-Var	O
which	O	O
resides	O	O
in	O	O
chromosome	O	O
16	O	O
.	O	O
Lack	O	O
of	O	O
a	O	O
C5a	O	O
inhibitor	O	O
activity	O	O
in	O	O
the	O	O
peritoneum	O	O
has	O	O
previously	O	O
been	O	O
proposed	O	O
in	O	O
part	O	O
to	O	O
contribute	O	O
in	O	O
propagation	O	O
of	O	O
the	O	O
serosal	O	O
inflammation	O	O
in	O	O
FMF	O	O
attacks	O	O
.	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
C5a	O	O
receptor	O	O
(	O	O
C5aR	O	O
)	O	O
gene	O	O
polymorphism	O	O
in	O	O
patients	O	O
with	O	O
FMF	O	O
and	O	O
its	O	O
relation	O	O
to	O	O
the	O	O
main	O	O
features	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
A	O	O
polymorphism	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
C5aR	O	O
gene	O	O
leading	O	O
to	O	O
C	O	O
to	O	O
T	O	O
transition	O	O
at	O	O
nucleotide	O	O
position	O	O
450	O	O
has	O	O
been	O	O
investigated	O	O
in	O	O
85	O	O
non	O	O
-	O	O
related	O	O
Turkish	O	O
FMF	O	O
patients	O	O
and	O	O
160	O	O
non	O	O
-	O	O
related	O	O
healthy	O	O
controls	O	O
by	O	O
using	O	O
PCR	O	O
-	O	O
RFLP	O	O
.	O	O
The	O	O
frequencies	O	O
of	O	O
C5aR	O	O
gene	O	O
450	O	O
CT	O	O
genotype	O	O
and	O	O
T	O	O
allele	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
Turkish	O	O
FMF	O	O
patients	O	O
and	O	O
healthy	O	O
subjects	O	O
(	O	O
14.12	O	O
and	O	O
8.24	O	O
%	O	O
for	O	O
FMF	O	O
vs.	O	O
10	O	O
and	O	O
5	O	O
%	O	O
for	O	O
controls	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
C5aR	O	O
gene	O	O
450	O	O
CT	O	O
genotype	O	O
tended	O	O
to	O	O
associate	O	O
with	O	O
the	O	O
presence	O	O
Henoch	O	O
-	O	O
Schonlein	O	O
purpura	O	O
(	O	O
OR	O	O
:	O	O
1.25	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
0.917	O	O
-	O	O
1.704	O	O
,	O	O
P	O	O
=	O	O
0.017	O	O
)	O	O
but	O	O
with	O	O
no	O	O
other	O	O
clinical	O	O
findings	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
C5aR	O	O
polymorphism	O	O
might	O	O
be	O	O
searched	O	O
in	O	O
populations	O	O
having	O	O
high	O	O
prevalence	O	O
of	O	O
FMF	O	O
.	O	O
Expression	O	O
of	O	O
the	O	O
familial	O	O
Mediterranean	O	O
fever	O	O
gene	O	O
is	O	O
regulated	O	O
by	O	O
nonsense	O	O
-	O	O
mediated	O	O
decay	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
MEditerranean	O	O
FeVer	O	O
(	B-Gene	O
MEFV	I-Gene	O
)	I-Gene	O
gene	O	O
are	O	O
responsible	B-Reg	O
for	O	O
familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
,	O	O
a	O	O
recessively	O	O
inherited	O	O
auto	O	O
-	O	O
inflammatory	O	O
disease	O	O
.	O	O
Cases	O	O
of	O	O
dominant	O	O
inheritance	O	O
and	O	O
phenotype	O	O
-	O	O
genotype	O	O
heterogeneity	O	O
have	O	O
been	O	O
reported	O	O
;	O	O
however	O	O
,	O	O
the	O	O
underlying	O	O
molecular	O	O
mechanism	O	O
is	O	O
not	O	O
currently	O	O
understood	O	O
.	O	O
The	O	O
FMF	O	O
protein	O	O
named	O	O
pyrin	O	O
or	O	O
marenostrin	O	O
(	O	O
P	O	O
/	O	O
M	O	O
)	O	O
is	O	O
thought	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
regulating	O	O
innate	O	O
immunity	O	O
but	O	O
its	O	O
function	O	O
remains	O	O
subject	O	O
to	O	O
controversy	O	O
.	O	O
Recent	O	O
studies	O	O
postulate	O	O
that	O	O
a	O	O
defect	O	O
in	O	O
MEFV	O	O
expression	O	O
regulation	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
FMF	O	O
physiopathology	O	O
.	O	O
Our	O	O
group	O	O
,	O	O
along	O	O
with	O	O
others	O	O
,	O	O
has	O	O
identified	O	O
several	O	O
alternatively	O	O
spliced	O	O
MEFV	O	O
transcripts	O	O
in	O	O
leukocytes	O	O
.	O	O
Since	O	O
alternative	O	O
splicing	O	O
and	O	O
nonsense	O	O
-	O	O
mediated	O	O
decay	O	O
(	O	O
NMD	O	O
)	O	O
pathways	O	O
are	O	O
usually	O	O
coupled	O	O
in	O	O
the	O	O
post	O	O
-	O	O
transcriptional	O	O
regulation	O	O
of	O	O
gene	O	O
expression	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
NMD	O	O
could	O	O
contribute	O	O
to	O	O
the	O	O
regulation	O	O
of	O	O
the	O	O
MEFV	O	O
gene	O	O
.	O	O
To	O	O
address	O	O
this	O	O
issue	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
indirect	O	O
and	O	O
direct	O	O
inhibition	O	O
of	O	O
NMD	O	O
on	O	O
expression	O	O
of	O	O
the	O	O
MEFV	O	O
transcripts	O	O
in	O	O
THP1	O	O
,	O	O
monocyte	O	O
and	O	O
neutrophil	O	O
cells	O	O
.	O	O
We	O	O
showed	O	O
that	O	O
MEFV	O	O
is	O	O
the	O	O
first	O	O
auto	O	O
-	O	O
inflammatory	O	O
gene	O	O
regulated	O	O
by	O	O
NMD	O	O
in	O	O
both	O	O
a	O	O
cell-	O	O
and	O	O
transcript	O	O
-	O	O
specific	O	O
manner	O	O
.	O	O
These	O	O
results	O	O
and	O	O
preliminary	O	O
western	O	O
-	O	O
blot	O	O
analyses	O	O
suggest	O	O
the	O	O
possible	O	O
translation	O	O
of	O	O
alternatively	O	O
spliced	O	O
MEFV	O	O
transcripts	O	O
into	O	O
several	O	O
P	O	O
/	O	O
M	O	O
variants	O	O
according	O	O
to	O	O
cell	O	O
type	O	O
and	O	O
inflammatory	O	O
state	O	O
.	O	O
Our	O	O
results	O	O
introduce	O	O
the	O	O
novel	O	O
hypothesis	O	O
that	O	O
variation	O	O
of	O	O
NMD	O	O
efficiency	O	O
could	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
FMF	O	O
physiopathology	O	O
as	O	O
a	O	O
potent	O	O
phenotypic	O	O
modifier	O	O
.	O	O
Novel	O	O
PORCN	B-Gene	O
mutations	B-Var	O
in	B-Reg	O
focal	B-Disease	O
dermal	I-Disease	O
hypoplasia	I-Disease	O
.	O	O
Focal	O	O
dermal	O	O
hypoplasia	O	O
(	O	O
FDH	O	O
)	O	O
,	O	O
Goltz	O	O
or	O	O
Goltz	O	O
-	O	O
Gorlin	O	O
syndrome	O	O
,	O	O
is	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
dominant	O	O
multisystem	O	O
disorder	O	O
characterized	O	O
primarily	O	O
by	O	O
involvement	O	O
of	O	O
the	O	O
skin	O	O
,	O	O
skeletal	O	O
system	O	O
and	O	O
eyes	O	O
.	O	O
We	O	O
screened	O	O
for	O	O
mutations	B-Var	O
in	O	O
the	O	O
PORCN	B-Gene	O
gene	O	O
in	B-Reg	O
eight	O	O
patients	O	O
of	O	O
Belgian	O	O
and	O	O
Finnish	O	O
origin	O	O
with	O	O
firm	O	O
clinical	O	O
suspicion	O	O
of	O	O
FDH	B-Disease	O
.	O	O
First	O	O
,	O	O
we	O	O
performed	O	O
quantitative	O	O
PCR	O	O
(	O	O
qPCR	O	O
)	O	O
analysis	O	O
to	O	O
define	O	O
the	O	O
copy	O	O
number	O	O
at	O	O
this	O	O
locus	O	O
.	O	O
Next	O	O
,	O	O
we	O	O
sequenced	O	O
the	O	O
coding	O	O
regions	O	O
and	O	O
flanking	O	O
intronic	O	O
sequences	O	O
of	O	O
the	O	O
PORCN	O	O
gene	O	O
.	O	O
Three	O	O
de	O	O
novo	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
our	O	O
patients	O	O
with	O	O
FDH	O	O
:	O	O
a	O	O
150-kb	O	O
deletion	O	O
removing	O	O
six	O	O
genes	O	O
including	O	O
PORCN	O	O
,	O	O
as	O	O
defined	O	O
by	O	O
qPCR	O	O
and	O	O
X	O	O
-	O	O
array	O	O
-	O	O
CGH	O	O
,	O	O
and	O	O
two	O	O
heterozygous	O	O
missense	O	O
mutations	O	O
;	O	O
c.992T	O	O
>	O	O
G	O	O
(	O	O
p	O	O
.	O	O
L331R	O	O
)	O	O
in	O	O
exon	O	O
11	O	O
and	O	O
c.1094G	O	O
>	O	O
A	O	O
(	O	O
p	O	O
.	O	O
R365Q	O	O
)	O	O
in	O	O
exon	O	O
13	O	O
of	O	O
the	O	O
gene	O	O
.	O	O
Both	O	O
point	O	O
mutations	O	O
changed	O	O
highly	O	O
conserved	O	O
amino	O	O
acids	O	O
and	O	O
were	O	O
not	O	O
found	O	O
in	O	O
300	O	O
control	O	O
X	O	O
chromosomes	O	O
.	O	O
The	O	O
three	O	O
patients	O	O
in	O	O
whom	O	O
mutations	O	O
were	O	O
identified	O	O
all	O	O
present	O	O
with	O	O
characteristic	O	O
dermal	O	O
findings	O	O
together	O	O
with	O	O
limb	O	O
manifestations	O	O
,	O	O
which	O	O
were	O	O
not	O	O
seen	O	O
in	O	O
our	O	O
mutation	O	O
-	O	O
negative	O	O
patients	O	O
.	O	O
The	O	O
clinical	O	O
characteristics	O	O
of	O	O
our	O	O
patients	O	O
with	O	O
PORCN	O	O
mutations	O	O
were	O	O
compared	O	O
with	O	O
the	O	O
previously	O	O
reported	O	O
mutation	O	O
-	O	O
positive	O	O
cases	O	O
.	O	O
In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
summarize	O	O
the	O	O
literature	O	O
on	O	O
PORCN	O	O
mutations	O	O
and	O	O
associated	O	O
phenotypes	O	O
.	O	O
Longitudinal	O	O
course	O	O
of	O	O
cognitive	O	O
,	O	O
adaptive	O	O
,	O	O
and	O	O
behavioral	O	O
characteristics	O	O
in	O	O
Costello	O	O
syndrome	O	O
.	O	O
Costello	B-Disease	O
syndrome	I-Disease	O
is	O	O
a	O	O
rare	O	O
rasopathy	O	O
caused	B-Reg	O
by	I-Reg	O
germline	O	O
mutations	B-Var	O
in	O	O
the	O	O
oncogene	O	O
HRAS	B-Gene	O
resulting	O	O
in	O	O
increased	B-PosReg	O
signal	B-MPA	O
transduction	I-MPA	O
through	O	O
the	O	O
Ras	B-Pathway	O
/	I-Pathway	O
mitogen	I-Pathway	O
-	I-Pathway	O
activated	I-Pathway	O
protein	I-Pathway	O
kinase	I-Pathway	O
pathway	I-Pathway	O
.	O	O
In	O	O
contrast	O	O
to	O	O
the	O	O
more	O	O
common	O	O
rasopathies	O	O
,	O	O
such	O	O
as	O	O
neurofibromatosis	O	O
type	O	O
1	O	O
and	O	O
Noonan	O	O
syndrome	O	O
,	O	O
limited	O	O
information	O	O
is	O	O
available	O	O
on	O	O
standardized	O	O
cognitive	O	O
testing	O	O
in	O	O
this	O	O
cohort	O	O
.	O	O
Past	O	O
research	O	O
indicated	O	O
a	O	O
mean	O	O
average	O	O
IQ	O	O
in	O	O
the	O	O
mild	O	O
mental	O	O
retardation	O	O
range	O	O
,	O	O
with	O	O
strengths	O	O
in	O	O
fluid	O	O
reasoning	O	O
(	O	O
FR	O	O
)	O	O
and	O	O
weakness	O	O
in	O	O
expressive	O	O
language	O	O
,	O	O
as	O	O
well	O	O
as	O	O
static	O	O
skills	O	O
over	O	O
time	O	O
.	O	O
Here	O	O
we	O	O
report	O	O
on	O	O
standardized	O	O
IQ	O	O
and	O	O
adaptive	O	O
functioning	O	O
in	O	O
18	O	O
individuals	O	O
with	O	O
Costello	O	O
syndrome	O	O
,	O	O
nine	O	O
males	O	O
and	O	O
nine	O	O
females	O	O
,	O	O
and	O	O
longitudinal	O	O
development	O	O
for	O	O
11	O	O
who	O	O
had	O	O
previous	O	O
testing	O	O
.	O	O
The	O	O
overall	O	O
IQ	O	O
,	O	O
ranging	O	O
from	O	O
severe	O	O
mental	O	O
retardation	O	O
to	O	O
the	O	O
average	O	O
range	O	O
,	O	O
with	O	O
a	O	O
mean	O	O
in	O	O
the	O	O
mildly	O	O
mentally	O	O
retarded	O	O
range	O	O
,	O	O
was	O	O
again	O	O
found	O	O
to	O	O
be	O	O
stable	O	O
,	O	O
but	O	O
an	O	O
interesting	O	O
pattern	O	O
in	O	O
the	O	O
development	O	O
of	O	O
nonverbal	O	O
FR	O	O
was	O	O
identified	O	O
.	O	O
Participants	O	O
showed	O	O
an	O	O
improvement	O	O
in	O	O
nonverbal	O	O
FR	O	O
,	O	O
followed	O	O
by	O	O
stable	O	O
skills	O	O
thereafter	O	O
,	O	O
suggesting	O	O
a	O	O
"	O	O
late	O	O
bloomer	O	O
"	O	O
effect	O	O
in	O	O
late	O	O
childhood	O	O
/	O	O
early	O	O
adolescence	O	O
.	O	O
Overall	O	O
adaptive	O	O
functioning	O	O
fell	O	O
into	O	O
the	O	O
range	O	O
of	O	O
Intellectual	O	O
Disability	O	O
for	O	O
70	O	O
%	O	O
of	O	O
subjects	O	O
,	O	O
with	O	O
Socialization	O	O
as	O	O
a	O	O
relative	O	O
strength	O	O
and	O	O
Daily	O	O
Living	O	O
Skills	O	O
an	O	O
area	O	O
of	O	O
relative	O	O
difficulty	O	O
.	O	O
Interestingly	O	O
,	O	O
females	O	O
were	O	O
found	O	O
to	O	O
be	O	O
higher	O	O
functioning	O	O
than	O	O
males	O	O
in	O	O
all	O	O
domains	O	O
,	O	O
including	O	O
Communication	O	O
,	O	O
Daily	O	O
Living	O	O
Skills	O	O
and	O	O
Socialization	O	O
.	O	O
Caregivers	O	O
reported	O	O
significantly	O	O
more	O	O
behavioral	O	O
concerns	O	O
in	O	O
males	O	O
,	O	O
including	O	O
internalizing	O	O
,	O	O
externalizing	O	O
,	O	O
and	O	O
other	O	O
maladaptive	O	O
behaviors	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
no	O	O
gender	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
cognitive	O	O
or	O	O
visuomotor	O	O
functioning	O	O
.	O	O
Molecular	O	O
analysis	O	O
of	O	O
42	O	O
patients	O	O
with	B-Reg	O
congenital	B-Disease	O
dyserythropoietic	I-Disease	O
anemia	I-Disease	O
type	I-Disease	O
II	I-Disease	O
:	I-Disease	O
new	O	O
mutations	B-Var	O
in	O	O
the	O	O
SEC23B	B-Gene	O
gene	O	O
and	O	O
a	O	O
search	O	O
for	O	O
a	O	O
genotype	O	O
-	O	O
phenotype	O	O
relationship	O	O
.	O	O
BACKGROUND	O	O
:	O	O
The	O	O
most	O	O
frequent	O	O
form	O	O
of	O	O
congenital	O	O
dyserythropoietic	O	O
anemia	O	O
is	O	O
the	O	O
type	O	O
II	O	O
form	O	O
.	O	O
Recently	O	O
it	O	O
was	O	O
shown	O	O
that	O	O
the	O	O
vast	O	O
majority	O	O
of	O	O
patients	O	O
with	O	O
congenital	B-Disease	O
dyserythropoietic	I-Disease	O
anemia	I-Disease	O
type	I-Disease	O
II	I-Disease	O
carry	B-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
SEC23B	B-Gene	O
gene	O	O
.	O	O
Here	O	O
we	O	O
established	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
42	O	O
cases	O	O
of	O	O
congenital	O	O
dyserythropoietic	O	O
anemia	O	O
type	O	O
II	O	O
and	O	O
attempted	O	O
to	O	O
define	O	O
a	O	O
genotype	O	O
-	O	O
phenotype	O	O
relationship	O	O
.	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
:	O	O
SEC23B	O	O
gene	O	O
sequencing	O	O
analysis	O	O
was	O	O
performed	O	O
to	O	O
assess	O	O
the	O	O
diversity	O	O
and	O	O
incidence	O	O
of	O	O
each	O	O
mutation	O	O
in	O	O
42	O	O
patients	O	O
with	O	O
congenital	O	O
dyserythropoietic	O	O
anemia	O	O
type	O	O
II	O	O
(	O	O
25	O	O
described	O	O
exclusively	O	O
in	O	O
this	O	O
work	O	O
)	O	O
,	O	O
from	O	O
the	O	O
Italian	O	O
and	O	O
the	O	O
French	O	O
Registries	O	O
,	O	O
and	O	O
the	O	O
relationship	O	O
of	O	O
these	O	O
mutations	O	O
with	O	O
the	O	O
clinical	O	O
presentation	O	O
.	O	O
To	O	O
this	O	O
purpose	O	O
,	O	O
we	O	O
divided	O	O
the	O	O
patients	O	O
into	O	O
two	O	O
groups	O	O
:	O	O
(	O	O
i	O	O
)	O	O
patients	O	O
with	O	O
two	O	O
missense	O	O
mutations	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
patients	O	O
with	O	O
one	O	O
nonsense	O	O
and	O	O
one	O	O
missense	O	O
mutation	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
found	O	O
22	O	O
mutations	O	O
of	O	O
uneven	O	O
frequency	O	O
,	O	O
including	O	O
seven	O	O
novel	O	O
mutations	O	O
.	O	O
Compound	O	O
heterozygosity	O	O
for	O	O
a	O	O
missense	O	O
and	O	O
a	O	O
nonsense	O	O
mutation	O	O
tended	O	O
to	O	O
produce	O	O
a	O	O
more	O	O
severe	O	O
clinical	O	O
presentation	O	O
,	O	O
a	O	O
lower	O	O
reticulocyte	O	O
count	O	O
,	O	O
a	O	O
higher	O	O
serum	O	O
ferritin	O	O
level	O	O
,	O	O
and	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
,	O	O
more	O	O
pronounced	O	O
transfusion	O	O
needs	O	O
,	O	O
than	O	O
homozygosity	O	O
or	O	O
compound	O	O
heterozygosity	O	O
for	O	O
two	O	O
missense	O	O
mutations	O	O
.	O	O
Homozygosity	O	O
or	O	O
compound	O	O
heterozygosity	O	O
for	O	O
two	O	O
nonsense	O	O
mutations	O	O
was	O	O
never	O	O
found	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
This	O	O
study	O	O
allowed	O	O
us	O	O
to	O	O
determine	O	O
the	O	O
most	O	O
frequent	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
congenital	O	O
dyserythropoietic	O	O
anemia	O	O
type	O	O
II	O	O
.	O	O
Correlations	O	O
between	O	O
the	O	O
mutations	O	O
and	O	O
various	O	O
biological	O	O
parameters	O	O
suggested	O	O
that	O	O
the	O	O
association	O	O
of	O	O
one	O	O
missense	O	O
mutation	O	O
and	O	O
one	O	O
nonsense	O	O
mutation	O	O
was	O	O
significantly	O	O
more	O	O
deleterious	O	O
that	O	O
the	O	O
association	O	O
of	O	O
two	O	O
missense	O	O
mutations	O	O
.	O	O
However	O	O
,	O	O
there	O	O
was	O	O
an	O	O
overlap	O	O
between	O	O
the	O	O
two	O	O
categories	O	O
.	O	O
Identification	O	O
and	O	O
characterization	O	O
of	O	O
novel	O	O
sequence	O	O
variations	O	O
in	O	O
MECP2	O	O
gene	O	O
in	O	O
Rett	O	O
syndrome	O	O
patients	O	O
.	O	O
Rett	B-Disease	O
syndrome	I-Disease	I-Disease
(	O	O
RS	O	O
)	O	O
is	O	O
a	O	O
neurodevelopmental	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
MECP2	B-Gene	B-Gene
gene	O	O
.	O	O
Exons	O	O
2	O	O
,	O	O
3	O	O
,	O	O
and	O	O
4	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
intronic	O	O
and	O	O
3'UTR	O	O
adjacent	O	O
regions	O	O
,	O	O
were	O	O
sequenced	O	O
in	O	O
80	O	O
patients	O	O
with	O	O
RS	O	O
.	O	O
Twenty	O	O
-	O	O
nine	O	O
sequence	O	O
variations	O	O
were	O	O
detected	O	O
in	O	O
49	O	O
patients	O	O
,	O	O
34	O	O
(	O	O
69.4	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
the	O	O
classic	O	O
form	O	O
of	O	O
RS	O	O
,	O	O
and	O	O
15	O	O
(	O	O
30.6	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
atypical	O	O
forms	O	O
of	O	O
RS	O	O
.	O	O
Thirteen	O	O
of	O	O
the	O	O
29	O	O
detected	O	O
mutations	O	O
represent	O	O
novel	O	O
sequence	O	O
variations	O	O
.	O	O
Missense	O	O
mutation	O	O
T158	O	O
M	O	O
was	O	O
the	O	O
most	O	O
commonly	O	O
observed	O	O
mutation	O	O
,	O	O
detected	O	O
in	O	O
nine	O	O
patients	O	O
(	O	O
11.2	O	O
%	O	O
)	O	O
.	O	O
Six	O	O
hotspot	O	O
pathogenic	O	O
mutations	O	O
(	O	O
R133C	O	O
,	O	O
T158	O	O
M	O	O
,	O	O
R168X	O	O
,	O	O
R255X	O	O
,	O	O
R270X	O	O
,	O	O
and	O	O
R294X	O	O
)	O	O
were	O	O
responsible	O	O
for	O	O
the	O	O
phenotype	O	O
in	O	O
26/80	O	O
patients	O	O
(	O	O
32.5	O	O
%	O	O
)	O	O
.	O	O
Ribosomal	O	O
protein	O	O
genes	O	O
RPS10	B-Gene	O
and	O	O
RPS26	B-Gene	O
are	O	O
commonly	O	O
mutated	B-Var	O
in	B-Reg	O
Diamond	B-Disease	O
-	I-Disease	O
Blackfan	I-Disease	O
anemia	I-Disease	O
.	O	O
Diamond	O	O
-	O	O
Blackfan	O	O
anemia	O	O
(	O	O
DBA	O	O
)	O	O
,	O	O
an	O	O
inherited	O	O
bone	O	O
marrow	O	O
failure	O	O
syndrome	O	O
characterized	O	O
by	O	O
anemia	O	O
that	O	O
usually	O	O
presents	O	O
before	O	O
the	O	O
first	O	O
birthday	O	O
or	O	O
in	O	O
early	O	O
childhood	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
birth	O	O
defects	O	O
and	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
cancer	O	O
.	O	O
Although	O	O
anemia	O	O
is	O	O
the	O	O
most	O	O
prominent	O	O
feature	O	O
of	O	O
DBA	O	O
,	O	O
the	O	O
disease	O	O
is	O	O
also	O	O
characterized	O	O
by	O	O
growth	O	O
retardation	O	O
and	O	O
congenital	O	O
malformations	O	O
,	O	O
in	O	O
particular	O	O
craniofacial	O	O
,	O	O
upper	O	O
limb	O	O
,	O	O
heart	O	O
,	O	O
and	O	O
urinary	O	O
system	O	O
defects	O	O
that	O	O
are	O	O
present	O	O
in	O	O
approximately	O	O
30%-50	O	O
%	O	O
of	O	O
patients	O	O
.	O	O
DBA	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
mutations	O	O
in	O	O
seven	O	O
ribosomal	O	O
protein	O	O
(	O	O
RP	O	O
)	O	O
genes	O	O
,	O	O
RPS19	O	O
,	O	O
RPS24	O	O
,	O	O
RPS17	O	O
,	O	O
RPL35A	O	O
,	O	O
RPL5	O	O
,	O	O
RPL11	O	O
,	O	O
and	O	O
RPS7	O	O
,	O	O
in	O	O
about	O	O
43	O	O
%	O	O
of	O	O
patients	O	O
.	O	O
To	O	O
continue	O	O
our	O	O
large	O	O
-	O	O
scale	O	O
screen	O	O
of	O	O
RP	O	O
genes	O	O
in	O	O
a	O	O
DBA	O	O
population	O	O
,	O	O
we	O	O
sequenced	O	O
35	O	O
ribosomal	O	O
protein	O	O
genes	O	O
,	O	O
RPL15	O	O
,	O	O
RPL24	O	O
,	O	O
RPL29	O	O
,	O	O
RPL32	O	O
,	O	O
RPL34	O	O
,	O	O
RPL9	O	O
,	O	O
RPL37	O	O
,	O	O
RPS14	O	O
,	O	O
RPS23	O	O
,	O	O
RPL10A	O	O
,	O	O
RPS10	O	O
,	O	O
RPS12	O	O
,	O	O
RPS18	O	O
,	O	O
RPL30	O	O
,	O	O
RPS20	O	O
,	O	O
RPL12	O	O
,	O	O
RPL7A	O	O
,	O	O
RPS6	O	O
,	O	O
RPL27A	O	O
,	O	O
RPLP2	O	O
,	O	O
RPS25	O	O
,	O	O
RPS3	O	O
,	O	O
RPL41	O	O
,	O	O
RPL6	O	O
,	O	O
RPLP0	O	O
,	O	O
RPS26	O	O
,	O	O
RPL21	O	O
,	O	O
RPL36AL	O	O
,	O	O
RPS29	O	O
,	O	O
RPL4	O	O
,	O	O
RPLP1	O	O
,	O	O
RPL13	O	O
,	O	O
RPS15A	O	O
,	O	O
RPS2	O	O
,	O	O
and	O	O
RPL38	O	O
,	O	O
in	O	O
our	O	O
DBA	O	O
patient	O	O
cohort	O	O
of	O	O
117	O	O
probands	O	O
.	O	O
We	O	O
identified	O	O
three	O	O
distinct	O	O
mutations	O	O
of	O	O
RPS10	O	O
in	O	O
five	O	O
probands	O	O
and	O	O
nine	O	O
distinct	O	O
mutations	O	O
of	O	O
RPS26	O	O
in	O	O
12	O	O
probands	O	O
.	O	O
Pre	O	O
-	O	O
rRNA	O	O
analysis	O	O
in	O	O
lymphoblastoid	O	O
cells	O	O
from	O	O
patients	O	O
bearing	O	O
mutations	B-Var	O
in	O	O
RPS10	B-Gene	O
and	O	O
RPS26	B-Gene	O
showed	O	O
elevated	B-PosReg	O
levels	B-MPA	O
of	I-MPA	O
18S	I-MPA	O
-	I-MPA	O
E	I-MPA	O
pre	I-MPA	O
-	I-MPA	O
rRNA	I-MPA	O
.	O	O
This	O	O
accumulation	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
phenotype	O	O
observed	O	O
in	O	O
HeLa	O	O
cells	O	O
after	O	O
knockdown	O	O
of	O	O
RPS10	O	O
or	O	O
RPS26	O	O
expression	O	O
with	O	O
siRNAs	O	O
,	O	O
which	O	O
indicates	O	O
that	O	O
mutations	B-Var	O
in	O	O
the	O	O
RPS10	B-Gene	O
and	O	O
RPS26	B-Gene	O
genes	O	O
in	O	O
DBA	O	O
patients	O	O
affect	B-Reg	O
the	O	O
function	B-MPA	O
of	I-MPA	O
the	I-MPA	O
proteins	I-MPA	O
in	I-MPA	O
rRNA	I-MPA	O
processing	O	O
.	O	O
Clinical	O	O
and	O	O
molecular	O	O
aspects	O	O
of	O	O
aniridia	O	O
.	O	O
Aniridia	O	O
is	O	O
a	O	O
severe	O	O
,	O	O
congenital	O	O
ocular	O	O
malformation	O	O
inherited	O	O
in	O	O
an	O	O
autosomal	O	O
-	O	O
dominant	O	O
fashion	O	O
with	O	O
high	O	O
penetrance	O	O
and	O	O
variable	O	O
expression	O	O
.	O	O
Eye	O	O
morphogenesis	O	O
in	O	O
humans	O	O
involves	O	O
a	O	O
molecular	O	O
genetic	O	O
cascade	O	O
in	O	O
which	O	O
a	O	O
number	O	O
of	O	O
developmental	O	O
genes	O	O
interact	O	O
in	O	O
a	O	O
highly	O	O
organized	O	O
process	O	O
during	O	O
the	O	O
embryonic	O	O
period	O	O
to	O	O
produce	O	O
functional	O	O
ocular	O	O
structures	O	O
.	O	O
Among	O	O
these	O	O
genes	O	O
,	O	O
paired	O	O
box	O	O
gene	O	O
6	O	O
(	O	O
PAX6	O	O
)	O	O
has	O	O
an	O	O
essential	O	O
role	O	O
as	O	O
it	O	O
encodes	O	O
a	O	O
phylogenetically	O	O
conserved	O	O
transcription	O	O
factor	O	O
almost	O	O
universally	O	O
employed	O	O
for	O	O
eye	O	O
formation	O	O
in	O	O
animals	O	O
with	O	O
bilateral	O	O
symmetry	O	O
,	O	O
despite	O	O
widely	O	O
different	O	O
embryological	O	O
origins	O	O
.	O	O
To	O	O
direct	O	O
eye	O	O
development	O	O
,	O	O
PAX6	O	O
regulates	O	O
the	O	O
tissue	O	O
-	O	O
specific	O	O
expression	O	O
of	O	O
diverse	O	O
molecules	O	O
,	O	O
hormones	O	O
,	O	O
and	O	O
structural	O	O
proteins	O	O
.	O	O
In	O	O
humans	O	O
,	O	O
PAX6	B-Gene	O
is	O	O
located	O	O
in	O	O
chromosome	O	O
11p13	O	O
,	O	O
and	O	O
its	O	O
mutations	B-Var	O
lead	B-Reg	O
to	I-Reg	O
a	O	O
variety	O	O
of	O	O
hereditary	B-CPA	O
ocular	I-CPA	O
malformations	I-CPA	O
of	O	O
the	O	O
anterior	O	O
and	O	O
posterior	O	O
segment	O	O
,	O	O
among	O	O
which	O	O
aniridia	O	O
and	O	O
most	O	O
probably	O	O
foveal	O	O
hypoplasia	O	O
are	O	O
the	O	O
major	O	O
signs	O	O
.	O	O
Aniridia	B-Disease	O
occurs	O	O
due	B-Reg	O
to	I-Reg	O
decreased	B-NegReg	O
dosage	B-MPA	O
of	O	O
the	O	O
PAX6	B-Gene	O
gene	O	O
and	O	O
exists	O	O
in	O	O
both	O	O
sporadic	O	O
and	O	O
familial	O	O
forms	O	O
.	O	O
The	O	O
mutations	O	O
are	O	O
scattered	O	O
throughout	O	O
the	O	O
gene	O	O
and	O	O
the	O	O
vast	O	O
majority	O	O
of	O	O
those	O	O
reported	O	O
so	O	O
far	O	O
are	O	O
nonsense	B-Var	O
mutations	I-Var	O
,	O	O
frameshift	B-Var	O
mutations	I-Var	O
,	O	O
or	O	O
splicing	B-Var	O
errors	I-Var	O
that	O	O
are	O	O
predicted	O	O
to	O	O
cause	B-Reg	O
pre	B-MPA	O
-	I-MPA	O
mature	I-MPA	O
truncation	I-MPA	O
of	O	O
the	O	O
PAX6	B-Gene	O
protein	B-Protein	O
,	O	O
causing	B-Reg	O
haploinsufficiency	B-MPA	B-Disease
.	O	O
Here	O	O
we	O	O
review	O	O
the	O	O
data	O	O
regarding	O	O
the	O	O
mechanisms	O	O
and	O	O
the	O	O
mutations	O	O
that	O	O
relate	O	O
to	O	O
aniridia	B-Disease	O
.	O	O
GARS	O	O
axonopathy	O	O
:	O	O
not	O	O
every	O	O
neuron	O	O
's	O	O
cup	O	O
of	O	O
tRNA	O	O
.	O	O
Charcot	B-Disease	O
-	I-Disease	O
Marie	I-Disease	O
-	I-Disease	O
Tooth	I-Disease	O
disease	I-Disease	O
type	I-Disease	O
2D	I-Disease	O
,	O	O
a	O	O
hereditary	O	O
axonal	O	O
neuropathy	O	O
,	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
glycyl	O	O
-	O	O
tRNA	O	O
synthetase	O	O
(	B-Gene	O
GARS	I-Gene	O
)	I-Gene	O
.	O	O
The	O	O
mutations	O	O
are	O	O
distributed	O	O
throughout	O	O
the	O	O
protein	O	O
in	O	O
multiple	O	O
functional	O	O
domains	O	O
.	O	O
In	O	O
biochemical	O	O
and	O	O
cell	O	O
culture	O	O
experiments	O	O
,	O	O
some	O	O
mutant	O	O
forms	O	O
of	O	O
GARS	O	O
have	O	O
been	O	O
indistinguishable	O	O
from	O	O
wild	O	O
-	O	O
type	O	O
protein	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
in	O	O
vitro	O	O
tests	O	O
might	O	O
not	O	O
adequately	O	O
assess	O	O
the	O	O
aberrant	O	O
activity	O	O
responsible	O	O
for	O	O
axonal	O	O
degeneration	O	O
.	O	O
Recently	O	O
,	O	O
mouse	O	O
and	O	O
fly	O	O
models	O	O
have	O	O
offered	O	O
new	O	O
insights	O	O
into	O	O
the	O	O
disease	O	O
mechanism	O	O
.	O	O
There	O	O
are	O	O
still	O	O
gaps	O	O
in	O	O
our	O	O
understanding	O	O
of	O	O
how	O	O
mutations	O	O
in	O	O
a	O	O
ubiquitously	O	O
expressed	O	O
component	O	O
of	O	O
the	O	O
translation	O	O
machinery	O	O
result	O	O
in	O	O
axonal	O	O
neuropathy	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
review	O	O
recent	O	O
reports	O	O
,	O	O
weigh	O	O
the	O	O
evidence	O	O
for	O	O
and	O	O
against	O	O
possible	O	O
mechanisms	O	O
and	O	O
suggest	O	O
areas	O	O
of	O	O
focus	O	O
for	O	O
future	O	O
work	O	O
.	O	O
Genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
in	O	O
a	O	O
large	O	O
population	O	O
of	O	O
muscular	B-Disease	O
dystrophy	I-Disease	O
patients	O	O
with	B-Reg	O
LAMA2	B-Gene	O
mutations	B-Var	O
.	O	O
Merosin	B-Disease	O
deficient	I-Disease	O
congenital	I-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
1A	I-Disease	O
(	O	O
MDC1A	O	O
)	O	O
results	B-Reg	O
from	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
LAMA2	B-Gene	O
gene	O	O
.	O	O
We	O	O
report	O	O
51	O	O
patients	O	O
with	O	O
MDC1A	O	O
and	O	O
examine	O	O
the	O	O
relationship	O	O
between	O	O
degree	O	O
of	O	O
merosin	O	O
expression	O	O
,	O	O
genotype	O	O
and	O	O
clinical	O	O
features	O	O
.	O	O
Thirty	O	O
-	O	O
three	O	O
patients	O	O
had	O	O
absence	O	O
of	O	O
merosin	O	O
and	O	O
13	O	O
showed	O	O
some	O	O
residual	O	O
merosin	O	O
.	O	O
Compared	O	O
to	O	O
the	O	O
residual	O	O
merosin	O	O
group	O	O
,	O	O
patients	O	O
with	O	O
absent	O	O
merosin	O	O
had	O	O
an	O	O
earlier	O	O
presentation	O	O
(	O	O
<	O	O
7days	O	O
)	O	O
(	O	O
P=0.0073	O	O
)	O	O
,	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
lack	O	O
independent	O	O
ambulation	O	O
(	O	O
P=0.0215	O	O
)	O	O
,	O	O
or	O	O
require	O	O
enteral	O	O
feeding	O	O
(	O	O
P=0.0099	O	O
)	O	O
and	O	O
ventilatory	O	O
support	O	O
(	O	O
P=0.0354	O	O
)	O	O
.	O	O
We	O	O
identified	O	O
33	O	O
novel	O	O
LAMA2	O	O
mutations	O	O
;	O	O
these	O	O
were	O	O
distributed	O	O
throughout	O	O
the	O	O
gene	O	O
in	O	O
patients	O	O
with	O	O
absent	O	O
merosin	O	O
,	O	O
with	O	O
minor	O	O
clusters	O	O
in	O	O
exon	O	O
27	O	O
,	O	O
14	O	O
,	O	O
25	O	O
and	O	O
26	O	O
(	O	O
55	O	O
%	O	O
of	O	O
mutations	O	O
)	O	O
.	O	O
Patients	O	O
with	O	O
residual	O	O
merosin	O	O
often	O	O
carried	O	O
at	O	O
least	O	O
one	O	O
splice	O	O
site	O	O
mutation	O	O
and	O	O
less	O	O
frequently	O	O
frameshift	O	O
mutations	O	O
.	O	O
This	O	O
large	O	O
study	O	O
identified	O	O
novel	O	O
LAMA2	O	O
mutations	O	O
and	O	O
highlights	O	O
the	O	O
role	O	O
of	O	O
immunohistochemical	O	O
studies	O	O
for	O	O
merosin	O	O
status	O	O
in	O	O
predicting	O	O
clinical	O	O
severity	O	O
of	O	O
MDC1A.	O	O
Novel	O	O
and	O	O
recurrent	O	O
mutations	O	O
in	O	O
the	O	O
filaggrin	O	O
gene	O	O
in	O	O
Chinese	O	O
patients	O	O
with	O	O
ichthyosis	O	O
vulgaris	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Ichthyosis	B-Disease	O
vulgaris	I-Disease	O
(	O	O
IV	O	O
)	O	O
is	O	O
a	O	O
common	O	O
inherited	O	O
skin	O	O
disorder	O	O
,	O	O
and	O	O
the	O	O
filament	O	O
aggregating	O	O
protein	O	O
(	O	O
filaggrin	O	O
)	O	O
is	O	O
a	O	O
key	O	O
protein	O	O
involved	O	O
in	O	O
skin	O	O
barrier	O	O
function	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
filaggrin	O	O
gene	O	O
(	B-Gene	O
FLG	I-Gene	O
)	I-Gene	O
have	O	O
recently	O	O
been	O	O
identified	O	O
as	O	O
the	O	O
cause	B-Reg	O
of	O	O
IV	B-Disease	O
.	O	O
However	O	O
,	O	O
there	O	O
have	O	O
been	O	O
no	O	O
reports	O	O
of	O	O
FLG	O	O
mutations	O	O
in	O	O
mainland	O	O
Chinese	O	O
families	O	O
with	O	O
IV	O	O
.	O	O
OBJECTIVES	O	O
:	O	O
To	O	O
identify	O	O
FLG	O	O
mutations	O	O
in	O	O
Chinese	O	O
patients	O	O
with	O	O
IV	O	O
.	O	O
METHODS	O	O
:	O	O
Eleven	O	O
unrelated	O	O
Chinese	O	O
families	O	O
with	O	O
IV	O	O
were	O	O
examined	O	O
for	O	O
FLG	O	O
mutations	O	O
with	O	O
denaturing	O	O
high	O	O
-	O	O
performance	O	O
liquid	O	O
chromatography	O	O
prescreening	O	O
and	O	O
sequencing	O	O
.	O	O
SNaPShot	O	O
was	O	O
employed	O	O
to	O	O
obtain	O	O
a	O	O
high	O	O
-	O	O
throughput	O	O
screening	O	O
for	O	O
the	O	O
identified	O	O
mutations	O	O
.	O	O
RESULTS	O	O
:	O	O
Three	O	O
mutations	O	O
-	O	O
one	O	O
novel	O	O
mutation	O	O
(	O	O
Q1256X	O	O
)	O	O
and	O	O
two	O	O
known	O	O
mutations	O	O
(	O	O
3321delA	O	O
and	O	O
E2422X	O	O
)	O	O
-	O	O
were	O	O
identified	O	O
in	O	O
these	O	O
families	O	O
.	O	O
The	O	O
novel	O	O
mutation	O	O
,	O	O
Q1256X	O	O
,	O	O
found	O	O
in	O	O
a	O	O
Chinese	O	O
family	O	O
with	O	O
IV	O	O
,	O	O
was	O	O
located	O	O
in	O	O
filaggrin	O	O
repeat	O	O
3	O	O
.	O	O
Mutation	O	O
3321delA	O	O
,	O	O
previously	O	O
found	O	O
in	O	O
Japanese	O	O
patients	O	O
,	O	O
was	O	O
present	O	O
in	O	O
eight	O	O
Chinese	O	O
families	O	O
with	O	O
IV	O	O
.	O	O
Mutation	O	O
E2422X	O	O
,	O	O
previously	O	O
found	O	O
in	O	O
a	O	O
Dutch	O	O
patient	O	O
of	O	O
Chinese	O	O
origin	O	O
,	O	O
was	O	O
present	O	O
in	O	O
two	O	O
Chinese	O	O
families	O	O
with	O	O
IV	O	O
.	O	O
Neither	O	O
of	O	O
the	O	O
null	O	O
mutations	O	O
,	O	O
Q1256X	O	O
and	O	O
E2422X	O	O
,	O	O
were	O	O
found	O	O
in	O	O
100	O	O
unrelated	O	O
control	O	O
cases	O	O
from	O	O
the	O	O
Chinese	O	O
population	O	O
;	O	O
however	O	O
,	O	O
the	O	O
mutation	O	O
ratio	O	O
for	O	O
3321delA	O	O
was	O	O
3	O	O
%	O	O
in	O	O
these	O	O
controls	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Our	O	O
study	O	O
suggests	O	O
that	O	O
each	O	O
population	O	O
may	O	O
have	O	O
a	O	O
unique	O	O
and	O	O
prevalent	O	O
set	O	O
of	O	O
FLG	O	O
mutations	O	O
.	O	O
Genetic	O	O
analysis	O	O
of	O	O
haemophilia	O	O
A	O	O
in	O	O
Taiwan	O	O
.	O	O
Haemophilia	B-Disease	O
A	I-Disease	O
(	O	O
HA	O	O
)	O	O
is	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
bleeding	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
factor	O	O
VIII	O	O
(	B-Gene	O
FVIII	I-Gene	O
)	I-Gene	O
gene	O	O
.	O	O
Identification	O	O
of	O	O
these	O	O
mutations	O	O
is	O	O
becoming	O	O
increasingly	O	O
important	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
clinical	O	O
settings	O	O
.	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
report	O	O
is	O	O
to	O	O
describe	O	O
our	O	O
experience	O	O
of	O	O
FVIII	O	O
gene	O	O
mutation	O	O
analysis	O	O
in	O	O
the	O	O
largest	O	O
cohort	O	O
of	O	O
patients	O	O
in	O	O
Taiwan	O	O
including	O	O
the	O	O
discovery	O	O
of	O	O
21	O	O
novel	O	O
mutations	O	O
.	O	O
We	O	O
tested	O	O
115	O	O
HA	O	O
patients	O	O
from	O	O
91	O	O
unrelated	O	O
families	O	O
,	O	O
including	O	O
79	O	O
severe	O	O
,	O	O
15	O	O
moderate	O	O
and	O	O
21	O	O
mild	O	O
types	O	O
starting	O	O
with	O	O
an	O	O
assay	O	O
for	O	O
the	O	O
intron	O	O
22	O	O
inversion	O	O
by	O	O
long	O	O
range	O	O
-	O	O
PCR	O	O
followed	O	O
if	O	O
necessary	O	O
by	O	O
additional	O	O
genetic	O	O
studies	O	O
.	O	O
Intron	O	O
22	O	O
inversion	O	O
accounted	O	O
for	O	O
27.8	O	O
%	O	O
of	O	O
the	O	O
total	O	O
and	O	O
36.7	O	O
%	O	O
of	O	O
severe	O	O
HA	O	O
patients	O	O
respectively	O	O
while	O	O
intron	O	O
1	O	O
inversion	O	O
comprised	O	O
7.6	O	O
%	O	O
of	O	O
severe	O	O
patients	O	O
.	O	O
These	O	O
were	O	O
clearly	O	O
different	O	O
from	O	O
the	O	O
known	O	O
data	O	O
in	O	O
caucasian	O	O
populations	O	O
.	O	O
Of	O	O
75	O	O
patients	O	O
without	O	O
intron	O	O
22	O	O
or	O	O
1	O	O
inversion	O	O
,	O	O
70	O	O
from	O	O
62	O	O
unrelated	O	O
families	O	O
revealed	O	O
56	O	O
different	O	O
mutations	O	O
by	O	O
denaturing	O	O
high	O	O
-	O	O
performance	O	O
liquid	O	O
chromatography	O	O
(	O	O
DHPLC	O	O
)	O	O
,	O	O
of	O	O
which	O	O
21	O	O
were	O	O
novel	O	O
.	O	O
Also	O	O
,	O	O
the	O	O
only	O	O
female	O	O
patient	O	O
with	O	O
severe	O	O
HA	O	O
was	O	O
found	O	O
to	O	O
have	O	O
heterozygous	O	O
non	O	O
-	O	O
sense	O	O
mutation	O	O
(	O	O
c.6683G	O	O
>	O	O
A	O	O
)	O	O
of	O	O
exon	O	O
24	O	O
.	O	O
Seven	O	O
patients	O	O
,	O	O
including	O	O
five	O	O
without	O	O
amplified	O	O
PCR	O	O
product	O	O
and	O	O
two	O	O
without	O	O
encoded	O	O
DNA	O	O
defect	O	O
turned	O	O
out	O	O
to	O	O
have	O	O
exon(s	O	O
)	O	O
deletion	O	O
or	O	O
insertion	O	O
by	O	O
reverse	O	O
transcript	O	O
PCR	O	O
(	O	O
RT	O	O
-	O	O
PCR	O	O
)	O	O
.	O	O
In	O	O
our	O	O
study	O	O
,	O	O
the	O	O
combination	O	O
of	O	O
various	O	O
molecular	O	O
techniques	O	O
including	O	O
LR	O	O
-	O	O
PCR	O	O
,	O	O
multiplex	O	O
PCR	O	O
,	O	O
DHPLC	O	O
and	O	O
RT	O	O
-	O	O
PCR	O	O
analysis	O	O
enabled	O	O
definitive	O	O
detection	O	O
of	O	O
the	O	O
causative	O	O
FVIII	O	O
gene	O	O
defects	O	O
in	O	O
112	O	O
of	O	O
113	O	O
(	O	O
99	O	O
%	O	O
)	O	O
HA	O	O
patients	O	O
.	O	O
Mutation	O	O
spectra	O	O
in	O	O
autosomal	O	O
dominant	O	O
and	O	O
recessive	O	O
retinitis	O	O
pigmentosa	O	O
in	O	O
northern	O	O
Sweden	O	O
.	O	O
Retinal	O	O
degenerations	O	O
represent	O	O
a	O	O
heterogeneous	O	O
group	O	O
of	O	O
disorders	O	O
affecting	O	O
the	O	O
function	O	O
of	O	O
the	O	O
retina	O	O
.	O	O
The	O	O
frequency	O	O
of	O	O
retinitis	O	O
pigmentosa	O	O
(	O	O
RP	O	O
)	O	O
is	O	O
1/3500	O	O
worldwide	O	O
,	O	O
however	O	O
,	O	O
in	O	O
northern	O	O
Sweden	O	O
it	O	O
is	O	O
1/2000	O	O
due	O	O
to	O	O
limited	O	O
migration	O	O
and	O	O
a	O	O
'	O	O
founder	O	O
'	O	O
effect	O	O
.	O	O
In	O	O
this	O	O
study	O	O
we	O	O
identified	O	O
genetic	O	O
mechanisms	O	O
underlying	O	O
autosomal	O	O
dominant	O	O
and	O	O
recessive	O	O
RP	O	O
present	O	O
in	O	O
northern	O	O
Sweden	O	O
.	O	O
Several	O	O
novel	O	O
mutations	O	O
unique	O	O
for	O	O
this	O	O
region	O	O
were	O	O
found	O	O
.	O	O
In	O	O
an	O	O
autosomal	O	O
recessive	O	O
form	O	O
of	O	O
RP	O	O
,	O	O
Bothnia	B-Disease	O
dystrophy	I-Disease	O
caused	B-Reg	B-Reg
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
RLBP1	B-Gene	O
gene	O	O
,	O	O
bi	O	O
-	O	O
allelic	O	O
mutations	O	O
R234W	O	O
,	O	O
M226	O	O
K	O	O
and	O	O
compound	O	O
heterozygosity	O	O
,	O	O
M226K+R234W	O	O
was	O	O
detected	O	O
.	O	O
In	O	O
dominant	O	O
form	O	O
of	O	O
RP	O	O
mapped	O	O
to	O	O
19q13.42	O	O
a	O	O
59	O	O
kb	O	O
genomic	O	O
deletion	O	O
including	O	O
the	O	O
PRPF31	O	O
and	O	O
three	O	O
other	O	O
genes	O	O
was	O	O
found	O	O
.	O	O
These	O	O
data	O	O
provide	O	O
additional	O	O
information	O	O
on	O	O
the	O	O
molecular	O	O
mechanisms	O	O
of	O	O
RP	O	O
evolvement	O	O
and	O	O
in	O	O
the	O	O
future	O	O
might	O	O
be	O	O
useful	O	O
in	O	O
development	O	O
of	O	O
therapeutic	O	O
strategies	O	O
.	O	O
Identification	O	O
of	O	O
the	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
allowed	O	O
introducing	O	O
molecular	O	O
genetic	O	O
testing	O	O
of	O	O
the	O	O
patients	O	O
and	O	O
their	O	O
families	O	O
into	O	O
the	O	O
clinical	O	O
practice	O	O
.	O	O
Sequence	O	O
variants	B-Var	O
of	O	O
the	O	O
DFNB31	B-Gene	O
gene	O	O
among	B-Reg	O
Usher	B-Disease	O
syndrome	I-Disease	O
patients	O	O
of	O	O
diverse	O	O
origin	O	O
.	O	O
PURPOSE	O	O
:	O	O
It	O	O
has	O	O
been	O	O
demonstrated	O	O
that	O	O
mutations	B-Var	O
in	O	O
deafness	O	O
,	O	O
autosomal	O	O
recessive	O	O
31	O	O
(	B-Gene	O
DFNB31	I-Gene	O
)	I-Gene	O
,	O	O
the	O	O
gene	O	O
encoding	O	O
whirlin	O	O
,	O	O
is	O	O
responsible	B-Reg	O
for	O	O
nonsyndromic	B-Disease	O
hearing	I-Disease	O
loss	I-Disease	O
(	O	O
NSHL	O	O
;	O	O
DFNB31	O	O
)	O	O
and	O	O
Usher	B-Disease	O
syndrome	I-Disease	B-Disease
type	I-Disease	I-Disease
II	I-Disease	I-Disease
(	O	O
USH2D	O	O
)	O	O
.	O	O
We	O	O
screened	O	O
DFNB31	O	O
in	O	O
a	O	O
large	O	O
cohort	O	O
of	O	O
patients	O	O
with	O	O
different	O	O
clinical	O	O
subtypes	O	O
of	O	O
Usher	O	O
syndrome	O	O
(	O	O
USH	O	O
)	O	O
to	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
DFNB31	O	O
mutations	O	O
among	O	O
USH	O	O
patients	O	O
.	O	O
METHODS	O	O
:	O	O
DFNB31	O	O
was	O	O
screened	O	O
in	O	O
149	O	O
USH2	O	O
,	O	O
29	O	O
USH1	O	O
,	O	O
six	O	O
atypical	O	O
USH	O	O
,	O	O
and	O	O
11	O	O
unclassified	O	O
USH	O	O
patients	O	O
from	O	O
diverse	O	O
ethnic	O	O
backgrounds	O	O
.	O	O
Mutation	O	O
detection	O	O
was	O	O
performed	O	O
by	O	O
direct	O	O
sequencing	O	O
of	O	O
all	O	O
coding	O	O
exons	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
identified	O	O
38	O	O
different	O	O
variants	O	O
among	O	O
195	O	O
patients	O	O
.	O	O
Most	O	O
variants	O	O
were	O	O
clearly	O	O
polymorphic	O	O
,	O	O
but	O	O
at	O	O
least	O	O
two	O	O
out	O	O
of	O	O
the	O	O
15	O	O
nonsynonymous	O	O
variants	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
R350W	I-Var	O
and	O	O
p	B-Var	O
.	I-Var	O
R882S	I-Var	O
)	I-Var	O
are	O	O
predicted	O	O
to	O	O
impair	B-NegReg	O
whirlin	B-Protein	O
structure	B-MPA	O
and	O	O
function	B-MPA	O
,	O	O
suggesting	O	O
eventual	O	O
pathogenicity	O	O
.	O	O
No	O	O
putatively	O	O
pathogenic	O	O
mutation	O	O
was	O	O
found	O	O
in	O	O
the	O	O
second	O	O
allele	O	O
of	O	O
patients	O	O
with	O	O
these	O	O
mutations	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
DFNB31	O	O
is	O	O
not	O	O
a	O	O
major	O	O
cause	O	O
of	O	O
USH	O	O
.	O	O
Partial	O	O
depletion	O	O
of	O	O
CREB	O	O
-	O	O
binding	O	O
protein	O	O
reduces	O	O
life	O	O
expectancy	O	O
in	O	O
a	O	O
mouse	O	O
model	O	O
of	O	O
Huntington	O	O
disease	O	O
.	O	O
Previous	O	O
studies	O	O
have	O	O
reported	O	O
that	O	O
mutant	B-Var	O
huntingtin	B-Gene	O
(	O	O
htt	O	O
)	O	O
interferes	B-Reg	O
with	O	O
cyclic	B-Protein	O
AMP	I-Protein	O
response	I-Protein	O
element	I-Protein	O
binding	I-Protein	O
protein	I-Protein	O
binding	B-Interaction	O
protein	B-Protein	O
(	O	O
CBP)-mediated	O	O
transcription	B-MPA	O
,	O	O
possibly	O	O
by	O	O
inhibiting	B-NegReg	O
the	O	O
acetylation	B-MPA	O
of	O	O
histones	B-Protein	O
.	O	O
In	O	O
Drosophila	O	O
models	O	O
that	O	O
express	O	O
fragments	O	O
of	O	O
mutant	O	O
htt	O	O
,	O	O
histone	O	O
deacetylase	O	O
inhibitors	O	O
reverse	O	O
deficits	O	O
in	O	O
histone	O	O
acetylation	O	O
,	O	O
rescue	O	O
photoreceptor	O	O
degeneration	O	O
,	O	O
and	O	O
prolong	O	O
their	O	O
survival	O	O
.	O	O
These	O	O
compounds	O	O
also	O	O
improve	O	O
motor	O	O
deficits	O	O
in	O	O
a	O	O
transgenic	O	O
mouse	O	O
model	O	O
of	O	O
Huntington	O	O
disease	O	O
(	O	O
HD	O	O
)	O	O
.	O	O
To	O	O
determine	O	O
whether	O	O
endogenous	O	O
CBP	O	O
depletion	O	O
contributes	O	O
to	O	O
HD	O	O
pathogenesis	O	O
,	O	O
we	O	O
crossed	O	O
HD	O	O
-	O	O
N171	O	O
-	O	O
82Q	O	O
transgenic	O	O
mice	O	O
with	O	O
mice	O	O
harboring	O	O
a	O	O
disrupted	O	O
CBP	O	O
gene	O	O
and	O	O
produced	O	O
mice	O	O
with	O	O
partial	O	O
(	O	O
50	O	O
%	O	O
)	O	O
depletion	O	O
of	O	O
CBP	O	O
.	O	O
This	O	O
reduction	O	O
of	O	O
CBP	O	O
levels	O	O
decreased	O	O
the	O	O
life	O	O
expectancy	O	O
of	O	O
the	O	O
HD	O	O
-	O	O
N171	O	O
-	O	O
82Q	O	O
Line	O	O
6	O	O
mouse	O	O
model	O	O
.	O	O
The	O	O
loss	O	O
of	O	O
CBP	O	O
had	O	O
no	O	O
obvious	O	O
impact	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
motor	O	O
impairment	O	O
,	O	O
degeneration	O	O
of	O	O
the	O	O
striatum	O	O
,	O	O
mutant	O	O
htt	O	O
inclusion	O	O
formation	O	O
,	O	O
or	O	O
global	O	O
levels	O	O
of	O	O
acetylated	O	O
histones	O	O
H3	O	O
or	O	O
H4	O	O
in	O	O
brain	O	O
.	O	O
In	O	O
cell	O	O
models	O	O
,	O	O
we	O	O
confirmed	O	O
that	O	O
mutant	O	O
htt	O	O
inclusions	O	O
recruit	O	O
human	O	O
CBP	O	O
but	O	O
found	O	O
no	O	O
evidence	O	O
for	O	O
interactions	O	O
between	O	O
soluble	O	O
forms	O	O
of	O	O
mutant	O	O
htt	O	O
and	O	O
CBP	O	O
.	O	O
Although	O	O
we	O	O
identified	O	O
no	O	O
neurological	O	O
explanation	O	O
for	O	O
the	O	O
decreased	O	O
life	O	O
expectancy	O	O
of	O	O
HD	O	O
-	O	O
N171	O	O
-	O	O
82Q	O	O
mice	O	O
with	O	O
partial	O	O
depletion	O	O
of	O	O
CBP	O	O
,	O	O
the	O	O
data	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
notion	O	O
that	O	O
CBP	O	O
function	O	O
mitigates	O	O
mutant	O	O
htt	O	O
toxicity	O	O
by	O	O
a	O	O
currently	O	O
unidentified	O	O
mechanism	O	O
.	O	O
Type	O	O
I	O	O
hyperprolinemia	O	O
:	O	O
genotype	O	O
/	O	O
phenotype	O	O
correlations	O	O
.	O	O
Type	B-Disease	O
I	I-Disease	O
hyperprolinemia	I-Disease	O
(	O	O
HPI	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
associated	O	O
with	O	O
cognitive	O	O
and	O	O
psychiatric	O	O
troubles	O	O
,	O	O
caused	O	O
by	O	O
alterations	O	O
of	O	O
the	O	O
Proline	O	O
Dehydrogenase	O	O
gene	O	O
(	O	O
PRODH	O	O
)	O	O
at	O	O
22q11	O	O
.	O	O
HPI	B-Disease	O
results	B-Reg	O
from	I-Reg	O
PRODH	B-Gene	O
deletion	B-Var	O
and/or	O	O
missense	B-Var	O
mutations	I-Var	O
reducing	B-NegReg	O
proline	B-Enzyme	O
oxidase	I-Enzyme	O
(	O	O
POX	O	O
)	O	O
activity	B-MPA	O
.	O	O
The	O	O
goals	O	O
of	O	O
this	O	O
study	O	O
were	O	O
first	O	O
to	O	O
measure	O	O
in	O	O
controls	O	O
the	O	O
frequency	O	O
of	O	O
PRODH	O	O
variations	O	O
described	O	O
in	O	O
HPI	O	O
patients	O	O
,	O	O
second	O	O
to	O	O
assess	O	O
the	O	O
functional	O	O
effect	O	O
of	O	O
PRODH	O	O
mutations	O	O
on	O	O
POX	O	O
activity	O	O
,	O	O
and	O	O
finally	O	O
to	O	O
establish	O	O
genotype	O	O
/	O	O
enzymatic	O	O
activity	O	O
correlations	O	O
in	O	O
a	O	O
new	O	O
series	O	O
of	O	O
HPI	O	O
patients	O	O
.	O	O
Eight	O	O
of	O	O
14	O	O
variants	O	O
occurred	O	O
at	O	O
polymorphic	O	O
frequency	O	O
in	O	O
114	O	O
controls	O	O
.	O	O
POX	O	O
activity	O	O
was	O	O
determined	O	O
for	O	O
six	O	O
novel	O	O
mutations	O	O
and	O	O
two	O	O
haplotypes	O	O
.	O	O
The	O	O
c.1331G	O	O
>	O	O
A	O	O
,	O	O
p	O	O
.	O	O
G444D	O	O
allele	O	O
has	O	O
a	O	O
drastic	O	O
effect	O	O
,	O	O
whereas	O	O
the	O	O
c.23C	B-Var	O
>	I-Var	O
T	I-Var	O
,	O	O
p	B-Var	O
.	I-Var	O
P8L	I-Var	O
allele	O	O
and	O	O
the	O	O
c.[56C	B-Var	O
>	I-Var	O
A	I-Var	O
;	I-Var	O
172G	I-Var	O
>	I-Var	O
A	I-Var	O
]	I-Var	O
,	O	O
p.[Q19P	B-Var	O
;	I-Var	O
A58	I-Var	O
T	I-Var	O
]	I-Var	O
haplotype	O	O
result	O	O
in	O	O
a	O	O
moderate	O	O
decrease	B-NegReg	O
in	O	O
activity	B-MPA	O
.	O	O
Among	O	O
the	O	O
19	O	O
HPI	O	O
patients	O	O
,	O	O
10	O	O
had	O	O
a	O	O
predicted	O	O
residual	O	O
activity	O	O
<	O	O
50	O	O
%	O	O
.	O	O
Eight	O	O
out	O	O
of	O	O
nine	O	O
subjects	O	O
with	O	O
a	O	O
predicted	O	O
residual	O	O
activity	O	O
>	O	O
or	O	O
=	O	O
50	O	O
%	O	O
bore	O	O
at	O	O
least	O	O
one	O	O
c.824C	O	O
>	O	O
A	O	O
,	O	O
p	O	O
.	O	O
T275N	O	O
allele	O	O
,	O	O
which	O	O
has	O	O
no	O	O
detrimental	O	O
effect	O	O
on	O	O
activity	O	O
but	O	O
whose	O	O
frequency	O	O
in	O	O
controls	O	O
is	O	O
only	O	O
3	O	O
%	O	O
.	O	O
Our	O	O
results	O	O
suggest	O	O
that	O	O
PRODH	B-Gene	O
mutations	B-Var	O
lead	O	O
to	O	O
a	O	O
decreased	B-NegReg	B-NegReg
POX	B-Enzyme	O
activity	B-MPA	B-CPA
or	O	O
affect	B-Reg	B-CPA
other	B-MPA	O
biological	I-MPA	B-CPA
parameters	I-MPA	I-CPA
causing	B-Reg	O
hyperprolinemia	B-Disease	O
.	O	O
Dihydropyrimidine	B-Disease	O
dehydrogenase	I-Disease	O
deficiency	I-Disease	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
novel	O	O
genomic	O	O
deletion	O	O
c.505_513del	B-Var	O
of	O	O
DPYD	B-Gene	O
.	O	O
Dihydropyrimidine	O	O
dehydrogenase	O	O
(	O	O
DPD	O	O
)	O	O
deficiency	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
of	O	O
the	O	O
pyrimidine	O	O
degradation	O	O
pathway	O	O
.	O	O
In	O	O
a	O	O
patient	O	O
presenting	O	O
with	O	O
convulsions	O	O
,	O	O
psychomotor	O	O
retardation	O	O
and	O	O
Reye	O	O
like	O	O
syndrome	O	O
,	O	O
strongly	O	O
elevated	O	O
levels	O	O
of	O	O
uracil	O	O
and	O	O
thymine	O	O
were	O	O
detected	O	O
in	O	O
urine	O	O
.	O	O
No	O	O
DPD	O	O
activity	O	O
could	O	O
be	O	O
detected	O	O
in	O	O
peripheral	O	O
blood	O	O
mononuclear	O	O
cells	O	O
.	O	O
Analysis	O	O
of	O	O
the	O	O
gene	O	O
encoding	O	O
DPD	O	O
(	O	O
DPYD	O	O
)	O	O
showed	O	O
that	O	O
the	O	O
patient	O	O
was	O	O
homozygous	O	O
for	O	O
a	O	O
novel	O	O
c.505_513del	O	O
(	O	O
p.169_171del	O	O
)	O	O
mutation	O	O
in	O	O
exon	O	O
6	O	O
of	O	O
DPYD	O	O
.	O	O
Analysis	O	O
of	O	O
mutations	B-Var	O
causing	B-Reg	O
biotinidase	B-Disease	O
deficiency	I-Disease	O
.	O	O
Biotinidase	O	O
deficiency	O	O
is	O	O
an	O	O
inherited	O	O
disorder	O	O
in	O	O
which	O	O
the	O	O
vitamin	O	O
,	O	O
biotin	O	O
,	O	O
is	O	O
not	O	O
recycled	O	O
.	O	O
Individuals	O	O
with	O	O
biotinidase	O	O
deficiency	O	O
can	O	O
develop	O	O
neurological	O	O
and	O	O
cutaneous	O	O
symptoms	O	O
if	O	O
they	O	O
are	O	O
not	O	O
treated	O	O
with	O	O
biotin	O	O
.	O	O
Biotinidase	O	O
deficiency	O	O
screening	O	O
has	O	O
been	O	O
incorporated	O	O
into	O	O
essentially	O	O
all	O	O
newborn	O	O
screening	O	O
programs	O	O
in	O	O
the	O	O
United	O	O
States	O	O
and	O	O
in	O	O
many	O	O
countries	O	O
.	O	O
We	O	O
now	O	O
report	O	O
140	O	O
known	O	O
mutations	B-Var	O
in	O	O
the	O	O
biotinidase	O	O
gene	O	O
(	B-Gene	O
BTD	I-Gene	O
)	I-Gene	O
that	O	O
cause	B-Reg	O
biotinidase	B-Disease	O
deficiency	I-Disease	O
.	O	O
All	O	O
types	O	O
of	O	O
mutations	B-Var	B-Var
have	O	O
been	O	O
found	O	O
to	O	O
cause	B-Reg	O
biotinidase	B-Disease	O
deficiency	I-Disease	B-Disease
.	O	O
Variants	O	O
have	O	O
been	O	O
identified	O	O
throughout	O	O
the	O	O
coding	O	O
sequence	O	O
.	O	O
Essentially	O	O
all	O	O
the	O	O
variants	B-Var	O
result	O	O
in	O	O
enzymatic	B-Enzyme	O
activities	B-MPA	O
with	O	O
less	B-NegReg	O
than	O	O
10	O	O
%	O	O
of	O	O
mean	O	O
normal	O	O
enzyme	O	O
activity	O	O
(	O	O
profound	O	O
biotinidase	O	O
deficiency	O	O
)	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
the	O	O
c.1330G	B-Var	O
>	I-Var	O
C	I-Var	O
(	O	O
p	O	O
.	O	O
D444H	O	O
)	O	O
mutation	O	O
,	O	O
which	O	O
results	O	O
in	O	O
an	O	O
enzyme	B-Enzyme	O
having	O	O
50	B-NegReg	O
%	I-NegReg	O
of	O	O
mean	O	O
normal	O	O
serum	B-MPA	O
activity	I-MPA	O
.	O	O
The	O	O
putative	O	O
three	O	O
-	O	O
dimensional	O	O
structure	O	O
of	O	O
biotinidase	O	O
has	O	O
been	O	O
predicted	O	O
by	O	O
homology	O	O
to	O	O
that	O	O
of	O	O
nitrilases	O	O
/	O	O
amidases	O	O
.	O	O
The	O	O
effect	O	O
of	O	O
the	O	O
various	O	O
missense	O	O
mutations	O	O
can	O	O
be	O	O
predicted	O	O
to	O	O
affect	O	O
various	O	O
important	O	O
sites	O	O
within	O	O
the	O	O
structure	O	O
of	O	O
the	O	O
enzyme	O	O
.	O	O
This	O	O
compilation	O	O
of	O	O
variants	O	O
causing	O	O
biotinidase	O	O
deficiency	O	O
will	O	O
be	O	O
useful	O	O
to	O	O
clinical	O	O
laboratories	O	O
that	O	O
are	O	O
performing	O	O
mutation	O	O
analysis	O	O
for	O	O
confirmational	O	O
testing	O	O
when	O	O
the	O	O
enzymatic	O	O
results	O	O
are	O	O
equivocal	O	O
for	O	O
children	O	O
identified	O	O
through	O	O
newborn	O	O
screening	O	O
.	O	O
N88S	B-Var	O
mutation	O	O
in	O	O
the	O	O
BSCL2	B-Gene	O
gene	O	O
in	B-Reg	O
a	O	O
Serbian	O	O
family	O	O
with	O	O
distal	B-Disease	O
hereditary	I-Disease	O
motor	I-Disease	O
neuropathy	I-Disease	O
type	I-Disease	O
V	I-Disease	O
or	O	O
Silver	B-Disease	O
syndrome	I-Disease	O
.	O	O
BACKGROUND	O	O
:	O	O
Distal	B-Disease	O
hereditary	I-Disease	O
motor	I-Disease	O
neuropathy	I-Disease	O
type	I-Disease	O
V	I-Disease	O
(	O	O
dHMN	O	O
-	O	O
V	O	O
)	O	O
and	O	O
Silver	B-Disease	O
syndrome	I-Disease	O
are	O	O
rare	O	O
phenotypically	O	O
overlapping	O	O
diseases	O	O
which	O	O
can	O	O
be	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	B-Var
in	O	O
the	O	O
Berardinelli	O	O
-	O	O
Seip	O	O
Congenital	O	O
Lipodystrophy	O	O
2	O	O
(	B-Gene	O
BSCL2	I-Gene	O
)	I-Gene	I-Gene
gene	O	O
or	O	O
Seipin	B-Gene	O
.	O	O
AIM	O	O
:	O	O
To	O	O
report	O	O
the	O	O
first	O	O
Serbian	O	O
family	O	O
with	O	O
a	O	O
BSCL2	O	O
mutation	O	O
showing	O	O
variable	O	O
expression	O	O
within	O	O
the	O	O
family	O	O
.	O	O
PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
55-year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
with	O	O
weakness	O	O
of	O	O
both	O	O
hands	O	O
at	O	O
the	O	O
age	O	O
of	O	O
45	O	O
.	O	O
At	O	O
age	O	O
47	O	O
,	O	O
she	O	O
noticed	O	O
distal	O	O
muscle	O	O
weakness	O	O
and	O	O
atrophy	O	O
in	O	O
her	O	O
legs	O	O
.	O	O
Physical	O	O
examination	O	O
revealed	O	O
atrophy	O	O
and	O	O
weakness	O	O
of	O	O
small	O	O
hand	O	O
muscles	O	O
and	O	O
mild	O	O
atrophy	O	O
and	O	O
weakness	O	O
of	O	O
the	O	O
lower	O	O
limbs	O	O
.	O	O
There	O	O
was	O	O
generalized	O	O
hyperreflexia	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
ankle	O	O
reflexes	O	O
which	O	O
were	O	O
diminished	O	O
.	O	O
Her	O	O
25year	O	O
-	O	O
old	O	O
son	O	O
had	O	O
only	O	O
stiffness	O	O
of	O	O
both	O	O
legs	O	O
at	O	O
the	O	O
age	O	O
of	O	O
22	O	O
.	O	O
Physical	O	O
examination	O	O
revealed	O	O
only	O	O
generalized	O	O
hyporeflexia	O	O
.	O	O
The	O	O
third	O	O
affected	O	O
member	O	O
in	O	O
this	O	O
family	O	O
was	O	O
her	O	O
55year	O	O
-	O	O
old	O	O
cousin	O	O
who	O	O
showed	O	O
a	O	O
more	O	O
prominent	O	O
involvement	O	O
of	O	O
leg	O	O
muscles	O	O
with	O	O
mild	O	O
asymmetrical	O	O
weakness	O	O
of	O	O
hand	O	O
muscles	O	O
and	O	O
no	O	O
pyramidal	O	O
tract	O	O
features	O	O
.	O	O
RESULTS	O	O
:	O	O
In	O	O
all	O	O
three	O	O
patients	O	O
sensory	O	O
nerve	O	O
conduction	O	O
velocities	O	O
(	O	O
NCV	O	O
)	O	O
were	O	O
normal	O	O
in	O	O
all	O	O
extremities	O	O
.	O	O
Compound	O	O
muscle	O	O
action	O	O
potential	O	O
(	O	O
CMAP	O	O
)	O	O
amplitudes	O	O
were	O	O
markedly	O	O
reduced	O	O
in	O	O
all	O	O
patients	O	O
.	O	O
Concentric	O	O
needle	O	O
EMG	O	O
showed	O	O
evidence	O	O
of	O	O
chronic	O	O
denervation	O	O
in	O	O
distal	O	O
muscles	O	O
.	O	O
DNA	O	O
sequencing	O	O
of	O	O
BSCL2	O	O
was	O	O
performed	O	O
and	O	O
a	O	O
heterozygous	O	O
N88S	O	O
missense	O	O
mutation	O	O
in	O	O
BSCL2	O	O
gene	O	O
was	O	O
detected	O	O
in	O	O
all	O	O
three	O	O
patients	O	O
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
report	O	O
is	O	O
further	O	O
confirmation	O	O
of	O	O
phenotypic	O	O
heterogenity	O	O
due	O	O
to	O	O
the	O	O
N88S	O	O
mutation	O	O
of	O	O
BSCL2	O	O
gene	O	O
in	O	O
the	O	O
same	O	O
family	O	O
.	O	O
DOK7	B-Gene	O
mutations	B-Var	O
presenting	B-Reg	O
as	I-Reg	O
a	O	O
proximal	B-Disease	O
myopathy	I-Disease	O
in	O	O
French	O	O
Canadians	O	O
.	O	O
DOK7	B-Gene	B-Gene
mutations	B-Var	B-Var
cause	B-Reg	B-Reg
a	O	O
congenital	B-Disease	B-Disease
myasthenic	I-Disease	I-Disease
syndrome	I-Disease	I-Disease
(	O	O
OMIM	O	O
254300	O	O
)	O	O
characterized	O	O
by	O	O
a	O	O
"	O	O
limb	O	O
-	O	O
girdle	O	O
"	O	O
phenotype	O	O
.	O	O
We	O	O
identified	O	O
7	O	O
French	O	O
-	O	O
Canadian	O	O
patients	O	O
with	O	O
a	O	O
previously	O	O
undiagnosed	O	O
proximal	O	O
myopathy	O	O
.	O	O
A	O	O
genome	O	O
wide	O	O
scan	O	O
was	O	O
performed	O	O
.	O	O
Homozygosity	O	O
mapping	O	O
identified	O	O
a	O	O
locus	O	O
on	O	O
chromosome	O	O
4p16.2	O	O
containing	O	O
DOK7	O	O
.	O	O
Sequencing	O	O
of	O	O
DOK7	O	O
revealed	O	O
homozygous	O	O
1124_1127dupTGCC	O	O
mutations	O	O
in	O	O
all	O	O
individuals	O	O
.	O	O
SNP	O	O
genotyping	O	O
of	O	O
42	O	O
kb	O	O
surrounding	O	O
DOK7	O	O
in	O	O
our	O	O
cohort	O	O
and	O	O
in	O	O
9	O	O
patients	O	O
of	O	O
various	O	O
European	O	O
origins	O	O
demonstrated	O	O
a	O	O
shared	O	O
haplotype	O	O
suggesting	O	O
a	O	O
common	O	O
ancestral	O	O
European	O	O
mutation	O	O
.	O	O
In	O	O
our	O	O
cohort	O	O
,	O	O
fatigability	O	O
was	O	O
not	O	O
prominent	O	O
;	O	O
rather	O	O
patients	O	O
reported	O	O
prolonged	O	O
periods	O	O
of	O	O
increased	O	O
weakness	O	O
.	O	O
Abnormalities	O	O
on	O	O
repetitive	O	O
nerve	O	O
stimulation	O	O
and	O	O
single	O	O
fiber	O	O
EMG	O	O
were	O	O
not	O	O
invariably	O	O
present	O	O
.	O	O
There	O	O
was	O	O
considerable	O	O
intra	O	O
-	O	O
familial	O	O
phenotypic	O	O
variability	O	O
,	O	O
and	O	O
we	O	O
report	O	O
an	O	O
asymptomatic	O	O
individual	O	O
.	O	O
DOK7	O	O
mutations	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
early	O	O
-	O	O
onset	O	O
myopathy	O	O
,	O	O
even	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
symptoms	O	O
suggesting	O	O
a	O	O
possible	O	O
myasthenia	O	O
.	O	O
Identification	O	O
of	O	O
known	O	O
and	O	O
novel	O	O
PTCH	B-Gene	O
mutations	B-Var	O
in	B-Reg	O
both	O	O
syndromic	O	O
and	O	O
non	O	O
-	O	O
syndromic	O	O
keratocystic	B-Disease	O
odontogenic	I-Disease	O
tumors	I-Disease	O
.	O	O
AIM	O	O
:	O	O
To	O	O
clarify	O	O
the	O	O
role	O	O
of	O	O
PTCH	O	O
in	O	O
patients	O	O
with	O	O
NBCCS	O	O
-	O	O
related	O	O
and	O	O
non	O	O
-	O	O
sydromic	O	O
keratocystic	O	O
odontogenic	O	O
tumors	O	O
.	O	O
METHODOLOGY	O	O
:	O	O
Mutation	O	O
analysis	O	O
was	O	O
undertaken	O	O
in	O	O
8	O	O
sporadic	O	O
and	O	O
4	O	O
NBCCS	O	O
-	O	O
associated	O	O
KCOTs	O	O
.	O	O
RESULTS	O	O
:	O	O
Four	O	O
novel	O	O
and	O	O
two	O	O
known	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
2	O	O
sporadic	O	O
and	O	O
3	O	O
syndromic	O	O
cases	O	O
,	O	O
two	O	O
of	O	O
which	O	O
being	O	O
germline	O	O
mutations	O	O
(	O	O
c.2179delT	O	O
,	O	O
c.2824delC	O	O
)	O	O
and	O	O
4	O	O
somatic	O	O
mutations	O	O
(	O	O
c.3162dupG	O	O
,	O	O
c.1362	O	O
-	O	O
1374dup	O	O
,	O	O
c.1012	O	O
C	O	O
>	O	O
T	O	O
,	O	O
c.403C	O	O
>	O	O
T	O	O
)	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Our	O	O
findings	O	O
suggest	O	O
that	O	O
defects	O	O
of	O	O
PTCH	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
pathogenesis	O	O
of	O	O
syndromic	O	O
as	O	O
well	O	O
as	O	O
a	O	O
subset	O	O
of	O	O
non	O	O
-	O	O
syndromic	O	O
KCOTs	O	O
.	O	O
NOTCH3	B-Gene	O
mutations	B-Var	O
and	O	O
clinical	O	O
features	O	O
in	O	O
33	O	O
mainland	O	O
Chinese	O	O
families	O	O
with	B-Reg	O
CADASIL	B-Disease	O
.	O	O
BACKGROUND	O	O
:	O	O
Cerebral	B-Disease	O
autosomal	I-Disease	O
dominant	I-Disease	O
arteriopathy	I-Disease	O
with	I-Disease	O
subcortical	I-Disease	O
infarcts	I-Disease	O
and	I-Disease	O
leucoencephalopathy	I-Disease	O
(	O	O
CADASIL	O	O
)	O	O
is	O	O
an	O	O
inherited	O	O
small	O	O
-	O	O
vessel	O	O
disease	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
NOTCH3	B-Gene	O
.	O	O
Although	O	O
CADASIL	O	O
cases	O	O
have	O	O
been	O	O
identified	O	O
worldwide	O	O
,	O	O
the	O	O
data	O	O
from	O	O
mainland	O	O
China	O	O
are	O	O
still	O	O
limited	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
identify	O	O
NOTCH3	O	O
mutations	O	O
and	O	O
analyse	O	O
the	O	O
clinical	O	O
and	O	O
MRI	O	O
findings	O	O
in	O	O
a	O	O
large	O	O
series	O	O
of	O	O
CADASIL	O	O
patients	O	O
from	O	O
mainland	O	O
China	O	O
.	O	O
METHODS	O	O
:	O	O
Direct	O	O
sequencing	O	O
of	O	O
NOTCH3	O	O
and/or	O	O
skin	O	O
or	O	O
sural	O	O
nerve	O	O
biopsies	O	O
were	O	O
performed	O	O
on	O	O
48	O	O
unrelated	O	O
suspected	O	O
CADASIL	O	O
cases	O	O
of	O	O
Chinese	O	O
descent	O	O
.	O	O
The	O	O
clinical	O	O
manifestations	O	O
and	O	O
MRI	O	O
features	O	O
were	O	O
retrospectively	O	O
collected	O	O
and	O	O
analysed	O	O
in	O	O
the	O	O
33	O	O
index	O	O
patients	O	O
with	O	O
confirmed	O	O
diagnosis	O	O
and	O	O
their	O	O
available	O	O
affected	O	O
family	O	O
members	O	O
.	O	O
RESULTS	O	O
:	O	O
20	O	O
different	O	O
NOTCH3	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
33	O	O
families	O	O
,	O	O
including	O	O
seven	O	O
novel	O	O
mutations	O	O
.	O	O
The	O	O
highest	O	O
mutation	O	O
frequency	O	O
was	O	O
in	O	O
exons	O	O
4	O	O
(	O	O
55	O	O
%	O	O
)	O	O
and	O	O
3	O	O
(	O	O
30	O	O
%	O	O
)	O	O
.	O	O
Granular	O	O
osmiophilic	O	O
material	O	O
in	O	O
smooth	O	O
muscle	O	O
cells	O	O
was	O	O
found	O	O
in	O	O
30	O	O
cases	O	O
who	O	O
were	O	O
biopsied	O	O
.	O	O
Clinical	O	O
presentation	O	O
included	O	O
TIA	O	O
/	O	O
stroke	O	O
in	O	O
82	O	O
%	O	O
,	O	O
cognitive	O	O
decline	O	O
in	O	O
60	O	O
%	O	O
,	O	O
and	O	O
migraine	O	O
with	O	O
aura	O	O
in	O	O
only	O	O
5	O	O
%	O	O
of	O	O
57	O	O
symptomatic	O	O
cases	O	O
.	O	O
MRI	O	O
detected	O	O
multiple	O	O
lacunar	O	O
infarcts	O	O
and	O	O
leucoaraiosis	O	O
in	O	O
all	O	O
symptomatic	O	O
cases	O	O
,	O	O
brainstem	O	O
lesions	O	O
in	O	O
64	O	O
%	O	O
of	O	O
symptomatic	O	O
cases	O	O
and	O	O
white	O	O
-	O	O
matter	O	O
lesions	O	O
in	O	O
the	O	O
temporal	O	O
pole	O	O
in	O	O
46	O	O
%	O	O
of	O	O
affected	O	O
members	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
mutational	O	O
spectrum	O	O
and	O	O
primary	O	O
clinical	O	O
features	O	O
of	O	O
patients	O	O
with	O	O
CADASIL	O	O
from	O	O
mainland	O	O
China	O	O
are	O	O
similar	O	O
to	O	O
those	O	O
in	O	O
Caucasians	O	O
.	O	O
However	O	O
,	O	O
migraine	O	O
with	O	O
aura	O	O
and	O	O
abnormal	O	O
white	O	O
matter	O	O
in	O	O
the	O	O
temporal	O	O
pole	O	O
are	O	O
less	O	O
common	O	O
than	O	O
among	O	O
Caucasians	O	O
,	O	O
while	O	O
brainstem	O	O
involvement	O	O
is	O	O
more	O	O
common	O	O
than	O	O
among	O	O
Caucasians	O	O
.	O	O
Prevalence	O	O
,	O	O
mutation	O	O
spectrum	O	O
and	O	O
phenotypic	O	O
variability	O	O
in	O	O
Norwegian	O	O
patients	O	O
with	O	O
Limb	O	O
Girdle	O	O
Muscular	O	O
Dystrophy	O	O
2I.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
FKRP	B-Gene	O
(	O	O
Fukutin	O	O
Related	O	O
Protein	O	O
)	O	O
gene	O	O
produce	B-Reg	O
a	O	O
range	O	O
of	O	O
phenotypes	O	O
including	O	O
Limb	B-Disease	O
Girdle	I-Disease	O
Muscular	I-Disease	O
Dystrophy	I-Disease	O
Type	I-Disease	O
2I	I-Disease	O
(	O	O
LGMD2I	O	O
)	O	O
.	O	O
In	O	O
order	O	O
to	O	O
investigate	O	O
the	O	O
prevalence	O	O
,	O	O
the	O	O
mutation	O	O
spectrum	O	O
and	O	O
possible	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
,	O	O
we	O	O
studied	O	O
a	O	O
cohort	O	O
of	O	O
Norwegian	O	O
patients	O	O
with	O	O
LGMD2I	O	O
,	O	O
ascertained	O	O
in	O	O
a	O	O
4-year	O	O
period	O	O
.	O	O
In	O	O
this	O	O
retrospective	O	O
study	O	O
of	O	O
genetically	O	O
tested	O	O
patients	O	O
,	O	O
we	O	O
identified	O	O
88	O	O
patients	O	O
from	O	O
69	O	O
families	O	O
,	O	O
who	O	O
were	O	O
either	O	O
homozygous	O	O
or	O	O
compound	O	O
heterozygous	O	O
for	O	O
FKRP	O	O
mutations	O	O
.	O	O
This	O	O
gives	O	O
a	O	O
minimum	O	O
prevalence	O	O
of	O	O
1/54,000	O	O
and	O	O
a	O	O
corresponding	O	O
carrier	O	O
frequency	O	O
of	O	O
1/116	O	O
in	O	O
the	O	O
Norwegian	O	O
population	O	O
.	O	O
Seven	O	O
different	O	O
FKRP	O	O
mutations	O	O
,	O	O
including	O	O
three	O	O
novel	O	O
changes	O	O
,	O	O
were	O	O
detected	O	O
.	O	O
Seventy	O	O
-	O	O
six	O	O
patients	O	O
were	O	O
homozygous	O	O
for	O	O
the	O	O
common	O	O
c.826C	O	O
>	O	O
A	O	O
mutation	O	O
.	O	O
These	O	O
patients	O	O
had	O	O
later	O	O
disease	O	O
onset	O	O
than	O	O
patients	O	O
who	O	O
were	O	O
compound	O	O
heterozygous	O	O
-	O	O
14.0	O	O
vs.	O	O
6.1	O	O
years	O	O
.	O	O
We	O	O
detected	O	O
substantial	O	O
variability	O	O
in	O	O
disease	O	O
severity	O	O
among	O	O
homozygous	O	O
patients	O	O
.	O	O
Novel	O	O
and	O	O
recurrent	O	O
connexin	O	O
30.3	O	O
and	O	O
connexin	O	O
31	O	O
mutations	O	O
associated	O	O
with	O	O
erythrokeratoderma	O	O
variabilis	O	O
.	O	O
Erythrokeratoderma	B-Disease	O
variabilis	I-Disease	O
(	O	O
EKV	O	O
)	O	O
is	O	O
characterized	O	O
by	O	O
fixed	O	O
hyperkeratotic	O	O
plaques	O	O
and	O	O
transient	O	O
erythema	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
genes	O	O
GJB3	B-Gene	O
and	O	O
GJB4	B-Gene	O
,	O	O
which	O	O
encode	O	O
connexin	O	O
(	O	O
Cx)31	O	O
and	O	O
Cx30.3	O	O
,	O	O
are	O	O
associated	B-Reg	O
with	O	O
EKV	B-Disease	O
.	O	O
We	O	O
report	O	O
one	O	O
novel	O	O
mutation	O	O
in	O	O
Cx31	O	O
and	O	O
one	O	O
recurrent	O	O
mutation	O	O
in	O	O
Cx30.3	O	O
in	O	O
two	O	O
different	O	O
families	O	O
.	O	O
One	O	O
novel	O	O
rare	O	O
sequence	O	O
variant	O	O
of	O	O
unknown	O	O
clinical	O	O
significance	O	O
was	O	O
also	O	O
identified	O	O
.	O	O
This	O	O
finding	O	O
extends	O	O
the	O	O
spectrum	O	O
of	O	O
known	O	O
EKV	O	O
-	O	O
associated	O	O
mutations	O	O
.	O	O
Thyroid	O	O
pathology	O	O
in	O	O
PTEN	O	O
-	O	O
hamartoma	O	O
tumor	O	O
syndrome	O	O
:	O	O
characteristic	O	O
findings	O	O
of	O	O
a	O	O
distinct	O	O
entity	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Phosphatase	O	O
and	O	O
tensin	O	O
homolog	O	O
deleted	O	O
on	O	O
chromosome	O	O
ten	O	O
(	B-Disease	O
PTEN)-hamartoma	I-Disease	O
tumor	I-Disease	O
syndrome	I-Disease	O
(	O	O
PHTS	O	O
)	O	O
is	O	O
a	O	O
complex	O	O
disorder	O	O
caused	O	O
by	O	O
germline	O	O
inactivating	B-NegReg	O
mutations	B-Var	O
of	O	O
the	O	O
PTEN	B-Gene	O
tumor	O	O
suppressor	O	O
gene	O	O
.	O	O
PHTS	O	O
includes	O	O
Cowden	O	O
syndrome	O	O
(	O	O
CS	O	O
)	O	O
,	O	O
Bannayan	O	O
-	O	O
Riley	O	O
-	O	O
Ruvalcaba	O	O
syndrome	O	O
(	O	O
BRRS	O	O
)	O	O
,	O	O
and	O	O
Proteus	O	O
-	O	O
like	O	O
syndromes	O	O
.	O	O
Affected	O	O
individuals	O	O
develop	O	O
both	O	O
benign	O	O
and	O	O
malignant	O	O
tumors	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
tissues	O	O
,	O	O
including	O	O
the	O	O
thyroid	O	O
.	O	O
This	O	O
study	O	O
is	O	O
to	O	O
better	O	O
characterize	O	O
and	O	O
describe	O	O
the	O	O
thyroid	O	O
pathology	O	O
within	O	O
the	O	O
different	O	O
entities	O	O
of	O	O
this	O	O
syndrome	O	O
,	O	O
and	O	O
examine	O	O
whether	O	O
there	O	O
is	O	O
an	O	O
association	O	O
between	O	O
specific	O	O
thyroid	O	O
findings	O	O
and	O	O
different	O	O
PTEN	O	O
mutations	O	O
.	O	O
METHODS	O	O
:	O	O
Twenty	O	O
patients	O	O
with	O	O
known	O	O
PTEN	O	O
mutations	O	O
,	O	O
and/or	O	O
clinical	O	O
diagnosis	O	O
of	O	O
PHTS	O	O
,	O	O
and	O	O
thyroid	O	O
pathology	O	O
were	O	O
identified	O	O
:	O	O
14	O	O
with	O	O
CS	O	O
and	O	O
6	O	O
with	O	O
BRRS	O	O
.	O	O
RESULTS	O	O
:	O	O
Thyroid	O	O
pathology	O	O
findings	O	O
were	O	O
as	O	O
follows	O	O
:	O	O
multiple	O	O
adenomatous	O	O
nodules	O	O
in	O	O
a	O	O
background	O	O
of	O	O
lymphocytic	O	O
thyroiditis	O	O
(	O	O
LT	O	O
)	O	O
in	O	O
75	O	O
%	O	O
,	O	O
papillary	O	O
carcinoma	O	O
in	O	O
60	O	O
%	O	O
,	O	O
LT	O	O
alone	O	O
in	O	O
55	O	O
%	O	O
,	O	O
follicular	O	O
carcinoma	O	O
in	O	O
45	O	O
%	O	O
,	O	O
C	O	O
-	O	O
cell	O	O
hyperplasia	O	O
in	O	O
55	O	O
%	O	O
,	O	O
and	O	O
follicular	O	O
adenomas	O	O
in	O	O
25	O	O
%	O	O
.	O	O
Within	O	O
the	O	O
papillary	O	O
carcinoma	O	O
group	O	O
,	O	O
there	O	O
were	O	O
6	O	O
microcarcinomas	O	O
,	O	O
5	O	O
follicular	O	O
variants	O	O
,	O	O
and	O	O
1	O	O
classical	O	O
type	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
There	O	O
were	O	O
no	O	O
morphologic	O	O
differences	O	O
between	O	O
the	O	O
thyroid	O	O
findings	O	O
in	O	O
CS	O	O
and	O	O
BRRS	O	O
.	O	O
Also	O	O
,	O	O
there	O	O
was	O	O
no	O	O
correlation	O	O
between	O	O
specific	O	O
PTEN	O	O
germline	O	O
mutations	O	O
(	O	O
exons	O	O
5	O	O
,	O	O
6	O	O
,	O	O
and	O	O
8)	O	O
and	O	O
pathologic	O	O
findings	O	O
.	O	O
Distinctive	O	O
and	O	O
characteristic	O	O
findings	O	O
in	O	O
PHTS	O	O
include	O	O
multiple	O	O
unique	O	O
adenomatous	O	O
nodules	O	O
in	O	O
a	O	O
background	O	O
of	O	O
LT	O	O
,	O	O
and	O	O
C	O	O
-	O	O
cell	O	O
hyperplasia	O	O
;	O	O
it	O	O
is	O	O
vital	O	O
that	O	O
pathologists	O	O
recognize	O	O
the	O	O
classical	O	O
histologic	O	O
features	O	O
of	O	O
this	O	O
syndrome	O	O
to	O	O
alert	O	O
clinicians	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
this	O	O
syndrome	O	O
in	O	O
their	O	O
patients	O	O
.	O	O
Variable	O	O
phenotypes	O	O
are	O	O
associated	O	O
with	O	O
PMP22	O	O
missense	O	O
mutations	O	O
.	O	O
Charcot	B-Disease	O
-	I-Disease	O
Marie	I-Disease	O
-	I-Disease	O
Tooth	I-Disease	O
disease	I-Disease	O
(	O	O
CMT	O	O
)	O	O
is	O	O
the	O	O
commonest	O	O
hereditary	O	O
neuropathy	O	O
encompassing	O	O
a	O	O
large	O	O
group	O	O
of	O	O
clinically	O	O
and	O	O
genetically	O	O
heterogeneous	O	O
disorders	O	O
.	O	O
The	O	O
commonest	O	O
form	O	O
of	O	O
CMT	B-Disease	O
,	O	O
CMT1A	B-Disease	O
,	O	O
is	O	O
usually	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
1.4	O	O
megabase	O	O
duplication	B-Var	O
of	O	O
chromosome	O	O
17	O	O
containing	O	O
the	O	O
PMP22	B-Gene	O
gene	O	O
.	O	O
Mutations	B-Var	O
of	O	O
PMP22	B-Gene	O
are	O	O
a	O	O
less	O	O
common	O	O
cause	B-Reg	O
of	O	O
CMT	B-Disease	O
.	O	O
We	O	O
describe	O	O
clinical	O	O
,	O	O
electrophysiological	O	O
and	O	O
molecular	O	O
findings	O	O
of	O	O
10	O	O
patients	O	O
carrying	O	O
PMP22	O	O
missense	O	O
mutations	O	O
.	O	O
The	O	O
phenotype	O	O
varied	O	O
from	O	O
mild	O	O
hereditary	O	O
neuropathy	O	O
with	O	O
liability	O	O
to	O	O
pressure	O	O
palsies	O	O
(	O	O
HNPP	O	O
)	O	O
to	O	O
severe	O	O
CMT1	O	O
.	O	O
We	O	O
identified	O	O
six	O	O
different	O	O
point	O	O
mutations	O	O
,	O	O
including	O	O
two	O	O
novel	O	O
mutations	O	O
.	O	O
Three	O	O
families	O	O
were	O	O
also	O	O
found	O	O
to	O	O
harbour	O	O
a	O	O
Thr118Met	O	O
mutation	O	O
.	O	O
Although	O	O
PMP22	O	O
point	O	O
mutations	O	O
are	O	O
not	O	O
common	O	O
,	O	O
our	O	O
findings	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
sequencing	O	O
the	O	O
PMP22	O	O
gene	O	O
in	O	O
patients	O	O
with	O	O
variable	O	O
CMT	O	O
phenotypes	O	O
and	O	O
also	O	O
confirm	O	O
that	O	O
the	O	O
PMP22	B-Gene	O
Thr118Met	B-Var	O
mutation	O	O
is	O	O
associated	B-Reg	O
with	I-Reg	O
a	O	O
neuropathy	B-CPA	O
albeit	O	O
with	O	O
reduced	O	O
penetrance	O	O
.	O	O
Genotype	O	O
-	O	O
phenotype	O	O
analysis	O	O
of	O	O
the	O	O
branchio	O	O
-	O	O
oculo	O	O
-	O	O
facial	O	O
syndrome	O	O
.	O	O
Branchio	B-Disease	O
-	I-Disease	O
oculo	I-Disease	O
-	I-Disease	O
facial	I-Disease	O
syndrome	I-Disease	O
(	O	O
BOFS	O	O
;	O	O
OMIM#113620	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
dominant	O	O
craniofacial	O	O
disorder	O	O
with	O	O
variable	O	O
expression	O	O
.	O	O
Major	O	O
features	O	O
include	O	O
cutaneous	O	O
and	O	O
ocular	O	O
abnormalities	O	O
,	O	O
characteristic	O	O
facies	O	O
,	O	O
renal	O	O
,	O	O
ectodermal	O	O
,	O	O
and	O	O
temporal	O	O
bone	O	O
anomalies	O	O
.	O	O
Having	O	O
determined	O	O
that	O	O
mutations	B-Var	O
involving	O	O
TFAP2A	B-Gene	O
result	B-Reg	O
in	I-Reg	O
BOFS	B-Disease	O
,	O	O
we	O	O
studied	O	O
a	O	O
total	O	O
of	O	O
30	O	O
families	O	O
(	O	O
41	O	O
affected	O	O
individuals	O	O
)	O	O
;	O	O
26/30	O	O
(	O	O
87	O	O
%	O	O
)	O	O
fulfilled	O	O
our	O	O
cardinal	O	O
diagnostic	O	O
criteria	O	O
.	O	O
The	O	O
original	O	O
family	O	O
with	O	O
the	O	O
3.2	O	O
Mb	O	O
deletion	O	O
including	O	O
the	O	O
TFAP2A	O	O
gene	O	O
remains	O	O
the	O	O
only	O	O
BOFS	O	O
family	O	O
without	O	O
the	O	O
typical	O	O
CL	O	O
/	O	O
P	O	O
and	O	O
the	O	O
only	O	O
family	O	O
with	O	O
a	O	O
deletion	O	O
.	O	O
We	O	O
have	O	O
identified	O	O
a	O	O
hotspot	O	O
region	O	O
in	O	O
the	O	O
highly	O	O
conserved	O	O
exons	O	O
4	O	O
and	O	O
5	O	O
of	O	O
TFAP2A	O	O
that	O	O
harbors	O	O
missense	O	O
mutations	O	O
in	O	O
27/30	O	O
(	O	O
90	O	O
%	O	O
)	O	O
families	O	O
.	O	O
Several	O	O
of	O	O
these	O	O
mutations	O	O
are	O	O
recurrent	O	O
.	O	O
Mosaicism	O	O
was	O	O
detected	O	O
in	O	O
one	O	O
family	O	O
.	O	O
To	O	O
date	O	O
,	O	O
genetic	O	O
heterogeneity	O	O
has	O	O
not	O	O
been	O	O
observed	O	O
.	O	O
Although	O	O
the	O	O
cardinal	O	O
criteria	O	O
for	O	O
BOFS	O	O
have	O	O
been	O	O
based	O	O
on	O	O
the	O	O
presence	O	O
of	O	O
each	O	O
of	O	O
the	O	O
core	O	O
defects	O	O
,	O	O
an	O	O
affected	O	O
family	O	O
member	O	O
or	O	O
thymic	O	O
remnant	O	O
,	O	O
we	O	O
documented	O	O
TFAP2A	O	O
mutations	O	O
in	O	O
three	O	O
(	O	O
10	O	O
%	O	O
)	O	O
probands	O	O
in	O	O
our	O	O
series	O	O
without	O	O
a	O	O
classic	O	O
cervical	O	O
cutaneous	O	O
defect	O	O
or	O	O
ectopic	O	O
thymus	O	O
.	O	O
Temporal	O	O
bone	O	O
anomalies	O	O
were	O	O
identified	O	O
in	O	O
3/5	O	O
patients	O	O
investigated	O	O
.	O	O
The	O	O
occurrence	O	O
of	O	O
CL	O	O
/	O	O
P	O	O
,	O	O
premature	O	O
graying	O	O
,	O	O
coloboma	O	O
,	O	O
heterochromia	O	O
irides	O	O
,	O	O
and	O	O
ectopic	O	O
thymus	O	O
,	O	O
are	O	O
evidence	O	O
for	O	O
BOFS	O	O
as	O	O
a	O	O
neurocristopathy	O	O
.	O	O
Intrafamilial	O	O
clinical	O	O
variability	O	O
can	O	O
be	O	O
marked	O	O
.	O	O
Although	O	O
there	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
mutation	O	O
-	O	O
specific	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
at	O	O
this	O	O
time	O	O
,	O	O
more	O	O
patients	O	O
need	O	O
to	O	O
be	O	O
studied	O	O
.	O	O
Clinical	O	O
testing	O	O
for	O	O
TFAP2A	O	O
mutations	O	O
is	O	O
now	O	O
available	O	O
and	O	O
will	O	O
assist	O	O
geneticists	O	O
in	O	O
confirming	O	O
the	O	O
typical	O	O
cases	O	O
or	O	O
excluding	O	O
the	O	O
diagnosis	O	O
in	O	O
atypical	O	O
cases	O	O
.	O	O
Twenty	O	O
-	O	O
five	O	O
novel	O	O
mutations	O	O
including	O	O
duplications	O	O
in	O	O
the	O	O
ATP7A	O	O
gene	O	O
.	O	O
Twenty	O	O
-	O	O
five	O	O
novel	O	O
mutations	O	O
including	O	O
duplications	O	O
in	O	O
the	O	O
ATP7A	O	O
gene	O	O
.	O	O
Menkes	B-Disease	O
disease	I-Disease	O
(	O	O
MD	O	O
)	O	O
and	O	O
occipital	B-Disease	O
horn	I-Disease	O
syndrome	I-Disease	O
(	O	O
OHS	O	O
)	O	O
are	O	O
allelic	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
copper	O	O
deficiency	O	O
disorders	O	O
resulting	B-Reg	O
from	I-Reg	O
ATP7A	B-Gene	O
gene	O	O
mutations	B-Var	O
.	O	O
MD	O	O
is	O	O
a	O	O
severe	O	O
condition	O	O
leading	O	O
to	O	O
progressive	O	O
neurological	O	O
degeneration	O	O
and	O	O
death	O	O
in	O	O
early	O	O
childhood	O	O
,	O	O
whereas	O	O
OHS	O	O
has	O	O
a	O	O
milder	O	O
phenotype	O	O
with	O	O
mainly	O	O
connective	O	O
tissue	O	O
abnormalities	O	O
.	O	O
Until	O	O
now	O	O
,	O	O
molecular	O	O
analyses	O	O
have	O	O
revealed	O	O
only	O	O
deletions	O	O
and	O	O
point	O	O
mutations	O	O
in	O	O
both	O	O
diseases	O	O
.	O	O
This	O	O
study	O	O
reports	O	O
new	O	O
molecular	O	O
data	O	O
in	O	O
a	O	O
series	O	O
of	O	O
40	O	O
patients	O	O
referred	O	O
for	O	O
either	O	O
MD	O	O
or	O	O
OHS	O	O
.	O	O
We	O	O
describe	O	O
23	O	O
point	O	O
mutations	O	O
(	O	O
9	O	O
missense	O	O
mutations	O	O
,	O	O
7	O	O
splice	O	O
site	O	O
variants	O	O
,	O	O
4	O	O
nonsense	O	O
mutations	O	O
,	O	O
and	O	O
3	O	O
small	O	O
insertions	O	O
or	O	O
deletions	O	O
)	O	O
and	O	O
7	O	O
intragenic	O	O
deletions	O	O
.	O	O
Of	O	O
these	O	O
,	O	O
18	O	O
point	O	O
mutations	O	O
and	O	O
3	O	O
deletions	O	O
are	O	O
novel	O	O
.	O	O
Furthermore	O	O
,	O	O
our	O	O
finding	O	O
of	O	O
four	O	O
whole	O	O
exon	O	O
duplications	O	O
enlarges	O	O
the	O	O
mutation	O	O
spectrum	O	O
in	O	O
the	O	O
ATP7A	O	O
gene	O	O
.	O	O
ATP7A	O	O
alterations	O	O
were	O	O
found	O	O
in	O	O
85	O	O
%	O	O
of	O	O
cases	O	O
.	O	O
Of	O	O
these	O	O
alterations	O	O
,	O	O
two	O	O
thirds	O	O
were	O	O
point	O	O
mutations	O	O
and	O	O
the	O	O
remaining	O	O
one	O	O
third	O	O
consisted	O	O
of	O	O
large	O	O
rearrangements	O	O
.	O	O
We	O	O
found	O	O
that	O	O
66.6	O	O
%	O	O
of	O	O
point	O	O
mutations	B-Var	O
resulted	O	O
in	O	O
impaired	B-NegReg	O
ATP7A	B-Gene	O
transcript	B-MPA	O
splicing	I-MPA	O
,	O	O
a	O	O
phenomenon	O	O
more	O	O
frequent	O	O
than	O	O
expected	O	O
.	O	O
This	O	O
finding	O	O
enabled	O	O
us	O	O
to	O	O
confirm	O	O
the	O	O
pathogenic	O	O
role	O	O
of	O	O
ATP7A	O	O
mutations	O	O
,	O	O
particularly	O	O
in	O	O
missense	O	O
and	O	O
splice	O	O
site	O	O
variants	O	O
.	O	O
Phenotypic	O	O
heterogeneity	O	O
in	O	O
a	O	O
large	O	O
Thai	O	O
slow	O	O
-	O	O
channel	O	O
congenital	O	O
myasthenic	O	O
syndrome	O	O
kinship	O	O
.	O	O
The	O	O
slow	B-Disease	O
-	I-Disease	O
channel	I-Disease	O
congenital	I-Disease	O
myasthenic	I-Disease	O
syndrome	I-Disease	O
(	O	O
SCCMS	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
dominant	O	O
neuromuscular	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
different	O	O
subunits	O	O
of	O	O
the	O	O
acetylcholine	O	O
receptor	O	O
(	B-Gene	O
AChR	I-Gene	O
)	I-Gene	O
.	O	O
We	O	O
here	O	O
report	O	O
our	O	O
clinical	O	O
findings	O	O
in	O	O
three	O	O
generations	O	O
of	O	O
a	O	O
large	O	O
Thai	O	O
kinship	O	O
suffering	O	O
from	O	O
SCCMS	O	O
and	O	O
trace	O	O
the	O	O
disease	O	O
to	O	O
the	O	O
p	O	O
.	O	O
Gly153Ser	O	O
mutation	O	O
in	O	O
the	O	O
AChR	O	O
α	O	O
subunit	O	O
.	O	O
The	O	O
same	O	O
mutation	O	O
had	O	O
previously	O	O
been	O	O
reported	O	O
only	O	O
in	O	O
Caucasian	O	O
but	O	O
not	O	O
in	O	O
Asian	O	O
patients	O	O
.	O	O
The	O	O
clinical	O	O
features	O	O
include	O	O
ptosis	O	O
,	O	O
ophthalmoparesis	O	O
,	O	O
and	O	O
weakness	O	O
of	O	O
the	O	O
cervical	O	O
and	O	O
finger	O	O
extensor	O	O
muscles	O	O
as	O	O
well	O	O
as	O	O
marked	O	O
phenotypic	O	O
heterogeneity	O	O
.	O	O
[	O	O
Anaemia	O	O
caused	O	O
by	O	O
a	O	O
congenital	O	O
haemoglobin	O	O
defect	O	O
can	O	O
also	O	O
occur	O	O
in	O	O
native	O	O
Dutch	O	O
patients	O	O
]	O	O
.	O	O
Anemie	O	O
door	O	O
aangeboren	O	O
afwijkingen	O	O
van	O	O
het	O	O
hemoglobine	O	O
,	O	O
ook	O	O
bij	O	O
autochtone	O	O
Nederlanders	O	O
.	O	O
An	O	O
11-year	O	O
-	O	O
old	O	O
boy	O	O
of	O	O
Dutch	O	O
descent	O	O
had	O	O
suffered	O	O
from	O	O
tiredness	O	O
,	O	O
pallor	O	O
and	O	O
poor	O	O
appetite	O	O
for	O	O
many	O	O
years	O	O
.	O	O
There	O	O
was	O	O
no	O	O
indication	O	O
of	O	O
chronic	O	O
infection	O	O
.	O	O
Iron	O	O
supplements	O	O
did	O	O
not	O	O
produce	O	O
sufficient	O	O
improvement	O	O
in	O	O
the	O	O
symptoms	O	O
.	O	O
Following	O	O
analysis	O	O
using	O	O
fast	O	O
protein	O	O
liquid	O	O
chromatography	O	O
and	O	O
DNA	O	O
sequencing	O	O
analysis	O	O
,	O	O
it	O	O
appeared	O	O
that	O	O
this	O	O
was	O	O
a	O	O
case	O	O
of	O	O
β	B-Disease	O
-	I-Disease	O
thalassaemia	I-Disease	O
intermedia	I-Disease	O
,	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
point	B-Var	O
mutation	I-Var	O
in	O	O
the	O	O
promotor	O	O
region	O	O
of	O	O
the	O	O
β	B-Gene	O
-	I-Gene	O
globulin	I-Gene	O
gene	O	O
.	O	O
The	O	O
boy	O	O
's	O	O
parents	O	O
both	O	O
proved	O	O
to	O	O
be	O	O
heterozygotes	O	O
for	O	O
this	O	O
point	O	O
mutation	O	O
.	O	O
A	O	O
second	O	O
patient	O	O
,	O	O
a	O	O
5-year	O	O
-	O	O
old	O	O
girl	O	O
of	O	O
Dutch	O	O
descent	O	O
,	O	O
suffered	O	O
from	O	O
an	O	O
icterus	O	O
following	O	O
a	O	O
respiratory	O	O
tract	O	O
infection	O	O
.	O	O
Splenomegaly	O	O
,	O	O
hyperbilirubinaemia	O	O
and	O	O
microcytic	O	O
anaemia	O	O
with	O	O
raised	O	O
reticulocyte	O	O
values	O	O
were	O	O
observed	O	O
.	O	O
Because	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
spherocytes	O	O
,	O	O
hereditary	O	O
spherocytosis	O	O
was	O	O
initially	O	O
suspected	O	O
.	O	O
On	O	O
further	O	O
analysis	O	O
Heinz	O	O
bodies	O	O
were	O	O
also	O	O
seen	O	O
,	O	O
following	O	O
which	O	O
DNA	O	O
sequencing	O	O
analysis	O	O
showed	O	O
a	O	O
de	O	O
novo	O	O
Hb	O	O
Köln	O	O
mutation	O	O
.	O	O
Congenital	O	O
haemoglobin	O	O
defects	O	O
are	O	O
usually	O	O
associated	O	O
with	O	O
people	O	O
originating	O	O
from	O	O
Africa	O	O
,	O	O
the	O	O
Mediterranean	O	O
,	O	O
the	O	O
Middle	O	O
-	O	O
East	O	O
or	O	O
South	O	O
-	O	O
East	O	O
Asia	O	O
.	O	O
That	O	O
such	O	O
abnormalities	O	O
can	O	O
also	O	O
occur	O	O
in	O	O
children	O	O
of	O	O
Dutch	O	O
descent	O	O
is	O	O
demonstrated	O	O
by	O	O
these	O	O
two	O	O
cases	O	O
.	O	O
Mild	O	O
recessive	O	O
dystrophic	B-Disease	O
epidermolysis	I-Disease	O
bullosa	I-Disease	O
associated	B-Reg	O
with	I-Reg	O
two	O	O
compound	O	O
heterozygous	O	O
COL7A1	B-Gene	O
mutations	B-Var	O
.	O	O
Dystrophic	B-Disease	O
epidermolysis	I-Disease	O
bullosa	I-Disease	O
is	O	O
a	O	O
group	O	O
of	O	O
inherited	O	O
skin	O	O
blistering	O	O
disorders	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
COL7A1	B-Gene	O
gene	O	O
coding	O	O
for	O	O
type	O	O
VII	O	O
collagen	O	O
.	O	O
More	O	O
than	O	O
500	O	O
different	O	O
COL7A1	B-Gene	O
mutations	B-Var	O
have	O	O
been	O	O
detected	B-Reg	O
in	O	O
dystrophic	B-Disease	O
epidermolysis	I-Disease	O
bullosa	I-Disease	O
to	O	O
date	O	O
.	O	O
Clarification	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
is	O	O
of	O	O
particular	O	O
importance	O	O
for	O	O
the	O	O
development	O	O
of	O	O
novel	O	O
therapeutic	O	O
approaches	O	O
.	O	O
Here	O	O
we	O	O
report	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
mild	O	O
dystrophic	O	O
epidermolysis	O	O
bullosa	O	O
harbouring	O	O
two	O	O
compound	O	O
heterozygous	O	O
COL7A1	O	O
mutations	O	O
,	O	O
namely	O	O
the	O	O
intronic	O	O
splice	O	O
site	O	O
mutation	O	O
c.3832	O	O
-	O	O
2A	O	O
>	O	O
G	O	O
and	O	O
the	O	O
glycine	O	O
substitution	O	O
p	O	O
.	O	O
G1347W.	O	O
Our	O	O
data	O	O
extend	O	O
the	O	O
current	O	O
knowledge	O	O
on	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
dystrophic	O	O
epidermolysis	O	O
bullosa	O	O
.	O	O
[	O	O
Association	O	O
of	O	O
mutation	O	O
types	O	O
and	O	O
distribution	O	O
characteristics	O	O
of	O	O
dystrophin	O	O
gene	O	O
with	O	O
clinical	O	O
symptoms	O	O
in	O	O
Chinese	O	O
population	O	O
]	O	O
.	O	O
Duchenne	O	O
muscular	O	O
dystrophy	O	O
(	O	O
DMD	O	O
)	O	O
is	O	O
X	O	O
-	O	O
linked	O	O
disorder	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
dystrophin	O	O
gene	O	O
.	O	O
To	O	O
investigate	O	O
mutation	O	O
types	O	O
and	O	O
distribution	O	O
characteristics	O	O
of	O	O
dystrophin	O	O
gene	O	O
in	O	O
Chinese	O	O
DMD	O	O
patients	O	O
,	O	O
we	O	O
used	O	O
Multiplex	O	O
Ligation	O	O
-	O	O
Dependent	O	O
Probe	O	O
Amplification	O	O
(	O	O
MLPA	O	O
)	O	O
to	O	O
analyze	O	O
the	O	O
dystrophin	O	O
gene	O	O
in	O	O
720	O	O
DMD	O	O
patients	O	O
,	O	O
their	O	O
mothers	O	O
,	O	O
and	O	O
20	O	O
normal	O	O
adult	O	O
males	O	O
.	O	O
Results	O	O
showed	O	O
that	O	O
detection	O	O
rate	O	O
was	O	O
64.9	O	O
%	O	O
(	O	O
467/720	O	O
)	O	O
in	O	O
all	O	O
the	O	O
patients	O	O
,	O	O
gene	O	O
deletion	O	O
rate	O	O
was	O	O
54.3	O	O
%	O	O
(	O	O
391/720	O	O
)	O	O
,	O	O
and	O	O
gene	O	O
duplication	O	O
rate	O	O
was	O	O
10.6	O	O
%	O	O
(	O	O
76/720	O	O
)	O	O
.	O	O
The	O	O
rate	O	O
of	O	O
deletion	O	O
mutant	O	O
occurred	O	O
in	O	O
Exon	O	O
45	O	O
-	O	O
54	O	O
was	O	O
71.9	O	O
%	O	O
(	O	O
281/391	O	O
)	O	O
in	O	O
all	O	O
gene	O	O
deletion	O	O
patients	O	O
;	O	O
meanwhile	O	O
,	O	O
the	O	O
rate	O	O
of	O	O
gene	O	O
duplication	O	O
occurred	O	O
in	O	O
Exon	O	O
1	O	O
-	O	O
40	O	O
was	O	O
82.9	O	O
%	O	O
(	O	O
63/76	O	O
)	O	O
in	O	O
all	O	O
gene	O	O
duplication	O	O
ones	O	O
.	O	O
In	O	O
all	O	O
the	O	O
patients	O	O
with	O	O
gene	O	O
deletion	O	O
and	O	O
duplication	O	O
,	O	O
the	O	O
rate	O	O
of	O	O
DMD	O	O
and	O	O
IMD	O	O
was	O	O
90.6	O	O
%	O	O
(	O	O
423/467	O	O
)	O	O
,	O	O
and	O	O
BMD	O	O
,	O	O
9.4	O	O
%	O	O
(	O	O
44/467	O	O
)	O	O
.	O	O
This	O	O
indicates	O	O
that	O	O
the	O	O
main	O	O
reason	B-Reg	O
of	O	O
duchenne	B-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
is	O	O
dystrophin	B-Gene	O
gene	I-Gene	O
deletion	B-Var	O
mutation	O	O
,	O	O
which	O	O
would	O	O
occur	O	O
in	O	O
any	O	O
gene	O	O
unevenly	O	O
with	O	O
hot	O	O
spots	O	O
of	O	O
mutation	O	O
.	O	O
The	O	O
location	O	O
and	O	O
fragment	O	O
length	O	O
of	O	O
gene	O	O
deletion	O	O
and	O	O
duplication	O	O
can	O	O
not	O	O
decide	O	O
the	O	O
severity	O	O
of	O	O
clinical	O	O
symptoms	O	O
directly	O	O
.	O	O
AXIN2-associated	O	O
autosomal	O	B-Disease
dominant	O	O
ectodermal	O	B-Disease
dysplasia	O	I-Disease
and	O	O
neoplastic	O	O
syndrome	O	O
.	O	O
We	O	O
describe	O	O
a	O	O
family	O	O
with	O	O
a	O	O
novel	O	O
,	O	O
inherited	O	O
AXIN2	O	O
mutation	O	O
(	O	O
c.1989G	O	O
>	O	O
A	O	O
)	O	O
segregating	O	O
in	O	O
an	O	O
autosomal	O	O
dominant	O	O
pattern	O	O
with	O	O
oligodontia	O	O
and	O	O
variable	O	O
other	O	O
findings	O	O
including	O	O
colonic	O	O
polyposis	O	O
,	O	O
gastric	O	O
polyps	O	O
,	O	O
a	O	O
mild	O	O
ectodermal	O	O
dysplasia	O	O
phenotype	O	O
with	O	O
sparse	O	O
hair	O	O
and	O	O
eyebrows	O	O
,	O	O
and	O	O
early	O	O
onset	O	O
colorectal	O	O
and	O	O
breast	O	O
cancers	O	O
.	O	O
This	O	O
novel	O	O
mutation	O	O
predicts	O	O
p	O	O
.	O	O
Trp663X	O	O
,	O	O
which	O	O
is	O	O
a	O	O
truncated	O	O
protein	O	O
that	O	O
is	O	O
missing	O	O
the	O	O
last	O	O
three	O	O
exons	O	O
,	O	O
including	O	O
the	O	O
DIX	O	O
(	O	O
Disheveled	O	O
and	O	O
AXIN	O	O
interacting	O	O
)	O	O
domain	O	O
.	O	O
This	O	O
nonsense	O	O
mutation	B-Var	O
is	O	O
predicted	O	O
to	O	O
destroy	B-NegReg	O
the	O	O
inhibitory	B-MPA	O
action	I-MPA	O
of	O	O
AXIN2	B-Gene	O
on	O	O
WNT	B-Pathway	O
signaling	I-Pathway	O
.	O	O
Previous	O	O
authors	O	O
have	O	O
described	O	O
an	O	O
unrelated	O	O
family	O	O
with	O	O
autosomal	O	O
dominant	O	O
oligodontia	O	O
and	O	O
a	O	O
variable	O	O
colorectal	O	O
phenotype	O	O
segregating	O	O
with	O	O
a	O	O
nonsense	O	O
mutation	O	O
of	O	O
AXIN2	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
frameshift	O	O
AXIN2	O	O
mutation	O	O
in	O	O
an	O	O
unrelated	O	O
individual	O	O
with	O	O
oligodontia	O	O
.	O	O
Our	O	O
report	O	O
provides	O	O
additional	O	O
evidence	O	O
supporting	O	O
an	O	O
autosomal	B-Var	O
dominant	I-Var	O
AXIN2-associated	B-Reg	O
ectodermal	B-Disease	O
dysplasia	I-Disease	O
and	O	O
neoplastic	B-Disease	O
syndrome	I-Disease	O
.	O	O
The	O	O
Down	O	O
syndrome	O	O
critical	O	O
region	O	O
regulates	O	O
retinogeniculate	O	O
refinement	O	O
.	O	O
Down	B-Disease	O
syndrome	I-Disease	I-Disease
(	O	O
DS	O	O
)	O	O
is	O	O
a	O	O
developmental	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
third	O	O
chromosome	O	O
21	O	O
in	O	O
humans	O	O
(	B-Var	O
Trisomy	I-Var	O
21	I-Var	O
)	I-Var	O
,	O	O
leading	O	O
to	O	O
neurological	O	O
deficits	O	O
and	O	O
cognitive	O	O
impairment	O	O
.	O	O
Studies	O	O
in	O	O
mouse	O	O
models	O	O
of	O	O
DS	O	O
suggest	O	O
that	O	O
cognitive	O	O
deficits	O	O
in	O	O
the	O	O
adult	O	O
are	O	O
associated	O	O
with	O	O
deficits	O	O
in	O	O
synaptic	O	O
learning	O	O
and	O	O
memory	O	O
mechanisms	O	O
,	O	O
but	O	O
it	O	O
is	O	O
unclear	O	O
whether	O	O
alterations	O	O
in	O	O
the	O	O
early	O	O
wiring	O	O
and	O	O
refinement	O	O
of	O	O
neuronal	O	O
circuits	O	O
contribute	O	O
to	O	O
these	O	O
deficits	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
early	O	O
developmental	O	O
refinement	O	O
of	O	O
visual	O	O
circuits	O	O
is	O	O
perturbed	O	O
in	O	O
mouse	O	O
models	O	O
of	O	O
Down	O	O
syndrome	O	O
.	O	O
Specifically	O	O
,	O	O
we	O	O
find	O	O
excessive	O	O
eye	O	O
-	O	O
specific	O	O
segregation	O	O
of	O	O
retinal	O	O
axons	O	O
in	O	O
the	O	O
dorsal	O	O
lateral	O	O
geniculate	O	O
nucleus	O	O
.	O	O
Indeed	O	O
,	O	O
the	O	O
degree	O	O
of	O	O
refinement	O	O
scales	O	O
with	O	O
defects	O	O
in	O	O
the	O	O
"	O	O
Down	O	O
syndrome	O	O
critical	O	O
region	O	O
"	O	O
(	O	O
DSCR	O	O
)	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O
We	O	O
further	O	O
identify	O	O
Dscam	O	O
(	O	O
Down	O	O
syndrome	O	O
cell	O	O
adhesion	O	O
molecule	O	O
)	O	O
,	O	O
a	O	O
gene	O	O
within	O	O
the	O	O
DSCR	O	O
,	O	O
as	O	O
a	O	O
regulator	O	O
of	O	O
eye	O	O
-	O	O
specific	O	O
segregation	O	O
of	O	O
retinogeniculate	O	O
projections	O	O
.	O	O
Although	O	O
Dscam	O	O
is	O	O
not	O	O
the	O	O
sole	O	O
gene	O	O
in	O	O
the	O	O
DSCR	O	O
contributing	O	O
to	O	O
enhanced	O	O
refinement	O	O
in	O	O
trisomy	O	O
,	O	O
Dscam	O	O
dosage	O	O
clearly	O	O
regulates	O	O
cell	O	O
spacing	O	O
and	O	O
dendritic	O	O
fasciculation	O	O
in	O	O
a	O	O
specific	O	O
class	O	O
of	O	O
retinal	O	O
ganglion	O	O
cells	O	O
.	O	O
Thus	O	O
,	O	O
altered	O	O
developmental	O	O
refinement	O	O
of	O	O
visual	O	O
circuits	O	O
that	O	O
occurs	O	O
before	O	O
sensory	O	O
experience	O	O
is	O	O
likely	O	O
to	O	O
contribute	O	O
to	O	O
visual	O	O
impairment	O	O
in	O	O
individuals	O	O
with	O	O
Down	O	O
syndrome	O	O
.	O	O
Identification	O	O
and	O	O
functional	O	O
consequences	O	O
of	O	O
a	O	O
recurrent	O	O
NLRP12	B-Gene	O
missense	B-Var	O
mutation	I-Var	O
in	B-Reg	O
periodic	B-Disease	O
fever	I-Disease	O
syndromes	I-Disease	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
gain	O	O
insight	O	O
into	O	O
the	O	O
molecular	O	O
bases	O	O
of	O	O
genetically	O	O
unexplained	O	O
periodic	O	O
fever	O	O
syndromes	O	O
(	O	O
PFS	O	O
)	O	O
by	O	O
screening	O	O
NLRP12	O	O
,	O	O
a	O	O
gene	O	O
in	O	O
which	O	O
only	O	O
a	O	O
nonsense	O	O
and	O	O
a	O	O
splice	O	O
site	O	O
mutation	O	O
have	O	O
so	O	O
far	O	O
been	O	O
identified	O	O
,	O	O
and	O	O
to	O	O
assess	O	O
the	O	O
functional	O	O
consequences	O	O
of	O	O
the	O	O
identified	O	O
missense	O	O
variation	O	O
.	O	O
METHODS	O	O
:	O	O
NLRP12	O	O
was	O	O
screened	O	O
for	O	O
mutations	O	O
by	O	O
direct	O	O
sequencing	O	O
.	O	O
Functional	O	O
assays	O	O
were	O	O
performed	O	O
in	O	O
HEK	O	O
293	O	O
T	O	O
cells	O	O
stably	O	O
expressing	O	O
the	O	O
proapoptotic	O	O
protein	O	O
ASC	O	O
and	O	O
procaspase	O	O
1	O	O
,	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
normal	O	O
and	O	O
mutated	O	O
NLRP12	O	O
proteins	O	O
on	O	O
speck	O	O
formation	O	O
,	O	O
caspase	O	O
1	O	O
signaling	O	O
,	O	O
and	O	O
NF	O	O
-	O	O
κB	O	O
activation	O	O
.	O	O
RESULTS	O	O
:	O	O
A	O	O
heterozygous	O	O
NLRP12	B-Gene	O
missense	O	O
mutation	O	O
involving	O	O
a	O	O
CpG	O	O
site	O	O
(	B-Var	O
c.1054C	I-Var	O
>	I-Var	O
T	I-Var	O
;	I-Var	O
p	O	O
.	O	O
Arg352Cys	O	O
)	O	O
was	O	O
identified	O	O
in	O	O
exon	O	O
3	O	O
,	O	O
which	O	O
encodes	B-Reg	O
the	O	O
nucleotide	B-Interaction	O
-	I-Interaction	O
binding	I-Interaction	O
site	O	O
(	O	O
NBS	O	O
)	O	O
of	O	O
the	O	O
protein	B-Protein	O
,	O	O
in	O	O
2	O	O
patients	O	O
from	O	O
different	O	O
countries	O	O
and	O	O
carrying	O	O
different	O	O
NLRP12	O	O
haplotypes	O	O
.	O	O
The	O	O
mutation	B-Var	O
,	O	O
which	O	O
does	O	O
not	O	O
alter	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
NLRP12	O	O
on	O	O
NF	O	O
-	O	O
κB	O	O
activation	O	O
,	O	O
increases	B-PosReg	O
speck	B-MPA	O
formation	I-MPA	O
and	O	O
activates	B-PosReg	O
caspase	B-MPA	O
1	I-MPA	O
signaling	I-MPA	O
.	O	O
To	O	O
define	O	O
this	O	O
new	O	O
class	O	O
of	O	O
PFS	O	O
,	O	O
we	O	O
propose	O	O
the	O	O
term	O	O
NLRP12-associated	O	O
disorders	O	O
(	O	O
NLRP12AD	O	O
)	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Given	O	O
the	O	O
rarity	O	O
of	O	O
known	O	O
NLRP12-associated	O	O
disorders	O	O
,	O	O
the	O	O
identification	O	O
of	O	O
this	O	O
NLRP12	O	O
molecular	O	O
defect	O	O
contributes	O	O
to	O	O
the	O	O
delineation	O	O
of	O	O
the	O	O
clinical	O	O
spectrum	O	O
associated	O	O
with	O	O
mutations	O	O
in	O	O
this	O	O
gene	O	O
and	O	O
highlights	O	O
the	O	O
importance	O	O
of	O	O
screening	O	O
NLRP12	O	O
in	O	O
patients	O	O
presenting	O	O
with	O	O
unexplained	O	O
PFS	O	O
.	O	O
This	O	O
study	O	O
also	O	O
demonstrates	O	O
,	O	O
by	O	O
means	O	O
of	O	O
functional	O	O
assays	O	O
,	O	O
the	O	O
deleterious	O	O
effect	O	O
of	O	O
this	O	O
recurrent	O	O
missense	O	O
mutation	O	O
;	O	O
the	O	O
gain	B-PosReg	O
of	I-PosReg	O
function	I-PosReg	O
for	O	O
speck	B-MPA	O
formation	I-MPA	O
and	O	O
caspase	B-MPA	O
1	I-MPA	O
signaling	I-MPA	O
associated	O	O
with	O	O
this	O	O
NBS	O	O
mutation	B-Var	O
is	O	O
consistent	O	O
with	O	O
the	O	O
inflammatory	O	O
phenotype	O	O
of	O	O
PFS	O	O
.	O	O
New	O	O
homozygous	O	O
SPINK5	O	O
mutation	O	O
,	O	O
p	O	O
.	O	O
Gln333X	O	O
,	O	O
in	O	O
a	O	O
Turkish	O	O
pedigree	O	O
with	O	O
Netherton	O	O
syndrome	O	O
.	O	O
Netherton	B-Disease	O
syndrome	I-Disease	O
(	O	O
NS	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
genodermatosis	O	O
caused	O	O
by	O	O
loss	B-NegReg	B-NegReg
-	I-NegReg	O
of	I-NegReg	I-NegReg
-	I-NegReg	I-NegReg
function	I-NegReg	I-NegReg
mutations	B-Var	B-Var
in	O	O
the	O	O
SPINK5	B-Gene	O
gene	O	O
.	O	O
The	O	O
clinical	O	O
features	O	O
include	O	O
congenital	O	O
ichthyosis	O	O
,	O	O
trichorrhexis	O	O
invaginata	O	O
and	O	O
atopy	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
report	O	O
a	O	O
new	O	O
homozygous	O	O
SPINK5	B-Gene	O
mutation	O	O
,	O	O
p	B-Var	O
.	I-Var	O
Gln333X	I-Var	O
,	O	O
responsible	B-Reg	O
for	O	O
NS	B-Disease	O
in	O	O
affected	O	O
members	O	O
of	O	O
two	O	O
closely	O	O
related	O	O
Turkish	O	O
families	O	O
,	O	O
and	O	O
provide	O	O
an	O	O
overview	O	O
of	O	O
the	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
in	O	O
this	O	O
condition	O	O
.	O	O
Severer	O	O
phenotype	O	O
in	O	O
Unverricht	B-Disease	O
-	I-Disease	O
Lundborg	I-Disease	O
disease	I-Disease	O
(	O	O
EPM1	O	O
)	O	O
patients	O	O
compound	O	O
heterozygous	O	O
for	B-Reg	O
the	O	O
dodecamer	O	O
repeat	O	O
expansion	O	O
and	O	O
the	O	O
c.202C	B-Var	O
>	I-Var	O
T	I-Var	O
mutation	O	O
in	O	O
the	O	O
CSTB	B-Gene	O
gene	O	O
.	O	O
BACKGROUND	O	O
/	O	O
AIMS	O	O
:	O	O
Unverricht	B-Disease	O
-	I-Disease	O
Lundborg	I-Disease	O
disease	I-Disease	O
(	O	O
EPM1	O	O
)	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
cystatin	O	O
B	O	B-Gene
(	B-Gene	O
CSTB	I-Gene	O
)	I-Gene	I-Gene
gene	O	O
.	O	O
Most	O	O
patients	O	O
are	O	O
homozygous	O	O
for	O	O
the	O	O
expanded	O	O
dodecamer	O	O
repeat	O	O
mutation	O	O
alleles	O	O
,	O	O
but	O	O
9	O	O
other	O	O
EPM1-associated	O	O
mutations	O	O
have	O	O
also	O	O
been	O	O
identified	O	O
.	O	O
We	O	O
describe	O	O
the	O	O
clinical	O	O
,	O	O
cognitive	O	O
and	O	O
imaging	O	O
characteristics	O	O
of	O	O
5	O	O
Finnish	O	O
EPM1	O	O
patients	O	O
who	O	O
are	O	O
compound	O	O
heterozygous	O	O
for	O	O
the	O	O
dodecamer	O	O
repeat	O	O
expansion	O	O
and	O	O
the	O	O
c.202C	O	O
>	O	O
T	O	O
mutations	O	O
.	O	O
METHODS	O	O
:	O	O
Five	O	O
compound	O	O
heterozygous	O	O
patients	O	O
and	O	O
21	O	O
patients	O	O
homozygous	O	O
for	O	O
the	O	O
expansion	O	O
mutation	O	O
,	O	O
participating	O	O
in	O	O
an	O	O
ongoing	O	O
nationwide	O	O
clinical	O	O
and	O	O
molecular	O	O
genetics	O	O
study	O	O
,	O	O
were	O	O
evaluated	O	O
using	O	O
the	O	O
Unified	O	O
Myoclonus	O	O
Rating	O	O
Scale	O	O
test	O	O
and	O	O
comprehensive	O	O
neuropsychological	O	O
testing	O	O
.	O	O
All	O	O
patients	O	O
underwent	O	O
MR	O	O
imaging	O	O
.	O	O
The	O	O
MR	O	O
data	O	O
were	O	O
also	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
24	O	O
healthy	O	O
control	O	O
subjects	O	O
.	O	O
RESULTS	O	O
:	O	O
Age	O	O
at	O	O
onset	O	O
of	O	O
symptoms	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
compound	O	O
heterozygotes	O	O
than	O	O
in	O	O
the	O	O
homozygous	O	O
EPM1	O	O
patients	O	O
.	O	O
They	O	O
also	O	O
had	O	O
severer	O	O
myoclonus	O	O
and	O	O
drug	O	O
-	O	O
resistant	O	O
tonic	O	O
-	O	O
clonic	O	O
seizures	O	O
.	O	O
Moreover	O	O
,	O	O
they	O	O
had	O	O
lower	O	O
cognitive	O	O
performance	O	O
.	O	O
In	O	O
MRI	O	O
a	O	O
voxel	O	O
-	O	O
based	O	O
morphometry	O	O
analysis	O	O
of	O	O
primary	O	O
and	O	O
premotor	O	O
cortex	O	O
,	O	O
supplementary	O	O
motor	O	O
cortex	O	O
and	O	O
thalami	O	O
revealed	O	O
gray	O	O
matter	O	O
volume	O	O
loss	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
healthy	O	O
controls	O	O
,	O	O
similar	O	O
to	O	O
patients	O	O
homozygous	O	O
for	O	O
the	O	O
expansion	O	O
mutation	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Patients	O	O
compound	O	O
heterozygous	O	O
for	O	O
the	O	O
dodecamer	O	O
repeat	O	O
expansion	O	O
and	O	O
the	O	O
c.202C	O	O
>	O	O
T	O	O
mutations	O	O
seem	O	O
to	O	O
have	O	O
a	O	O
severer	O	O
form	O	O
of	O	O
EPM1	O	O
than	O	O
patients	O	O
homozygous	O	O
for	O	O
the	O	O
expansion	O	O
mutation	O	O
.	O	O
These	O	O
findings	O	O
have	O	O
implications	O	O
for	O	O
counseling	O	O
of	O	O
EPM1	O	O
patients	O	O
with	O	O
different	O	O
genetic	O	O
defects	O	O
.	O	O
Acquisition	O	O
of	O	O
steady	O	O
-	O	O
state	O	O
operant	O	O
behavior	O	O
in	O	O
long	O	O
-	O	O
living	O	O
Ames	O	O
Dwarf	O	O
mice	O	O
.	O	O
Ames	O	O
dwarf	O	O
mice	O	O
have	O	O
a	O	O
Prop-1	B-Gene	O
mutation	B-Var	O
that	O	O
has	O	O
been	O	O
identified	O	O
with	O	O
increased	B-PosReg	O
levels	B-MPA	O
of	I-MPA	O
IGF	I-MPA	O
-	I-MPA	O
I	I-MPA	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
upregulation	B-PosReg	O
of	O	O
neuroprotective	B-CPA	O
systems	I-CPA	O
,	O	O
and	O	O
increased	O	O
lifespan	O	O
.	O	O
To	O	O
elucidate	O	O
the	O	O
behavioral	O	O
effects	O	O
of	O	O
the	O	O
Prop-1	O	O
mutation	O	O
,	O	O
8	O	O
Ames	O	O
dwarf	O	O
and	O	O
7	O	O
normal	O	O
mice	O	O
(	O	O
all	O	O
of	O	O
whom	O	O
were	O	O
8	O	O
months	O	O
of	O	O
age	O	O
or	O	O
younger	O	O
)	O	O
were	O	O
compared	O	O
on	O	O
a	O	O
differential	O	O
-	O	O
reinforcement	O	O
-	O	O
of	O	O
-	O	O
low	O	O
-	O	O
rate	O	O
-	O	O
of	O	O
-	O	O
responding	O	O
schedule	O	O
of	O	O
reinforcement	O	O
and	O	O
a	O	O
matching	O	O
-	O	O
to	O	O
-	O	O
sample	O	O
task	O	O
.	O	O
On	O	O
both	O	O
tasks	O	O
,	O	O
nosepokes	O	O
were	O	O
reinforced	O	O
with	O	O
access	O	O
to	O	O
a	O	O
saccharin	O	O
solution	O	O
.	O	O
Comparisons	O	O
were	O	O
based	O	O
on	O	O
several	O	O
measures	O	O
of	O	O
behavioral	O	O
efficiency	O	O
:	O	O
pause	O	O
durations	O	O
,	O	O
intertrial	O	O
intervals	O	O
,	O	O
and	O	O
numbers	O	O
of	O	O
responses	O	O
.	O	O
Ames	O	O
dwarf	O	O
mice	O	O
were	O	O
generally	O	O
less	O	O
efficient	O	O
than	O	O
normal	O	O
mice	O	O
.	O	O
One	O	O
possible	O	O
cause	O	O
of	O	O
this	O	O
outcome	O	O
is	O	O
that	O	O
relatively	O	O
young	O	O
Ames	O	O
dwarf	O	O
mice	O	O
show	O	O
less	O	O
cognitive	O	O
development	O	O
than	O	O
age	O	O
-	O	O
matched	O	O
normal	O	O
mice	O	O
.	O	O
[	B-Gene	O
GNE	I-Gene	O
gene	O	O
mutation	B-Var	O
analysis	O	O
in	O	O
5	O	O
patients	O	O
with	B-Reg	O
distal	B-Disease	O
myopathy	I-Disease	O
with	I-Disease	O
rimmed	I-Disease	O
vacuoles	I-Disease	O
]	I-Disease	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
investigate	O	O
GNE	O	O
gene	O	O
mutations	O	O
in	O	O
5	O	O
Chinese	O	O
patients	O	O
with	O	O
distal	O	O
myopathy	O	O
with	O	O
rimmed	O	O
vacuoles	O	O
(	O	O
DMRV	O	O
)	O	O
.	O	O
METHODS	O	O
:	O	O
Five	O	O
patients	O	O
with	O	O
typical	O	O
clinical	O	O
and	O	O
pathological	O	O
features	O	O
of	O	O
DMRV	O	O
were	O	O
studied	O	O
.	O	O
All	O	O
the	O	O
11	O	O
coding	O	O
exons	O	O
and	O	O
the	O	O
flanking	O	O
intron	O	O
sequences	O	O
of	O	O
GNE	O	O
gene	O	O
were	O	O
amplified	O	O
by	O	O
PCR	O	O
and	O	O
sequenced	O	O
.	O	O
Four	O	O
family	O	O
members	O	O
of	O	O
case	O	O
5	O	O
were	O	O
also	O	O
examined	O	O
for	O	O
GNE	O	O
gene	O	O
mutations	O	O
.	O	O
RESULTS	O	O
:	O	O
All	O	O
the	O	O
patients	O	O
were	O	O
identified	O	O
to	O	O
have	O	O
different	O	O
GNE	O	O
gene	O	O
mutations	O	O
:	O	O
Cases	O	O
1	O	O
-	O	O
4	O	O
had	O	O
complex	O	O
heterozygous	O	O
mutations	O	O
and	O	O
case	O	O
5	O	O
had	O	O
homozygous	O	O
mutation	O	O
.	O	O
Six	O	O
reported	O	O
mutations	O	O
had	O	O
been	O	O
identified	O	O
,	O	O
including	O	O
1	O	O
nonsense	O	O
mutation	O	O
(	O	O
p	O	O
.	O	O
R8X	O	O
)	O	O
and	O	O
5	O	O
missense	O	O
mutations	O	O
(	O	O
p	O	O
.	O	O
D176V	O	O
,	O	O
p	O	O
.	O	O
I298	O	O
T	O	O
,	O	O
p	O	O
.	O	O
A591	O	O
T	O	O
,	O	O
P.A631V	O	O
,	O	O
and	O	O
p	O	O
.	O	O
V696	O	O
M	O	O
)	O	O
.	O	O
A	O	O
novel	O	O
mutation	O	O
(	O	O
c.317T	O	O
>	O	O
C	O	O
,	O	O
p	O	O
.	O	O
I106	O	O
T	O	O
)	O	O
was	O	O
identified	O	O
in	O	O
case	O	O
2	O	O
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
p	B-Var	O
.	I-Var	O
R8X	I-Var	O
,	O	O
p	B-Var	O
.	I-Var	O
I298	I-Var	O
T	I-Var	O
,	O	O
p	B-Var	B-Var
.	I-Var	I-Var
A591	I-Var	O
T	I-Var	O
and	O	O
p	B-Var	O
.	I-Var	O
V696	I-Var	O
M	I-Var	O
mutations	O	O
in	O	O
GNE	B-Gene	O
gene	O	O
in	O	O
Chinese	O	O
population	O	O
,	O	O
and	O	O
a	O	O
novel	O	O
mutation	O	O
p	B-Var	O
.	I-Var	O
I106	I-Var	O
T	I-Var	O
was	O	O
identified	O	O
.	O	O
These	O	O
findings	O	O
further	O	O
expand	O	O
the	O	O
clinical	O	O
and	O	O
genetic	O	O
spectrum	O	O
of	B-Reg	O
DMRV	B-Disease	O
in	O	O
China	O	O
.	O	O
Congenital	O	O
variant	O	O
of	O	O
Rett	O	O
syndrome	O	O
due	O	O
to	O	O
an	O	O
intragenic	O	O
large	O	O
deletion	O	O
in	O	O
MECP2	O	O
.	O	O
Rett	B-Disease	O
syndrome	I-Disease	O
(	O	O
RTT	O	O
)	O	O
is	O	O
a	O	O
neurodevelopmental	O	O
disorder	O	O
that	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
causes	O	O
of	O	O
mental	O	O
retardation	O	O
in	O	O
females	O	O
.	O	O
RTT	O	O
diagnosis	O	O
is	O	O
based	O	O
on	O	O
distinct	O	O
clinical	O	O
criteria	O	O
.	O	O
We	O	O
describe	O	O
here	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
severe	O	O
phenotype	O	O
of	O	O
congenital	O	O
variant	O	O
RTT	O	O
.	O	O
The	O	O
patient	O	O
originally	O	O
presented	O	O
with	O	O
severe	O	O
developmental	O	O
delay	O	O
prior	O	O
to	O	O
the	O	O
age	O	O
of	O	O
6	O	O
months	O	O
and	O	O
later	O	O
exhibited	O	O
characteristic	O	O
features	O	O
of	O	O
RTT	O	O
that	O	O
included	O	O
air	O	O
swallowing	O	O
,	O	O
bruxism	O	O
,	O	O
and	O	O
hand	O	O
stereotypies	O	O
.	O	O
Results	O	O
of	O	O
an	O	O
array	O	O
-	O	O
based	O	O
comparative	O	O
genomic	O	O
hybridization	O	O
analysis	O	O
indicated	O	O
there	O	O
was	O	O
a	O	O
very	O	O
small	O	O
microdeletion	O	O
in	O	O
Xq28	O	O
.	O	O
Multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
analysis	O	O
further	O	O
confirmed	O	O
there	O	O
were	O	O
heterozygous	O	O
deletions	O	O
of	O	O
intron	O	O
2	O	O
,	O	O
exon	O	O
3	O	O
,	O	O
intron	O	O
3	O	O
,	O	O
and	O	O
part	O	O
of	O	O
exon	O	O
4	O	O
in	O	O
MECP2	O	O
.	O	O
Findings	O	O
in	O	O
the	O	O
present	O	O
patient	O	O
confirm	O	O
the	O	O
view	O	O
that	O	O
large	O	O
MECP2	B-Gene	O
deletions	B-Var	O
are	O	O
an	O	O
important	O	O
cause	B-Reg	O
of	O	O
severe	O	O
congenital	O	O
variant	O	O
RTT	B-Disease	O
.	O	O
To	O	O
ensure	O	O
an	O	O
accurate	O	O
diagnosis	O	O
of	O	O
congenital	O	O
variant	O	O
RTT	O	O
,	O	O
a	O	O
multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
analysis	O	O
of	O	O
MECP2	O	O
should	O	O
be	O	O
performed	O	O
in	O	O
patients	O	O
suspected	O	O
of	O	O
having	O	O
this	O	O
disorder	O	O
.	O	O
A	O	O
new	O	O
frame	B-Var	O
-	I-Var	O
shifting	I-Var	O
mutation	O	O
of	O	O
UGT1A1	B-Gene	O
gene	O	O
causes	B-Reg	O
type	B-Disease	O
I	I-Disease	O
Crigler	I-Disease	O
-	I-Disease	O
Najjar	I-Disease	O
syndrome	I-Disease	O
.	O	O
We	O	O
present	O	O
a	O	O
case	O	O
of	O	O
severe	O	O
persisting	O	O
unconjugated	O	O
hyperbilirubinemia	O	O
in	O	O
a	O	O
Uigur	O	O
infant	O	O
boy	O	O
,	O	O
eventually	O	O
diagnosed	O	O
as	O	O
Crigler	O	O
-	O	O
Najjar	O	O
syndrome	O	O
type	O	O
I.	O	O
DNA	O	O
analysis	O	O
of	O	O
his	O	O
blood	O	O
of	O	O
the	O	O
UGT1A1	O	O
gene	O	O
sequence	O	O
demonstrated	O	O
that	O	O
he	O	O
was	O	O
homozygous	O	O
for	O	O
an	O	O
insertion	O	O
mutation	O	O
causing	O	O
a	O	O
change	O	O
of	O	O
the	O	O
coding	O	O
exons	O	O
with	O	O
a	O	O
frame	O	O
-	O	O
shift	O	O
,	O	O
resulting	O	O
in	O	O
the	O	O
substitution	O	O
of	O	O
27	O	O
abnormal	O	O
amino	O	O
acid	O	O
residues	O	O
in	O	O
his	O	O
hepatic	O	O
bilirubin	O	O
uridine	O	O
diphosphoglucuronyl	O	O
transferase	O	O
enzyme	O	O
.	O	O
Both	O	O
of	O	O
his	O	O
parents	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
same	O	O
mutation	O	O
.	O	O
A	O	O
novel	O	O
frame	O	O
-	O	O
shifting	O	O
mutation	O	O
of	O	O
the	O	O
UGT1A1	O	O
gene	O	O
was	O	O
found	O	O
,	O	O
confirming	O	O
the	O	O
diagnosis	O	O
of	O	O
Crigler	O	O
-	O	O
Najjar	O	O
syndrome	O	O
type	O	O
I	O	O
for	O	O
this	O	O
patient	O	O
.	O	O
X	O	O
inactivation	O	O
in	O	O
females	O	O
with	O	O
X	O	O
-	O	O
linked	O	O
Charcot	O	O
-	O	O
Marie	O	O
-	O	O
Tooth	O	O
disease	O	O
.	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
Charcot	I-Disease	O
-	I-Disease	O
Marie	I-Disease	O
-	I-Disease	O
Tooth	I-Disease	O
disease	I-Disease	O
(	O	O
CMT1X	O	O
)	O	O
is	O	O
the	O	O
second	O	O
most	O	O
common	O	O
inherited	O	O
neuropathy	O	O
,	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
gap	O	O
junction	O	O
beta-1	O	O
(	B-Gene	O
GJB1	I-Gene	O
)	I-Gene	O
.	O	O
Males	O	O
have	O	O
a	O	O
uniformly	O	O
moderately	O	O
severe	O	O
phenotype	O	O
while	O	O
females	O	O
have	O	O
a	O	O
variable	O	O
phenotype	O	O
,	O	O
suggested	O	O
to	O	O
be	O	O
due	O	O
to	O	O
X	O	O
inactivation	O	O
.	O	O
We	O	O
aimed	O	O
to	O	O
assess	O	O
X	O	O
inactivation	O	O
pattern	O	O
in	O	O
females	O	O
with	O	O
CMT1X	O	O
and	O	O
correlate	O	O
this	O	O
with	O	O
phenotype	O	O
using	O	O
the	O	O
CMT	O	O
examination	O	O
score	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
X	O	O
inactivation	O	O
pattern	O	O
accounted	O	O
for	O	O
the	O	O
variable	O	O
phenotype	O	O
in	O	O
females	O	O
with	O	O
CMT1X.	O	O
We	O	O
determined	O	O
X	O	O
inactivation	O	O
pattern	O	O
in	O	O
67	O	O
females	O	O
with	O	O
CMT1X	O	O
and	O	O
24	O	O
controls	O	O
using	O	O
the	O	O
androgen	O	O
receptor	O	O
assay	O	O
.	O	O
We	O	O
were	O	O
able	O	O
to	O	O
determine	O	O
which	O	O
X	O	O
chromosome	O	O
carried	O	O
the	O	O
GJB1	O	O
mutation	O	O
in	O	O
30	O	O
females	O	O
.	O	O
There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
X	O	O
inactivation	O	O
pattern	O	O
between	O	O
patients	O	O
and	O	O
controls	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
there	O	O
was	O	O
no	O	O
correlation	O	O
between	O	O
X	O	O
inactivation	O	O
pattern	O	O
in	O	O
blood	O	O
and	O	O
phenotype	O	O
.	O	O
A	O	O
possible	O	O
explanation	O	O
for	O	O
these	O	O
findings	O	O
is	O	O
that	O	O
the	O	O
X	O	O
inactivation	O	O
pattern	O	O
in	O	O
Schwann	O	O
cells	O	O
rather	O	O
than	O	O
in	O	O
blood	O	O
may	O	O
explain	O	O
the	O	O
variable	O	O
phenotype	O	O
in	O	O
females	O	O
with	O	O
CMT1X.	O	O
Autosomal	B-Disease	O
dominant	I-Disease	O
polycystic	I-Disease	O
kidney	I-Disease	O
disease	I-Disease	O
:	I-Disease	O
comprehensive	O	O
mutation	B-Var	O
analysis	O	O
of	O	O
PKD1	B-Gene	O
and	O	O
PKD2	B-Gene	O
in	B-Reg	O
700	O	O
unrelated	O	O
patients	O	O
.	O	O
Autosomal	B-Disease	O
dominant	I-Disease	O
polycystic	I-Disease	O
kidney	I-Disease	O
disease	I-Disease	O
(	O	O
ADPKD	O	O
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
inherited	O	O
kidney	O	O
disorder	O	O
,	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
PKD1	B-Gene	O
or	O	O
PKD2	B-Gene	O
.	O	O
The	O	O
molecular	O	O
diagnosis	O	O
of	O	O
ADPKD	O	O
is	O	O
complicated	O	O
by	O	O
extensive	O	O
allelic	O	O
heterogeneity	O	O
and	O	O
particularly	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
six	O	O
highly	O	O
homologous	O	O
sequences	O	O
of	O	O
PKD1	O	O
exons	O	O
1	O	O
-	O	O
33	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
screened	O	O
PKD1	O	O
and	O	O
PKD2	O	O
for	O	O
both	O	O
conventional	O	O
mutations	O	O
and	O	O
gross	O	O
genomic	O	O
rearrangements	O	O
in	O	O
up	O	O
to	O	O
700	O	O
unrelated	O	O
ADPKD	O	O
patients	O	O
--	O	O
the	O	O
largest	O	O
patient	O	O
cohort	O	O
to	O	O
date	O	O
--	O	O
by	O	O
means	O	O
of	O	O
direct	O	O
sequencing	O	O
,	O	O
followed	O	O
by	O	O
quantitative	O	O
fluorescent	O	O
multiplex	O	O
polymerase	O	O
chain	O	O
reaction	O	O
or	O	O
array	O	O
-	O	O
comparative	O	O
genomic	O	O
hybridization	O	O
.	O	O
This	O	O
resulted	O	O
in	O	O
the	O	O
identification	O	O
of	O	O
the	O	O
largest	O	O
number	O	O
of	O	O
new	O	O
pathogenic	O	O
mutations	O	O
(	O	O
n	O	O
=	O	O
351	O	O
)	O	O
in	O	O
a	O	O
single	O	O
publication	O	O
,	O	O
expanded	O	O
the	O	O
spectrum	O	O
of	O	O
known	O	O
ADPKD	O	O
pathogenic	O	O
mutations	O	O
by	O	O
41.8	O	O
%	O	O
for	O	O
PKD1	O	O
and	O	O
by	O	O
23.8	O	O
%	O	O
for	O	O
PKD2	O	O
,	O	O
and	O	O
provided	O	O
new	O	O
insights	O	O
into	O	O
several	O	O
issues	O	O
,	O	O
such	O	O
as	O	O
the	O	O
population	O	O
-	O	O
dependent	O	O
distribution	O	O
of	O	O
recurrent	O	O
mutations	O	O
compared	O	O
with	O	O
founder	O	O
mutations	O	O
and	O	O
the	O	O
relative	O	O
paucity	O	O
of	O	O
pathogenic	O	O
missense	O	O
mutations	O	O
in	O	O
the	O	O
PKD2	O	O
gene	O	O
.	O	O
Our	O	O
study	O	O
,	O	O
together	O	O
with	O	O
others	O	O
,	O	O
highlights	O	O
the	O	O
importance	O	O
of	O	O
developing	O	O
novel	O	O
approaches	O	O
for	O	O
both	O	O
mutation	O	O
detection	O	O
and	O	O
functional	O	O
validation	O	O
of	O	O
nondefinite	O	O
pathogenic	O	O
mutations	O	O
to	O	O
increase	O	O
the	O	O
diagnostic	O	O
value	O	O
of	O	O
molecular	O	O
testing	O	O
for	O	O
ADPKD	O	O
.	O	O
A	O	O
novel	O	O
classification	O	O
system	O	O
to	O	O
predict	O	O
the	O	O
pathogenic	O	O
effects	O	O
of	O	O
CHD7	B-Gene	O
missense	B-Var	O
variants	I-Var	O
in	B-Reg	O
CHARGE	B-Disease	O
syndrome	I-Disease	O
.	O	O
CHARGE	B-Disease	O
syndrome	I-Disease	O
is	O	O
characterized	O	O
by	O	O
the	O	O
variable	O	O
occurrence	O	O
of	O	O
multisensory	O	O
impairment	O	O
,	O	O
congenital	O	O
anomalies	O	O
,	O	O
and	O	O
developmental	O	O
delay	O	O
,	O	O
and	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
heterozygous	B-Var	O
mutations	I-Var	O
in	O	O
the	O	O
CHD7	B-Gene	O
gene	O	O
.	O	O
Correct	O	O
interpretation	O	O
of	O	O
CHD7	O	O
variants	O	O
is	O	O
essential	O	O
for	O	O
genetic	O	O
counseling	O	O
.	O	O
This	O	O
is	O	O
particularly	O	O
difficult	O	O
for	O	O
missense	O	O
variants	O	O
because	O	O
most	O	O
variants	O	O
in	O	O
the	O	O
CHD7	O	O
gene	O	O
are	O	O
private	O	O
and	O	O
a	O	O
functional	O	O
assay	O	O
is	O	O
not	O	O
yet	O	O
available	O	O
.	O	O
We	O	O
have	O	O
therefore	O	O
developed	O	O
a	O	O
novel	O	O
classification	O	O
system	O	O
to	O	O
predict	O	O
the	O	O
pathogenic	O	O
effects	O	O
of	O	O
CHD7	O	O
missense	O	O
variants	O	O
that	O	O
can	O	O
be	O	O
used	O	O
in	O	O
a	O	O
diagnostic	O	O
setting	O	O
.	O	O
Our	O	O
classification	O	O
system	O	O
combines	O	O
the	O	O
results	O	O
from	O	O
two	O	O
computational	O	O
algorithms	O	O
(	O	O
PolyPhen-2	O	O
and	O	O
Align	O	O
-	O	O
GVGD	O	O
)	O	O
and	O	O
the	O	O
prediction	O	O
of	O	O
a	O	O
newly	O	O
developed	O	O
structural	O	O
model	O	O
of	O	O
the	O	O
chromo-	O	O
and	O	O
helicase	O	O
domains	O	O
of	O	O
CHD7	O	O
with	O	O
segregation	O	O
and	O	O
phenotypic	O	O
data	O	O
.	O	O
The	O	O
combination	O	O
of	O	O
different	O	O
variables	O	O
will	O	O
lead	O	O
to	O	O
a	O	O
more	O	O
confident	O	O
prediction	O	O
of	O	O
pathogenicity	O	O
than	O	O
was	O	O
previously	O	O
possible	O	O
.	O	O
We	O	O
have	O	O
used	O	O
our	O	O
system	O	O
to	O	O
classify	O	O
145	O	O
CHD7	O	O
missense	O	O
variants	O	O
.	O	O
Our	O	O
data	O	O
show	O	O
that	O	O
pathogenic	O	O
missense	O	O
mutations	O	O
are	O	O
mainly	O	O
present	O	O
in	O	O
the	O	O
middle	O	O
of	O	O
the	O	O
CHD7	O	O
gene	O	O
,	O	O
whereas	O	O
benign	O	O
variants	O	O
are	O	O
mainly	O	O
clustered	O	O
in	O	O
the	O	O
5	O	O
'	O	O
and	O	O
3	O	O
'	O	O
regions	O	O
.	O	O
Finally	O	O
,	O	O
we	O	O
show	O	O
that	O	O
CHD7	O	O
missense	O	O
mutations	O	O
are	O	O
,	O	O
in	O	O
general	O	O
,	O	O
associated	O	O
with	O	O
a	O	O
milder	O	O
phenotype	O	O
than	O	O
truncating	O	O
mutations	O	O
.	O	O
Novel	O	O
mutation	O	O
in	O	O
SLC9A6	O	O
gene	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
Christianson	O	O
syndrome	O	O
and	O	O
retinitis	O	O
pigmentosum	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
SLC9A6	B-Gene	O
gene	O	O
cause	B-Reg	O
Christianson	B-Disease	B-Disease
syndrome	I-Disease	I-Disease
in	O	O
boys	O	O
.	O	O
This	O	O
X	O	O
-	O	O
linked	O	O
syndrome	O	O
is	O	O
characterized	O	O
by	O	O
profound	O	O
mental	O	O
retardation	O	O
with	O	O
autistic	O	O
behavior	O	O
,	O	O
microcephaly	O	O
,	O	O
epilepsy	O	O
,	O	O
ophthalmoplegia	O	O
,	O	O
and	O	O
ataxia	O	O
.	O	O
Progressive	O	O
cerebellar	O	O
atrophy	O	O
with	O	O
motor	O	O
regression	O	O
is	O	O
a	O	O
remarkable	O	O
feature	O	O
in	O	O
some	O	O
patients	O	O
.	O	O
We	O	O
report	O	O
on	O	O
a	O	O
22year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
with	O	O
Christianson	O	O
syndrome	O	O
carrying	O	O
the	O	O
novel	O	O
p	O	O
.	O	O
Gln306X	O	O
mutation	O	O
.	O	O
The	O	O
infantile	O	O
phenotype	O	O
suggested	O	O
pervasive	O	O
developmental	O	O
disorder	O	O
,	O	O
then	O	O
profound	O	O
mental	O	O
retardation	O	O
ensued	O	O
.	O	O
In	O	O
later	O	O
childhood	O	O
,	O	O
progressive	O	O
cerebellar	O	O
atrophy	O	O
was	O	O
diagnosed	O	O
on	O	O
serial	O	O
brain	O	O
MRIs	O	O
and	O	O
motor	O	O
regression	O	O
occurred	O	O
.	O	O
Furthermore	O	O
,	O	O
ophthalmological	O	O
evaluations	O	O
showed	O	O
a	O	O
retinitis	O	O
pigmentosum	O	O
previously	O	O
unreported	O	O
in	O	O
this	O	O
condition	O	O
.	O	O
We	O	O
conclude	O	O
that	O	O
the	O	O
natural	O	O
history	O	O
of	O	O
the	O	O
disease	O	O
in	O	O
this	O	O
patient	O	O
tends	O	O
to	O	O
confirm	O	O
the	O	O
degenerative	O	O
nature	O	O
of	O	O
Christianson	O	O
syndrome	O	O
,	O	O
and	O	O
that	O	O
retinal	O	O
degeneration	O	O
may	O	O
be	O	O
part	O	O
of	O	O
the	O	O
condition	O	O
.	O	O
Before	O	O
the	O	O
onset	O	O
of	O	O
degeneration	O	O
,	O	O
the	O	O
syndromic	O	O
association	O	O
of	O	O
severe	O	O
mental	O	O
retardation	O	O
,	O	O
autistic	O	O
behavior	O	O
,	O	O
external	O	O
ophthalmoplegia	O	O
,	O	O
and	O	O
facial	O	O
dysmorphism	O	O
in	O	O
male	O	O
patients	O	O
is	O	O
a	O	O
clue	O	O
to	O	O
the	O	O
diagnosis	O	O
.	O	O
Mutation	B-Var	O
analysis	O	O
in	O	O
two	O	O
Chinese	O	O
families	O	O
with	B-Reg	O
multiple	B-Disease	O
endocrine	I-Disease	O
neoplasia	I-Disease	O
type	I-Disease	O
1	I-Disease	O
.	O	O
OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
aimed	O	O
at	O	O
identifing	O	O
mutations	O	O
in	O	O
two	O	O
Chinese	O	O
genealogies	O	O
with	O	O
MEN1	B-Gene	O
.	O	O
SUBJECTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Three	O	O
members	O	O
of	O	O
two	O	O
Chinese	O	O
families	O	O
with	O	O
MEN1	O	O
were	O	O
enrolled	O	O
in	O	O
this	O	O
study	O	O
,	O	O
and	O	O
all	O	O
of	O	O
the	O	O
coding	O	O
regions	O	O
and	O	O
adjacent	O	O
sequences	O	O
of	O	O
the	O	O
MEN1	O	O
gene	O	O
were	O	O
amplified	O	O
and	O	O
sequenced	O	O
.	O	O
RESULTS	O	O
:	O	O
A	O	O
recurrent	O	O
mutation	O	O
of	O	O
heterozygous	O	O
change	O	O
T	O	O
>	O	O
A	O	O
at	O	O
IVS	O	O
4	O	O
+	O	O
1	O	O
was	O	O
found	O	O
in	O	O
family	O	O
I	O	O
,	O	O
and	O	O
a	O	O
novel	O	O
insGAGGTGG	O	O
mutation	O	O
(	O	O
c.703	O	O
-	O	O
709dup7bp	O	O
)	O	O
resulted	O	O
in	O	O
a	O	O
frameshift	O	O
(	O	O
p	O	O
.	O	O
A237Gfsx13	O	O
)	O	O
in	O	O
family	O	O
II	O	O
.	O	O
CONCLUSION	O	O
:	O	O
We	O	O
are	O	O
able	O	O
to	O	O
add	O	O
a	O	O
new	O	O
mutation	O	O
of	O	O
MEN1	O	O
gene	O	O
in	O	O
Chinese	O	O
patients	O	O
with	O	O
MEN1	O	O
that	O	O
will	O	O
be	O	O
useful	O	O
for	O	O
the	O	O
diagnosis	O	O
and	O	O
treatment	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
Two	O	O
novel	O	O
mutations	O	O
in	O	O
the	O	O
lactase	O	O
gene	O	O
in	O	O
a	O	O
Japanese	O	O
infant	O	O
with	O	O
congenital	O	O
lactase	O	O
deficiency	O	O
.	O	O
Intestinal	O	O
lactase	O	O
is	O	O
required	O	O
for	O	O
the	O	O
hydrolysis	O	O
of	O	O
lactose	O	O
that	O	O
is	O	O
the	O	O
most	O	O
essential	O	O
carbohydrate	O	O
in	O	O
milk	O	O
and	O	O
the	O	O
primary	O	O
diet	O	O
source	O	O
of	O	O
newborn	O	O
.	O	O
Congenital	B-Disease	O
lactase	I-Disease	O
deficiency	I-Disease	O
[	O	O
CLD	O	O
(	O	O
MIM	O	O
223000	O	O
)	O	O
]	O	O
is	O	O
a	O	O
severe	O	O
gastrointestinal	O	O
disorder	O	O
and	O	O
is	O	O
characterized	O	O
by	O	O
watery	O	O
diarrhea	O	O
due	O	O
to	O	O
an	O	O
extremely	O	O
low	O	O
or	O	O
the	O	O
lack	O	O
of	O	O
lactase	O	O
activity	O	O
in	O	O
the	O	O
intestinal	O	O
wall	O	O
from	O	O
birth	O	O
.	O	O
CLD	O	O
is	O	O
a	O	O
rare	O	O
disease	O	O
and	O	O
occurs	O	O
more	O	O
frequently	O	O
in	O	O
Finland	O	O
.	O	O
Recent	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
mutations	B-Var	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
lactase	O	O
(	B-Gene	O
LCT	I-Gene	O
)	I-Gene	O
gene	O	O
underlie	B-Reg	O
CLD	B-Disease	O
in	O	O
patients	O	O
from	O	O
Finland	O	O
and	O	O
other	O	O
European	O	O
countries	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
report	O	O
two	O	O
novel	O	O
mutations	O	O
in	O	O
the	O	O
LCT	O	O
gene	O	O
in	O	O
a	O	O
Japanese	O	O
female	O	O
infant	O	O
with	O	O
clinical	O	O
features	O	O
consistent	O	O
with	O	O
those	O	O
of	O	O
CLD	O	O
.	O	O
She	O	O
suffered	O	O
from	O	O
severe	O	O
watery	O	O
diarrhea	O	O
from	O	O
the	O	O
age	O	O
of	O	O
2	O	O
days	O	O
on	O	O
breast	O	O
milk	O	O
/	O	O
lactose	O	O
containing	O	O
cow	O	O
's	O	O
milk	O	O
formula	O	O
.	O	O
With	O	O
the	O	O
lactose	O	O
-	O	O
free	O	O
hydrolyzed	O	O
cow	O	O
's	O	O
milk	O	O
formula	O	O
,	O	O
diarrhea	O	O
was	O	O
stopped	O	O
,	O	O
and	O	O
she	O	O
has	O	O
now	O	O
developed	O	O
well	O	O
on	O	O
a	O	O
lactose	O	O
-	O	O
free	O	O
diet	O	O
.	O	O
She	O	O
shows	O	O
a	O	O
lactose	O	O
-	O	O
intolerance	O	O
pattern	O	O
on	O	O
the	O	O
lactose	O	O
challenge	O	O
test	O	O
.	O	O
Sequence	O	O
analysis	O	O
revealed	O	O
the	O	O
two	O	O
mutations	O	O
in	O	O
her	O	O
LCT	B-Gene	O
gene	O	O
:	O	O
c.4419C	B-Var	O
>	I-Var	O
G	I-Var	O
(	O	O
p	O	O
.	O	O
Y1473X	O	O
)	O	O
in	O	O
exon	O	O
10	O	O
transmitted	O	O
from	O	O
her	O	O
mother	O	O
and	O	O
c.5387delA	B-Var	O
(	O	O
p	O	O
.	O	O
D1796fs	O	O
)	O	O
in	O	O
exon	O	O
16	O	O
transmitted	O	O
from	O	O
her	O	O
father	O	O
.	O	O
Both	O	O
mutations	O	O
cause	B-Reg	O
premature	B-MPA	O
truncation	I-MPA	O
of	O	O
lactase	B-Protein	O
polypeptide	I-Protein	O
and	O	O
are	O	O
supposed	O	O
to	O	O
be	B-Reg	O
responsible	I-Reg	O
for	I-Reg	O
CLD	B-Disease	O
.	O	O
To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
on	O	O
mutations	O	O
in	O	O
the	O	O
LCT	O	O
gene	O	O
in	O	O
Japan	O	O
.	O	O
We	O	O
suggest	O	O
that	O	O
an	O	O
increased	O	O
awareness	O	O
is	O	O
required	O	O
regarding	O	O
CLD	O	O
.	O	O
Analysis	O	O
of	O	O
gene	O	O
mutations	O	O
in	O	O
Chinese	O	O
patients	O	O
with	O	O
maple	O	O
syrup	O	O
urine	O	O
disease	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
Maple	B-Disease	O
syrup	I-Disease	O
urine	I-Disease	O
disease	I-Disease	O
(	O	O
MSUD	O	O
)	O	O
is	O	O
predominantly	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
BCKDHA	B-Gene	O
,	O	O
BCKDHB	B-Gene	O
and	O	O
DBT	B-Gene	O
genes	O	O
,	O	O
which	O	O
encode	O	O
for	O	O
the	O	O
E1α	O	O
,	O	O
E1β	O	O
and	O	O
E2	O	O
subunits	O	O
of	O	O
the	O	O
branched	O	O
-	O	O
chain	O	O
α	O	O
-	O	O
keto	O	O
acid	O	O
dehydrogenase	O	O
complex	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
screen	O	O
DNA	O	O
samples	O	O
from	O	O
16	O	O
Chinese	O	O
MSUD	O	O
patients	O	O
and	O	O
assess	O	O
a	O	O
potential	O	O
correlation	O	O
between	O	O
genotype	O	O
and	O	O
phenotype	O	O
.	O	O
METHODS	O	O
:	O	O
BCKDHA	O	O
,	O	O
BCKDHB	O	O
and	O	O
DBT	O	O
genes	O	O
were	O	O
analyzed	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
and	O	O
direct	O	O
sequencing	O	O
.	O	O
Segments	O	O
bearing	O	O
novel	O	O
mutations	O	O
were	O	O
identified	O	O
by	O	O
PCR	O	O
-	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
(	O	O
PCR	O	O
-	O	O
RFLP	O	O
)	O	O
analysis	O	O
.	O	O
RESULTS	O	O
:	O	O
Within	O	O
the	O	O
variant	O	O
alleles	O	O
,	O	O
28	O	O
mutations	O	O
(	O	O
28/32	O	O
,	O	O
87.5	O	O
%	O	O
)	O	O
,	O	O
were	O	O
detected	O	O
in	O	O
15	O	O
patients	O	O
,	O	O
while	O	O
one	O	O
patient	O	O
displayed	O	O
no	O	O
mutations	O	O
.	O	O
Mutations	O	O
were	O	O
comprised	O	O
of	O	O
20	O	O
different	O	O
:	O	O
6	O	O
BCKDHA	O	O
gene	O	O
mutations	O	O
in	O	O
4	O	O
cases	O	O
,	O	O
10	O	O
BCKDHB	O	O
gene	O	O
mutations	O	O
in	O	O
8	O	O
cases	O	O
and	O	O
4	O	O
DBT	O	O
gene	O	O
mutations	O	O
in	O	O
3	O	O
cases	O	O
.	O	O
From	O	O
these	O	O
,	O	O
14	O	O
were	O	O
novel	O	O
,	O	O
which	O	O
included	O	O
3	O	O
mutations	O	O
in	O	O
the	O	O
BCKDHA	O	O
gene	O	O
,	O	O
7	O	O
in	O	O
the	O	O
BCKDHB	O	O
gene	O	O
and	O	O
4	O	O
in	O	O
the	O	O
DBT	O	O
gene	O	O
.	O	O
Only	O	O
two	O	O
patients	O	O
with	O	O
mutations	O	O
in	O	O
the	O	O
BCKDHB	O	O
and	O	O
DBT	O	O
genes	O	O
were	O	O
thiamine	O	O
-	O	O
responsive	O	O
and	O	O
presented	O	O
a	O	O
better	O	O
clinical	O	O
outcome	O	O
.	O	O
CONCLUSION	O	O
:	O	O
We	O	O
identified	O	O
20	O	O
different	O	O
mutations	O	O
within	O	O
the	O	O
BCKDHA	O	O
,	O	O
BCKDHB	O	O
and	O	O
DBT	O	O
genes	O	O
among	O	O
16	O	O
Chinese	O	O
MSUD	O	O
patients	O	O
,	O	O
including	O	O
14	O	O
novel	O	O
mutations	O	O
.	O	O
The	O	O
majority	O	O
were	O	O
non	O	O
-	O	O
responsive	O	O
to	O	O
thiamine	O	O
,	O	O
associating	O	O
with	O	O
a	O	O
worse	O	O
clinical	O	O
outcome	O	O
.	O	O
Our	O	O
data	O	O
provide	O	O
the	O	O
basis	O	O
for	O	O
further	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
studies	O	O
in	O	O
these	O	O
patients	O	O
,	O	O
which	O	O
will	O	O
be	O	O
beneficial	O	O
for	O	O
early	O	O
diagnosis	O	O
and	O	O
in	O	O
directing	O	O
the	O	O
approach	O	O
to	O	O
clinical	O	O
intervention	O	O
.	O	O
Cell	O	O
models	O	O
for	O	O
McArdle	O	O
disease	O	O
and	O	O
aminoglycoside	O	O
-	O	O
induced	O	O
read	O	O
-	O	O
through	O	O
of	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
.	O	O
McArdle	B-Disease	O
disease	I-Disease	O
results	B-Reg	O
from	I-Reg	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
muscle	O	O
glycogen	O	O
phosphorylase	O	O
(	B-Gene	O
PYGM	I-Gene	O
)	I-Gene	O
protein	O	O
and	O	O
the	O	O
two	O	O
most	O	O
common	O	O
mutations	O	O
are	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
(	B-Var	O
R50X	I-Var	O
)	I-Var	O
and	O	O
a	O	O
missense	O	O
mutation	O	O
(	B-Var	O
G205S	I-Var	O
)	I-Var	O
.	O	O
Myoblasts	O	O
from	O	O
patients	O	O
can	O	O
not	O	O
be	O	O
used	O	O
to	O	O
create	O	O
a	O	O
cell	O	O
model	O	O
of	O	O
McArdle	O	O
disease	O	O
because	O	O
even	O	O
normal	O	O
myoblasts	O	O
produce	O	O
little	O	O
or	O	O
no	O	O
PYGM	O	O
protein	O	O
in	O	O
cell	O	O
culture	O	O
.	O	O
We	O	O
therefore	O	O
created	O	O
cell	O	O
models	O	O
by	O	O
expressing	O	O
wild	O	O
-	O	O
type	O	O
or	O	O
mutant	O	O
(	O	O
R50X	O	O
or	O	O
G205S	O	O
)	O	O
PYGM	O	O
from	O	O
cDNA	O	O
integrated	O	O
into	O	O
the	O	O
genome	O	O
of	O	O
Chinese	O	O
hamster	O	O
ovary	O	O
cells	O	O
.	O	O
These	O	O
cell	O	O
lines	O	O
enable	O	O
the	O	O
study	O	O
of	O	O
McArdle	O	O
mutations	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
nonsense	O	O
-	O	O
mediated	O	O
decay	O	O
of	O	O
mRNA	O	O
transcripts	O	O
.	O	O
Although	O	O
all	O	O
cell	O	O
lines	O	O
produced	O	O
stable	O	O
mRNA	O	O
,	O	O
only	O	O
wild	O	O
-	O	O
type	O	O
produced	O	O
detectable	O	O
PYGM	O	O
protein	O	O
.	O	O
Our	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
G205S	B-Var	O
mutation	O	O
affects	O	O
PYGM	B-Gene	O
by	O	O
causing	B-Reg	O
misfolding	B-MPA	O
and	O	O
accelerated	B-Reg	O
protein	B-Protein	B-MPA
turnover	B-MPA	O
.	O	O
Using	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
region	O	O
of	O	O
PYGM	O	O
containing	O	O
the	O	O
R50X	O	O
mutation	O	O
fused	O	O
to	O	O
green	O	O
fluorescent	O	O
protein	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
demonstrate	O	O
both	O	O
small	O	O
amounts	O	O
of	O	O
truncated	O	O
protein	O	O
production	O	O
and	O	O
read	O	O
-	O	O
through	O	O
of	O	O
the	O	O
R50X	O	O
premature	O	O
termination	O	O
codon	O	O
induced	O	O
by	O	O
the	O	O
aminoglycoside	O	O
,	O	O
G418	O	O
.	O	O
Origins	O	O
of	O	O
albino	O	O
and	O	O
hooded	O	O
rats	O	O
:	O	O
implications	O	O
from	O	O
molecular	O	O
genetic	O	O
analysis	O	O
across	O	O
modern	O	O
laboratory	O	O
rat	O	O
strains	O	O
.	O	O
Albino	O	O
and	O	O
hooded	O	O
(	O	O
or	O	O
piebald	O	O
)	O	O
rats	O	O
are	O	O
one	O	O
of	O	O
the	O	O
most	O	O
frequently	O	O
used	O	O
laboratory	O	O
animals	O	O
for	O	O
the	O	O
past	O	O
150	O	O
years	O	O
.	O	O
Despite	O	O
this	O	O
fact	O	O
,	O	O
the	O	O
origin	O	O
of	O	O
the	O	O
albino	O	O
mutation	O	O
as	O	O
well	O	O
as	O	O
the	O	O
genetic	O	O
basis	O	O
of	O	O
the	O	O
hooded	O	O
phenotype	O	O
remained	O	O
unclear	O	O
.	O	O
Recently	O	O
,	O	O
the	O	O
albino	B-CPA	O
mutation	O	O
has	O	O
been	O	O
identified	O	O
as	B-Reg	O
the	O	O
Arg299His	B-Var	O
missense	I-Var	O
mutation	I-Var	O
in	O	O
the	O	O
Tyrosinase	B-Gene	O
gene	I-Gene	O
and	O	O
the	O	O
hooded	O	O
(	O	O
H	O	O
)	O	O
locus	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
the	O	O
∼460-kb	O	O
region	O	O
in	O	O
which	O	O
only	O	O
the	O	O
Kit	O	O
gene	O	O
exists	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
surveyed	O	O
172	O	O
laboratory	O	O
rat	O	O
strains	O	O
for	O	O
the	O	O
albino	O	O
mutation	O	O
and	O	O
the	O	O
hooded	O	O
(	O	O
h	O	O
)	O	O
mutation	O	O
that	O	O
we	O	O
identified	O	O
by	O	O
positional	O	O
cloning	O	O
approach	O	O
to	O	O
investigate	O	O
possible	O	O
genetic	O	O
roots	O	O
and	O	O
relationships	O	O
of	O	O
albino	O	O
and	O	O
hooded	O	O
rats	O	O
.	O	O
All	O	O
of	O	O
117	O	O
existing	O	O
laboratory	O	O
albino	O	O
rats	O	O
shared	O	O
the	O	O
same	O	O
albino	O	O
missense	O	O
mutation	O	O
,	O	O
indicating	O	O
they	O	O
had	O	O
only	O	O
one	O	O
single	O	O
ancestor	O	O
.	O	O
Genetic	O	O
fine	O	O
mapping	O	O
followed	O	O
by	O	O
de	O	O
novo	O	O
sequencing	O	O
of	O	O
BAC	O	O
inserts	O	O
covering	O	O
the	O	O
H	O	O
locus	O	O
revealed	O	O
that	O	O
an	O	O
endogenous	O	O
retrovirus	O	O
(	O	O
ERV	O	O
)	O	O
element	O	O
was	O	O
inserted	O	O
into	O	O
the	O	O
first	O	O
intron	O	O
of	O	O
the	O	O
Kit	O	O
gene	O	O
where	O	O
the	O	O
hooded	O	O
allele	O	O
maps	O	O
.	O	O
A	O	O
solitary	O	O
long	O	O
terminal	O	O
repeat	O	O
(	O	O
LTR	O	O
)	O	O
was	O	O
found	O	O
at	O	O
the	O	O
same	O	O
position	O	O
to	O	O
the	O	O
ERV	O	O
insertion	O	O
in	O	O
another	O	O
allele	O	O
of	O	O
the	O	O
H	O	O
locus	O	O
,	O	O
which	O	O
causes	O	O
the	O	O
so	O	O
called	O	O
Irish	O	O
(	O	O
h(i	O	O
)	O	O
)	O	O
phenotype	O	O
.	O	O
The	O	O
ERV	O	O
and	O	O
the	O	O
solitary	O	O
LTR	O	O
insertions	O	O
were	O	O
completely	O	O
associated	O	O
with	O	O
the	O	O
hooded	O	O
and	O	O
Irish	O	O
coat	O	O
patterns	O	O
,	O	O
respectively	O	O
,	O	O
across	O	O
all	O	O
colored	O	O
rat	O	O
strains	O	O
examined	O	O
.	O	O
Interestingly	O	O
,	O	O
all	O	O
117	O	O
albino	O	O
rat	O	O
strains	O	O
shared	O	O
the	O	O
ERV	O	O
insertion	O	O
without	O	O
any	O	O
exception	O	O
,	O	O
which	O	O
strongly	O	O
suggests	O	O
that	O	O
the	O	O
albino	O	O
mutation	O	O
had	O	O
originally	O	O
occurred	O	O
in	O	O
hooded	O	O
rats	O	O
.	O	O
Identification	O	O
of	O	O
a	O	O
novel	O	O
arylsulfatase	B-Gene	O
B	I-Gene	O
gene	I-Gene	O
mutation	B-Var	O
in	B-Reg	O
three	O	O
unrelated	O	O
Iranian	O	O
mucopolysaccharidosis	B-Disease	O
type	I-Disease	O
-	I-Disease	O
VI	I-Disease	O
patients	O	O
with	O	O
different	O	O
phenotype	O	O
severity	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Mucopolysaccharidosis	B-Disease	O
type	I-Disease	O
-	I-Disease	O
VI	I-Disease	O
(	O	O
MPS	O	O
-	O	O
VI	O	O
)	O	O
,	O	O
which	O	O
is	O	O
inherited	O	O
as	O	O
an	O	O
autosomal	O	O
recessive	O	O
trait	O	O
,	O	O
results	B-Reg	O
from	I-Reg	O
the	O	O
deficiency	B-NegReg	O
of	O	O
N	B-Enzyme	O
-	I-Enzyme	O
acetylgalactosamine	I-Enzyme	O
4-sulfatase	I-Enzyme	O
(	O	O
arylsulfatase	O	O
B	O	O
)	O	O
activity	B-MPA	O
and	O	O
the	O	O
lysosomal	B-MPA	O
accumulation	B-PosReg	O
of	O	O
dermatan	O	O
sulfate	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
ARSB	O	O
mutation	O	O
analysis	O	O
was	O	O
performed	O	O
on	O	O
three	O	O
unrelated	O	O
patients	O	O
who	O	O
were	O	O
originally	O	O
from	O	O
the	O	O
West	O	O
Azerbaijan	O	O
province	O	O
of	O	O
Iran	O	O
.	O	O
METHODS	O	O
:	O	O
After	O	O
PCR	O	O
and	O	O
direct	O	O
DNA	O	O
sequencing	O	O
,	O	O
DNA	O	O
extraction	O	O
was	O	O
performed	O	O
.	O	O
RESULTS	O	O
:	O	O
Sequencing	O	O
analysis	O	O
revealed	O	O
a	O	O
novel	O	O
homozygous	O	O
missense	O	O
mutation	O	O
in	O	O
the	O	O
ARSB	O	O
gene	O	O
at	O	O
c.1457A	O	O
<	O	O
G	O	O
[	O	O
p.	O	O
D486V	O	O
]	O	O
in	O	O
three	O	O
unrelated	O	O
Iranian	O	O
MPS	O	O
-	O	O
VI	O	O
patients	O	O
with	O	O
different	O	O
phenotype	O	O
severity	O	O
.	O	O
CONCLUSION	O	O
:	O	O
The	O	O
mutation	O	O
type	O	O
in	O	O
three	O	O
patients	O	O
was	O	O
the	O	O
same	O	O
;	O	O
probably	O	O
,	O	O
because	O	O
of	O	O
a	O	O
foundation	O	O
effect	O	O
on	O	O
their	O	O
population	O	O
.	O	O
C.428_451	O	O
dup(24bp	O	O
)	O	O
mutation	O	O
of	O	O
the	O	O
ARX	O	O
gene	O	O
detected	O	O
in	O	O
a	O	O
Turkish	O	O
family	O	O
.	O	O
ARX	B-Gene	O
mutations	B-Var	O
give	B-Reg	O
rise	I-Reg	O
to	I-Reg	O
both	O	O
syndromic	O	O
and	O	O
nonsyndromic	O	O
forms	O	O
of	O	O
mental	B-Disease	I-CPA
retardation	I-Disease	O
(	O	O
MR	O	O
)	O	O
.	O	O
We	O	O
investigated	O	O
the	O	O
most	O	O
common	O	O
ARX	O	O
mutations	O	O
,	O	O
c.428_451	O	O
dup(24bp	O	O
)	O	O
and	O	O
c.333ins	O	O
(	O	O
GCG)7	O	O
in	O	O
a	O	O
series	O	O
of	O	O
370	O	O
mentally	O	O
retarded	O	O
FMR1	O	O
(	O	O
CGG)n	O	O
expansion	O	O
mutation	O	O
negative	O	O
Turkish	O	O
patients	O	O
using	O	O
PCR	O	O
amplification	O	O
and	O	O
high	O	O
resolution	O	O
MetaPhor	O	O
agarose	O	O
gel	O	O
electrophoresis	O	O
.	O	O
Sequence	O	O
analysis	O	O
was	O	O
also	O	O
performed	O	O
for	O	O
confirmation	O	O
and	O	O
discrimination	O	O
of	O	O
the	O	O
mutations	O	O
.	O	O
One	O	O
patient	O	O
representing	O	O
non	O	O
-	O	O
syndromic	O	O
X	O	O
-	O	O
linked	O	O
MR	B-Disease	O
showed	B-Reg	O
an	O	O
abnormal	O	O
band	O	O
pattern	O	O
on	O	O
agarose	O	O
gel	O	O
and	O	O
sequence	O	O
analysis	O	O
of	O	O
exon	O	O
2	O	O
of	O	O
the	O	O
ARX	B-Gene	O
gene	O	O
revealed	O	O
that	O	O
the	O	O
patient	O	O
had	O	O
the	O	O
c.428_451	B-Var	O
dup(24bp	I-Var	O
)	I-Var	O
mutation	O	O
.	O	O
When	O	O
we	O	O
screened	O	O
the	O	O
family	O	O
members	O	O
,	O	O
we	O	O
found	O	O
that	O	O
his	O	O
sister	O	O
and	O	O
mother	O	O
were	O	O
also	O	O
carrier	O	O
for	O	O
the	O	O
same	O	O
mutation	O	O
.	O	O
The	O	O
proband	O	O
showed	O	O
mild	O	O
MR	O	O
and	O	O
subtle	O	O
clinical	O	O
findings	O	O
like	O	O
dysarthria	O	O
and	O	O
lack	O	O
of	O	O
fine	O	O
motor	O	O
functions	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
the	O	O
patients	O	O
with	O	O
weak	O	O
fine	O	O
motor	O	O
skills	O	O
and	O	O
positive	O	O
family	O	O
history	O	O
for	O	O
X	O	O
-	O	O
linked	O	O
MR	O	O
should	O	O
be	O	O
screened	O	O
for	O	O
the	O	O
most	O	O
common	O	O
ARX	O	O
gene	O	O
mutations	O	O
.	O	O
Analysis	O	O
of	O	O
a	O	O
Chinese	O	O
pedigree	O	O
with	O	O
Zellweger	B-Disease	O
syndrome	I-Disease	O
reveals	B-Reg	O
a	O	O
novel	O	O
PEX1	B-Gene	O
mutation	B-Var	O
by	O	O
next	O	O
-	O	O
generation	O	O
sequencing	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Autosomal	O	O
recessive	O	O
Zellweger	B-Disease	O
spectrum	I-Disease	O
disorder	I-Disease	O
(	O	O
ZSD	O	O
)	O	O
,	O	O
the	O	O
main	O	O
subgroup	O	O
of	O	O
the	O	O
peroxisome	O	O
biogenesis	O	O
disorders	O	O
(	O	O
PBDs	O	O
)	O	O
,	O	O
can	O	O
be	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
any	O	O
of	O	O
the	O	O
13	O	O
PEX	B-Gene	O
genes	O	O
.	O	O
Zellweger	O	O
syndrome	O	O
(	O	O
ZS	O	O
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
and	O	O
severe	O	O
phenotype	O	O
in	O	O
the	O	O
heterogeneous	O	O
ZSD	O	O
.	O	O
For	O	O
the	O	O
large	O	O
number	O	O
genes	O	O
involved	O	O
,	O	O
it	O	O
is	O	O
difficult	O	O
to	O	O
make	O	O
a	O	O
precise	O	O
genetic	O	O
diagnosis	O	O
by	O	O
traditional	O	O
methods	O	O
at	O	O
a	O	O
time	O	O
.	O	O
A	O	O
combination	O	O
of	O	O
enrichment	O	O
of	O	O
targeted	O	O
genes	O	O
and	O	O
next	O	O
-	O	O
generation	O	O
sequencing	O	O
(	O	O
NGS	O	O
)	O	O
would	O	O
result	O	O
in	O	O
both	O	O
high	O	O
efficiency	O	O
and	O	O
low	O	O
cost	O	O
for	O	O
targeted	O	O
sequencing	O	O
of	O	O
genes	O	O
of	O	O
interest	O	O
.	O	O
METHODS	O	O
:	O	O
To	O	O
identify	O	O
potential	O	O
mutations	O	O
in	O	O
a	O	O
Chinese	O	O
family	O	O
associated	O	O
with	O	O
Zellweger	O	O
syndrome	O	O
,	O	O
1930	O	O
kb	O	O
of	O	O
all	O	O
the	O	O
targeted	O	O
region	O	O
of	O	O
PEX	O	O
genes	O	O
were	O	O
captured	O	O
and	O	O
sequenced	O	O
using	O	O
NGS	O	O
.	O	O
We	O	O
also	O	O
performed	O	O
Sanger	O	O
sequencing	O	O
to	O	O
validate	O	O
the	O	O
NGS	O	O
results	O	O
.	O	O
RESULTS	O	O
:	O	O
Here	O	O
,	O	O
we	O	O
reported	O	O
a	O	O
Chinese	O	O
patient	O	O
diagnosed	O	O
as	O	O
a	O	O
severe	O	O
classic	O	O
type	O	O
of	O	O
PBD	O	O
based	O	O
on	O	O
a	O	O
clinical	O	O
investigation	O	O
.	O	O
We	O	O
then	O	O
performed	O	O
microarray	O	O
-	O	O
based	O	O
NGS	O	O
to	O	O
detect	O	O
the	O	O
variants	O	O
in	O	O
PEX	O	O
genes	O	O
of	O	O
the	O	O
whole	O	O
family	O	O
.	O	O
One	O	O
reported	O	O
heterozygosis	O	O
mutation	O	O
(	O	O
c.782_783delAA	O	O
)	O	O
was	O	O
identified	O	O
in	O	O
the	O	O
patient	O	O
's	O	O
father	O	O
and	O	O
one	O	O
novel	O	O
heterozygosis	O	O
missense	O	O
mutation	O	O
(	O	O
c.475G	O	O
>	O	O
C	O	O
)	O	O
was	O	O
found	O	O
in	O	O
the	O	O
patient	O	O
's	O	O
mother	O	O
,	O	O
the	O	O
patient	O	O
inherited	O	O
both	O	O
mutations	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
results	O	O
proved	O	O
that	O	O
the	O	O
application	O	O
of	O	O
target	O	O
sequence	O	O
capture	O	O
using	O	O
chip	O	O
and	O	O
high	O	O
-	O	O
throughput	O	O
NGS	O	O
is	O	O
a	O	O
valuable	O	O
tool	O	O
for	O	O
the	O	O
molecular	O	O
diagnosis	O	O
of	O	O
peroxisome	O	O
biogenesis	O	O
disorders	O	O
.	O	O
The	O	O
accuracy	O	O
,	O	O
high	O	O
-	O	O
throughput	O	O
and	O	O
speed	O	O
of	O	O
the	O	O
method	O	O
make	O	O
it	O	O
suitable	O	O
for	O	O
clinical	O	O
application	O	O
.	O	O
Aspartylglucosaminuria	B-Disease	O
:	I-Disease	O
unusual	O	O
neonatal	O	O
presentation	O	O
in	O	O
Qatari	O	O
twins	O	O
with	B-Reg	O
a	O	O
novel	O	O
aspartylglucosaminidase	B-Gene	O
gene	I-Gene	O
mutation	B-Var	O
and	O	O
3	O	O
new	O	O
cases	O	O
in	O	O
a	O	O
Turkish	O	O
family	O	O
.	O	O
Aspartylglucosaminuria	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
lysosomal	O	O
storage	O	O
disorder	O	O
leading	O	O
early	O	O
to	O	O
a	O	O
progressive	O	O
intellectual	O	O
disability	O	O
.	O	O
Monozygous	O	O
Qatari	O	O
twins	O	O
presented	O	O
with	O	O
an	O	O
unusual	O	O
perinatal	O	O
manifestation	O	O
characterized	O	O
by	O	O
severe	O	O
muscular	O	O
hypotonia	O	O
,	O	O
scarce	O	O
spontaneous	O	O
movements	O	O
,	O	O
multiple	O	O
contractures	O	O
,	O	O
and	O	O
respiratory	O	O
insufficiency	O	O
.	O	O
Biochemical	O	O
investigations	O	O
suggested	B-Reg	O
aspartylglucosaminuria	B-Disease	O
,	O	O
and	O	O
a	O	O
novel	O	O
homozygous	O	O
mutation	O	O
c.439T	B-Var	O
>	I-Var	I-Var
C	I-Var	O
(	O	O
p	O	O
.	O	O
S147P	O	O
)	O	O
was	O	O
found	O	O
in	O	O
the	O	O
aspartylglucosaminidase	B-Gene	O
gene	I-Gene	O
.	O	O
However	O	O
,	O	O
it	O	O
can	O	O
not	O	O
be	O	O
excluded	O	O
that	O	O
the	O	O
unusual	O	O
neonatal	O	O
presentation	O	O
is	O	O
due	O	O
to	O	O
an	O	O
additional	O	O
autosomal	O	O
recessive	O	O
disease	O	O
in	O	O
this	O	O
multiply	O	O
consanguineous	O	O
family	O	O
.	O	O
The	O	O
classical	O	O
aspartylglucosaminuria	O	O
phenotype	O	O
(	O	O
progressive	O	O
speech	O	O
delay	O	O
,	O	O
psychomotor	O	O
retardation	O	O
,	O	O
and	O	O
behavioral	O	O
abnormalities	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
3	O	O
Turkish	O	O
siblings	O	O
.	O	O
Although	O	O
aspartylglucosaminuria	O	O
was	O	O
suspected	O	O
early	O	O
,	O	O
the	O	O
definite	O	O
diagnosis	O	O
was	O	O
not	O	O
confirmed	O	O
until	O	O
the	O	O
age	O	O
of	O	O
18	O	O
years	O	O
.	O	O
A	O	O
novel	O	O
homozygous	O	O
mutation	O	O
c.346C	O	O
>	O	I-Var
T	O	O
(	O	O
p	O	O
.	O	O
R116W	O	O
)	O	O
was	O	O
found	O	O
.	O	O
These	O	O
5	O	O
cases	O	O
emphasize	O	O
that	O	O
aspartylglucosaminuria	O	O
is	O	O
panethnic	O	O
and	O	O
may	O	O
possibly	O	O
present	O	O
with	O	O
prenatal	O	O
manifestation	O	O
.	O	O
Screening	O	O
for	O	O
aspartylglucosaminuria	O	O
should	O	O
be	O	O
done	O	O
in	O	O
all	O	O
patients	O	O
with	O	O
unexplained	O	O
psychomotor	O	O
retardation	O	O
.	O	O
Mutations	O	O
of	O	O
the	O	O
thyroid	O	O
peroxidase	O	O
gene	O	O
in	O	O
Chinese	O	O
siblings	O	O
with	O	O
congenital	O	O
goitrous	O	O
hypothyroidism	O	O
.	O	O
OBJECTIVES	O	O
:	O	O
To	O	O
investigate	O	O
thyroid	O	O
peroxidase	O	O
gene	O	O
(	B-Gene	O
TPO	I-Gene	O
)	I-Gene	O
mutations	B-Var	O
in	B-Reg	O
a	O	O
Chinese	O	O
siblings	O	O
with	O	O
congenital	B-Disease	O
goitrous	I-Disease	O
hypothyroidism	I-Disease	O
(	O	O
CGH	O	O
)	O	O
.	O	O
SUBJECTS	O	O
AND	O	O
METHODS	O	O
:	O	O
The	O	O
proband	O	O
,	O	O
his	O	O
sister	O	O
,	O	O
and	O	O
their	O	O
parents	O	O
were	O	O
enrolled	O	O
.	O	O
All	O	O
subjects	O	O
underwent	O	O
clinical	O	O
examination	O	O
and	O	O
laboratory	O	O
tests	O	O
.	O	O
Mutation	O	O
screening	O	O
of	O	O
the	O	O
TPO	O	O
gene	O	O
was	O	O
performed	O	O
by	O	O
sequencing	O	O
fragments	O	O
amplified	O	O
from	O	O
extracted	O	O
genomic	O	O
DNA	O	O
.	O	O
RESULTS	O	O
:	O	O
The	O	O
siblings	O	O
were	O	O
diagnosed	O	O
as	O	O
CGH	O	O
with	O	O
neurodevelopmental	O	O
deficits	O	O
.	O	O
Two	O	O
compound	O	O
heterozygous	O	O
inactivating	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
the	O	O
two	O	O
patients	O	O
:	O	O
a	O	O
frameshift	O	O
mutation	O	O
between	O	O
positions	O	O
2268	O	O
and	O	O
2269	O	O
(	O	O
c.2268	O	O
-	O	O
2269	O	O
insT	O	O
)	O	O
and	O	O
a	O	O
missense	O	O
mutation	O	O
at	O	O
c.2089	O	O
G	O	O
>	O	O
A	O	O
(	O	O
p	O	O
.	O	O
G667S	O	O
)	O	O
of	O	O
the	O	O
TPO	O	O
gene	O	O
.	O	O
Their	O	O
parents	O	O
,	O	O
with	O	O
normal	O	O
thyroid	O	O
hormone	O	O
levels	O	O
,	O	O
were	O	O
heterozygous	O	O
for	O	O
mutations	O	O
c.2268	O	O
-	O	O
2269	O	O
insT	O	O
and	O	O
c.2089	O	O
G	O	O
>	O	O
A	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
polymorphisms	O	O
of	O	O
c.1207	O	O
G	O	O
>	O	I-Var
T	O	O
,	O	O
c.1283	O	O
G	O	O
>	O	I-Var
C	O	O
,	O	O
and	O	O
c.2088	O	O
C	O	O
>	O	I-Var
T	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
family	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
CGH	B-Disease	O
of	O	O
the	O	O
Chinese	O	O
siblings	O	O
was	O	O
due	B-Reg	O
to	I-Reg	O
the	O	O
TPO	B-Gene	O
gene	O	O
mutations	O	O
(	B-Var	O
c.2268	I-Var	O
-	I-Var	O
2269	I-Var	O
insT	I-Var	O
and	O	O
c.2089	B-Var	O
G	I-Var	O
>	I-Var	O
A	I-Var	O
)	I-Var	O
.	O	O
Nebulin	O	O
(	O	O
NEB	O	O
)	O	O
mutations	O	O
in	O	O
a	O	O
childhood	O	O
onset	O	O
distal	O	O
myopathy	O	O
with	O	O
rods	O	O
and	O	O
cores	O	O
uncovered	O	O
by	O	O
next	O	O
generation	O	O
sequencing	O	O
.	O	O
Recessive	O	O
nebulin	O	O
(	B-Gene	O
NEB	I-Gene	O
)	I-Gene	O
mutations	B-Var	O
are	O	O
a	O	O
common	O	O
cause	B-Reg	O
of	O	O
nemaline	B-Disease	O
myopathy	I-Disease	O
(	O	O
NM	O	O
)	O	O
,	O	O
typically	O	O
characterized	O	O
by	O	O
generalized	O	O
weakness	O	O
of	O	O
early	O	O
-	O	O
onset	O	O
and	O	O
nemaline	O	O
rods	O	O
on	O	O
muscle	O	O
biopsy	O	O
.	O	O
Exceptional	O	O
adult	O	O
cases	O	O
with	O	O
additional	O	O
cores	O	O
and	O	O
an	O	O
isolated	O	O
distal	O	O
weakness	O	O
have	O	O
been	O	O
reported	O	O
.	O	O
The	O	O
large	O	O
NEB	O	O
gene	O	O
with	O	O
183	O	O
exons	O	O
has	O	O
been	O	O
an	O	O
obstacle	O	O
for	O	O
the	O	O
genetic	O	O
work	O	O
-	O	O
up	O	O
.	O	O
Here	O	O
we	O	O
report	O	O
a	O	O
childhood	O	O
-	O	O
onset	O	O
case	O	O
with	O	O
distal	O	O
weakness	O	O
and	O	O
a	O	O
core	O	O
-	O	O
rod	O	O
myopathy	O	O
,	O	O
associated	O	O
with	O	O
recessive	O	O
NEB	O	O
mutations	O	O
identified	O	O
by	O	O
next	O	O
generation	O	O
sequencing	O	O
(	O	O
NGS	O	O
)	O	O
.	O	O
This	O	O
6-year	O	O
-	O	O
old	O	O
boy	O	O
presented	O	O
with	O	O
a	O	O
history	O	O
of	O	O
gross	O	O
-	O	O
motor	O	O
difficulties	O	O
following	O	O
a	O	O
normal	O	O
early	O	O
development	O	O
.	O	O
He	O	O
had	O	O
distal	O	O
leg	O	O
weakness	O	O
with	O	O
bilateral	O	O
foot	O	O
drop	O	O
,	O	O
as	O	O
well	O	O
as	O	O
axial	O	O
muscle	O	O
weakness	O	O
,	O	O
scoliosis	O	O
and	O	O
spinal	O	O
rigidity	O	O
;	O	O
additionally	O	O
he	O	O
required	O	O
nocturnal	O	O
respiratory	O	O
support	O	O
.	O	O
Muscle	O	O
magnetic	O	O
resonance	O	O
(	O	O
MR	O	O
)	O	O
imaging	O	O
showed	O	O
distal	O	O
involvement	O	O
in	O	O
the	O	O
medial	O	O
and	O	O
anterior	O	O
compartment	O	O
of	O	O
the	O	O
lower	O	O
leg	O	O
.	O	O
A	O	O
muscle	O	O
biopsy	O	O
featured	O	O
both	O	O
rods	O	O
and	O	O
cores	O	O
.	O	O
Initial	O	O
targeted	O	O
testing	O	O
identified	O	O
a	O	O
heterozygous	O	O
Nebulin	O	O
exon	O	O
55	O	O
deletion	O	O
.	O	O
Further	O	O
analysis	O	O
using	O	O
NGS	O	O
revealed	O	O
a	O	O
frameshifting	O	O
4	O	O
bp	O	O
duplication	O	O
,	O	O
c.24372_24375dup	O	O
(	O	O
P.Val8126fs	O	O
)	O	O
,	O	O
on	O	O
the	O	O
opposite	O	O
allele	O	O
.	O	O
This	O	O
case	O	O
illustrates	O	O
that	O	O
NEB	B-Gene	O
mutations	B-Var	B-Var
can	O	O
cause	B-Reg	O
childhood	O	B-MPA
onset	O	I-Disease
distal	O	I-CPA
NM	B-Disease	O
,	O	O
with	O	O
additional	O	O
cores	O	O
on	O	O
muscle	O	O
biopsy	O	O
and	O	O
proves	O	O
the	O	O
diagnostic	O	O
utility	O	O
of	O	O
NGS	O	O
for	O	O
myopathies	O	O
,	O	O
particularly	O	O
when	O	O
large	O	O
genes	O	O
are	O	O
implicated	O	O
.	O	O
EDM1	O	O
:	O	O
a	O	O
novel	O	O
point	B-Var	O
mutation	I-Var	O
in	O	O
cartilage	O	O
oligomeric	O	O
matrix	O	O
protein	O	O
gene	O	O
in	O	O
a	O	O
Chinese	O	O
family	O	O
with	B-Reg	O
multiple	B-Disease	O
epiphyseal	I-Disease	O
dysplasia	I-Disease	I-Disease
.	O	O
BACKGROUND	O	O
:	O	O
Multiple	B-Disease	O
epiphysis	I-Disease	O
dysplasia	I-Disease	O
(	O	O
MED	O	O
)	O	O
is	O	O
a	O	O
common	O	O
skeletal	O	O
dysplasia	O	O
with	O	O
a	O	O
significant	O	O
locus	O	O
heterogeneity	O	O
.	O	O
In	B-Reg	O
the	O	O
majority	O	O
of	O	O
clinically	O	O
defined	O	O
cases	O	O
,	O	O
mutations	B-Var	O
have	O	O
been	O	O
identified	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
cartilage	O	O
algometric	O	O
matrix	O	O
protein	O	O
(	B-Gene	O
COMP	I-Gene	O
)	I-Gene	O
.	O	O
METHODS	O	O
:	O	O
Five	O	O
patients	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O
Linkage	O	O
analysis	O	O
and	O	O
mutation	O	O
analysis	O	O
of	O	O
the	O	O
COMP	O	O
gene	O	O
were	O	O
conducted	O	O
in	O	O
the	O	O
patients	O	O
and	O	O
their	O	O
family	O	O
members	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
have	O	O
identified	O	O
a	O	O
novel	O	O
mutation	O	O
in	O	O
axon	O	O
14	O	O
of	O	O
COMP	O	O
gene	O	O
in	O	O
the	O	O
family	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
This	O	O
mutation	O	O
produced	O	O
a	O	O
severe	O	O
MED	O	O
phenotype	O	O
with	O	O
marked	O	O
short	O	O
stature	O	O
,	O	O
early	O	O
onset	O	O
osteoarthritis	O	O
,	O	O
and	O	O
remarkable	O	O
radiographic	O	O
changes	O	O
.	O	O
Our	O	O
results	O	O
extended	O	O
the	O	O
range	O	O
of	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
in	O	O
COMP	O	O
gene	O	O
and	O	O
contributed	O	O
more	O	O
information	O	O
about	O	O
relationship	O	O
between	O	O
mutations	O	O
and	O	O
phenotype	O	O
.	O	O
A	O	O
patient	O	O
with	O	O
limb	B-Disease	O
girdle	I-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
carries	B-Reg	O
a	O	O
TRIM32	B-Gene	O
deletion	B-Var	O
,	O	O
detected	O	O
by	O	O
a	O	O
novel	O	O
CGH	O	O
array	O	O
,	O	O
in	O	O
compound	O	O
heterozygosis	O	O
with	O	O
a	O	O
nonsense	O	O
mutation	O	O
.	O	O
Limb	B-Disease	O
girdle	I-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
2H	I-Disease	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
muscular	O	O
dystrophy	O	O
,	O	O
clinically	O	O
highly	O	O
variable	O	O
,	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
TRIM32	B-Gene	O
gene	O	O
.	O	O
Here	O	O
we	O	O
describe	O	O
a	O	O
35-years	O	O
-	O	O
old	O	O
who	O	O
experienced	O	O
progressive	O	O
muscle	O	O
weakness	O	O
.	O	O
The	O	O
muscle	O	O
biopsy	O	O
revealed	O	O
an	O	O
unspecific	O	O
pattern	O	O
of	O	O
atrophic	O	O
and	O	O
hypertrophic	O	O
fibers	O	O
;	O	O
the	O	O
immunohistochemistry	O	O
for	O	O
several	O	O
proteins	O	O
was	O	O
normal	O	O
.	O	O
Comparative	O	O
genomic	O	O
hybridization	O	O
(	O	O
CGH	O	O
)	O	O
analysis	O	O
showed	O	O
a	O	O
heterozygous	O	O
deletion	O	O
of	O	O
the	O	O
entire	O	O
TRIM32	O	O
gene	O	O
.	O	O
On	O	O
the	O	O
other	O	O
allele	O	O
we	O	O
identified	O	O
the	O	O
R316X	O	O
nonsense	O	O
mutation	O	O
.	O	O
The	O	O
genetic	O	O
diagnosis	O	O
of	O	O
LGMD2H	O	O
in	O	O
this	O	O
case	O	O
was	O	O
reached	O	O
by	O	O
using	O	O
a	O	O
novel	O	O
high	O	O
throughput	O	O
diagnostic	O	O
tool	O	O
.	O	O
Epigenetic	O	O
and	O	O
genetic	O	O
alterations	O	O
of	O	O
the	O	O
imprinting	O	O
disorder	O	O
Beckwith	O	O
-	O	O
Wiedemann	O	O
syndrome	O	O
and	O	O
related	O	O
disorders	O	O
.	O	O
Genomic	O	O
imprinting	O	O
is	O	O
an	O	O
epigenetic	O	O
phenomenon	O	O
that	O	O
leads	O	O
to	O	O
parent	O	O
-	O	O
specific	O	O
differential	O	O
expression	O	O
of	O	O
a	O	O
subset	O	O
of	O	O
genes	O	O
.	O	O
Most	O	O
imprinted	O	O
genes	O	O
form	O	O
clusters	O	O
,	O	O
or	O	O
imprinting	O	O
domains	O	O
,	O	O
and	O	O
are	O	O
regulated	O	O
by	O	O
imprinting	O	O
control	O	O
regions	O	O
.	O	O
As	O	O
imprinted	O	O
genes	O	O
have	O	O
an	O	O
important	O	O
role	O	O
in	O	O
growth	O	O
and	O	O
development	O	O
,	O	O
aberrant	O	O
expression	O	O
of	O	O
imprinted	O	O
genes	O	O
due	O	O
to	O	O
genetic	O	O
or	O	O
epigenetic	O	O
abnormalities	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
human	O	O
disorders	O	O
,	O	O
or	O	O
imprinting	O	O
disorders	O	O
.	O	O
Beckwith	B-Disease	O
-	I-Disease	O
Wiedemann	I-Disease	O
syndrome	I-Disease	O
(	O	O
BWS	O	O
)	O	O
is	O	O
a	O	O
representative	O	O
imprinting	O	O
disorder	O	O
characterized	O	O
by	O	O
macrosomia	O	O
,	O	O
macroglossia	O	O
and	O	O
abdominal	O	O
wall	O	O
defects	O	O
,	O	O
and	O	O
exhibits	O	O
a	O	O
predisposition	O	O
to	O	O
tumorigenesis	O	O
.	O	O
The	O	O
relevant	O	O
imprinted	O	O
chromosomal	O	O
region	O	O
in	O	O
BWS	O	O
is	O	O
11p15.5	O	O
,	O	O
which	O	O
consists	O	O
of	O	O
two	O	O
imprinting	O	O
domains	O	O
,	O	O
IGF2	O	O
/	O	O
H19	O	O
and	O	O
CDKN1C	O	O
/	O	O
KCNQ1OT1	O	O
.	O	O
BWS	O	O
has	O	O
five	O	O
known	O	O
causative	O	O
epigenetic	O	O
and	O	O
genetic	O	O
alterations	O	O
:	O	O
loss	O	O
of	O	O
methylation	O	O
(	O	O
LOM	O	O
)	O	O
at	O	O
KvDMR1	O	O
,	O	O
gain	O	O
of	O	O
methylation	O	O
(	O	O
GOM	O	O
)	O	O
at	O	O
H19DMR	O	O
,	O	O
paternal	O	O
uniparental	O	O
disomy	O	O
,	O	O
CDKN1C	O	O
mutations	O	O
and	O	O
chromosomal	O	O
rearrangements	O	O
.	O	O
Opposite	O	O
methylation	O	O
defects	O	O
,	O	O
GOM	O	O
and	O	O
LOM	O	O
,	O	O
at	O	O
H19DMR	O	O
are	O	O
known	O	O
to	O	O
cause	O	O
clinically	O	O
opposite	O	O
disorders	O	O
:	O	O
BWS	O	O
and	O	O
Silver	O	O
-	O	O
Russell	O	O
syndrome	O	O
,	O	O
respectively	O	O
.	O	O
Interestingly	O	O
,	O	O
a	O	O
recent	O	O
study	O	O
discovered	O	O
that	O	O
loss	B-NegReg	O
of	I-NegReg	O
function	I-NegReg	O
or	O	O
gain	B-PosReg	O
of	I-PosReg	O
function	I-PosReg	O
of	O	O
CDKN1C	B-Gene	O
also	O	O
causes	O	O
clinically	O	O
opposite	O	O
disorders	O	O
,	O	O
BWS	B-Disease	O
and	O	O
IMAGe	B-Disease	O
(	I-Disease	O
intrauterine	I-Disease	O
growth	I-Disease	O
restriction	I-Disease	O
,	O	O
metaphyseal	I-Disease	O
dysplasia	I-Disease	O
,	O	O
adrenal	I-Disease	O
hypoplasia	I-Disease	O
congenita	I-Disease	O
,	O	O
and	I-Disease	O
genital	I-Disease	O
anomalies	I-Disease	O
)	I-Disease	O
syndrome	I-Disease	O
,	O	O
respectively	O	O
.	O	O
Furthermore	O	O
,	O	O
several	O	O
clinical	O	O
studies	O	O
have	O	O
suggested	O	O
a	O	O
relationship	O	O
between	O	O
assisted	O	O
reproductive	O	O
technology	O	O
(	O	O
ART	O	O
)	O	O
and	O	O
the	O	O
risk	O	O
of	O	O
imprinting	O	O
disorders	O	O
,	O	O
along	O	O
with	O	O
the	O	O
existence	O	O
of	O	O
trans	O	O
-	O	O
acting	O	O
factors	O	O
that	O	O
regulate	O	O
multiple	O	O
imprinted	O	O
differentially	O	O
methylated	O	O
regions	O	O
.	O	O
In	O	O
this	O	O
review	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
latest	O	O
knowledge	O	O
surrounding	O	O
the	O	O
imprinting	O	O
mechanism	O	O
of	O	O
11p15.5	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
epigenetic	O	O
and	O	O
genetic	O	O
etiologies	O	O
of	O	O
BWS	O	O
,	O	O
associated	O	O
childhood	O	O
tumors	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
ART	O	O
and	O	O
multilocus	O	O
hypomethylation	O	O
disorders	O	O
.	O	O
Characterization	O	O
of	O	O
seizure	O	O
-	O	O
like	O	O
events	O	O
recorded	O	O
in	O	O
vivo	O	O
in	O	O
a	O	O
mouse	O	O
model	O	O
of	O	O
Rett	O	O
syndrome	O	O
.	O	O
Rett	B-Disease	B-Disease
syndrome	I-Disease	I-Disease
is	O	O
a	O	O
neurodevelopmental	O	O
disorder	O	O
caused	B-Reg	B-Reg
by	I-Reg	O
mutations	B-Var	B-Var
in	O	O
the	O	O
X	O	B-Gene
-	O	O
linked	O	I-Gene
gene	O	O
encoding	O	O
methyl	O	O
-	O	O
CpG	O	I-Protein
-	O	I-Protein
binding	O	I-Protein
protein	O	I-Protein
2	O	O
(	B-Gene	O
MECP2	I-Gene	O
)	I-Gene	O
.	O	O
Spontaneous	O	O
recurrent	O	O
discharge	O	O
episodes	O	O
are	O	O
displayed	O	O
in	O	O
Rett	O	O
-	O	O
related	O	O
seizures	O	O
as	O	O
in	O	O
other	O	O
types	O	O
of	O	O
epilepsies	O	O
.	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
paper	O	O
is	O	O
to	O	O
investigate	O	O
the	O	O
seizure	O	O
-	O	O
like	O	O
event	O	O
(	O	O
SLE	O	O
)	O	O
and	O	O
inter	O	O
-	O	O
SLE	O	O
states	O	O
in	O	O
a	O	O
female	O	O
MeCP2-deficient	O	O
mouse	O	O
model	O	O
of	O	O
Rett	O	O
syndrome	O	O
and	O	O
compare	O	O
them	O	O
to	O	O
those	O	O
found	O	O
in	O	O
other	O	O
spontaneous	O	O
recurrent	O	O
epilepsy	O	O
models	O	O
.	O	O
The	O	O
study	O	O
was	O	O
performed	O	O
on	O	O
a	O	O
small	O	O
population	O	O
of	O	O
female	O	O
MeCP2-deficient	O	O
mice	O	O
using	O	O
telemetric	O	O
local	O	O
field	O	O
potential	O	O
(	O	O
LFP	O	O
)	O	O
recordings	O	O
over	O	O
a	O	O
24	O	O
h	O	O
period	O	O
.	O	O
Durations	O	O
of	O	O
SLEs	O	O
and	O	O
inter	O	O
-	O	O
SLEs	O	O
were	O	O
extracted	O	O
using	O	O
a	O	O
rule	O	O
-	O	O
based	O	O
automated	O	O
SLE	O	O
detection	O	O
system	O	O
for	O	O
both	O	O
daytime	O	O
and	O	O
nighttime	O	O
,	O	O
as	O	O
well	O	O
as	O	O
high	O	O
and	O	O
low	O	O
power	O	O
levels	O	O
of	O	O
the	O	O
delta	O	O
frequency	O	O
range	O	O
(	O	O
0.5	O	O
-	O	O
4	O	O
Hz	O	O
)	O	O
of	O	O
the	O	O
recorded	O	O
LFPs	O	O
.	O	O
The	O	O
results	O	O
suggest	O	O
SLE	O	O
occurrences	O	O
are	O	O
not	O	O
influenced	O	O
by	O	O
circadian	O	O
rhythms	O	O
,	O	O
but	O	O
had	O	O
a	O	O
significantly	O	O
greater	O	O
association	O	O
with	O	O
delta	O	O
power	O	O
.	O	O
Investigating	O	O
inter	O	O
-	O	O
SLE	O	O
and	O	O
SLE	O	O
states	O	O
by	O	O
fitting	O	O
duration	O	O
histograms	O	O
to	O	O
the	O	O
gamma	O	O
distribution	O	O
showed	O	O
that	O	O
SLE	O	O
initiation	O	O
and	O	O
termination	O	O
were	O	O
associated	O	O
with	O	O
random	O	O
and	O	O
deterministic	O	O
mechanisms	O	O
,	O	O
respectively	O	O
.	O	O
These	O	O
findings	O	O
when	O	O
compared	O	O
to	O	O
reported	O	O
studies	O	O
on	O	O
epilepsy	O	O
suggest	O	O
that	O	O
Rett	O	O
-	O	O
related	O	O
seizures	O	O
share	O	O
many	O	O
similarities	O	O
with	O	O
absence	O	O
epilepsy	O	O
.	O	O
Familial	B-Disease	O
lipoprotein	I-Disease	O
lipase	I-Disease	O
deficiency	I-Disease	O
:	I-Disease	O
a	O	O
case	O	O
of	O	O
compound	O	O
heterozygosity	O	O
of	O	O
a	O	O
novel	O	O
duplication	O	O
(	O	O
R44Kfs*4	O	O
)	O	O
and	O	O
a	O	O
common	O	O
mutation	O	O
(	B-Var	O
N291S	I-Var	O
)	I-Var	O
in	B-Reg	O
the	O	O
lipoprotein	B-Gene	O
lipase	I-Gene	O
gene	I-Gene	O
.	O	O
Familial	B-Disease	O
lipoprotein	I-Disease	O
lipase	I-Disease	O
(	I-Disease	O
LPL	I-Disease	O
)	I-Disease	O
deficiency	I-Disease	O
(	O	O
FLLD	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
genetic	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
homozygous	O	O
or	O	O
compound	O	O
heterozygous	O	O
mutations	B-Var	O
in	O	O
the	O	O
LPL	B-Gene	O
gene	O	O
.	O	O
FLLD	O	O
individuals	O	O
usually	O	O
express	O	O
an	O	O
impaired	O	O
or	O	O
non	O	O
-	O	O
functional	O	O
LPL	O	O
enzyme	O	O
with	O	O
low	O	O
or	O	O
absent	O	O
triglyceride	O	O
(	O	O
TG	O	O
)	O	O
hydrolysis	O	O
activity	O	O
causing	O	O
severe	O	O
hypertriglyceridaemia	O	O
.	O	O
Here	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
FLLD	O	O
in	O	O
a	O	O
29-year	O	O
-	O	O
old	O	O
man	O	O
,	O	O
who	O	O
initially	O	O
presented	O	O
with	O	O
eruptive	O	O
cutaneous	O	O
xanthomata	O	O
,	O	O
elevated	O	O
plasma	O	O
TG	O	O
concentration	O	O
but	O	O
no	O	O
other	O	O
co	O	O
-	O	O
morbidities	O	O
.	O	O
Subsequent	O	O
genetic	O	O
testing	O	O
of	O	O
the	O	O
patient	O	O
revealed	O	O
compound	O	O
heterozygosity	O	O
of	O	O
a	O	O
novel	O	O
duplication	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
R44Kfs*4	I-Var	O
)	I-Var	O
leading	B-Reg	O
to	I-Reg	O
a	O	O
premature	B-MPA	O
stop	I-MPA	O
codon	O	O
in	O	O
exon	O	O
2	O	O
and	O	O
a	O	O
known	O	O
mutation	O	O
(	B-Var	O
N291S	I-Var	O
)	I-Var	O
in	O	O
exon	O	O
5	O	O
of	O	O
the	O	O
LPL	B-Gene	O
gene	O	O
.	O	O
Further	O	O
biochemical	O	O
analysis	O	O
of	O	O
the	O	O
patient	O	O
's	O	O
postheparin	O	O
plasma	O	O
confirmed	O	O
a	O	O
reduction	B-NegReg	O
of	O	O
total	O	O
lipase	B-Enzyme	O
activity	B-MPA	O
compared	O	O
with	O	O
his	O	O
heterozygous	O	O
father	O	O
carrying	O	O
the	O	O
common	O	O
N291S	B-Var	O
mutation	O	O
and	O	O
to	O	O
a	O	O
healthy	O	O
control	O	O
.	O	O
Also	O	O
the	O	O
patient	O	O
showed	O	O
increased	B-PosReg	O
(	O	O
1.85-fold	O	O
)	O	O
activity	B-MPA	O
of	O	O
hepatic	B-Enzyme	O
lipase	I-Enzyme	O
(	O	O
HL	O	O
)	O	O
,	O	O
indicating	O	O
a	O	O
functional	O	O
link	O	O
between	O	O
HL	O	O
and	O	O
LPL	O	O
.	O	O
In	O	O
summary	O	O
,	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
FLLD	B-Disease	O
caused	B-Reg	O
by	I-Reg	O
compound	O	O
heterozygosity	O	O
of	O	O
a	O	O
new	O	O
duplication	B-Var	O
and	O	O
a	O	O
common	O	O
mutation	B-Var	O
in	O	O
the	O	O
LPL	B-Gene	O
gene	O	O
,	O	O
resulting	O	O
in	O	O
residual	B-NegReg	O
LPL	B-Enzyme	O
activity	B-MPA	O
.	O	O
With	O	O
such	O	O
mutations	O	O
,	O	O
individuals	O	O
may	O	O
not	O	O
receive	O	O
a	O	O
diagnosis	O	O
before	O	O
classical	O	O
FLLD	O	O
symptoms	O	O
appear	O	O
later	O	O
in	O	O
adulthood	O	O
.	O	O
Nevertheless	O	O
,	O	O
early	O	O
diagnosis	O	O
and	O	O
lipid	O	O
-	O	O
lowering	O	O
treatment	O	O
may	O	O
favour	O	O
a	O	O
reduced	O	O
risk	O	O
of	O	O
premature	O	O
cardiovascular	O	O
disease	O	O
or	O	O
acute	O	O
pancreatitis	O	O
in	O	O
such	O	O
individuals	O	O
.	O	O
Microarray	O	O
analysis	O	O
of	O	O
unbalanced	O	O
translocation	O	O
in	O	O
Wolf	O	O
-	O	O
Hirschhorn	O	O
syndrome	O	O
.	O	O
Wolf	B-Disease	O
-	I-Disease	O
Hirschhorn	I-Disease	O
syndrome	I-Disease	O
(	O	O
WHS	O	O
)	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
deletions	B-Var	O
involving	O	O
chromosome	O	O
region	O	O
4p16.3	B-Gene	O
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
growth	O	O
delay	O	O
,	O	O
mild	O	O
-	O	O
to	O	O
-	O	O
severe	O	O
mental	O	O
retardation	O	O
,	O	O
hypotonia	O	O
,	O	O
facial	O	O
dysmorphisms	O	O
and	O	O
shows	O	O
extensive	O	O
phenotypic	O	O
variability	O	O
include	O	O
feeding	O	O
difficulties	O	O
,	O	O
epilepsy	O	O
and	O	O
congenital	O	O
anomalies	O	O
.	O	O
Variation	O	O
in	O	O
the	O	O
size	O	O
of	O	O
the	O	O
deletion	O	O
involving	O	O
chromosome	O	O
region	O	O
4p16.3	O	O
may	O	O
explain	O	O
the	O	O
clinical	O	O
variation	O	O
.	O	O
However	O	O
,	O	O
previous	O	O
studies	O	O
indicate	O	O
that	O	O
duplication	O	O
for	O	O
another	O	O
chromosome	O	O
region	O	O
due	O	O
to	O	O
an	O	O
unbalanced	O	O
translocation	O	O
elucidate	O	O
approximately	O	O
40	O	O
-	O	O
45	O	O
%	O	O
WHS	O	O
patients	O	O
.	O	O
Therefore	O	O
,	O	O
we	O	O
used	O	O
whole	O	O
genomic	O	O
cytogenetics	O	O
array	O	O
to	O	O
analyze	O	O
the	O	O
entire	O	O
genome	O	O
at	O	O
a	O	O
significantly	O	O
higher	O	O
resolution	O	O
over	O	O
conventional	O	O
cytogenetics	O	O
to	O	O
characterize	O	O
the	O	O
exact	O	O
subtelomeric	O	O
aberration	O	O
region	O	O
of	O	O
one	O	O
patient	O	O
with	O	O
developmental	O	O
delay	O	O
and	O	O
several	O	O
facial	O	O
characteristics	O	O
reminiscent	O	O
Wolf	O	O
-	O	O
Hirschhorn	O	O
syndrome	O	O
.	O	O
Here	O	O
we	O	O
report	O	O
that	O	O
our	O	O
patient	O	O
had	O	O
3.7	O	O
Mb	O	O
deletion	O	O
at	O	O
the	O	O
4p16.2	O	O
and	O	O
6.8	O	O
Mb	O	O
duplication	O	O
at	O	O
8p23.1	O	O
resulted	O	O
from	O	O
the	O	O
unbalanced	O	O
translocations	O	O
der(4)t(4;8)(p16.2;p23.1	O	O
)	O	O
.	O	O
We	O	O
confirmed	O	O
that	O	O
our	O	O
patient	O	O
with	O	O
monosomy	O	O
4p16.2	O	O
which	O	O
is	O	O
consistent	O	O
with	O	O
Wolf	O	O
-	O	O
Hirschhorn	O	O
syndrome	O	O
and	O	O
trisomy	O	O
8p23.1	O	O
.	O	O
The	O	O
combination	O	O
of	O	O
the	O	O
4p	O	O
deletion	O	O
with	O	O
8p	O	O
partial	O	O
trisomy	O	O
explains	O	O
the	O	O
complex	O	O
phenotype	O	O
presented	O	O
by	O	O
our	O	O
patient	O	O
.	O	O
Novel	O	O
ALPL	O	O
genetic	O	O
alteration	O	O
associated	O	O
with	O	O
an	O	O
odontohypophosphatasia	O	O
phenotype	O	O
.	O	O
Hypophosphatasia	B-Disease	O
(	O	O
HPP	O	O
)	O	O
is	O	O
an	O	O
inherited	O	O
disorder	O	O
of	O	O
mineral	O	O
metabolism	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
ALPL	B-Gene	O
,	O	O
encoding	O	O
tissue	O	O
non	O	O
-	O	O
specific	O	O
alkaline	O	O
phosphatase	O	O
(	O	O
TNAP	O	O
)	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
report	O	O
the	O	O
molecular	O	O
findings	O	O
from	O	O
monozygotic	O	O
twins	O	O
,	O	O
clinically	O	O
diagnosed	O	O
with	O	O
tooth	O	O
-	O	O
specific	O	O
odontohypophosphatasia	O	O
(	O	O
odonto	O	O
-	O	O
HPP	O	O
)	O	O
.	O	O
Sequencing	O	O
of	O	O
ALPL	O	O
identified	O	O
two	O	O
genetic	O	O
alterations	O	O
in	O	O
the	O	O
probands	O	O
,	O	O
including	O	O
a	O	O
heterozygous	O	O
missense	O	O
mutation	O	O
c.454C	B-Var	O
>	I-Var	I-Var
T	I-Var	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
change	O	O
of	O	O
arginine	O	O
152	O	O
to	O	O
cysteine	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
R152C	I-Var	O
)	I-Var	O
,	O	O
and	O	O
a	O	O
novel	O	O
heterozygous	O	O
gene	O	O
deletion	O	O
c.1318_1320delAAC	B-Var	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
the	O	O
loss	O	O
of	O	O
an	O	O
asparagine	O	O
residue	O	O
at	O	O
codon	O	O
440	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
N440del	I-Var	O
)	I-Var	O
.	O	O
Clinical	O	O
identification	O	O
of	O	O
low	O	O
serum	O	O
TNAP	O	O
activity	O	O
,	O	O
dental	O	O
abnormalities	O	O
,	O	O
and	O	O
pedigree	O	O
data	O	O
strongly	O	O
suggests	O	O
a	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
between	O	O
p	O	O
.	O	O
N440del	O	O
and	O	O
odonto	O	O
-	O	O
HPP	O	O
in	O	O
this	O	O
family	O	O
.	O	O
Computational	O	O
analysis	O	O
of	O	O
the	O	O
p	B-Var	O
.	I-Var	O
N440del	I-Var	O
protein	O	O
structure	O	O
revealed	O	O
an	O	O
alteration	B-Reg	O
in	O	O
the	O	O
tertiary	B-MPA	O
structure	I-MPA	O
affecting	B-Reg	O
the	O	O
collagen	B-Interaction	O
-	I-Interaction	O
binding	I-Interaction	O
site	I-Interaction	O
(	O	O
loop	O	O
422	O	O
-	O	O
452	O	O
)	O	O
,	O	O
which	O	O
could	O	O
potentially	O	O
impair	B-NegReg	O
the	O	O
mineralization	B-MPA	O
process	I-MPA	O
.	O	O
Nevertheless	O	O
,	O	O
the	O	O
probands	O	O
(	O	O
compound	O	O
heterozygous	O	O
:	O	O
p.[N440del];[R152C	O	O
]	O	O
)	O	O
feature	O	O
early	O	O
-	O	O
onset	O	O
and	O	O
severe	O	O
odonto	O	O
-	O	O
HPP	O	O
phenotype	O	O
,	O	O
whereas	O	O
the	O	O
father	O	O
(	O	O
p.[N440del];[=	O	O
]	O	O
)	O	O
has	O	O
only	O	O
moderate	O	O
symptoms	O	O
,	O	O
suggesting	O	O
p	O	O
.	O	O
R152C	O	O
may	O	O
contribute	O	O
or	O	O
predispose	O	O
to	O	O
a	O	O
more	O	O
severe	O	O
dental	O	O
phenotype	O	O
in	O	O
combination	O	O
with	O	O
the	O	O
deletion	O	O
.	O	O
These	O	O
results	O	O
assist	O	O
in	O	O
defining	O	O
the	O	O
genotype	O	O
-	O	O
phenotype	O	O
associations	O	O
for	O	O
odonto	O	O
-	O	O
HPP	O	O
,	O	O
and	O	O
further	O	O
identify	O	O
the	O	O
collagen	O	O
-	O	O
binding	O	O
site	O	O
as	O	O
a	O	O
region	O	O
of	O	O
potential	O	O
structural	O	O
importance	O	O
for	O	O
TNAP	O	O
function	O	O
in	O	O
the	O	O
biomineralization	O	O
.	O	O
Analysis	O	O
of	O	O
STK11	O	O
gene	O	O
variant	O	O
in	O	O
five	O	O
Chinese	O	O
patients	O	O
with	O	O
Peutz	O	O
-	O	O
Jeghers	O	O
syndrome	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Peutz	B-Disease	O
-	I-Disease	O
Jeghers	I-Disease	O
syndrome	I-Disease	O
(	O	O
PJS	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
dominant	O	O
inherited	O	O
disorder	O	O
characterized	O	O
by	O	O
gastrointestinal	O	O
hamartomatous	O	O
polyps	O	O
and	O	O
mucocutaneous	O	O
pigmentation	O	O
.	O	O
Germline	O	O
mutation	B-Var	O
of	O	O
a	O	O
serine	O	O
/	O	O
threonine	O	O
kinase	O	O
11(STK11	B-Gene	O
)	I-Gene	O
gene	O	O
has	O	O
been	O	O
identified	O	O
as	O	O
a	O	O
cause	B-Reg	O
of	O	O
PJS	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
five	O	O
Chinese	O	O
PJS	O	O
patients	O	O
.	O	O
METHODS	O	O
:	O	O
Blood	O	O
samples	O	O
were	O	O
collected	O	O
from	O	O
five	O	O
unrelated	O	O
Chinese	O	O
PJS	O	O
patients	O	O
and	O	O
their	O	O
parents	O	O
.	O	O
The	O	O
entire	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
STK11	O	O
gene	O	O
was	O	O
amplified	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
and	O	O
analyzed	O	O
by	O	O
direct	O	O
sequencing	O	O
.	O	O
RESULTS	O	O
:	O	O
Three	O	O
different	O	O
frameshift	O	O
mutations	O	O
(	O	O
c.519insTGTG	O	O
,	O	O
c.792_793insT	O	O
,	O	O
and	O	O
c.334_335insC	O	O
)	O	O
,	O	O
all	O	O
of	O	O
which	O	O
would	O	O
cause	O	O
truncation	O	O
of	O	O
the	O	O
gene	O	O
product	O	O
,	O	O
were	O	O
found	O	O
in	O	O
three	O	O
patients	O	O
.	O	O
One	O	O
missense	O	O
mutation	O	O
(	O	O
p	O	O
.	O	O
Ser307Thr	O	O
)	O	O
and	O	O
one	O	O
3bp	O	O
deletion	O	O
mutation	O	O
(	O	O
c.228	O	O
-	O	O
230del	O	O
CGT	O	O
)	O	O
were	O	O
identified	O	O
in	O	O
the	O	O
remaining	O	O
two	O	O
patients	O	O
.	O	O
All	O	O
of	O	O
the	O	O
five	O	O
investigated	O	O
patients	O	O
carried	O	O
de	O	O
novo	O	O
mutations	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
results	O	O
support	O	O
that	O	O
mutation	B-Var	O
of	O	O
the	O	O
LKB1	B-Gene	O
gene	O	O
is	O	O
a	O	O
cause	B-Reg	O
of	O	O
PJS	B-Disease	O
,	O	O
and	O	O
expand	O	O
the	O	O
spectrum	O	O
of	O	O
the	O	O
STK11	O	O
gene	O	O
mutations	O	O
.	O	O
Recurrent	O	O
de	O	O
novo	O	O
c.316G	O	O
>	O	O
A	O	O
mutation	O	O
in	O	O
NIPA1	O	O
hotspot	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
NIPA1	B-Gene	O
cause	B-Reg	O
autosomal	O	O
dominant	O	O
form	O	O
of	O	O
hereditary	B-Disease	O
spastic	I-Disease	O
paraplegia	I-Disease	O
.	O	O
Allelic	O	O
heterogeneity	O	O
of	O	O
known	O	O
NIPA1	B-Gene	O
mutations	O	O
is	O	O
quite	O	O
limited	O	O
and	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
is	O	O
c.316G	B-Var	O
>	I-Var	O
A	I-Var	O
resulting	B-Reg	O
in	I-Reg	O
p	B-Protein	O
.	I-Protein	O
G106R	I-Protein	O
protein	O	O
change	B-MPA	O
.	O	O
Here	O	O
we	O	O
report	O	O
the	O	O
first	O	O
direct	O	O
evidence	O	O
of	O	O
de	O	O
novo	O	O
c.316G	O	O
>	O	O
A	O	O
mutation	O	O
in	O	O
the	O	O
same	O	O
hotspot	O	O
of	O	O
the	O	O
gene	O	O
in	O	O
two	O	O
unrelated	O	O
patients	O	O
who	O	O
had	O	O
otherwise	O	O
a	O	O
prototypical	O	O
NIPA1-associated	O	O
phenotype	O	O
with	O	O
a	O	O
severe	O	O
form	O	O
of	O	O
uncomplicated	O	O
spastic	O	O
paraplegia	O	O
.	O	O
De	O	O
novo	O	O
nature	O	O
of	O	O
these	O	O
mutations	O	O
was	O	O
confirmed	O	O
by	O	O
sequencing	O	O
both	O	O
sets	O	O
of	O	O
clinically	O	O
unaffected	O	O
parents	O	O
and	O	O
confirmation	O	O
of	O	O
paternity	O	O
.	O	O
We	O	O
also	O	O
discuss	O	O
likely	O	O
molecular	O	O
mechanisms	O	O
accounting	O	O
for	O	O
recurrent	O	O
mutations	O	O
in	O	O
this	O	O
segment	O	O
of	O	O
the	O	O
gene	O	O
.	O	O
Apparently	O	O
sporadic	O	O
patients	O	O
without	O	O
a	O	O
positive	O	O
family	O	O
history	O	O
of	O	O
hereditary	O	O
spastic	O	O
paraplegia	O	O
need	O	O
to	O	O
be	O	O
also	O	O
evaluated	O	O
for	O	O
possible	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
in	O	O
genes	O	O
that	O	O
are	O	O
inherited	O	O
in	O	O
an	O	O
autosomal	O	O
dominant	O	O
fashion	O	O
.	O	O
Late	O	O
adult	O	O
-	O	O
onset	O	O
of	O	O
X	O	O
-	O	O
linked	O	O
myopathy	O	O
with	O	O
excessive	O	O
autophagy	O	O
.	O	O
INTRODUCTION	O	O
:	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
myopathy	I-Disease	O
with	I-Disease	O
excessive	I-Disease	O
autophagy	I-Disease	O
(	O	O
XMEA	O	O
)	O	O
is	O	O
characterized	O	O
by	O	O
autophagic	O	O
vacuoles	O	O
with	O	O
sarcolemmal	O	O
features	O	O
.	O	O
Mutations	B-Var	O
in	O	O
VMA21	B-Gene	O
result	O	O
in	O	O
insufficient	B-NegReg	O
lysosome	B-MPA	O
acidification	I-MPA	O
,	O	O
causing	B-Reg	O
progressive	B-CPA	O
proximal	I-CPA	O
weakness	I-CPA	O
with	O	O
onset	O	O
before	O	O
age	O	O
20	O	O
years	O	O
and	O	O
loss	O	O
of	O	O
ambulation	O	O
by	O	O
middle	O	O
age	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
onset	O	O
of	O	O
slowly	O	O
progressive	O	O
proximal	O	O
weakness	O	O
of	O	O
the	O	O
lower	O	O
limbs	O	O
after	O	O
age	O	O
50	O	O
,	O	O
who	O	O
maintains	O	O
ambulation	O	O
with	O	O
the	O	O
assistance	O	O
of	O	O
a	O	O
cane	O	O
at	O	O
age	O	O
71	O	O
.	O	O
RESULTS	O	O
:	O	O
Muscle	O	O
biopsy	O	O
at	O	O
age	O	O
66	O	O
showed	O	O
complex	O	O
muscle	O	O
fiber	O	O
splitting	O	O
,	O	O
internalized	O	O
capillaries	O	O
,	O	O
and	O	O
vacuolar	O	O
changes	O	O
characteristic	O	O
of	O	O
autophagic	O	O
vacuolar	O	O
myopathy	O	O
.	O	O
Vacuoles	O	O
stained	O	O
positive	O	O
for	O	O
sarcolemmal	O	O
proteins	O	O
,	O	O
LAMP2	O	O
,	O	O
and	O	O
complement	O	O
C5b-9	O	O
.	O	O
Ultrastructural	O	O
evaluation	O	O
further	O	O
revealed	O	O
basal	O	O
lamina	O	O
reduplication	O	O
and	O	O
extensive	O	O
autophagosome	O	O
extrusion	O	O
.	O	O
Sanger	O	O
sequencing	O	O
identified	O	O
a	O	O
known	O	O
pathologic	O	O
splice	O	O
site	O	O
mutation	O	O
in	O	O
VMA21	O	O
(	O	O
c.164	O	O
-	O	O
7T	O	O
>	O	O
G	O	O
)	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
This	O	O
case	O	O
expands	O	O
the	O	O
clinical	O	O
phenotype	O	O
of	O	O
XMEA	O	O
and	O	O
suggests	O	O
VMA21	O	O
sequencing	O	O
be	O	O
considered	O	O
in	O	O
evaluating	O	O
men	O	O
with	O	O
LAMP2-positive	O	O
autophagic	O	O
vacuolar	O	O
myopathy	O	O
.	O	O
Novel	O	O
homozygous	O	O
PANK2	B-Gene	O
mutation	B-Var	O
causing	B-Reg	O
atypical	O	O
pantothenate	B-Disease	O
kinase	I-Disease	O
-	I-Disease	O
associated	I-Disease	O
neurodegeneration	I-Disease	O
(	O	O
PKAN	O	O
)	O	O
in	O	O
a	O	O
Cypriot	O	O
family	O	O
.	O	O
Pantothenate	B-Disease	O
kinase	I-Disease	O
-	I-Disease	O
associated	I-Disease	O
neurodegeneration	I-Disease	O
(	O	O
PKAN	O	O
)	O	O
is	O	O
the	O	O
commonest	O	O
,	O	O
recessively	O	O
inherited	O	O
form	O	O
of	O	O
neurodegeneration	O	O
with	O	O
brain	O	O
iron	O	O
accumulation	O	O
(	O	O
NBIA	O	O
)	O	O
resulting	B-Reg	O
from	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
pantothenate	O	O
kinase	O	O
2	O	O
(	B-Gene	O
PANK2	I-Gene	O
)	I-Gene	O
gene	O	O
on	O	O
chromosome	O	O
20	O	O
.	O	O
PKAN	O	O
is	O	O
usually	O	O
rapidly	O	O
progressive	O	O
,	O	O
presenting	O	O
in	O	O
the	O	O
vast	O	O
majority	O	O
in	O	O
the	O	O
first	O	O
decade	O	O
of	O	O
life	O	O
(	O	O
classic	O	O
form	O	O
)	O	O
.	O	O
A	O	O
rarer	O	O
,	O	O
later	O	O
onset	O	O
and	O	O
slowly	O	O
progressive	O	O
(	O	O
atypical	O	O
)	O	O
PKAN	O	O
form	O	O
also	O	O
exists	O	O
.	O	O
We	O	O
present	O	O
two	O	O
siblings	O	O
of	O	O
Cypriot	O	O
descent	O	O
,	O	O
a	O	O
27-year	O	O
-	O	O
old	O	O
man	O	O
and	O	O
his	O	O
clinically	O	O
asymptomatic	O	O
younger	O	O
sister	O	O
,	O	O
both	O	O
of	O	O
whom	O	O
were	O	O
found	O	O
to	O	O
be	O	O
homozygous	O	O
for	O	O
a	O	O
novel	O	O
c.695A	O	O
>	O	O
G	O	O
(	O	O
p	O	O
.	O	O
Asp232Gly	O	O
)	O	O
missense	O	O
mutation	O	O
in	O	O
exon	O	O
2	O	O
of	O	O
the	O	O
PANK2	O	O
gene	O	O
.	O	O
The	O	O
index	O	O
patient	O	O
presented	O	O
with	O	O
a	O	O
5-year	O	O
history	O	O
of	O	O
slowly	O	O
progressive	O	O
gait	O	O
disturbance	O	O
,	O	O
dysarthria	O	O
,	O	O
mild	O	O
axial	O	O
rigidity	O	O
and	O	O
bradykinesia	O	O
.	O	O
His	O	O
brain	O	O
MRI	O	O
scan	O	O
revealed	O	O
the	O	O
characteristic	O	O
"	O	O
eye	O	O
-	O	O
of	O	O
-	O	O
the	O	O
-	O	O
tiger	O	O
"	O	O
sign	O	O
.	O	O
Atypical	O	O
genetically	O	O
confirmed	O	O
PKAN	O	O
cases	O	O
are	O	O
sparsely	O	O
reported	O	O
and	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
the	O	O
differential	O	O
diagnosis	O	O
of	O	O
patients	O	O
presenting	O	O
with	O	O
a	O	O
progressive	O	O
extrapyramidal	O	O
syndrome	O	O
particularly	O	O
if	O	O
the	O	O
radiographic	O	O
findings	O	O
are	O	O
suggestive	O	O
of	O	O
iron	O	O
accumulation	O	O
.	O	O
Effective	O	O
treatment	O	O
strategies	O	O
for	O	O
PKAN	O	O
are	O	O
not	O	O
currently	O	O
available	O	O
and	O	O
symptomatic	O	O
therapy	O	O
is	O	O
often	O	O
unsatisfactory	O	O
.	O	O
However	O	O
,	O	O
early	O	O
diagnosis	O	O
including	O	O
the	O	O
presymptomatic	O	O
stage	O	O
is	O	O
important	O	O
for	O	O
genetic	O	O
counseling	O	O
and	O	O
will	O	O
be	O	O
crucial	O	O
for	O	O
testing	O	O
novel	O	O
therapeutics	O	O
in	O	O
the	O	O
future	O	O
.	O	O
A	O	O
novel	O	O
SUCLA2	B-Gene	O
mutation	B-Var	B-Var
in	O	O
a	O	O
Portuguese	O	O
child	O	O
associated	O	O
with	B-Reg	O
"	O	B-MPA
mild	O	I-MPA
"	O	I-MPA
methylmalonic	B-Disease	O
aciduria	I-Disease	O
.	O	O
Succinyl	O	O
-	O	O
coenzyme	O	O
A	O	O
synthase	O	O
is	O	O
a	O	O
mitochondrial	O	O
matrix	O	O
enzyme	O	O
that	O	O
catalyzes	O	O
the	O	O
reversible	O	O
synthesis	O	O
of	O	O
succinate	O	O
and	O	O
adenosine	O	O
triphosphate	O	O
(	O	O
ATP	O	O
)	O	O
from	O	O
succinyl	O	O
-	O	O
coenzyme	O	O
A	O	O
and	O	O
adenosine	O	O
diphosphate	O	O
(	O	O
ADP	O	O
)	O	O
in	O	O
the	O	O
tricarboxylic	O	O
acid	O	O
cycle	O	O
.	O	O
This	O	O
enzyme	O	O
is	O	O
made	O	O
up	O	O
of	O	O
α	O	O
and	O	O
β	O	O
subunits	O	O
encoded	O	O
by	O	O
SUCLG1	O	O
and	O	O
SUCLA2	O	O
,	O	O
respectively	O	O
.	O	O
We	O	O
present	O	O
a	O	O
child	O	O
with	O	O
severe	O	O
muscular	O	O
hypotonia	O	O
,	O	O
dystonia	O	O
,	O	O
failure	O	O
to	O	O
thrive	O	O
,	O	O
sensorineural	O	O
deafness	O	O
,	O	O
and	O	O
dysmorphism	O	O
.	O	O
Metabolic	O	O
investigations	O	O
disclosed	O	O
hyperlactacidemia	O	O
,	O	O
moderate	O	O
urinary	O	O
excretion	O	O
of	O	O
methylmalonic	O	O
acid	O	O
,	O	O
and	O	O
elevated	O	O
levels	O	O
of	O	O
C4-dicarboxylic	O	O
carnitine	O	O
in	O	O
blood	O	O
.	O	O
We	O	O
identified	O	O
a	O	O
novel	O	O
homozygous	O	O
p	O	O
.	O	O
M329V	O	O
in	O	O
SUCLA2	B-Gene	O
.	O	O
In	O	O
cultured	O	O
cells	O	O
,	O	O
the	O	O
p	B-Var	O
.	I-Var	O
M329V	I-Var	O
resulted	O	O
in	O	O
a	O	O
reduced	B-NegReg	O
amount	B-MPA	O
of	O	O
the	O	O
SUCLA2	B-Gene	O
protein	B-Protein	O
,	O	O
impaired	B-NegReg	O
production	B-CPA	B-MPA
of	I-CPA	O
mitochondrial	I-CPA	B-MPA
ATP	I-CPA	O
,	O	O
and	O	O
enhanced	B-PosReg	B-PosReg
production	B-CPA	B-MPA
of	I-CPA	O
reactive	I-CPA	O
oxygen	I-CPA	O
species	I-CPA	O
,	O	O
which	O	O
was	O	O
partially	O	O
reduced	O	O
by	O	O
using	O	O
5-aminoimidazole-4-carboxamide	O	O
ribonucleotide	O	O
in	O	O
the	O	O
culture	O	O
medium	O	O
.	O	O
Expanding	O	O
the	O	O
array	O	O
of	O	O
SUCLA2	O	O
mutations	O	O
,	O	O
we	O	O
suggested	O	O
that	O	O
reactive	O	O
oxygen	O	O
species	O	O
scavengers	O	O
are	O	O
likely	O	O
to	O	O
impact	O	O
on	O	O
disease	O	O
prognosis	O	O
.	O	O
Molecular	O	O
profiling	O	O
of	O	O
complete	O	O
congenital	O	O
stationary	O	O
night	O	O
blindness	O	O
:	O	O
a	O	O
pilot	O	O
study	O	O
on	O	O
an	O	O
Indian	O	O
cohort	O	O
.	O	O
PURPOSE	O	O
:	O	O
Congenital	B-Disease	O
stationary	I-Disease	O
night	I-Disease	O
blindness	I-Disease	O
(	O	O
CSNB	O	O
)	O	O
is	O	O
a	O	O
non	O	O
-	O	O
progressive	O	O
retinal	O	O
disorder	O	O
that	O	O
shows	O	O
genetic	O	O
and	O	O
clinical	O	O
heterogeneity	O	O
.	O	O
CSNB	O	O
is	O	O
inherited	O	O
as	O	O
an	O	O
autosomal	O	O
recessive	O	O
,	O	O
autosomal	O	O
dominant	O	O
,	O	O
or	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
trait	O	O
and	O	O
shows	O	O
a	O	O
good	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
.	O	O
Clinically	O	O
,	O	O
CSNB	O	O
is	O	O
classified	O	O
as	O	O
the	O	O
Riggs	O	O
type	O	O
and	O	O
the	O	O
Schubert	O	O
-	O	O
Bornschein	O	O
type	O	O
.	O	O
The	O	O
latter	O	O
form	O	O
is	O	O
further	O	O
sub	O	O
-	O	O
classified	O	O
into	O	O
complete	O	O
and	O	O
incomplete	O	O
forms	O	O
based	O	O
on	O	O
specific	O	O
waveforms	O	O
on	O	O
the	O	O
electroretinogram	O	O
(	O	O
ERG	O	O
)	O	O
.	O	O
There	O	O
are	O	O
no	O	O
molecular	O	O
genetic	O	O
data	O	O
for	O	O
CSNB	O	O
in	O	O
the	O	O
Indian	O	O
population	O	O
.	O	O
Therefore	O	O
,	O	O
we	O	O
present	O	O
for	O	O
the	O	O
first	O	O
time	O	O
molecular	O	O
profiling	O	O
of	O	O
eight	O	O
families	O	O
with	O	O
complete	O	O
CSNB	O	O
(	O	O
cCSNB	O	O
)	O	O
.	O	O
METHODS	O	O
:	O	O
The	O	O
index	O	O
patients	O	O
and	O	O
their	O	O
other	O	O
affected	O	O
family	O	O
members	O	O
were	O	O
comprehensively	O	O
evaluated	O	O
for	O	O
the	O	O
phenotype	O	O
,	O	O
including	O	O
complete	O	O
ophthalmic	O	O
evaluation	O	O
,	O	O
ERG	O	O
,	O	O
fundus	O	O
autofluorescence	O	O
,	O	O
optical	O	O
coherence	O	O
tomography	O	O
,	O	O
and	O	O
color	O	O
vision	O	O
test	O	O
.	O	O
The	O	O
known	O	O
gene	O	O
defects	O	O
for	O	O
cCSNB	O	O
,	O	O
LRIT3	O	O
,	O	O
TRPM1	O	O
,	O	O
GRM6	O	O
,	O	O
GPR179	O	O
,	O	O
and	O	O
NYX	O	O
,	O	O
were	O	O
screened	O	O
by	O	O
PCR	O	O
direct	O	O
sequencing	O	O
.	O	O
Bioinformatic	O	O
analyses	O	O
were	O	O
performed	O	O
using	O	O
SIFT	O	O
and	O	O
PolyPhen	O	O
for	O	O
the	O	O
identified	O	O
missense	O	O
mutations	O	O
.	O	O
RESULTS	O	O
:	O	O
All	O	O
eight	O	O
affected	O	O
index	O	O
patients	O	O
and	O	O
affected	O	O
family	O	O
members	O	O
were	O	O
identified	O	O
as	O	O
having	B-Reg	O
cCSNB	B-Disease	O
based	O	O
on	O	O
their	O	O
ERG	O	O
waveforms	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
TRPM1	B-Gene	O
gene	O	O
were	O	O
identified	O	O
in	O	O
six	O	O
index	O	O
patients	O	O
.	O	O
The	O	O
two	O	O
remaining	O	O
index	O	O
patients	O	O
each	O	O
carried	O	O
a	O	O
GPR179	B-Gene	O
and	O	O
GRM6	B-Gene	O
mutation	B-Var	O
.	O	O
Seven	O	O
of	O	O
the	O	O
patients	O	O
revealed	O	O
homozygous	O	O
mutations	O	O
,	O	O
while	O	O
one	O	O
patient	O	O
showed	O	O
a	O	O
compound	O	O
heterozygous	O	O
mutation	O	O
.	O	O
Six	O	O
of	O	O
the	O	O
eight	O	O
mutations	O	O
identified	O	O
are	O	O
novel	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
on	O	O
molecular	O	O
profiling	O	O
of	O	O
candidate	O	O
genes	O	O
in	O	O
CSNB	O	O
in	O	O
an	O	O
Indian	O	O
cohort	O	O
.	O	O
As	O	O
shown	O	O
for	O	O
other	O	O
cohorts	O	O
,	O	O
TRPM1	B-Gene	O
seems	O	O
to	O	O
be	O	O
a	O	O
major	O	O
gene	O	O
defect	B-Var	O
in	O	O
patients	O	O
with	B-Reg	O
cCSNB	B-Disease	O
in	O	O
India	O	O
.	O	O
UBQLN2	B-Gene	O
mutation	B-Var	O
causing	B-Reg	O
heterogeneous	B-Disease	O
X	I-Disease	O
-	I-Disease	O
linked	I-Disease	O
dominant	I-Disease	O
neurodegeneration	I-Disease	O
.	O	O
We	O	O
report	O	O
a	O	O
5-generation	O	O
family	O	O
with	O	O
phenotypically	O	O
diverse	O	O
neurodegenerative	O	O
disease	O	O
including	O	O
relentlessly	O	O
progressive	O	O
choreoathetoid	O	O
movements	O	O
,	O	O
dysarthria	O	O
,	O	O
dysphagia	O	O
,	O	O
spastic	O	O
paralysis	O	O
,	O	O
and	O	O
behavioral	O	O
dementia	O	O
in	O	O
descendants	O	O
of	O	O
a	O	O
67-year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
amyotrophic	O	O
lateral	O	O
sclerosis	O	O
.	O	O
Disease	O	O
onset	O	O
varied	O	O
with	O	O
gender	O	O
,	O	O
occurring	O	O
in	O	O
male	O	O
children	O	O
and	O	O
adult	O	O
women	O	O
.	O	O
Exome	O	O
sequence	O	O
analyses	O	O
revealed	O	O
a	O	O
novel	O	O
mutation	O	O
(	O	O
c.1490C	O	O
>	O	O
T	O	O
,	O	O
p	O	O
.	O	O
P497L	O	O
)	O	O
in	O	O
the	O	O
ubiquilin-2	O	O
gene	O	O
(	O	O
UBQLN2	O	O
)	O	O
with	O	O
X	O	O
-	O	O
linked	O	O
inheritance	O	O
in	O	O
all	O	O
studied	O	O
affected	O	O
individuals	O	O
.	O	O
As	O	O
ubiquilin-2-positive	O	O
inclusions	O	O
were	O	O
identified	O	O
in	O	O
brain	O	O
,	O	O
we	O	O
suggest	O	O
that	O	O
mutant	B-Var	O
peptide	O	O
predisposes	B-Reg	O
to	I-Reg	O
protein	B-Protein	O
misfolding	B-MPA	O
and	O	O
accumulation	B-PosReg	O
.	O	O
Our	O	O
findings	O	O
expand	O	O
the	O	O
spectrum	O	O
of	O	O
neurodegenerative	O	O
phenotypes	O	O
caused	O	O
by	O	O
UBQLN2	O	O
mutations	O	B-Var
.	O	O
Splicing	B-Var	O
mutation	I-Var	O
in	O	O
MVK	B-Gene	O
is	O	O
a	O	O
cause	B-Reg	O
of	O	O
porokeratosis	B-Disease	O
of	I-Disease	O
Mibelli	I-Disease	O
.	O	O
Porokeratosis	O	O
is	O	O
a	O	O
chronic	O	O
skin	O	O
disorder	O	O
characterized	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
patches	O	O
with	O	O
elevated	O	O
,	O	O
thick	O	O
,	O	O
keratotic	O	O
borders	O	O
,	O	O
with	O	O
histological	O	O
cornoid	O	O
lamella	O	O
.	O	O
Classic	O	O
porokeratosis	O	O
of	O	O
Mibelli	O	O
(	O	O
PM	O	O
)	O	O
frequently	O	O
appears	O	O
in	O	O
childhood	O	O
with	O	O
a	O	O
risk	O	O
of	O	O
malignant	O	O
transformation	O	O
.	O	O
Disseminated	O	O
superficial	O	O
actinic	O	O
porokeratosis	O	O
(	O	O
DSAP	O	O
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
subtype	O	O
of	O	O
porokeratosis	O	O
with	O	O
genetic	O	O
heterogeneities	O	O
,	O	O
and	O	O
mevalonate	O	O
kinase	O	O
gene	O	O
(	O	O
MVK	O	O
)	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
minor	O	O
portion	O	O
of	O	O
DSAP	O	O
families	O	O
of	O	O
Chinese	O	O
origin	O	O
.	O	O
To	O	O
confirm	O	O
the	O	O
previous	O	O
findings	O	O
about	O	O
MVK	O	O
mutations	O	O
in	O	O
DSAP	O	O
patients	O	O
and	O	O
test	O	O
MVK	O	O
's	O	O
role(s	O	O
)	O	O
in	O	O
PM	O	O
development	O	O
,	O	O
we	O	O
performed	O	O
genomic	O	O
sequence	O	O
analysis	O	O
for	O	O
3	O	O
DSAP	O	O
families	O	O
and	O	O
1	O	O
PM	O	O
family	O	O
of	O	O
Chinese	O	O
origin	O	O
.	O	O
We	O	O
identified	O	O
a	O	O
splicing	O	O
mutation	O	O
of	O	O
MVK	O	O
gene	O	O
,	O	O
designated	O	O
as	O	O
c.1039	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
,	O	O
in	O	O
the	O	O
PM	O	O
family	O	O
.	O	O
No	O	O
MVK	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
three	O	O
DSAP	O	O
families	O	O
.	O	O
Sequence	O	O
analysis	O	O
for	O	O
complementary	O	O
DNA	O	O
templates	O	O
from	O	O
PM	O	O
lesions	O	O
of	O	O
all	O	O
patients	O	O
revealed	O	O
a	O	O
mutation	O	O
at	O	O
splice	O	O
donor	O	O
site	O	O
of	O	O
intron	O	O
10	O	O
,	O	O
designated	O	O
as	O	O
c.1039	B-Var	O
+	I-Var	O
1G	I-Var	O
>	I-Var	O
A	I-Var	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
the	O	O
splicing	B-MPA	O
defect	I-MPA	O
and	O	O
termination	B-MPA	O
codon	I-MPA	O
52	O	O
amino	O	O
acids	O	O
after	O	O
exon	O	O
10	O	O
.	O	O
Although	O	O
no	O	O
MVK	O	O
mutations	O	O
in	O	O
DSAP	O	O
patients	O	O
were	O	O
found	O	O
as	O	O
reported	O	O
previously	O	O
,	O	O
we	O	O
identified	O	O
MVK	O	O
simultaneously	O	O
responsible	O	O
for	O	O
PM	O	O
development	O	O
.	O	O
Whole	O	O
exome	O	O
sequencing	O	O
reveals	O	O
concomitant	O	O
mutations	B-Var	O
of	O	O
multiple	O	O
FA	B-Gene	O
genes	O	O
in	B-Reg	O
individual	O	O
Fanconi	B-Disease	B-Disease
anemia	I-Disease	I-Disease
patients	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Fanconi	O	B-Disease
anemia	O	I-Disease
(	O	O
FA	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
inherited	O	O
genetic	O	O
syndrome	O	O
with	O	O
highly	O	O
variable	O	O
clinical	O	O
manifestations	O	O
.	O	O
Fifteen	O	O
genetic	O	O
subtypes	O	O
of	O	O
FA	O	O
have	O	O
been	O	O
identified	O	O
.	O	O
Traditional	O	O
complementation	O	O
tests	O	O
for	O	O
grouping	O	O
studies	O	O
have	O	O
been	O	O
used	O	O
generally	O	O
in	O	O
FA	O	O
patients	O	O
and	O	O
in	O	O
stepwise	O	O
methods	O	O
to	O	O
identify	O	O
the	O	O
FA	O	O
type	O	O
,	O	O
which	O	O
can	O	O
result	O	O
in	O	O
incomplete	O	O
genetic	O	O
information	O	O
from	O	O
FA	O	O
patients	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
diagnosed	O	O
five	O	O
pediatric	O	O
patients	O	O
with	O	O
FA	O	O
based	O	O
on	O	O
clinical	O	O
manifestations	O	O
,	O	O
and	O	O
we	O	O
performed	O	O
exome	O	O
sequencing	O	O
of	O	O
peripheral	O	O
blood	O	O
specimens	O	O
from	O	O
these	O	O
patients	O	O
and	O	O
their	O	O
family	O	O
members	O	O
.	O	O
The	O	O
related	O	O
sequencing	O	O
data	O	O
were	O	O
then	O	O
analyzed	O	O
by	O	O
bioinformatics	O	O
,	O	O
and	O	O
the	O	O
FANC	O	O
gene	O	O
mutations	O	O
identified	O	O
by	O	O
exome	O	O
sequencing	O	O
were	O	O
confirmed	O	O
by	O	O
PCR	O	O
re	O	O
-	O	O
sequencing	O	O
.	O	O
RESULTS	O	O
:	O	O
Homozygous	O	O
and	O	O
compound	O	O
heterozygous	O	O
mutations	O	O
of	O	O
FANC	O	O
genes	O	O
were	O	O
identified	O	O
in	O	O
all	O	O
of	O	O
the	O	O
patients	O	O
.	O	O
The	O	O
FA	O	O
subtypes	O	O
of	O	O
the	O	O
patients	O	O
included	O	O
FANCA	O	O
,	O	O
FANCM	O	O
and	O	O
FANCD2	O	O
.	O	O
Interestingly	O	O
,	O	O
four	O	O
FA	O	O
patients	O	O
harbored	O	O
multiple	O	O
mutations	O	O
in	O	O
at	O	O
least	O	O
two	O	O
FA	O	O
genes	O	O
,	O	O
and	O	O
some	O	O
of	O	O
these	O	O
mutations	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O
These	O	O
patients	O	O
'	O	O
clinical	O	O
manifestations	O	O
were	O	O
vastly	O	O
different	O	O
from	O	O
each	O	O
other	O	O
,	O	O
as	O	O
were	O	O
their	O	O
treatment	O	O
responses	O	O
to	O	O
androstanazol	O	O
and	O	O
prednisone	O	O
.	O	O
This	O	O
finding	O	O
suggests	O	O
that	O	O
heterozygous	O	O
mutation(s	O	O
)	O	O
in	O	O
FA	O	O
genes	O	O
could	O	O
also	O	O
have	O	O
diverse	O	O
biological	O	O
and/or	O	O
pathophysiological	O	O
effects	O	O
on	O	O
FA	O	O
patients	O	O
or	O	O
FA	O	O
gene	O	O
carriers	O	O
.	O	O
Interestingly	O	O
,	O	O
we	O	O
were	O	O
not	O	O
able	O	O
to	O	O
identify	O	O
de	O	O
novo	O	O
mutations	O	O
in	O	O
the	O	O
genes	O	O
implicated	O	O
in	O	O
DNA	O	O
repair	O	O
pathways	O	O
when	O	O
the	O	O
sequencing	O	O
data	O	O
of	O	O
patients	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
their	O	O
parents	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Our	O	O
results	O	O
indicate	O	O
that	O	O
Chinese	O	O
FA	O	O
patients	O	O
and	O	O
carriers	O	O
might	O	O
have	O	O
higher	O	O
and	O	O
more	O	O
complex	O	O
mutation	O	O
rates	O	O
in	O	O
FANC	O	O
genes	O	O
than	O	O
have	O	O
been	O	O
conventionally	O	O
recognized	O	O
.	O	O
Testing	O	O
of	O	O
the	O	O
fifteen	O	O
FANC	O	O
genes	O	O
in	O	O
FA	O	O
patients	O	O
and	O	O
their	O	O
family	O	O
members	O	O
should	O	O
be	O	O
a	O	O
regular	O	O
clinical	O	O
practice	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
care	O	O
for	O	O
the	O	O
individual	O	O
patient	O	O
,	O	O
to	O	O
counsel	O	O
the	O	O
family	O	O
and	O	O
to	O	O
obtain	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
FA	O	O
pathophysiology	O	O
.	O	O
Mutations	B-Var	O
in	O	O
SMARCAD1	B-Gene	O
cause	B-Reg	O
autosomal	B-Disease	B-Disease
dominant	I-Disease	O
adermatoglyphia	I-Disease	O
and	O	O
perturb	B-Reg	O
the	O	O
expression	B-MPA	B-MPA
of	O	O
epidermal	O	O
differentiation	O	O
-	O	O
associated	O	O
genes	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Autosomal	O	O
dominant	O	O
adermatoglyphia	O	O
(	O	O
ADG	O	O
)	O	O
is	O	O
characterized	O	O
by	O	O
lack	O	O
of	O	O
palmoplantar	O	O
epidermal	O	O
ridges	O	O
.	O	O
Recently	O	O
,	O	O
ADG	O	O
was	O	O
found	O	O
to	O	O
be	O	O
caused	O	O
in	O	O
one	O	O
family	O	O
by	O	O
a	O	O
mutation	O	O
in	O	O
SMARCAD1	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
SNF	O	O
subfamily	O	O
of	O	O
the	O	O
helicase	O	O
protein	O	O
superfamily	O	O
.	O	O
OBJECTIVES	O	O
:	O	O
To	O	O
investigate	O	O
the	O	O
genetic	O	O
basis	O	O
of	O	O
ADG	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
used	O	O
direct	O	O
sequencing	O	O
and	O	O
global	O	O
gene	O	O
expression	O	O
analysis	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
identified	O	O
three	O	O
novel	O	O
heterozygous	O	O
mutations	O	O
in	O	O
SMARCAD1	O	O
(	O	O
c.378	O	O
+	O	O
2	O	O
T	O	O
>	O	O
C	O	O
,	O	O
c.378	O	O
+	O	O
5	O	O
G	O	O
>	O	O
C	O	O
and	O	O
c.378	O	O
+	O	O
1	O	O
G	O	O
>	O	O
A	O	O
)	O	O
in	O	O
a	O	O
total	O	O
of	O	O
six	O	O
patients	O	O
.	O	O
Surprisingly	O	O
,	O	O
all	O	O
four	O	O
ADG	O	O
-	O	O
causing	O	O
mutations	B-Var	O
identified	O	O
to	O	O
date	O	O
disrupt	B-NegReg	O
a	O	O
single	B-MPA	O
conserved	I-MPA	O
donor	I-MPA	O
splice	I-MPA	O
site	I-MPA	O
adjacent	O	O
to	O	O
the	O	O
3	O	O
'	O	O
end	O	O
of	O	O
a	O	O
noncoding	O	O
exon	O	O
and	O	O
are	O	O
predicted	O	O
to	O	O
result	O	O
in	O	O
haploinsufficiency	B-NegReg	O
for	O	O
a	O	O
skin	B-MPA	O
-	I-MPA	O
specific	I-MPA	O
isoform	I-MPA	O
of	O	O
SMARCAD1	B-Gene	O
.	O	O
These	O	O
data	O	O
indicate	O	O
a	O	O
pivotal	O	O
role	O	O
for	O	O
the	O	O
SMARCAD1-skin	O	O
specific	O	O
isoform	O	O
in	O	O
dermatoglyph	O	O
formation	O	O
.	O	O
In	O	O
order	O	O
to	O	O
better	O	O
understand	O	O
the	O	O
consequences	O	O
of	O	O
ADG	O	O
-	O	O
associated	O	O
mutations	O	O
,	O	O
we	O	O
ascertained	O	O
the	O	O
global	O	O
transcription	O	O
profiles	O	O
of	O	O
primary	O	O
keratinocytes	O	O
downregulated	O	O
for	O	O
SMARCAD1	O	O
and	O	O
of	O	O
patient	O	O
-	O	O
derived	O	O
keratinocytes	O	O
.	O	O
A	O	O
total	O	O
of	O	O
eight	O	O
genes	O	O
were	O	O
found	O	O
to	O	O
be	O	O
differentially	O	O
expressed	O	O
in	O	O
both	O	O
patient	O	O
-	O	O
derived	O	O
and	O	O
knocked	O	O
down	O	O
keratinocytes	O	O
.	O	O
Of	O	O
interest	O	O
,	O	O
these	O	O
differentially	O	O
expressed	O	O
genes	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
epidermal	O	O
ontogenesis	O	O
and	O	O
differentiation	O	O
,	O	O
and	O	O
in	O	O
psoriasis	O	O
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
abnormal	O	O
finger	O	O
ridge	O	O
patterns	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
present	O	O
data	O	O
suggest	O	O
that	O	O
ADG	O	O
is	O	O
genetically	O	O
homogeneous	O	O
and	O	O
result	O	O
from	O	O
perturbed	O	O
expression	O	O
of	O	O
epidermal	O	O
differentiation	O	O
-	O	O
associated	O	O
genes	O	O
.	O	O
Genetics	O	O
and	O	O
pathophysiology	O	O
of	O	O
primary	O	O
dystonia	O	O
with	O	O
special	O	O
emphasis	O	O
on	O	O
DYT1	O	O
and	O	O
DYT5	O	O
.	O	O
DYT1	O	O
and	O	O
DYT5	O	O
are	O	O
early	O	O
-	O	O
onset	O	O
dominant	O	O
inherited	O	O
dystonias	O	O
.	O	O
DYT1	B-Disease	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
of	O	O
the	O	O
TOR1A	B-Gene	O
gene	O	O
,	O	O
located	O	O
on	O	O
9q34	O	O
,	O	O
which	O	O
causes	O	O
dysfunction	B-NegReg	O
of	O	O
the	O	O
D1	B-Pathway	O
direct	I-Pathway	O
pathway	I-Pathway	O
or	O	O
the	O	O
indirect	B-Pathway	O
pathway	I-Pathway	O
.	O	O
Dysfunction	O	O
of	O	O
the	O	O
former	O	O
causes	O	O
postural	B-Disease	O
-	I-Disease	O
type	I-Disease	O
and	I-Disease	O
segmental	I-Disease	O
dystonia	I-Disease	O
;	I-Disease	O
the	O	O
latter	O	O
causes	O	O
action	B-Disease	O
-	I-Disease	O
type	I-Disease	O
dystonia	I-Disease	O
.	O	O
In	O	O
families	O	O
with	O	O
action	O	O
-	O	O
type	O	O
dystonia	O	O
,	O	O
there	O	O
are	O	O
cases	O	O
with	O	O
focal	O	O
and	O	O
segmental	O	O
dystonia	O	O
.	O	O
Ages	O	O
of	O	O
onset	O	O
of	O	O
postural	O	O
-	O	O
type	O	O
dystonia	O	O
are	O	O
around	O	O
6	O	O
years	O	O
,	O	O
and	O	O
8	O	O
to	O	O
10	O	O
years	O	O
in	O	O
cases	O	O
of	O	O
action	O	O
-	O	O
type	O	O
dystonia	O	O
.	O	O
Focal	O	O
and	O	O
segmental	O	O
dystonia	O	O
develops	O	O
in	O	O
the	O	O
teens	O	O
.	O	O
Mental	O	O
and	O	O
psychological	O	O
functions	O	O
are	O	O
preserved	O	O
.	O	O
DYT5	B-Disease	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
heterozygous	O	O
mutations	B-Var	O
of	O	O
the	O	O
GCH1	B-Gene	B-Gene
gene	O	O
,	O	O
located	O	O
on	O	O
14q22.1-q22.2	O	O
.	O	O
Again	O	O
,	O	O
mental	O	O
and	O	O
psychological	O	O
functions	O	O
are	O	O
preserved	O	O
.	O	O
Clinically	O	O
,	O	O
there	O	O
are	O	O
two	O	O
types	O	O
:	O	O
postural	O	O
and	O	O
action	O	O
.	O	O
Postural	O	O
-	O	O
type	O	O
dystonia	O	O
occurs	O	O
around	O	O
6	O	O
years	O	O
of	O	O
age	O	O
,	O	O
with	O	O
postural	O	O
dystonia	O	O
of	O	O
one	O	O
leg	O	O
,	O	O
and	O	O
all	O	O
extremities	O	O
and	O	O
trunk	O	O
muscles	O	O
are	O	O
involved	O	O
by	O	O
the	O	O
late	O	O
teens	O	O
.	O	O
Action	O	O
-	O	O
type	O	O
dystonia	O	O
shows	O	O
dystonic	O	O
movements	O	O
from	O	O
around	O	O
8	O	O
to	O	O
10	O	O
years	O	O
of	O	O
age	O	O
.	O	O
In	O	O
both	O	O
types	O	O
,	O	O
all	O	O
symptoms	O	O
show	O	O
diurnal	O	O
fluctuations	O	O
that	O	O
diminish	O	O
with	O	O
age	O	O
and	O	O
are	O	O
no	O	O
longer	O	O
apparent	O	O
in	O	O
the	O	O
late	O	O
teens	O	O
.	O	O
L	O	O
-	O	O
dopa	O	O
produces	O	O
dramatic	O	O
effects	O	O
,	O	O
which	O	O
continue	O	O
throughout	O	O
the	O	O
course	O	O
of	O	O
the	O	O
illness	O	O
.	O	O
In	O	O
both	O	O
postural	O	O
and	O	O
action	O	O
types	O	O
,	O	O
each	O	O
family	O	O
or	O	O
sporadic	O	O
case	O	O
has	O	O
a	O	O
particular	O	O
mutation	O	O
.	O	O
It	O	O
remains	O	O
unclear	O	O
why	O	O
specific	O	O
mutations	O	O
cause	O	O
certain	O	O
age-	O	O
and	O	O
gender	O	O
-	O	O
specific	O	O
symptoms	O	O
.	O	O
First	O	O
report	O	O
of	O	O
a	O	O
deletion	O	O
encompassing	O	O
an	O	O
entire	O	O
exon	O	O
in	O	O
the	O	O
homogentisate	O	O
1,2-dioxygenase	O	O
gene	O	O
causing	O	O
alkaptonuria	O	O
.	O	O
Alkaptonuria	B-Disease	O
is	O	O
often	O	O
diagnosed	O	O
clinically	O	O
with	O	O
episodes	O	O
of	O	O
dark	O	O
urine	O	O
,	O	O
biochemically	O	O
by	O	O
the	O	O
accumulation	O	O
of	O	O
peripheral	O	O
homogentisic	O	O
acid	O	O
and	O	O
molecularly	O	O
by	B-Reg	O
the	I-Reg	O
presence	I-Reg	O
of	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
homogentisate	O	O
1,2-dioxygenase	O	O
gene	O	O
(	B-Gene	O
HGD	I-Gene	O
)	I-Gene	O
.	O	O
Alkaptonuria	B-Disease	O
is	O	O
invariably	O	O
associated	B-Reg	O
with	I-Reg	O
HGD	B-Gene	O
mutations	B-Var	O
,	O	O
which	O	O
consist	O	O
of	O	O
single	B-Var	O
nucleotide	I-Var	O
variants	I-Var	O
and	O	O
small	B-Var	O
insertions	I-Var	O
/	I-Var	O
deletions	I-Var	O
.	O	O
Surprisingly	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
deletions	O	O
beyond	O	O
a	O	O
few	O	O
nucleotides	O	O
among	O	O
over	O	O
150	O	O
reported	O	O
deleterious	O	O
mutations	O	O
has	O	O
not	O	O
been	O	O
described	O	O
,	O	O
raising	O	O
the	O	O
suspicion	O	O
that	O	O
this	O	O
gene	O	O
might	O	O
be	O	O
protected	O	O
against	O	O
the	O	O
detrimental	O	O
mechanisms	O	O
of	O	O
gene	O	O
rearrangements	O	O
.	O	O
The	O	O
quest	O	O
for	O	O
an	O	O
HGD	O	O
mutation	O	O
in	O	O
a	O	O
proband	O	O
with	O	O
AKU	O	O
revealed	O	O
with	O	O
a	O	O
SNP	O	O
array	O	O
five	O	O
large	O	O
regions	O	O
of	O	O
homozygosity	O	O
(	O	O
5	O	O
-	O	O
16	O	O
Mb	O	O
)	O	O
,	O	O
one	O	O
of	O	O
which	O	O
includes	O	O
the	O	O
HGD	O	O
gene	O	O
.	O	O
A	O	O
homozygous	O	O
deletion	O	O
of	O	O
649	O	O
bp	O	O
deletion	O	O
that	O	O
encompasses	O	O
the	O	O
72	O	O
nucleotides	O	O
of	O	O
exon	O	O
2	O	O
and	O	O
surrounding	O	O
DNA	O	O
sequences	O	O
in	O	O
flanking	O	O
introns	O	O
of	O	O
the	O	O
HGD	O	O
gene	O	O
was	O	O
unveiled	O	O
in	O	O
a	O	O
proband	O	O
with	O	O
AKU	O	O
.	O	O
The	O	O
nature	O	O
of	O	O
this	O	O
deletion	O	O
suggests	O	O
that	O	O
this	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
could	O	O
generate	O	O
a	O	O
protein	O	O
without	O	O
exon	O	O
2	O	O
.	O	O
Thus	O	O
,	O	O
we	O	O
modeled	O	O
the	O	O
tertiary	O	O
structure	O	O
of	O	O
the	O	O
mutant	O	O
protein	O	O
structure	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
exon	O	O
2	O	O
deletion	O	O
.	O	O
While	O	O
the	O	O
two	O	O
β	O	O
-	O	O
pleated	O	O
sheets	O	O
encoded	O	O
by	O	O
exon	O	O
2	O	O
were	O	O
missing	O	O
in	O	O
the	O	O
mutant	O	O
structure	O	O
,	O	O
other	O	O
β	O	O
-	O	O
pleated	O	O
sheets	O	O
are	O	O
largely	O	O
unaffected	O	O
by	O	O
the	O	O
deletion	O	O
.	O	O
However	O	O
,	O	O
nine	O	O
novel	O	O
α	O	O
-	O	O
helical	O	O
coils	O	O
substituted	O	O
the	O	O
eight	O	O
coils	O	O
present	O	O
in	O	O
the	O	O
native	O	O
HGD	O	O
crystal	O	O
structure	O	O
.	O	O
Thus	O	O
,	O	O
this	O	O
deletion	B-Var	O
results	B-Reg	O
in	I-Reg	O
a	O	O
deleterious	O	O
enzyme	B-Enzyme	O
,	O	O
which	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
proband	O	O
's	O	O
phenotype	O	O
.	O	O
Screening	O	O
for	O	O
mutations	O	O
in	O	O
the	O	O
HGD	O	O
gene	O	O
,	O	O
particularly	O	O
in	O	O
the	O	O
Middle	O	O
East	O	O
,	O	O
ought	O	O
to	O	O
include	O	O
this	O	O
exon	O	O
2	O	O
deletion	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
its	O	O
frequency	O	O
and	O	O
uncover	O	O
its	O	O
origin	O	O
.	O	O
Identification	O	O
of	O	O
two	O	O
novel	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
X	O	O
-	O	O
linked	O	O
primary	O	O
immunodeficiencies	O	O
.	O	O
Primary	B-Disease	O
immunodeficiency	I-Disease	O
diseases	I-Disease	O
(	O	O
PID	O	O
)	O	O
are	O	O
a	O	O
heterogeneous	O	O
group	O	O
of	O	O
inherited	O	O
disorders	O	O
with	O	O
defects	O	O
in	O	O
one	O	O
or	O	O
more	O	O
component	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
analyzed	O	O
gene	O	O
mutations	O	O
in	O	O
four	O	O
X	O	O
-	O	O
linked	O	O
PID	O	O
pedigrees	O	O
,	O	O
which	O	O
include	O	O
one	O	O
X-	O	O
linked	O	O
agammaglobulinemia	O	O
(	O	O
XLA	O	O
)	O	O
pedigree	O	O
,	O	O
one	O	O
X	O	O
-	O	O
linked	O	O
chronic	O	O
granulomatous	O	O
disease	O	O
(	O	O
XCGD	O	O
)	O	O
pedigree	O	O
,	O	O
and	O	O
two	O	O
X	O	O
-	O	O
linked	O	O
Hyper	O	O
IgM	O	O
syndrome	O	O
(	O	O
XHIGM	O	O
)	O	O
pedigrees	O	O
.	O	O
Sequence	O	O
analysis	O	O
of	O	O
the	O	O
BTK	B-Gene	O
gene	O	O
revealed	O	O
a	O	O
novel	O	O
mutation	O	O
(	B-Var	O
c.1802_1803delinsGCC	I-Var	O
,	O	O
p	O	O
.	O	O
Phe601CysfsX3	O	O
)	O	O
which	O	O
results	B-Reg	O
in	O	O
the	O	O
developmental	B-CPA	O
arrest	I-CPA	O
of	I-CPA	O
B	I-CPA	O
cells	I-CPA	O
in	O	O
the	O	O
bone	O	O
marrow	O	O
.	O	O
Sequence	O	O
analysis	O	O
of	O	O
the	O	O
CYBB	B-Gene	O
gene	O	O
revealed	O	O
a	O	O
recurrent	O	O
frameshift	O	O
mutation	O	O
(	B-Var	O
c.1313_1314delinsT	I-Var	O
)	I-Var	O
in	O	O
exon	O	O
10	O	O
,	O	O
which	O	O
generates	B-Reg	O
a	O	O
premature	B-MPA	O
stop	I-MPA	O
codon	O	O
(	O	O
p	O	O
.	O	O
Lys438IlefsX63	O	O
)	O	O
.	O	O
One	O	O
novel	O	O
frameshift	O	O
mutation	O	O
(	B-Var	O
c.114delG	I-Var	O
,	O	O
p	O	O
.	O	O
Ser39GlnfsX14	O	O
)	O	O
and	O	O
one	O	O
recurrent	O	O
missense	O	O
mutation	O	O
(	B-Var	O
c.499G	I-Var	O
>	I-Var	O
C	I-Var	O
,	O	O
p	O	O
.	O	O
Gly167Arg	O	O
)	O	O
were	O	O
found	O	O
in	O	O
the	O	O
CD40LG	B-Gene	B-Gene
gene	O	O
and	O	O
cause	O	O
defective	B-NegReg	B-CPA
T	B-CPA	I-CPA
cell	I-CPA	I-CPA
functioning	I-CPA	I-CPA
.	O	O
In	O	O
conclusion	O	O
,	O	O
our	O	O
study	O	O
identified	O	O
two	O	O
novel	O	O
mutations	O	O
on	O	O
the	O	O
BTK	O	O
and	O	O
CD40LG	O	O
genes	O	O
in	O	O
Chinese	O	O
patients	O	O
and	O	O
established	O	O
accurate	O	O
and	O	O
simple	O	O
genetic	O	O
diagnostic	O	O
methods	O	O
for	O	O
three	O	O
X	O	O
-	O	O
linked	O	O
PID	O	O
.	O	O
Novel	O	O
COL9A3	B-Gene	O
mutation	B-Var	O
in	O	O
a	O	O
family	O	O
diagnosed	O	O
with	B-Reg	O
multiple	B-Disease	O
epiphyseal	I-Disease	O
dysplasia	I-Disease	O
:	I-Disease	O
a	O	O
case	O	O
report	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Multiple	O	O
epiphyseal	O	O
dysplasia	O	O
is	O	O
a	O	O
common	O	O
skeletal	O	O
dysplasia	O	O
characterized	O	O
by	O	O
mild	O	O
short	O	O
stature	O	O
,	O	O
early	O	O
-	O	O
onset	O	O
osteoarthritis	O	O
mainly	O	O
involving	O	O
the	O	O
hip	O	O
and	O	O
knee	O	O
joints	O	O
,	O	O
and	O	O
abnormally	O	O
small	O	O
and/or	O	O
irregular	O	O
epiphyses	O	O
.	O	O
Multiple	O	O
epiphyseal	O	O
dysplasia	O	O
is	O	O
clinically	O	O
and	O	O
genetically	O	O
heterogeneous	O	O
and	O	O
six	O	O
genes	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
phenotype	O	O
of	O	O
multiple	O	O
epiphyseal	O	O
dysplasia	O	O
.	O	O
CASE	O	O
PRESENTATION	O	O
:	O	O
A	O	O
12-year	O	O
-	O	O
old	O	O
Korean	O	O
boy	O	O
presented	O	O
with	O	O
intermittent	O	O
knee	O	O
pain	O	O
.	O	O
His	O	O
height	O	O
was	O	O
144.6	O	O
cm	O	O
(	O	O
20th	O	O
percentile	O	O
)	O	O
and	O	O
family	O	O
history	O	O
was	O	O
notable	O	O
for	O	O
early	O	O
-	O	O
onset	O	O
osteoarthritis	O	O
in	O	O
his	O	O
father	O	O
.	O	O
The	O	O
proband	O	O
's	O	O
x	O	O
-	O	O
rays	O	O
revealed	O	O
epiphyseal	O	O
changes	O	O
characteristic	O	O
of	O	O
multiple	O	O
epiphyseal	O	O
dysplasia	O	O
associated	O	O
with	O	O
a	O	O
collagen	O	O
IX	O	O
defect	O	O
,	O	O
with	O	O
manifestations	O	O
primarily	O	O
restricted	O	O
to	O	O
the	O	O
knees	O	O
.	O	O
Mutational	O	O
analysis	O	O
identified	O	O
a	O	O
novel	O	O
c.104G	B-Var	O
>	I-Var	O
A	I-Var	O
substitution	O	O
in	O	O
exon	O	O
2	O	O
of	O	O
COL9A3	B-Gene	O
,	O	O
resulting	B-Reg	O
in	I-Reg	O
p	B-Var	O
.	I-Var	O
Gly35Asp	I-Var	O
in	O	O
the	O	O
proband	O	O
and	O	O
his	O	O
father	O	O
.	O	O
In	O	O
silico	O	O
analyses	O	O
predicted	O	O
the	O	O
p	O	O
.	O	O
Gly35Asp	O	O
amino	O	O
acid	O	O
change	O	O
to	O	O
be	O	O
detelerious	O	O
,	O	O
and	O	O
molecular	O	O
dynamics	O	O
simulation	O	O
demonstrated	O	O
a	O	O
major	O	O
structural	O	O
change	O	O
in	O	O
the	O	O
heterotrimeric	O	O
collagen	O	O
IX	O	O
.	O	O
CONCLUSION	O	O
:	O	O
So	O	O
far	O	O
,	O	O
three	O	O
COL9A3	O	O
mutations	O	O
,	O	O
have	O	O
been	O	O
reported	O	O
.	O	O
These	O	O
three	O	O
mutations	B-Var	O
are	O	O
located	O	O
at	O	O
the	O	O
splice	O	O
donor	O	O
or	O	O
acceptor	O	O
site	O	O
of	O	O
COL9A3	B-Gene	O
and	O	O
cause	B-Reg	O
skipping	B-MPA	O
of	I-MPA	O
exon	I-MPA	O
3	I-MPA	O
,	O	O
resulting	B-Reg	O
in	I-Reg	O
the	O	O
deletion	B-Var	O
of	O	O
12	O	O
aminoacids	O	O
in	O	O
the	O	O
COL3	O	O
domain	O	O
of	O	O
COL9A3	B-Gene	O
.	O	O
In	O	O
contrast	O	O
,	O	O
the	O	O
novel	O	O
missense	O	O
mutation	O	O
identified	O	O
in	O	O
this	O	O
two	O	O
-	O	O
generation	O	O
family	O	O
with	O	O
multiple	O	O
epiphyseal	O	O
dysplasia	O	O
is	O	O
a	O	O
missense	O	O
mutation	B-Var	O
affecting	B-Reg	O
the	O	O
Gly	B-MPA	O
residue	I-MPA	O
of	O	O
the	O	O
Pro	O	O
-	O	O
Pro	O	O
-	O	O
Gly	O	O
repeat	O	O
sequence	O	O
in	O	O
the	O	O
COL3	O	O
domain	O	O
of	O	O
collage	O	O
IX	O	O
,	O	O
with	O	O
accompanying	O	O
major	O	O
structural	B-MPA	O
change	O	O
of	O	O
the	O	O
collagen	B-Protein	O
peptide	O	O
.	O	O
Rett	O	O
-	O	O
like	O	O
onset	O	O
in	O	O
late	B-Disease	O
-	I-Disease	O
infantile	I-Disease	O
neuronal	I-Disease	O
ceroid	I-Disease	O
lipofuscinosis	I-Disease	O
(	O	B-Gene
CLN7	O	O
)	O	I-Gene
caused	B-Reg	O
by	I-Reg	O
compound	O	O
heterozygous	O	O
mutation	B-Var	O
in	O	O
the	O	O
MFSD8	B-Gene	O
gene	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
data	O	O
on	O	O
clinical	O	O
onset	O	O
signs	O	O
.	O	O
BACKGROUND	O	O
:	O	O
We	O	O
present	O	O
clinical	O	O
and	O	O
molecular	O	O
findings	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
ceroid	O	O
-	O	O
lipofuscinosis	O	O
CLN7	B-Disease	O
,	O	O
with	B-Reg	O
a	O	O
compound	O	O
heterozygous	O	O
mutation	B-Var	O
of	O	O
the	O	O
MFSD8	B-Gene	O
gene	O	O
,	O	O
with	O	O
Rett	O	O
syndrome	O	O
clinical	O	O
signs	O	O
onset	O	O
and	O	O
a	O	O
later	O	O
development	O	O
of	O	O
full	O	O
picture	O	O
of	O	O
vLINCL	O	O
.	O	O
CASE	O	O
PRESENTATION	O	O
:	O	O
A	O	O
7	O	O
years	O	O
-	O	O
old	O	O
female	O	O
patient	O	O
with	O	O
normal	O	O
development	O	O
until	O	O
the	O	O
age	O	O
12	O	O
months	O	O
,	O	O
developed	O	O
Rett	O	O
like	O	O
clinical	O	O
picture	O	O
(	O	O
psychomotor	O	O
regression	O	O
,	O	O
microcephaly	O	O
,	O	O
stereotypic	O	O
hands	O	O
movements	O	O
in	O	O
the	O	O
midline	O	O
,	O	O
hyperventilation	O	O
episodes	O	O
)	O	O
present	O	O
at	O	O
the	O	O
onset	O	O
of	O	O
her	O	O
condition	O	O
(	O	O
age	O	O
18	O	O
months	O	O
)	O	O
,	O	O
features	O	O
still	O	O
present	O	O
at	O	O
the	O	O
initial	O	O
evaluation	O	O
in	O	O
our	O	O
clinic	O	O
at	O	O
age	O	O
5	O	O
years	O	O
.	O	O
RESULTS	O	O
:	O	O
MECP2	O	O
(	O	O
methyl	O	O
CpG	O	O
binding	O	O
protein	O	O
2	O	O
)	O	O
gene	O	O
mutation	O	O
was	O	O
negative	O	O
.	O	O
At	O	O
age	O	O
6	O	O
years	O	O
she	O	O
was	O	O
readmitted	O	O
for	O	O
severe	O	O
ataxia	O	O
and	O	O
blindness	O	O
,	O	O
seizures	O	O
,	O	O
and	O	O
severe	O	O
developmental	O	O
regression	O	O
leading	O	O
to	O	O
NCL	O	O
(	O	O
neuronal	O	O
ceroid	O	O
lipofuscinosis	O	O
)	O	O
suspicion	O	O
.	O	O
EEG	O	O
showed	O	O
slow	O	O
background	O	O
with	O	O
IRDA	O	O
(	O	O
intermittent	O	O
rhythmic	O	O
delta	O	O
activity	O	O
)	O	O
.	O	O
A	O	O
conjunctive	O	O
biopsy	O	O
showed	O	O
abnormal	O	O
curvilinear	O	O
and	O	O
fingerprint	O	O
lysosomal	O	O
deposits	O	O
,	O	O
and	O	O
genetic	O	O
analysis	O	O
revealed	O	O
two	O	O
heterozygous	O	O
mutations	O	O
of	O	O
MFSD8	O	O
gene	O	O
(	O	O
c.881C	O	O
>	O	O
A	O	O
p	O	O
.	O	O
Thr294Lys	O	O
and	O	O
c.754	O	O
+	O	O
2	O	O
T	O	O
>	O	O
A	O	O
)	O	O
each	O	O
inherited	O	O
from	O	O
carrier	O	O
parents	O	O
and	O	O
a	O	O
heterozygous	O	O
variant	O	O
(	O	O
c.470A	O	O
>	O	O
C	O	O
p	O	O
.	O	O
Asp157Ala	O	O
)	O	O
of	O	O
CLN5	O	O
gene	O	O
.	O	O
CONCLUSION	O	O
:	O	O
NCL	O	O
should	O	O
be	O	O
suspected	O	O
and	O	O
MFSD8	O	O
genetic	O	O
testing	O	O
should	O	O
also	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
Rett	O	O
like	O	O
phenotype	O	O
at	O	O
onset	O	O
and	O	O
negative	O	O
MECP2	O	O
mutation	O	O
.	O	O
Such	O	O
cases	O	O
should	O	O
be	O	O
carefully	O	O
and	O	O
frequently	O	O
re	O	O
-	O	O
evaluated	O	O
in	O	O
order	O	O
to	O	O
avoid	O	O
delayed	O	O
diagnosis	O	O
and	O	O
offer	O	O
proper	O	O
genetic	O	O
advice	O	O
to	O	O
the	O	O
family	O	O
.	O	O
In	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
might	O	O
be	O	O
the	O	O
first	O	O
case	O	O
of	O	O
CLN7	O	O
disease	O	O
with	O	O
Rett	O	O
like	O	O
onset	O	O
described	O	O
in	O	O
the	O	O
literature	O	O
,	O	O
which	O	O
developed	O	O
typical	O	O
vLINCL	O	O
clinical	O	O
phenotype	O	O
after	O	O
age	O	O
5.5	O	O
years	O	O
.	O	O
A	O	O
short	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
showing	O	O
NCL	O	O
onset	O	O
modalities	O	O
is	O	O
presented	O	O
.	O	O
Novel	O	O
homozygous	B-Var	O
deletion	I-Var	O
of	O	O
segmental	O	O
KAL1	B-Gene	O
and	O	O
entire	O	O
STS	B-Gene	O
cause	B-Reg	O
Kallmann	B-Disease	B-Disease
syndrome	I-Disease	I-Disease
and	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
ichthyosis	I-Disease	O
in	O	O
a	O	O
Chinese	O	O
family	O	O
.	O	O
Kallmann	O	O
syndrome	O	O
(	O	O
KS	O	O
)	O	O
is	O	O
a	O	O
genetically	O	O
heterogeneous	O	O
disease	O	O
characterised	O	O
by	O	O
hypogonadotrophic	O	O
hypogonadism	O	O
in	O	O
association	O	O
with	O	O
anosmia	O	O
or	O	O
hyposmia	O	O
.	O	O
This	O	O
condition	O	O
affects	O	O
1	O	O
in	O	O
10	O	O
000	O	O
men	O	O
and	O	O
1	O	O
in	O	O
50	O	O
000	O	O
women	O	O
.	O	O
Defects	O	O
in	O	O
seventeen	O	O
genes	O	O
including	O	O
KAL1	O	O
gene	O	O
contribute	O	O
to	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
KS	O	O
.	O	O
We	O	O
report	O	O
the	O	O
clinical	O	O
characteristics	O	O
,	O	O
molecular	O	O
causes	O	O
and	O	O
treatment	O	O
outcome	O	O
of	O	O
two	O	O
Chinese	O	O
brothers	O	O
with	O	O
KS	O	O
and	O	O
X	O	O
-	O	O
linked	O	O
ichthyosis	O	O
.	O	O
The	O	O
phenotypes	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
characterised	O	O
by	O	O
bilateral	O	O
cryptorchidism	O	O
,	O	O
unilateral	O	O
renal	O	O
agenesis	O	O
in	O	O
one	O	O
patient	O	O
but	O	O
normal	O	O
kidney	O	O
development	O	O
in	O	O
another	O	O
.	O	O
The	O	O
patients	O	O
had	O	O
low	O	O
serum	O	O
testosterone	O	O
,	O	O
follicle	O	O
-	O	O
stimulating	O	O
hormone	O	O
and	O	O
luteinising	O	O
hormone	O	O
levels	O	O
and	O	O
a	O	O
blunt	O	O
response	O	O
to	O	O
the	O	O
gonadotrophin	O	O
-	O	O
releasing	O	O
hormone	O	O
stimulation	O	O
test	O	O
.	O	O
After	O	O
human	O	O
chorionic	O	O
gonadotrophin	O	O
treatment	O	O
,	O	O
the	O	O
serum	O	O
testosterone	O	O
levels	O	O
were	O	O
normalized	O	O
,	O	O
and	O	O
the	O	O
pubic	O	O
hair	O	O
,	O	O
penis	O	O
length	O	O
and	O	O
testicular	O	O
volumes	O	O
were	O	O
greatly	O	O
improved	O	O
in	O	O
both	O	O
of	O	O
the	O	O
patients	O	O
.	O	O
The	O	O
two	O	O
affected	O	O
siblings	O	O
had	O	O
the	O	O
same	O	O
novel	O	O
deletion	O	O
at	O	O
Xp22.3	O	O
including	O	O
exons	O	O
9	O	O
-	O	O
14	O	O
of	O	O
KAL1	O	O
gene	O	O
and	O	O
entire	O	O
STS	O	O
gene	O	O
.	O	O
Our	O	O
study	O	O
broadens	O	O
the	O	O
mutation	B-Var	O
spectrum	O	O
in	O	O
the	O	O
KAL1	B-Gene	O
gene	O	O
associated	B-Reg	O
with	I-Reg	O
KS	B-Disease	O
and	O	O
facilitates	O	O
the	O	O
genetic	O	O
diagnosis	O	O
and	O	O
counselling	O	O
for	O	O
KS	O	O
.	O	O
[	O	O
Heterozygote	O	O
forms	O	O
of	O	O
familial	O	O
Mediterranean	O	O
fever	O	O
can	O	O
be	O	O
manifested	O	O
in	O	O
adults	O	O
as	O	O
myofacial	O	O
pain	O	O
syndrome	O	O
]	O	O
.	O	O
Heterozygote	O	O
Formen	O	O
des	O	O
familiären	O	O
Mittelmeerfiebers	O	O
können	O	O
beim	O	O
Erwachsenen	O	O
als	O	O
myofasziales	O	O
Schmerzsyndrom	O	O
imponieren	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
is	O	O
a	O	O
disease	O	O
characterized	O	O
by	O	O
recurrent	O	O
fever	O	O
,	O	O
serositis	O	O
,	O	O
arthritis	O	O
and	O	O
unspecific	O	O
myalgia	O	O
.	O	O
It	O	O
is	O	O
prevalent	O	O
among	O	O
Mediterranean	O	O
people	O	O
and	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
associated	B-Reg	O
with	O	O
mutations	B-Var	O
in	O	O
the	O	O
Mediterranean	O	O
fever	O	O
(	B-Gene	O
MEFV	I-Gene	O
)	I-Gene	O
gene	O	O
which	O	O
,	O	O
encodes	O	O
pyrin	O	O
a	O	O
regulatory	O	O
protein	O	O
of	O	O
the	O	O
inflammasome	O	O
.	O	O
As	O	O
heterozygous	B-Var	O
mutations	I-Var	O
in	O	O
MEFV	B-Gene	O
can	O	O
be	O	O
associated	B-Reg	O
with	O	O
only	O	O
mild	O	B-Disease
inflammatory	O	I-Disease
symptoms	O	I-Disease
,	O	O
such	O	O
as	O	O
arthralgia	B-CPA	O
or	O	O
chronic	B-CPA	O
fibromyalgic	I-CPA	O
pain	I-CPA	O
,	O	O
FMF	O	O
may	O	O
be	O	O
underdiagnosed	O	O
in	O	O
the	O	O
current	O	O
diagnostic	O	O
work	O	O
-	O	O
up	O	O
of	O	O
musculoskeletal	O	O
diseases	O	O
.	O	O
METHODS	O	O
:	O	O
The	O	O
selection	O	O
of	O	O
patients	O	O
was	O	O
carried	O	O
out	O	O
according	O	O
to	O	O
the	O	O
following	O	O
criteria	O	O
:	O	O
myofacial	O	O
pain	O	O
syndrome	O	O
,	O	O
seronegative	O	O
oligoarthralgia	O	O
,	O	O
a	O	O
slight	O	O
inflammatory	O	O
constellation	O	O
and	O	O
ethnic	O	O
origin	O	O
from	O	O
the	O	O
Mediterranean	O	O
area	O	O
.	O	O
When	O	O
these	O	O
criteria	O	O
were	O	O
fulfilled	O	O
a	O	O
molecular	O	O
genetic	O	O
investigation	O	O
was	O	O
carried	O	O
out	O	O
RESULTS	O	O
:	O	O
This	O	O
article	O	O
presents	O	O
evidence	O	O
that	O	O
9	O	O
out	O	O
of	O	O
12	O	O
Mediterranean	O	O
patients	O	O
with	O	O
recurrent	O	O
myofascial	B-Disease	O
pain	I-Disease	O
syndrome	I-Disease	O
and	O	O
mild	B-CPA	O
inflammation	I-CPA	O
revealed	B-Reg	O
heterozygote	B-Var	O
mutations	I-Var	O
in	O	O
the	O	O
MEFV	B-Gene	O
gene	O	O
and	O	O
7	O	O
of	O	O
these	O	O
patients	O	O
benefitted	O	O
from	O	O
treatment	O	O
with	O	O
colchicine	O	O
.	O	O
DISCUSSION	O	O
:	O	O
As	O	O
colchicine	O	O
treatment	O	O
not	O	O
only	O	O
improved	O	O
the	O	O
myofascial	O	O
pain	O	O
but	O	O
also	O	O
prevented	O	O
FMF	O	O
-	O	O
associated	O	O
amyloidosis	O	O
and	O	O
nephropathy	O	O
,	O	O
differential	O	O
diagnosis	O	O
of	O	O
fibromyalgia	O	O
in	O	O
patients	O	O
of	O	O
Mediterranean	O	O
origin	O	O
should	O	O
include	O	O
FMF	O	O
and	O	O
a	O	O
genetic	O	O
screening	O	O
of	O	O
the	O	O
MEFV	O	O
locus	O	O
.	O	O
In	O	O
silico	O	O
analyses	O	O
of	O	O
missense	O	O
mutations	O	O
in	O	O
coagulation	O	O
factor	O	O
VIII	O	O
:	O	O
identification	O	O
of	O	O
severity	O	O
determinants	O	O
of	O	O
haemophilia	O	O
A.	O	O
Factor	O	O
VIII	O	O
(	B-Gene	O
FVIII	I-Gene	O
)	I-Gene	O
mutations	B-Var	O
cause	B-Reg	O
haemophilia	B-Disease	O
A	I-Disease	O
(	O	O
HA	O	O
)	O	O
,	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
coagulation	O	O
disorder	O	O
.	O	O
Over	O	O
1000	O	O
missense	O	O
mutations	O	O
in	O	O
FVIII	O	O
are	O	O
known	O	O
and	O	O
they	O	O
lead	O	O
to	O	O
variable	O	O
clinical	O	O
phenotypes	O	O
(	O	O
severe	O	O
,	O	O
moderate	O	O
and	O	O
mild	O	O
)	O	O
.	O	O
The	O	O
exact	O	O
molecular	O	O
basis	O	O
of	O	O
this	O	O
phenotypic	O	O
heterogeneity	O	O
by	O	O
FVIII	O	O
missense	O	O
mutations	O	O
is	O	O
elusive	O	O
to	O	O
date	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
severity	O	O
determinants	O	O
that	O	O
cause	O	O
phenotypic	O	O
heterogeneity	O	O
of	O	O
HA	O	O
.	O	O
We	O	O
compiled	O	O
and	O	O
curated	O	O
a	O	O
data	O	O
set	O	O
of	O	O
766	O	O
missense	O	O
mutations	O	O
from	O	O
the	O	O
repertoire	O	O
of	O	O
missense	O	O
mutations	O	O
in	O	O
FVIII	O	O
.	O	O
We	O	O
analysed	O	O
these	O	O
mutations	O	O
by	O	O
computational	O	O
programs	O	O
(	O	O
e.g.	O	O
Swiss	O	O
-	O	O
PdbViewer	O	O
)	O	O
and	O	O
different	O	O
mutation	O	O
analysis	O	O
servers	O	O
(	O	O
e.g.	O	O
SIFT	O	O
,	O	O
PROVEAN	O	O
,	O	O
CUPSAT	O	O
,	O	O
PolyPhen2	O	O
,	O	O
MutPred	O	O
)	O	O
;	O	O
and	O	O
various	O	O
sequence-	O	O
and	O	O
structure	O	O
-	O	O
based	O	O
parameters	O	O
were	O	O
assessed	O	O
for	O	O
any	O	O
significant	O	O
distribution	O	O
bias	O	O
among	O	O
different	O	O
HA	O	O
phenotypes	O	O
.	O	O
Our	O	O
analyses	O	O
suggest	O	O
that	O	O
'	O	O
mutations	O	O
in	O	O
evolutionary	O	O
conserved	O	O
residues	O	O
'	O	O
,	O	O
'	O	O
mutations	O	O
in	O	O
buried	O	O
residues	O	O
'	O	O
,	O	O
mutation	B-Reg	O
-	I-Reg	O
induced	I-Reg	O
'	O	O
steric	O	O
clash	O	O
'	O	O
and	O	O
'	B-MPA	O
surface	I-MPA	O
electrostatic	I-MPA	O
potential	I-MPA	O
alteration	I-MPA	O
'	I-MPA	O
act	O	O
as	O	O
risk	O	O
factors	B-Reg	O
towards	O	O
severe	O	O
HA	B-Disease	O
.	O	O
We	O	O
have	O	O
developed	O	O
a	O	O
grading	O	O
system	O	O
for	O	O
FVIII	O	O
mutations	O	O
combining	O	O
the	O	O
severity	O	O
determinants	O	O
,	O	O
and	O	O
the	O	O
grading	O	O
pattern	O	O
correlates	O	O
with	O	O
HA	O	O
phenotype	O	O
.	O	O
This	O	O
study	O	O
will	O	O
help	O	O
to	O	O
correctly	O	O
associate	O	O
the	O	O
HA	O	O
phenotype	O	O
with	O	O
a	O	O
mutation	O	O
and	O	O
aid	O	O
early	O	O
characterization	O	O
of	O	O
novel	O	O
variants	O	O
.	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
adrenal	I-Disease	O
hypoplasia	I-Disease	O
congenita	I-Disease	O
:	I-Disease	O
clinical	O	O
and	O	O
follow	O	O
-	O	O
up	O	O
findings	O	O
of	O	O
two	O	O
kindreds	O	O
,	O	O
one	O	O
with	B-Reg	O
a	O	O
novel	O	O
NR0B1	B-Gene	O
mutation	B-Var	O
.	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
adrenal	I-Disease	O
hypoplasia	I-Disease	O
congenita	I-Disease	O
typically	O	O
manifests	O	O
as	O	O
primary	O	O
adrenal	B-Disease	O
insufficiency	I-Disease	O
in	O	O
the	O	O
newborn	O	O
age	O	B-CPA
and	O	O
hypogonadotropic	B-Disease	O
hypogonadism	I-Disease	B-CPA
in	O	O
males	O	B-Gene
,	O	O
being	O	O
caused	B-Reg	B-Reg
by	I-Reg	O
mutations	B-Var	B-Var
in	O	O
NR0B1	B-Gene	B-Gene
gene	O	O
.	O	O
We	O	O
present	O	O
the	O	O
clinical	O	O
and	O	O
follow	O	O
-	O	O
up	O	O
findings	O	O
of	O	O
two	O	O
kindreds	O	O
with	O	O
NR0B1	O	O
mutations	O	O
.	O	O
The	O	O
proband	O	O
of	O	O
kindred	O	O
A	O	O
had	O	O
a	O	O
diagnosis	O	O
of	O	O
primary	O	O
adrenal	O	O
insufficiency	O	O
when	O	O
he	O	O
was	O	O
a	O	O
newborn	O	O
.	O	O
Family	O	O
history	O	O
was	O	O
relevant	O	O
for	O	O
a	O	O
maternal	O	O
uncle	O	O
death	O	O
at	O	O
the	O	O
newborn	O	O
age	O	O
.	O	O
Beyond	O	O
2	O	O
year	O	O
-	O	O
old	O	O
steroid	O	O
measurements	O	O
rendered	O	O
undetectable	O	O
and	O	O
delayed	O	O
bone	O	O
age	O	O
was	O	O
noticed	O	O
.	O	O
Molecular	O	O
analysis	O	O
of	O	O
NR0B1	B-Gene	O
gene	O	O
revealed	O	O
a	O	O
previously	O	O
unreported	O	O
mutation	O	O
(	B-Var	O
c.1084A	I-Var	O
>	I-Var	O
T	I-Var	O
)	I-Var	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
,	O	O
p	B-MPA	O
.	I-MPA	O
Lys362	I-MPA	O
*	I-MPA	O
,	O	O
in	O	O
exon	O	O
1	O	O
.	O	O
His	O	O
mother	O	O
and	O	O
sister	O	O
were	O	O
asymptomatic	O	O
carriers	O	O
.	O	O
At	O	O
14	O	O
year	O	O
-	O	O
old	O	O
he	O	O
had	O	O
3	O	O
mL	O	O
of	O	O
testicular	O	O
volume	O	O
and	O	O
biochemical	O	O
surveys	O	O
(	O	O
LH	O	O
<	O	O
0.1	O	O
UI	O	O
/	O	O
L	O	O
,	O	O
total	O	O
testosterone	O	O
<	O	O
10	O	O
ng	O	O
/	O	O
dL	O	O
)	O	O
concordant	O	O
with	O	O
hypogonadotrophic	O	O
hypogonadism	O	O
.	O	O
Kindred	O	O
B	O	O
had	O	O
two	O	O
males	O	O
diagnosed	O	O
with	O	O
adrenal	O	O
insufficiency	O	O
at	O	O
the	O	O
newborn	O	O
age	O	O
.	O	O
By	O	O
3	O	O
year	O	O
-	O	O
old	O	O
both	O	O
siblings	O	O
had	O	O
undetectable	O	O
androgen	O	O
levels	O	O
and	O	O
delayed	O	O
bone	O	O
age	O	O
.	O	O
NR0B1	O	O
molecular	O	O
analysis	O	O
identified	O	O
a	O	O
nonsense	O	O
mutation	O	O
in	O	O
both	O	O
cases	O	O
,	O	O
c.243C	O	O
>	O	I-Var
G	O	O
;	O	O
p	O	O
.	O	O
Tyr81	O	O
*	O	O
,	O	O
in	O	O
exon	O	O
1	O	O
.	O	O
Their	O	O
mother	O	O
and	O	O
sister	O	O
were	O	O
asymptomatic	O	O
carriers	O	O
.	O	O
At	O	O
14	O	O
year	O	O
-	O	O
old	O	O
(	O	O
Tanner	O	O
stage	O	O
1	O	O
)	O	O
hypothalamic	O	O
-	O	O
pituitary	O	O
-	O	O
gonadal	O	O
axis	O	O
evaluation	O	O
in	O	O
both	O	O
males	O	O
(	O	O
LH	O	O
<	O	O
0.1UI	O	O
/	O	O
L	O	O
,	O	O
total	O	O
testosterone	O	O
<	O	O
10	O	O
ng	O	O
/	O	O
dL	O	O
)	O	O
confirmed	O	O
hypogonadotropic	O	O
hypogonadism	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
biochemical	O	O
profiles	O	O
,	O	O
bone	O	B-CPA
age	O	O
and	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
inheritance	O	O
led	O	O
to	O	O
suspicion	O	O
of	O	O
NR0B1	O	O
mutations	O	O
.	O	O
Two	O	O
nonsense	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
both	O	O
kindreds	O	O
,	O	O
one	O	O
previously	O	O
unreported	O	O
(	O	O
c.1084A	O	O
>	O	O
T	O	O
;	O	O
p	O	O
.	O	O
Lys362	O	O
*	O	O
)	O	O
.	O	O
Mutation	O	O
identification	O	O
allowed	O	O
the	O	O
timely	O	O
institution	O	O
of	O	O
testosterone	O	O
in	O	O
patients	O	O
at	O	O
puberty	O	O
and	O	O
an	O	O
appropriate	O	O
genetic	O	O
counselling	O	O
for	O	O
relatives	O	O
.	O	O
Phenotypic	O	O
Variability	O	O
and	O	O
Newly	O	O
Identified	O	O
Mutations	B-Var	O
of	O	O
the	O	O
IVD	B-Gene	O
Gene	O	O
in	O	O
Japanese	O	O
Patients	O	O
with	B-Reg	O
Isovaleric	B-Disease	O
Acidemia	I-Disease	O
.	O	O
Isovaleric	O	O
acidemia	O	O
(	O	O
IVA	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
inborn	O	O
error	O	O
affecting	O	O
leucine	O	O
metabolism	O	O
.	O	O
It	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
deficiency	O	O
in	O	O
isovaleryl	O	O
-	O	O
CoA	O	O
dehydrogenase	O	O
(	O	O
IVD	O	O
)	O	O
,	O	O
a	O	O
mitochondrial	O	O
matrix	O	O
enzyme	O	O
that	O	O
catalyzes	O	O
the	O	O
oxidation	O	O
of	O	O
isovaleryl	O	O
-	O	O
CoA	O	O
to	O	O
3-methylcrotonyl	O	O
-	O	O
CoA.	O	O
IVD	O	O
is	O	O
a	O	O
FAD	O	O
-	O	O
containing	O	O
enzyme	O	O
,	O	O
consisting	O	O
of	O	O
four	O	O
identical	O	O
subunits	O	O
.	O	O
Clinical	O	O
features	O	O
of	O	O
IVA	O	O
include	O	O
poor	O	O
feeding	O	O
,	O	O
vomiting	O	O
,	O	O
lethargy	O	O
,	O	O
developmental	O	O
delay	O	O
,	O	O
metabolic	O	O
acidosis	O	O
,	O	O
and	O	O
a	O	O
characteristic	O	O
"	O	O
sweaty	O	O
foot	O	O
"	O	O
odor	O	O
.	O	O
IVA	O	O
is	O	O
one	O	O
of	O	O
the	O	O
target	O	O
disorders	O	O
for	O	O
newborn	O	O
screening	O	O
by	O	O
tandem	O	O
mass	O	O
spectrometry	O	O
(	O	O
MS	O	O
/	O	O
MS	O	O
)	O	O
.	O	O
The	O	O
human	O	O
IVD	O	O
gene	O	O
is	O	O
located	O	O
on	O	O
chromosome	O	O
15q	O	O
.	O	O
To	O	O
date	O	O
,	O	O
over	O	O
50	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
have	O	O
been	O	O
reported	O	O
worldwide	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
searched	O	O
for	O	O
IVD	O	O
mutations	O	O
in	O	O
five	O	O
Japanese	O	O
patients	O	O
with	O	O
IVA	O	O
(	O	O
neonatal	O	O
type	O	O
,	O	O
two	O	O
patients	O	O
;	O	O
chronic	O	O
intermittent	O	O
type	O	O
,	O	O
two	O	O
patients	O	O
;	O	O
and	O	O
mild	O	O
biochemical	O	O
type	O	O
,	O	O
one	O	O
patient	O	O
)	O	O
.	O	O
The	O	O
diagnosis	O	O
of	O	O
IVA	O	O
was	O	O
confirmed	O	O
by	O	O
urinary	O	O
organic	O	O
acid	O	O
analysis	O	O
using	O	O
gas	O	O
chromatography	O	O
and	O	O
mass	O	O
spectrometry	O	O
.	O	O
All	O	O
coding	O	O
exons	O	O
and	O	O
the	O	O
flanking	O	O
introns	O	O
in	O	O
the	O	O
IVD	O	O
gene	O	O
were	O	O
amplified	O	O
by	O	O
PCR	O	O
and	O	O
were	O	O
directly	O	O
sequenced	O	O
.	O	O
We	O	O
thus	O	O
identified	O	O
six	O	O
hitherto	O	O
unknown	O	O
mutations	O	O
(	O	O
p	O	O
.	O	O
G94D	O	O
,	O	O
p	O	O
.	O	O
E116	O	O
K	O	O
,	O	O
p	O	O
.	O	O
M167	O	O
T	O	O
,	O	O
p	O	O
.	O	O
L243P	O	O
,	O	O
p	O	O
.	O	O
L246P	O	O
,	O	O
and	O	O
c.696	O	O
+	O	O
1G	O	O
>	O	O
T	O	O
)	O	O
and	O	O
four	O	O
previously	O	O
reported	O	O
(	O	O
p	O	O
.	O	O
R53P	O	O
,	O	O
p	O	O
.	O	O
R395C	O	O
,	O	O
p	O	O
.	O	O
Y403C	O	O
,	O	O
and	O	O
p	O	O
.	O	O
E411	O	O
K	O	I-Var
)	O	O
pathogenic	O	O
mutations	O	O
.	O	O
All	O	O
patients	O	O
were	O	O
compound	O	O
heterozygotes	O	O
,	O	O
and	O	O
each	O	O
mutation	O	O
was	O	O
identified	O	O
in	O	O
a	O	O
single	O	O
patient	O	O
.	O	O
Pathogenicity	O	O
of	O	O
newly	O	O
identified	O	O
mutations	O	O
was	O	O
validated	O	O
using	O	O
computational	O	O
programs	O	O
.	O	O
Among	O	O
them	O	O
,	O	O
the	O	O
p	B-Var	O
.	I-Var	O
M167	I-Var	O
T	I-Var	O
is	O	O
believed	O	O
to	O	O
influence	B-Reg	O
FAD	B-Interaction	O
binding	I-Interaction	O
,	O	O
as	O	O
the	O	O
position	O	O
167	O	O
is	O	O
present	O	O
in	O	O
one	O	O
of	O	O
the	O	O
FAD	O	O
-	O	O
binding	O	O
sites	O	O
.	O	O
Our	O	O
results	O	O
have	O	O
illustrated	O	O
the	O	O
heterogeneous	O	O
mutation	O	O
spectrum	O	O
and	O	O
clinical	O	O
presentation	O	O
of	O	O
IVA	O	O
in	O	O
the	O	O
Japanese	O	O
patients	O	O
.	O	O
Molecular	O	O
and	O	O
clinical	O	O
features	O	O
of	O	O
inherited	O	O
neuropathies	O	O
due	O	O
to	O	O
PMP22	O	O
duplication	O	O
.	O	O
PMP22	O	O
is	O	O
a	O	O
transmembrane	O	O
glycoprotein	O	O
component	O	O
of	O	O
myelin	O	O
,	O	O
important	O	O
for	O	O
myelin	O	O
functioning	O	O
.	O	O
Mutation	B-Var	O
of	O	O
PMP22	B-Gene	O
gene	O	O
which	O	O
encodes	O	O
for	O	O
the	O	O
production	O	O
of	O	O
PMP22	O	O
glycoprotein	O	O
is	O	O
associated	B-Reg	O
with	I-Reg	O
a	O	O
variety	O	O
of	O	O
inherited	O	O
neuropathies	B-Disease	O
.	O	O
This	O	O
literature	O	O
review	O	O
sought	O	O
to	O	O
review	O	O
the	O	O
molecular	O	O
mechanism	O	O
and	O	O
clinical	O	O
features	O	O
of	O	O
inherited	O	O
neuropathies	O	O
caused	O	O
by	O	O
PMP22	O	O
duplication	O	O
.	O	O
PMP22	O	O
duplication	O	O
causes	O	O
CMT1A	O	O
which	O	O
accounts	O	O
for	O	O
more	O	O
than	O	O
half	O	O
of	O	O
all	O	O
CMT	O	O
cases	O	O
and	O	O
about	O	O
70	O	O
%	O	O
of	O	O
CMT1	O	O
cases	O	O
.	O	O
It	O	O
manifests	O	O
with	O	O
muscle	O	O
weakness	O	O
,	O	O
depressed	O	O
reflexes	O	O
,	O	O
impaired	O	O
distal	O	O
sensation	O	O
,	O	O
hand	O	O
and	O	O
foot	O	O
deformities	O	O
,	O	O
slowing	O	O
of	O	O
NCV	O	O
and	O	O
onion	O	O
bulbs	O	O
.	O	O
With	O	O
no	O	O
specific	O	O
treatment	O	O
available	O	O
,	O	O
it	O	O
is	O	O
managed	O	O
conservatively	O	O
.	O	O
Future	O	O
treatment	O	O
may	O	O
be	O	O
based	O	O
on	O	O
the	O	O
molecular	O	O
genetics	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
A	O	O
novel	O	O
gene	O	O
insertion	B-Var	O
combined	O	O
with	O	O
a	O	O
missense	O	O
mutation	O	O
causing	B-Reg	O
factor	B-Disease	O
VII	I-Disease	O
deficiency	I-Disease	O
in	O	O
two	O	O
unrelated	O	O
Chinese	O	O
families	O	O
.	O	O
Hereditary	O	O
coagulation	O	O
factor	O	O
VII	O	O
(	O	O
FVII	O	O
)	O	O
deficiency	O	O
is	O	O
a	O	O
rare	O	O
bleeding	O	O
disorder	O	O
characterized	O	O
by	O	O
reduced	O	O
FVII	O	O
activity	O	O
(	O	O
FVII	O	O
:	O	O
C	O	O
)	O	O
and	O	O
inconsistent	O	O
FVII	O	O
antigen	O	O
(	O	O
FVII	O	O
:	O	O
Ag	O	O
)	O	O
.	O	O
In	O	O
our	O	O
study	O	O
,	O	O
two	O	O
pregnant	O	O
probands	O	O
were	O	O
diagnosed	O	O
with	O	O
FVII	O	O
deficiency	O	O
,	O	O
based	O	O
on	O	O
the	O	O
tests	O	O
that	O	O
FVII	O	O
:	O	O
C	O	O
were	O	O
both	O	O
3	O	O
%	O	O
and	O	O
FVII	O	O
:	O	O
Ag	O	O
were	O	O
less	O	O
than	O	O
7.5	O	O
%	O	O
.	O	O
Gene	O	O
sequencing	O	O
revealed	O	O
the	O	O
same	O	O
compound	O	O
mutations	O	O
,	O	O
a	O	O
recurrent	O	O
missense	O	O
mutation	O	O
p	O	O
.	O	O
Arg277Cys	O	O
and	O	O
a	O	O
novel	O	O
insertion	O	O
mutation	O	O
g.11520	O	O
-	O	O
11521insT.	O	O
What	O	O
is	O	O
more	O	O
,	O	O
haplotype	O	O
analysis	O	O
of	O	O
SNPs	O	O
excluded	O	O
the	O	O
possibility	O	O
of	O	O
consanguinity	O	O
between	O	O
the	O	O
two	O	O
families	O	O
.	O	O
According	O	O
to	O	O
the	O	O
model	O	O
,	O	O
we	O	O
speculated	O	O
that	O	O
although	O	O
the	O	O
insertion	B-Var	O
mutation	O	O
was	O	O
close	O	O
to	O	O
the	O	O
carboxy	O	O
-	O	O
terminal	O	O
,	O	O
it	O	O
induced	B-PosReg	O
the	O	O
protein	B-MPA	O
extension	I-MPA	O
and	O	O
affected	B-Reg	O
the	B-MPA	O
3	I-MPA	O
'	I-MPA	O
untranslated	I-MPA	O
region	I-MPA	O
of	O	O
F7	B-Gene	O
gene	O	O
,	O	O
which	O	O
is	O	O
significant	O	O
to	O	O
posttranscriptional	O	O
regulation	O	O
.	O	O
Hypothetically	O	O
,	O	O
the	O	O
stability	O	O
or	O	O
translational	O	O
efficiency	O	O
of	O	O
mRNA	O	O
may	O	O
be	O	O
influenced	O	O
,	O	O
resulting	O	O
in	O	O
reducing	O	O
FVII	O	O
:	O	O
C.	O	O
Hereditary	O	O
spastic	O	O
paraplegia	O	O
SPG4	O	O
:	O	O
what	O	O
is	O	O
known	O	O
and	O	O
not	O	O
known	O	O
about	O	O
the	O	O
disease	O	O
.	O	O
Mutations	O	O
in	O	O
more	O	O
than	O	O
70	O	O
distinct	O	O
loci	O	O
and	O	O
more	O	O
than	O	O
50	O	O
mutated	O	O
gene	O	O
products	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
patients	O	O
with	O	O
hereditary	B-Disease	O
spastic	I-Disease	O
paraplegias	I-Disease	O
,	O	O
a	O	O
diverse	O	O
group	O	O
of	O	O
neurological	O	O
disorders	O	O
characterized	O	O
predominantly	O	O
,	O	O
but	O	O
not	O	O
exclusively	O	O
,	O	O
by	O	O
progressive	O	O
lower	O	O
limb	O	O
spasticity	O	O
and	O	O
weakness	O	O
resulting	O	O
from	O	O
distal	O	O
degeneration	O	O
of	O	O
corticospinal	O	O
tract	O	O
axons	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
SPAST	B-Gene	O
(	O	O
previously	O	O
known	O	O
as	O	O
SPG4	B-Gene	O
)	I-Gene	O
gene	O	O
that	O	O
encodes	O	O
the	O	O
microtubule	O	O
-	O	O
severing	O	O
protein	O	O
called	O	O
spastin	O	O
,	O	O
are	O	O
the	O	O
most	O	O
common	O	O
cause	B-Reg	O
of	O	O
the	O	O
disease	B-Disease	O
.	O	O
The	O	O
aetiology	O	O
of	O	O
the	O	O
disease	O	O
is	O	O
poorly	O	O
understood	O	O
,	O	O
but	O	O
partial	O	O
loss	B-NegReg	O
of	O	O
microtubule	B-CPA	O
-	I-CPA	O
severing	I-CPA	O
activity	I-CPA	O
resulting	O	O
from	O	O
inactivating	B-Var	O
mutations	I-Var	O
in	O	O
one	O	O
SPAST	B-Gene	O
allele	O	O
is	O	O
the	O	O
most	O	O
postulated	O	O
explanation	O	O
.	O	O
Microtubule	O	O
severing	O	O
is	O	O
important	O	O
for	O	O
regulating	O	O
various	O	O
aspects	O	O
of	O	O
the	O	O
microtubule	O	O
array	O	O
,	O	O
including	O	O
microtubule	O	O
number	O	O
,	O	O
length	O	O
,	O	O
and	O	O
mobility	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
higher	O	O
numbers	O	O
of	O	O
dynamic	O	O
plus	O	O
-	O	O
ends	O	O
of	O	O
microtubules	O	O
,	O	O
resulting	O	O
from	O	O
microtubule	O	O
-	O	O
severing	O	O
events	O	O
,	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
endosomal	O	O
tubulation	O	O
and	O	O
fission	O	O
.	O	O
Even	O	O
so	O	O
,	O	O
there	O	O
is	O	O
growing	O	O
evidence	O	O
that	O	O
decreased	O	O
severing	O	O
of	O	O
microtubules	O	O
does	O	O
not	O	O
fully	O	O
explain	O	O
HSP	O	O
-	O	O
SPG4	O	O
.	O	O
The	O	O
presence	O	O
of	O	O
two	O	O
translation	O	O
initiation	O	O
codons	O	O
in	O	O
SPAST	O	O
allows	O	O
synthesis	O	O
of	O	O
two	O	O
spastin	O	O
isoforms	O	O
:	O	O
a	O	O
full	O	O
-	O	O
length	O	O
isoform	O	O
called	O	O
M1	O	O
and	O	O
a	O	O
slightly	O	O
shorter	O	O
isoform	O	O
called	O	O
M87	O	O
.	O	O
M87	O	O
is	O	O
more	O	O
abundant	O	O
in	O	O
both	O	O
neuronal	O	O
and	O	O
non	O	O
-	O	O
neuronal	O	O
tissues	O	O
.	O	O
Studies	O	O
on	O	O
rodents	O	O
suggest	O	O
that	O	O
M1	O	O
is	O	O
only	O	O
readily	O	O
detected	O	O
in	O	O
adult	O	O
spinal	O	O
cord	O	O
,	O	O
which	O	O
is	O	O
where	O	O
nerve	O	O
degeneration	O	O
mainly	O	O
occurs	O	O
in	O	O
humans	O	O
with	O	O
HSP	O	O
-	O	O
SPG4	O	O
.	O	O
M1	O	O
,	O	O
due	O	O
to	O	O
its	O	O
hydrophobic	O	O
N	O	O
-	O	O
terminal	O	O
domain	O	O
not	O	O
shared	O	O
by	O	O
M87	O	O
,	O	O
may	O	O
insert	O	O
into	O	O
endoplasmic	O	O
reticulum	O	O
membrane	O	O
,	O	O
and	O	O
together	O	O
with	O	O
reticulons	O	O
,	O	O
atlastin	O	O
and	O	O
REEP1	O	O
,	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
morphogenesis	O	O
of	O	O
this	O	O
organelle	O	O
.	O	O
Some	B-Var	B-Gene
mutated	I-Var	B-Var
spastins	B-Protein	O
may	O	O
act	O	O
in	O	O
dominant	O	O
-	O	O
negative	O	O
fashion	O	O
to	O	O
lower	B-NegReg	O
microtubule	B-CPA	O
-	I-CPA	O
severing	I-CPA	O
activity	I-CPA	O
,	O	O
but	O	O
others	B-Var	O
have	O	O
detrimental	B-NegReg	O
effects	I-NegReg	O
on	O	O
neurons	B-CPA	O
without	O	O
further	O	O
lowering	O	O
microtubule	O	O
severing	O	O
.	O	O
The	O	O
observed	O	O
adverse	B-NegReg	O
effects	I-NegReg	O
on	O	O
microtubule	B-CPA	O
dynamics	I-CPA	O
,	O	O
axonal	B-CPA	O
transport	I-CPA	O
,	O	O
endoplasmic	B-CPA	O
reticulum	I-CPA	O
,	O	O
and	O	O
endosomal	B-CPA	O
trafficking	I-CPA	O
are	O	O
likely	O	O
caused	O	O
not	O	O
only	O	O
by	O	O
diminished	B-NegReg	O
severing	B-CPA	O
of	I-CPA	O
microtubules	I-CPA	O
,	O	O
but	O	O
also	O	O
by	O	O
neurotoxicity	B-CPA	O
of	B-Reg	O
mutant	B-Var	O
spastin	B-Protein	O
proteins	I-Protein	O
,	O	O
chiefly	O	O
M1	B-Protein	O
.	O	O
Some	O	O
large	O	O
deletions	O	O
in	O	O
SPAST	O	O
might	O	O
also	O	O
affect	O	O
the	O	O
function	O	O
of	O	O
adjacent	O	O
genes	O	O
,	O	O
further	O	O
complicating	O	O
the	O	O
aetiology	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
Clinical	O	O
phenotype	O	O
in	O	O
genetically	O	O
confirmed	O	O
von	O	O
Willebrand	O	O
disease	O	O
type	O	O
2N	O	O
patients	O	O
reflects	O	O
a	O	O
haemophilia	O	O
A	O	O
phenotype	O	O
.	O	O
INTRODUCTION	O	O
:	O	O
Von	B-Disease	O
Willebrand	I-Disease	O
disease	I-Disease	O
(	I-Disease	O
VWD	I-Disease	O
)	I-Disease	O
type	I-Disease	O
2N	I-Disease	O
is	O	O
characterized	O	O
by	O	O
a	O	O
defective	B-NegReg	O
binding	B-Interaction	O
of	O	O
factor	B-Protein	O
VIII	I-Protein	O
(	O	O
FVIII	O	O
)	O	O
to	O	O
von	B-Protein	O
Willebrand	I-Protein	O
factor	I-Protein	O
(	O	O
VWF	O	O
)	O	O
resulting	O	O
in	O	O
diminished	B-NegReg	O
plasma	B-CPA	O
FVIII	I-CPA	O
levels	I-CPA	O
and	O	O
a	O	O
clinical	O	O
phenotype	O	O
mimicking	O	O
mild	O	O
haemophilia	O	O
A.	O	O
Several	O	O
mutations	B-Var	O
in	O	O
the	O	O
FVIII	O	O
binding	O	O
site	O	O
of	O	O
VWF	B-Gene	O
have	O	O
been	O	O
reported	O	O
.	O	O
AIM	O	O
:	O	O
This	O	O
study	O	O
aims	O	O
to	O	O
examine	O	O
the	O	O
effect	O	O
of	O	O
genotype	O	O
on	O	O
clinical	O	O
phenotype	O	O
in	O	O
a	O	O
cohort	O	O
of	O	O
VWD	O	O
2N	O	O
patients	O	O
.	O	O
METHODS	O	O
:	O	O
Patients	O	O
with	O	O
at	O	O
least	O	O
one	O	O
genetically	O	O
confirmed	O	O
2N	O	O
mutation	O	O
were	O	O
selected	O	O
retrospectively	O	O
from	O	O
a	O	O
cohort	O	O
of	O	O
patients	O	O
with	O	O
suspected	O	O
VWD	O	O
.	O	O
Clinical	O	O
and	O	O
laboratory	O	O
phenotypes	O	O
including	O	O
bleeding	O	O
scores	O	O
(	O	O
BS	O	O
)	O	O
were	O	O
obtained	O	O
and	O	O
analysed	O	O
.	O	O
RESULTS	O	O
:	O	O
Forty	O	O
-	O	O
two	O	O
VWD	O	O
2N	O	O
patients	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
44	O	O
years	O	O
were	O	O
included	O	O
.	O	O
Eleven	O	O
patients	O	O
were	O	O
homozygous	O	O
or	O	O
compound	O	O
heterozygous	O	O
(	O	O
genetically	O	O
confirmed	O	O
group	O	O
)	O	O
and	O	O
31	O	O
patients	O	O
were	O	O
heterozygously	O	O
affected	O	O
(	O	O
carriers	O	O
group	O	O
)	O	O
.	O	O
Statistically	O	O
significant	O	O
differences	O	O
between	O	O
genetically	O	O
confirmed	O	O
VWD	O	O
2N	O	O
patients	O	O
and	O	O
carriers	O	O
were	O	O
found	O	O
in	O	O
FVIII	O	O
activity	O	O
,	O	O
VWF	O	O
antigen	O	O
levels	O	O
,	O	O
VWF	O	O
-	O	O
FVIII	O	O
binding	O	O
capacity	O	O
,	O	O
FVIII	O	O
/	O	O
VWF	O	O
antigen	O	O
ratio	O	O
(	O	O
all	O	O
P<0.001	O	O
)	O	O
,	O	O
VWF	O	O
-	O	O
ristocetin	O	O
activity	O	O
(	O	O
p=0.001	O	O
)	O	O
and	O	O
VWF	O	O
collagen	O	O
binding	O	O
(	O	O
P	O	O
=	O	O
0.002	O	O
)	O	O
.	O	O
Median	O	O
BS	O	O
was	O	O
6	O	O
in	O	O
genetically	O	O
confirmed	O	O
VWD	O	O
2N	O	O
patients	O	O
compared	O	O
with	O	O
3	O	O
in	O	O
carriers	O	O
(	O	O
P	O	O
=	O	O
0.047	O	O
)	O	O
.	O	O
Haemarthrosis	O	O
,	O	O
muscle	O	O
haematomas	O	O
and	O	O
postpartum	O	O
haemorrhage	O	O
were	O	O
only	O	O
reported	O	O
in	O	O
genetically	O	O
confirmed	O	O
2N	O	O
patients	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Phenotypic	O	O
analysis	O	O
showed	O	O
that	O	O
all	O	O
laboratory	O	O
parameters	O	O
are	O	O
lower	O	O
in	O	O
genetically	O	O
confirmed	O	O
VWD	O	O
2N	O	O
patients	O	O
compared	O	O
with	O	O
heterozygous	O	O
2N	O	O
carriers	O	O
.	O	O
The	O	O
clinical	O	O
phenotype	O	O
in	O	O
genetically	O	O
confirmed	O	O
VWD	O	O
2N	O	O
patients	O	O
is	O	O
comparable	O	O
to	O	O
mild	O	O
haemophilia	O	O
A	O	O
patients	O	O
and	O	O
more	O	O
severe	O	O
than	O	O
heterozygous	O	O
2N	O	O
carriers	O	O
.	O	O
A	O	O
novel	O	O
SLC12A3	B-Gene	O
gene	O	O
homozygous	O	O
mutation	B-Var	O
of	B-Reg	O
Gitelman	B-Disease	O
syndrome	I-Disease	O
in	O	O
an	O	O
Asian	O	O
pedigree	O	O
and	O	O
literature	O	O
review	O	O
.	O	O
OBJECTIVES	O	O
:	O	O
Gitelman	B-Disease	O
syndrome	I-Disease	O
(	O	O
GS	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
disease	O	O
characterized	O	O
by	O	O
hypokalemic	O	O
metabolic	O	O
alkalosis	O	O
in	O	O
combination	O	O
with	O	O
significant	O	O
hypomagnesemia	O	O
and	O	O
hypocalciuria	O	O
which	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
SLC12A3	B-Gene	O
gene	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
reported	O	O
a	O	O
case	O	O
of	O	O
GS	O	O
pedigree	O	O
and	O	O
reviewed	O	O
pertinent	O	O
literature	O	O
so	O	O
as	O	O
to	O	O
explore	O	O
the	O	O
relationship	O	O
between	O	O
clinical	O	O
characteristics	O	O
and	O	O
genotype	O	O
meanwhile	O	O
provide	O	O
recommendations	O	O
for	O	O
the	O	O
diagnosis	O	O
and	O	O
treatment	O	O
of	O	O
GS	O	O
.	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
:	O	O
This	O	O
is	O	O
a	O	O
pedigree	O	O
-	O	O
based	O	O
genetic	O	O
study	O	O
of	O	O
GS	O	O
and	O	O
11	O	O
members	O	O
from	O	O
one	O	O
family	O	O
were	O	O
included	O	O
.	O	O
We	O	O
summarized	O	O
their	O	O
clinical	O	O
features	O	O
,	O	O
analyzed	O	O
laboratory	O	O
parameters	O	O
related	O	O
to	O	O
GS	O	O
and	O	O
SLC12A3	O	O
gene	O	O
.	O	O
RESULTS	O	O
:	O	O
The	O	O
proband	O	O
experienced	O	O
intermittent	O	O
severe	O	O
symptoms	O	O
of	O	O
weakness	O	O
accompanied	O	O
by	O	O
significant	O	O
hypokalemia	O	O
,	O	O
hypomagnesemia	O	O
and	O	O
hypocalciuria	O	O
in	O	O
laboratory	O	O
test	O	O
with	O	O
poor	O	O
treatments	O	O
.	O	O
His	O	O
mother	O	O
had	O	O
more	O	O
slight	O	O
symptoms	O	O
of	O	O
weakness	O	O
than	O	O
him	O	O
with	O	O
mild	O	O
hypokalemia	O	O
and	O	O
hypocalciuria	O	O
.	O	O
Mild	O	O
hypomagnesemia	O	O
was	O	O
also	O	O
observed	O	O
in	O	O
his	O	O
sister	O	O
with	O	O
occasional	O	O
weakness	O	O
.	O	O
All	O	O
other	O	O
pedigree	O	O
members	O	O
had	O	O
normal	O	O
laboratory	O	O
test	O	O
with	O	O
no	O	O
GS	O	O
-	O	O
related	O	O
symptoms	O	O
.	O	O
A	O	O
homozygous	O	O
mutation	O	O
of	O	O
SLC12A3	O	O
gene	O	O
(	O	O
c.488C	O	O
>	O	O
T	O	O
)	O	O
was	O	O
detected	O	O
by	O	O
genetic	O	O
testing	O	O
in	O	O
three	O	O
members	O	O
,	O	O
and	O	O
six	O	O
were	O	O
carriers	O	O
of	O	O
this	O	O
mutation	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Genotype	O	O
and	O	O
phenotype	O	O
vary	O	O
significantly	O	O
among	O	O
GS	O	O
patients	O	O
.	O	O
Male	O	O
patients	O	O
tend	O	O
to	O	O
experience	O	O
more	O	O
severe	O	O
symptoms	O	O
and	O	O
poor	O	O
treatment	O	O
effect	O	O
.	O	O
Further	O	O
large	O	O
-	O	O
scale	O	O
population	O	O
,	O	O
animal	O	O
,	O	O
and	O	O
molecular	O	O
biology	O	O
experiments	O	O
are	O	O
required	O	O
to	O	O
investigate	O	O
the	O	O
complexity	O	O
of	O	O
GS	O	O
and	O	O
to	O	O
find	O	O
a	O	O
better	O	O
treatment	O	O
regimen	O	O
for	O	O
this	O	O
disease	O	O
.	O	O
Darier	O	O
disease	O	O
in	O	O
israel	O	O
:	O	O
combined	O	O
evaluation	O	O
of	O	O
genetic	O	O
and	O	O
neuropsychiatric	O	O
aspects	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Darier	B-Disease	O
disease	I-Disease	O
(	O	O
DD	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
genodermatose	O	O
caused	B-Reg	O
by	I-Reg	O
heterozygous	O	O
mutations	B-Var	O
in	O	O
the	O	O
ATP2A2	B-Gene	O
gene	O	O
and	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
neuropsychiatric	O	O
manifestations	O	O
.	O	O
OBJECTIVES	O	O
:	O	O
To	O	O
investigate	O	O
the	O	O
genetic	O	O
basis	O	O
of	O	O
Israeli	O	O
patients	O	O
with	O	O
DD	O	O
,	O	O
and	O	O
its	O	O
association	O	O
with	O	O
neuropsychiatric	O	O
phenotype	O	O
.	O	O
METHODS	O	O
:	O	O
A	O	O
cohort	O	O
of	O	O
32	O	O
families	O	O
comprising	O	O
74	O	O
affected	O	O
individuals	O	O
and	O	O
13	O	O
unaffected	O	O
family	O	O
members	O	O
recruited	O	O
from	O	O
the	O	O
Haemek	O	O
Dermatology	O	O
Department	O	O
and	O	O
other	O	O
dermatology	O	O
clinics	O	O
in	O	O
Israel	O	O
were	O	O
evaluated	O	O
by	O	O
detailed	O	O
questionnaires	O	O
,	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
genetic	O	O
analysis	O	O
.	O	O
Main	O	O
outcome	O	O
measures	O	O
were	O	O
genetic	O	O
mutations	O	O
,	O	O
psychiatric	O	O
profile	O	O
,	O	O
and	O	O
their	O	O
association	O	O
.	O	O
RESULTS	O	O
:	O	O
23	O	O
mutations	O	O
in	O	O
ATP2A2	O	O
gene	O	O
were	O	O
scattered	O	O
over	O	O
the	O	O
entire	O	O
gene	O	O
,	O	O
14	O	O
of	O	O
them	O	O
novel	O	O
.	O	O
Two	O	O
families	O	O
shared	O	O
the	O	O
same	O	O
mutation	O	O
.	O	O
Twenty	O	O
-	O	O
one	O	O
patients	O	O
(	O	O
28.3	O	O
%	O	O
)	O	O
had	O	O
a	O	O
history	O	O
of	O	O
psychiatric	O	O
disorder	O	O
,	O	O
most	O	O
of	O	O
them	O	O
mood	O	O
disorders	O	O
;	O	O
another	O	O
7	O	O
(	O	O
9.4	O	O
%	O	O
)	O	O
patients	O	O
were	O	O
highly	O	O
suspected	O	O
of	O	O
having	O	O
a	O	O
psychiatric	O	O
disorder	O	O
;	O	O
21	O	O
(	O	O
27.6	O	O
%	O	O
)	O	O
reported	O	O
suicidal	O	O
thoughts	O	O
;	O	O
and	O	O
5	O	O
(	O	O
6.6	O	O
%	O	O
)	O	O
had	O	O
attempted	O	O
suicide	O	O
.	O	O
Psychiatric	O	O
phenotype	O	O
demonstrated	O	O
inter-	O	O
and	O	O
intra	O	O
-	O	O
familial	O	O
variability	O	O
,	O	O
and	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
disease	O	O
severity	O	O
,	O	O
family	O	O
history	O	O
of	O	O
psychiatric	O	O
disease	O	O
,	O	O
or	O	O
mutation	O	O
location	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
cohort	O	O
demonstrated	O	O
genetic	O	O
heterogeneity	O	O
with	O	O
no	O	O
mutation	O	O
cluster	O	O
along	O	O
the	O	O
gene	O	O
,	O	O
and	O	O
high	O	O
prevalence	O	O
of	O	O
psychiatric	O	O
disorders	O	O
.	O	O
Although	O	O
no	O	O
clear	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
was	O	O
found	O	O
,	O	O
the	O	O
results	O	O
point	O	O
to	O	O
a	O	O
major	O	O
effect	O	O
of	O	O
genetic	O	O
background	O	O
on	O	O
psychiatric	O	O
phenotype	O	O
,	O	O
together	O	O
with	O	O
other	O	O
modifiers	O	O
.	O	O
This	O	O
article	O	O
is	O	O
protected	O	O
by	O	O
copyright	O	O
.	O	O
All	O	O
rights	O	O
reserved	O	O
.	O	O
A	O	O
recurrent	B-Var	O
germline	I-Var	O
mutation	I-Var	O
in	O	O
the	O	O
PIGA	B-Gene	O
gene	O	O
causes	B-Reg	O
Simpson	B-Disease	O
-	I-Disease	O
Golabi	I-Disease	O
-	I-Disease	O
Behmel	I-Disease	O
syndrome	I-Disease	O
type	I-Disease	O
2	I-Disease	O
.	O	O
Hypomorphic	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
PIGA	O	O
(	O	O
phosphatidylinositol	O	O
glycan	O	O
class	O	O
A	O	O
)	O	O
gene	O	O
recently	O	O
were	O	O
recognized	O	O
as	O	O
the	O	O
cause	O	O
of	O	O
a	O	O
clinically	O	O
heterogeneous	O	O
spectrum	O	O
of	O	O
X	O	O
-	O	O
linked	O	O
disorders	O	O
including	O	O
(	O	O
i	O	O
)	O	O
early	O	O
onset	O	O
epileptic	O	O
encephalopathy	O	O
with	O	O
severe	O	O
muscular	O	O
hypotonia	O	O
,	O	O
dysmorphism	O	O
,	O	O
multiple	O	O
congenital	O	O
anomalies	O	O
,	O	O
and	O	O
early	O	O
death	O	O
(	O	O
"	O	O
MCAHS2	O	O
"	O	O
)	O	O
,	O	O
(	O	O
ii	O	O
)	O	O
neurodegenerative	O	O
encephalopathy	O	O
with	O	O
systemic	O	O
iron	O	O
overload	O	O
(	O	O
ferro	O	O
-	O	O
cerebro	O	O
-	O	O
cutaneous	O	O
syndrome	O	O
,	O	O
"	O	O
FCCS	O	O
"	O	O
)	O	O
,	O	O
and	O	O
(	O	O
iii	O	O
)	O	O
intellectual	O	O
disability	O	O
and	O	O
seizures	O	O
without	O	O
dysmorphism	O	O
.	O	O
Previous	O	O
studies	O	O
showed	O	O
that	O	O
the	O	O
recurrent	O	O
PIGA	O	O
germline	O	O
mutation	O	O
c.1234C	O	B-Var
>	O	I-Var
T	O	I-Var
(	O	O
p	O	O
.	O	O
Arg412	O	O
*	O	O
)	O	O
leads	O	O
to	O	O
a	O	O
clinical	O	O
phenotype	O	O
at	O	O
the	O	O
most	O	O
severe	O	O
end	O	O
of	O	O
the	O	O
spectrum	O	O
associated	O	O
with	O	O
early	O	O
infantile	O	O
lethality	O	O
.	O	O
We	O	O
identified	O	O
three	O	O
additional	O	O
individuals	O	O
from	O	O
two	O	O
unrelated	O	O
families	O	O
with	O	O
the	O	O
same	O	O
PIGA	O	O
mutation	O	O
.	O	O
Major	O	O
clinical	O	O
findings	O	O
include	O	O
early	O	O
onset	O	O
intractable	O	O
epileptic	O	O
encephalopathy	O	O
with	O	O
a	O	O
burst	O	O
-	O	O
suppression	O	O
pattern	O	O
on	O	O
EEG	O	O
,	O	O
generalized	O	O
muscular	O	O
hypotonia	O	O
,	O	O
structural	O	O
brain	O	O
abnormalities	O	O
,	O	O
macrocephaly	O	O
and	O	O
increased	O	O
birth	O	O
weight	O	O
,	O	O
joint	O	O
contractures	O	O
,	O	O
coarse	O	O
facial	O	O
features	O	O
,	O	O
widely	O	O
spaced	O	O
eyes	O	O
,	O	O
a	O	O
short	O	O
nose	O	O
with	O	O
anteverted	O	O
nares	O	O
,	O	O
gingival	O	O
overgrowth	O	O
,	O	O
a	O	O
wide	O	O
mouth	O	O
,	O	O
short	O	O
limbs	O	O
with	O	O
short	O	O
distal	O	O
phalanges	O	O
,	O	O
and	O	O
a	O	O
small	O	O
penis	O	O
.	O	O
Based	O	O
on	O	O
the	O	O
phenotypic	O	O
overlap	O	O
with	O	O
Simpson	O	O
-	O	O
Golabi	O	O
-	O	O
Behmel	O	O
syndrome	O	O
type	O	O
2	O	O
(	O	O
SGBS2	O	O
)	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
both	O	O
disorders	O	O
might	O	O
have	O	O
the	O	O
same	O	O
underlying	O	O
cause	O	O
.	O	O
We	O	O
were	O	O
able	O	O
to	O	O
confirm	O	O
the	O	O
same	O	O
c.1234C	O	O
>	O	O
T	O	O
(	O	O
p	O	O
.	O	O
Arg412	O	O
*	O	O
)	O	O
mutation	O	O
in	O	O
the	O	O
DNA	O	O
sample	O	O
from	O	O
an	O	O
affected	O	O
fetus	O	O
of	O	O
the	O	O
original	O	O
family	O	O
affected	O	O
with	O	O
SGBS2	O	O
.	O	O
We	O	O
conclude	O	O
that	O	O
the	O	O
recurrent	O	O
PIGA	B-Gene	O
germline	O	O
mutation	O	O
c.1234C	B-Var	O
>	I-Var	O
T	I-Var	O
leads	B-Reg	O
to	I-Reg	O
a	O	O
recognizable	B-CPA	O
clinical	I-CPA	O
phenotype	I-CPA	O
with	O	O
a	O	O
poor	O	O
prognosis	O	O
and	O	O
is	O	O
the	O	O
cause	B-Reg	O
of	O	O
SGBS2	B-Disease	O
.	O	O
©	O	O
2015	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc.	O	O
Incontinentia	O	O
pigmenti	O	O
(	O	O
Bloch	O	O
-	O	O
Sulzberger	O	O
syndrome	O	O
)	O	O
.	O	O
Incontinentia	B-Disease	O
pigmenti	I-Disease	O
(	O	O
IP	O	O
;	O	O
Bloch	O	O
-	O	O
Sulzberger	O	O
syndrome	O	O
;	O	O
OMIM	O	O
#	O	O
308300	O	O
)	O	O
is	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
dominant	O	O
neurocutaneous	O	O
disorder	O	O
with	O	O
presumed	O	O
male	O	O
lethality	O	O
.	O	O
It	O	O
is	O	O
usually	O	O
diagnosed	O	O
in	O	O
female	O	O
newborns	O	O
based	O	O
on	O	O
skin	O	O
features	O	O
(	O	O
erythematous	O	O
,	O	O
vesicular	O	O
,	O	O
or	O	O
bullous	O	O
eruption	O	O
in	O	O
linear	O	O
streaks	O	O
)	O	O
.	O	O
The	O	O
skin	O	O
lesions	O	O
evolve	O	O
into	O	O
a	O	O
verrucous	O	O
stage	O	O
,	O	O
followed	O	O
by	O	O
atrophy	O	O
and	O	O
scarring	O	O
,	O	O
leaving	O	O
linear	O	O
areas	O	O
of	O	O
hypopigmentation	O	O
and	O	O
hyperpigmented	O	O
macules	O	O
in	O	O
bizarre	O	O
patterns	O	O
following	O	O
Blaschko	O	O
's	O	O
lines	O	O
.	O	O
Systemic	O	O
and	O	O
neurologic	O	O
complications	O	O
include	O	O
focal	O	O
seizures	O	O
and	O	O
hemorrhagic	O	O
cerebral	O	O
infarction	O	O
in	O	O
infants	O	O
,	O	O
and	O	O
retinal	O	O
vasculopathy	O	O
leading	O	O
to	O	O
blindness	O	O
.	O	O
Hypodontia	O	O
,	O	O
conical	O	O
or	O	O
pegged	O	O
teeth	O	O
,	O	O
and	O	O
linear	O	O
areas	O	O
of	O	O
alopecia	O	O
persist	O	O
into	O	O
adulthood	O	O
.	O	O
IP	B-Disease	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutation	B-Var	O
of	O	O
the	O	O
IKBKG	B-Gene	O
/	I-Gene	O
NEMO	I-Gene	O
gene	O	O
on	O	O
Xq28	O	O
.	O	O
Deletion	O	O
of	O	O
exons	O	O
4	O	O
to	O	O
10	O	O
(	O	O
NEMOΔ4	O	O
-	O	O
10	O	O
)	O	O
accounts	O	O
for	O	O
about	O	O
80	O	O
%	O	O
of	O	O
cases	O	O
(	O	O
familial	O	O
and	O	O
sporadic	O	O
)	O	O
.	O	O
NEMO	B-Gene	O
mutation	B-Var	O
leads	O	O
to	O	O
loss	B-NegReg	O
of	I-NegReg	O
function	I-NegReg	O
of	O	O
NF	B-MPA	O
-	I-MPA	O
κB	I-MPA	O
,	O	O
a	O	O
critical	O	O
protein	O	O
that	O	O
modulates	O	O
cellular	O	B-CPA
proliferation	O	I-CPA
,	O	O
apoptosis	O	O
,	O	O
and	O	O
response	O	O
to	O	O
proinflammatory	O	O
factors	O	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
the	O	O
characteristic	O	O
features	O	O
of	O	O
IP	B-Disease	O
.	O	O
In	O	O
female	O	O
carriers	O	O
,	O	O
selective	O	O
loss	O	O
of	O	O
cells	O	O
expressing	O	O
the	O	O
mutant	O	B-Var
X	O	O
-	O	O
chromosome	O	O
results	O	O
in	O	O
completely	O	O
skewed	O	O
X	O	O
-	O	O
inactivation	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
cases	O	O
.	O	O
Study	O	O
of	O	O
mouse	O	O
models	O	O
in	O	O
which	O	O
various	O	O
components	O	O
of	O	O
the	O	O
NF	O	O
-	O	O
κB	O	O
pathway	O	O
(	O	O
including	O	O
NEMO	O	O
)	O	O
have	O	O
been	O	O
knocked	O	O
out	O	O
has	O	O
contributed	O	O
significantly	O	O
to	O	O
our	O	O
understanding	O	O
of	O	O
disease	O	O
pathogenesis	O	O
.	O	O
Lipoid	O	O
proteinosis	O	O
.	O	O
Lipoid	B-Disease	O
proteinosis	I-Disease	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
ECM1	B-Gene	O
,	O	O
encoding	O	O
extracellular	O	O
matrix	O	O
protein	O	O
1	O	O
,	O	O
a	O	O
glycoprotein	O	O
expressed	O	O
in	O	O
many	O	O
organs	O	O
and	O	O
which	O	O
has	O	O
important	O	O
protein	O	O
-	O	O
protein	O	O
interactions	O	O
in	O	O
tissue	O	O
homeostasis	O	O
.	O	O
Although	O	O
the	O	O
disease	O	O
usually	O	O
presents	O	O
clinically	O	O
with	O	O
warty	O	O
infiltration	O	O
of	O	O
the	O	O
skin	O	O
and	O	O
mucous	O	O
membranes	O	O
and	O	O
a	O	O
hoarse	O	O
voice	O	O
,	O	O
neuropsychological	O	O
and	O	O
neuropsychiatric	O	O
abnormalities	O	O
are	O	O
often	O	O
prominent	O	O
features	O	O
.	O	O
There	O	O
may	O	O
be	O	O
bean-	O	O
or	O	O
comma	O	O
-	O	O
shaped	O	O
intracranial	O	O
calcifications	O	O
,	O	O
often	O	O
selectively	O	O
affecting	O	O
the	O	O
amygdala	O	O
.	O	O
Patients	O	O
with	O	O
lipoid	O	O
proteinosis	O	O
therefore	O	O
have	O	O
been	O	O
used	O	O
as	O	O
models	O	O
for	O	O
demonstrating	O	O
physiologic	O	O
and	O	O
pathologic	O	O
abnormalities	O	O
of	O	O
the	O	O
amygdala	O	O
with	O	O
respect	O	O
to	O	O
fear	O	O
processing	O	O
,	O	O
affect	O	O
and	O	O
cognition	O	O
,	O	O
anxiety	O	O
and	O	O
memory	O	O
.	O	O
Clinically	O	O
,	O	O
patients	O	O
may	O	O
also	O	O
have	O	O
epilepsy	O	O
,	O	O
especially	O	O
involving	O	O
the	O	O
temporal	O	O
lobes	O	O
.	O	O
Less	O	O
common	O	O
or	O	O
rare	O	O
disease	O	O
associations	O	O
are	O	O
headache	O	O
(	O	O
including	O	O
migraine	O	O
)	O	O
,	O	O
ataxia	O	O
,	O	O
dizziness	O	O
,	O	O
schizophrenia	O	O
,	O	O
generalized	O	O
dystonia	O	O
,	O	O
transient	O	O
brachiofacial	O	O
paralysis	O	O
,	O	O
and	O	O
intracerebral	O	O
hemorrhage	O	O
.	O	O
Beyond	O	O
the	O	O
foci	O	O
of	O	O
calcification	O	O
,	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
neurologic	O	O
abnormalities	O	O
in	O	O
lipoid	O	O
proteinosis	O	O
is	O	O
unknown	O	O
,	O	O
although	O	O
the	O	O
ECM1	O	O
protein	O	O
can	O	O
normally	O	O
bind	O	O
to	O	O
various	O	O
extracellular	O	O
matrix	O	O
proteins	O	O
and	O	O
glycosaminoglycans	O	O
as	O	O
well	O	O
as	O	O
certain	O	O
enzymes	O	O
,	O	O
including	O	O
matrix	O	O
metalloproteinase	O	O
9	O	O
.	O	O
Loss	O	O
of	O	O
key	O	O
protein	O	O
-	O	O
protein	O	O
interactions	O	O
may	O	O
underscore	O	O
some	O	O
of	O	O
the	O	O
disease	O	O
pathophysiology	O	O
.	O	O
There	O	O
is	O	O
currently	O	O
no	O	O
effective	O	O
treatment	O	O
for	O	O
lipoid	O	O
proteinosis	O	O
and	O	O
clinical	O	O
care	O	O
is	O	O
largely	O	O
supportive	O	O
.	O	O
Paternal	O	O
uniparental	O	O
disomy	O	O
11p15.5	O	O
in	O	O
the	O	O
pancreatic	O	O
nodule	O	O
of	O	O
an	O	O
infant	O	O
with	O	O
Costello	O	O
syndrome	O	O
:	O	O
Shared	O	O
mechanism	O	O
for	O	O
hyperinsulinemic	O	O
hypoglycemia	O	O
in	O	O
neonates	O	O
with	O	O
Costello	O	O
and	O	O
Beckwith	O	O
-	O	O
Wiedemann	O	O
syndrome	O	O
and	O	O
somatic	O	O
loss	O	O
of	O	O
heterozygosity	O	O
in	O	O
Costello	O	O
syndrome	O	O
driving	O	O
clonal	O	O
expansion	O	O
.	O	O
Costello	B-Disease	B-Disease
syndrome	I-Disease	I-Disease
(	O	O
CS	O	O
)	O	O
entails	O	O
a	O	O
cancer	O	O
predisposition	O	O
and	O	O
is	O	O
caused	O	O
by	O	O
activating	B-PosReg	O
HRAS	B-Gene	O
mutations	B-Var	O
,	O	O
typically	O	O
arising	O	O
de	O	O
novo	O	O
in	O	O
the	O	O
paternal	O	O
germline	O	O
.	O	O
Hypoglycemia	O	O
is	O	O
common	O	O
in	O	O
CS	O	O
neonates	O	O
.	O	O
A	O	O
previously	O	O
reported	O	O
individual	O	O
with	O	O
the	O	O
rare	O	O
HRAS	O	O
p	O	O
.	O	O
Gln22Lys	O	O
had	O	O
hyperinsulinemic	O	O
hypoglycemia	O	O
.	O	O
Autopsy	O	O
showed	O	O
a	O	O
discrete	O	O
pancreatic	O	O
nodule	O	O
.	O	O
The	O	O
morphologic	O	O
and	O	O
immunohistochemistry	O	O
findings	O	O
,	O	O
including	O	O
loss	O	O
of	O	O
p57(Kip2	O	O
)	O	O
protein	O	O
,	O	O
were	O	O
identical	O	O
to	O	O
a	O	O
focal	O	O
lesion	O	O
of	O	O
congenital	O	O
hyperinsulinism	O	O
,	O	O
however	O	O
,	O	O
no	O	O
KCNJ11	O	O
or	O	O
ABCC8	O	O
mutation	O	O
was	O	O
identified	O	O
and	O	O
germline	O	O
derived	O	O
DNA	O	O
showed	O	O
no	O	O
alternation	O	O
of	O	O
the	O	O
maternal	O	O
or	O	O
paternal	O	O
11p15	O	O
alleles	O	O
.	O	O
Here	O	O
we	O	O
report	O	O
paternal	O	O
uniparental	O	O
disomy	O	O
(	O	O
pUPD	O	O
)	O	O
within	O	O
the	O	O
lesion	O	O
,	O	O
similar	O	O
to	O	O
the	O	O
pUPD11p15.5	O	O
in	O	O
Beckwith	O	O
-	O	O
Wiedemann	O	O
syndrome	O	O
(	O	O
BWS	O	O
)	O	O
.	O	O
The	O	O
similar	O	O
extent	O	O
of	O	O
the	O	O
pUPD	O	O
suggests	O	O
a	O	O
similar	O	O
mechanism	O	O
driving	O	O
hyperinsulinemia	O	O
in	O	O
both	O	O
conditions	O	O
.	O	O
After	O	O
coincidental	O	O
somatic	O	O
LOH	O	B-CPA
and	O	O
pUPD	O	O
,	O	O
the	O	O
growth	O	O
promoting	O	O
effects	O	O
of	O	O
the	O	O
paternally	O	O
derived	O	O
HRAS	O	O
mutation	O	O
,	O	O
in	O	O
combination	O	O
with	O	O
the	O	O
increased	O	O
function	O	O
of	O	O
the	O	O
adjacent	O	O
paternally	O	O
expressed	O	O
IGF2	O	O
,	O	O
may	O	O
together	O	O
result	O	O
in	O	O
clonal	O	O
expansion	O	O
.	O	O
Although	O	O
this	O	O
somatic	O	O
LOH	O	O
within	O	O
pancreatic	O	O
tissue	O	O
resulted	O	O
in	O	O
hyperinsulinism	O	O
,	O	O
similar	O	O
LOH	O	O
in	O	O
mesenchymal	O	O
cells	O	O
may	O	O
drive	O	O
embryonal	O	O
rhabdomyosarcoma	O	O
(	O	O
ERMS	O	O
)	O	O
.	O	O
Interestingly	O	O
,	O	O
biallelic	O	O
IGF2	O	O
expression	O	O
has	O	O
been	O	O
linked	O	O
to	O	O
rhabdomyosarcoma	O	O
tumorigenesis	O	O
and	O	O
pUPD11	O	O
occurred	O	O
in	O	O
all	O	O
8	O	O
ERMS	O	O
samples	O	O
from	O	O
CS	O	O
individuals	O	O
.	O	O
Somatic	O	O
KRAS	O	O
and	O	O
HRAS	O	O
mutations	O	O
occur	O	O
with	O	O
comparable	O	O
frequency	O	O
in	O	O
isolated	O	O
malignancies	O	O
.	O	O
Yet	O	O
,	O	O
the	O	O
malignancy	O	O
risk	O	O
in	O	O
CS	O	O
is	O	O
notably	O	O
higher	O	O
than	O	O
in	O	O
Noonan	O	O
syndrome	O	O
with	O	O
a	O	O
KRAS	O	O
mutation	O	O
.	O	O
It	O	O
is	O	O
conceivable	O	O
that	O	O
HRAS	O	O
co	O	O
-	O	O
localization	O	O
with	O	O
IGF2	O	O
and	O	O
the	O	O
combined	O	O
effect	O	O
of	O	O
pUPD	O	O
11p15.5	O	O
on	O	O
both	O	O
genes	O	O
contributes	O	O
to	O	O
the	O	O
oncogenic	O	O
potential	O	O
.	O	O
©	O	O
2015	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc.	O	O
Progranulin	O	O
deficiency	O	O
induces	O	O
overactivation	O	O
of	O	O
WNT5A	O	O
expression	O	O
via	O	O
TNF	O	O
-	O	O
α	O	O
/	O	O
NF	O	O
-	O	O
κB	O	O
pathway	O	O
in	O	O
peripheral	O	O
cells	O	O
from	O	O
frontotemporal	O	O
dementia	O	O
-	O	O
linked	O	O
granulin	O	O
mutation	O	O
carriers	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
progranulin	O	O
gene	O	O
(	B-Gene	O
GRN	I-Gene	O
)	I-Gene	O
mutations	B-Var	O
have	O	O
been	O	O
identified	O	O
as	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
frontotemporal	B-Disease	O
lobar	I-Disease	O
degeneration	I-Disease	O
with	O	O
transactive	O	O
response	O	O
(	O	O
TAR	O	O
)	O	O
DNA	O	O
-	O	O
binding	O	O
protein	O	O
43	O	O
(	O	O
TDP-43	O	O
)	O	O
pathology	O	O
(	O	O
frontotemporal	O	O
lobar	O	O
degeneration	O	O
[	O	O
FTLD]-TDP	O	O
)	O	O
;	O	O
however	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
association	O	O
between	O	O
progranulin	O	O
(	O	O
PGRN	O	O
)	O	O
deficiency	O	O
and	O	O
neuronal	O	O
loss	O	O
in	O	O
individuals	O	O
with	O	O
FTLD	O	O
-	O	O
TDP	O	O
.	O	O
Previously	O	O
we	O	O
reported	O	O
enhanced	O	O
proliferative	O	O
activity	O	O
associated	O	O
with	O	O
the	O	O
activation	O	O
of	O	O
WNT5A	O	O
/	O	O
CDK6	O	O
/	O	O
pRb	O	O
signalling	O	O
in	O	O
PGRN	O	O
-	O	O
deficient	O	O
cells	O	O
.	O	O
The	O	O
objective	O	O
of	O	O
this	O	O
work	O	O
was	O	O
to	O	O
elucidate	O	O
the	O	O
association	O	O
between	O	O
PGRN	O	O
deficiency	O	O
,	O	O
WNT5A	O	O
signalling	O	O
and	O	O
cell	O	O
proliferation	O	O
in	O	O
immortalized	O	O
lymphoblasts	O	O
from	O	O
carriers	O	O
of	O	O
the	O	O
c.709	O	O
-	O	O
1	O	O
G	O	O
>	O	O
A	O	O
GRN	O	O
mutation	O	O
(	O	O
asymptomatic	O	O
and	O	O
FTLD	O	O
-	O	O
TDP	O	O
)	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
assessed	O	O
cell	O	O
proliferation	O	O
in	O	O
carriers	O	O
of	O	O
the	O	O
c.709	O	O
-	O	O
1	O	O
G	O	I-Var
>	O	O
A	O	O
GRN	O	I-Gene
gene	O	O
mutation	O	O
and	O	O
controls	O	O
without	O	O
GRN	O	O
mutation	O	O
and	O	O
without	O	O
sign	O	O
of	O	O
neurologic	O	O
degeneration	O	O
by	O	O
cell	O	O
counting	O	O
or	O	O
using	O	O
an	O	O
MTT	O	O
assay	O	O
.	O	O
We	O	O
used	O	O
a	O	O
luciferase	O	O
assay	O	O
to	O	O
measure	O	O
the	O	O
nuclear	O	O
factor	O	O
-	O	O
κ	O	O
(	O	O
NF	O	O
-	O	O
κ	O	O
)	O	O
activity	O	O
.	O	O
We	O	O
evaluated	O	O
messenger	O	O
RNA	O	O
levels	O	O
using	O	O
quantitative	O	O
real	O	O
-	O	O
time	O	O
polymerase	O	O
chain	O	O
reaction	O	O
and	O	O
protein	O	O
levels	O	O
by	O	O
immunoblotting	O	O
.	O	O
Co	O	O
-	O	O
immunoprecipitation	O	O
was	O	O
used	O	O
to	O	O
analyze	O	O
the	O	O
interaction	O	O
between	O	O
PGRN	O	O
and	O	O
its	O	O
receptors	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
enrolled	O	O
19	O	O
carriers	O	O
of	O	O
the	O	O
GRN	O	O
gene	O	O
mutation	O	O
and	O	O
10	O	O
controls	O	O
in	O	O
this	O	O
study	O	O
.	O	O
The	O	O
PGRN	B-Var	O
-	I-Var	O
deficient	I-Var	O
cells	O	O
showed	O	O
increased	B-PosReg	O
expression	B-MPA	O
of	O	O
WNT5A	B-Gene	O
due	O	O
to	O	O
NF	B-Pathway	O
-	I-Pathway	O
κB	I-Pathway	O
signalling	I-Pathway	O
overactivation	B-PosReg	O
.	O	O
We	O	O
observed	O	O
a	O	O
competition	O	O
between	O	O
PGRN	O	O
and	O	O
tumour	O	O
necrosis	O	O
factor	O	O
-	O	O
α	O	O
(	O	O
TNF	O	O
-	O	O
α	O	O
)	O	O
for	O	O
binding	O	O
both	O	O
TNF	O	O
receptors	O	O
(	O	O
TNFR	O	O
)	O	O
I	O	O
and	O	O
II	O	O
.	O	O
Blocking	O	O
NF	O	O
-	O	O
κB	O	O
signalling	O	O
using	O	O
wedelolactone	O	O
or	O	O
specific	O	O
antibodies	O	O
against	O	O
TNFRs	O	O
inhibited	O	O
WNT5A	O	O
overexpression	O	O
and	O	O
proliferation	O	O
of	O	O
PGRN	O	O
-	O	O
deficient	O	O
cells	O	O
.	O	O
Conversely	O	O
,	O	O
the	O	O
activation	O	O
of	O	O
NF	O	O
-	O	O
κB	O	O
signalling	O	O
by	O	O
TNF	O	O
-	O	O
α	O	O
increased	O	O
WNT5A	O	O
-	O	O
dependent	O	O
proliferation	O	O
of	O	O
control	O	O
cells	O	O
.	O	O
LIMITATIONS	O	O
:	O	O
All	O	O
cell	O	O
lines	O	O
were	O	O
derived	O	O
from	O	O
individuals	O	O
harboring	O	O
the	O	O
same	O	O
splicing	O	O
GRN	O	O
mutation	O	O
.	O	O
Nevertheless	O	O
,	O	O
most	O	O
of	O	O
the	O	O
known	O	O
GRN	B-Gene	O
mutations	B-Var	O
lead	B-Reg	O
to	I-Reg	O
haploinsufficiency	B-Var	O
of	O	O
the	O	O
protein	B-Protein	O
.	O	O
CONCLUSION	O	O
:	O	O
Our	O	O
results	O	O
revealed	O	O
an	O	O
important	O	O
role	O	O
of	O	O
NF	O	O
-	O	O
κB	O	O
signalling	O	O
in	O	O
PGRN	O	O
-	O	O
associated	O	O
FTLD	O	O
-	O	O
TDP	O	O
and	O	O
confirm	O	O
that	O	O
PGRN	O	O
can	O	O
bind	O	O
to	O	O
TNF	O	O
-	O	O
a	O	O
receptors	O	O
regulating	O	O
the	O	O
expression	O	O
of	O	O
WNT5A	O	O
,	O	O
suggesting	O	O
novel	O	O
targets	O	O
for	O	O
treatment	O	O
of	O	O
FTLD	O	O
-	O	O
TDP	O	O
linked	O	O
to	O	O
GRN	O	O
mutations	O	O
.	O	O
ADIPOR1	B-Gene	O
is	O	O
Mutated	B-Var	O
in	B-Reg	O
Syndromic	O	O
Retinitis	B-Disease	O
Pigmentosa	I-Disease	O
.	O	O
Retinitis	O	O
pigmentosa	O	O
(	O	O
RP	O	O
)	O	O
is	O	O
a	O	O
genetically	O	O
heterogeneous	O	O
retinal	O	O
disorder	O	O
.	O	O
Despite	O	O
the	O	O
numerous	O	O
genes	O	O
associated	O	O
with	O	O
RP	O	O
already	O	O
identified	O	O
,	O	O
the	O	O
genetic	O	O
basis	O	O
remains	O	O
unknown	O	O
in	O	O
a	O	O
substantial	O	O
number	O	O
of	O	O
patients	O	O
and	O	O
families	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
performed	O	O
whole	O	O
exome	O	O
sequencing	O	O
to	O	O
investigate	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
a	O	O
syndromic	O	O
RP	O	O
case	O	O
which	O	O
can	O	O
not	O	O
be	O	O
solved	O	O
by	O	O
mutations	O	O
in	O	O
known	O	O
disease	O	O
-	O	O
causing	O	O
genes	O	O
.	O	O
After	O	O
applying	O	O
a	O	O
series	O	O
of	O	O
variant	O	O
filtering	O	O
strategies	O	O
,	O	O
we	O	O
identified	O	O
an	O	O
apparently	O	O
homozygous	O	O
frameshift	O	O
mutation	O	O
,	O	O
c.31delC	O	O
(	O	O
p	O	O
.	O	O
Q11Rfs*24	O	O
)	O	O
in	O	O
the	O	O
ADIPOR1	O	O
gene	O	O
.	O	O
The	O	O
reported	O	O
phenotypes	O	O
of	O	O
Adipor1-null	O	O
mice	O	O
contain	O	O
retinal	O	O
dystrophy	O	O
,	O	O
obesity	O	O
and	O	O
behavioral	O	O
abnormalities	O	O
,	O	O
which	O	O
highly	O	O
mimic	O	O
those	O	O
in	O	O
the	O	O
syndromic	O	O
RP	O	O
patient	O	O
.	O	O
We	O	O
further	O	O
confirmed	O	O
ADIPOR1	O	O
retina	O	O
expression	O	O
by	O	O
immunohistochemistry	O	O
.	O	O
Our	O	O
results	O	O
established	O	O
ADIPOR1	O	O
as	O	O
a	O	O
novel	O	O
disease	O	O
-	O	O
causing	O	O
gene	O	O
for	O	O
syndromic	O	O
RP	O	O
and	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
fatty	O	O
acid	O	O
transport	O	O
in	O	O
the	O	O
retina	O	O
.	O	O
This	O	O
article	O	O
is	O	O
protected	O	O
by	O	O
copyright	O	O
.	O	O
All	O	O
rights	O	O
reserved	O	O
.	O	O
Dysferlinopathy	O	O
in	O	O
Iran	O	O
:	O	O
Clinical	O	O
and	O	O
genetic	O	O
report	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Dysferlinopathy	B-Disease	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
very	O	O
wide	O	O
range	O	O
of	O	O
autosomal	O	O
recessively	O	O
inherited	O	O
mutations	B-Var	O
of	O	O
the	O	O
Dysferlin	B-Gene	O
gene	I-Gene	O
.	O	O
It	O	O
causes	B-Reg	O
a	O	O
spectrum	O	O
of	O	O
muscle	O	O
diseases	O	O
including	O	O
limb	B-Disease	O
-	I-Disease	O
girdle	I-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
(	O	O
LGMD	O	O
)	O	O
2B	O	O
and	O	O
Miyoshi	B-Disease	O
myopathy	I-Disease	O
(	O	O
MM	O	O
)	O	O
.	O	O
We	O	O
describe	O	O
the	O	O
clinical	O	O
course	O	O
and	O	O
mutational	O	O
analyses	O	O
of	O	O
15	O	O
Iranian	O	O
patients	O	O
with	O	O
dysferlinopathy	O	O
from	O	O
9	O	O
different	O	O
families	O	O
.	O	O
METHODS	O	O
:	O	O
Genomic	O	O
DNA	O	O
was	O	O
extracted	O	O
from	O	O
peripheral	O	O
blood	O	O
and	O	O
55	O	O
exons	O	O
and	O	O
flanking	O	O
intronic	O	O
boundaries	O	O
of	O	O
the	O	O
dysferlin	O	O
gene	O	O
(	O	O
DYSF	O	O
;	O	O
NM_003494.2	O	O
)	O	O
were	O	O
screened	O	O
for	O	O
mutations	O	O
and	O	O
analyzed	O	O
.	O	O
RESULTS	O	O
:	O	O
From	O	O
15	O	O
studied	O	O
patients	O	O
in	O	O
9	O	O
families	O	O
,	O	O
5	O	O
patients	O	O
were	O	O
male	O	O
.	O	O
Seven	O	O
families	O	O
had	O	O
consanguineous	O	O
marriage	O	O
.	O	O
Median	O	O
age	O	O
of	O	O
onset	O	O
was	O	O
16.8	O	O
;	O	O
and	O	O
the	O	O
median	O	O
age	O	O
of	O	O
diagnosis	O	O
was	O	O
26.6	O	O
.	O	O
The	O	O
onset	O	O
was	O	O
clearly	O	O
distal	O	O
in	O	O
7	O	O
patients	O	O
,	O	O
and	O	O
proximal	O	O
in	O	O
6	O	O
patients	O	O
.	O	O
Three	O	O
patients	O	O
had	O	O
partial	O	O
biceps	O	O
atrophy	O	O
and	O	O
13	O	O
showed	O	O
prominent	O	O
calf	O	O
muscle	O	O
wasting	O	O
.	O	O
Foot	O	O
plantar	O	O
flexors	O	O
,	O	O
deep	O	O
finger	O	O
flexors	O	O
and	O	O
hip	O	O
adductors	O	O
were	O	O
predominantly	O	O
involved	O	O
.	O	O
Genetic	O	O
testing	O	O
showed	O	O
homozygous	O	O
mutation	O	O
of	O	O
dysferlin	O	O
gene	O	O
in	O	O
9	O	O
probands	O	O
,	O	O
5	O	O
of	O	O
which	O	O
were	O	O
not	O	O
previously	O	O
reported	O	O
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
work	O	O
,	O	O
in	O	O
fact	O	O
,	O	O
may	O	O
help	O	O
shed	O	O
some	O	O
light	O	O
on	O	O
the	O	O
pattern	O	O
of	O	O
this	O	O
morbidity	O	O
in	O	O
Iran	O	O
,	O	O
an	O	O
effort	O	O
that	O	O
may	O	O
have	O	O
not	O	O
been	O	O
attempted	O	O
so	O	O
far	O	O
.	O	O
Limb	O	O
-	O	O
girdle	O	O
muscular	O	O
dystrophy	O	O
type	O	O
2A	O	O
in	O	O
Brazilian	O	O
children	O	O
.	O	O
Calpainopathy	O	O
is	O	O
an	O	O
autosomal	B-Disease	O
recessive	I-Disease	O
limb	I-Disease	O
girdle	I-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
(	O	O
LGMD2A	O	O
)	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
CAPN3	B-Gene	O
gene	O	O
.	O	O
Objective	O	O
To	O	O
present	O	O
clinical	O	O
and	O	O
histological	O	O
findings	O	O
in	O	O
six	O	O
children	O	O
with	O	O
a	O	O
molecular	O	O
diagnosis	O	O
of	O	O
LGMD2A	O	O
and	O	O
additionally	O	O
the	O	O
MRI	O	O
findings	O	O
in	O	O
two	O	O
of	O	O
them	O	O
.	O	O
Method	O	O
We	O	O
retrospectively	O	O
assessed	O	O
medical	O	O
records	O	O
of	O	O
6	O	O
patients	O	O
with	O	O
mutation	O	O
on	O	O
CAPN3	O	O
gene	O	O
.	O	O
Results	O	O
All	O	O
patients	O	O
were	O	O
female	O	O
(	O	O
three	O	O
to	O	O
12	O	O
years	O	O
)	O	O
.	O	O
The	O	O
mean	O	O
of	O	O
age	O	O
of	O	O
disease	O	O
onset	O	O
was	O	O
9	O	O
years	O	O
.	O	O
All	O	O
of	O	O
them	O	O
showed	O	O
progressive	O	O
weakness	O	O
with	O	O
predominance	O	O
in	O	O
lower	O	O
limbs	O	O
.	O	O
Other	O	O
findings	O	O
were	O	O
scapular	O	O
winging	O	O
,	O	O
joint	O	O
contractures	O	O
and	O	O
calf	O	O
hypertrophy	O	O
.	O	O
One	O	O
female	O	O
had	O	O
a	O	O
more	O	O
severe	O	O
phenotype	O	O
than	O	O
her	O	O
dizygotic	O	O
twin	O	O
sister	O	O
that	O	O
was	O	O
confirmed	O	O
by	O	O
muscle	O	O
MRI	O	O
.	O	O
Muscle	O	O
biopsies	O	O
showed	O	O
a	O	O
dystrophic	O	O
pattern	O	O
in	O	O
all	O	O
patients	O	O
.	O	O
Conclusion	O	O
In	O	O
this	O	O
cohort	O	O
of	O	O
children	O	O
with	O	O
LGMD2A	O	O
,	O	O
the	O	O
clinical	O	O
aspects	O	O
were	O	O
similar	O	O
to	O	O
adults	O	O
with	O	O
the	O	O
same	O	O
disorder	O	O
.	O	O
Frequency	O	O
of	O	O
mutations	O	O
in	O	O
Mediterranean	O	O
fever	O	O
gene	O	O
,	O	O
with	O	O
gender	O	O
and	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
a	O	O
Turkish	O	O
population	O	O
.	O	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
hereditary	O	O
inflammatory	O	O
periodic	O	O
disease	O	O
,	O	O
characterized	O	O
by	O	O
recurrent	O	O
episodes	O	O
of	O	O
fever	O	O
,	O	O
abdominal	O	O
pain	O	O
,	O	O
synovitis	O	O
and	O	O
pleurisy	O	O
.	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
frequency	O	O
and	O	O
distribution	O	O
of	O	O
Mediterranean	O	O
fever	O	O
(	B-Gene	O
MEFV	I-Gene	O
)	I-Gene	O
gene	O	O
mutations	B-Var	O
and	O	O
to	O	O
investigate	O	O
the	O	O
clinical	O	O
characteristics	O	O
and	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
in	B-Reg	O
patients	O	O
with	O	O
FMF	B-Disease	O
in	O	O
Aydin	O	O
,	O	O
a	O	O
province	O	O
in	O	O
western	O	O
Anatolia	O	O
,	O	O
Turkey	O	O
.	O	O
Therefore	O	O
,	O	O
we	O	O
retrospectively	O	O
analysed	O	O
MEFV	O	O
gene	O	O
mutations	O	O
in	O	O
383	O	O
patients	O	O
with	O	O
suspected	O	O
FMF	O	O
and	O	O
the	O	O
clinical	O	O
features	O	O
of	O	O
327	O	O
among	O	O
them	O	O
.	O	O
The	O	O
MEFV	O	O
gene	O	O
mutations	O	O
were	O	O
investigated	O	O
using	O	O
the	O	O
reverse	O	O
dot	O	O
-	O	O
blot	O	O
hybridization	O	O
technique	O	O
.	O	O
We	O	O
detected	O	O
26	O	O
different	O	O
genotypes	O	O
and	O	O
11	O	O
different	O	O
mutations	O	O
.	O	O
The	O	O
most	O	O
common	O	O
mutations	O	O
in	O	O
our	O	O
cohort	O	O
were	O	O
p	O	O
.	O	O
M694V	O	O
(	O	O
41.15	O	O
%	O	O
)	O	O
,	O	O
p	O	O
.	O	O
E148Q	O	O
(	O	O
20.35	O	O
%	O	O
)	O	O
,	O	O
p	O	O
.	O	O
M680I(G	O	O
/	O	O
C	O	O
)	O	O
(	O	O
12.39	O	O
%	O	O
)	O	O
and	O	O
p	O	O
.	O	O
R761H	O	O
(	O	O
9.73	O	O
%	O	O
)	O	O
.	O	O
Abdominal	O	O
pain	O	O
(	O	O
86.2	O	O
%	O	O
)	O	O
,	O	O
fever	O	O
(	O	O
80.7	O	O
%	O	O
)	O	O
,	O	O
arthralgia	O	O
(	O	O
57.2	O	O
%	O	O
)	O	O
,	O	O
vomiting	O	O
(	O	O
36.1	O	O
%	O	O
)	O	O
,	O	O
arthritis	O	O
(	O	O
34.6	O	O
%	O	O
)	O	O
,	O	O
fatigue	O	O
(	O	O
31.5	O	O
%	O	O
)	O	O
,	O	O
anorexia	O	O
(	O	O
22.9	O	O
%	O	O
)	O	O
and	O	O
chest	O	O
pain	O	O
(	O	O
19.0	O	O
%	O	O
)	O	O
were	O	O
the	O	O
most	O	O
prevalent	O	O
clinical	O	O
features	O	O
in	O	O
our	O	O
patients	O	O
.	O	O
This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
from	O	O
Aydin	O	O
in	O	O
which	O	O
the	O	O
distribution	O	O
of	O	O
MEFV	B-Gene	O
gene	O	O
mutations	B-Var	O
and	O	O
clinical	O	O
features	O	O
were	O	O
evaluated	O	O
in	B-Reg	O
patients	O	O
with	O	O
FMF	B-Disease	O
.	O	O
We	O	O
found	O	O
that	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
was	O	O
p	O	O
.	O	O
M694V	O	O
in	O	O
our	O	O
region	O	O
,	O	O
while	O	O
the	O	O
frequency	O	O
of	O	O
the	O	O
p	O	O
.	O	O
R761H	O	O
mutation	O	O
was	O	O
higher	O	O
compared	O	O
to	O	O
other	O	O
regions	O	O
of	O	O
Turkey	O	O
with	O	O
respect	O	O
to	O	O
extracted	O	O
data	O	O
from	O	O
previous	O	O
similar	O	O
studies	O	O
.	O	O
Presented	O	O
results	O	O
supported	O	O
the	O	O
clinical	O	O
findings	O	O
in	O	O
the	O	O
literature	O	O
that	O	O
the	O	O
homozygous	O	O
p	O	O
.	O	O
M694V	O	O
and	O	O
compound	O	O
heterozygous	O	O
genotype	O	O
were	O	O
associated	O	O
with	O	O
more	O	O
severe	O	O
courses	O	O
in	O	O
FMF	O	O
patients	O	O
.	O	O
Delayed	O	O
hemoglobin	O	O
switching	O	O
and	O	O
perinatal	O	O
neocytolysis	O	O
in	O	O
mice	O	O
with	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
function	O	O
erythropoietin	O	O
receptor	O	O
.	O	O
Mutations	B-Var	O
of	O	O
the	O	O
truncated	O	O
cytoplasmic	O	O
domain	O	O
of	O	O
human	O	O
erythropoietin	O	O
receptor	O	O
(	B-Gene	O
EPOR	I-Gene	O
)	I-Gene	O
result	B-Reg	O
in	I-Reg	O
gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
function	I-PosReg	O
of	O	O
erythropoietin	B-Pathway	O
(	I-Pathway	O
EPO	I-Pathway	O
)	I-Pathway	O
signaling	I-Pathway	O
and	O	O
a	O	O
dominantly	B-Disease	O
inherited	I-Disease	O
polycythemia	I-Disease	O
,	O	O
primary	B-Disease	O
familial	I-Disease	B-Disease
and	I-Disease	O
congenital	I-Disease	B-Disease
polycythemia	I-Disease	I-Disease
(	O	O
PFCP	O	O
)	O	O
.	O	O
We	O	O
interrogated	O	O
the	O	O
unexplained	O	O
transient	O	O
absence	O	O
of	O	O
perinatal	O	O
polycythemia	O	O
observed	O	O
in	O	O
PFCP	O	O
patients	O	O
using	O	O
an	O	O
animal	O	O
model	O	O
of	O	O
PFCP	O	O
to	O	O
examine	O	O
its	O	O
erythropoiesis	O	O
during	O	O
embryonic	O	O
,	O	O
perinatal	O	O
,	O	O
and	O	O
early	O	O
postnatal	O	O
periods	O	O
.	O	O
In	O	O
this	O	O
model	O	O
,	O	O
we	O	O
replaced	O	O
the	O	O
murine	O	O
EpoR	O	O
gene	O	O
(	O	O
mEpoR	O	O
)	O	O
with	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
human	O	O
EPOR	O	O
(	O	O
wtHEPOR	O	O
)	O	O
or	O	O
mutant	O	O
human	O	O
EPOR	O	O
gene	O	O
(	O	O
mtHEPOR	O	O
)	O	O
and	O	O
previously	O	O
reported	O	O
that	O	O
the	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mtHEPOR	O	O
mice	O	O
become	O	O
polycythemic	O	O
at	O	O
3~6	O	O
weeks	O	O
of	O	O
age	O	O
,	O	O
but	O	O
not	O	O
at	O	O
birth	O	O
,	O	O
similar	O	O
to	O	O
the	O	O
phenotype	O	O
of	O	O
PFCP	O	O
patients	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
wtHEPOR	O	O
mice	O	O
had	O	O
sustained	O	O
anemia	O	O
.	O	O
We	O	O
report	O	O
that	O	O
the	O	O
mtHEPOR	O	O
fetuses	O	O
are	O	O
polycythemic	O	O
,	O	O
but	O	O
their	O	O
polycythemia	O	O
is	O	O
abrogated	O	O
in	O	O
the	O	O
perinatal	O	O
period	O	O
and	O	O
reappears	O	O
again	O	O
at	O	O
3	O	O
weeks	O	O
after	O	O
birth	O	O
.	O	O
mtHEPOR	O	O
fetuses	O	O
have	O	O
a	O	O
delayed	O	O
switch	O	O
from	O	O
primitive	O	O
to	O	O
definitive	O	O
erythropoiesis	O	O
,	O	O
augmented	O	O
erythropoietin	O	O
signaling	O	O
,	O	O
and	O	O
prolonged	O	O
Stat5	O	O
phosphorylation	O	O
while	O	O
the	O	O
wtHEPOR	O	O
fetuses	O	O
are	O	O
anemic	O	O
.	O	O
Our	O	O
study	O	O
demonstrates	O	O
the	O	O
in	O	O
vivo	O	O
effect	O	O
of	O	O
excessive	O	O
EPO	O	O
/	O	O
EPOR	O	O
signaling	O	O
on	O	O
developmental	O	O
erythropoiesis	O	O
switch	O	O
and	O	O
describes	O	O
that	O	O
fetal	O	O
polycythemia	O	O
in	O	O
this	O	O
PFCP	O	O
model	O	O
is	O	O
followed	O	O
by	O	O
transient	O	O
correction	O	O
of	O	O
polycythemia	O	O
in	O	O
perinatal	O	O
life	O	O
associated	O	O
with	O	O
low	O	O
Epo	O	O
levels	O	O
and	O	O
increased	O	O
exposure	O	O
of	O	O
erythrocytes	O	O
'	O	O
phosphatidylserine	O	O
.	O	O
We	O	O
suggest	O	O
that	O	O
neocytolysis	O	O
contributes	O	O
to	O	O
the	O	O
observed	O	O
perinatal	O	O
correction	O	O
of	O	O
polycythemia	O	O
in	O	O
mtHEPOR	O	O
newborns	O	O
as	O	O
embryos	O	O
leaving	O	O
the	O	O
hypoxic	O	O
uterus	O	O
are	O	O
exposed	O	O
to	O	O
normoxia	O	O
at	O	O
birth	O	O
.	O	O
KEY	O	O
MESSAGE	O	O
:	O	O
Human	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
function	O	O
EPOR	B-Gene	O
(	O	O
mtHEPOR	O	O
)	O	O
causes	B-Reg	O
fetal	B-Disease	O
polycythemia	I-Disease	O
in	O	O
knock	B-Var	O
-	I-Var	O
in	I-Var	O
mice	O	O
.	O	O
Wild	O	O
-	O	O
type	O	O
human	O	O
EPOR	O	O
causes	O	O
fetal	O	O
anemia	O	O
in	O	O
knock	O	O
-	O	O
in	O	O
mouse	O	O
model	O	O
.	O	O
mtHEPOR	O	O
mice	O	O
have	O	O
delayed	O	O
switch	O	O
from	O	O
primitive	O	O
to	O	O
definitive	O	O
erythropoiesis	O	O
.	O	O
Polycythemia	O	O
of	O	O
mtHEPOR	O	O
mice	O	O
is	O	O
transiently	O	O
corrected	O	O
in	O	O
perinatal	O	O
life	O	O
.	O	O
mtHEPOR	O	O
newborns	O	O
have	O	O
low	O	O
Epo	O	O
and	O	O
increased	O	O
exposure	O	O
of	O	O
erythrocytes	O	O
'	O	O
phosphatidylserine	O	O
.	O	O
Renal	O	O
Cell	O	O
Carcinoma	O	O
Programmed	O	O
Death	O	O
-	O	O
ligand	O	O
1	O	O
,	O	O
a	O	O
New	O	O
Direct	O	O
Target	O	O
of	O	O
Hypoxia	O	O
-	O	O
inducible	O	O
Factor-2	O	O
Alpha	O	O
,	O	O
is	O	O
Regulated	O	O
by	O	O
von	O	O
Hippel	O	O
-	O	O
Lindau	O	O
Gene	O	O
Mutation	O	O
Status	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Clear	O	O
cell	O	O
renal	O	B-Disease
cell	O	I-Disease
carcinomas	O	I-Disease
(	O	O
ccRCC	O	O
)	O	O
frequently	O	O
display	O	O
a	O	O
loss	O	O
of	O	O
function	O	O
of	O	O
the	O	O
von	O	O
Hippel	O	O
-	O	O
Lindau	O	O
(	O	B-Gene
VHL	O	O
)	O	I-Gene
gene	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
elucidate	O	O
the	O	O
putative	O	O
relationship	O	O
between	O	O
VHL	O	O
mutation	O	O
status	O	O
and	O	O
immune	O	O
checkpoint	O	O
ligand	O	O
programmed	O	O
death	O	O
-	O	O
ligand	O	O
1	O	O
(	O	O
PD	O	O
-	O	O
L1	O	O
)	O	O
expression	O	O
.	O	O
DESIGN	O	O
,	O	O
SETTING	O	O
,	O	O
AND	O	O
PARTICIPANTS	O	O
:	O	O
A	O	O
series	O	O
of	O	O
32	O	O
renal	O	O
tumors	O	O
composed	O	O
of	O	O
11	O	O
VHL	O	O
tumor	O	O
-	O	O
associated	O	O
and	O	O
21	O	O
sporadic	O	O
RCCs	O	O
were	O	O
used	O	O
to	O	O
evaluate	O	O
PD	O	O
-	O	O
L1	O	O
expression	O	O
levels	O	O
after	O	O
sequencing	O	O
of	O	O
the	O	O
three	O	O
exons	O	O
and	O	O
exon	O	O
-	O	O
intron	O	O
junctions	O	O
of	O	O
the	O	O
VHL	O	O
gene	O	O
.	O	O
The	O	O
786-O	O	O
,	O	O
A498	O	O
,	O	O
and	O	O
RCC4	O	O
cell	O	O
lines	O	O
were	O	O
used	O	O
to	O	O
investigate	O	O
the	O	O
mechanisms	O	O
of	O	O
PD	O	O
-	O	O
L1	O	O
regulation	O	O
.	O	O
OUTCOME	O	O
MEASUREMENTS	O	O
AND	O	O
STATISTICAL	O	O
ANALYSIS	O	O
:	O	O
Fisher	O	O
's	O	O
exact	O	O
test	O	O
was	O	O
used	O	O
for	O	O
VHL	O	O
mutation	O	O
and	O	O
Kruskal	O	O
-	O	O
Wallis	O	O
test	O	O
for	O	O
PD	O	O
-	O	O
L1	O	O
expression	O	O
.	O	O
If	O	O
no	O	O
covariate	O	O
accounted	O	O
for	O	O
the	O	O
association	O	O
of	O	O
VHL	O	O
and	O	O
PD	O	O
-	O	O
L1	O	O
,	O	O
then	O	O
a	O	O
Kruskal	O	O
-	O	O
Wallis	O	O
test	O	O
was	O	O
used	O	O
;	O	O
otherwise	O	O
Cochran	O	O
-	O	O
Mantel	O	O
-	O	O
Haenzsel	O	O
test	O	O
was	O	O
used	O	O
.	O	O
We	O	O
also	O	O
used	O	O
the	O	O
Fligner	O	O
-	O	O
Policello	O	O
test	O	O
to	O	O
compare	O	O
two	O	O
medians	O	O
when	O	O
the	O	O
distributions	O	O
had	O	O
different	O	O
dispersions	O	O
.	O	O
RESULTS	O	O
AND	O	O
LIMITATIONS	O	O
:	O	O
We	O	O
demonstrated	O	O
that	O	O
tumors	O	O
from	O	O
ccRCC	O	O
patients	O	O
with	O	O
VHL	B-Gene	O
biallelic	O	O
inactivation	B-Var	O
(	O	O
ie	O	O
,	O	O
loss	O	O
of	O	O
function	O	O
)	O	O
display	O	O
a	O	O
significant	O	O
increase	B-PosReg	O
in	O	O
PD	B-Protein	B-Protein
-	I-Protein	I-MPA
L1	I-Protein	I-MPA
expression	B-MPA	I-MPA
compared	O	O
with	O	O
ccRCC	O	O
tumors	O	O
carrying	O	O
one	O	O
VHL	O	O
wild	O	O
-	O	O
type	O	O
allele	O	O
.	O	O
Using	O	O
the	O	O
inducible	O	O
VHL	O	O
786-O	O	O
-	O	O
derived	O	O
cell	O	O
lines	O	O
with	O	O
varying	O	O
hypoxia	O	O
-	O	O
inducible	O	O
factor-2	O	O
alpha	O	O
(	O	O
HIF-2α	O	O
)	O	O
stabilization	O	O
levels	O	O
,	O	O
we	O	O
showed	O	O
that	O	O
PD	B-Protein	O
-	I-Protein	O
L1	I-Protein	O
expression	B-MPA	O
levels	I-MPA	O
positively	O	O
correlate	B-Reg	O
with	O	O
VHL	B-Gene	O
mutation	B-Var	O
and	O	O
HIF-2α	O	O
expression	O	O
.	O	O
Targeting	O	O
HIF-2α	O	O
decreased	O	O
PD	O	O
-	O	O
L1	O	O
,	O	O
while	O	O
HIF-2α	O	O
overexpression	O	O
increased	O	O
PD	O	O
-	O	O
L1	O	O
mRNA	O	O
and	O	O
protein	O	O
levels	O	O
in	O	O
ccRCC	O	O
cells	O	O
.	O	O
Interestingly	O	O
,	O	O
chromatin	O	O
immunoprecipitation	O	O
and	O	O
luciferase	O	O
assays	O	O
revealed	O	O
a	O	O
direct	O	O
binding	O	O
of	O	O
HIF-2α	O	O
to	O	O
a	O	O
transcriptionally	O	O
active	O	O
hypoxia	O	O
-	O	O
response	O	O
element	O	O
in	O	O
the	O	O
human	O	O
PD	O	O
-	O	O
L1	O	O
proximal	O	O
promoter	O	O
in	O	O
786-O	O	O
cells	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Our	O	O
work	O	O
provides	O	O
the	O	O
first	O	O
evidence	O	O
that	O	O
VHL	B-Gene	O
mutations	B-Var	O
positively	O	O
correlate	B-Reg	O
with	O	O
PD	B-Protein	O
-	I-Protein	O
L1	I-Protein	O
expression	B-MPA	O
in	O	O
ccRCC	O	O
and	O	O
may	O	O
influence	B-Reg	O
the	O	O
response	B-MPA	O
to	I-MPA	O
ccRCC	I-MPA	I-CPA
anti	I-MPA	O
-	I-MPA	I-Protein
PD	I-MPA	O
-	I-MPA	I-Protein
L1	I-MPA	O
/	I-MPA	I-Protein
PD-1	I-MPA	I-Protein
immunotherapy	I-MPA	O
.	O	O
PATIENT	O	O
SUMMARY	O	O
:	O	O
We	O	O
investigated	O	O
the	O	O
relationship	O	O
between	O	O
von	O	O
Hippel	O	O
-	O	O
Lindau	O	O
mutations	O	O
and	O	O
programmed	O	O
death	O	O
-	O	O
ligand	O	O
1	O	O
expression	O	O
.	O	O
We	O	O
demonstrated	O	O
that	O	O
von	B-Gene	O
Hippel	I-Gene	O
-	I-Gene	O
Lindau	I-Gene	O
mutation	B-Var	O
status	O	O
significantly	O	O
correlated	B-Reg	O
with	O	O
programmed	B-MPA	O
death	I-MPA	O
-	I-MPA	O
ligand	I-MPA	O
1	I-MPA	O
expression	I-MPA	O
in	O	O
clear	O	O
cell	O	B-CPA
renal	O	O
cell	O	B-CPA
carcinomas	O	I-CPA
.	O	O
Huntington	O	O
's	O	O
Disease	O	O
:	O	O
Relationship	O	O
Between	O	O
Phenotype	O	O
and	O	O
Genotype	O	O
.	O	O
Huntington	B-Disease	B-Disease
's	I-Disease	I-Disease
disease	I-Disease	I-Disease
(	O	O
HD	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
dominant	O	O
inherited	O	O
neurodegenerative	O	O
disease	O	O
with	O	O
the	O	O
typical	O	O
manifestations	O	O
of	O	O
involuntary	O	O
movements	O	O
,	O	O
psychiatric	O	O
and	O	O
behavior	O	O
disorders	O	O
,	O	O
and	O	O
cognitive	O	O
impairment	O	O
.	O	O
It	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
the	O	O
dynamic	B-Var	O
mutation	I-Var	O
in	I-Var	O
CAG	I-Var	O
triplet	I-Var	O
repeat	I-Var	O
number	I-Var	O
in	I-Var	O
exon	I-Var	O
1	I-Var	O
of	O	O
huntingtin	O	O
(	B-Gene	O
HTT	I-Gene	O
)	I-Gene	O
gene	O	O
.	O	O
The	O	O
symptoms	O	O
of	O	O
HD	O	O
especially	O	O
the	O	O
age	O	O
at	O	O
onset	O	O
are	O	O
related	O	O
to	O	O
the	O	O
genetic	O	O
characteristics	O	O
,	O	O
both	O	O
the	O	O
CAG	O	O
triplet	O	O
repeat	O	O
and	O	O
the	O	O
modified	O	O
factors	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
reviewed	O	O
the	O	O
recent	O	O
advancement	O	O
on	O	O
the	O	O
genotype	O	O
-	O	O
phenotype	O	O
relationship	O	O
of	O	O
HD	O	O
,	O	O
mainly	O	O
focus	O	O
on	O	O
the	O	O
characteristics	O	O
of	O	O
different	O	O
expanded	O	O
CAG	O	O
repeat	O	O
number	O	O
,	O	O
genetic	O	O
modifiers	O	O
,	O	O
and	O	O
CCG	O	O
repeat	O	O
number	O	O
in	O	O
the	O	O
3	O	O
'	O	O
end	O	O
of	O	O
CAG	O	O
triplet	O	O
repeat	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
the	O	O
phenotype	O	O
.	O	O
We	O	O
also	O	O
reviewed	O	O
the	O	O
special	O	O
forms	O	O
of	O	O
HD	O	O
(	O	O
juvenile	O	O
HD	O	O
,	O	O
atypical	O	O
onset	O	O
HD	O	O
,	O	O
and	O	O
homozygous	O	O
HD	O	O
)	O	O
and	O	O
their	O	O
phenotype	O	O
-	O	O
genotype	O	O
correlations	O	O
.	O	O
The	O	O
review	O	O
will	O	O
aid	O	O
clinicians	O	O
to	O	O
predict	O	O
the	O	O
onset	O	O
age	O	O
and	O	O
disease	O	O
course	O	O
of	O	O
HD	O	O
,	O	O
give	O	O
the	O	O
genetic	O	O
counseling	O	O
,	O	O
and	O	O
accelerate	O	O
research	O	O
into	O	O
the	O	O
HD	O	O
mechanism	O	O
.	O	O
Polyamine	B-Enzyme	O
oxidase	I-Enzyme	O
5	I-Enzyme	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutations	B-Var	O
in	O	O
Arabidopsis	O	O
thaliana	O	O
trigger	B-Reg	O
metabolic	B-MPA	O
and	I-MPA	O
transcriptional	I-MPA	B-CPA
reprogramming	I-MPA	I-CPA
and	O	O
promote	B-PosReg	O
salt	B-MPA	B-CPA
stress	I-MPA	I-CPA
tolerance	I-MPA	O
.	O	O
The	O	O
family	O	O
of	O	O
polyamine	O	O
oxidases	O	O
(	O	O
PAO	O	O
)	O	O
in	O	O
Arabidopsis	O	O
(	O	O
AtPAO1	O	O
-	O	O
5	O	O
)	O	O
mediates	O	O
polyamine	O	O
(	O	O
PA	O	O
)	O	O
back	O	O
-	O	O
conversion	O	O
,	O	O
which	O	O
reverses	O	O
the	O	O
PA	O	O
biosynthetic	O	O
pathway	O	O
from	O	O
spermine	O	O
and	O	O
its	O	O
structural	O	O
isomer	O	O
thermospermine	O	O
(	O	O
tSpm	O	O
)	O	O
into	O	O
spermidine	O	O
and	O	O
then	O	O
putrescine	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
the	O	O
involvement	O	O
of	O	O
PA	O	O
back	O	O
-	O	O
conversion	O	O
in	O	O
Arabidopsis	O	O
salinity	O	O
tolerance	O	O
.	O	O
AtPAO5	O	O
is	O	O
the	O	O
Arabidopsis	O	O
PAO	O	O
gene	O	O
member	O	O
most	O	O
transcriptionally	O	O
induced	O	O
by	O	O
salt	O	O
stress	O	O
.	O	O
Two	O	O
independent	O	O
loss	O	O
-	O	I-NegReg
of	O	O
-	O	O
function	O	O
mutants	B-Var	O
(	O	O
atpao5	O	O
-	O	O
2	O	O
and	O	O
atpao5	O	O
-	O	O
3	O	O
)	O	O
were	O	O
found	O	O
to	O	O
exhibit	O	O
constitutively	O	O
higher	B-PosReg	B-PosReg
tSpm	B-MPA	O
levels	I-MPA	I-CPA
,	O	O
with	O	O
associated	O	O
increased	O	B-PosReg
salt	O	O
tolerance	O	O
.	O	O
Using	O	O
global	O	O
transcriptional	O	O
and	O	O
metabolomic	O	O
analyses	O	O
,	O	O
the	O	O
underlying	O	O
mechanisms	O	O
were	O	O
studied	O	O
.	O	O
Stimulation	B-PosReg	O
of	O	O
abscisic	B-MPA	O
acid	I-MPA	O
and	I-MPA	O
jasmonate	I-MPA	O
(	I-MPA	O
JA	I-MPA	O
)	I-MPA	O
biosynthesis	I-MPA	O
and	O	O
accumulation	B-MPA	O
of	I-MPA	O
important	I-MPA	O
compatible	I-MPA	O
solutes	I-MPA	O
,	O	O
such	O	O
as	O	O
sugars	O	O
,	O	O
polyols	O	O
and	O	O
proline	O	O
,	O	O
as	O	O
well	O	O
as	O	O
TCA	B-MPA	O
cycle	I-MPA	O
intermediates	I-MPA	O
were	O	O
observed	O	O
in	O	O
atpao5	O	O
mutants	B-Var	O
under	O	O
salt	O	O
stress	O	O
.	O	O
Expression	O	O
analyses	O	O
indicate	O	O
that	O	O
tSpm	O	O
modulates	O	O
the	O	O
transcript	O	O
levels	O	O
of	O	O
several	O	O
target	O	O
genes	O	O
,	O	O
including	O	O
many	O	O
involved	O	O
in	O	O
the	O	O
biosynthesis	O	O
and	O	O
signalling	O	O
of	O	O
JA	O	O
,	O	O
some	O	O
of	O	O
which	O	O
are	O	O
already	O	O
known	O	O
to	O	O
promote	O	O
salinity	O	O
tolerance	O	O
.	O	O
Transcriptional	O	O
modulation	O	O
by	O	O
tSpm	O	O
is	O	O
isomer	O	O
-	O	O
dependent	O	O
,	O	O
thus	O	O
demonstrating	O	O
the	O	O
specificity	O	O
of	O	O
this	O	O
response	O	O
.	O	O
Overall	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
tSpm	O	O
triggers	O	O
metabolic	O	O
and	O	O
transcriptional	O	O
reprogramming	O	O
that	O	O
promotes	O	O
salt	O	O
stress	O	O
tolerance	O	O
in	O	O
Arabidopsis	O	O
.	O	O
Recessive	B-Disease	O
dystrophic	I-Disease	O
epidermolysis	I-Disease	O
bullosa	I-Disease	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
de	B-CPA	O
novo	I-CPA	O
interstitial	I-CPA	O
deletion	B-NegReg	O
spanning	O	O
COL7A1	B-Gene	O
and	O	O
a	O	O
hemizygous	O	O
splicing	B-Var	O
mutation	I-Var	O
in	I-Var	O
trans	I-Var	O
.	O	O
BACKGROUND	O	O
:	O	O
Recessive	B-Disease	O
dystrophic	I-Disease	O
epidermolysis	I-Disease	O
bullosa	I-Disease	O
(	O	O
RDEB	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
heritable	O	O
blistering	O	O
skin	O	O
condition	O	O
caused	O	O
by	O	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutations	B-Var	O
in	O	O
the	O	O
COL7A1	B-Gene	O
gene	O	O
.	O	O
Incongruent	O	O
gene	O	O
transmission	O	O
is	O	O
occasionally	O	O
reported	O	O
in	O	O
recessive	O	O
diseases	O	O
,	O	O
and	O	O
its	O	O
underlying	O	O
mechanism	O	O
is	O	O
often	O	O
uniparental	O	O
disomy	O	O
(	O	O
UPD	O	O
)	O	O
.	O	O
AIM	O	O
:	O	O
To	O	O
understand	O	O
the	O	O
genetic	O	O
basis	O	O
of	O	O
incongruent	O	O
gene	O	O
transmission	O	O
in	O	O
a	O	O
Chinese	O	O
family	O	O
with	O	O
RDEB	O	O
,	O	O
in	O	O
which	O	O
a	O	O
discrepancy	O	O
of	O	O
COL7A1	O	O
genotyping	O	O
was	O	O
encountered	O	O
during	O	O
our	O	O
mutation	O	O
analysis	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
used	O	O
a	O	O
pCAS2	O	O
minigene	O	O
-	O	O
based	O	O
in	O	O
vitro	O	O
splicing	O	O
assay	O	O
to	O	O
confirm	O	O
the	O	O
pathogenicity	O	O
of	O	O
the	O	O
splicing	O	O
variant	O	O
we	O	O
identified	O	O
in	O	O
the	O	O
proband	O	O
.	O	O
Next	O	O
,	O	O
a	O	O
combination	O	O
of	O	O
genetic	O	O
tools	O	O
,	O	O
including	O	O
whole	O	O
-	O	O
genome	O	O
SNP	O	O
array	O	O
analysis	O	O
and	O	O
multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
copy	O	O
number	O	O
analysis	O	O
,	O	O
was	O	O
used	O	O
to	O	O
unravel	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
discrepancy	O	O
in	O	O
the	O	O
COL7A1	O	O
genotyping	O	O
.	O	O
RESULTS	O	O
:	O	O
Sanger	O	O
sequencing	O	O
identified	O	O
a	O	O
novel	O	O
,	O	O
single	O	O
-	O	O
peak	O	O
mutation	O	O
,	O	O
c.4980	O	O
+	O	O
5G	O	O
>	O	O
C	O	O
,	O	O
in	O	O
COL7A1	O	O
in	O	O
the	O	O
proband	O	O
,	O	O
which	O	O
was	O	O
heterozygous	O	O
in	O	O
his	O	O
father	O	O
and	O	O
wild	O	O
type	O	O
in	O	O
his	O	O
mother	O	O
.	O	O
In	O	O
vitro	O	O
splicing	O	O
assay	O	O
showed	O	O
that	O	O
c.4980	O	O
+	O	O
5G	O	O
>	O	O
C	O	O
was	O	O
pathogenic	O	O
and	O	O
led	O	O
to	O	O
skipping	O	O
of	O	O
COL7A1	O	O
exon	O	O
53	O	O
.	O	O
SNP	O	O
array	O	O
analysis	O	O
and	O	O
multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
of	O	O
the	O	O
proband	O	O
's	O	O
DNA	O	O
revealed	O	O
a	O	O
maternally	O	O
derived	O	O
,	O	O
de	O	O
novo	O	O
,	O	O
interstitial	O	O
deletion	O	O
on	O	O
chromosome	O	O
3p21.31	O	O
,	O	O
which	O	O
removed	O	O
COL7A1	O	O
and	O	O
15	O	O
flanking	O	O
genes	O	O
,	O	O
excluding	O	O
the	O	O
possibility	O	O
of	O	O
UPD	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Our	O	O
findings	O	O
favour	O	O
an	O	O
exceptionally	O	O
rare	O	O
event	O	O
,	O	O
namely	O	O
a	O	O
de	O	O
novo	O	O
COL7A1	O	O
microdeletion	O	O
in	O	O
concurrence	O	O
with	O	O
an	O	O
inherited	O	O
mutation	O	O
in	O	O
trans	O	O
.	O	O
This	O	O
study	O	O
should	O	O
aid	O	O
molecular	O	O
diagnosis	O	O
and	O	O
genetic	O	O
counselling	O	O
of	O	O
RDEB	O	O
and	O	O
possibly	O	O
other	O	O
recessive	O	O
diseases	O	O
in	O	O
which	O	O
genotyping	O	O
discrepancy	O	O
is	O	O
encountered	O	O
.	O	O
A	O	O
novel	O	O
frameshift	O	O
mutation	O	O
leading	O	O
to	O	O
inherited	O	O
type	O	O
I	O	O
antithrombin	O	O
deficiency	O	O
.	O	O
Inherited	B-Disease	O
antithrombin	I-Disease	O
(	I-Disease	O
AT	I-Disease	O
)	I-Disease	O
deficiency	I-Disease	O
is	O	O
an	O	O
autosomal	O	O
dominant	O	O
thrombotic	O	O
disorder	O	O
.	O	O
We	O	O
encountered	O	O
a	O	O
case	O	O
of	O	O
inherited	O	O
type	O	O
I	O	O
AT	B-Disease	O
deficiency	I-Disease	O
and	O	O
identified	B-Reg	O
the	O	O
mutation	O	O
responsible	O	O
;	O	O
a	O	O
novel	O	O
5406delA	B-Var	O
mutation	I-Var	O
in	O	O
the	O	O
SERPINC1	B-Gene	O
gene	O	O
appeared	O	O
to	O	O
have	O	O
caused	B-Reg	O
a	O	O
frameshift	B-MPA	O
with	I-MPA	O
premature	I-MPA	O
termination	I-MPA	O
at	I-MPA	O
amino	I-MPA	O
acid	I-MPA	O
+283	I-MPA	O
.	O	O
The	O	O
recombinant	O	O
AT	O	O
protein	O	O
including	O	O
5406delA	O	O
was	O	O
not	O	O
detected	O	O
in	O	O
cell	O	O
lysates	O	O
or	O	O
culture	O	O
supernatants	O	O
.	O	O
These	O	O
results	O	O
will	O	O
contribute	O	O
to	O	O
the	O	O
creation	O	O
of	O	O
an	O	O
accurate	O	O
database	O	O
and	O	O
define	O	O
the	O	O
molecular	O	O
basis	O	O
for	O	O
AT	O	O
deficiency	O	O
.	O	O
Increase	O	O
in	O	O
NRAS	O	O
mutant	O	O
allele	O	O
percentage	O	O
during	O	O
metastatic	O	O
melanoma	O	O
progression	O	O
.	O	O
One	O	O
-	O	O
fifth	O	O
of	O	O
cutaneous	B-Disease	O
melanomas	I-Disease	O
have	O	O
dominant	O	O
gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
function	I-PosReg	O
mutations	B-Var	O
of	O	O
the	O	O
NRAS	B-Gene	O
oncogene	O	O
.	O	O
We	O	O
report	O	O
the	O	O
first	O	O
two	O	O
cases	O	O
of	O	O
increasing	O	O
NRAS	O	O
mutant	O	O
allele	O	O
frequency	O	O
in	O	O
melanoma	O	O
metastases	O	O
and	O	O
show	O	O
that	O	O
the	O	O
chromosomal	O	O
mechanism	O	O
of	O	O
this	O	O
homozygosity	O	O
is	O	O
an	O	O
increased	O	O
polysomy	O	O
of	O	O
chromosome	O	O
1	O	O
.	O	O
We	O	O
observed	O	O
an	O	O
increase	O	O
in	O	O
NRAS	O	O
mutant	O	O
allele	O	O
percentage	O	O
(	O	O
NRAS	O	O
-	O	O
MA%	O	O
)	O	O
in	O	O
the	O	O
metastatic	O	O
melanoma	O	O
progression	O	O
from	O	O
2	O	O
patients	O	O
with	O	O
melanomas	O	O
harbouring	O	O
a	O	O
NRAS	O	O
mutation	O	O
(	O	O
p	O	O
.	O	O
Q61	O	O
K	O	O
in	O	O
case	O	O
1	O	O
and	O	O
p	O	O
.	O	O
Q61R	O	O
in	O	O
case	O	O
2	O	O
)	O	O
.	O	O
In	O	O
case	O	O
1	O	O
,	O	O
we	O	O
observed	O	O
a	O	O
NRAS	O	O
-	O	O
MA%	O	O
increase	O	O
from	O	O
18	O	O
%	O	O
within	O	O
the	O	O
first	O	O
metastatic	O	O
node	O	O
to	O	O
81	O	O
%	O	O
,	O	O
92	O	O
%	O	O
and	O	O
85	O	O
%	O	O
respectively	O	O
in	O	O
the	O	O
three	O	O
subsequent	O	O
metastases	O	O
:	O	O
lymph	O	O
node	O	O
,	O	O
brain	O	O
and	O	O
subcutaneous	O	O
metastases	O	O
biopsied	O	O
1	O	O
,	O	O
6	O	O
and	O	O
17	O	O
months	O	O
,	O	O
respectively	O	O
,	O	O
after	O	O
the	O	O
initial	O	O
lymph	O	O
node	O	O
biopsy	O	O
.	O	O
In	O	O
case	O	O
2	O	O
,	O	O
we	O	O
observed	O	O
an	O	O
increase	O	O
in	O	O
NRAS	O	O
-	O	O
MA%	O	O
from	O	O
40	O	O
%	O	O
within	O	O
the	O	O
primary	O	O
melanoma	O	O
to	O	O
63	O	O
%	O	O
within	O	O
the	O	O
metastatic	O	O
lymph	O	O
node	O	O
.	O	O
FISH	O	O
analysis	O	O
showed	O	O
the	O	O
same	O	O
results	O	O
in	O	O
both	O	O
cases	O	O
:	O	O
a	O	O
frequent	O	O
polysomy	O	O
of	O	O
chromosome	O	O
1	O	O
in	O	O
metastasis	O	O
samples	O	O
with	O	O
NRAS	O	O
mutant	O	O
allele	O	O
percentage	O	O
>	O	O
60	O	O
%	O	O
,	O	O
while	O	O
most	O	O
cells	O	O
were	O	O
disomic	O	O
in	O	O
the	O	O
samples	O	O
with	O	O
well	O	O
-	O	O
balanced	O	O
heterozygous	O	O
mutations	O	O
.	O	O
The	O	O
percentage	O	O
of	O	O
NRAS	O	O
mutant	O	O
allele	O	O
may	O	O
increase	O	O
during	O	O
metastatic	O	O
progression	O	O
and	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
chromosomal	O	O
instability	O	O
.	O	O
Further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
evaluate	O	O
the	O	O
prognostic	O	O
impact	O	O
of	O	O
the	O	O
NRAS	O	O
homozygous	O	O
status	O	O
and/or	O	O
polyploidy	O	O
in	O	O
metastatic	O	O
cutaneous	O	O
melanomas	O	O
.	O	O
A	O	O
Comprehensive	O	O
Analysis	O	O
of	O	O
Choroideremia	O	O
:	O	O
From	O	O
Genetic	O	O
Characterization	O	O
to	O	O
Clinical	O	O
Practice	O	O
.	O	O
Choroideremia	B-Disease	O
(	O	O
CHM	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
X	O	O
-	O	O
linked	O	O
disease	O	O
leading	O	O
to	O	O
progressive	O	O
retinal	O	O
degeneration	O	O
resulting	O	O
in	O	O
blindness	O	O
.	O	O
The	O	O
disorder	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
CHM	B-Gene	O
gene	O	O
encoding	O	O
REP-1	O	O
protein	O	O
,	O	O
an	O	O
essential	O	O
component	O	O
of	O	O
the	O	O
Rab	O	O
geranylgeranyltransferase	O	O
(	O	O
GGTase	O	O
)	O	O
complex	O	O
.	O	O
In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
evaluated	O	O
a	O	O
multi	O	O
-	O	O
technique	O	O
analysis	O	O
algorithm	O	O
to	O	O
describe	O	O
the	O	O
mutational	O	O
spectrum	O	O
identified	O	O
in	O	O
a	O	O
large	O	O
cohort	O	O
of	O	O
cases	O	O
and	O	O
further	O	O
correlate	O	O
CHM	O	O
variants	O	O
with	O	O
phenotypic	O	O
characteristics	O	O
and	O	O
biochemical	O	O
defects	O	O
of	O	O
choroideremia	O	O
patients	O	O
.	O	O
Molecular	O	O
genetic	O	O
testing	O	O
led	O	O
to	O	O
the	O	O
characterization	O	O
of	O	O
36	O	O
out	O	O
of	O	O
45	O	O
unrelated	O	O
CHM	O	O
families	O	O
(	O	O
80	O	O
%	O	O
)	O	O
,	O	O
allowing	O	O
the	O	O
clinical	O	O
reclassification	O	O
of	O	O
four	O	O
CHM	O	O
families	O	O
.	O	O
Haplotype	O	O
reconstruction	O	O
showed	O	O
independent	O	O
origins	O	O
for	O	O
the	O	O
recurrent	O	O
p	O	O
.	O	O
Arg293	O	O
*	O	O
and	O	O
p	O	O
.	O	O
Lys178Argfs*5	O	O
mutations	O	O
,	O	O
suggesting	O	O
the	O	O
presence	O	O
of	O	O
hotspots	O	O
in	O	O
CHM	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
identification	O	O
of	O	O
two	O	O
different	O	O
unrelated	O	O
events	O	O
involving	O	O
exon	O	O
9	O	O
deletion	O	B-Var
.	O	O
No	O	O
certain	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
could	O	O
be	O	O
established	O	O
.	O	O
Furthermore	O	O
,	O	O
all	O	O
the	O	O
patients	O	O
´	O	O
fibroblasts	O	O
analyzed	O	O
presented	O	O
significantly	O	O
increased	O	O
levels	O	O
of	O	O
unprenylated	O	O
Rabs	O	O
proteins	O	O
compared	O	O
to	O	O
control	O	O
cells	O	O
;	O	O
however	O	O
,	O	O
this	O	O
was	O	O
not	O	O
related	O	O
to	O	O
the	O	O
genotype	O	O
.	O	O
This	O	O
research	O	O
demonstrates	O	O
the	O	O
major	O	O
potential	O	O
of	O	O
the	O	O
algorithm	O	O
proposed	O	O
for	O	O
diagnosis	O	O
.	O	O
Our	O	O
data	O	O
enhance	O	O
the	O	O
importance	O	O
of	O	O
establish	O	O
a	O	O
differential	O	O
diagnosis	O	O
with	O	O
other	O	O
retinal	O	O
dystrophies	O	O
,	O	O
supporting	O	O
the	O	O
idea	O	O
of	O	O
an	O	O
underestimated	O	O
prevalence	O	O
of	O	O
choroideremia	O	O
.	O	O
Moreover	O	O
,	O	O
they	O	O
suggested	O	O
that	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
disorder	O	O
can	O	O
not	O	O
be	O	O
exclusively	O	O
explained	O	O
by	O	O
the	O	O
genotype	O	O
.	O	O
Four	O	O
novel	O	O
ATP2C1	B-Gene	O
mutations	B-Var	O
in	O	O
Chinese	O	O
patients	O	O
with	B-Reg	O
Hailey	B-Disease	O
-	I-Disease	O
Hailey	I-Disease	O
disease	I-Disease	O
.	O	O
Hailey	O	O
-	O	O
Hailey	O	O
disease	O	O
(	O	O
HHD	O	O
)	O	O
is	O	O
a	O	O
kind	O	O
of	O	O
autosomal	O	O
dominant	O	O
dermatosis	O	O
.	O	O
The	O	O
ATP2C1	O	O
gene	O	O
has	O	O
been	O	O
identified	O	O
as	O	O
the	O	O
pathogenic	O	O
gene	O	O
of	O	O
HHD	O	O
since	O	O
2000	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
direct	O	O
DNA	O	O
sequencing	O	O
was	O	O
used	O	O
to	O	O
identify	O	O
ATP2C1	O	O
gene	O	O
mutations	O	O
in	O	O
four	O	O
Chinese	O	O
families	O	O
and	O	O
two	O	O
sporadic	O	O
cases	O	O
with	O	O
HHD	O	O
.	O	O
The	O	O
entire	O	O
coding	O	O
and	O	O
flanking	O	O
intronic	O	O
sequences	O	O
of	O	O
ATP2C1	O	O
were	O	O
screened	O	O
for	O	O
mutations	O	O
and	O	O
five	O	O
heterozygous	O	O
mutations	O	O
of	O	O
the	O	O
ATP2C1	O	O
gene	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
four	O	O
pedigrees	O	O
and	O	O
two	O	O
sporadic	O	O
cases	O	O
with	O	O
HHD	O	O
.	O	O
Four	O	O
of	O	O
them	O	O
were	O	O
novel	O	O
,	O	O
including	O	O
three	O	O
frame	O	O
-	O	O
shift	O	O
mutations	O	O
(	O	O
c.1330delC	O	O
,	O	O
c.888_889insT	O	O
,	O	O
c.478_479insA	O	O
)	O	O
and	O	O
one	O	O
nonsense	O	O
mutation	O	O
(	O	O
c.1720C	O	O
>	O	O
T	O	O
)	O	O
.	O	O
These	O	O
data	O	O
added	O	O
new	O	O
variants	O	O
to	O	O
the	O	O
database	O	O
of	O	O
ATP2C1	B-Gene	O
mutations	B-Var	O
associated	B-Reg	O
with	I-Reg	O
HHD	B-Disease	O
.	O	O
Glycogen	O	O
storage	O	O
disease	O	O
type	O	O
III	O	O
:	O	O
diagnosis	O	O
,	O	O
genotype	O	O
,	O	O
management	O	O
,	O	O
clinical	O	O
course	O	O
and	O	O
outcome	O	O
.	O	O
Glycogen	B-Disease	O
storage	I-Disease	O
disease	I-Disease	O
type	I-Disease	O
III	I-Disease	O
(	O	O
GSDIII	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
disorder	O	O
of	O	O
glycogenolysis	O	O
due	B-Reg	O
to	I-Reg	O
AGL	B-Gene	O
gene	O	O
mutations	B-Var	O
,	O	O
causing	O	O
glycogen	O	O
debranching	O	O
enzyme	O	O
deficiency	O	O
and	O	O
storage	O	O
of	O	O
limited	O	O
dextrin	O	O
.	O	O
Patients	O	O
with	O	O
GSDIIIa	O	O
show	O	O
involvement	O	O
of	O	O
liver	O	O
and	O	O
cardiac	O	O
/	O	O
skeletal	O	O
muscle	O	O
,	O	O
whereas	O	O
GSDIIIb	O	O
patients	O	O
display	O	O
only	O	O
liver	O	O
symptoms	O	O
and	O	O
signs	O	O
.	O	O
The	O	O
International	O	O
Study	O	O
on	O	O
Glycogen	O	O
Storage	O	O
Disease	O	O
(	O	O
ISGSDIII	O	O
)	O	O
is	O	O
a	O	O
descriptive	O	O
retrospective	O	O
,	O	O
international	O	O
,	O	O
multi	O	O
-	O	O
centre	O	O
cohort	O	O
study	O	O
of	O	O
diagnosis	O	O
,	O	O
genotype	O	O
,	O	O
management	O	O
,	O	O
clinical	O	O
course	O	O
and	O	O
outcome	O	O
of	O	O
175	O	O
patients	O	O
from	O	O
147	O	O
families	O	O
(	O	O
86	O	O
%	O	O
GSDIIIa	O	O
;	O	O
14	O	O
%	O	O
GSDIIIb	O	O
)	O	O
,	O	O
with	O	O
follow	O	O
-	O	O
up	O	O
into	O	O
adulthood	O	O
in	O	O
91	O	O
patients	O	O
.	O	O
In	O	O
total	O	O
58	O	O
AGL	O	O
mutations	O	O
(	O	O
non	O	O
-	O	O
missense	O	O
mutations	O	O
were	O	O
overrepresented	O	O
and	O	O
21	O	O
novel	O	O
mutations	O	O
were	O	O
observed	O	O
)	O	O
were	O	O
identified	O	O
in	O	O
76	O	O
families	O	O
.	O	O
GSDIII	O	O
patients	O	O
first	O	O
presented	O	O
before	O	O
the	O	O
age	O	O
of	O	O
1.5	O	O
years	O	O
,	O	O
hepatomegaly	O	O
was	O	O
the	O	O
most	O	O
common	O	O
presenting	O	O
clinical	O	O
sign	O	O
.	O	O
Dietary	O	O
management	O	O
was	O	O
very	O	O
diverse	O	O
and	O	O
included	O	O
frequent	O	O
meals	O	O
,	O	O
uncooked	O	O
cornstarch	O	O
and	O	O
continuous	O	O
gastric	O	O
drip	O	O
feeding	O	O
.	O	O
Chronic	O	O
complications	O	O
involved	O	O
the	O	O
liver	O	O
(	O	O
hepatic	O	O
cirrhosis	O	O
,	O	O
adenoma(s	O	O
)	O	O
,	O	O
and/or	O	O
hepatocellular	O	O
carcinoma	O	O
in	O	O
11	O	O
%	O	O
)	O	O
,	O	O
heart	O	O
(	O	O
cardiac	O	O
involvement	O	O
and	O	O
cardiomyopathy	O	O
,	O	O
in	O	O
58	O	O
%	O	O
and	O	O
15	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
generally	O	O
presenting	O	O
in	O	O
early	O	O
childhood	O	O
)	O	O
,	O	O
and	O	O
muscle	O	O
(	O	O
pain	O	O
in	O	O
34	O	O
%	O	O
)	O	O
.	O	O
Type	O	O
2	O	O
diabetes	O	O
mellitus	O	O
was	O	O
diagnosed	O	O
in	O	O
eight	O	O
out	O	O
of	O	O
91	O	O
adult	O	O
patients	O	O
(	O	O
9	O	O
%	O	O
)	O	O
.	O	O
In	O	O
adult	O	O
patients	O	O
no	O	O
significant	O	O
correlation	O	O
was	O	O
detected	O	O
between	O	O
(	O	O
non-	O	O
)	O	O
missense	O	O
AGL	O	O
genotypes	O	O
and	O	O
hepatic	O	O
,	O	O
cardiac	O	O
or	O	O
muscular	O	O
complications	O	O
.	O	O
This	O	O
study	O	O
demonstrates	O	O
heterogeneity	O	O
in	O	O
a	O	O
large	O	O
cohort	O	O
of	O	O
ageing	O	O
GSDIII	O	O
patients	O	O
.	O	O
An	O	O
international	O	O
GSD	O	O
patient	O	O
registry	O	O
is	O	O
warranted	O	O
to	O	O
prospectively	O	O
define	O	O
the	O	O
clinical	O	O
course	O	O
,	O	O
heterogeneity	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
different	O	O
dietary	O	O
interventions	O	O
in	O	O
patients	O	O
with	O	O
GSDIII	O	O
.	O	O
Gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
Function	I-PosReg	O
Mutations	B-Var	O
in	O	O
RARB	B-Gene	O
Cause	B-Reg	O
Intellectual	B-MPA	B-Disease
Disability	I-MPA	I-Disease
with	O	O
Progressive	B-MPA	O
Motor	I-MPA	B-Disease
Impairment	I-MPA	I-Disease
.	O	O
Retinoic	O	O
acid	O	O
(	O	O
RA	O	O
)	O	O
signaling	O	O
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
the	O	O
development	O	O
and	O	O
function	O	O
of	O	O
several	O	O
systems	O	O
in	O	O
mammals	O	O
.	O	O
We	O	O
previously	O	O
discovered	O	O
that	O	O
the	O	O
de	O	O
novo	O	O
mutations	O	O
c.1159C	B-Var	B-Var
>	I-Var	I-Var
T	I-Var	I-Var
(	O	O
p	O	O
.	O	O
Arg387Cys	O	O
)	O	O
and	O	O
c.1159C	B-Var	O
>	I-Var	I-Var
A	I-Var	O
(	O	O
p	O	O
.	O	O
Arg387Ser	O	O
)	O	O
in	O	O
the	O	O
RA	O	O
Receptor	O	O
Beta	O	O
(	B-Gene	B-Gene
RARB	I-Gene	O
)	I-Gene	I-Gene
gene	O	O
cause	B-Reg	B-Reg
microphthalmia	B-Disease	O
and	O	O
diaphragmatic	B-Disease	B-Disease
hernia	I-Disease	I-Disease
.	O	O
However	O	O
,	O	O
the	O	O
natural	O	O
history	O	O
of	O	O
affected	O	O
subjects	O	O
beyond	O	O
the	O	O
prenatal	O	O
or	O	O
neonatal	O	O
period	O	O
was	O	O
unknown	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
describe	O	O
nine	O	O
additional	O	O
subjects	O	O
with	O	O
microphthalmia	O	O
who	O	O
have	O	O
de	O	O
novo	O	O
mutations	O	O
in	O	O
RARB	O	O
,	O	O
including	O	O
the	O	O
previously	O	O
described	O	O
p	O	O
.	O	O
Arg387Cys	O	O
as	O	O
well	O	O
as	O	O
the	O	O
novel	O	O
c.887G	O	O
>	O	O
C	O	O
(	O	O
p	O	O
.	O	O
Gly296Ala	O	O
)	O	O
and	O	O
c.638T	O	O
>	O	O
C	O	O
(	O	O
p	O	O
.	O	O
Leu213Pro	O	O
)	O	O
.	O	O
Moreover	O	O
,	O	O
we	O	O
review	O	O
the	O	O
information	O	O
on	O	O
four	O	O
previously	O	O
reported	O	O
cases	O	O
.	O	O
All	O	O
subjects	O	O
who	O	O
survived	O	O
the	O	O
neonatal	O	O
period	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
displayed	O	O
severe	O	O
global	O	O
developmental	O	O
delay	O	O
with	O	O
progressive	O	O
motor	O	O
impairment	O	O
due	O	O
to	O	O
spasticity	O	O
and/or	O	O
dystonia	O	O
(	O	O
with	O	O
or	O	O
without	O	O
chorea	O	O
)	O	O
.	O	O
The	O	O
majority	O	O
of	O	O
subjects	O	O
also	O	O
showed	O	O
Chiari	O	O
type	O	O
I	O	O
malformation	O	O
and	O	O
severe	O	O
feeding	O	O
difficulties	O	O
.	O	O
We	O	O
previously	O	O
found	O	O
that	O	O
p	O	O
.	O	O
Arg387Cys	O	O
and	O	O
p	O	O
.	O	O
Arg387Ser	O	O
induce	O	O
a	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
function	O	O
.	O	O
We	O	O
show	O	O
here	O	O
that	O	O
the	O	O
p	B-Var	O
.	I-Var	O
Gly296Ala	I-Var	O
and	O	O
p	B-Var	O
.	I-Var	O
Leu213Pro	I-Var	O
RARB	B-Gene	O
mutations	O	B-Var
further	O	O
promote	B-PosReg	B-NegReg
the	O	O
RA	B-MPA	O
ligand	I-MPA	B-MPA
-	I-MPA	I-MPA
induced	I-MPA	O
transcriptional	I-MPA	I-MPA
activity	I-MPA	O
by	O	O
twofold	O	O
to	O	O
threefold	O	O
over	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
receptor	O	O
,	O	O
also	O	O
indicating	O	O
a	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mechanism	O	O
.	O	O
These	O	O
observations	O	O
suggest	O	O
that	O	O
precise	O	O
regulation	O	O
of	O	O
RA	O	O
signaling	O	O
is	O	O
required	O	O
for	O	O
brain	O	O
development	O	O
and/or	O	O
function	O	O
in	O	O
humans	O	O
.	O	O
Long	O	O
-	O	O
term	O	O
vemurafenib	O	O
treatment	O	O
drives	B-Reg	O
inhibitor	B-MPA	O
resistance	I-MPA	O
through	O	O
a	O	O
spontaneous	O	O
KRAS	B-Gene	O
G12D	B-Var	O
mutation	O	O
in	O	O
a	O	O
BRAF	O	O
V600E	O	O
papillary	O	O
thyroid	O	O
carcinoma	O	O
model	O	O
.	O	O
The	O	O
BRAF	O	O
V600E	O	O
mutation	O	O
is	O	O
commonly	O	O
observed	O	O
in	O	O
papillary	O	O
thyroid	O	O
cancer	O	O
(	O	O
PTC	O	O
)	O	O
and	O	O
predominantly	O	O
activates	O	O
the	O	O
MAPK	O	O
pathway	O	O
.	O	O
Presence	O	O
of	O	O
BRAF	O	O
V600E	O	O
predicts	O	O
increasing	O	O
risk	O	O
of	O	O
recurrence	O	O
and	O	O
higher	O	O
mortality	O	O
rate	O	O
,	O	O
and	O	O
treatment	O	O
options	O	O
for	O	O
such	O	O
patients	O	O
are	O	O
limited	O	O
.	O	O
Vemurafenib	O	O
,	O	O
a	O	O
BRAF	O	O
V600E	O	O
inhibitor	O	O
,	O	O
is	O	O
initially	O	O
effective	O	O
,	O	O
but	O	O
cells	O	O
inevitably	O	O
develop	O	O
alternative	O	O
mechanisms	O	O
of	O	O
pathway	O	O
activation	O	O
.	O	O
Mechanisms	O	O
of	O	O
primary	O	O
resistance	O	O
have	O	O
been	O	O
described	O	O
in	O	O
short	O	O
-	O	O
term	O	O
cultures	O	O
of	O	O
PTC	O	O
cells	O	O
;	O	O
however	O	O
,	O	O
mechanisms	O	O
of	O	O
acquired	O	O
resistance	O	O
have	O	O
not	O	O
.	O	O
In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
possible	O	O
adaptive	O	O
mechanisms	O	O
of	O	O
BRAF	O	O
V600E	O	O
inhibitor	O	O
resistance	O	O
in	O	O
KTC1	O	O
thyroid	O	O
cancer	O	O
cells	O	O
following	O	O
long	O	O
-	O	O
term	O	O
vemurafenib	O	O
exposure	O	O
.	O	O
We	O	O
found	O	O
that	O	O
a	O	O
subpopulation	O	O
of	O	O
KTC1	O	O
cells	O	O
acquired	O	O
resistance	O	O
to	O	O
vemurafenib	O	O
following	O	O
5	O	O
months	O	O
of	O	O
treatment	O	O
with	O	O
the	O	O
inhibitor	O	O
.	O	O
Resistance	O	O
coincided	O	O
with	O	O
the	O	O
spontaneous	O	O
acquisition	O	O
of	O	O
a	O	O
KRAS	O	O
G12D	O	O
activating	O	O
mutation	O	O
.	O	O
Increases	O	O
in	O	O
activated	O	O
AKT	O	O
,	O	O
ERK1/2	O	O
,	O	O
and	O	O
EGFR	O	O
were	O	O
observed	O	O
in	O	O
these	O	O
cells	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
the	O	O
resistant	O	O
cells	O	O
were	O	O
less	O	O
sensitive	O	O
to	O	O
combinations	O	O
of	O	O
vemurafenib	O	O
and	O	O
MEK1	O	O
inhibitor	O	O
or	O	O
AKT	O	O
inhibitor	O	O
.	O	O
These	O	O
results	O	O
support	O	O
the	O	O
KRAS	B-Gene	O
G12D	B-Var	O
mutation	O	O
as	O	O
a	O	O
genetic	O	O
mechanism	O	O
of	O	O
spontaneously	O	O
acquired	B-Reg	O
secondary	B-MPA	O
BRAF	I-MPA	O
inhibitor	I-MPA	O
resistance	I-MPA	O
in	O	O
BRAF	O	O
V600E	O	O
thyroid	O	O
cancer	O	O
cells	O	O
.	O	O
Loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutations	B-Var	O
in	O	O
the	O	O
APX1	B-Gene	O
gene	O	O
result	O	O
in	O	O
enhanced	B-PosReg	B-PosReg
selenium	B-MPA	O
tolerance	I-MPA	I-CPA
in	O	O
Arabidopsis	O	O
thaliana	O	O
.	O	O
It	O	O
is	O	O
generally	O	O
recognized	O	O
that	O	O
excess	O	O
selenium	O	O
(	O	O
Se	O	O
)	O	O
has	O	O
a	O	O
negative	O	O
effect	O	O
on	O	O
the	O	O
growth	O	O
and	O	O
development	O	O
of	O	O
plants	O	O
.	O	O
Numerous	O	O
studies	O	O
have	O	O
identified	O	O
key	O	O
genes	O	O
involved	O	O
in	O	O
selenium	O	O
tolerance	O	O
in	O	O
plants	O	O
;	O	O
however	O	O
,	O	O
our	O	O
understanding	O	O
of	O	O
its	O	O
molecular	O	O
mechanisms	O	O
is	O	O
far	O	O
from	O	O
complete	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
isolated	O	O
an	O	O
Arabidopsis	O	O
selenium	O	O
-	O	O
resistant	O	O
mutant	B-Var	O
from	O	O
the	O	O
mutant	O	O
XVE	O	O
pool	O	O
lines	O	B-PosReg
because	O	O
of	O	O
its	O	O
increased	B-PosReg	B-PosReg
root	B-MPA	O
growth	I-MPA	I-MPA
and	O	O
fresh	B-MPA	O
weight	I-MPA	O
in	O	O
Se	O	O
stress	O	O
,	O	O
and	O	O
cloned	O	O
the	O	O
gene	O	O
,	O	O
which	O	O
encodes	O	O
the	O	O
cytosolic	O	O
ascorbate	O	O
peroxidase	O	O
(	O	O
APX1	O	O
)	O	O
.	O	O
Two	O	O
other	O	O
APX1	O	O
gene	O	O
knockout	O	O
allelic	O	O
lines	O	O
were	O	O
also	O	O
selenium	O	O
resistant	O	O
,	O	O
and	O	O
the	O	O
APX1-complementary	O	O
COM1	O	O
restored	O	O
the	O	O
growth	O	O
state	O	O
of	O	O
wild	O	O
type	O	O
under	O	O
Se	O	O
stress	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
these	O	O
APX1	O	O
allelic	O	O
lines	O	O
accumulated	O	O
more	O	O
Se	O	O
than	O	O
did	O	O
wild	O	O
-	O	O
type	O	O
plants	O	O
when	O	O
subjected	O	O
to	O	O
Se	O	O
stress	O	O
.	O	O
Further	O	O
analysis	O	O
revealed	O	O
that	O	O
the	O	O
APX1-mediated	O	O
Se	O	O
tolerance	O	O
was	O	O
associated	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
with	O	O
the	O	O
enhanced	O	O
activities	O	O
of	O	O
antioxidant	O	O
enzymes	O	O
catalase	O	O
,	O	O
glutathione	O	O
peroxidase	O	O
and	O	O
glutathione	O	O
reductase	O	O
.	O	O
Moreover	O	O
,	O	O
enhanced	B-PosReg	O
Se	B-MPA	O
resistance	I-MPA	O
of	O	O
the	O	O
mutants	B-Var	O
was	O	O
associated	B-Reg	O
with	O	O
glutathione	B-MPA	O
(	O	O
GSH	O	O
)	O	O
,	O	O
which	O	O
had	O	O
the	O	O
higher	O	O
expression	O	O
level	O	O
of	O	O
GSH1	O	O
gene	O	O
involved	O	O
in	O	O
GSH	O	O
synthesis	O	O
and	O	O
consequently	O	O
increased	O	O
GSH	O	O
content	O	O
.	O	O
Our	O	O
results	O	O
provide	O	O
genetic	O	O
evidence	O	O
indicating	O	O
that	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
of	O	O
APX1	O	O
results	O	O
in	O	O
tolerance	O	O
to	O	O
Se	O	O
stress	O	O
.	O	O
Coexistence	O	O
of	O	O
Mosaic	O	O
Uniparental	O	O
Isodisomy	O	O
and	O	O
a	O	O
KCNJ11	O	O
Mutation	O	O
Presenting	O	O
as	O	O
Diffuse	O	O
Congenital	O	O
Hyperinsulinism	O	O
and	O	O
Hemihypertrophy	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Isolated	O	O
hyperinsulinaemic	B-Disease	O
hypoglycaemia	I-Disease	O
(	O	O
HH	O	O
)	O	O
commonly	O	O
results	B-Reg	O
from	I-Reg	O
recessively	B-Var	O
inherited	I-Var	O
mutations	I-Var	O
in	O	O
the	O	O
ABCC8	B-Gene	O
and	O	O
KCNJ11	B-Gene	O
genes	O	O
that	O	O
are	O	O
located	O	O
on	O	O
chromosome	O	O
11p15.1	O	O
.	O	O
More	O	O
rarely	O	O
,	O	O
HH	O	O
can	O	O
feature	O	O
in	O	O
patients	O	O
with	O	O
Beckwith	O	O
-	O	O
Wiedemann	O	O
syndrome	O	O
(	O	O
BWS	O	O
)	O	O
,	O	O
a	O	O
congenital	O	O
overgrowth	O	O
disorder	O	O
,	O	O
resulting	O	O
from	O	O
defects	O	O
at	O	O
a	O	O
differentially	O	O
methylated	O	O
region	O	O
telomeric	O	O
to	O	O
the	O	O
K	O	O
-	O	O
ATP	O	O
channel	O	O
genes	O	O
at	O	O
chromosome	O	O
11p15.5	O	O
.	O	O
SUBJECT	O	O
:	O	O
We	O	O
undertook	O	O
genetic	O	O
testing	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
diazoxide	O	O
-	O	O
unresponsive	O	O
HH	O	O
diagnosed	O	O
at	O	O
birth	O	O
.	O	O
Physical	O	O
examination	O	O
later	O	O
revealed	O	O
hemihypertrophy	O	O
of	O	O
the	O	O
right	O	O
arm	O	O
,	O	O
a	O	O
feature	O	O
of	O	O
BWS	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
identified	O	O
a	O	O
novel	O	O
mosaic	O	O
,	O	O
paternally	O	O
-	O	O
inherited	O	O
KCNJ11	O	O
mutation(s	O	O
)	O	O
in	O	O
the	O	O
patient	O	O
.	O	O
Further	O	O
analysis	O	O
confirmed	O	O
uniparental	O	O
disomy	O	O
(	O	O
UPD	O	O
)	O	O
of	O	O
chromosome	O	O
11	O	O
,	O	O
which	O	O
extended	O	O
across	O	O
the	O	O
KCNJ11	O	O
gene	O	O
at	O	O
11p15.1	O	O
and	O	O
the	O	O
BWS	O	O
locus	O	O
at	O	O
11p15.5	O	O
.	O	O
CONCLUSION	O	O
:	O	O
These	O	O
results	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
considering	O	O
UPD	O	O
as	O	O
a	O	O
mechanism	O	O
of	O	O
disease	O	O
in	O	O
patients	O	O
with	O	O
HH	O	O
and	O	O
a	O	O
paternally	O	O
inherited	O	O
K	O	O
-	O	O
ATP	O	O
channel	O	O
mutation	O	O
,	O	O
especially	O	O
when	O	O
additional	O	O
syndromic	O	O
features	O	O
are	O	O
present	O	O
.	O	O
Loss	O	O
of	O	O
T	O	O
-	O	O
cell	O	O
quiescence	O	O
by	O	O
targeting	O	O
Slfn2	O	O
prevents	O	O
the	O	O
development	O	O
and	O	O
progression	O	O
of	O	O
T	O	O
-	O	O
ALL	O	O
.	O	O
T	O	O
-	O	O
cell	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
(	O	O
T	O	O
-	O	O
ALL	O	O
)	O	O
is	O	O
an	O	O
aggressive	O	O
malignancy	O	O
of	O	O
thymocytes	O	O
.	O	O
Despite	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
T	O	O
-	O	O
ALL	O	O
,	O	O
approximately	O	O
20	O	O
%	O	O
of	O	O
children	O	O
and	O	O
most	O	O
adults	O	O
undergo	O	O
relapse	O	O
.	O	O
Previous	O	O
findings	O	O
demonstrated	O	O
that	O	O
loss	B-NegReg	O
of	O	O
T	B-CPA	O
-	I-CPA	O
cell	I-CPA	O
quiescence	I-CPA	O
due	O	O
to	O	O
a	O	O
mutation	B-Var	O
in	O	O
the	O	O
Slfn2	B-Gene	O
gene	O	O
(	O	O
elektra	O	O
)	O	O
leads	B-Reg	O
to	I-Reg	O
acquisition	O	O
of	O	O
an	O	O
aberrant	B-CPA	B-PosReg
developmental	I-CPA	I-CPA
program	I-CPA	O
by	O	O
which	O	O
T	O	O
-	O	O
cells	O	O
lose	B-NegReg	O
their	O	O
renewal	B-CPA	O
capabilities	I-CPA	O
and	O	O
undergo	B-CPA	B-CPA
apoptosis	I-CPA	I-CPA
.	O	O
Here	O	O
we	O	O
show	O	O
that	O	O
the	O	O
elektra	O	O
mutation	O	O
in	O	O
Slfn2	O	O
completely	O	O
prevents	O	O
a	O	O
severe	O	O
lymphoproliferative	O	O
disease	O	O
caused	O	O
by	O	O
overexpression	O	O
of	O	O
BCL2	O	O
in	O	O
combination	O	O
with	O	O
Fas	O	O
deficiency	O	O
in	O	O
mice	O	O
.	O	O
Moreover	O	O
,	O	O
Slfn2	O	O
impaired	O	O
-	O	O
function	O	O
protects	O	O
mice	O	O
from	O	O
experimental	O	O
disease	O	O
similar	O	O
to	O	O
human	O	O
T	O	O
-	O	O
ALL	O	O
by	O	O
severely	O	O
impairing	O	O
the	O	O
proliferation	O	O
potential	O	O
and	O	O
survival	O	O
of	O	O
leukemic	O	O
T	O	O
-	O	O
cells	O	O
,	O	O
partially	O	O
by	O	O
activation	O	O
of	O	O
the	O	O
p53	O	O
tumor	O	O
suppressor	O	O
protein	O	O
.	O	O
Our	O	O
study	O	O
suggest	O	O
that	O	O
in	O	O
certain	O	O
malignancies	O	O
,	O	O
such	O	O
as	O	O
T	O	O
-	O	O
ALL	O	O
,	O	O
a	O	O
novel	O	O
therapeutic	O	O
strategy	O	O
may	O	O
be	O	O
applied	O	O
by	O	O
imposing	O	O
aberrant	O	O
development	O	O
of	O	O
leukemic	O	O
cells	O	O
.	O	O
Furthermore	O	O
,	O	O
as	O	O
the	O	O
elektra	O	O
mutation	B-Var	O
in	O	O
Slfn2	B-Gene	O
seems	O	O
to	O	O
impair	B-Reg	O
only	O	O
T	B-CPA	O
-	I-CPA	O
cells	I-CPA	O
and	O	O
monocytes	B-CPA	B-CPA
,	O	O
targeting	O	O
Slfn2	O	O
is	O	O
expected	O	O
to	O	O
be	O	O
harmless	O	O
to	O	O
other	O	O
cell	O	O
types	O	O
,	O	O
and	O	O
thereby	O	O
could	O	O
be	O	O
a	O	O
promising	O	O
target	O	O
for	O	O
treating	O	O
malignancies	O	O
.	O	O
Together	O	O
our	O	O
results	O	O
demonstrate	O	O
the	O	O
potential	O	O
of	O	O
targeting	O	O
Slfn2	O	O
and	O	O
its	O	O
human	O	O
paralog	O	O
for	O	O
T	O	O
-	O	O
ALL	O	O
treatment	O	O
.	O	O
Mutational	B-Var	O
Spectrum	O	O
of	O	O
the	O	O
MEFV	B-Gene	O
Gene	O	O
in	O	O
AA	O	O
Amyloidosis	O	O
Associated	B-Reg	O
With	I-Reg	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
Fever	I-Disease	O
.	O	O
INTRODUCTION	O	O
:	O	O
Familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
(	O	O
FMF	O	O
)	O	O
is	O	O
a	O	O
recessively	O	O
inherited	O	O
disease	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
recurrent	O	O
episodic	O	O
fever	O	O
,	O	O
abdominal	O	O
pain	O	O
,	O	O
and	O	O
polyserositis	O	O
.	O	O
It	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	B-Var
in	O	O
the	O	O
MEFV	B-Gene	B-Gene
gene	O	O
,	O	O
encoding	O	O
the	O	O
pyrin	O	O
protein	O	O
.	O	O
The	O	O
most	O	O
important	O	O
complication	O	O
of	O	O
FMF	O	O
is	O	O
secondary	O	O
(	O	O
AA	O	O
)	O	O
amyloidosis	O	O
that	O	O
leads	O	O
to	O	O
kidney	O	O
failure	O	O
.	O	O
This	O	O
study	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
frequency	O	O
and	O	O
distribution	O	O
of	O	O
MEFV	O	O
mutations	O	O
in	O	O
Turkish	O	O
patients	O	O
with	O	O
FMF	O	O
-	O	O
associated	O	O
AA	O	O
amyloidosis	O	O
.	O	O
MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
57	O	O
patients	O	O
with	O	O
FMF	O	O
-	O	O
associated	O	O
AA	O	O
amyloidosis	O	O
and	O	O
60	O	O
healthy	O	O
controls	O	O
were	O	O
included	O	O
in	O	O
this	O	O
study	O	O
.	O	O
We	O	O
analyzed	O	O
the	O	O
MEFV	O	O
gene	O	O
for	O	O
E148Q	O	O
,	O	O
M694V	O	O
,	O	O
M680I	O	O
,	O	O
and	O	O
V726A	O	O
mutations	O	O
and	O	O
R202Q	O	O
variant	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
and	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
methods	O	O
.	O	O
Results	O	O
.	O	O
The	O	O
male	O	O
-	O	O
female	O	O
ratio	O	O
was	O	O
0.72	O	O
.	O	O
The	O	O
mean	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
29.8	O	O
±	O	O
12.8	O	O
years	O	O
.	O	O
Among	O	O
the	O	O
patients	O	O
,	O	O
the	O	O
rate	O	O
of	O	O
the	O	O
MEFV	O	O
mutations	O	O
was	O	O
found	O	O
to	O	O
be	O	O
77.2	O	O
%	O	O
.	O	O
The	O	O
most	O	O
frequently	O	O
observed	O	O
genotype	O	O
was	O	O
homozygous	O	O
M694V	O	O
mutation	O	O
,	O	O
which	O	O
was	O	O
present	O	O
in	O	O
17	O	O
patients	O	O
(	O	O
29.8	O	O
%	O	O
,	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
,	O	O
followed	O	O
by	O	O
compound	O	O
heterozygous	O	O
M680I	O	O
/	O	O
M694V	O	O
(	O	O
14.3	O	O
%	O	O
,	O	O
P	O	O
=	O	O
.01	O	O
)	O	O
.	O	O
The	O	O
R202Q	O	O
allele	O	O
frequencies	O	O
were	O	O
significantly	O	O
different	O	O
between	O	O
patients	O	O
and	O	O
control	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.02	O	O
;	O	O
odds	O	O
ratio	O	O
,	O	O
0.53	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0.30	O	O
to	O	O
0.94	O	O
)	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
In	O	O
this	O	O
study	O	O
,	O	O
mutation	O	O
analysis	O	O
of	O	O
MEFV	O	O
gene	O	O
confirmed	O	O
that	O	O
the	O	O
most	O	O
frequent	O	O
mutation	O	O
was	O	O
homozygous	O	O
M694V	O	O
genotype	O	O
.	O	O
R202Q	O	O
may	O	O
be	O	O
important	O	O
in	O	O
patients	O	O
with	O	O
FMF	O	O
-	O	O
associated	O	O
AA	O	O
amyloidosis	O	O
.	O	O
Thus	O	O
,	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
investigation	O	O
of	O	O
R202Q	O	O
should	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
genetic	O	O
test	O	O
for	O	O
Turkish	O	O
FMF	O	O
patients	O	O
.	O	O
Oncogenic	O	O
Mutant	O	O
p53	O	O
Gain	O	O
of	O	O
Function	O	O
Nourishes	O	O
the	O	O
Vicious	O	O
Cycle	O	O
of	O	O
Tumor	O	B-CPA
Development	O	I-CPA
and	O	O
Cancer	O	O
Stem	O	O
-	O	I-CPA
Cell	O	I-CPA
Formation	O	O
.	O	O
More	O	O
than	O	O
half	O	O
of	O	O
human	O	O
tumors	O	O
harbor	O	O
an	O	O
inactivated	O	O
p53	O	O
tumor	O	O
-	O	O
suppressor	O	O
gene	O	O
.	O	O
It	O	O
is	O	O
well	O	O
accepted	O	O
that	O	O
mutant	B-Var	B-Var
p53	B-Gene	B-Gene
shows	O	O
an	O	O
oncogenic	O	O
gain	O	B-PosReg
-	O	I-PosReg
of	O	I-PosReg
-	O	I-PosReg
function	O	I-PosReg
(	O	O
GOF	O	O
)	O	O
activity	O	O
that	O	O
facilitates	B-PosReg	O
the	O	O
transformed	B-MPA	O
phenotype	I-MPA	O
of	I-MPA	O
cancer	I-MPA	O
cells	I-MPA	O
.	O	O
In	O	O
addition	O	O
,	O	O
a	O	O
growing	O	O
body	O	O
of	O	O
evidence	O	O
supports	O	O
the	O	O
notion	O	O
that	O	O
cancer	O	O
stem	O	O
cells	O	O
comprise	O	O
a	O	O
seminal	O	O
constituent	O	O
in	O	O
the	O	O
initiation	O	O
and	O	O
progression	O	O
of	O	O
cancer	O	O
development	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
elaborate	O	O
on	O	O
the	O	O
mutant	B-Var	O
p53	B-Gene	O
oncogenic	O	O
GOF	B-PosReg	O
leading	O	O
toward	O	O
the	B-MPA	O
acquisition	I-MPA	O
of	I-MPA	O
a	I-MPA	O
transformed	I-MPA	O
phenotype	I-MPA	O
,	O	O
as	O	O
well	O	O
as	O	O
placing	O	O
mutant	O	O
p53	O	O
as	O	O
a	O	O
major	O	O
component	O	O
in	O	O
the	O	O
establishment	O	O
of	O	O
cancer	O	O
stem	O	O
cell	O	O
entity	O	O
.	O	O
Therefore	O	O
,	O	O
therapy	O	O
targeted	O	O
toward	O	O
cancer	O	O
stem	O	O
cells	O	O
harboring	O	O
mutant	O	O
p53	O	O
is	O	O
expected	O	O
to	O	O
pave	O	O
the	O	O
way	O	O
to	O	O
eradicate	O	O
tumor	O	B-CPA
growth	O	I-CPA
and	O	O
recurrence	O	B-CPA
.	O	O
N	O	O
-	O	O
glycan	O	O
containing	O	O
a	O	O
core	O	O
α1,3-fucose	O	O
residue	O	O
is	O	O
required	O	O
for	O	O
basipetal	O	O
auxin	O	O
transport	O	O
and	O	O
gravitropic	O	O
response	O	O
in	O	O
rice	O	O
(	O	O
Oryza	O	O
sativa	O	O
)	O	O
.	O	O
In	O	O
plants	O	O
,	O	O
α1,3-fucosyltransferase	O	O
(	O	O
FucT	O	O
)	O	O
catalyzes	O	O
the	O	O
transfer	O	O
of	O	O
fucose	O	O
from	O	O
GDP	O	O
-	O	O
fucose	O	O
to	O	O
asparagine	O	O
-	O	O
linked	O	O
GlcNAc	O	O
of	O	O
the	O	O
N	O	O
-	O	O
glycan	O	O
core	O	O
in	O	O
the	O	O
medial	O	O
Golgi	O	O
.	O	O
To	O	O
explore	O	O
the	O	O
physiological	O	O
significance	O	O
of	O	O
this	O	O
processing	O	O
,	O	O
we	O	O
isolated	O	O
two	O	O
Oryza	O	O
sativa	O	O
(	O	O
rice	O	O
)	O	O
mutants	O	O
(	O	O
fuct-1	O	O
and	O	O
fuct-2	O	O
)	O	O
with	O	O
loss	O	O
of	O	O
FucT	O	O
function	O	O
.	O	O
Biochemical	O	O
analyses	O	O
of	O	O
the	O	O
N	O	O
-	O	O
glycan	O	O
structure	O	O
confirmed	O	O
that	O	O
α1,3-fucose	O	O
is	O	O
missing	B-Var	O
from	O	O
the	O	O
N	O	O
-	O	O
glycans	O	O
of	O	O
allelic	O	O
fuct-1	B-Gene	O
and	O	O
fuct-2	B-Gene	O
.	O	O
Compared	O	O
with	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
cv	O	O
Kitaake	O	O
,	O	O
fuct-1	O	O
displayed	O	O
a	O	O
larger	B-PosReg	O
tiller	B-MPA	O
angle	I-MPA	O
,	O	O
shorter	B-NegReg	O
internode	B-MPA	O
and	O	O
panicle	B-MPA	O
lengths	O	O
,	O	O
and	O	O
decreased	B-NegReg	O
grain	B-MPA	O
filling	I-MPA	O
as	O	O
well	O	O
as	O	O
an	O	O
increase	B-PosReg	O
in	O	O
chalky	B-MPA	O
grains	I-MPA	O
with	I-MPA	O
abnormal	I-MPA	O
shape	I-MPA	O
.	O	O
The	O	O
mutant	O	O
allele	O	O
fuct-2	O	O
gave	O	O
rise	O	O
to	O	O
similar	O	O
developmental	O	O
abnormalities	O	O
,	O	O
although	O	O
they	O	O
were	O	O
milder	O	O
than	O	O
those	O	O
of	O	O
fuct-1	O	O
.	O	O
Restoration	O	O
of	O	O
a	O	O
normal	O	O
tiller	O	O
angle	O	O
in	O	O
fuct-1	O	O
by	O	O
complementation	O	O
demonstrated	O	O
that	O	O
the	O	O
phenotype	O	O
is	O	O
caused	O	O
by	O	O
the	O	O
loss	O	O
of	O	O
FucT	O	O
function	O	O
.	O	O
Both	O	O
fuct-1	O	O
and	O	O
fuct-2	O	O
plants	O	O
exhibited	O	O
reduced	O	O
gravitropic	O	O
responses	O	O
.	O	O
Expression	O	O
of	O	O
the	O	O
genes	O	O
involved	O	O
in	O	O
tiller	O	O
and	O	O
leaf	O	O
angle	O	O
control	O	O
was	O	O
also	O	O
affected	O	O
in	O	O
the	O	O
mutants	O	O
.	O	O
We	O	O
demonstrate	O	O
that	O	O
reduced	O	B-NegReg
basipetal	O	O
auxin	O	B-CPA
transport	O	O
and	O	O
low	O	O
auxin	O	O
accumulation	O	O
at	O	O
the	O	O
base	O	O
of	O	O
the	O	O
shoot	O	O
in	O	O
fuct-1	O	O
account	O	O
for	O	O
both	O	O
the	O	O
reduced	O	O
gravitropic	O	O
response	O	O
and	O	O
the	O	O
increased	O	O
tiller	O	O
angle	O	O
.	O	O
Hajdu	O	O
-	O	O
Cheney	O	O
Syndrome	O	O
,	O	O
a	O	O
Disease	O	O
Associated	O	O
with	O	O
NOTCH2	O	O
Mutations	O	O
.	O	O
Notch	O	O
plays	O	O
an	O	O
important	O	O
function	O	O
in	O	O
skeletal	O	O
homeostasis	O	O
,	O	O
osteoblastogenesis	O	O
,	O	O
and	O	O
osteoclastogenesis	O	O
.	O	O
Hajdu	B-Disease	O
-	I-Disease	O
Cheney	I-Disease	O
syndrome	I-Disease	O
(	O	O
HCS	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
disease	O	O
associated	O	O
with	O	O
mutations	B-Var	O
in	O	O
NOTCH2	B-Gene	O
leading	B-Reg	O
to	I-Reg	O
the	O	O
translation	B-MPA	O
of	I-MPA	O
a	I-MPA	O
truncated	I-MPA	O
NOTCH2	B-Gene	O
stable	O	O
protein	B-Protein	O
.	O	O
As	O	O
a	O	O
consequence	O	O
,	O	O
a	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
NOTCH2	O	O
function	O	O
is	O	O
manifested	O	O
.	O	O
HCS	O	O
is	O	O
inherited	O	O
as	O	O
an	O	O
autosomal	O	O
dominant	O	O
disease	O	O
although	O	O
sporadic	O	O
cases	O	O
exist	O	O
.	O	O
HCS	O	O
is	O	O
characterized	O	O
by	O	O
craniofacial	O	O
developmental	O	O
defects	O	O
,	O	O
including	O	O
platybasia	O	O
and	O	O
wormian	O	O
bones	O	O
,	O	O
osteoporosis	O	O
with	O	O
fractures	O	O
,	O	O
and	O	O
acro	O	O
-	O	O
osteolysis	O	O
.	O	O
Subjects	O	O
may	O	O
suffer	O	O
severe	O	O
neurological	O	O
complications	O	O
,	O	O
and	O	O
HCS	O	O
presents	O	O
with	O	O
cardiovascular	O	O
defects	O	O
and	O	O
polycystic	O	O
kidneys	O	O
.	O	O
An	O	O
experimental	O	O
mouse	O	O
model	O	O
harboring	O	O
a	O	O
HCSNotch2	O	O
mutation	O	O
exhibits	O	O
osteopenia	O	O
secondary	O	O
to	O	O
enhanced	O	O
bone	O	O
resorption	O	O
suggesting	O	O
this	O	O
as	O	O
a	O	O
possible	O	O
mechanism	O	O
for	O	O
the	O	O
skeletal	O	O
disease	O	O
.	O	O
If	O	O
the	O	O
same	O	O
mechanisms	O	O
were	O	O
operational	O	O
in	O	O
humans	O	O
,	O	O
anti	O	O
-	O	O
resorptive	O	O
therapy	O	O
could	O	O
correct	O	O
the	O	O
bone	O	O
loss	O	O
,	O	O
but	O	O
not	O	O
necessarily	O	O
the	O	O
acro	O	O
-	O	O
osteolysis	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
HCS	O	O
is	O	O
a	O	O
devastating	O	O
disease	O	O
associated	O	O
with	O	O
a	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
NOTCH2	O	O
function	O	O
resulting	O	O
in	O	O
diverse	O	O
clinical	O	O
manifestations	O	O
.	O	O
Phenotypes	O	O
and	O	O
Genotypes	O	O
in	O	O
Five	O	O
Children	O	O
with	O	O
Congenital	O	O
Insensitivity	O	O
to	O	O
Pain	O	O
with	O	O
Anhidrosis	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Congenital	B-Disease	O
insensitivity	I-Disease	O
to	I-Disease	O
pain	I-Disease	O
with	I-Disease	O
anhidrosis	I-Disease	O
is	O	O
an	O	O
extremely	O	O
rare	O	O
hereditary	O	O
disorder	O	O
linked	B-Reg	O
to	I-Reg	O
variants	B-Var	O
in	O	O
NTRK1	B-Gene	O
.	O	O
Our	O	O
goal	O	O
was	O	O
to	O	O
characterize	O	O
the	O	O
clinical	O	O
features	O	O
and	O	O
the	O	O
genetic	O	O
basis	O	O
of	O	O
the	O	O
disorder	O	O
in	O	O
Chinese	O	O
patients	O	O
.	O	O
METHODS	O	O
:	O	O
Patients	O	O
were	O	O
enrolled	O	O
via	O	O
social	O	O
networking	O	O
.	O	O
Clinical	O	O
features	O	O
were	O	O
investigated	O	O
by	O	O
interview	O	O
,	O	O
chart	O	O
review	O	O
,	O	O
and	O	O
physical	O	O
examination	O	O
.	O	O
DNA	O	O
was	O	O
extracted	O	O
from	O	O
peripheral	O	O
blood	O	O
to	O	O
genotype	O	O
NTRK1	O	O
in	O	O
patients	O	O
and	O	O
their	O	O
parents	O	O
.	O	O
Variants	O	O
identified	O	O
were	O	O
checked	O	O
against	O	O
a	O	O
control	O	O
cohort	O	O
by	O	O
high	O	O
-	O	O
throughput	O	O
sequencing	O	O
,	O	O
and	O	O
the	O	O
effects	O	O
of	O	O
these	O	O
variants	O	O
were	O	O
assessed	O	O
in	O	O
silico	O	O
.	O	O
RESULTS	O	O
:	O	O
Clinical	O	O
features	O	O
in	O	O
five	O	O
patients	O	O
were	O	O
cataloged	O	O
,	O	O
and	O	O
six	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
NTRK1	O	O
variants	O	O
were	O	O
identified	O	O
,	O	O
including	O	O
a	O	O
frameshift	O	O
variant	O	O
c.963delG	O	O
,	O	O
a	O	O
nonsense	O	O
variant	O	O
c.1804C	O	O
>	O	I-Var
T	O	O
,	O	O
an	O	O
intron	O	O
variant	O	O
c.851	O	O
-	O	O
33T	O	O
>	O	O
A	O	O
,	O	O
and	O	O
three	O	O
missense	O	O
variants	O	O
c.1802T	O	O
>	O	O
G	O	O
,	O	O
c.2074C	O	O
>	O	I-Var
T	O	O
,	O	O
and	O	O
c.2311C	O	O
>	O	O
T.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
results	O	O
expand	O	O
the	O	O
spectrum	O	O
of	O	O
clinical	O	O
and	O	O
genetic	O	O
features	O	O
of	O	O
congenital	O	O
insensitivity	O	O
to	O	O
pain	O	O
with	O	O
anhidrosis	O	O
and	O	O
will	O	O
help	O	O
facilitate	O	O
analysis	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
association	O	O
in	O	O
the	O	O
future	O	O
.	O	O
The	O	O
impact	O	O
of	O	O
intermittent	O	O
versus	O	O
continuous	O	O
exposure	O	O
to	O	O
EGFR	O	O
tyrosine	O	O
kinase	O	O
inhibitor	O	O
on	O	O
selection	O	O
of	O	O
EGFR	O	O
T790M	O	O
-	O	O
mutant	O	O
drug	O	O
-	O	O
resistant	O	O
clones	O	O
in	O	O
a	O	O
lung	O	O
cancer	O	O
cell	O	O
line	O	O
carrying	O	O
activating	O	O
EGFR	O	O
mutation	O	O
.	O	O
Drug	O	O
-	O	O
resistant	O	O
cell	O	O
lines	O	O
are	O	O
essential	O	O
tools	O	O
for	O	O
investigating	O	O
the	O	O
mechanisms	O	O
of	O	O
resistance	O	O
to	O	O
molecular	O	O
-	O	O
targeted	O	O
anti	O	O
-	O	O
cancer	O	O
drugs	O	O
.	O	O
However	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
how	O	O
to	O	O
establish	O	O
clinically	O	O
relevant	O	O
drug	O	O
-	O	O
resistant	O	O
cell	O	O
lines	O	O
.	O	O
Our	O	O
study	O	O
examined	O	O
the	O	O
impact	O	O
of	O	O
a	O	O
drug	O	O
-	O	O
free	O	O
period	O	O
on	O	O
the	O	O
establishment	O	O
of	O	O
a	O	O
cell	O	O
line	O	O
with	O	O
clinically	O	O
relevant	O	O
resistance	O	O
to	O	O
molecular	O	O
-	O	O
targeted	O	O
drugs	O	O
.	O	O
We	O	O
used	O	O
PC9	O	O
cells	O	O
,	O	O
a	O	O
lung	O	O
cancer	O	O
cell	O	O
line	O	O
carrying	O	O
EGFR	O	O
mutation	O	O
,	O	O
because	O	O
this	O	O
is	O	O
a	O	O
validated	O	O
target	O	O
for	O	O
EGFR	O	O
tyrosine	O	O
kinase	O	O
inhibitors	O	O
(	O	O
TKI	O	O
)	O	O
.	O	O
PC9	O	O
cells	O	O
were	O	O
intermittently	O	O
or	O	O
continuously	O	O
exposed	O	O
to	O	O
increasing	O	O
concentrations	O	O
of	O	O
gefitinib	O	O
(	O	O
0.01	O	O
μM	O	O
to	O	O
1.0	O	O
μM	O	O
)	O	O
and	O	O
the	O	O
emergence	O	O
of	O	O
the	O	O
most	O	O
common	O	O
acquired	O	O
resistance	O	O
mutation	O	O
in	O	O
EGFR	O	O
,	O	O
T790	O	O
M	O	O
,	O	O
was	O	O
determined	O	O
.	O	O
T790	O	O
M	O	O
was	O	O
detected	O	O
at	O	O
a	O	O
25-fold	O	O
lower	O	O
drug	O	O
concentration	O	O
in	O	O
cells	O	O
continuously	O	O
exposed	O	O
to	O	O
gefitinib	O	O
(	O	O
PC9	O	O
/	O	O
GRc	O	O
)	O	O
than	O	O
in	O	O
cells	O	O
intermittently	O	O
exposed	O	O
to	O	O
gefitinib	O	O
(	O	O
PC9	O	O
/	O	O
GRi	O	O
)	O	O
(	O	O
0.04	O	O
μM	O	O
vs	O	O
1.0	O	O
μM	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
The	O	O
mutation	B-Var	O
frequencies	O	O
at	O	O
those	O	O
drug	O	O
concentrations	O	O
were	O	O
19.8	O	O
%	O	O
and	O	O
8.0	O	O
%	O	O
in	O	O
PC9	O	O
/	O	O
GRc	O	O
and	O	O
PC9	O	O
/	O	O
GRi	O	O
cells	O	O
,	O	O
respectively	O	O
.	O	O
After	O	O
drug	O	O
-	O	O
free	O	O
culture	O	O
for	O	O
8	O	O
weeks	O	O
,	O	O
resistance	B-MPA	O
to	I-MPA	O
gefitinib	I-MPA	O
decreased	B-NegReg	O
in	O	O
the	O	O
PC9	O	O
/	O	O
GRi	O	O
cells	O	O
but	O	O
not	O	O
in	O	O
the	O	O
PC9	O	O
/	O	O
GRc	O	O
cells	O	O
.	O	O
In	O	O
the	O	O
PC9	O	O
/	O	O
GRc	O	O
cells	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
the	O	O
T790	O	O
M	O	O
mutation	O	O
was	O	O
consistently	O	O
about	O	O
20	O	O
%	O	O
from	O	O
0.04	O	O
μM	O	O
to	O	O
1.0	O	O
μM	O	O
of	O	O
gefitinib	O	O
.	O	O
In	O	O
the	O	O
PC9	O	O
/	O	O
GRc	O	O
cells	O	O
,	O	O
the	O	O
T790	O	O
M	O	O
mutation	O	O
was	O	O
detected	O	O
in	O	O
all	O	O
single	O	O
-	O	O
cell	O	O
clones	O	O
,	O	O
at	O	O
frequencies	O	O
ranging	O	O
from	O	O
7.0	O	O
%	O	O
to	O	O
37.0	O	O
%	O	O
,	O	O
with	O	O
a	O	O
median	O	O
of	O	O
19.5	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
17.3%-20.9	O	O
%	O	O
)	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
compared	O	O
with	O	O
intermittent	O	O
drug	O	O
exposure	O	O
,	O	O
continuous	O	O
exposure	O	O
might	O	O
select	O	O
better	O	O
minor	O	O
drug	O	O
-	O	O
resistant	O	O
clones	O	O
when	O	O
creating	O	O
cell	O	O
lines	O	O
resistant	O	O
to	O	O
molecular	O	O
-	O	O
targeted	O	O
drugs	O	O
.	O	O
Identification	O	O
of	O	O
mutations	B-Var	O
in	O	O
the	O	O
F8	B-Gene	O
and	O	O
F9	B-Gene	O
gene	O	O
in	O	O
families	O	O
with	B-Reg	O
haemophilia	B-Disease	O
using	O	O
targeted	O	O
high	O	O
-	O	O
throughput	O	O
sequencing	O	O
.	O	O
INTRODUCTION	O	O
:	O	O
At	O	O
present	O	O
,	O	O
many	O	O
methods	O	O
are	O	O
available	O	O
for	O	O
the	O	O
genetic	O	O
diagnosis	O	O
of	O	O
haemophilia	O	O
,	O	O
including	O	O
indirect	O	O
linkage	O	O
analysis	O	O
,	O	O
direct	O	O
sequencing	O	O
.	O	O
However	O	O
,	O	O
these	O	O
methods	O	O
are	O	O
time	O	O
-	O	O
consuming	O	O
,	O	O
labourious	O	O
,	O	O
and	O	O
limited	O	O
in	O	O
their	O	O
application	O	O
.	O	O
Therefore	O	O
,	O	O
the	O	O
development	O	O
of	O	O
new	O	O
,	O	O
more	O	O
effective	O	O
techniques	O	O
is	O	O
necessary	O	O
.	O	O
AIM	O	O
:	O	O
To	O	O
detect	O	O
the	O	O
F8	B-Gene	O
and	O	O
F9	B-Gene	O
gene	O	O
mutations	B-Var	O
in	O	O
patients	O	O
with	B-Reg	O
haemophilia	B-Disease	O
and	O	O
their	O	O
female	O	O
relatives	O	O
in	O	O
29	O	O
haemophilia	O	O
A	O	O
(	O	O
HA	O	O
)	O	O
and	O	O
11	O	O
haemophilia	O	O
B	O	O
(	O	O
HB	O	O
)	O	O
families	O	O
.	O	O
METHODS	O	O
:	O	O
*	O	O
FVIII	O	O
:	O	O
C	O	O
and	O	O
FIX	O	O
:	O	O
C	O	O
were	O	O
analyzed	O	O
using	O	O
one	O	O
-	O	O
stage	O	O
method	O	O
,	O	O
and	O	O
factor	O	O
VIII	O	O
and	O	O
factor	O	O
IX	O	O
inhibitors	O	O
were	O	O
tested	O	O
using	O	O
the	O	O
Bethesda	O	O
method	O	O
.	O	O
Intron	O	O
22	O	O
and	O	O
one	O	O
inversions	O	O
were	O	O
identified	O	O
using	O	O
long	O	O
-	O	O
distance	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
and	O	O
standard	O	O
PCR	O	O
.	O	O
Non	O	O
-	O	O
inversion	O	O
mutations	O	O
of	O	O
the	O	O
F8	O	O
and	O	O
F9	O	O
gene	O	O
were	O	O
identified	O	O
by	O	O
targeted	O	O
high	O	O
-	O	O
throughput	O	O
sequencing	O	O
.	O	O
All	O	O
mutations	O	O
were	O	O
verified	O	O
by	O	O
Sanger	O	O
sequencing	O	O
.	O	O
RESULTS	O	O
:	O	O
Intron	O	O
22	O	O
inversion	O	O
was	O	O
detected	O	O
in	O	O
eight	O	O
HA	O	O
families	O	O
and	O	O
intron	O	O
one	O	O
inversion	O	O
was	O	O
detected	O	O
in	O	O
one	O	O
HA	O	O
family	O	O
.	O	O
Apart	O	O
from	O	O
the	O	O
inversion	O	O
mutations	O	O
,	O	O
20	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
HA	O	O
families	O	O
,	O	O
including	O	O
17	O	O
previously	O	O
reported	O	O
and	O	O
three	O	O
novel	O	O
mutations	O	O
:	O	O
c.5724G	O	O
>	O	O
A	O	O
(	O	O
p	O	O
.	O	O
Trp1908	O	O
*	O	O
)	O	O
,	O	O
c.6116	O	O
-	O	O
1_6120delGAGTGTinsTCC	O	O
(	O	O
p	O	O
.	O	O
Lys2039Ilefs*13	O	O
)	O	O
,	O	O
and	O	O
c.5220	O	O
-	O	O
2A	O	O
>	O	O
C.	O	O
We	O	O
found	O	O
a	O	O
complex	O	O
rearrangement	O	O
in	O	O
HA	O	O
:	O	O
intron	O	O
one	O	O
inversion	O	O
concomitant	O	O
with	O	O
exon	O	O
one	O	O
deletion	O	O
.	O	O
In	O	O
HB	O	O
,	O	O
eight	O	O
recurrent	O	O
mutations	O	O
were	O	O
detected	O	O
,	O	O
including	O	O
six	O	O
missense	O	O
mutations	O	O
and	O	O
two	O	O
nonsense	O	O
mutations	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Targeted	O	O
high	O	O
-	O	O
throughput	O	O
sequencing	O	O
is	O	O
an	O	O
effective	O	O
technique	O	O
to	O	O
detect	O	O
the	O	O
F8	O	O
and	O	O
F9	O	O
gene	O	O
mutations	O	O
,	O	O
especially	O	O
for	O	O
the	O	O
discovery	O	O
of	O	O
novel	O	O
mutations	O	O
.	O	O
The	O	O
method	O	O
is	O	O
highly	O	O
accurate	O	O
,	O	O
time	O	O
-	O	O
saving	O	O
and	O	O
shows	O	O
great	O	O
advantage	O	O
in	O	O
uncovering	O	O
large	O	O
deletion	O	O
mutations	O	O
and	O	O
also	O	O
in	O	O
distinguishing	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
genotype	O	O
and	O	O
heterozygous	O	O
large	O	O
deletions	O	O
.	O	O
Loss	B-NegReg	O
of	I-NegReg	O
function	I-NegReg	O
mutations	B-Var	B-Var
in	O	O
RP1	B-Gene	O
are	O	O
responsible	O	O
for	O	O
retinitis	B-Disease	O
pigmentosa	I-Disease	O
in	O	O
consanguineous	O	B-Disease
familial	O	I-Disease
cases	O	O
.	O	O
PURPOSE	O	O
:	O	O
This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
identify	O	O
causal	O	O
mutations	O	O
responsible	O	O
for	O	O
autosomal	O	O
recessive	O	O
retinitis	O	O
pigmentosa	O	O
(	O	O
arRP	O	O
)	O	O
in	O	O
consanguineous	O	O
families	O	O
.	O	O
METHODS	O	O
:	O	O
Large	O	O
consanguineous	O	O
families	O	O
were	O	O
ascertained	O	O
from	O	O
the	O	O
Punjab	O	O
province	O	O
of	O	O
Pakistan	O	O
.	O	O
An	O	O
ophthalmic	O	O
examination	O	O
consisting	O	O
of	O	O
a	O	O
fundus	O	O
evaluation	O	O
and	O	O
electroretinography	O	O
(	O	O
ERG	O	O
)	O	O
was	O	O
completed	O	O
,	O	O
and	O	O
small	O	O
aliquots	O	O
of	O	O
blood	O	O
were	O	O
collected	O	O
from	O	O
all	O	O
participating	O	O
individuals	O	O
.	O	O
Genomic	O	O
DNA	O	O
was	O	O
extracted	O	O
from	O	O
white	O	O
blood	O	O
cells	O	O
,	O	O
and	O	O
a	O	O
genome	O	O
-	O	O
wide	O	O
linkage	O	O
or	O	O
a	O	O
locus	O	O
-	O	O
specific	O	O
exclusion	O	O
analysis	O	O
was	O	O
completed	O	O
with	O	O
polymorphic	O	O
short	O	O
tandem	O	O
repeats	O	O
(	O	O
STRs	O	O
)	O	O
.	O	O
Two	O	O
-	O	O
point	O	O
logarithm	O	O
of	O	O
odds	O	O
(	O	O
LOD	O	O
)	O	O
scores	O	O
were	O	O
calculated	O	O
,	O	O
and	O	O
all	O	O
coding	O	O
exons	O	O
and	O	O
exon	O	O
-	O	O
intron	O	O
boundaries	O	O
of	O	O
RP1	O	O
were	O	O
sequenced	O	O
to	O	O
identify	O	O
the	O	O
causal	O	O
mutation	O	O
.	O	O
RESULTS	O	O
:	O	O
The	O	O
ophthalmic	O	O
examination	O	O
showed	O	O
that	O	O
affected	O	O
individuals	O	O
in	O	O
all	O	O
families	O	O
manifest	O	O
cardinal	O	O
symptoms	O	O
of	O	O
RP	O	O
.	O	O
Genome	O	O
-	O	O
wide	O	O
scans	O	O
localized	O	O
the	O	O
disease	O	O
phenotype	O	O
to	O	O
chromosome	O	O
8q	O	O
,	O	O
a	O	O
region	O	O
harboring	O	O
RP1	O	O
,	O	O
a	O	O
gene	O	O
previously	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
RP	O	O
.	O	O
Sanger	O	O
sequencing	O	O
identified	O	O
a	O	O
homozygous	O	O
single	O	O
base	O	O
deletion	O	O
in	O	O
exon	O	O
4	O	O
:	O	O
c.3697delT	O	O
(	O	O
p	O	O
.	O	O
S1233Pfs22	O	O
*	O	O
)	O	O
,	O	O
a	O	O
single	O	O
base	O	O
substitution	O	O
in	O	O
intron	O	O
3	O	O
:	O	O
c.787	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
(	O	O
p	O	O
.	O	O
I263Nfs8	O	O
*	O	O
)	O	O
,	O	O
a	O	O
2	O	O
bp	O	O
duplication	O	O
in	O	O
exon	O	O
2	O	O
:	O	O
c.551_552dupTA	O	O
(	O	O
p	O	O
.	O	O
Q185Yfs4	O	O
*	O	O
)	O	O
and	O	O
an	O	O
11,117	O	O
bp	O	O
deletion	O	O
that	O	O
removes	O	O
all	O	O
three	O	O
coding	O	O
exons	O	O
of	O	O
RP1	O	O
.	O	O
These	O	O
variations	O	O
segregated	O	O
with	O	O
the	O	O
disease	O	O
phenotype	O	O
within	O	O
the	O	O
respective	O	O
families	O	O
and	O	O
were	O	O
not	O	O
present	O	O
in	O	O
ethnically	O	O
matched	O	O
control	O	O
samples	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
strongly	O	O
suggest	O	O
that	O	O
these	O	O
mutations	O	O
in	O	O
RP1	O	O
are	O	O
responsible	O	O
for	O	O
the	O	O
retinal	O	O
phenotype	O	O
in	O	O
affected	O	O
individuals	O	O
of	O	O
all	O	O
four	O	O
consanguineous	O	O
families	O	O
.	O	O
Ectrodactyly	B-Disease	O
and	I-Disease	O
Lethal	I-Disease	O
Pulmonary	I-Disease	O
Acinar	I-Disease	O
Dysplasia	I-Disease	O
Associated	B-Reg	O
with	O	O
Homozygous	O	O
FGFR2	B-Gene	O
Mutations	B-Var	O
Identified	O	O
by	O	O
Exome	O	O
Sequencing	O	O
.	O	O
Ectrodactyly	O	O
/	O	O
split	O	O
hand	O	O
-	O	O
foot	O	O
malformation	O	O
is	O	O
genetically	O	O
heterogeneous	O	O
with	O	O
more	O	O
than	O	O
100	O	O
syndromic	O	O
associations	O	O
.	O	O
Acinar	O	O
dysplasia	O	O
is	O	O
a	O	O
rare	O	O
congenital	O	O
lung	O	O
lesion	O	O
of	O	O
unknown	O	O
etiology	O	O
,	O	O
which	O	O
is	O	O
frequently	O	O
lethal	O	O
postnatally	O	O
.	O	O
To	O	O
date	O	O
,	O	O
there	O	O
have	O	O
been	O	O
no	O	O
reports	O	O
of	O	O
combinations	O	O
of	O	O
these	O	O
two	O	O
phenotypes	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
present	O	O
an	O	O
infant	O	O
from	O	O
a	O	O
consanguineous	O	O
union	O	O
with	O	O
both	O	O
ectrodactyly	O	O
and	O	O
autopsy	O	O
confirmed	O	O
acinar	O	O
dysplasia	O	O
.	O	O
SNP	O	O
array	O	O
and	O	O
whole	O	O
-	O	O
exome	O	O
sequencing	O	O
analyses	O	O
of	O	O
the	O	O
affected	O	O
infant	O	O
identified	O	O
a	O	O
novel	O	O
homozygous	O	O
Fibroblast	O	O
Growth	O	O
Factor	O	O
Receptor	O	O
2	O	O
(	O	O
FGFR2	O	O
)	O	O
missense	O	O
mutation	O	O
(	O	O
p	O	O
.	O	O
R255Q	O	O
)	O	O
in	O	O
the	O	O
IgIII	O	O
domain	O	O
(	O	O
D3	O	O
)	O	O
.	O	O
Expression	O	O
studies	O	O
of	O	O
Fgfr2	O	O
in	O	O
development	O	O
show	O	O
localization	O	O
to	O	O
the	O	O
affected	O	O
limbs	O	O
and	O	O
organs	O	O
.	O	O
Molecular	O	O
modeling	O	O
and	O	O
genetic	O	O
and	O	O
functional	O	O
assays	O	O
support	O	O
that	O	O
this	O	O
mutation	O	O
is	O	O
at	O	O
least	O	O
a	O	O
partial	O	O
loss	B-NegReg	B-NegReg
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutation	B-Var	O
,	O	O
and	O	O
contributes	O	O
to	O	O
ectrodactyly	B-Disease	O
and	I-Disease	O
acinar	I-Disease	O
dysplasia	I-Disease	B-CPA
only	O	O
in	O	O
homozygosity	O	O
,	O	O
unlike	O	O
previously	O	O
reported	O	O
heterozygous	O	O
activating	O	O
FGFR2	B-Gene	O
mutations	B-Var	O
that	O	O
cause	B-Reg	O
Crouzon	B-Disease	O
,	O	O
Apert	B-Disease	O
,	O	O
and	O	O
Pfeiffer	B-Disease	O
syndromes	I-Disease	O
.	O	O
This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
mutations	O	O
in	O	O
a	O	O
human	O	O
disease	O	O
with	O	O
ectrodactyly	O	O
with	O	O
pulmonary	O	O
acinar	O	O
dysplasia	O	O
and	O	O
,	O	O
as	O	O
such	O	O
,	O	O
homozygous	O	O
loss	O	B-NegReg
-	O	O
of	O	I-NegReg
-	O	I-NegReg
function	O	I-NegReg
FGFR2	O	B-Gene
mutations	O	B-Var
represent	O	O
a	O	O
unique	O	B-Disease
syndrome	O	I-Disease
.	O	O
X	B-Disease	O
-	I-Disease	O
linked	I-Disease	O
Congenital	I-Disease	O
Adrenal	I-Disease	O
Hypoplasia	I-Disease	O
with	B-Reg	O
a	O	O
Novel	O	O
NR0B1	B-Gene	O
/	I-Gene	O
DAX	I-Gene	O
Gene	O	O
Mutation	B-Var	O
.	O	O
BACKGROUND	O	O
:	O	O
The	O	O
etiology	O	O
of	O	O
primary	O	O
adrenal	O	O
insufficiency	O	O
has	O	O
implications	O	O
for	O	O
further	O	O
management	O	O
of	O	O
the	O	O
condition	O	O
.	O	O
CASE	O	O
CHARACTERISTICS	O	O
:	O	O
A	O	O
5-year	O	O
-	O	O
old	O	O
boy	O	O
presented	O	O
in	O	O
adrenal	O	O
crisis	O	O
with	O	O
glucocorticoid	O	O
and	O	O
mineralocorticoid	O	O
deficiency	O	O
.	O	O
OBSERVATION	O	O
:	O	O
Investigations	O	O
confirmed	O	O
primary	O	O
adrenal	B-CPA	O
insufficiency	B-NegReg	O
and	O	O
ruled	O	O
out	O	O
the	O	O
common	O	O
etiologies	O	O
.	O	O
Genetic	O	O
testing	O	O
identified	O	O
a	O	O
novel	O	O
NR0B1	B-Gene	O
/	I-Gene	O
DAX	I-Gene	O
gene	O	O
mutation	B-Var	O
.	O	O
MESSAGE	O	O
:	O	O
A	O	O
genetic	O	O
diagnosis	O	O
in	O	O
children	O	O
with	O	O
primary	O	O
adrenal	O	O
insufficiency	O	O
is	O	O
useful	O	O
to	O	O
provide	O	O
genetic	O	O
counselling	O	O
.	O	O
Severe	O	O
Early	B-Disease	B-Disease
-	I-Disease	I-Disease
Onset	I-Disease	I-Disease
Combined	I-Disease	O
Immunodeficiency	I-Disease	O
due	O	O
to	O	O
Heterozygous	O	O
Gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	I-PosReg
Function	I-PosReg	I-PosReg
Mutations	B-Var	O
in	O	O
STAT1	B-Gene	O
.	O	O
PURPOSE	O	O
:	O	O
Loss	O	O
and	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
function	O	O
(	O	O
GOF	O	O
)	O	O
mutations	O	B-Var
in	O	O
human	O	O
signal	O	B-Gene
transducer	O	O
and	O	O
activator	O	B-Gene
of	O	O
transcription	O	I-Gene
1	O	O
(	O	O
STAT1	O	O
)	O	O
lead	O	O
to	O	O
distinct	O	O
phenotypes	O	O
.	O	O
Although	O	O
recurrent	O	O
infections	O	O
are	O	O
common	O	O
to	O	O
both	O	O
types	O	O
of	O	O
STAT1	O	O
mutations	O	O
,	O	O
GOF	B-PosReg	O
mutations	B-Var	B-Var
are	O	O
distinguished	O	O
by	O	O
chronic	B-Disease	O
mucocutaneous	I-Disease	B-Disease
candidiasis	I-Disease	O
and	O	O
autoimmunity	B-Disease	O
.	O	O
However	O	O
,	O	O
the	O	O
clinical	O	O
spectra	O	O
of	O	O
STAT1	O	O
GOF	O	O
mutations	O	O
continue	O	O
to	O	O
expand	O	O
.	O	O
We	O	O
here	O	O
describe	O	O
two	O	O
patients	O	O
with	O	O
STAT1	B-Gene	O
GOF	B-PosReg	O
mutations	B-Var	O
presenting	O	O
early	O	O
in	O	O
life	O	O
with	O	O
combined	B-Disease	O
immunodeficiency	I-Disease	O
(	O	O
CID	O	O
)	O	O
.	O	O
METHODS	O	O
:	O	O
Clinical	O	O
data	O	O
and	O	O
laboratory	O	O
findings	O	O
including	O	O
immunophenotyping	O	O
,	O	O
level	O	O
of	O	O
interferon	O	O
(	O	O
IFN)-γ	O	O
/	O	O
IL-17(+	O	O
)	O	O
T	O	O
cells	O	O
,	O	O
interferon	O	O
-	O	O
induced	O	O
STAT1	O	O
phosphorylation	O	O
,	O	O
and	O	O
JAK	O	O
inhibitor	O	O
assays	O	O
were	O	O
evaluated	O	O
.	O	O
Sequencing	O	O
of	O	O
STAT1	O	O
gene	O	O
was	O	O
performed	O	O
by	O	O
Sanger	O	O
sequencer	O	O
.	O	O
RESULTS	O	O
:	O	O
Patient	O	O
1	O	O
(	O	O
P1	O	O
)	O	O
had	O	O
persistent	O	O
oral	O	O
candidiasis	O	O
and	O	O
cytomegalovirus	O	O
(	O	O
CMV	O	O
)	O	O
infection	O	O
since	O	O
2	O	O
months	O	O
of	O	O
age	O	O
and	O	O
later	O	O
developed	O	O
cavitary	O	O
lung	O	O
lesions	O	O
due	O	O
to	O	O
Mycobacterium	O	O
tuberculosis	O	O
.	O	O
Patient	O	O
2	O	O
(	O	O
P2	O	O
)	O	O
presented	O	O
with	O	O
oral	O	O
candidiasis	O	O
and	O	O
recurrent	O	O
pneumonia	O	O
at	O	O
4	O	O
months	O	O
of	O	O
age	O	O
and	O	O
subsequently	O	O
developed	O	O
CMV	O	O
pneumonitis	O	O
.	O	O
Both	O	O
patients	O	O
suffered	O	O
heterozygous	O	O
missense	B-Var	B-Var
mutations	I-Var	I-Var
in	O	O
STAT1	B-Gene	O
,	O	O
leading	B-Reg	O
to	I-Reg	O
deleterious	O	O
amino	O	O
acid	O	O
substitutions	B-Var	O
in	O	O
the	O	O
DNA	O	O
binding	O	O
domain	O	O
(	O	O
P1	O	O
:	O	O
c.1154C	B-Var	O
>	I-Var	O
T	I-Var	O
;	I-Var	O
p	B-Var	O
.	I-Var	O
T385	I-Var	O
M	I-Var	O
;	I-Var	O
P2	O	O
.	O	O
c.971	B-Var	O
G	I-Var	O
>	I-Var	O
T	I-Var	O
;	I-Var	O
p	B-Var	O
.	I-Var	O
C324F	I-Var	O
)	I-Var	O
.	O	O
Circulating	O	O
CD4(+	O	O
)	O	O
T	O	O
cells	O	O
of	O	O
both	O	O
patients	O	O
exhibited	O	O
increased	B-PosReg	O
interferon	B-MPA	O
-	I-MPA	O
γ	I-MPA	O
and	O	O
decreased	B-NegReg	O
IL-17	B-MPA	O
expression	I-MPA	O
as	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O
They	O	O
also	O	O
exhibited	O	O
increased	B-PosReg	O
IFN	B-MPA	O
-	I-MPA	O
β	I-MPA	O
and	O	O
-γ	B-MPA	O
-	I-MPA	O
induced	I-MPA	O
STAT1	I-MPA	O
phosphorylation	I-MPA	O
that	O	O
was	O	O
reversed	O	O
upon	O	O
treatment	O	O
with	O	O
the	O	O
JAK	O	O
kinase	O	O
inhibitor	O	O
ruxolitinib	O	O
.	O	O
CONCLUSION	O	O
:	O	O
STAT1	O	O
GOF	O	O
mutations	O	O
may	O	O
present	O	O
early	O	O
in	O	O
life	O	O
with	O	O
CID	O	O
,	O	O
consistent	O	O
with	O	O
the	O	O
clinical	O	O
heterogeneity	O	O
of	O	O
the	O	O
disease	O	O
.	O	O
JAK	O	O
kinase	O	O
inhibitors	O	O
may	O	O
potentially	O	O
be	O	O
useful	O	O
in	O	O
some	O	O
patients	O	O
as	O	O
adjunct	O	O
therapy	O	O
pending	O	O
definitive	O	O
treatment	O	O
with	O	O
bone	O	O
marrow	O	O
transplantation	O	O
.	O	O
Directed	O	O
evolution	O	O
of	O	O
a	O	O
sphingomyelin	O	O
flippase	O	O
reveals	O	O
mechanism	O	O
of	O	O
substrate	O	O
backbone	O	O
discrimination	O	O
by	O	O
a	O	O
P4-ATPase	O	O
.	O	O
Phospholipid	O	O
flippases	O	O
in	O	O
the	O	O
type	O	O
IV	O	O
P	O	O
-	O	O
type	O	O
ATPase	O	O
(	O	O
P4-ATPases	O	O
)	O	O
family	O	O
establish	O	O
membrane	O	O
asymmetry	O	O
and	O	O
play	O	O
critical	O	O
roles	O	O
in	O	O
vesicular	O	O
transport	O	O
,	O	O
cell	O	O
polarity	O	O
,	O	O
signal	O	O
transduction	O	O
,	O	O
and	O	O
neurologic	O	O
development	O	O
.	O	O
All	O	O
characterized	O	O
P4-ATPases	O	O
flip	O	O
glycerophospholipids	O	O
across	O	O
the	O	O
bilayer	O	O
to	O	O
the	O	O
cytosolic	O	O
leaflet	O	O
of	O	O
the	O	O
membrane	O	O
,	O	O
but	O	O
how	O	O
these	O	O
enzymes	O	O
distinguish	O	O
glycerophospholipids	O	O
from	O	O
sphingolipids	O	O
is	O	O
not	O	O
known	O	O
.	O	O
We	O	O
used	O	O
a	O	O
directed	O	O
evolution	O	O
approach	O	O
to	O	O
examine	O	O
the	O	O
molecular	O	O
mechanisms	O	O
through	O	O
which	O	O
P4-ATPases	O	O
discriminate	O	O
substrate	O	O
backbone	O	O
.	O	O
A	O	O
mutagenesis	O	O
screen	O	O
in	O	O
the	O	O
yeast	O	O
Saccharomyces	O	O
cerevisiae	O	O
has	O	O
identified	O	O
several	O	O
gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
function	I-PosReg	O
mutations	B-Var	O
in	O	O
the	O	O
P4-ATPase	B-Enzyme	O
Dnf1	O	O
that	O	O
facilitate	B-PosReg	O
the	O	O
transport	B-MPA	O
of	O	O
a	O	O
novel	O	O
lipid	O	O
substrate	O	O
,	O	O
sphingomyelin	O	O
.	O	O
We	O	O
found	O	O
that	O	O
a	O	O
highly	O	O
conserved	O	O
asparagine	O	O
(	O	O
N220	O	O
)	O	O
in	O	O
the	O	O
first	O	O
transmembrane	O	O
segment	O	O
is	O	O
a	O	O
key	O	O
enforcer	O	O
of	O	O
glycerophospholipid	O	O
selection	O	O
,	O	O
and	O	O
specific	O	O
substitutions	O	O
at	O	O
this	O	O
site	O	O
allow	O	O
transport	O	O
of	O	O
sphingomyelin	O	O
.	O	O
Loss	B-NegReg	O
of	I-NegReg	O
function	I-NegReg	O
mutation	B-Var	O
in	O	O
LOX	B-Gene	O
causes	O	O
thoracic	B-Disease	O
aortic	I-Disease	O
aneurysm	I-Disease	O
and	I-Disease	O
dissection	I-Disease	O
in	O	O
humans	O	O
.	O	O
Thoracic	O	O
aortic	O	O
aneurysms	O	O
and	O	O
dissections	O	O
(	O	O
TAAD	O	O
)	O	O
represent	O	O
a	O	O
substantial	O	O
cause	O	O
of	O	O
morbidity	O	O
and	O	O
mortality	O	O
worldwide	O	O
.	O	O
Many	O	O
individuals	O	O
presenting	O	O
with	O	O
an	O	O
inherited	O	O
form	O	O
of	O	O
TAAD	O	O
do	O	O
not	O	O
have	O	O
causal	O	O
mutations	O	O
in	O	O
the	O	O
set	O	O
of	O	O
genes	O	O
known	O	O
to	O	O
underlie	O	O
disease	O	O
.	O	O
Using	O	O
whole	O	O
-	O	O
genome	O	O
sequencing	O	O
in	O	O
two	O	O
first	O	O
cousins	O	O
with	O	O
TAAD	O	O
,	O	O
we	O	O
identified	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
the	O	O
lysyl	O	O
oxidase	O	O
(	B-Gene	O
LOX	I-Gene	O
)	I-Gene	O
gene	O	O
(	B-Var	O
c.893	I-Var	O
T	I-Var	O
>	I-Var	O
G	I-Var	O
encoding	O	O
p	B-Var	O
.	I-Var	O
Met298Arg	I-Var	O
)	I-Var	O
that	O	O
cosegregated	O	O
with	O	O
disease	O	O
in	O	O
the	O	O
family	O	O
.	O	O
Using	O	O
clustered	O	O
regularly	O	O
interspaced	O	O
short	O	O
palindromic	O	O
repeats	O	O
(	O	O
CRISPR)/clustered	O	O
regularly	O	O
interspaced	O	O
short	O	O
palindromic	O	O
repeats	O	O
-	O	O
associated	O	O
protein-9	O	O
nuclease	O	O
(	O	O
Cas9	O	O
)	O	O
genome	O	O
engineering	O	O
tools	O	O
,	O	O
we	O	O
introduced	O	O
the	O	O
human	O	O
mutation	O	O
into	O	O
the	O	O
homologous	O	O
position	O	O
in	O	O
the	O	O
mouse	O	O
genome	O	O
,	O	O
creating	O	O
mice	O	O
that	O	O
were	O	O
heterozygous	O	O
and	O	O
homozygous	O	O
for	O	O
the	O	O
human	O	O
allele	O	O
.	O	O
Mutant	O	O
mice	O	O
that	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
human	O	O
allele	O	O
displayed	O	O
disorganized	O	O
ultrastructural	O	O
properties	O	O
of	O	O
the	O	O
aortic	O	O
wall	O	O
characterized	O	O
by	O	O
fragmented	O	O
elastic	O	O
lamellae	O	O
,	O	O
whereas	O	O
mice	O	O
homozygous	O	O
for	O	O
the	O	O
human	O	O
allele	O	O
died	O	O
shortly	O	O
after	O	O
parturition	O	O
from	O	O
ascending	O	O
aortic	O	O
aneurysm	O	O
and	O	O
spontaneous	O	O
hemorrhage	O	O
.	O	O
These	O	O
data	O	O
suggest	O	O
that	O	O
a	O	O
missense	B-Var	O
mutation	I-Var	O
in	O	O
LOX	B-Gene	O
is	O	O
associated	B-Reg	O
with	O	O
aortic	B-Disease	O
disease	I-Disease	O
in	O	O
humans	O	O
,	O	O
likely	O	O
through	O	O
insufficient	B-NegReg	O
cross	B-Interaction	O
-	I-Interaction	O
linking	I-Interaction	O
of	O	O
elastin	B-Protein	O
and	O	O
collagen	B-MPA	O
in	O	O
the	O	O
aortic	O	O
wall	O	O
.	O	O
Mutation	B-Var	O
carriers	O	O
may	O	O
be	O	O
predisposed	B-Reg	O
to	O	O
vascular	B-Disease	O
diseases	I-Disease	O
because	O	O
of	O	O
weakened	B-NegReg	O
vessel	B-CPA	O
walls	I-CPA	O
under	O	O
stress	O	O
conditions	O	O
.	O	O
LOX	O	O
sequencing	O	O
for	O	O
clinical	O	O
TAAD	O	O
may	O	O
identify	O	O
additional	O	O
mutation	O	O
carriers	O	O
in	O	O
the	O	O
future	O	O
.	O	O
Additional	O	O
studies	O	O
using	O	O
our	O	O
mouse	O	O
model	O	O
of	O	O
LOX	O	O
-	O	O
associated	O	O
TAAD	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
clarify	O	O
the	O	O
mechanism	O	O
of	O	O
disease	O	O
and	O	O
identify	O	O
novel	O	O
therapeutics	O	O
specific	O	O
to	O	O
this	O	O
genetic	O	O
cause	O	O
.	O	O
Fanconi	O	O
-	O	O
Bickel	O	O
syndrome	O	O
in	O	O
two	O	O
Palestinian	O	O
children	O	O
:	O	O
marked	O	O
phenotypic	O	O
variability	O	O
with	O	O
identical	O	O
mutation	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Fanconi	B-Disease	O
-	I-Disease	O
Bickel	I-Disease	O
syndrome	I-Disease	O
(	O	O
FBS	O	O
,	O	O
OMIM	O	O
227810	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
recessive	O	O
disease	O	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
deficiency	B-Var	O
of	O	O
glucose	O	O
transporter	O	O
2	O	O
(	B-Gene	O
GLUT2	I-Gene	O
)	I-Gene	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
facilitative	O	O
glucose	O	O
transporter	O	O
family	O	O
(	O	O
Santer	O	O
et	O	O
al	O	O
.	O	O
J	O	O
Inherit	O	O
Metab	O	O
Dis	O	O
21:191	O	O
-	O	O
194	O	O
,	O	O
1998	O	O
)	O	O
.	O	O
The	O	O
typical	O	O
clinical	O	O
picture	O	O
is	O	O
characterized	O	O
by	O	O
hepatorenal	O	O
glycogen	O	O
accumulation	O	O
resulting	O	O
in	O	O
hepato-	O	O
and	O	O
nephromegaly	O	O
,	O	O
impaired	O	O
utilization	O	O
of	O	O
glucose	O	O
and	O	O
galactose	O	O
,	O	O
proximal	O	O
renal	O	O
tubular	O	O
dysfunction	O	O
,	O	O
rickets	O	O
and	O	O
severe	O	O
short	O	O
stature	O	O
.	O	O
CASE	O	O
PRESENTATION	O	O
:	O	O
We	O	O
report	O	O
2	O	O
Palestinian	O	O
patients	O	O
from	O	O
2	O	O
families	O	O
who	O	O
were	O	O
homozygous	O	O
for	O	O
the	O	O
mutation	O	O
p	O	O
.	O	O
R301X	O	O
(	O	O
C	O	O
>	O	O
T	O	O
)	O	O
in	O	O
exon	O	O
7of	O	O
GLUT2	O	O
gene	O	O
.	O	O
Patient	O	O
1	O	O
showed	O	O
clinical	O	O
and	O	O
laboratory	O	O
improvement	O	O
with	O	O
age	O	O
characterized	O	O
by	O	O
normal	O	O
growth	O	O
and	O	O
resolution	O	O
of	O	O
rickets	O	O
.	O	O
Patient	O	O
2	O	O
had	O	O
severe	O	O
phenotype	O	O
characterized	O	O
by	O	O
progressive	O	O
weight	O	O
loss	O	O
,	O	O
persistent	O	O
metabolic	O	O
acidosis	O	O
,	O	O
marked	O	O
polyuria	O	O
and	O	O
clinical	O	O
and	O	O
laboratory	O	O
findings	O	O
of	O	O
rickets	O	O
progressing	O	O
to	O	O
death	O	O
at	O	O
age	O	O
10	O	O
months	O	O
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
report	O	O
further	O	O
expands	O	O
the	O	O
clinical	O	O
spectrum	O	O
of	O	O
FBS	O	O
even	O	O
with	O	O
identical	O	O
mutations	O	O
.	O	O
Other	O	O
yet	O	O
unknown	O	O
genetic	O	O
,	O	O
environmental	O	O
or	O	O
stochastic	O	O
factors	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
phenotypic	O	O
variability	O	O
.	O	O
Gli2	O	O
gene	O	O
-	O	O
environment	O	O
interactions	O	O
contribute	O	O
to	O	O
the	O	O
etiological	O	O
complexity	O	O
of	O	O
holoprosencephaly	O	O
:	O	O
evidence	O	O
from	O	O
a	O	O
mouse	O	O
model	O	O
.	O	O
Holoprosencephaly	B-Disease	O
(	O	O
HPE	O	O
)	O	O
is	O	O
a	O	O
common	O	O
and	O	O
severe	O	O
human	O	O
developmental	O	O
abnormality	O	O
marked	O	O
by	O	O
malformations	O	O
of	O	O
the	O	O
forebrain	O	O
and	O	O
face	O	O
.	O	O
Although	O	O
several	O	O
genetic	O	O
mutations	O	O
have	O	O
been	O	O
linked	O	O
to	O	O
HPE	O	O
,	O	O
phenotypic	O	O
outcomes	O	O
range	O	O
dramatically	O	O
,	O	O
and	O	O
most	O	O
cases	O	O
can	O	O
not	O	O
be	O	O
attributed	O	O
to	O	O
a	O	O
specific	O	O
cause	O	O
.	O	O
Gene	O	O
-	O	O
environment	O	O
interaction	O	O
has	O	O
been	O	O
invoked	O	O
as	O	O
a	O	O
premise	O	O
to	O	O
explain	O	O
the	O	O
etiological	O	O
complexity	O	O
of	O	O
HPE	O	O
,	O	O
but	O	O
identification	O	O
of	O	O
interacting	O	O
factors	O	O
has	O	O
been	O	O
extremely	O	O
limited	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
mutations	B-Var	O
in	O	O
Gli2	B-Gene	O
,	O	O
which	O	O
encodes	O	O
a	O	O
Hedgehog	O	O
pathway	O	O
transcription	O	O
factor	O	O
,	O	O
can	O	O
cause	B-Reg	O
or	O	O
predispose	O	O
to	O	O
HPE	B-Disease	O
depending	O	O
upon	O	O
gene	O	O
dosage	O	O
.	O	O
On	O	O
the	O	O
C57BL/6J	O	O
background	O	O
,	O	O
homozygous	B-Var	O
GLI2	B-Gene	O
loss	B-NegReg	O
of	I-NegReg	O
function	I-NegReg	O
results	O	O
in	O	O
the	O	O
characteristic	O	O
brain	O	O
and	O	O
facial	O	O
features	O	O
seen	O	O
in	O	O
severe	O	O
human	O	O
HPE	B-Disease	O
,	O	O
including	O	O
midfacial	O	O
hypoplasia	O	O
,	O	O
hypotelorism	O	O
and	O	O
medial	O	O
forebrain	O	O
deficiency	O	O
with	O	O
loss	O	O
of	O	O
ventral	O	O
neurospecification	O	O
.	O	O
Although	O	O
normally	O	O
indistinguishable	O	O
from	O	O
wild	O	O
-	O	O
type	O	O
littermates	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
mice	O	O
with	O	O
single	O	O
-	O	O
allele	O	O
Gli2	O	O
mutations	O	O
exhibit	O	O
increased	O	O
penetrance	O	O
and	O	O
severity	O	O
of	O	O
HPE	O	O
in	O	O
response	O	O
to	O	O
low	O	O
-	O	O
dose	O	O
teratogen	O	O
exposure	O	O
.	O	O
This	O	O
genetic	O	O
predisposition	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
Gli2	O	O
dosage	O	O
-	O	O
dependent	O	O
attenuation	O	O
of	O	O
Hedgehog	O	O
ligand	O	O
responsiveness	O	O
at	O	O
the	O	O
cellular	O	O
level	O	O
.	O	O
In	O	O
addition	O	O
to	O	O
revealing	O	O
a	O	O
causative	O	O
role	O	O
for	O	O
GLI2	O	O
in	O	O
HPE	O	O
genesis	O	O
,	O	O
these	O	O
studies	O	O
demonstrate	O	O
a	O	O
mechanism	O	O
by	O	O
which	O	O
normally	O	O
silent	O	O
genetic	O	O
and	O	O
environmental	O	O
factors	O	O
can	O	O
interact	O	O
to	O	O
produce	O	O
severe	O	O
outcomes	O	O
.	O	O
Taken	O	O
together	O	O
,	O	O
these	O	O
findings	O	O
provide	O	O
a	O	O
framework	O	O
for	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
extreme	O	O
phenotypic	O	O
variability	O	O
observed	O	O
in	O	O
humans	O	O
carrying	O	O
GLI2	O	O
mutations	O	O
and	O	O
a	O	O
paradigm	O	O
for	O	O
reducing	O	O
the	O	O
incidence	O	O
of	O	O
this	O	O
morbid	O	O
birth	O	O
defect	O	O
.	O	O
Identification	O	O
of	O	O
15	O	O
novel	O	O
partial	O	O
SHOX	O	O
deletions	O	O
and	O	O
13	O	O
partial	O	O
duplications	O	O
,	O	O
and	O	O
a	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
reveals	O	O
intron	O	O
3	O	O
to	O	O
be	O	O
a	O	O
hotspot	O	O
region	O	O
.	O	O
Short	O	O
stature	O	O
homeobox	O	O
gene	O	O
(	O	O
SHOX	O	O
)	O	O
is	O	O
located	O	O
in	O	O
the	O	O
pseudoautosomal	O	O
region	O	O
1	O	O
of	O	O
the	O	O
sex	O	O
chromosomes	O	O
.	O	O
It	O	O
encodes	O	O
a	O	O
transcription	O	O
factor	O	O
implicated	O	O
in	O	O
the	O	O
skeletal	O	O
growth	O	O
.	O	O
Point	B-Var	O
mutations	I-Var	O
,	O	O
deletions	B-Var	O
or	O	O
duplications	B-Var	O
of	O	O
SHOX	B-Gene	O
or	O	O
its	O	O
transcriptional	O	O
regulatory	O	O
elements	O	O
are	O	O
associated	B-Reg	O
with	O	O
two	O	O
skeletal	O	O
dysplasias	O	O
,	O	O
Léri	B-Disease	O
-	I-Disease	O
Weill	I-Disease	O
dyschondrosteosis	I-Disease	O
(	O	O
LWD	O	O
)	O	O
and	O	O
Langer	B-Disease	O
mesomelic	I-Disease	O
dysplasia	I-Disease	O
(	O	O
LMD	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
a	O	O
small	O	O
proportion	O	O
of	O	O
idiopathic	B-Disease	O
short	I-Disease	O
stature	I-Disease	O
(	O	O
ISS	O	O
)	O	O
individuals	O	O
.	O	O
We	O	O
have	O	O
identified	O	O
a	O	O
total	O	O
of	O	O
15	O	O
partial	O	O
SHOX	O	O
deletions	O	O
and	O	O
13	O	O
partial	O	O
SHOX	O	O
duplications	O	O
in	O	O
LWD	O	O
,	O	O
LMD	O	O
and	O	O
ISS	O	O
patients	O	O
referred	O	O
for	O	O
routine	O	O
SHOX	O	O
diagnostics	O	O
during	O	O
a	O	O
10	O	O
year	O	O
period	O	O
(	O	O
2004	O	O
-	O	O
2014	O	O
)	O	O
.	O	O
Subsequently	O	O
,	O	O
we	O	O
characterized	O	O
these	O	O
alterations	O	O
using	O	O
MLPA	O	O
(	O	O
multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
assay	O	O
)	O	O
,	O	O
fine	O	O
-	O	O
tiling	O	O
array	O	O
CGH	O	O
(	O	O
comparative	O	O
genomic	O	O
hybridation	O	O
)	O	O
and	O	O
breakpoint	O	O
PCR	O	O
.	O	O
Nearly	O	O
half	O	O
of	O	O
the	O	O
alterations	O	O
have	O	O
a	O	O
distal	O	O
or	O	O
proximal	O	O
breakpoint	O	O
in	O	O
intron	O	O
3	O	O
.	O	O
Evaluation	O	O
of	O	O
our	O	O
data	O	O
and	O	O
that	O	O
in	O	O
the	O	O
literature	O	O
reveals	O	O
that	O	O
although	O	O
partial	O	O
deletions	O	O
and	O	O
duplications	O	O
only	O	O
account	O	O
for	O	O
a	O	O
small	O	O
fraction	O	O
of	O	O
SHOX	O	O
alterations	O	O
,	O	O
intron	O	O
3	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
breakpoint	O	O
hotspot	O	O
,	O	O
with	O	O
alterations	O	O
arising	O	O
by	O	O
non	O	O
-	O	O
allelic	O	O
homologous	O	O
recombination	O	O
,	O	O
non	O	O
-	O	O
homologous	O	O
end	O	O
joining	O	O
or	O	O
other	O	O
complex	O	O
mechanisms	O	O
.	O	O
VHL	O	O
Germline	O	O
Mutations	O	O
in	O	O
Argentinian	O	O
Patients	O	O
with	O	O
Clinical	O	O
Diagnoses	O	O
or	O	O
Single	O	O
Typical	O	O
Manifestations	O	O
of	O	O
Type	O	O
1	O	O
von	O	O
Hippel	O	O
-	O	O
Lindau	O	O
Disease	O	O
.	O	O
AIMS	O	O
:	O	O
von	B-Disease	O
Hippel	I-Disease	O
-	I-Disease	O
Lindau	I-Disease	O
(	O	O
VHL	O	O
)	O	O
disease	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
VHL	B-Gene	O
tumor	O	O
suppressor	O	O
gene	O	O
.	O	O
As	O	O
tumors	O	O
that	O	O
develop	O	O
in	O	O
the	O	O
context	O	O
of	O	O
VHL	O	O
also	O	O
occur	O	O
in	O	O
a	O	O
sporadic	O	O
context	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
this	O	O
syndrome	O	O
may	O	O
be	O	O
underestimated	O	O
.	O	O
Our	O	O
aim	O	O
was	O	O
to	O	O
identify	O	O
VHL	O	O
gene	O	O
mutations	O	O
in	O	O
Argentinian	O	O
patients	O	O
who	O	O
fulfilled	O	O
the	O	O
clinical	O	O
criteria	O	O
for	O	O
type	O	O
1	O	O
VHL	O	O
disease	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
VHL	O	O
-	O	O
associated	O	O
manifestations	O	O
that	O	O
did	O	O
not	O	O
meet	O	O
these	O	O
criteria	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
performed	O	O
a	O	O
retrospective	O	O
cohort	O	O
study	O	O
,	O	O
including	O	O
patients	O	O
who	O	O
met	O	O
current	O	O
diagnostic	O	O
criteria	O	O
for	O	O
type	O	O
1	O	O
VHL	O	O
(	O	O
Group	O	O
1	O	O
,	O	O
n	O	O
=	O	O
19	O	O
)	O	O
and	O	O
patients	O	O
with	O	O
VHL	O	O
-	O	O
associated	O	O
manifestations	O	O
that	O	O
did	O	O
not	O	O
meet	O	O
these	O	O
criteria	O	O
(	O	O
Group	O	O
2	O	O
,	O	O
n	O	O
=	O	O
21	O	O
)	O	O
.	O	O
Genomic	O	O
DNA	O	O
was	O	O
extracted	O	O
from	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
.	O	O
Mutation	O	O
analysis	O	O
involved	O	O
DNA	O	O
sequencing	O	O
,	O	O
while	O	O
large	O	O
deletions	O	O
were	O	O
determined	O	O
by	O	O
universal	O	O
primer	O	O
quantitative	O	O
fluorescent	O	O
multiplex	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
UPQFM	O	O
-	O	O
PCR	O	O
)	O	O
and	O	O
multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
(	O	O
MLPA	O	O
)	O	O
analysis	O	O
.	O	O
RESULTS	O	O
:	O	O
VHL	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
16/19	O	O
(	O	O
84.2	O	O
%	O	O
)	O	O
patients	O	O
in	O	O
Group	O	O
1	O	O
and	O	O
included	O	O
:	O	O
gross	O	O
deletions	O	O
(	O	O
4/16	O	O
)	O	O
;	O	O
nonsense	O	O
mutations	O	O
(	O	O
6/16	O	O
)	O	O
;	O	O
frameshift	O	O
mutations	O	O
(	O	O
4/16	O	O
)	O	O
;	O	O
missense	O	O
mutations	O	O
(	O	O
1/16	O	O
)	O	O
;	O	O
and	O	O
splicing	O	O
mutations	O	O
(	O	O
1/16	O	O
)	O	O
.	O	O
Three	O	O
of	O	O
these	O	O
mutations	O	O
were	O	O
novel	O	O
.	O	O
No	O	O
alterations	O	O
were	O	O
found	O	O
in	O	O
3	O	O
of	O	O
19	O	O
VHL	O	O
patients	O	O
.	O	O
In	O	O
Group	O	O
2	O	O
,	O	O
one	O	O
nonsense	O	O
VHL	O	O
mutation	O	O
was	O	O
detected	O	O
in	O	O
a	O	O
young	O	O
patient	O	O
with	O	O
a	O	O
solitary	O	O
central	O	O
nervous	O	O
system	O	O
hemangioblastoma	O	O
without	O	O
familial	O	O
history	O	O
.	O	O
A	O	O
study	O	O
of	O	O
30	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
revealed	O	O
four	O	O
carriers	O	O
with	O	O
VHL	O	O
mutations	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
We	O	O
found	O	O
three	O	O
novel	O	O
mutations	O	O
in	O	O
the	O	O
VHL	O	O
gene	O	O
in	O	O
our	O	O
population	O	O
.	O	O
Our	O	O
results	O	O
emphasize	O	O
the	O	O
importance	O	O
of	O	O
a	O	O
complete	O	O
genetic	O	O
study	O	O
of	O	O
VHL	O	O
to	O	O
confirm	O	O
type	O	O
1	O	O
VHL	O	O
disease	O	O
,	O	O
not	O	O
only	O	O
in	O	O
patients	O	O
with	O	O
clinical	O	O
diagnostic	O	O
criteria	O	O
but	O	O
also	O	O
in	O	O
those	O	O
presenting	O	O
a	O	O
single	O	O
typical	O	O
manifestation	O	O
.	O	O
Dysferlin	O	O
Gene	O	O
Mutation	O	O
Spectrum	O	O
in	O	O
a	O	O
Large	O	O
Cohort	O	O
of	O	O
Chinese	O	O
Patients	O	O
with	O	O
Dysferlinopathy	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Dysferlinopathy	B-Disease	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
dysferlin	O	O
(	B-Gene	O
DYSF	I-Gene	O
)	I-Gene	O
gene	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
described	O	O
the	O	O
genetic	O	O
features	O	O
of	O	O
a	O	O
large	O	O
cohort	O	O
of	O	O
Chinese	O	O
patients	O	O
with	O	O
this	O	O
disease	O	O
.	O	O
METHODS	O	O
:	O	O
Eighty	O	O
-	O	O
nine	O	O
index	O	O
patients	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O
DYSF	O	O
gene	O	O
analysis	O	O
was	O	O
performed	O	O
by	O	O
Sanger	O	O
sequencing	O	O
in	O	O
41	O	O
patients	O	O
and	O	O
targeted	O	O
next	O	O
generation	O	O
sequencing	O	O
(	O	O
NGS	O	O
)	O	O
in	O	O
48	O	O
patients	O	O
.	O	O
Multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
(	O	O
MLPA	O	O
)	O	O
was	O	O
performed	O	O
to	O	O
detect	O	O
exon	O	O
duplication	O	O
/	O	O
deletion	O	O
in	O	O
patients	O	O
with	O	O
only	O	O
one	O	O
pathogenic	O	O
mutation	O	O
.	O	O
RESULTS	O	O
:	O	O
Among	O	O
the	O	O
89	O	O
index	O	O
patients	O	O
,	O	O
79	O	O
patients	O	O
were	O	O
demonstrated	O	O
to	O	O
carry	O	O
two	O	O
disease	O	O
-	O	O
causing	O	O
(	O	O
73	O	O
cases	O	O
)	O	O
or	O	O
possibly	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
(	O	O
6	O	O
cases	O	O
)	O	O
,	O	O
including	O	O
26	O	O
patients	O	O
with	O	O
homozygous	O	O
mutations	O	O
.	O	O
We	O	O
identified	O	O
105	O	O
different	O	O
mutations	O	O
,	O	O
including	O	O
59	O	O
novel	O	O
ones	O	O
.	O	O
Notably	O	O
,	O	O
in	O	O
13	O	O
patients	O	O
in	O	O
whom	O	O
only	O	O
one	O	O
pathogenic	O	O
mutation	O	O
was	O	O
initially	O	O
found	O	O
by	O	O
Sanger	O	O
sequencing	O	O
or	O	O
NGS	O	O
,	O	O
3	O	O
were	O	O
further	O	O
identified	O	O
to	O	O
carry	O	O
exon	O	O
deletions	O	O
by	O	O
MLPA	O	O
.	O	O
The	O	O
mutations	O	O
identified	O	O
in	O	O
this	O	O
study	O	O
appeared	O	O
to	O	O
cluster	O	O
in	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
region	O	O
.	O	O
Mutation	O	O
types	O	O
included	O	O
missense	O	O
mutations	O	O
(	O	O
30.06	O	O
%	O	O
)	O	O
,	O	O
nonsense	O	O
mutations	O	O
(	O	O
17.18	O	O
%	O	O
)	O	O
,	O	O
frameshift	O	O
mutations	O	O
(	O	O
30.67	O	O
%	O	O
)	O	O
,	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
(	O	O
2.45	O	O
%	O	O
)	O	O
,	O	O
intronic	O	O
mutations	O	O
(	O	O
17.79	O	O
%	O	O
)	O	O
,	O	O
and	O	O
exonic	O	O
rearrangement	O	O
(	O	O
1.84	O	O
%	O	O
)	O	O
.	O	O
No	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
was	O	O
identified	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
DYSF	O	O
mutations	O	O
in	O	O
Chinese	O	O
patients	O	O
clustered	O	O
in	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
region	O	O
of	O	O
the	O	O
gene	O	O
.	O	O
Exonic	O	O
rearrangements	O	O
were	O	O
found	O	O
in	O	O
23	O	O
%	O	O
of	O	O
patients	O	O
with	O	O
only	O	O
one	O	O
pathogenic	O	O
mutation	O	O
identified	O	O
by	O	O
Sanger	O	O
sequencing	O	O
or	O	O
NGS	O	O
.	O	O
The	O	O
novel	O	O
mutations	O	O
found	O	O
in	O	O
this	O	O
study	O	O
greatly	O	O
expanded	O	O
the	O	O
mutational	O	O
spectrum	O	O
of	O	O
dysferlinopathy	O	O
.	O	O
Whole	O	O
-	O	O
exome	O	O
sequencing	O	O
identifies	O	O
multiple	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutations	O	O
of	O	O
NF	O	O
-	O	O
κB	O	O
pathway	O	O
regulators	O	O
in	O	O
nasopharyngeal	O	O
carcinoma	O	O
.	O	O
Nasopharyngeal	O	O
carcinoma	O	O
(	O	O
NPC	O	O
)	O	O
is	O	O
an	O	O
epithelial	O	O
malignancy	O	O
with	O	O
a	O	O
unique	O	O
geographical	O	O
distribution	O	O
.	O	O
The	O	O
genomic	O	O
abnormalities	O	O
leading	O	O
to	O	O
NPC	O	O
pathogenesis	O	O
remain	O	O
unclear	O	O
.	O	O
In	O	O
total	O	O
,	O	O
135	O	O
NPC	O	O
tumors	O	O
were	O	O
examined	O	O
to	O	O
characterize	O	O
the	O	O
mutational	O	O
landscape	O	O
using	O	O
whole	O	O
-	O	O
exome	O	O
sequencing	O	O
and	O	O
targeted	O	O
resequencing	O	O
.	O	O
An	O	O
APOBEC	O	O
cytidine	O	O
deaminase	O	O
mutagenesis	O	O
signature	O	O
was	O	O
revealed	O	O
in	O	O
the	O	O
somatic	O	O
mutations	O	O
.	O	O
Noticeably	O	O
,	O	O
multiple	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
several	O	O
NF	O	O
-	O	O
κB	O	O
signaling	O	O
negative	O	O
regulators	O	O
NFKBIA	O	O
,	O	O
CYLD	O	O
,	O	O
and	O	O
TNFAIP3	O	O
Functional	O	O
studies	O	O
confirmed	O	O
that	O	O
inhibition	O	O
of	O	O
NFKBIA	O	O
had	O	O
a	O	O
significant	O	O
impact	O	O
on	O	O
NF	O	O
-	O	O
κB	O	O
activity	O	O
and	O	O
NPC	O	O
cell	O	O
growth	O	O
.	O	O
The	O	O
identified	O	O
loss	B-NegReg	B-NegReg
-	I-NegReg	I-NegReg
of	I-NegReg	I-NegReg
-	I-NegReg	I-NegReg
function	I-NegReg	I-NegReg
mutations	B-Var	B-Var
in	O	O
NFKBIA	B-Gene	O
leading	O	O
to	O	O
protein	B-MPA	O
truncation	I-MPA	O
contributed	O	O
to	O	O
the	O	O
altered	B-Reg	O
NF	B-Pathway	O
-	I-Pathway	O
κB	I-Pathway	O
activity	B-MPA	I-MPA
,	O	O
which	O	O
is	O	O
critical	O	O
for	O	O
NPC	O	O
tumorigenesis	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
somatic	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
several	O	O
cancer	O	O
-	O	O
relevant	O	O
pathways	O	O
,	O	O
including	O	O
cell	O	O
cycle	O	O
-	O	O
phase	O	O
transition	O	O
,	O	O
cell	O	O
death	O	O
,	O	O
EBV	O	O
infection	O	O
,	O	O
and	O	O
viral	O	O
carcinogenesis	O	O
.	O	O
These	O	O
data	O	O
provide	O	O
an	O	O
enhanced	O	O
road	O	O
map	O	O
for	O	O
understanding	O	O
the	O	O
molecular	O	O
basis	O	O
underlying	O	O
NPC	O	O
.	O	O
ACOX2	O	O
deficiency	O	O
:	O	O
A	O	O
disorder	O	O
of	O	O
bile	O	O
acid	O	O
synthesis	O	O
with	O	O
transaminase	O	O
elevation	O	O
,	O	O
liver	O	O
fibrosis	O	O
,	O	O
ataxia	O	O
,	O	O
and	O	O
cognitive	O	O
impairment	O	O
.	O	O
Acyl	O	O
CoA	O	O
Oxidase	O	O
2	O	O
(	O	O
ACOX2	O	O
)	O	O
encodes	O	O
branched	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
CoA	O	O
oxidase	O	O
,	O	O
a	O	O
peroxisomal	O	O
enzyme	O	O
believed	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
metabolism	O	O
of	O	O
branched	O	O
-	O	O
chain	O	O
fatty	O	O
acids	O	O
and	O	O
bile	O	O
acid	O	O
intermediates	O	O
.	O	O
Deficiency	O	O
of	O	O
this	O	O
enzyme	O	O
has	O	O
not	O	O
been	O	O
described	O	O
previously	O	O
.	O	O
We	O	O
report	O	O
an	O	O
8-y	O	O
-	O	O
old	O	O
male	O	O
with	O	O
intermittently	O	O
elevated	O	O
transaminase	O	O
levels	O	O
,	O	O
liver	O	O
fibrosis	O	O
,	O	O
mild	O	O
ataxia	O	O
,	O	O
and	O	O
cognitive	O	O
impairment	O	O
.	O	O
Exome	O	O
sequencing	O	O
revealed	O	O
a	O	O
previously	O	O
unidentified	O	O
homozygous	O	O
premature	O	O
termination	O	O
mutation	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
Y69	I-Var	O
*	I-Var	O
)	I-Var	O
in	O	O
ACOX2	B-Gene	O
Immunohistochemistry	O	O
confirmed	O	O
the	O	O
absence	B-NegReg	O
of	O	O
ACOX2	B-Gene	O
expression	B-MPA	O
in	O	O
the	O	O
patient	O	O
's	O	O
liver	O	O
,	O	O
and	O	O
biochemical	O	O
analysis	O	O
showed	O	O
marked	O	O
elevation	B-PosReg	O
of	O	O
intermediate	B-MPA	O
bile	I-MPA	O
acids	I-MPA	O
upstream	O	O
of	O	O
ACOX2	O	O
.	O	O
These	O	O
findings	O	O
define	O	O
a	O	O
potentially	O	O
treatable	O	O
inborn	O	O
error	O	O
of	O	O
bile	O	O
acid	O	O
biosynthesis	O	O
caused	O	O
by	O	O
ACOX2	O	O
deficiency	O	O
.	O	O
Prevalence	O	O
and	O	O
phenotypic	O	O
characterization	O	O
of	O	O
MC4R	O	O
variants	O	O
in	O	O
a	O	O
large	O	O
pediatric	O	O
cohort	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
We	O	O
aimed	O	O
to	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
melanocortin-4	O	O
receptor	O	O
(	O	O
MC4R	O	O
)	O	O
variants	O	O
in	O	O
a	O	O
large	O	O
German	O	O
cohort	O	O
of	O	O
children	O	O
with	O	O
obesity	O	O
in	O	O
a	O	O
pediatric	O	O
outpatient	O	O
clinic	O	O
and	O	O
to	O	O
ascertain	O	O
whether	O	O
there	O	O
is	O	O
a	O	O
specific	O	O
phenotype	O	O
associated	O	O
with	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
variants	O	O
as	O	O
previously	O	O
reported	O	O
.	O	O
STUDY	O	O
DESIGN	O	O
:	O	O
Eight	O	O
hundred	O	O
and	O	O
ninety	O	O
-	O	O
nine	O	O
patients	O	O
from	O	O
our	O	O
pediatric	O	O
obesity	O	O
clinic	O	O
were	O	O
screened	O	O
for	O	O
MC4R	O	O
variants	O	O
by	O	O
DNA	O	O
sequencing	O	O
after	O	O
PCR	O	O
amplification	O	O
.	O	O
Retrospective	O	O
statistical	O	O
analysis	O	O
of	O	O
anthropometric	O	O
and	O	O
metabolic	O	O
characteristics	O	O
was	O	O
performed	O	O
,	O	O
comparing	O	O
patients	O	O
with	O	O
and	O	O
without	O	O
MC4R	O	O
variants	O	O
across	O	O
the	O	O
entire	O	O
cohort	O	O
(	O	O
n=586	O	O
)	O	O
as	O	O
well	O	O
as	O	O
in	O	O
case	O	O
-	O	O
control	O	O
analysis	O	O
using	O	O
patients	O	O
with	O	O
common	O	O
sequence	O	O
MC4R	O	O
individually	O	O
matched	O	O
for	O	O
age	O	O
,	O	O
sex	O	O
and	O	O
body	O	O
mass	O	O
index	O	O
standard	O	O
deviation	O	O
score	O	O
(	O	O
SDS	O	O
)	O	O
(	O	O
n=11	O	O
case	O	O
-	O	O
control	O	O
pairs	O	O
)	O	O
.	O	O
RESULTS	O	O
:	O	O
We	O	O
identified	O	O
heterozygous	O	O
variants	O	O
within	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
MC4R	B-Gene	O
gene	O	O
in	O	O
n=22	O	O
(	O	O
2.45	O	O
%	O	O
)	O	O
patients	O	O
.	O	O
Fourteen	O	O
(	O	O
1.56	O	O
%	O	O
)	O	O
had	O	O
a	O	O
variant	B-Var	O
that	O	O
impaired	B-NegReg	O
receptor	B-CPA	O
function	I-CPA	O
.	O	O
One	O	O
new	O	O
frameshift	O	O
(	O	O
p	O	O
.	O	O
F152Sfs	O	O
)	O	O
,	O	O
an	O	O
yet	O	O
unpublished	O	O
nonsense	O	O
mutation	O	O
(	O	O
p	O	O
.	O	O
Q156X	O	O
)	O	O
and	O	O
one	O	O
nonsynonymous	O	O
variation	O	O
(	O	O
p	O	O
.	O	O
V65E	O	O
)	O	O
described	O	O
in	O	O
the	O	O
Mouse	O	O
Genome	O	O
Database	O	O
were	O	O
detected	O	O
.	O	O
Across	O	O
the	O	O
whole	O	O
cohort	O	O
,	O	O
at	O	O
all	O	O
ages	O	O
,	O	O
mean	O	O
height	O	O
SDS	O	O
in	O	O
subjects	O	O
with	O	O
impaired	O	O
receptor	O	O
function	O	O
was	O	O
higher	O	O
than	O	O
in	O	O
patients	O	O
with	O	O
common	O	O
sequence	O	O
MC4R.	O	O
In	O	O
matched	O	O
individuals	O	O
,	O	O
this	O	O
trend	O	O
persisted	O	O
(	O	O
8	O	O
of	O	O
the	O	O
11	O	O
pairs	O	O
)	O	O
within	O	O
the	O	O
case	O	O
-	O	O
control	O	O
setting	O	O
.	O	O
No	O	O
differences	O	O
were	O	O
found	O	O
regarding	O	O
metabolic	O	O
characteristics	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
observed	O	O
prevalence	O	O
of	O	O
mutations	O	O
causing	O	O
impaired	O	O
receptor	O	O
function	O	O
in	O	O
this	O	O
large	O	O
cohort	O	O
is	O	O
comparable	O	O
to	O	O
other	O	O
pediatric	O	O
cohorts	O	O
.	O	O
MC4R	O	O
deficiency	O	O
tends	O	O
to	O	O
lead	O	O
to	O	O
a	O	O
taller	O	O
stature	O	O
,	O	O
confirming	O	O
previous	O	O
clinical	O	O
reports	O	O
.	O	O
The	O	O
association	O	O
of	O	O
MC4R	O	O
mutations	O	O
with	O	O
a	O	O
distinct	O	O
phenotype	O	O
concerning	O	O
metabolic	O	O
characteristics	O	O
remains	O	O
questionable	O	O
.	O	O
Novel	O	O
MBTPS2	B-Gene	O
missense	B-Var	O
mutation	I-Var	O
causes	B-Reg	O
a	O	O
keratosis	B-Disease	O
follicularis	I-Disease	O
spinulosa	I-Disease	O
decalvans	I-Disease	O
phenotype	O	O
:	O	O
mutation	O	O
update	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O
Keratosis	B-Disease	O
follicularis	I-Disease	O
spinulosa	I-Disease	O
decalvans	I-Disease	O
(	O	O
KFSD	O	O
)	O	O
is	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
condition	O	O
characterized	O	O
by	O	O
keratotic	O	O
follicular	O	O
papules	O	O
and	O	O
progressive	O	O
alopecia	O	O
,	O	O
which	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
MBTPS2	B-Gene	O
gene	O	O
.	O	O
We	O	O
carried	O	O
out	O	O
a	O	O
genetic	O	O
study	O	O
on	O	O
a	O	O
child	O	O
who	O	O
was	O	O
suspected	O	O
clinically	O	O
to	O	O
have	O	O
KFSD	O	O
.	O	O
Sanger	O	O
sequencing	O	O
was	O	O
performed	O	O
to	O	O
detect	O	O
mutations	O	O
in	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
of	O	O
MBTPS2	O	O
.	O	O
A	O	O
novel	O	O
missense	O	O
mutation	O	O
(	B-Var	O
c.599C	I-Var	O
>	I-Var	O
T	I-Var	O
)	I-Var	O
was	O	O
identified	O	O
in	O	O
the	O	O
patient	O	O
,	O	O
confirming	B-Reg	O
a	O	O
diagnosis	O	O
of	O	O
KFSD	B-Disease	O
.	O	O
We	O	O
reviewed	O	O
related	O	O
cases	O	O
with	O	O
MBTPS2	O	O
mutations	O	O
for	O	O
evidence	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
.	O	O
Temperature	O	O
-	O	O
dependent	O	O
autoimmunity	O	O
mediated	O	O
by	O	O
chs1	O	O
requires	O	O
its	O	O
neighboring	O	O
TNL	O	O
gene	O	O
SOC3	O	O
.	O	O
Toll	O	O
/	O	O
interleukin	O	O
receptor	O	O
(	O	O
TIR)-nucleotide	O	O
binding	O	O
site	O	O
(	O	O
NB)-type	O	O
(	O	O
TN	O	O
)	O	O
proteins	O	O
are	O	O
encoded	O	O
by	O	O
a	O	O
family	O	O
of	O	O
21	O	O
genes	O	O
in	O	O
the	O	O
Arabidopsis	O	O
genome	O	O
.	O	O
Previous	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
TN	O	O
gene	O	O
CHS1	O	O
activates	O	O
the	O	O
activation	O	O
of	O	O
defense	O	O
responses	O	O
at	O	O
low	O	O
temperatures	O	O
.	O	O
However	O	O
,	O	O
the	O	O
underlying	O	O
molecular	O	O
mechanism	O	O
remains	O	O
unknown	O	O
.	O	O
To	O	O
genetically	O	O
dissect	O	O
chs1-mediated	O	O
signaling	O	O
,	O	O
we	O	O
isolated	O	O
genetic	O	O
suppressors	O	O
of	O	O
chs1	O	O
-	O	O
2	O	O
(	O	O
soc	O	O
)	O	O
.	O	O
Several	O	O
independent	O	O
soc	O	O
mutants	O	O
carried	O	O
mutations	O	O
in	O	O
the	O	O
same	O	O
TIR	O	O
-	O	O
NB	O	O
-	O	O
leucine	O	O
-	O	O
rich	O	O
repeat	O	O
(	O	O
LRR	O	O
)	O	I-Gene
(	O	O
TNL)-encoding	O	O
gene	O	O
SOC3	O	O
,	O	O
which	O	O
is	O	O
adjacent	O	O
to	O	O
CHS1	O	O
on	O	O
chromosome	O	O
1	O	O
.	O	O
Expression	B-MPA	O
of	O	O
SOC3	B-Gene	O
was	O	O
upregulated	B-PosReg	O
in	O	O
the	O	O
chs1	B-Gene	O
-	I-Gene	O
2	I-Gene	O
mutant	B-Var	O
.	O	O
Mutations	O	O
in	O	O
six	O	O
soc3	O	O
alleles	O	O
and	O	O
downregulation	O	O
of	O	O
SOC3	O	O
by	O	O
an	O	O
artificial	O	O
microRNA	O	O
construct	O	O
fully	O	O
rescued	O	O
the	O	O
chilling	O	O
sensitivity	O	O
and	O	O
defense	O	O
defects	O	O
of	O	O
chs1	O	O
-	O	O
2	O	O
.	O	O
Biochemical	O	O
studies	O	O
showed	O	O
that	O	O
CHS1	O	O
interacted	O	O
with	O	O
the	O	O
NB	O	O
and	O	O
LRR	O	O
domains	O	O
of	O	O
SOC3	O	O
;	O	O
however	O	O
,	O	O
mutated	O	O
chs1	O	O
interacted	O	O
with	O	O
the	O	O
TIR	O	O
,	O	O
NB	O	O
and	O	O
LRR	O	O
domains	O	O
of	O	O
SOC3	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O
This	O	O
study	O	O
reveals	O	O
that	O	O
the	O	O
TN	O	O
protein	O	O
CHS1	O	O
interacts	O	O
with	O	O
the	O	O
TNL	O	O
protein	O	O
SOC3	O	O
to	O	O
modulate	O	O
temperature	O	O
-	O	O
dependent	O	O
autoimmunity	O	O
.	O	O
INPPL1	B-Gene	O
gene	O	O
mutations	B-Var	O
in	B-Reg	O
opsismodysplasia	B-Disease	O
.	O	O
The	O	O
INPPL1	O	O
(	O	O
inositol	O	O
polyphosphate	O	O
phosphatase	O	O
-	O	O
like	O	O
1	O	O
)	O	O
gene	O	O
encodes	O	O
the	O	O
inositol	O	O
phosphatase	O	O
,	O	O
SHIP2	O	O
(	O	O
for	O	O
src	O	O
homology	O	O
2	O	O
domain	O	O
-	O	O
containing	O	O
inositol	O	O
phosphatase	O	O
2	O	O
)	O	O
.	O	O
SHIP2	O	O
functions	O	O
to	O	O
dephosphorylate	O	O
,	O	O
and	O	O
negatively	O	O
regulate	O	O
,	O	O
the	O	O
lipid	O	O
second	O	O
messenger	O	O
phosphatidylinositol	O	O
(	O	O
3,4,5)P3	O	O
.	O	O
SHIP2	O	O
has	O	O
been	O	O
well	O	O
studied	O	O
in	O	O
the	O	O
area	O	O
of	O	O
insulin	O	O
resistance	O	O
and	O	O
obesity	O	O
but	O	O
has	O	O
roles	O	O
in	O	O
cancer	O	O
and	O	O
other	O	O
disorders	O	O
.	O	O
Recently	O	O
,	O	O
it	O	O
was	O	O
reported	O	O
that	O	O
mutations	B-Var	O
in	O	O
INPPL1	B-Gene	O
cause	B-Reg	O
opsismodysplasia	B-Disease	O
,	O	O
a	O	O
rare	O	O
,	O	O
autosomal	O	O
recessive	O	O
severe	O	O
skeletal	O	O
dysplasia	O	B-Disease
.	O	O
This	O	O
review	O	O
focuses	O	O
on	O	O
the	O	O
mutations	O	O
associated	O	O
with	O	O
opsismodysplasia	O	O
and	O	O
explores	O	O
the	O	O
role	O	O
of	O	O
INPPL1/	O	O
SHIP2	O	O
in	O	O
skeletal	O	O
development	O	O
.	O	O
Genetic	O	O
screening	O	O
of	O	O
the	O	O
FLCN	O	O
gene	O	O
identify	O	O
six	O	O
novel	O	O
variants	O	O
and	O	O
a	O	O
Danish	O	O
founder	O	O
mutation	O	O
.	O	O
Pathogenic	O	O
germline	O	O
mutations	B-Var	O
in	O	O
the	O	O
folliculin	O	O
(	B-Gene	O
FLCN	I-Gene	O
)	I-Gene	O
tumor	O	O
suppressor	O	O
gene	O	O
predispose	O	O
to	B-Reg	O
Birt	B-Disease	O
-	I-Disease	O
Hogg	I-Disease	O
-	I-Disease	O
Dubé	I-Disease	O
(	O	O
BHD	O	O
)	O	O
syndrome	O	O
,	O	O
a	O	O
rare	O	O
disease	O	O
characterized	O	O
by	O	O
the	O	O
development	O	O
of	O	O
cutaneous	O	O
hamartomas	O	O
(	O	O
fibrofolliculomas	O	O
)	O	O
,	O	O
multiple	O	O
lung	O	O
cysts	O	O
,	O	O
spontaneous	O	O
pneumothoraces	O	O
and	O	O
renal	O	O
cell	O	O
cancer	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
report	O	O
the	O	O
identification	O	O
of	O	O
13	O	O
variants	O	O
and	O	O
three	O	O
polymorphisms	O	O
in	O	O
the	O	O
FLCN	O	O
gene	O	O
in	O	O
143	O	O
Danish	O	O
patients	O	O
or	O	O
families	O	O
with	O	O
suspected	O	O
BHD	O	O
syndrome	O	O
.	O	O
Functional	O	O
mini	O	O
-	O	O
gene	O	O
splicing	O	O
analysis	O	O
revealed	O	O
that	O	O
two	O	O
intronic	O	O
variants	O	O
(	O	O
c.1062	O	O
+	O	O
2T	O	O
>	O	O
G	O	O
and	O	O
c.1177	O	O
-	O	O
5_1177	O	O
-	O	O
3del	O	O
)	O	O
introduced	O	O
splicing	O	O
aberrations	O	O
.	O	O
Eleven	O	O
families	O	O
exhibited	O	O
the	O	O
c.1062	O	O
+	O	O
2T	O	O
>	O	I-Var
G	O	I-Var
mutation	O	O
.	O	O
Combined	O	O
single	O	O
nucleotide	O	O
polymorphism	O	O
array	O	O
-	O	O
haplotype	O	O
analysis	O	O
showed	O	O
that	O	O
these	O	O
families	O	O
share	O	O
a	O	O
3-Mb	O	O
genomic	O	O
fragment	O	O
containing	O	O
the	O	O
FLCN	O	O
gene	O	O
,	O	O
revealing	O	O
that	O	O
the	O	O
c.1062	O	O
+	O	O
2T	O	O
>	O	O
G	O	I-Var
mutation	O	O
is	O	O
a	O	O
Danish	O	O
founder	O	O
mutation	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
in	O	O
silico	O	O
prediction	O	O
and	O	O
functional	O	O
splicing	O	O
assays	O	O
,	O	O
we	O	O
classify	O	O
the	O	O
16	O	O
identified	O	O
variants	O	O
in	O	O
the	O	O
FLCN	O	O
gene	O	O
as	O	O
follows	O	O
:	O	O
nine	O	O
as	O	O
pathogenic	O	O
,	O	O
one	O	O
as	O	O
likely	O	O
pathogenic	O	O
,	O	O
three	O	O
as	O	O
likely	O	O
benign	O	O
and	O	O
three	O	O
as	O	O
polymorphisms	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
the	O	O
study	O	O
describes	O	O
the	O	O
FLCN	O	O
mutation	O	O
spectrum	O	O
in	O	O
Danish	O	O
BHD	O	O
patients	O	O
,	O	O
and	O	O
contributes	O	O
to	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
BHD	O	O
syndrome	O	O
and	O	O
management	O	O
of	O	O
BHD	O	O
patients	O	O
.	O	O
Structural	O	O
brain	O	O
abnormalities	O	O
in	O	O
a	O	O
single	O	O
gene	O	O
disorder	O	O
associated	O	O
with	O	O
epilepsy	O	O
,	O	O
language	O	O
impairment	O	O
and	O	O
intellectual	O	O
disability	O	O
.	O	O
Childhood	O	O
speech	O	O
and	O	O
language	O	O
deficits	O	O
are	O	O
highly	O	O
prevalent	O	O
and	O	O
are	O	O
a	O	O
common	O	O
feature	O	O
of	O	O
neurodevelopmental	O	O
disorders	O	O
.	O	O
However	O	O
,	O	O
it	O	O
is	O	O
difficult	O	O
to	O	O
investigate	O	O
the	O	O
underlying	O	O
causal	O	O
pathways	O	O
because	O	O
many	O	O
diagnostic	O	O
groups	O	O
have	O	O
a	O	O
heterogeneous	O	O
aetiology	O	O
.	O	O
Studying	O	O
disorders	O	O
with	O	O
a	O	O
shared	O	O
genetic	O	O
cause	O	O
and	O	O
shared	O	O
cognitive	O	O
deficits	O	O
can	O	O
provide	O	O
crucial	O	O
insight	O	O
into	O	O
the	O	O
cellular	O	O
mechanisms	O	O
and	O	O
neural	O	O
systems	O	O
that	O	O
give	O	O
rise	O	O
to	O	O
those	O	O
impairments	O	O
.	O	O
The	O	O
current	O	O
study	O	O
investigated	O	O
structural	O	O
brain	O	O
differences	O	O
of	O	O
individuals	O	O
with	O	O
mutations	B-Var	O
in	O	O
ZDHHC9	B-Gene	O
,	O	O
which	O	O
is	O	O
associated	B-Reg	O
with	I-Reg	O
a	O	O
specific	O	O
neurodevelopmental	O	O
phenotype	O	O
including	O	O
prominent	O	O
speech	B-Disease	O
and	I-Disease	O
language	I-Disease	O
impairments	I-Disease	O
and	O	O
intellectual	B-Disease	O
disability	I-Disease	O
.	O	O
We	O	O
used	O	O
multiple	O	O
structural	O	O
neuroimaging	O	O
methods	O	O
to	O	O
characterise	O	O
neuroanatomy	O	O
in	O	O
this	O	O
group	O	O
,	O	O
and	O	O
observed	O	O
bilateral	O	O
reductions	O	O
in	O	O
cortical	O	O
thickness	O	O
in	O	O
areas	O	O
surrounding	O	O
the	O	O
temporo	O	O
-	O	O
parietal	O	O
junction	O	O
,	O	O
parietal	O	O
lobule	O	O
,	O	O
and	O	O
inferior	O	O
frontal	O	O
lobe	O	O
,	O	O
and	O	O
decreased	O	O
microstructural	O	O
integrity	O	O
of	O	O
cortical	O	O
,	O	O
subcortical	O	O
-	O	O
cortical	O	O
,	O	O
and	O	O
interhemispheric	O	O
white	O	O
matter	O	O
projections	O	O
.	O	O
These	O	O
findings	O	O
are	O	O
compared	O	O
to	O	O
reports	O	O
for	O	O
other	O	O
genetic	O	O
groups	O	O
and	O	O
genetically	O	O
heterogeneous	O	O
disorders	O	O
with	O	O
a	O	O
similar	O	O
presentation	O	O
.	O	O
Overlap	O	O
in	O	O
the	O	O
neuroanatomical	O	O
phenotype	O	O
suggests	O	O
a	O	O
common	O	O
pathway	O	O
that	O	O
particularly	O	O
affects	O	O
the	O	O
development	O	O
of	O	O
temporo	O	O
-	O	O
parietal	O	O
and	O	O
inferior	O	O
frontal	O	O
areas	O	O
,	O	O
and	O	O
their	O	O
connections	O	O
.	O	O
Pharmacological	O	O
Chaperoning	O	O
:	O	O
A	O	O
Potential	O	O
Treatment	O	O
for	O	O
PMM2-CDG	O	O
.	O	O
The	O	O
congenital	B-Disease	O
disorder	I-Disease	O
of	I-Disease	O
glycosylation	I-Disease	O
(	I-Disease	O
CDG	I-Disease	O
)	I-Disease	O
due	I-Disease	O
to	I-Disease	O
phosphomannomutase	I-Disease	O
2	I-Disease	O
deficiency	I-Disease	O
(	O	O
PMM2-CDG	O	O
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
N	O	O
-	O	O
glycosylation	O	O
disorder	O	O
,	O	O
is	O	O
a	O	O
multisystem	O	O
disease	O	O
for	O	O
which	O	O
no	O	O
effective	O	O
treatment	O	O
is	O	O
available	O	O
.	O	O
The	O	O
recent	O	O
functional	O	O
characterization	O	O
of	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
described	O	O
in	O	O
patients	O	O
with	O	O
PMM2-CDG	B-Disease	O
led	O	O
to	O	O
the	O	O
idea	O	O
of	O	O
a	O	O
therapeutic	O	O
strategy	O	O
involving	O	O
pharmacological	O	O
chaperones	O	O
(	O	O
PC	O	O
)	O	O
to	O	O
rescue	O	O
PMM2	B-Gene	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutations	B-Var	O
.	O	O
The	O	O
present	O	O
work	O	O
describes	O	O
the	O	O
high	O	O
-	O	O
throughput	O	O
screening	O	O
,	O	O
by	O	O
differential	O	O
scanning	O	O
fluorimetry	O	O
,	O	O
of	O	O
10,000	O	O
low	O	O
-	O	O
molecular	O	O
-	O	O
weight	O	O
compounds	O	O
from	O	O
a	O	O
commercial	O	O
library	O	O
,	O	O
to	O	O
search	O	O
for	O	O
possible	O	O
PCs	O	O
for	O	O
the	O	O
enzyme	O	O
PMM2	O	O
.	O	O
This	O	O
exercise	O	O
identified	O	O
eight	O	O
compounds	O	O
that	O	O
increased	O	O
the	O	O
thermal	O	O
stability	O	O
of	O	O
PMM2	O	O
.	O	O
Of	O	O
these	O	O
,	O	O
four	O	O
compounds	O	O
functioned	O	O
as	O	O
potential	O	O
PCs	O	O
that	O	O
significantly	O	O
increased	O	O
the	O	O
stability	O	O
of	O	O
several	O	O
destabilizing	O	O
and	O	O
oligomerization	O	O
mutants	O	O
and	O	O
also	O	O
increased	O	O
PMM	O	O
activity	O	O
in	O	O
a	O	O
disease	O	O
model	O	O
of	O	O
cells	O	O
overexpressing	O	O
PMM2	O	O
mutations	O	B-Var
.	O	O
Structural	O	O
analysis	O	O
revealed	O	O
one	O	O
of	O	O
these	O	O
compounds	O	O
to	O	O
provide	O	O
an	O	O
excellent	O	O
starting	O	O
point	O	O
for	O	O
chemical	O	O
optimization	O	O
since	O	O
it	O	O
passed	O	O
tests	O	O
based	O	O
on	O	O
a	O	O
number	O	O
of	O	O
pharmacochemical	O	O
quality	O	O
filters	O	O
.	O	O
The	O	O
present	O	O
results	O	O
provide	O	O
the	O	O
first	O	O
proof	O	O
-	O	O
of	O	O
-	O	O
concept	O	O
of	O	O
a	O	O
possible	O	O
treatment	O	O
for	O	O
PMM2-CDG	O	O
and	O	O
describe	O	O
a	O	O
promising	O	O
chemical	O	O
structure	O	O
as	O	O
a	O	O
starting	O	O
point	O	O
for	O	O
the	O	O
development	O	O
of	O	O
new	O	O
therapeutic	O	O
agents	O	O
for	O	O
this	O	O
severe	O	O
orphan	O	O
disease	O	O
.	O	O
Subtypes	O	O
of	O	O
SERPINC1	O	O
mutations	O	O
and	O	O
the	O	O
thrombotic	O	O
phenotype	O	O
of	O	O
inherited	O	O
antithrombin	O	O
deficient	O	O
individuals	O	O
in	O	O
Chinese	O	O
Han	O	O
population	O	O
.	O	O
Inherited	B-Disease	O
antithrombin	I-Disease	O
(	I-Disease	O
AT	I-Disease	O
)	I-Disease	O
deficiency	I-Disease	O
is	O	O
a	O	O
rare	O	O
autosomal	O	O
disease	O	O
that	O	O
could	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
venous	O	O
thromboembolism	O	O
(	O	O
VTE	O	O
)	O	O
and	O	O
usually	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
of	O	O
SERPINC1	B-Gene	O
.	O	O
Although	O	O
a	O	O
number	O	O
of	O	O
mutations	O	O
of	O	O
SERPINC1	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
Chinese	O	O
Han	O	O
population	O	O
,	O	O
the	O	O
impact	O	O
of	O	O
different	O	O
subtypes	O	O
of	O	O
these	O	O
mutations	O	O
on	O	O
the	O	O
thrombotic	O	O
phenotype	O	O
is	O	O
still	O	O
unknown	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
retrospective	O	O
cohort	O	O
study	O	O
including	O	O
169	O	O
AT	O	O
patients	O	O
from	O	O
63	O	O
families	O	O
to	O	O
compare	O	O
the	O	O
clinical	O	O
features	O	O
between	O	O
null	O	O
mutation	O	O
carriers	O	O
and	O	O
missense	O	O
mutation	O	O
carriers	O	O
.	O	O
We	O	O
found	O	O
that	O	O
patients	O	O
carrying	O	O
null	O	O
mutations	O	O
have	O	O
a	O	O
higher	O	O
risk	O	O
of	O	O
VTE	O	O
(	O	O
HR	O	O
2.29	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.16	O	O
-	O	O
4.69	O	O
,	O	O
P=0.02	O	O
adjusted	O	O
for	O	O
sex	O	O
and	O	O
VTE	O	O
family	O	O
history	O	O
)	O	O
and	O	O
earlier	O	O
median	O	O
onset	O	O
age	O	O
of	O	O
VTE	O	O
(	O	O
27	O	O
vs.	O	O
32years	O	O
,	O	O
P=0.045	O	O
)	O	O
as	O	O
well	O	O
as	O	O
lower	O	O
AT	O	O
activities	O	O
(	O	O
47.6±1.0	O	O
%	O	O
vs.	O	O
59.1±2.3	O	O
%	O	O
,	O	O
P<0.001	O	O
)	O	O
than	O	O
those	O	O
with	O	O
missense	O	O
mutations	O	O
.	O	O
We	O	O
also	O	O
observed	O	O
that	O	O
thrombus	O	O
location	O	O
sites	O	O
showed	O	O
no	O	O
difference	O	O
between	O	O
null	O	O
mutation	O	O
carriers	O	O
and	O	O
missense	O	O
mutation	O	O
carriers	O	O
,	O	O
gene	O	O
locations	O	O
of	O	O
the	O	O
mutations	O	O
did	O	O
not	O	O
relate	O	O
with	O	O
the	O	O
incidence	O	O
rate	O	O
of	O	O
VTE	O	O
.	O	O
This	O	O
study	O	O
demonstrated	O	O
that	O	O
different	O	O
types	O	O
of	O	O
SERPINC1	O	O
mutations	O	O
may	O	O
play	O	O
different	O	O
roles	O	O
in	O	O
the	O	O
development	O	O
of	O	O
VTE	O	O
and	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
VTE	O	O
.	O	O
Loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
of	O	O
an	O	O
Arabidopsis	O	O
NADPH	B-Enzyme	O
pyrophosphohydrolase	I-Enzyme	O
,	O	O
AtNUDX19	O	O
,	O	O
impacts	B-Reg	O
on	O	O
the	O	O
pyridine	B-MPA	O
nucleotides	I-MPA	O
status	I-MPA	O
and	O	O
confers	B-PosReg	O
photooxidative	B-CPA	O
stress	I-CPA	O
tolerance	I-CPA	O
.	O	O
The	O	O
levels	O	O
and	O	O
redox	O	O
states	O	O
of	O	O
pyridine	O	O
nucleotides	O	O
,	O	O
such	O	O
as	O	O
NADP(H	O	O
)	O	O
,	O	O
regulate	O	O
the	O	O
cellular	O	O
redox	O	O
homeostasis	O	O
,	O	O
which	O	O
is	O	O
crucial	O	O
for	O	O
photooxidative	O	O
stress	O	O
response	O	O
in	O	O
plants	O	O
.	O	O
However	O	O
,	O	O
how	O	O
they	O	O
are	O	O
controlled	O	O
is	O	O
poorly	O	O
understood	O	O
.	O	O
An	O	O
Arabidopsis	O	O
Nudix	O	O
hydrolase	O	O
,	O	O
AtNUDX19	O	O
,	O	O
was	O	O
previously	O	O
identified	O	O
to	O	O
have	O	O
NADPH	O	O
hydrolytic	O	O
activity	O	O
in	O	O
vitro	O	O
,	O	O
suggesting	O	O
this	O	O
enzyme	O	O
to	O	O
be	O	O
a	O	O
regulator	O	O
of	O	O
the	O	O
NADPH	O	O
status	O	O
.	O	O
We	O	O
herein	O	O
examined	O	O
the	O	O
physiological	O	O
role	O	O
of	O	O
AtNUDX19	B-Gene	O
using	O	O
its	O	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutants	B-Var	O
.	O	O
NADPH	B-CPA	O
levels	I-CPA	O
were	O	O
increased	B-PosReg	O
in	O	O
nudx19	B-Gene	O
mutants	B-Var	O
under	O	O
both	O	O
normal	O	O
and	O	O
high	O	O
light	O	O
conditions	O	O
,	O	O
while	O	O
NADP(+	B-MPA	O
)	I-MPA	O
and	O	O
NAD(+	B-MPA	O
)	I-MPA	O
levels	I-MPA	O
were	O	O
decreased	B-PosReg	O
.	O	O
Despite	O	O
the	O	O
high	O	O
redox	O	O
states	O	O
of	O	O
NADP(H	O	O
)	O	O
,	O	O
nudx19	O	O
mutants	O	O
exhibited	O	O
high	O	O
tolerance	O	O
to	O	O
moderate	O	O
light-	O	O
or	O	O
methylviologen	O	O
-	O	O
induced	O	O
photooxidative	O	O
stresses	O	O
.	O	O
This	O	O
tolerance	O	O
might	O	O
be	O	O
partially	O	O
attributed	O	O
to	O	O
the	O	O
activation	O	O
of	O	O
either	O	O
or	O	O
both	O	O
photosynthesis	O	O
and	O	O
the	O	O
antioxidant	O	O
system	O	O
.	O	O
Furthermore	O	O
,	O	O
a	O	O
microarray	O	O
analysis	O	O
suggested	O	O
the	O	O
role	O	O
of	O	O
ANUDX19	O	O
in	O	O
regulation	O	O
of	O	O
the	O	O
salicylic	O	O
acid	O	O
(	O	O
SA	O	O
)	O	O
response	O	O
in	O	O
a	O	O
negative	O	O
manner	O	O
.	O	O
Indeed	O	O
,	O	O
nudx19	O	O
mutants	O	O
accumulated	O	O
SA	O	O
and	O	O
showed	O	O
high	O	O
sensitivity	O	O
to	O	O
the	O	O
hormone	O	O
.	O	O
Our	O	O
findings	O	O
demonstrate	O	O
that	O	O
ANUDX19	O	O
acts	O	O
as	O	O
an	O	O
NADPH	O	O
pyrophosphohydrolase	O	O
to	O	O
modulate	O	O
cellular	O	O
levels	O	O
and	O	O
redox	O	O
states	O	O
of	O	O
pyridine	O	O
nucleotides	O	O
and	O	O
fine	O	O
-	O	O
tunes	O	O
photooxidative	O	O
stress	O	O
response	O	O
through	O	O
the	O	O
regulation	O	O
of	O	O
photosynthesis	O	O
,	O	O
antioxidant	O	O
system	O	O
,	O	O
and	O	O
possibly	O	O
hormonal	O	O
signaling	O	O
.	O	O
Compound	O	O
heterozygous	O	O
LDLR	O	B-Gene
variant	O	O
in	O	O
severely	O	O
affected	O	O
familial	O	B-Disease
hypercholesterolemia	O	I-Disease
patient	O	O
.	O	O
Familial	B-Disease	B-Disease
hypercholesterolemia	I-Disease	I-Disease
(	O	O
FH	O	O
)	O	O
is	O	O
most	O	O
commonly	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
LDL	O	O
receptor	O	O
(	B-Gene	B-Gene
LDLR	I-Gene	O
)	I-Gene	I-Gene
,	O	O
which	O	O
is	O	O
responsible	O	O
for	O	O
hepatic	O	O
clearance	O	O
of	O	O
LDL	O	O
from	O	O
the	O	O
blood	O	O
circulation	O	O
.	O	O
We	O	O
described	O	O
a	O	O
severely	O	O
affected	O	O
FH	O	O
proband	O	O
and	O	O
their	O	O
first	O	O
-	O	O
degree	O	O
blood	O	O
relatives	O	O
;	O	O
the	O	O
proband	O	O
was	O	O
resistant	O	O
to	O	O
statin	O	O
therapy	O	O
and	O	O
was	O	O
managed	O	O
on	O	O
an	O	O
LDL	O	O
apheresis	O	O
program	O	O
.	O	O
In	O	O
order	O	O
to	O	O
find	O	O
the	O	O
causative	O	O
genetic	O	O
variant	O	O
in	O	O
this	O	O
family	O	O
,	O	O
direct	O	O
exon	O	O
sequencing	O	O
of	O	O
the	O	O
LDLR	O	O
,	O	O
APOB	O	O
and	O	O
PCSK9	O	O
genes	O	O
was	O	O
performed	O	O
.	O	O
We	O	O
identified	O	O
a	O	O
compound	O	O
heterozygous	O	O
mutation	O	O
in	O	O
the	O	O
proband	O	O
with	O	O
missense	O	O
p.(W577C	O	O
)	O	O
and	O	O
frameshift	O	O
p.(G676Afs33	O	O
)	O	O
variants	O	O
at	O	O
exons	O	O
12	O	O
and	O	O
14	O	O
of	O	O
the	O	O
LDLR	O	O
gene	O	O
respectively	O	O
.	O	O
DNA	O	O
sequencing	O	O
of	O	O
LDLR	O	O
gene	O	O
from	O	O
the	O	O
parents	O	O
demonstrated	O	O
that	O	O
the	O	O
missense	O	O
variant	O	O
was	O	O
inherited	O	O
from	O	O
the	O	O
mother	O	O
and	O	O
frameshift	O	O
variant	O	O
was	O	O
inherited	O	O
from	O	O
the	O	O
father	O	O
.	O	O
The	O	O
frameshift	B-Var	B-Var
variant	I-Var	O
resulted	O	O
in	O	O
a	O	O
stop	B-MPA	O
signal	I-MPA	O
33	I-MPA	O
codons	I-MPA	O
downstream	I-MPA	O
of	O	O
the	O	O
deletion	B-NegReg	O
,	O	O
which	O	O
most	O	O
likely	O	O
led	O	O
to	O	O
a	O	O
truncated	B-Protein	O
protein	I-Protein	O
that	O	O
lacks	B-NegReg	O
important	B-MPA	O
functional	I-MPA	O
domains	I-MPA	O
,	O	O
including	O	O
the	O	O
trans	O	O
-	O	O
membrane	O	O
domain	O	O
and	O	O
the	O	O
cytoplasmic	O	O
tail	O	O
domain	O	O
.	O	O
The	O	O
missense	O	O
variant	O	O
is	O	O
also	O	O
predicted	O	O
to	O	O
be	O	O
likely	O	O
pathogenic	O	O
and	O	O
affect	O	O
EGF	O	O
-	O	O
precursor	O	O
homology	O	O
domain	O	O
of	O	O
the	O	O
LDLR	O	O
protein	O	O
.	O	O
The	O	O
segregation	O	O
pattern	O	O
of	O	O
the	O	O
variants	O	O
was	O	O
consistent	O	O
with	O	O
the	O	O
lipid	O	O
profile	O	O
,	O	O
suggesting	O	O
a	O	O
more	O	O
severe	O	O
FH	O	O
phenotype	O	O
when	O	O
the	O	O
variants	O	O
are	O	O
in	O	O
the	O	O
compound	O	O
heterozygous	O	O
state	O	O
.	O	O
The	O	O
finding	O	O
of	O	O
a	O	O
compound	O	O
heterozygous	O	O
mutation	O	O
causing	O	O
severe	O	O
FH	O	O
phenotype	O	O
is	O	O
important	O	O
for	O	O
the	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
and	O	O
also	O	O
enlarges	O	O
the	O	O
spectrum	O	O
of	O	O
FH	O	O
-	O	O
causative	O	O
LDLR	O	O
variants	O	O
in	O	O
the	O	O
Arab	O	O
population	O	O
,	O	O
including	O	O
the	O	O
Saudi	O	O
population	O	O
.	O	O
Activity	O	O
of	O	O
NaV1.2	O	O
promotes	O	O
neurodegeneration	O	O
in	O	O
an	O	O
animal	O	O
model	O	O
of	O	O
multiple	O	O
sclerosis	O	O
.	O	O
Counteracting	O	O
the	O	O
progressive	O	O
neurological	O	O
disability	O	O
caused	O	O
by	O	O
neuronal	O	O
and	O	O
axonal	O	O
loss	O	O
is	O	O
the	O	O
major	O	O
unmet	O	O
clinical	O	O
need	O	O
in	O	O
multiple	O	O
sclerosis	O	O
therapy	O	O
.	O	O
However	O	O
,	O	O
the	O	O
mechanisms	O	O
underlying	O	O
irreversible	O	O
neuroaxonal	O	O
degeneration	O	O
in	O	O
multiple	O	O
sclerosis	O	O
and	O	O
its	O	O
animal	O	O
model	O	O
experimental	O	O
autoimmune	O	O
encephalomyelitis	O	O
(	O	O
EAE	O	O
)	O	O
are	O	O
not	O	O
well	O	O
understood	O	O
.	O	O
A	O	O
long	O	O
-	O	O
standing	O	O
hypothesis	O	O
holds	O	O
that	O	O
the	O	O
distribution	O	O
of	O	O
voltage	O	O
-	O	O
gated	O	O
sodium	O	O
channels	O	O
along	O	O
demyelinated	O	O
axons	O	O
contributes	O	O
to	O	O
neurodegeneration	O	O
by	O	O
increasing	O	O
neuroaxonal	O	O
sodium	O	O
influx	O	O
and	O	O
energy	O	O
demand	O	O
during	O	O
CNS	O	O
inflammation	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
tested	O	O
this	O	O
hypothesis	O	O
in	O	O
vivo	O	O
by	O	O
inserting	O	O
a	O	O
human	O	O
gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
function	I-PosReg	O
mutation	B-Var	O
in	O	O
the	O	O
mouse	O	O
NaV1.2-encoding	O	O
gene	O	O
Scn2a	B-Gene	O
that	O	O
is	O	O
known	O	O
to	O	O
increase	O	O
NaV1.2-mediated	O	O
persistent	O	O
sodium	O	O
currents	O	O
.	O	O
In	O	O
mutant	O	B-Var
mice	O	O
,	O	O
CNS	B-CPA	O
inflammation	I-CPA	O
during	I-CPA	O
EAE	I-CPA	O
leads	O	O
to	O	O
elevated	B-PosReg	B-PosReg
neuroaxonal	B-CPA	O
degeneration	I-CPA	B-CPA
and	O	O
increased	B-PosReg	B-PosReg
disability	B-CPA	I-CPA
and	O	O
lethality	B-CPA	O
compared	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
littermate	O	O
controls	O	O
.	O	O
Importantly	O	O
,	O	O
immune	O	O
cell	O	O
infiltrates	O	O
were	O	O
not	O	O
different	O	O
between	O	O
mutant	O	O
EAE	O	O
mice	O	O
and	O	O
wild	O	O
-	O	O
type	O	O
EAE	O	O
mice	O	O
.	O	O
Thus	O	O
,	O	O
this	O	O
study	O	O
shows	O	O
that	O	O
increased	O	O
neuronal	O	O
NaV1.2	O	O
activity	O	O
exacerbates	O	O
inflammation	O	O
-	O	O
induced	O	O
neurodegeneration	O	O
irrespective	O	O
of	O	O
immune	O	O
cell	O	I-CPA
alterations	O	O
and	O	O
identifies	O	O
NaV1.2	O	O
as	O	O
a	O	O
promising	O	O
neuroprotective	O	O
drug	O	O
target	O	O
in	O	O
multiple	O	O
sclerosis	O	O
.	O	O
Exome	O	O
sequencing	O	O
reveals	O	O
germline	O	O
gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
function	I-PosReg	O
EGFR	B-Gene	O
mutation	B-Var	O
in	O	O
an	O	O
adult	O	O
with	O	O
Lhermitte	B-Disease	O
-	I-Disease	O
Duclos	I-Disease	O
disease	I-Disease	O
.	O	O
Lhermitte	B-Disease	O
-	I-Disease	O
Duclos	I-Disease	O
disease	I-Disease	O
(	O	O
LDD	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
cerebellar	O	O
disorder	O	O
believed	O	O
to	O	O
be	O	O
pathognomonic	O	O
for	O	O
Cowden	O	O
syndrome	O	O
.	O	O
Presently	O	O
,	O	O
the	O	O
only	O	O
known	O	O
etiology	B-Reg	O
is	O	O
germline	O	O
PTEN	B-Gene	O
mutation	B-Var	O
.	O	O
We	O	O
report	O	O
a	O	O
41-yr	O	O
-	O	O
old	O	O
white	O	O
female	O	O
diagnosed	O	O
with	O	O
LDD	O	O
and	O	O
wild	O	O
-	O	O
type	O	O
for	O	O
PTEN	O	O
.	O	O
Exome	O	O
sequencing	O	O
revealed	O	O
a	O	O
germline	O	O
heterozygous	O	O
EGFR	B-Gene	O
mutation	B-Var	O
that	O	O
breaks	B-NegReg	O
a	O	O
disulfide	B-MPA	O
bond	I-MPA	O
in	I-MPA	O
the	I-MPA	O
receptor	I-MPA	O
's	I-MPA	O
extracellular	I-MPA	O
domain	I-MPA	O
,	O	O
resulting	O	O
in	O	O
constitutive	B-MPA	O
activation	B-PosReg	O
.	O	O
Functional	O	O
studies	O	O
demonstrate	O	O
activation	B-PosReg	O
of	O	O
ERK	B-Pathway	O
/	I-Pathway	O
AKT	I-Pathway	B-CPA
signaling	I-Pathway	O
pathways	I-Pathway	O
,	O	O
mimicking	O	O
PTEN	B-Gene	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
downstream	O	O
effects	O	O
.	O	O
The	O	O
identification	O	O
of	O	O
EGFR	O	O
as	O	O
a	O	O
candidate	O	O
LDD	O	O
susceptibility	O	O
gene	O	O
contributes	O	O
to	O	O
advancement	O	O
of	O	O
molecular	O	O
diagnosis	O	O
and	O	O
targeted	O	O
therapy	O	O
for	O	O
this	O	O
rare	O	O
condition	O	O
with	O	O
limited	O	O
treatment	O	O
options	O	O
.	O	O
GBA2	B-Gene	O
Mutations	B-Var	O
Cause	B-Reg	O
a	O	O
Marinesco	B-Disease	O
-	I-Disease	O
Sjögren	I-Disease	O
-	I-Disease	O
Like	I-Disease	O
Syndrome	I-Disease	O
:	I-Disease	O
Genetic	O	O
and	O	O
Biochemical	O	O
Studies	O	O
.	O	O
BACKGROUND	O	O
:	O	O
With	O	O
the	O	O
advent	O	O
new	O	O
sequencing	O	O
technologies	O	O
,	O	O
we	O	O
now	O	O
have	O	O
the	O	O
tools	O	O
to	O	O
understand	O	O
the	O	O
phenotypic	O	O
diversity	O	O
and	O	O
the	O	O
common	O	O
occurrence	O	O
of	O	O
phenocopies	O	O
.	O	O
We	O	O
used	O	O
these	O	O
techniques	O	O
to	O	O
investigate	O	O
two	O	O
Norwegian	O	O
families	O	O
with	O	O
an	O	O
autosomal	O	O
recessive	O	O
cerebellar	O	O
ataxia	O	O
with	O	O
cataracts	O	O
and	O	O
mental	O	O
retardation	O	O
.	O	O
METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Single	O	O
nucleotide	O	O
polymorphism	O	O
(	O	O
SNP	O	O
)	O	O
chip	O	O
analysis	O	O
followed	O	O
by	O	O
Exome	O	O
sequencing	O	O
identified	O	O
a	O	O
2	O	O
bp	O	O
homozygous	O	O
deletion	O	O
in	O	O
GBA2	O	O
in	O	O
both	O	O
families	O	O
,	O	O
c.1528_1529del	B-Var	O
[	O	O
p	O	O
.	O	O
Met510Valfs*17	O	O
]	O	O
.	O	O
Furthermore	O	O
,	O	O
we	O	O
report	O	O
the	O	O
biochemical	O	O
characterization	O	O
of	O	O
GBA2	O	O
in	O	O
these	O	O
patients	O	O
.	O	O
Our	O	O
studies	O	O
show	O	O
that	O	O
a	O	O
reduced	B-NegReg	B-NegReg
activity	B-MPA	B-MPA
of	O	O
GBA2	B-Gene	O
is	O	O
sufficient	O	O
to	O	O
elevate	B-PosReg	O
the	O	O
levels	B-MPA	O
of	O	O
glucosylceramide	B-MPA	O
to	O	O
similar	O	O
levels	O	O
as	O	O
seen	O	O
in	O	O
Gaucher	O	O
disease	O	O
.	O	O
Furthermore	O	O
,	O	O
leucocytes	O	O
seem	O	O
to	O	O
be	O	O
the	O	O
proper	O	O
enzyme	O	O
source	O	O
for	O	O
in	O	O
vitro	O	O
analysis	O	O
of	O	O
GBA2	O	O
activity	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
We	O	O
report	O	O
GBA2	B-Gene	O
mutations	B-Var	O
causing	B-Reg	O
a	O	O
Marinesco	B-Disease	O
-	I-Disease	O
Sjögren	I-Disease	O
-	I-Disease	O
like	I-Disease	O
syndrome	I-Disease	O
in	O	O
two	O	O
Norwegian	O	O
families	O	O
.	O	O
One	O	O
of	O	O
the	O	O
families	O	O
was	O	O
originally	O	O
diagnosed	O	O
with	O	O
Marinesco	O	O
-	O	O
Sjögren	O	O
syndrome	O	O
based	O	O
on	O	O
an	O	O
autosomal	O	O
recessive	O	O
cerebellar	O	O
ataxia	O	O
with	O	O
cataracts	O	O
and	O	O
mental	O	O
retardation	O	O
.	O	O
Our	O	O
findings	O	O
highlight	O	O
the	O	O
phenotypic	O	O
variability	O	O
associated	O	O
with	O	O
GBA2	O	O
mutations	O	O
,	O	O
and	O	O
suggest	O	O
that	O	O
patients	O	O
with	O	O
Marinesco	O	O
-	O	O
Sjögren	O	O
-	O	O
like	O	O
syndromes	O	O
should	O	O
be	O	O
tested	O	O
for	O	O
mutations	O	O
in	O	O
this	O	O
gene	O	O
.	O	O
Compound	O	O
Heterozygosity	O	O
for	O	O
Null	B-Var	O
Mutations	I-Var	O
and	O	O
a	O	O
Common	O	O
Hypomorphic	O	O
Risk	O	O
Haplotype	O	O
in	O	O
TBX6	B-Gene	O
Causes	B-Reg	O
Congenital	B-Disease	O
Scoliosis	I-Disease	O
.	O	O
Congenital	O	O
scoliosis	O	O
(	O	O
CS	O	O
)	O	O
occurs	O	O
as	O	O
a	O	O
result	O	O
of	O	O
vertebral	O	O
malformations	O	O
and	O	O
has	O	O
an	O	O
incidence	O	O
of	O	O
0.5	O	O
-	O	O
1/1,000	O	O
births	O	O
.	O	O
Recently	O	O
,	O	O
TBX6	O	O
on	O	O
chromosome	O	O
16p11.2	O	O
was	O	O
reported	O	O
as	O	O
a	O	O
disease	O	O
gene	O	O
for	O	O
CS	O	O
;	O	O
about	O	O
10	O	O
%	O	O
of	O	O
Chinese	O	O
CS	O	O
patients	O	O
were	O	O
compound	O	O
heterozygotes	O	O
for	O	O
rare	O	O
null	O	O
mutations	O	O
and	O	O
a	O	O
common	O	O
haplotype	O	O
defined	O	O
by	O	O
three	O	O
SNPs	O	O
in	O	O
TBX6	O	O
.	O	O
All	O	O
patients	O	O
had	O	O
hemivertebrae	O	O
.	O	O
We	O	O
recruited	O	O
94	O	O
Japanese	O	O
CS	O	O
patients	O	O
,	O	O
investigated	O	O
the	O	O
TBX6	O	O
locus	O	O
for	O	O
both	O	O
mutations	O	O
and	O	O
the	O	O
risk	O	O
haplotype	O	O
,	O	O
examined	O	O
transcriptional	O	O
activities	O	O
of	O	O
mutant	O	O
TBX6	O	O
in	O	O
vitro	O	O
,	O	O
and	O	O
evaluated	O	O
clinical	O	O
and	O	O
radiographic	O	O
features	O	O
.	O	O
We	O	O
identified	O	O
TBX6	O	O
null	O	O
mutations	O	O
in	O	O
nine	O	O
patients	O	O
,	O	O
including	O	O
a	O	O
missense	O	O
mutation	O	O
that	O	O
had	O	O
a	O	O
loss	O	O
of	O	O
function	O	O
in	O	O
vitro	O	O
.	O	O
All	O	O
had	O	O
the	O	O
risk	O	O
haplotype	O	O
in	O	O
the	O	O
opposite	O	O
allele	O	O
.	O	O
One	O	O
of	O	O
the	O	O
mutations	O	O
showed	O	O
dominant	O	O
negative	O	O
effect	O	O
.	O	O
Although	O	O
all	O	O
Chinese	O	O
patients	O	O
had	O	O
one	O	O
or	O	O
more	O	O
hemivertebrae	O	O
,	O	O
two	O	O
Japanese	O	O
patients	O	O
did	O	O
not	O	O
have	O	O
hemivertebra	O	O
.	O	O
The	O	O
compound	O	O
heterozygosity	O	O
of	O	O
null	O	O
mutations	O	O
and	O	O
the	O	O
common	O	O
risk	O	O
haplotype	O	O
in	O	O
TBX6	O	O
also	O	O
causes	O	O
CS	O	O
in	O	O
Japanese	O	O
patients	O	O
with	O	O
similar	O	O
incidence	O	O
.	O	O
Hemivertebra	O	O
was	O	O
not	O	O
a	O	O
specific	O	O
type	O	O
of	O	O
spinal	O	O
malformation	O	O
in	O	O
TBX6-associated	O	O
CS	O	O
(	O	O
TACS	O	O
)	O	O
.	O	O
A	O	O
heterozygous	O	O
TBX6	B-Gene	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutation	B-Var	O
has	O	O
been	O	O
reported	O	O
in	O	O
a	O	O
family	O	O
with	O	O
autosomal	B-Disease	O
-	I-Disease	O
dominant	I-Disease	O
spondylocostal	I-Disease	O
dysostosis	I-Disease	O
,	O	O
but	O	O
it	O	O
may	O	O
represent	O	O
a	O	O
spectrum	O	O
of	O	O
the	O	O
same	O	O
disease	O	O
with	O	O
TACS	O	O
.	O	O
Aspartylglucosaminuria	B-Disease	O
caused	B-Reg	O
by	I-Reg	O
a	O	O
novel	O	O
homozygous	O	O
mutation	B-Var	O
in	O	O
the	O	O
AGA	B-Gene	O
gene	O	O
was	O	O
identified	O	O
by	O	O
an	O	O
exome	O	O
-	O	O
first	O	O
approach	O	O
in	O	O
a	O	O
patient	O	O
from	O	O
Japan	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Aspartylglucosaminuria	O	O
(	O	O
AGU	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
lysosomal	O	O
storage	O	O
disorder	O	O
caused	O	O
by	O	O
a	O	O
deficiency	O	O
of	O	O
the	O	O
lysosomal	O	O
enzyme	O	O
,	O	O
aspartylglucosaminidase	O	O
(	O	O
AGA	O	O
)	O	O
.	O	O
This	O	O
disorder	O	O
is	O	O
rare	O	O
in	O	O
the	O	O
general	O	O
population	O	O
except	O	O
in	O	O
Finland	O	O
.	O	O
Since	O	O
the	O	O
most	O	O
characteristic	O	O
feature	O	O
of	O	O
this	O	O
disorder	O	O
is	O	O
a	O	O
progressive	O	O
developmental	O	O
regression	O	O
,	O	O
patients	O	O
often	O	O
show	O	O
no	O	O
specific	O	O
symptoms	O	O
in	O	O
the	O	O
initial	O	O
stages	O	O
,	O	O
and	O	O
thus	O	O
early	O	O
diagnosis	O	O
is	O	O
often	O	O
challenging	O	O
.	O	O
CASE	O	O
REPORT	O	O
:	O	O
We	O	O
encountered	O	O
a	O	O
16-year	O	O
-	O	O
old	O	O
boy	O	O
who	O	O
began	O	O
to	O	O
show	O	O
difficulties	O	O
in	O	O
his	O	O
speech	O	O
at	O	O
the	O	O
age	O	O
of	O	O
6years	O	O
.	O	O
Due	O	O
to	O	O
a	O	O
mild	O	O
regression	O	O
in	O	O
his	O	O
development	O	O
,	O	O
he	O	O
gradually	O	O
lost	O	B-NegReg
common	O	O
daily	O	O
abilities	O	O
.	O	O
His	O	O
diagnosis	O	O
was	O	O
first	O	O
obtained	O	O
through	O	O
exome	O	O
sequencing	O	O
that	O	O
identified	O	O
a	O	O
novel	O	O
homozygous	O	O
mutation	O	O
in	O	O
the	O	O
AGA	O	O
gene	O	O
.	O	O
This	O	O
result	O	O
was	O	O
reasonable	O	O
because	O	O
of	O	O
parental	O	O
consanguinity	O	O
.	O	O
Reduced	O	O
enzymatic	O	O
activity	O	O
of	O	O
AGA	O	O
was	O	O
then	O	O
confirmed	O	O
.	O	O
His	O	O
urine	O	O
was	O	O
retrospectively	O	O
screened	O	O
by	O	O
matrix	O	O
-	O	O
assisted	O	O
laser	O	O
desorption	O	O
/	O	O
ionization	O	O
time	O	O
-	O	O
of	O	O
-	O	O
flight	O	O
mass	O	O
spectrometry	O	O
(	O	O
MALDI	O	O
-	O	O
TOF	O	O
-	O	O
MS	O	O
)	O	O
and	O	O
a	O	O
specific	O	O
pattern	O	O
of	O	O
abnormal	O	O
metabolites	O	O
was	O	O
identified	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Because	O	O
both	O	O
exome	O	O
sequencing	O	O
and	O	O
MALDI	O	O
-	O	O
TOF	O	O
-	O	O
MS	O	O
screening	O	O
are	O	O
adaptable	O	O
and	O	O
comprehensive	O	O
,	O	O
future	O	O
combinatory	O	O
use	O	O
of	O	O
these	O	O
methods	O	O
would	O	O
be	O	O
useful	O	O
for	O	O
diagnosis	O	O
of	O	O
rare	O	O
inborn	O	O
errors	O	O
of	O	O
metabolism	O	O
such	O	O
as	O	O
AGU	O	O
.	O	O
WT1	O	O
Haploinsufficiency	O	O
Supports	O	O
Milder	O	O
Renal	O	O
Manifestation	O	O
in	O	O
Two	O	O
Patients	O	O
with	O	O
Denys	O	O
-	O	O
Drash	O	O
Syndrome	O	O
.	O	O
Denys	B-Disease	O
-	I-Disease	O
Drash	I-Disease	O
syndrome	I-Disease	O
(	O	O
DDS	O	O
)	O	O
is	O	O
characterized	O	O
by	O	O
nephropathy	O	O
,	O	O
genital	O	O
abnormalities	O	O
,	O	O
and	O	O
predisposition	O	O
to	O	O
Wilms	O	O
'	O	O
tumor	O	O
.	O	O
DDS	O	O
patients	O	O
usually	O	O
present	B-Reg	O
heterozygous	O	O
de	O	O
novo	O	O
germline	O	O
WT1	B-Gene	O
mutations	B-Var	O
.	O	O
The	O	O
WT1	O	O
gene	O	O
comprises	O	O
10	O	O
exons	O	O
encoding	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
transactivation	O	O
and	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
DNA	O	O
-	O	O
binding	O	O
regions	O	O
.	O	O
Two	O	O
unrelated	O	O
patients	O	O
with	O	O
genital	O	O
ambiguity	O	O
and	O	O
Wilms	O	O
'	O	O
tumor	O	O
were	O	O
analyzed	O	O
by	O	O
sequencing	O	O
of	O	O
the	O	O
WT1	O	O
gene	O	O
,	O	O
and	O	O
3	O	O
mutations	O	O
in	O	O
exon	O	O
1	O	O
were	O	O
identified	O	O
of	O	O
which	O	O
2	O	O
are	O	O
novel	O	O
.	O	O
Patient	O	O
1	O	O
carried	O	O
a	O	O
c.555delC	B-Var	O
mutation	O	O
that	O	O
causes	B-Reg	O
a	O	O
frameshift	B-Var	O
and	O	O
a	O	O
premature	B-MPA	O
stop	I-MPA	O
codon	O	O
.	O	O
Patient	O	O
2	O	O
carried	O	O
both	O	O
c.421A	B-Var	O
>	I-Var	O
C	I-Var	I-Var
and	O	O
c.424C	B-Var	B-Var
>	I-Var	I-Var
T	I-Var	I-Var
aberrations	O	O
that	O	O
lead	B-Reg	O
to	I-Reg	O
the	O	O
missense	O	O
p	B-Var	O
.	I-Var	O
Lys141Gln	I-Var	O
and	O	O
the	O	O
nonsense	O	O
p	B-Var	O
.	I-Var	O
Lys142	I-Var	O
*	I-Var	O
mutation	O	O
,	O	O
respectively	O	O
.	O	O
As	O	O
both	O	O
patients	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
mutations	O	O
,	O	O
we	O	O
tested	O	O
their	O	O
parents	O	O
who	O	O
did	O	O
not	O	O
carry	O	O
any	O	O
mutation	O	O
.	O	O
Therefore	O	O
,	O	O
the	O	O
3	O	O
WT1	O	O
mutations	O	O
occurred	O	O
de	O	O
novo	O	O
in	O	O
both	O	O
patients	O	O
.	O	O
Heterozygous	O	O
mutations	B-Var	B-Var
result	O	O
in	O	O
WT1	B-Gene	O
haploinsufficiency	O	O
as	O	O
they	O	O
impair	B-NegReg	O
protein	B-Protein	O
production	B-MPA	B-MPA
.	O	O
They	O	O
are	O	O
associated	O	O
with	O	O
a	O	O
milder	O	O
DDS	O	O
phenotype	O	O
as	O	O
observed	O	O
in	O	O
the	O	O
patients	O	O
studied	O	O
here	O	O
.	O	O
Delineating	O	O
the	O	O
phenotypic	O	O
spectrum	O	O
of	O	O
Bainbridge	B-Disease	O
-	I-Disease	O
Ropers	I-Disease	O
syndrome	I-Disease	O
:	I-Disease	O
12	O	O
new	O	O
patients	O	O
with	O	O
de	O	O
novo	O	O
,	O	O
heterozygous	O	O
,	O	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutations	B-Var	O
in	O	O
ASXL3	B-Gene	O
and	O	O
review	O	O
of	O	O
published	O	O
literature	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Bainbridge	B-Disease	O
-	I-Disease	O
Ropers	I-Disease	O
syndrome	I-Disease	O
(	O	O
BRPS	O	O
)	O	O
is	O	O
a	O	O
recently	O	O
described	O	O
developmental	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
de	O	O
novo	O	O
truncating	B-Var	O
mutations	I-Var	O
in	O	O
the	O	O
additional	O	O
sex	O	O
combs	O	O
like	O	O
3	O	O
(	B-Gene	O
ASXL3	I-Gene	O
)	I-Gene	O
gene	O	O
.	O	O
To	O	O
date	O	O
,	O	O
there	O	O
have	O	O
been	O	O
fewer	O	O
than	O	O
10	O	O
reported	O	O
patients	O	O
.	O	O
OBJECTIVES	O	O
:	O	O
Here	O	O
,	O	O
we	O	O
delineate	O	O
the	O	O
BRPS	O	O
phenotype	O	O
further	O	O
by	O	O
describing	O	O
a	O	O
series	O	O
of	O	O
12	O	O
previously	O	O
unreported	O	O
patients	O	O
identified	O	O
by	O	O
the	O	O
Deciphering	O	O
Developmental	O	O
Disorders	O	O
study	O	O
.	O	O
METHODS	O	O
:	O	O
Trio	O	O
-	O	O
based	O	O
exome	O	O
sequencing	O	O
was	O	O
performed	O	O
on	O	O
all	O	O
12	O	O
patients	O	O
included	O	O
in	O	O
this	O	O
study	O	O
,	O	O
which	O	O
found	O	O
a	O	O
de	O	O
novo	O	O
truncating	O	O
mutation	O	O
in	O	O
ASXL3	O	O
.	O	O
Detailed	O	O
phenotypic	O	O
information	O	O
and	O	O
patient	O	O
images	O	O
were	O	O
collected	O	O
and	O	O
summarised	O	O
as	O	O
part	O	O
of	O	O
this	O	O
study	O	O
.	O	O
RESULTS	O	O
:	O	O
By	O	O
obtaining	O	O
genotype	O	O
:	O	O
phenotype	O	O
data	O	O
,	O	O
we	O	O
have	O	O
been	O	O
able	O	O
to	O	O
demonstrate	O	O
a	O	O
second	O	O
mutation	O	O
cluster	O	O
region	O	O
within	O	O
ASXL3	O	O
.	O	O
This	O	O
report	O	O
expands	O	O
the	O	O
phenotype	O	O
of	O	O
older	O	O
patients	O	O
with	O	O
BRPS	O	O
;	O	O
common	O	O
emerging	O	O
features	O	O
include	O	O
severe	O	O
intellectual	O	O
disability	O	O
(	O	O
11/12	O	O
)	O	O
,	O	O
poor/	O	O
absent	O	O
speech	O	O
(	O	O
12/12	O	O
)	O	O
,	O	O
autistic	O	O
traits	O	O
(	O	O
9/12	O	O
)	O	O
,	O	O
distinct	O	O
face	O	O
(	O	O
arched	O	O
eyebrows	O	O
,	O	O
prominent	O	O
forehead	O	O
,	O	O
high	O	O
-	O	O
arched	O	O
palate	O	O
,	O	O
hypertelorism	O	O
and	O	O
downslanting	O	O
palpebral	O	O
fissures	O	O
)	O	O
,	O	O
(	O	O
9/12	O	O
)	O	O
,	O	O
hypotonia	O	O
(	O	O
11/12	O	O
)	O	O
and	O	O
significant	O	O
feeding	O	O
difficulties	O	O
(	O	O
9/12	O	O
)	O	O
when	O	O
young	O	O
.	O	O
DISCUSSION	O	O
:	O	O
Similarities	O	O
in	O	O
the	O	O
patients	O	O
reported	O	O
previously	O	O
in	O	O
comparison	O	O
with	O	O
this	O	O
cohort	O	O
included	O	O
their	O	O
distinctive	O	O
craniofacial	O	O
features	O	O
,	O	O
feeding	O	O
problems	O	O
,	O	O
absent	O	O
/	O	O
limited	O	O
speech	O	O
and	O	O
intellectual	O	O
disability	O	O
.	O	O
Shared	O	O
behavioural	O	O
phenotypes	O	O
include	O	O
autistic	O	O
traits	O	O
,	O	O
hand	O	O
-	O	O
flapping	O	O
,	O	O
rocking	O	O
,	O	O
aggressive	O	O
behaviour	O	O
and	O	O
sleep	O	O
disturbance	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
This	O	O
series	O	O
expands	O	O
the	O	O
phenotypic	O	O
spectrum	O	O
of	O	O
this	O	O
severe	O	O
disorder	O	O
and	O	O
highlights	O	O
its	O	O
surprisingly	O	O
high	O	O
frequency	O	O
.	O	O
With	O	O
the	O	O
advent	O	O
of	O	O
advanced	O	O
genomic	O	O
screening	O	O
,	O	O
we	O	O
are	O	O
likely	O	O
to	O	O
identify	O	O
more	O	O
variants	O	O
in	O	O
this	O	O
gene	O	O
presenting	O	O
with	O	O
a	O	O
variable	O	O
phenotype	O	O
,	O	O
which	O	O
this	O	O
study	O	O
will	O	O
explore	O	O
.	O	O
Rhomboid	O	O
family	O	O
member	O	O
2	O	O
regulates	O	O
cytoskeletal	O	O
stress	O	O
-	O	O
associated	O	O
Keratin	O	O
16	O	O
.	O	O
Keratin	O	O
16	O	O
(	O	O
K16	O	O
)	O	O
is	O	O
a	O	O
cytoskeletal	O	O
scaffolding	O	O
protein	O	O
highly	O	O
expressed	O	O
at	O	O
pressure	O	O
-	O	O
bearing	O	O
sites	O	O
of	O	O
the	O	O
mammalian	O	O
footpad	O	O
.	O	O
It	O	O
can	O	O
be	O	O
induced	O	O
in	O	O
hyperproliferative	O	O
states	O	O
such	O	O
as	O	O
wound	O	O
healing	O	O
,	O	O
inflammation	O	O
and	O	O
cancer	O	O
.	O	O
Here	O	O
we	O	O
show	O	O
that	O	O
the	O	O
inactive	O	O
rhomboid	O	O
protease	O	O
RHBDF2	O	O
(	O	O
iRHOM2	O	O
)	O	O
regulates	O	O
thickening	O	O
of	O	O
the	O	O
footpad	O	O
epidermis	O	O
through	O	O
its	O	O
interaction	O	O
with	O	O
K16	O	O
.	O	O
K16	O	O
expression	O	O
is	O	O
absent	O	O
in	O	O
the	O	O
thinned	O	O
footpads	O	O
of	O	O
irhom2(-/-	O	O
)	O	O
mice	O	O
compared	O	O
with	O	O
irhom2(+/+)mice	O	O
,	O	O
due	O	O
to	O	O
reduced	O	O
keratinocyte	O	O
proliferation	O	O
.	O	O
Gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
function	I-PosReg	O
mutations	B-Var	O
in	O	O
iRHOM2	B-Gene	O
underlie	O	O
Tylosis	B-Disease	O
with	I-Disease	O
oesophageal	I-Disease	O
cancer	I-Disease	O
(	O	O
TOC	O	O
)	O	O
,	O	O
characterized	O	O
by	O	O
palmoplantar	O	O
thickening	O	O
,	O	O
upregulate	B-PosReg	O
K16	B-MPA	O
with	O	O
robust	O	O
downregulation	B-NegReg	O
of	O	O
its	O	O
type	B-MPA	O
II	I-MPA	O
keratin	I-MPA	O
binding	I-MPA	B-CPA
partner	I-MPA	O
,	O	O
K6	I-MPA	O
.	O	O
By	O	O
orchestrating	O	O
the	O	O
remodelling	O	O
and	O	O
turnover	O	O
of	O	O
K16	O	O
,	O	O
and	O	O
uncoupling	O	O
it	O	O
from	O	O
K6	O	O
,	O	O
iRHOM2	O	O
regulates	O	O
the	O	O
epithelial	O	O
response	O	O
to	O	O
physical	O	O
stress	O	O
.	O	O
These	O	O
findings	O	O
contribute	O	O
to	O	O
our	O	O
understanding	O	O
of	O	O
the	O	O
molecular	O	O
mechanisms	O	O
underlying	O	O
hyperproliferation	O	O
of	O	O
the	O	O
palmoplantar	O	O
epidermis	O	O
in	O	O
both	O	O
physiological	O	O
and	O	O
disease	O	O
states	O	O
,	O	O
and	O	O
how	O	O
this	O	O
'	O	O
stress	O	O
'	O	O
keratin	O	O
is	O	O
regulated	O	O
.	O	O
Loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutation	B-Var	O
of	O	O
the	O	O
calcium	B-Protein	O
sensor	I-Protein	O
CBL1	I-Protein	O
increases	B-PosReg	O
aluminum	B-MPA	O
sensitivity	I-MPA	O
in	O	O
Arabidopsis	O	B-Gene
.	O	O
Despite	O	O
the	O	O
physiological	O	O
importance	O	O
of	O	O
aluminum	O	O
(	O	O
Al	O	O
)	O	O
phytotoxicity	O	O
for	O	O
plants	O	O
,	O	O
it	O	O
remained	O	O
unknown	O	O
if	O	O
,	O	O
and	O	O
how	O	O
,	O	O
calcineurin	O	O
B	O	O
-	O	O
like	O	O
calcium	O	O
sensors	O	O
(	O	O
CBLs	O	O
)	O	O
and	O	O
CBL	O	O
-	O	O
interacting	O	O
protein	O	O
kinases	O	O
(	O	O
CIPKs	O	O
)	O	O
are	O	O
involved	O	O
in	O	O
Al	O	O
resistance	O	O
.	O	O
We	O	O
performed	O	O
a	O	O
comparative	O	O
physiological	O	O
and	O	O
whole	O	O
transcriptome	O	O
investigation	O	O
of	O	O
an	O	O
Arabidopsis	O	O
CBL1	B-Gene	O
mutant	B-Var	O
(	O	O
cbl1	O	O
)	O	O
and	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
(	O	O
WT	O	O
)	O	O
.	O	O
cbl1	O	O
plants	O	O
exudated	O	O
less	B-NegReg	O
Al	B-MPA	O
-	I-MPA	O
chelating	I-MPA	O
malate	I-MPA	O
,	O	O
accumulated	O	O
more	B-PosReg	O
Al	B-MPA	O
,	O	O
and	O	O
displayed	O	O
a	O	O
severe	B-CPA	O
root	I-CPA	O
growth	I-CPA	O
reduction	B-NegReg	O
in	O	O
response	O	O
to	O	O
Al	O	O
.	O	O
Genes	O	O
involved	O	O
in	O	O
metabolism	O	O
,	O	O
transport	O	O
,	O	O
cell	O	O
wall	O	O
modification	O	O
,	O	O
transcription	O	O
and	O	O
oxidative	O	O
stress	O	O
were	O	O
differentially	O	O
regulated	O	O
between	O	O
the	O	O
two	O	O
lines	O	O
,	O	O
under	O	O
both	O	O
control	O	O
and	O	O
Al	O	O
stress	O	O
treatments	O	O
.	O	O
Exposure	O	O
to	O	O
Al	O	O
resulted	O	O
in	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
a	O	O
large	O	O
set	O	O
of	O	O
genes	O	O
only	O	O
in	O	O
WT	O	O
and	O	O
not	O	O
cbl1	O	O
shoots	O	O
,	O	O
while	O	O
a	O	O
different	O	O
set	O	O
of	O	O
genes	O	O
were	O	O
down	O	O
-	O	O
regulated	O	O
in	O	O
cbl1	O	O
but	O	O
not	O	O
in	O	O
WT	O	O
roots	O	O
.	O	O
These	O	O
differences	O	O
allowed	O	O
us	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
to	O	O
define	O	O
a	O	O
calcium	O	O
-	O	O
regulated	O	O
/	O	O
dependent	O	O
transcriptomic	O	O
network	O	O
for	O	O
Al	O	O
stress	O	O
responses	O	O
.	O	O
Our	O	O
analyses	O	O
reveal	O	O
not	O	O
only	O	O
the	O	O
fundamental	O	O
role	O	O
of	O	O
CBL1	O	O
in	O	O
the	O	O
adjustment	O	O
of	O	O
central	O	O
transcriptomic	O	O
networks	O	O
involved	O	O
in	O	O
maintaining	O	O
adequate	O	O
physiological	O	O
homeostasis	O	O
processes	O	O
,	O	O
but	O	O
also	O	O
that	O	O
a	O	O
high	O	O
shoot	O	O
-	O	O
root	O	O
dynamics	O	O
is	O	O
required	O	O
for	O	O
the	O	O
proper	O	O
deployment	O	O
of	O	O
Al	O	O
resistance	O	O
responses	O	O
in	O	O
the	O	O
root	O	O
.	O	O
Clinical	O	O
and	O	O
molecular	O	O
consequences	O	O
of	O	O
disease	O	O
-	O	O
associated	O	O
de	O	O
novo	O	O
mutations	O	O
in	O	O
SATB2	O	O
.	O	O
PURPOSE	O	O
:	O	O
To	O	O
characterize	O	O
features	O	O
associated	O	O
with	O	O
de	O	O
novo	O	O
mutations	O	O
affecting	O	O
SATB2	O	O
function	O	O
in	O	O
individuals	O	O
ascertained	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
intellectual	O	O
disability	O	O
.	O	O
METHODS	O	O
:	O	O
Twenty	O	O
previously	O	O
unreported	O	O
individuals	O	O
with	O	O
19	O	O
different	O	O
SATB2	O	O
mutations	O	O
(	O	O
11	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
and	O	O
8	O	O
missense	O	O
variants	O	O
)	O	O
were	O	O
studied	O	O
.	O	O
Fibroblasts	O	O
were	O	O
used	O	O
to	O	O
measure	O	O
mutant	O	O
protein	O	O
production	O	O
.	O	O
Subcellular	O	O
localization	O	O
and	O	O
mobility	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
and	O	O
mutant	O	O
SATB2	O	O
were	O	O
assessed	O	O
using	O	O
fluorescently	O	O
tagged	O	O
protein	O	O
.	O	O
RESULTS	O	O
:	O	O
Recurrent	O	O
clinical	O	O
features	O	O
included	O	O
neurodevelopmental	O	O
impairment	O	O
(	O	O
19/19	O	O
)	O	O
,	O	O
absent	O	O
/	O	O
near	O	O
absent	O	O
speech	O	O
(	O	O
16/19	O	O
)	O	O
,	O	O
normal	O	O
somatic	O	O
growth	O	O
(	O	O
17/19	O	O
)	O	O
,	O	O
cleft	O	O
palate	O	O
(	O	O
9/19	O	O
)	O	O
,	O	O
drooling	O	O
(	O	O
12/19	O	O
)	O	O
,	O	O
and	O	O
dental	O	O
anomalies	O	O
(	O	O
8/19	O	O
)	O	O
.	O	O
Six	O	O
of	O	O
eight	O	O
missense	O	O
variants	O	O
clustered	O	O
in	O	O
the	O	O
first	O	O
CUT	O	O
domain	O	O
.	O	O
Sibling	O	O
recurrence	O	O
due	O	O
to	O	O
gonadal	O	O
mosaicism	O	O
was	O	O
seen	O	O
in	O	O
one	O	O
family	O	O
.	O	O
A	O	O
nonsense	B-Var	O
mutation	I-Var	O
in	I-Var	O
the	I-Var	O
last	I-Var	O
exon	I-Var	O
resulted	B-Reg	O
in	I-Reg	O
production	O	O
of	O	O
a	O	O
truncated	B-MPA	O
protein	B-Protein	O
retaining	O	O
all	O	O
three	O	O
DNA	O	O
-	O	O
binding	O	O
domains	O	O
.	O	O
SATB2	B-Gene	O
nuclear	O	O
mobility	O	O
was	O	O
mutation	O	O
-	O	O
dependent	O	O
;	O	O
p	B-Var	O
.	I-Var	O
Arg389Cys	I-Var	O
in	I-Var	O
CUT1	I-Var	O
increased	B-PosReg	O
mobility	B-MPA	O
and	O	O
both	O	O
p	B-Var	O
.	I-Var	O
Gly515Ser	I-Var	O
in	I-Var	O
CUT2	I-Var	O
and	O	O
p	B-Var	O
.	I-Var	O
Gln566Lys	I-Var	O
between	I-Var	O
CUT2	I-Var	O
and	I-Var	O
HOX	I-Var	O
reduced	B-NegReg	O
mobility	B-MPA	O
.	O	O
The	O	O
clinical	O	O
features	O	O
in	O	O
individuals	O	O
with	O	O
missense	O	O
variants	O	O
were	O	O
indistinguishable	O	O
from	O	O
those	O	O
with	O	O
loss	O	O
of	O	O
function	O	O
.	O	O
CONCLUSION	O	O
:	O	O
SATB2	B-Gene	O
haploinsufficiency	B-Var	O
is	O	O
a	O	O
common	O	O
cause	B-Reg	O
of	O	O
syndromic	B-Disease	O
intellectual	I-Disease	O
disability	I-Disease	O
.	O	O
When	O	O
mutant	B-Var	O
SATB2	B-Gene	O
protein	O	O
is	O	O
produced	O	O
,	O	O
the	O	O
protein	B-Protein	O
appears	O	O
functionally	B-MPA	O
inactive	B-NegReg	O
with	O	O
a	O	O
disrupted	O	O
pattern	O	O
of	O	O
chromatin	O	O
or	O	O
matrix	O	O
association	O	O
.	O	O
Genet	O	O
Med	O	O
advance	O	O
online	O	O
publication	O	O
02	O	O
February	O	O
2017	O	O
.	O	O
Loss	B-Var	O
of	O	O
Ssq1	B-Gene	O
leads	B-Reg	O
to	O	O
mitochondrial	B-CPA	O
dysfunction	I-CPA	O
,	O	O
activation	B-CPA	O
of	I-CPA	O
autophagy	I-CPA	O
and	O	O
cell	B-CPA	O
cycle	I-CPA	O
arrest	I-CPA	O
due	O	O
to	O	O
iron	B-MPA	O
overload	B-PosReg	O
triggered	O	O
by	O	O
mitochondrial	B-MPA	O
iron	I-MPA	O
-	I-MPA	O
sulfur	I-MPA	O
cluster	I-MPA	O
assembly	I-MPA	O
defects	B-NegReg	O
in	O	O
Candida	O	O
albicans	O	O
.	O	O
Iron	O	O
-	O	O
sulfur	O	O
clusters	O	O
perform	O	O
essential	O	O
functions	O	O
in	O	O
enzymatic	O	O
catalysis	O	O
and	O	O
homeostatic	O	O
regulation	O	O
.	O	O
Here	O	O
we	O	O
for	O	O
the	O	O
first	O	O
time	O	O
identified	O	O
Ssq1	O	O
as	O	O
an	O	O
essential	O	O
component	O	O
for	O	O
iron	O	O
-	O	O
sulfur	O	O
cluster	O	O
assembly	O	O
in	O	O
Candida	O	O
albicans	O	O
.	O	O
Ssq1	O	O
played	O	O
an	O	O
important	O	O
role	O	O
in	O	O
cell	O	O
growth	O	O
.	O	O
Shutting	O	O
off	O	O
SSQ1	O	O
led	O	O
to	O	O
accumulation	O	O
of	O	O
intracellular	O	O
iron	O	O
,	O	O
especially	O	O
in	O	O
mitochondria	O	O
,	O	O
and	O	O
disorder	O	O
of	O	O
intracellular	O	O
iron	O	O
regulation	O	O
.	O	O
In	O	O
tetO	O	O
-	O	O
SSQ1	O	O
,	O	O
iron	O	O
overloading	O	O
triggered	O	O
the	O	O
oxidative	O	O
damage	O	O
of	O	O
mitochondrial	O	O
function	O	O
.	O	O
Surprisingly	O	O
,	O	O
disruption	O	O
of	O	O
SSQ1	O	O
activated	O	O
autophagic	O	O
pathway	O	O
.	O	O
The	O	O
mitochondrial	B-CPA	O
dysfunction	I-CPA	O
was	O	O
further	O	O
aggravated	B-NegReg	O
when	O	O
CCZ1	B-Gene	O
(	O	O
which	O	O
is	O	O
essential	O	O
for	O	O
autophagy	O	O
)	O	O
and	O	O
SSQ1	B-Gene	O
was	O	O
simultaneously	O	O
deleted	B-Var	O
,	O	O
suggesting	O	O
that	O	O
autophagy	O	O
played	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
maintenance	O	O
of	O	O
mitochondrial	O	O
function	O	O
in	O	O
tetO	O	O
-	O	O
SSQ1	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
double	O	O
deletion	B-Var	O
of	O	O
SSQ1	B-Gene	O
and	O	O
CCZ1	B-Gene	O
further	O	O
elevated	B-PosReg	O
cellular	B-MPA	O
iron	I-MPA	O
levels	I-MPA	O
in	O	O
comparison	O	O
with	O	O
tetO	O	O
-	O	O
SSQ1	O	O
,	O	O
indicating	O	O
that	O	O
autophagy	O	O
participated	O	O
in	O	O
maintenance	O	O
of	O	O
iron	O	O
homeostasis	O	O
.	O	O
Furthermore	O	O
,	O	O
we	O	O
found	O	O
that	O	O
loss	B-Var	O
of	O	O
SSQ1	B-Gene	O
led	O	O
to	O	O
increasing	B-PosReg	B-PosReg
protein	B-Protein	O
expression	B-MPA	B-MPA
of	O	O
Rnr1	B-Gene	O
and	O	O
redistribution	B-MPA	O
of	O	O
Rnr2	B-Gene	O
from	O	O
the	O	O
nucleus	O	O
to	O	O
cytoplasm	O	O
,	O	O
and	O	O
further	O	O
resulted	B-Reg	O
in	O	O
cell	B-CPA	O
cycle	I-CPA	O
arrest	I-CPA	O
.	O	O
The	O	O
results	O	O
implied	O	O
that	O	O
cell	O	O
cycle	O	O
arrest	O	O
was	O	O
caused	O	O
by	O	O
activating	O	O
the	O	O
checkpoint	O	O
pathway	O	O
because	O	O
of	O	O
impairing	O	O
the	O	O
iron	O	O
-	O	O
sulfur	O	O
cluster	O	O
assembly	O	O
in	O	O
tetO	O	O
-	O	O
SSQ1	O	O
.	O	O
Shutting	O	O
off	O	O
SSQ1	O	O
led	O	O
to	O	O
a	O	O
significant	O	O
defect	O	O
in	O	O
filamentous	O	O
development	O	O
.	O	O
Interestingly	O	O
,	O	O
the	O	O
tetO	O	O
-	O	O
SSQ1ccz1Δ	O	O
/	O	O
Δ	O	O
growth	O	O
was	O	O
inhibited	O	O
on	O	O
hyphae	O	O
-	O	O
inducing	O	O
solid	O	O
media	O	O
.	O	O
Both	O	O
tetO	O	O
-	O	O
SSQ1	O	O
and	O	O
tetO	O	O
-	O	O
SSQ1ccz1Δ	O	O
/	O	O
Δ	O	O
exhibited	O	O
extremely	O	O
attenuated	O	O
virulence	O	O
,	O	O
indicating	O	O
that	O	O
Ssq1	O	O
might	O	O
provide	O	O
a	O	O
promising	O	O
target	O	O
for	O	O
antifungal	O	O
drugs	O	O
development	O	O
.	O	O
In	O	O
summary	O	O
,	O	O
our	O	O
findings	O	O
provide	O	O
new	O	O
insights	O	O
into	O	O
the	O	O
understanding	O	O
of	O	O
iron	O	O
-	O	O
sulfur	O	O
cluster	O	O
assembly	O	O
-	O	O
related	O	O
gene	O	O
in	O	O
C.	O	O
albicans	O	O
.	O	O
Identification	O	O
of	O	O
TAZ	B-Gene	O
mutations	B-Var	O
in	O	O
pediatric	O	O
patients	O	O
with	B-Reg	O
cardiomyopathy	B-Disease	O
by	O	O
targeted	O	O
next	O	O
-	O	O
generation	O	O
sequencing	O	O
in	O	O
a	O	O
Chinese	O	O
cohort	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Barth	O	O
syndrome	O	O
(	O	O
BTHS	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
disease	O	O
characterized	O	O
by	O	O
cardiomyopathy	O	O
,	O	O
neutropenia	O	O
,	O	O
skeletal	O	O
myopathy	O	O
and	O	O
growth	O	O
delay	O	O
.	O	O
Early	O	O
diagnosis	O	O
and	O	O
appropriate	O	O
treatment	O	O
may	O	O
improve	O	O
the	O	O
prognosis	O	O
of	O	O
this	O	O
disease	O	O
.	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
determine	O	O
the	O	O
role	O	O
of	O	O
targeted	O	O
next	O	O
-	O	O
generation	O	O
sequencing	O	O
(	O	O
NGS	O	O
)	O	O
in	O	O
the	O	O
early	O	O
diagnosis	O	O
of	O	O
BTHS	O	O
in	O	O
children	O	O
with	O	O
cardiomyopathy	O	O
.	O	O
METHODS	O	O
:	O	O
During	O	O
the	O	O
period	O	O
between	O	O
2012	O	O
and	O	O
2015	O	O
,	O	O
a	O	O
gene	O	O
panel	O	O
-	O	O
based	O	O
NGS	O	O
approach	O	O
was	O	O
used	O	O
to	O	O
search	O	O
for	O	O
potentially	O	O
disease	O	O
-	O	O
causing	O	O
genetic	O	O
variants	O	O
in	O	O
all	O	O
patients	O	O
referred	O	O
to	O	O
our	O	O
institution	O	O
with	O	O
a	O	O
clinical	O	O
diagnosis	O	O
of	O	O
primary	O	O
cardiomyopathy	O	O
.	O	O
NGS	O	O
was	O	O
performed	O	O
using	O	O
the	O	O
Illumina	O	O
sequencing	O	O
system	O	O
.	O	O
RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
180	O	O
Chinese	O	O
pediatric	O	O
patients	O	O
(	O	O
114	O	O
males	O	O
and	O	O
66	O	O
females	O	O
)	O	O
diagnosed	O	O
with	O	O
primary	O	O
cardiomyopathy	O	O
were	O	O
enrolled	O	O
in	O	O
this	O	O
study	O	O
.	O	O
TAZ	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
four	O	O
of	O	O
the	O	O
male	O	O
index	O	O
patients	O	O
,	O	O
including	O	O
two	O	O
novel	O	O
mutations	O	O
(	O	O
c.527A	O	O
>	O	O
G	O	O
,	O	O
p	O	O
.	O	O
H176R	O	O
and	O	O
c.134_136delinsCC	O	O
,	O	O
p	O	O
.	O	O
H45PfsX38	O	O
)	O	O
.	O	O
All	O	O
four	O	O
probands	O	O
and	O	O
two	O	O
additional	O	O
affected	O	O
male	O	O
family	O	O
members	O	O
were	O	O
born	O	O
at	O	O
full	O	O
term	O	O
with	O	O
a	O	O
median	O	O
birth	O	O
weight	O	O
of	O	O
2350	O	O
g	O	O
(	O	O
range	O	O
,	O	O
2000	O	O
-	O	O
2850	O	O
g	O	O
)	O	O
.	O	O
The	O	O
median	O	O
age	O	O
at	O	O
diagnosis	O	O
of	O	O
cardiomyopathy	O	O
was	O	O
3.0	O	O
months	O	O
(	O	O
range	O	O
,	O	O
1.0	O	O
-	O	O
20.0	O	O
months	O	O
)	O	O
.	O	O
The	O	O
baseline	O	O
echocardiography	O	O
revealed	O	O
prominent	O	O
dilation	O	O
and	O	O
trabeculations	O	O
of	O	O
the	O	O
left	O	O
ventricle	O	O
with	O	O
impaired	O	O
systolic	O	O
function	O	O
in	O	O
the	O	O
six	O	O
patients	O	O
,	O	O
four	O	O
of	O	O
which	O	O
fulfilled	O	O
the	O	O
diagnostic	O	O
criteria	O	O
of	O	O
left	O	O
ventricular	O	O
noncompaction	O	O
.	O	O
Other	O	O
aspects	O	O
of	O	O
their	O	O
clinical	O	O
presentations	O	O
included	O	O
hypotonia	O	O
(	O	O
6/6	O	O
)	O	O
,	O	O
growth	O	O
delay	O	O
(	O	O
6/6	O	O
)	O	O
,	O	O
neutropenia	O	O
(	O	O
3/6	O	O
)	O	O
and	O	O
3-methylglutaconic	O	O
aciduria	O	O
(	O	O
4/5	O	O
)	O	O
.	O	O
Five	O	O
patients	O	O
died	O	O
at	O	O
a	O	O
median	O	O
age	O	O
of	O	O
7.5	O	O
months	O	O
(	O	O
range	O	O
,	O	O
7.0	O	O
-	O	O
12.0	O	O
months	O	O
)	O	O
.	O	O
The	O	O
cause	O	O
of	O	O
death	O	O
was	O	O
heart	O	O
failure	O	O
associated	O	O
with	O	O
infection	O	O
in	O	O
three	O	O
patients	O	O
and	O	O
cardiac	O	O
arrhythmia	O	O
in	O	O
two	O	O
patients	O	O
.	O	O
The	O	O
remaining	O	O
one	O	O
patient	O	O
survived	O	O
beyond	O	O
infancy	O	O
but	O	O
had	O	O
fallen	O	O
into	O	O
a	O	O
persistent	O	O
vegetative	O	O
state	O	O
after	O	O
suffering	O	O
from	O	O
cardiac	O	O
arrest	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
systematic	O	O
mutation	O	O
screening	O	O
of	O	O
TAZ	O	O
in	O	O
a	O	O
large	O	O
cohort	O	O
of	O	O
pediatric	O	O
patients	O	O
with	O	O
primary	O	O
cardiomyopathy	O	O
using	O	O
the	O	O
NGS	O	O
approach	O	O
.	O	O
TAZ	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
4/114	O	O
(	O	O
3.5	O	O
%	O	O
)	O	O
male	O	O
patients	O	O
with	O	O
primary	O	O
cardiomyopathy	O	O
.	O	O
Our	O	O
findings	O	O
indicate	O	O
that	O	O
the	O	O
inclusion	O	O
of	O	O
TAZ	O	O
gene	O	O
testing	O	O
in	O	O
cardiomyopathy	O	O
genetic	O	O
testing	O	O
panels	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
early	O	O
diagnosis	O	O
of	O	O
BTHS	O	O
.	O	O
Mutations	B-Var	O
in	O	O
DONSON	B-Gene	O
disrupt	B-NegReg	O
replication	B-MPA	O
fork	I-MPA	O
stability	I-MPA	O
and	O	O
cause	B-Reg	O
microcephalic	B-Disease	B-Disease
dwarfism	I-Disease	I-CPA
.	O	O
To	O	O
ensure	O	O
efficient	O	O
genome	O	O
duplication	O	O
,	O	O
cells	O	O
have	O	O
evolved	O	O
numerous	O	O
factors	O	O
that	O	O
promote	O	O
unperturbed	O	O
DNA	O	O
replication	O	O
and	O	O
protect	O	O
,	O	O
repair	O	O
and	O	O
restart	O	O
damaged	O	O
forks	O	O
.	O	O
Here	O	O
we	O	O
identify	O	O
downstream	O	O
neighbor	O	O
of	O	O
SON	O	O
(	O	O
DONSON	O	O
)	O	O
as	O	O
a	O	O
novel	O	O
fork	O	O
protection	O	O
factor	O	O
and	O	O
report	O	O
biallelic	O	O
DONSON	O	O
mutations	O	O
in	O	O
29	O	O
individuals	O	O
with	O	O
microcephalic	O	O
dwarfism	O	O
.	O	O
We	O	O
demonstrate	O	O
that	O	O
DONSON	O	O
is	O	O
a	O	O
replisome	O	O
component	O	O
that	O	O
stabilizes	O	O
forks	O	O
during	O	O
genome	O	O
replication	O	O
.	O	O
Loss	B-Var	O
of	O	O
DONSON	B-Gene	O
leads	B-Reg	O
to	I-Reg	O
severe	O	O
replication	B-MPA	O
-	I-MPA	O
associated	I-MPA	O
DNA	I-MPA	O
damage	I-MPA	O
arising	O	O
from	O	O
nucleolytic	O	O
cleavage	O	O
of	O	O
stalled	O	O
replication	O	O
forks	O	O
.	O	O
Furthermore	O	O
,	O	O
ATM-	B-MPA	O
and	I-MPA	O
Rad3-related	I-MPA	O
(	I-MPA	O
ATR)-dependent	I-MPA	O
signaling	I-MPA	O
in	O	O
response	O	O
to	O	O
replication	O	O
stress	O	O
is	O	O
impaired	B-NegReg	O
in	O	O
DONSON	B-Var	O
-	I-Var	O
deficient	I-Var	O
cells	O	O
,	O	O
resulting	O	O
in	O	O
decreased	B-NegReg	O
checkpoint	B-MPA	O
activity	I-MPA	O
and	O	O
the	O	O
potentiation	B-PosReg	O
of	O	O
chromosomal	B-MPA	O
instability	I-MPA	O
.	O	O
Hypomorphic	B-Var	O
mutations	I-Var	O
in	O	O
DONSON	B-Gene	O
substantially	O	O
reduce	B-NegReg	O
DONSON	B-Gene	O
protein	B-Protein	O
levels	B-MPA	O
and	O	O
impair	B-NegReg	O
fork	B-MPA	O
stability	I-MPA	O
in	O	O
cells	O	O
from	O	O
patients	O	O
,	O	O
consistent	O	O
with	O	O
defective	O	O
DNA	O	O
replication	O	O
underlying	O	O
the	O	O
disease	O	O
phenotype	O	O
.	O	O
In	O	O
summary	O	O
,	O	O
we	O	O
have	O	O
identified	O	O
mutations	B-Var	O
in	O	O
DONSON	B-Gene	O
as	O	O
a	O	O
common	O	O
cause	B-Reg	O
of	O	O
microcephalic	B-Disease	O
dwarfism	I-Disease	O
and	O	O
established	O	O
DONSON	O	O
as	O	O
a	O	O
critical	O	O
replication	O	O
fork	O	O
protein	O	O
required	O	O
for	O	O
mammalian	O	O
DNA	O	O
replication	O	O
and	O	O
genome	O	O
stability	O	O
.	O	O
Phenotypic	O	O
spectrum	O	O
of	O	O
Charcot	B-Disease	O
-	I-Disease	O
Marie	I-Disease	O
-	I-Disease	O
Tooth	I-Disease	O
disease	O	O
due	B-Reg	O
to	I-Reg	O
LITAF	B-Gene	O
/	I-Gene	O
SIMPLE	I-Gene	O
mutations	B-Var	O
:	I-Var	O
a	O	O
study	O	O
of	O	O
18	O	O
patients	O	O
.	O	O
BACKGROUND	O	O
AND	O	O
PURPOSE	O	O
:	O	O
Charcot	B-Disease	O
-	I-Disease	O
Marie	I-Disease	O
-	I-Disease	O
Tooth	I-Disease	O
(	O	O
CMT	O	O
)	O	O
1C	O	O
due	B-Reg	O
to	I-Reg	O
mutations	B-Var	O
in	O	O
LITAF	B-Gene	O
/	I-Gene	O
SIMPLE	I-Gene	O
is	O	O
a	O	O
rare	O	O
subtype	O	O
amongst	O	O
the	O	O
autosomal	O	O
dominant	O	O
demyelinating	O	O
forms	O	O
of	O	O
CMT	O	O
.	O	O
Our	O	O
objective	O	O
was	O	O
to	O	O
report	O	O
the	O	O
clinical	O	O
and	O	O
electrophysiological	O	O
characteristics	O	O
of	O	O
18	O	O
CMT1C	O	O
patients	O	O
and	O	O
compare	O	O
them	O	O
to	O	O
20	O	O
patients	O	O
with	O	O
PMP22	O	O
mutations	O	O
:	O	O
10	O	O
CMT1A	O	O
patients	O	O
and	O	O
10	O	O
patients	O	O
with	O	O
hereditary	O	O
neuropathy	O	O
with	O	O
liability	O	O
to	O	O
pressure	O	O
palsies	O	O
(	O	O
HNPP	O	O
)	O	O
.	O	O
METHODS	O	O
:	O	O
Charcot	O	O
-	O	O
Marie	O	O
-	O	O
Tooth	O	O
1C	O	O
patients	O	O
were	O	O
followed	O	O
-	O	O
up	O	O
in	O	O
referral	O	O
centres	O	O
for	O	O
neuromuscular	O	O
diseases	O	O
or	O	O
were	O	O
identified	O	O
by	O	O
familial	O	O
survey	O	O
.	O	O
All	O	O
CMT1A	O	O
and	O	O
HNPP	O	O
patients	O	O
were	O	O
recruited	O	O
at	O	O
the	O	O
referral	O	O
centre	O	O
for	O	O
neuromuscular	O	O
diseases	O	O
of	O	O
Pitié	O	O
-	O	O
Salpêtrière	O	O
Hospital	O	O
.	O	O
RESULTS	O	O
:	O	O
Two	O	O
phenotypes	O	O
were	O	O
identified	O	O
amongst	O	O
18	O	O
CMT1C	O	O
patients	O	O
:	O	O
the	O	O
classical	O	O
CMT	O	O
form	O	O
(	O	O
'	O	O
CMT	O	O
-	O	O
like	O	O
'	O	O
,	O	O
11	O	O
cases	O	O
)	O	O
and	O	O
a	O	O
predominantly	O	O
sensory	O	O
form	O	O
(	O	O
'	O	O
sensory	O	O
form	O	O
'	O	O
,	O	O
seven	O	O
cases	O	O
)	O	O
.	O	O
The	O	O
mean	O	O
CMT	O	O
neuropathy	O	O
score	O	O
was	O	O
4.45	O	O
in	O	O
CMT1C	O	O
patients	O	O
.	O	O
Motor	O	O
nerve	O	O
conduction	O	O
velocities	O	O
in	O	O
the	O	O
upper	O	O
limbs	O	O
were	O	O
significantly	O	O
more	O	O
reduced	O	O
in	O	O
CMT1A	O	O
than	O	O
in	O	O
CMT1C	O	O
patients	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
motor	O	O
nerve	O	O
conduction	O	O
velocity	O	O
of	O	O
the	O	O
median	O	O
nerve	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
CMT1C	O	O
compared	O	O
to	O	O
the	O	O
HNPP	O	O
group	O	O
.	O	O
Distal	O	O
motor	O	O
latency	O	O
was	O	O
significantly	O	O
more	O	O
prolonged	O	O
in	O	O
CMT1A	O	O
patients	O	O
compared	O	O
to	O	O
the	O	O
CMT1C	O	O
and	O	O
HNPP	O	O
groups	O	O
,	O	O
the	O	O
latter	O	O
two	O	O
groups	O	O
having	O	O
similar	O	O
distal	O	O
motor	O	O
latency	O	O
values	O	O
.	O	O
Molecular	O	O
analysis	O	O
revealed	O	O
five	O	O
new	O	O
LITAF	O	O
/	O	O
SIMPLE	O	O
mutations	O	O
(	O	O
Ala111Thr	O	O
,	O	O
Gly112Ala	O	O
,	O	O
Trp116Arg	O	O
,	O	O
Pro135Leu	O	O
,	O	O
Arg160Cys	O	O
)	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Our	O	O
study	O	O
delineates	O	O
CMT1C	O	O
as	O	O
mostly	O	O
a	O	O
mild	O	O
form	O	O
of	O	O
neuropathy	O	O
,	O	O
and	O	O
gives	O	O
clinical	O	O
and	O	O
electrophysiological	O	O
clues	O	O
differentiating	O	O
CMT1C	O	O
from	O	O
CMT1A	O	O
and	O	O
HNPP	O	O
.	O	O
Delineating	O	O
phenotypes	O	O
in	O	O
CMT	O	O
subtypes	O	O
is	O	O
important	O	O
to	O	O
orient	O	O
molecular	O	O
diagnosis	O	O
and	O	O
to	O	O
help	O	O
to	O	O
interpret	O	O
complex	O	O
molecular	O	O
findings	O	O
.	O	O
A	O	O
Novel	O	O
Homozygous	O	O
Missense	O	O
Mutation	B-Var	O
in	O	O
HOXC13	B-Gene	O
Leads	B-Reg	O
to	I-Reg	O
Autosomal	O	O
Recessive	O	O
Pure	B-Disease	O
Hair	I-Disease	O
and	I-Disease	O
Nail	I-Disease	O
Ectodermal	I-Disease	B-Disease
Dysplasia	I-Disease	I-Disease
.	O	O
Pure	O	O
hair	O	O
and	O	O
nail	O	O
ectodermal	O	O
dysplasia	O	O
(	O	O
PHNED	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
disorder	O	O
that	O	O
presents	O	O
with	O	O
hypotrichosis	O	O
and	O	O
nail	O	O
dystrophy	O	O
while	O	O
sparing	O	O
other	O	O
ectodermal	O	O
structures	O	O
such	O	O
as	O	O
teeth	O	O
and	O	O
sweat	O	O
glands	O	O
.	O	O
We	O	O
describe	O	O
a	O	O
homozygous	O	O
novel	O	O
missense	O	O
mutation	B-Var	O
in	O	O
the	O	O
HOXC13	B-Gene	O
gene	O	O
that	O	O
resulted	B-Reg	O
in	I-Reg	O
autosomal	O	O
recessive	O	O
PHNED	B-Disease	O
in	O	O
a	O	O
Hispanic	O	O
child	O	O
.	O	O
The	O	O
mutation	O	B-Var
c.812A	O	I-Var
>	O	I-Var
G	O	I-Var
(	O	O
p	O	O
.	O	O
Gln271Arg	O	O
)	O	O
is	O	O
located	O	O
within	O	O
the	O	O
DNA	O	O
-	O	O
binding	O	O
domain	O	O
of	O	O
the	O	O
HOXC13	O	O
gene	O	O
,	O	O
cosegregates	O	O
within	O	O
the	O	O
family	O	O
,	O	O
and	O	O
is	O	O
predicted	O	O
to	O	O
be	O	O
maximally	O	O
damaging	O	O
.	O	O
This	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
a	O	O
missense	O	O
HOXC13	B-Gene	O
mutation	B-Var	O
resulting	B-Reg	O
in	I-Reg	O
PHNED	B-Disease	O
and	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
PHNED	O	O
identified	O	O
in	O	O
a	O	O
North	O	O
American	O	O
family	O	O
.	O	O
Our	O	O
findings	O	O
illustrate	O	O
the	O	O
critical	O	O
role	O	O
of	O	O
HOXC13	O	O
in	O	O
human	O	O
hair	O	O
and	O	O
nail	O	O
development	O	O
.	O	O
SERPINC1	B-Gene	O
gene	O	O
mutations	B-Var	O
in	B-Reg	O
antithrombin	B-Disease	O
deficiency	I-Disease	O
.	O	O
Existing	O	O
evidence	O	O
suggests	O	O
that	O	O
in	O	O
most	O	O
cases	O	O
antithrombin	B-Disease	O
deficiency	I-Disease	O
can	O	O
be	O	O
explained	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
its	O	O
gene	O	O
,	O	O
SERPINC1	B-Gene	O
.	O	O
We	O	O
investigated	O	O
the	O	O
molecular	O	O
background	O	O
of	O	O
antithrombin	O	O
deficiency	O	O
in	O	O
a	O	O
single	O	O
centre	O	O
family	O	O
cohort	O	O
study	O	O
.	O	O
We	O	O
included	O	O
a	O	O
total	O	O
of	O	O
21	O	O
families	O	O
comprising	O	O
15	O	O
original	O	O
probands	O	O
and	O	O
sixty	O	O
-	O	O
six	O	O
relatives	O	O
,	O	O
6	O	O
of	O	O
who	O	O
were	O	O
surrogate	O	O
probands	O	O
for	O	O
the	O	O
genetic	O	O
analysis	O	O
.	O	O
Antithrombin	O	O
activity	O	O
and	O	O
antigen	O	O
levels	O	O
were	O	O
measured	O	O
.	O	O
The	O	O
heparin	O	O
-	O	O
antithrombin	O	O
binding	O	O
ratio	O	O
assay	O	O
was	O	O
used	O	O
to	O	O
distinguish	O	O
between	O	O
the	O	O
different	O	O
subtypes	O	O
of	O	O
type	O	O
II	O	O
antithrombin	O	O
deficiency	O	O
.	O	O
SERPINC1	O	O
mutations	O	O
were	O	O
detected	O	O
by	O	O
direct	O	O
sequencing	O	O
of	O	O
all	O	O
7	O	O
exons	O	O
and	O	O
regulatory	O	O
regions	O	O
,	O	O
and	O	O
multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
.	O	O
Eighty	O	O
-	O	O
six	O	O
per	O	O
cent	O	O
of	O	O
the	O	O
families	O	O
had	O	O
a	O	O
detrimental	O	O
SERPINC1	O	O
gene	O	O
mutation	O	O
that	O	O
segregated	O	O
in	O	O
the	O	O
family	O	O
.	O	O
We	O	O
detected	O	O
13	O	O
different	O	O
SERPINC1	O	O
gene	O	O
mutations	O	O
of	O	O
which	O	O
5	O	O
were	O	O
novel	O	O
.	O	O
Among	O	O
all	O	O
these	O	O
mutations	O	O
,	O	O
44	O	O
%	O	O
was	O	O
associated	O	O
with	O	O
type	O	O
I	O	O
deficiency	O	O
,	O	O
whereas	O	O
the	O	O
remainder	O	O
was	O	O
associated	O	O
with	O	O
type	O	O
II	O	O
heparin	O	O
binding	O	O
site	O	O
(	O	O
11	O	O
%	O	O
)	O	O
,	O	O
type	O	O
II	O	O
pleiotropic	O	O
effect	O	O
(	O	O
33	O	O
%	O	O
)	O	O
,	O	O
type	O	O
II	O	O
reactive	O	O
site	O	O
(	O	O
6	O	O
%	O	O
)	O	O
or	O	O
had	O	O
the	O	O
antithrombin	O	O
Cambridge	O	O
II	O	O
mutation	O	O
(	O	O
6	O	O
%	O	O
)	O	O
.	O	O
The	O	O
current	O	O
study	O	O
reports	O	O
several	O	O
novel	O	O
SERPINC1	O	O
mutations	O	O
,	O	O
thereby	O	O
adding	O	O
to	O	O
our	O	O
knowledge	O	O
of	O	O
the	O	O
molecular	O	O
background	O	O
of	O	O
antithrombin	O	O
deficiency	O	O
.	O	O
Finally	O	O
,	O	O
our	O	O
results	O	O
point	O	O
out	O	O
the	O	O
importance	O	O
of	O	O
future	O	O
research	O	O
outside	O	O
the	O	O
conventional	O	O
SERPINC1	O	O
gene	O	O
approach	O	O
.	O	O
Control	O	O
of	O	O
Kir	O	O
channel	O	O
gating	O	O
by	O	O
cytoplasmic	O	O
domain	O	O
interface	O	O
interactions	O	O
.	O	O
Inward	O	O
rectifier	O	O
potassium	O	O
(	O	O
Kir	O	O
)	O	O
channels	O	O
are	O	O
expressed	O	O
in	O	O
almost	O	O
all	O	O
mammalian	O	O
tissues	O	O
and	O	O
play	O	O
critical	O	O
roles	O	O
in	O	O
the	O	O
control	O	O
of	O	O
excitability	O	O
.	O	O
Pancreatic	O	O
ATP	O	O
-	O	O
sensitive	O	O
K	O	O
(	O	O
KATP	O	O
)	O	O
channels	O	O
are	O	O
key	O	O
regulators	O	O
of	O	O
insulin	O	O
secretion	O	O
and	O	O
comprise	O	O
Kir6.2	O	O
subunits	O	O
coupled	O	O
to	O	O
sulfonylurea	O	O
receptors	O	O
.	O	O
Because	O	O
these	O	O
channels	O	O
are	O	O
reversibly	O	O
inhibited	O	O
by	O	O
cytoplasmic	O	O
ATP	O	O
,	O	O
they	O	O
link	O	O
cellular	O	O
metabolism	O	O
with	O	O
membrane	O	O
excitability	O	O
.	O	O
Loss	B-NegReg	B-NegReg
-	I-NegReg	I-NegReg
of	I-NegReg	I-NegReg
-	I-NegReg	I-NegReg
function	I-NegReg	I-NegReg
mutations	B-Var	B-Var
in	O	O
the	O	O
pore	O	O
-	O	O
forming	O	O
Kir6.2	B-Gene	O
subunit	O	B-Gene
cause	O	O
congenital	B-Disease	B-CPA
hyperinsulinism	I-Disease	O
as	O	O
a	O	O
result	O	O
of	O	O
diminished	B-NegReg	O
channel	B-MPA	B-CPA
activity	I-MPA	I-CPA
.	O	O
Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
several	O	O
disease	O	O
mutations	B-Var	O
,	O	O
which	O	O
disrupt	B-NegReg	O
intersubunit	B-CPA	O
salt	I-CPA	O
bridges	I-CPA	O
at	O	O
the	O	O
interface	O	O
of	O	O
the	O	O
cytoplasmic	O	O
domains	O	O
(	O	O
CD	O	O
-	O	O
I	O	O
)	O	O
of	O	O
adjacent	O	O
subunits	O	O
,	O	O
induce	O	O
loss	B-NegReg	O
of	O	O
channel	B-MPA	O
activity	I-MPA	O
via	O	O
a	O	O
novel	O	O
channel	O	O
behavior	O	O
:	O	O
after	O	O
ATP	O	O
removal	O	O
,	O	O
channels	O	O
open	O	O
but	O	O
then	O	O
rapidly	O	O
inactivate	O	O
.	O	O
Re	O	O
-	O	O
exposure	O	O
to	O	O
inhibitory	O	O
ATP	O	O
causes	O	O
recovery	O	O
from	O	O
this	O	O
inactivation	O	O
.	O	O
Inactivation	O	O
can	O	O
be	O	O
abolished	O	O
by	O	O
application	O	O
of	O	O
phosphatidylinositol-4,5-bisphosphate	O	O
(	O	O
PIP2	O	O
)	O	O
to	O	O
the	O	O
cytoplasmic	O	O
face	O	O
of	O	O
the	O	O
membrane	O	O
,	O	O
an	O	O
effect	O	O
that	O	O
can	O	O
be	O	O
explained	O	O
by	O	O
a	O	O
simple	O	O
kinetic	O	O
model	O	O
in	O	O
which	O	O
PIP2	O	O
binding	O	O
competes	O	O
with	O	O
the	O	O
inactivation	O	O
process	O	O
.	O	O
Kir2.1	O	O
channels	O	O
contain	O	O
homologous	O	O
salt	O	O
bridges	O	O
,	O	O
and	O	O
we	O	O
find	O	O
that	O	O
mutations	O	O
that	O	O
disrupt	O	O
CD	O	O
-	O	O
I	O	O
interactions	O	O
in	O	O
Kir2.1	O	O
also	O	O
reduce	O	B-NegReg
channel	O	B-MPA
activity	O	I-MPA
and	O	O
PIP2	O	O
sensitivity	O	B-CPA
.	O	O
Kir2.1	O	O
channels	O	O
also	O	O
contain	O	O
an	O	O
additional	O	O
CD	O	O
-	O	O
I	O	O
salt	O	O
bridge	O	O
that	O	O
is	O	O
not	O	O
present	O	O
in	O	O
Kir6.2	O	O
channels	O	O
.	O	O
Introduction	O	O
of	O	O
this	O	O
salt	O	O
bridge	O	O
into	O	O
Kir6.2	O	O
partially	O	O
rescues	O	O
inactivating	O	O
mutants	O	O
from	O	O
the	O	O
phenotype	O	O
.	O	O
These	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
stability	O	O
of	O	O
the	O	O
intersubunit	O	O
CD	O	O
-	O	O
I	O	O
is	O	O
a	O	O
major	O	O
determinant	O	O
of	O	O
the	O	O
inactivation	O	O
process	O	O
in	O	O
Kir6.2	O	O
and	O	O
may	O	O
control	O	O
gating	O	O
in	O	O
other	O	O
Kir	O	O
channels	O	O
.	O	O
Patient	O	O
-	O	O
specific	O	O
induced	O	O
pluripotent	O	O
stem	O	O
cells	O	O
to	O	O
evaluate	O	O
the	O	O
pathophysiology	O	O
of	O	O
TRNT1-associated	O	O
Retinitis	O	O
pigmentosa	O	O
.	O	O
Retinitis	B-Disease	O
pigmentosa	I-Disease	O
(	O	O
RP	O	O
)	O	O
is	O	O
a	O	O
heterogeneous	O	O
group	O	O
of	O	O
monogenic	O	O
disorders	O	O
characterized	O	O
by	O	O
progressive	O	O
death	O	O
of	O	O
the	O	O
light	O	O
-	O	O
sensing	O	O
photoreceptor	O	O
cells	O	O
of	O	O
the	O	O
outer	O	O
neural	O	O
retina	O	O
.	O	O
We	O	O
recently	O	O
identified	O	O
novel	O	O
hypomorphic	O	O
mutations	B-Var	O
in	O	O
the	O	O
tRNA	O	O
Nucleotidyl	O	O
Transferase	O	O
,	O	O
CCA	O	O
-	O	O
Adding	O	O
1	O	O
(	B-Gene	O
TRNT1	I-Gene	O
)	I-Gene	O
gene	O	O
that	O	O
cause	B-Reg	O
early	O	O
-	O	O
onset	O	O
RP	B-Disease	O
.	O	O
To	O	O
model	O	O
this	O	O
disease	O	O
in	O	O
vitro	O	O
,	O	O
we	O	O
generated	O	O
patient	O	O
-	O	O
specific	O	O
iPSCs	O	O
and	O	O
iPSC	O	O
-	O	O
derived	O	O
retinal	O	O
organoids	O	O
from	O	O
dermal	O	O
fibroblasts	O	O
of	O	O
patients	O	O
with	O	O
molecularly	O	O
confirmed	O	O
TRNT1-associated	O	O
RP	O	O
.	O	O
Pluripotency	O	O
was	O	O
confirmed	O	O
using	O	O
rt	O	O
-	O	O
PCR	O	O
,	O	O
immunocytochemistry	O	O
,	O	O
and	O	O
a	O	O
TaqMan	O	O
Scorecard	O	O
Assay	O	O
.	O	O
Mutations	B-Var	B-Var
in	O	O
TRNT1	B-Gene	O
caused	O	O
reduced	B-NegReg	O
levels	B-MPA	O
of	I-MPA	O
full	I-MPA	O
-	I-MPA	O
length	I-MPA	O
TRNT1	B-Gene	O
protein	B-Protein	O
and	O	O
expression	B-MPA	O
of	I-MPA	O
a	I-MPA	O
truncated	I-MPA	O
smaller	I-MPA	O
protein	B-Protein	O
in	O	O
both	O	O
patient	O	O
-	O	O
specific	O	O
iPSCs	O	O
and	O	O
iPSC	O	O
-	O	O
derived	O	O
retinal	O	O
organoids	O	O
.	O	O
Patient	O	O
-	O	O
specific	O	O
iPSCs	O	O
and	O	O
iPSC	O	O
-	O	O
derived	O	O
retinal	O	O
organoids	O	O
exhibited	O	O
a	O	O
deficit	O	O
in	O	O
autophagy	O	O
,	O	O
as	O	O
evidenced	O	O
by	O	O
aberrant	O	O
accumulation	O	O
of	O	O
LC3-II	O	O
and	O	O
elevated	O	O
levels	O	O
of	O	O
oxidative	O	O
stress	O	O
.	O	O
Autologous	O	O
stem	O	O
cell	O	O
-	O	O
based	O	O
disease	O	O
modeling	O	O
will	O	O
provide	O	O
a	O	O
platform	O	O
for	O	O
testing	O	O
multiple	O	O
avenues	O	O
of	O	O
treatment	O	O
in	O	O
patients	O	O
suffering	O	O
from	O	O
TRNT1-associated	O	O
RP	O	O
.	O	O
Gain	B-Var	O
-	I-Var	O
of	I-Var	O
-	I-Var	O
function	I-Var	O
p53	B-Gene	O
activates	B-PosReg	O
multiple	O	O
signaling	B-Pathway	O
pathways	I-Pathway	O
to	O	O
induce	B-PosReg	O
oncogenicity	B-CPA	B-Disease
in	O	O
lung	B-Disease	B-Disease
cancer	I-Disease	I-Disease
cells	O	O
.	O	O
Gain	B-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
function	I-PosReg	O
(	O	O
GOF	O	O
)	O	O
mutants	B-Var	O
of	O	O
p53	B-Gene	O
upregulate	B-PosReg	O
genes	B-Gene	O
implicated	B-Reg	O
in	O	O
cell	B-CPA	B-CPA
proliferation	I-CPA	I-CPA
and	O	O
oncogenesis	B-CPA	O
.	O	O
Here	O	O
,	O	O
we	O	O
report	O	O
that	O	O
GOF	B-Var	O
p53	B-Gene	O
induces	O	O
tumorigenicity	O	O
through	O	O
simultaneous	O	O
activation	B-PosReg	O
of	O	O
key	B-Pathway	O
oncogenic	I-Pathway	O
pathways	I-Pathway	O
including	O	O
those	O	O
controlling	O	O
putative	O	O
tumor	O	O
-	O	O
initiating	O	O
cell	O	O
functions	O	O
.	O	O
We	O	O
determined	O	O
that	O	O
in	O	O
cells	O	O
expressing	O	O
p53-R273H	B-Var	O
,	O	O
GOF	O	O
p53	O	O
simultaneously	O	O
upregulates	B-PosReg	O
genes	O	O
from	O	O
multiple	B-Pathway	O
signaling	I-Pathway	O
pathways	I-Pathway	O
by	O	O
recognizing	O	O
promoters	O	O
containing	O	O
distinct	O	O
transcription	O	O
factor	O	O
(	O	O
TF	O	O
)	O	O
binding	O	O
sites	O	O
.	O	O
Our	O	O
analytical	O	O
data	O	O
support	O	O
a	O	O
model	O	O
in	O	O
which	O	O
GOF	B-Var	O
p53	B-Gene	O
complexes	O	O
with	O	O
two	O	O
TFs	O	O
on	O	O
the	O	O
promoter	O	O
-	O	O
a	O	O
mediator	O	O
protein	O	O
,	O	O
Med17	O	O
,	O	O
and	O	O
a	O	O
histone	O	O
acetyl	O	O
transferase	O	O
,	O	O
activating	B-PosReg	O
histone	B-MPA	O
acetylation	I-MPA	O
-	I-MPA	O
and	I-MPA	O
enhances	B-PosReg	O
gene	B-MPA	O
expression	I-MPA	O
to	O	O
signal	O	O
cell	O	O
proliferation	O	O
and	O	O
oncogenesis	O	O
.	O	O
Thus	O	O
,	O	O
therapeutic	O	O
inhibition	O	O
of	O	O
one	O	O
GOF	O	O
p53-induced	O	O
pathway	O	O
would	O	O
be	O	O
insufficient	O	O
to	O	O
prevent	O	O
tumor	O	O
growth	O	O
as	O	O
the	O	O
oncoprotein	O	O
activates	O	O
a	O	O
multitude	O	O
of	O	O
parallel	O	O
pathways	O	O
.	O	O
This	O	O
discovery	O	O
suggests	O	O
enormous	O	O
selection	O	O
advantage	O	O
for	O	O
cancer	O	O
cells	O	O
with	O	O
GOF	O	O
p53	O	O
to	O	O
induce	O	O
oncogenic	O	O
growth	O	O
,	O	O
highlighting	O	O
the	O	O
problems	O	O
of	O	O
cancer	O	O
therapy	O	O
.	O	O
Hand	O	O
eczema	O	O
,	O	O
atopic	O	O
dermatitis	O	O
and	O	O
filaggrin	O	O
mutations	O	O
in	O	O
adult	O	O
Danes	O	O
:	O	O
a	O	O
registry	O	O
-	O	O
based	O	O
study	O	O
assessing	O	O
risk	O	O
of	O	O
disability	O	O
pension	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Atopic	O	O
dermatitis	O	O
and	O	O
hand	O	O
eczema	O	O
often	O	O
impair	O	O
the	O	O
ability	O	O
of	O	O
people	O	O
to	O	O
work	O	O
.	O	O
Only	O	O
a	O	O
few	O	O
studies	O	O
have	O	O
investigated	O	O
whether	O	O
individuals	O	O
with	O	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
filaggrin	O	O
gene	O	O
(	B-Gene	O
FLG	I-Gene	O
)	I-Gene	O
mutations	B-Var	O
,	O	O
who	O	O
often	O	O
have	O	O
severe	O	O
and	O	O
early	O	O
onset	O	O
of	O	O
dermatitis	B-Disease	O
,	O	O
experience	O	O
occupational	O	O
consequences	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
investigate	O	O
the	O	O
personal	O	O
consequences	O	O
of	O	O
having	O	O
atopic	O	O
dermatitis	O	O
and/or	O	O
hand	O	O
eczema	O	O
and	O	O
FLG	O	O
mutations	O	O
.	O	O
METHOD	O	O
:	O	O
Adult	O	O
Danes	O	O
from	O	O
the	O	O
general	O	O
population	O	O
(	O	O
n	O	O
=	O	O
3247	O	O
)	O	O
and	O	O
patients	O	O
with	O	O
atopic	O	O
dermatitis	O	O
and/or	O	O
hand	O	O
eczema	O	O
(	O	O
n	O	O
=	O	O
496	O	O
)	O	O
were	O	O
genotyped	O	O
for	O	O
common	O	O
FLG	O	O
mutations	O	O
,	O	O
and	O	O
completed	O	O
a	O	O
questionnaire	O	O
about	O	O
skin	O	O
symptoms	O	O
and	O	O
hand	O	O
eczema	O	O
.	O	O
Socioeconomic	O	O
variables	O	O
,	O	O
including	O	O
disability	O	O
pension	O	O
,	O	O
and	O	O
information	O	O
on	O	O
work	O	O
in	O	O
risk	O	O
occupations	O	O
were	O	O
retrieved	O	O
from	O	O
national	O	O
registries	O	O
.	O	O
The	O	O
reasons	O	O
for	O	O
granting	O	O
disability	O	O
pension	O	O
were	O	O
unknown	O	O
.	O	O
RESULTS	O	O
:	O	O
Disability	O	O
pension	O	O
was	O	O
associated	O	O
with	O	O
hand	O	O
eczema	O	O
in	O	O
the	O	O
general	O	O
population	O	O
,	O	O
especially	O	O
among	O	O
individuals	O	O
with	O	O
a	O	O
history	O	O
of	O	O
atopic	O	O
dermatitis	O	O
.	O	O
Moreover	O	O
,	O	O
self	O	O
-	O	O
reported	O	O
hand	O	O
eczema	O	O
and	O	O
atopic	O	O
dermatitis	O	O
were	O	O
associated	O	O
with	O	O
particularly	O	O
high	O	O
risk	O	O
of	O	O
disability	O	O
pension	O	O
among	O	O
FLG	O	O
mutation	O	O
carriers	O	O
[	O	O
odds	O	O
ratio	O	O
(	O	O
OR	O	O
)	O	O
4.02	O	O
and	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
:	O	O
1.15	O	O
-	O	O
14.11	O	O
;	O	O
and	O	O
OR	O	O
6.01	O	O
and	O	O
95%CI	O	O
:	O	O
2.37	O	O
-	O	O
15.34	O	O
,	O	O
respectively	O	O
]	O	O
.	O	O
Furthermore	O	O
,	O	O
60	O	O
%	O	O
of	O	O
the	O	O
FLG	O	O
mutation	O	O
carriers	O	O
with	O	O
atopic	O	O
dermatitis	O	O
who	O	O
developed	O	O
hand	O	O
eczema	O	O
had	O	O
experienced	O	O
symptoms	O	O
before	O	O
adulthood	O	O
.	O	O
CONCLUSION	O	O
:	O	O
In	O	O
the	O	O
general	O	O
population	O	O
,	O	O
self	O	O
-	O	O
reported	O	O
hand	O	O
eczema	O	O
and	O	O
atopic	O	O
dermatitis	O	O
,	O	O
particularly	O	O
in	O	O
individuals	O	O
with	O	O
a	O	O
genetically	O	O
impaired	O	O
skin	O	O
barrier	O	O
,	O	O
were	O	O
associated	O	O
with	O	O
disability	O	O
pension	O	O
,	O	O
suggesting	O	O
that	O	O
FLG	B-Gene	O
mutations	B-Var	O
carriers	B-Reg	O
with	I-Reg	O
a	O	O
history	O	O
of	O	O
atopic	B-Disease	O
dermatitis	I-Disease	O
and	O	O
hand	B-Disease	O
eczema	I-Disease	O
could	O	O
benefit	O	O
from	O	O
early	O	O
attention	O	O
with	O	O
respect	O	O
to	O	O
choice	O	O
of	O	O
occupation	O	O
.	O	O
ATM	O	O
Gene	O	O
Mutation	O	O
Detection	O	O
Techniques	O	O
and	O	O
Functional	O	O
Analysis	O	O
.	O	O
Ataxia	B-Disease	O
Telangiectasia	I-Disease	O
(	O	O
A	O	O
-	O	O
T	O	O
)	O	O
is	O	O
caused	O	O
by	O	O
biallelic	O	O
inactivation	B-NegReg	O
of	O	O
the	O	O
Ataxia	O	O
Telangiectasia	O	O
Mutated	O	O
(	B-Gene	O
ATM	I-Gene	O
)	I-Gene	O
gene	O	O
,	O	O
due	O	O
to	O	O
nonsense	B-Var	O
or	I-Var	O
missense	I-Var	O
mutations	I-Var	O
,	O	O
small	O	O
insertions	O	O
/	O	O
deletions	O	O
(	B-Var	O
indels	I-Var	O
)	I-Var	O
,	O	O
splicing	B-Var	O
alterations	I-Var	O
,	O	O
and	O	O
large	B-Var	O
genomic	I-Var	O
rearrangements	I-Var	O
.	O	O
After	O	O
establishing	O	O
A	O	O
-	O	O
T	O	O
clinical	O	O
diagnosis	O	O
,	O	O
a	O	O
molecular	O	O
confirmation	O	O
is	O	O
needed	O	O
,	O	O
based	O	O
on	O	O
the	O	O
detection	O	O
of	O	O
one	O	O
of	O	O
these	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutations	O	O
in	O	O
at	O	O
least	O	O
one	O	O
allele	O	O
.	O	O
In	O	O
most	O	O
cases	O	O
,	O	O
the	O	O
pathogenicity	O	O
of	O	O
the	O	O
detected	O	O
mutations	O	O
is	O	O
sufficient	O	O
to	O	O
make	O	O
a	O	O
definitive	O	O
diagnosis	O	O
.	O	O
More	O	O
rarely	O	O
,	O	O
mutations	O	O
of	O	O
unknown	O	O
consequences	O	O
are	O	O
identified	O	O
and	O	O
direct	O	O
biological	O	O
analyses	O	O
are	O	O
required	O	O
to	O	O
establish	O	O
their	O	O
pathogenic	O	O
characters	O	O
.	O	O
In	O	O
such	O	O
cases	O	O
,	O	O
complementary	O	O
analyses	O	O
of	O	O
ATM	O	O
expression	O	B-MPA
,	O	O
localization	O	O
,	O	O
and	O	O
activity	O	O
allow	O	O
fine	O	O
characterization	O	O
of	O	O
these	O	O
mutations	O	O
and	O	O
facilitate	O	O
A	O	O
-	O	O
T	O	O
diagnosis	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
present	O	O
genetic	O	O
and	O	O
biochemical	O	O
protocols	O	O
currently	O	O
used	O	O
in	O	O
the	O	O
laboratory	O	O
that	O	O
have	O	O
proven	O	O
to	O	O
be	O	O
highly	O	O
accurate	O	O
,	O	O
reproducible	O	O
,	O	O
and	O	O
quantitative	O	O
.	O	O
We	O	O
also	O	O
provide	O	O
additional	O	O
discussion	O	O
on	O	O
the	O	O
critical	O	O
points	O	O
of	O	O
the	O	O
techniques	O	O
presented	O	O
here	O	O
.	O	O
Truncating	O	O
mutations	O	O
in	O	O
SPAST	O	O
patients	O	O
are	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
rate	O	O
of	O	O
psychiatric	O	O
comorbidities	O	O
in	O	O
hereditary	O	O
spastic	O	O
paraplegia	O	O
.	O	O
BACKGROUND	O	O
:	O	O
The	O	O
hereditary	B-Disease	O
spastic	I-Disease	O
paraplegias	I-Disease	O
(	O	O
HSPs	O	O
)	O	O
are	O	O
a	O	O
rare	O	O
and	O	O
heterogeneous	O	O
group	O	O
of	O	O
neurodegenerative	O	O
disorders	O	O
that	O	O
are	O	O
clinically	O	O
characterised	O	O
by	O	O
progressive	O	O
lower	O	O
limb	O	O
spasticity	O	O
.	O	O
They	O	O
are	O	O
classified	O	O
as	O	O
either	O	O
'	O	O
pure	O	O
'	O	O
or	O	O
'	O	O
complex	O	O
'	O	O
where	O	O
spastic	O	O
paraplegia	O	O
is	O	O
complicated	O	O
with	O	O
additional	O	O
neurological	O	O
features	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
spastin	O	O
gene	O	O
(	B-Gene	O
SPAST	I-Gene	O
)	I-Gene	O
are	O	O
the	O	O
most	O	O
common	O	O
cause	B-Reg	O
of	O	O
HSP	B-Disease	O
and	O	O
typically	O	O
present	O	O
with	O	O
a	O	O
pure	O	O
form	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
assessed	O	O
in	O	O
detail	O	O
the	O	O
phenotypic	O	O
and	O	O
genetic	O	O
spectrum	O	O
of	O	O
SPAST	O	O
-	O	O
related	O	O
HSP	O	O
focused	O	O
on	O	O
118	O	O
patients	O	O
carrying	O	O
SPAST	O	O
mutations	O	O
.	O	O
RESULTS	O	O
:	O	O
This	O	O
study	O	O
,	O	O
one	O	O
of	O	O
the	O	O
largest	O	O
cohorts	O	O
of	O	O
genetically	O	O
confirmed	O	O
spastin	O	O
patients	O	O
to	O	O
date	O	O
,	O	O
contributes	O	O
with	O	O
the	O	O
discovery	O	O
of	O	O
a	O	O
significant	O	O
number	O	O
of	O	O
novel	O	O
SPAST	O	O
mutations	O	O
.	O	O
Our	O	O
data	O	O
reveal	O	O
a	O	O
high	O	O
rate	O	O
of	O	O
complex	O	O
cases	O	O
(	O	O
25	O	O
%	O	O
)	O	O
,	O	O
with	O	O
psychiatric	O	O
disorders	O	O
among	O	O
the	O	O
most	O	O
common	O	O
comorbidity	O	O
(	O	O
10	O	O
%	O	O
of	O	O
all	O	O
SPASTpatients	O	O
)	O	O
.	O	O
Further	O	O
,	O	O
we	O	O
identify	O	O
a	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
between	O	O
patients	O	O
carrying	O	O
loss	B-NegReg	O
-	I-NegReg	O
of	I-NegReg	O
-	I-NegReg	O
function	I-NegReg	O
mutations	B-Var	O
in	O	O
SPAST	B-Gene	O
and	O	O
the	O	O
presence	O	O
of	O	O
psychiatric	B-Disease	O
disorders	I-Disease	O
.	O	O
R202Q	B-Var	O
/	I-Var	O
M694V	I-Var	O
as	O	O
novel	O	O
MEFV	B-Gene	O
gene	O	O
mutations	O	O
in	B-Reg	O
chronic	B-Disease	O
periodontitis	I-Disease	O
and	O	O
familial	B-Disease	O
Mediterranean	I-Disease	O
fever	I-Disease	O
.	O	O
BACKGROUND	O	O
AND	O	O
OBJECTIVE	O	O
:	O	O
Familial	O	O
Mediterranean	O	O
fever	O	O
(	O	O
FMF	O	O
)	O	O
and	O	O
chronic	O	O
periodontitis	O	O
are	O	O
inflammatory	O	O
diseases	O	O
leading	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
inflammasomes	O	O
.	O	O
To	O	O
date	O	O
,	O	O
no	O	O
published	O	O
studies	O	O
have	O	O
reported	O	O
on	O	O
mutations	O	O
in	O	O
the	O	O
Mediterranean	O	O
fever	O	O
(	O	O
MEFV	O	O
)	O	O
gene	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
periodontitis	O	O
,	O	O
although	O	O
the	O	O
roles	B-Reg	O
of	O	O
MEFV	B-Gene	O
gene	O	O
mutations	B-Var	O
in	O	O
FMF	B-Disease	O
and	O	O
FMF	B-Disease	O
-	I-Disease	O
associated	I-Disease	O
amyloidosis	I-Disease	O
(	O	O
FMF	O	O
-	O	O
A	O	O
)	O	O
are	O	O
well	O	O
known	O	O
.	O	O
Therefore	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
frequencies	O	O
of	O	O
MEFV	O	O
gene	O	O
mutations	O	O
and	O	O
serum	O	O
amyloid	O	O
A	O	O
(	O	O
SAA	O	O
)	O	O
and	O	O
high	O	O
-	O	O
sensitivity	O	O
C	O	O
-	O	O
reactive	O	O
protein	O	O
(	O	O
hs	O	O
-	O	O
CRP	O	O
)	O	O
levels	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
periodontitis	O	O
,	O	O
FMF	O	O
and	O	O
FMF	O	O
-	O	O
A.	O	O
MATERIAL	O	O
AND	O	O
METHODS	O	O
:	O	O
The	O	O
study	O	O
population	O	O
included	O	O
122	O	O
patients	O	O
with	O	O
FMF	O	O
and	O	O
128	O	O
subjects	O	O
who	O	O
were	O	O
systemically	O	O
healthy	O	O
.	O	O
Clinical	O	O
periodontal	O	O
parameters	O	O
,	O	O
including	O	O
the	O	O
plaque	O	O
index	O	O
,	O	O
gingival	O	O
index	O	O
,	O	O
probing	O	O
pocket	O	O
depth	O	O
,	O	O
clinical	O	O
attachment	O	O
level	O	O
and	O	O
percentage	O	O
of	O	O
bleeding	O	O
on	O	O
probing	O	O
were	O	O
recorded	O	O
.	O	O
Blood	O	O
samples	O	O
were	O	O
obtained	O	O
from	O	O
patients	O	O
with	O	O
FMF	O	O
and	O	O
systemically	O	O
healthy	O	O
controls	O	O
,	O	O
and	O	O
all	O	O
mutations	O	O
located	O	O
on	O	O
exons	O	O
2	O	O
and	O	O
10	O	O
of	O	O
the	O	O
MEFV	O	O
gene	O	O
were	O	O
analyzed	O	O
by	O	O
DNA	O	O
Sanger	O	O
Sequencing	O	O
,	O	O
which	O	O
is	O	O
the	O	O
gold	O	O
standard	O	O
.	O	O
SAA	O	O
and	O	O
high	O	O
-	O	O
sensitive	O	O
CRP	O	O
levels	O	O
were	O	O
also	O	O
assessed	O	O
.	O	O
RESULTS	O	O
:	O	O
Mean	O	O
gingival	O	O
index	O	O
,	O	O
percentage	O	O
of	O	O
bleeding	O	O
on	O	O
probing	O	O
,	O	O
probing	O	O
pocket	O	O
depth	O	O
and	O	O
clinical	O	O
attachment	O	O
level	O	O
,	O	O
and	O	O
the	O	O
levels	O	O
of	O	O
SAA	O	O
and	O	O
hs	O	O
-	O	O
CRP	O	O
were	O	O
higher	O	O
in	O	O
the	O	O
FMF	O	O
-	O	O
A	O	O
group	O	O
than	O	O
those	O	O
in	O	O
the	O	O
FMF	O	O
and	O	O
control	O	O
groups	O	O
.	O	O
The	O	O
two	O	O
most	O	O
relevant	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
FMF	O	O
were	O	O
heterozygous	O	O
M694V	O	O
(	O	O
46.2	O	O
%	O	O
)	O	O
,	O	O
and	O	O
heterozygous	O	O
R202Q	O	O
(	O	O
32.7	O	O
%	O	O
)	O	O
.	O	O
The	O	O
frequencies	O	O
of	O	O
the	O	O
homozygous	O	O
M694V	O	O
and	O	O
R202Q	O	O
mutations	O	O
in	O	O
the	O	O
FMF	O	O
-	O	O
A	O	O
group	O	O
were	O	O
53.8	O	O
%	O	O
and	O	O
46.1	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
complex	O	O
R202Q	O	O
/	O	O
M694V	O	O
homozygous	O	O
state	O	O
led	O	O
to	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
chronic	O	O
periodontitis	O	O
(	O	O
odds	O	O
ratio	O	O
:	O	O
3.6	O	O
)	O	O
,	O	O
and	O	O
FMF	O	O
-	O	O
A	O	O
(	O	O
odds	O	O
ratio	O	O
:	O	O
7.6	O	O
)	O	O
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
to	O	O
report	O	O
the	O	O
R202Q	O	O
mutation	O	O
in	O	O
patients	O	O
with	O	O
periodontitis	O	O
.	O	O
Furthermore	O	O
,	O	O
the	O	O
MEFV	O	O
gene	O	O
-	O	O
mediated	O	O
inflammatory	O	O
pathway	O	O
increased	O	B-PosReg
serum	O	O
acute	O	I-CPA
phase	O	O
reactants	O	O
,	O	O
and	O	O
the	O	O
changes	O	O
in	O	O
the	O	O
R202Q	B-Var	O
and	O	O
M694V	B-Var	O
could	O	O
play	B-Reg	O
a	I-Reg	O
role	I-Reg	O
in	O	O
inflammatory	B-Disease	O
-	I-Disease	O
genetic	I-Disease	O
diseases	I-Disease	O
,	O	O
such	O	O
as	O	O
FMF	O	O
,	O	O
FMF	O	O
-	O	O
associated	O	O
amyloidosis	O	O
and	O	O
chronic	O	O
periodontitis	O	O
.	O	O
Linking	O	O
the	O	O
degree	O	O
of	O	O
virilization	O	O
in	O	O
females	O	O
with	O	O
congenital	O	O
adrenal	O	O
hyperplasia	O	O
to	O	O
genotype	O	O
.	O	O
Mutations	B-Var	O
of	O	O
CYP21A2	B-Gene	O
variably	O	O
decrease	B-NegReg	O
21-hydroxylase	B-Enzyme	O
activity	B-MPA	O
and	O	O
result	B-Reg	O
in	I-Reg	O
a	O	O
spectrum	O	O
of	O	O
disease	O	O
expressions	O	O
in	O	O
patients	O	O
with	O	O
congenital	B-Disease	O
adrenal	I-Disease	O
hyperplasia	I-Disease	O
(	O	O
CAH	O	O
)	O	O
.	O	O
We	O	O
examined	O	O
the	O	O
association	O	O
between	O	O
CYP21A2	O	O
mutations	O	O
and	O	O
virilization	O	O
(	O	O
Prader	O	O
score	O	O
)	O	O
in	O	O
females	O	O
with	O	O
CAH	O	O
.	O	O
The	O	O
study	O	O
population	O	O
included	O	O
187	O	O
CAH	B-Disease	O
females	O	O
with	B-Reg	O
fully	O	O
characterized	O	O
CYP21A2	B-Gene	O
mutations	B-Var	O
.	O	O
One	O	O
hundred	O	O
fifty	O	O
-	O	O
eight	O	O
patients	O	O
were	O	O
sorted	O	O
into	O	O
groups	O	O
by	O	O
expected	O	O
enzyme	O	O
activity	O	O
(	O	O
percent	O	O
of	O	O
normal	O	O
activity	O	O
)	O	O
of	O	O
the	O	O
less	O	O
severely	O	O
affected	O	O
allele	O	O
:	O	O
(	O	O
A	O	O
)	O	O
null	O	O
,	O	O
0	O	O
%	O	O
;	O	O
(	O	O
B	O	O
)	O	O
I2	O	O
G	O	O
,	O	O
1	O	O
%	O	O
;	O	O
(	O	O
C	O	O
)	O	O
I172N	O	O
,	O	O
2	O	O
%	O	O
;	O	O
and	O	O
(	O	O
D	O	O
)	O	O
V281L	O	O
,	O	O
>	O	O
2	O	O
%	O	O
.	O	O
We	O	O
observed	O	O
an	O	O
inverse	O	O
relationship	O	O
between	O	O
virilization	O	O
and	O	O
residual	O	O
enzyme	O	O
activity	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O
Subjects	O	O
in	O	O
group	O	O
A	O	O
or	O	O
B	O	O
had	O	O
a	O	O
significantly	O	O
higher	O	O
likelihood	O	O
(	O	O
unadjusted	O	O
odds	O	O
ratio	O	O
:	O	O
16	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
of	O	O
developing	O	O
severe	O	O
virilization	O	O
compared	O	O
with	O	O
those	O	O
in	O	O
group	O	O
C.	O	O
Surprisingly	O	O
,	O	O
24	O	O
%	O	O
of	O	O
group	O	O
D	O	O
patients	O	O
,	O	O
whose	O	O
mutation	O	O
is	O	O
usually	O	O
associated	O	O
with	O	O
nonclassical	O	O
(	O	O
NC	O	O
)	O	O
CAH	O	O
,	O	O
had	O	O
severe	O	O
virilization	O	O
.	O	O
Among	O	O
subjects	O	O
with	O	O
the	O	O
NC	O	O
P30L	O	O
mutation	O	O
,	O	O
66	O	O
%	O	O
expressed	O	O
unexpected	O	O
virilization	O	O
.	O	O
Virilization	O	O
,	O	O
usually	O	O
leading	O	O
to	O	O
extensive	O	O
reconstructive	O	O
surgery	O	O
,	O	O
is	O	O
highly	O	O
likely	O	O
in	O	O
patients	O	O
with	O	O
null	O	O
or	O	O
I2	O	O
G	O	O
mutations	O	O
;	O	O
however	O	O
,	O	O
NC	O	O
mutations	O	O
(	O	O
P30L	O	O
/	O	O
V281L	O	O
)	O	O
may	O	O
also	O	O
lead	O	O
to	O	O
unexpected	O	O
virilization	O	O
.	O	O
These	O	O
findings	O	O
have	O	O
implications	O	O
for	O	O
prenatal	O	O
counseling	O	O
and	O	O
highlight	O	O
the	O	O
need	O	O
for	O	O
additional	O	O
investigations	O	O
into	O	O
other	O	O
factors	O	O
that	O	O
influence	O	O
virilization	O	O
in	O	O
CAH	O	O
.	O	O
A	O	O
Novel	O	O
Missense	B-Var	O
Mutation	I-Var	O
in	O	O
Peripheral	B-Protein	O
Myelin	I-Protein	O
Protein-22	I-Protein	O
Causes	B-Reg	O
Charcot	B-Disease	O
-	I-Disease	O
Marie	I-Disease	O
-	I-Disease	O
Tooth	I-Disease	O
Disease	I-Disease	O
.	O	O
BACKGROUND	O	O
:	O	O
Charcot	O	O
-	O	O
Marie	O	O
-	O	O
Tooth	O	O
disease	O	O
(	O	O
CMT	O	O
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
inherited	O	O
peripheral	O	O
neuropathy	O	O
.	O	O
A	O	O
great	O	O
number	O	O
of	O	O
causative	O	O
genes	O	O
have	O	O
been	O	O
described	O	O
in	O	O
CMT	O	O
,	O	O
and	O	O
among	O	O
them	O	O
,	O	O
the	O	O
heterozygous	O	O
duplication	O	O
of	O	O
peripheral	O	O
myelin	O	O
protein-22	O	O
(	O	O
PMP22	O	O
)	O	O
is	O	O
the	O	O
major	O	O
cause	O	O
.	O	O
Although	O	O
the	O	O
missense	B-Var	O
mutation	I-Var	O
in	O	O
PMP22	B-Gene	O
is	O	O
rarely	O	O
reported	O	O
,	O	O
it	O	O
has	O	O
been	O	O
demonstrated	O	O
to	O	O
be	O	O
associated	B-Reg	O
with	O	O
CMT	B-Disease	O
.	O	O
This	O	O
study	O	O
described	O	O
a	O	O
novel	O	O
missense	B-Var	O
mutation	I-Var	O
of	O	O
PMP22	B-Gene	O
in	B-Reg	O
a	O	O
Chinese	O	O
family	O	O
with	O	O
CMT	B-Disease	O
phenotype	O	O
.	O	O
METHODS	O	O
:	O	O
Targeted	O	O
next	O	O
-	O	O
generation	O	O
sequencing	O	O
(	O	O
NGS	O	O
)	O	O
was	O	O
used	O	O
to	O	O
screen	O	O
the	O	O
causative	O	O
genes	O	O
in	O	O
a	O	O
family	O	O
featured	O	O
with	O	O
an	O	O
autosomal	O	O
dominant	O	O
demyelinating	O	O
form	O	O
of	O	O
CMT	O	O
.	O	O
The	O	O
potential	O	O
variants	O	O
identified	O	O
by	O	O
targeted	O	O
NGS	O	O
were	O	O
verified	O	O
by	O	O
Sanger	O	O
sequencing	O	O
and	O	O
classified	O	O
according	O	O
to	O	O
the	O	O
American	O	O
College	O	O
of	O	O
Medical	O	O
Genetics	O	O
and	O	O
Genomics	O	O
standards	O	O
and	O	O
guidelines	O	O
.	O	O
Further	O	O
cell	O	O
transfection	O	O
studies	O	O
were	O	O
performed	O	O
to	O	O
characterize	O	O
the	O	O
function	O	O
of	O	O
the	O	O
novel	O	O
variant	O	O
.	O	O
RESULTS	O	O
:	O	O
Using	O	O
targeted	O	O
NGS	O	O
,	O	O
a	O	O
novel	O	O
heterozygous	O	O
missense	O	O
variant	O	O
in	O	O
PMP22	O	O
(	O	O
c.320G	O	O
>	O	O
A	O	O
,	O	O
p	O	O
.	O	O
G107D	O	O
)	O	O
was	O	O
identified	O	O
.	O	O
In	O	O
vitro	O	O
cell	O	O
functional	O	O
studies	O	O
revealed	O	O
that	O	O
mutant	O	B-Var
PMP22	B-Gene	O
protein	B-Protein	O
carrying	O	O
p	B-Var	B-Var
.	I-Var	I-Var
G107D	I-Var	O
mutation	O	O
lost	B-NegReg	O
the	O	O
ability	B-CPA	O
to	I-CPA	O
reach	I-CPA	O
the	I-CPA	O
plasma	I-CPA	O
membrane	I-CPA	O
,	O	O
was	O	O
mainly	O	O
retained	O	O
in	O	O
the	O	O
endoplasmic	O	O
reticulum	O	O
,	O	O
and	O	O
induced	B-Reg	O
cell	B-CPA	O
apoptosis	I-CPA	O
.	O	O
CONCLUSIONS	O	O
:	O	O
This	O	O
study	O	O
supported	O	O
the	O	O
notion	O	O
that	O	O
missense	B-Var	O
mutations	I-Var	O
in	O	O
PMP22	B-Gene	O
give	O	O
rise	O	O
to	O	O
a	O	O
CMT	B-Disease	O
phenotype	O	O
,	O	O
possibly	O	O
through	O	O
a	O	O
toxic	B-PosReg	O
gain	I-PosReg	O
-	I-PosReg	O
of	I-PosReg	O
-	I-PosReg	O
function	I-PosReg	O
mechanism	O	O
.	O	O
[	O	O
Genetic	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
for	O	O
a	O	O
haemophilia	B-Disease	O
A	I-Disease	O
family	O	O
with	B-Reg	O
two	O	O
novel	O	O
mutations	B-Var	O
of	O	O
F8	B-Gene	O
gene	O	O
]	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
conduct	O	O
genetic	O	O
diagnosis	O	O
for	O	O
a	O	O
family	O	O
affected	O	O
with	O	O
hamophilia	O	O
A.	O	O
METHODS	O	O
:	O	O
Potential	O	O
mutations	O	O
of	O	O
the	O	O
F8	O	O
gene	O	O
were	O	O
analyzed	O	O
with	O	O
PCR	O	O
and	O	O
Sanger	O	O
sequencing	O	O
.	O	O
Carriers	O	O
of	O	O
the	O	O
mutation	O	O
were	O	O
identified	O	O
through	O	O
linkage	O	O
analysis	O	O
using	O	O
short	O	O
tandem	O	O
repeat	O	O
(	O	O
STR	O	O
)	O	O
markers	O	O
.	O	O
Suspected	O	O
mutations	O	O
were	O	O
verified	O	O
among	O	O
100	O	O
healthy	O	O
controls	O	O
to	O	O
rule	O	O
out	O	O
genetic	O	O
polymorphism	O	O
.	O	O
Prenatal	O	O
diagnosis	O	O
was	O	O
provided	O	O
based	O	O
on	O	O
the	O	O
above	O	O
results	O	O
.	O	O
RESULTS	O	O
:	O	O
Sequencing	O	O
analysis	O	O
has	O	O
identified	O	O
two	O	O
mutations	O	O
,	O	O
c.1	O	O
A	O	O
>	O	O
T	O	O
and	O	O
c.4	O	O
C	O	O
>	O	O
T	O	O
,	O	O
which	O	O
have	O	O
replaced	O	O
the	O	O
start	O	O
codon	O	O
(	O	O
ATG	O	O
)	O	O
with	O	O
leucine	O	O
(	O	O
TTG	O	O
)	O	O
and	O	O
glutamine	O	O
(	O	O
GAA	O	O
)	O	O
with	O	O
the	O	O
stop	O	O
codon	O	O
(	O	O
TAA	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
same	O	O
mutations	O	O
were	O	O
not	O	O
found	O	O
among	O	O
the	O	O
100	O	O
healthy	O	O
controls	O	O
.	O	O
The	O	O
patient	O	O
's	O	O
mother	O	O
and	O	O
sister	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
same	O	O
mutations	O	O
.	O	O
Upon	O	O
prenatal	O	O
diagnosis	O	O
,	O	O
the	O	O
fetus	O	O
was	O	O
determined	O	O
as	O	O
a	O	O
male	O	O
and	O	O
did	O	O
not	O	O
harbor	O	O
the	O	O
above	O	O
mutations	O	O
.	O	O
Linkage	O	O
analysis	O	O
also	O	O
confirmed	O	O
that	O	O
the	O	O
fetus	O	O
has	O	O
inherited	O	O
the	O	O
non	O	O
-	O	O
risk	O	O
X	O	O
chromosome	O	O
from	O	O
his	O	O
maternal	O	O
grandfather	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Detection	O	O
of	O	O
pathogenic	O	O
mutations	O	O
can	O	O
enable	O	O
prenatal	O	O
diagnosis	O	O
for	O	O
the	O	O
disease	O	O
.	O	O
Comprehensive	O	O
analysis	O	O
for	O	O
genetic	O	O
diagnosis	O	O
of	O	O
Dystrophinopathies	O	O
in	O	O
Japan	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Duchenne	B-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
(	O	O
DMD	O	O
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
disease	O	O
in	O	O
children	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
DMD	B-Gene	O
gene	O	O
,	O	O
and	O	O
DMD	O	O
and	O	O
Becker	O	O
muscular	O	O
dystrophy	O	O
(	O	O
BMD	O	O
)	O	O
are	O	O
collectively	O	O
called	O	O
dystrophinopathies	O	O
.	O	O
Dystrophinopathies	O	O
show	O	O
a	O	O
complex	O	O
mutation	O	O
spectrum	O	O
.	O	O
The	O	O
importance	O	O
of	O	O
mutation	O	O
databases	O	O
,	O	O
with	O	O
clinical	O	O
phenotypes	O	O
and	O	O
protein	O	O
studies	O	O
of	O	O
patients	O	O
,	O	O
is	O	O
increasingly	O	O
recognized	O	O
as	O	O
a	O	O
reference	O	O
for	O	O
genetic	O	O
diagnosis	O	O
and	O	O
for	O	O
the	O	O
development	O	O
of	O	O
gene	O	O
therapy	O	O
.	O	O
METHODS	O	O
:	O	O
We	O	O
used	O	O
the	O	O
data	O	O
from	O	O
the	O	O
Japanese	O	O
Registry	O	O
of	O	O
Muscular	O	O
Dystrophy	O	O
(	O	O
Remudy	O	O
)	O	O
compiled	O	O
during	O	O
from	O	O
July	O	O
2009	O	O
to	O	O
March	O	O
2017	O	O
,	O	O
and	O	O
reviewed	O	O
1497	O	O
patients	O	O
with	O	O
dystrophinopathies	O	O
.	O	O
RESULTS	O	O
:	O	O
The	O	O
spectrum	O	O
of	O	O
identified	O	O
mutations	O	O
contained	O	O
exon	O	O
deletions	O	O
(	O	O
61	O	O
%	O	O
)	O	O
,	O	O
exon	O	O
duplications	O	O
(	O	O
13	O	O
%	O	O
)	O	O
,	O	O
nonsense	O	O
mutations	O	O
(	O	O
13	O	O
%	O	O
)	O	O
,	O	O
small	O	O
deletions	O	O
(	O	O
5	O	O
%	O	O
)	O	O
,	O	O
small	O	O
insertions	O	O
(	O	O
3	O	O
%	O	O
)	O	O
,	O	O
splice	O	O
-	O	O
site	O	O
mutations	O	O
(	O	O
4	O	O
%	O	O
)	O	O
,	O	O
and	O	O
missense	O	O
mutations	O	O
(	O	O
1	O	O
%	O	O
)	O	O
.	O	O
Exon	O	O
deletions	O	O
were	O	O
found	O	O
most	O	O
frequently	O	O
in	O	O
the	O	O
central	O	O
hot	O	O
spot	O	O
region	O	O
between	O	O
exons	O	O
45	O	O
-	O	O
52	O	O
(	O	O
42	O	O
%	O	O
)	O	O
,	O	O
and	O	O
most	O	O
duplications	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
proximal	O	O
hot	O	O
spot	O	O
region	O	O
between	O	O
exons	O	O
3	O	O
-	O	O
25	O	O
(	O	O
47	O	O
%	O	O
)	O	O
.	O	O
In	O	O
the	O	O
371	O	O
patients	O	O
harboring	O	O
a	O	O
small	O	O
mutation	O	O
,	O	O
194	O	O
mutations	O	O
were	O	O
reported	O	O
and	O	O
187	O	O
mutations	O	O
were	O	O
unreported	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
We	O	O
report	O	O
the	O	O
largest	O	O
dystrophinopathies	O	O
mutation	O	O
dataset	O	O
in	O	O
Japan	O	O
from	O	O
a	O	O
national	O	O
patient	O	O
registry	O	O
,	O	O
"	O	O
Remudy	O	O
"	O	O
.	O	O
This	O	O
dataset	O	O
provides	O	O
a	O	O
useful	O	O
reference	O	O
to	O	O
support	O	O
the	O	O
genetic	O	O
diagnosis	O	O
and	O	O
treatment	O	O
of	O	O
dystrophinopathy	O	O
.	O	O
A	O	O
Defective	O	O
mRNA	O	O
Cleavage	O	O
and	O	O
Polyadenylation	O	O
Complex	O	O
Facilitates	O	O
Expansions	O	O
of	O	O
Transcribed	O	O
(	O	O
GAA)n	O	O
Repeats	O	O
Associated	O	O
with	O	O
Friedreich	O	O
's	O	O
Ataxia	O	O
.	O	O
Expansions	O	O
of	O	O
microsatellite	O	O
repeats	O	O
are	O	O
responsible	O	O
for	O	O
numerous	O	O
hereditary	O	O
diseases	O	O
in	O	O
humans	O	O
,	O	O
including	O	O
myotonic	O	O
dystrophy	O	O
and	O	O
Friedreich	O	O
's	O	O
ataxia	O	O
.	O	O
Whereas	O	O
the	O	O
length	O	O
of	O	O
an	O	O
expandable	O	O
repeat	O	O
is	O	O
the	O	O
main	O	O
factor	O	O
determining	O	O
disease	O	O
inheritance	O	O
,	O	O
recent	O	O
data	O	O
point	O	O
to	O	O
genomic	O	O
trans	O	O
modifiers	O	O
that	O	O
can	O	O
impact	O	O
the	O	O
likelihood	O	O
of	O	O
expansions	O	O
and	O	O
disease	O	O
progression	O	O
.	O	O
Detection	O	O
of	O	O
these	O	O
modifiers	O	O
may	O	O
lead	O	O
to	O	O
understanding	O	O
and	O	O
treating	O	O
repeat	O	O
expansion	O	O
diseases	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
method	O	O
for	O	O
the	O	O
rapid	O	O
,	O	O
genome	O	O
-	O	O
wide	O	O
identification	O	O
of	O	O
trans	O	O
modifiers	O	O
for	O	O
repeat	O	O
expansion	O	O
in	O	O
a	O	O
yeast	O	O
experimental	O	O
system	O	O
.	O	O
Using	O	O
this	O	O
method	O	O
,	O	O
we	O	O
found	O	O
that	O	O
missense	B-Var	O
mutations	I-Var	O
in	O	O
the	O	O
endoribonuclease	O	O
subunit	O	O
(	B-Gene	O
Ysh1	I-Gene	O
)	I-Gene	O
of	O	O
the	O	O
mRNA	O	O
cleavage	O	O
and	O	O
polyadenylation	O	O
complex	O	O
dramatically	O	O
increase	B-PosReg	O
the	B-MPA	O
rate	I-MPA	O
of	I-MPA	O
(	I-MPA	O
GAA)n	I-MPA	O
repeat	I-MPA	O
expansions	I-MPA	O
but	O	O
only	O	O
when	O	O
they	O	O
are	O	O
actively	O	O
transcribed	O	O
.	O	O
These	O	O
expansions	O	O
correlate	O	O
with	O	O
slower	B-NegReg	O
transcription	B-MPA	O
elongation	I-MPA	O
caused	O	O
by	O	O
the	O	O
ysh1	B-Gene	O
mutation	B-Var	O
.	O	O
These	O	O
results	O	O
reveal	O	O
an	O	O
interplay	O	O
between	O	O
RNA	O	O
processing	O	O
and	O	O
repeat	O	O
-	O	O
mediated	O	O
genome	O	O
instability	O	O
,	O	O
confirming	O	O
the	O	O
validity	O	O
of	O	O
our	O	O
approach	O	O
.	O	O
Diverse	O	O
phenotype	O	O
of	O	O
hypokalaemic	O	O
periodic	O	O
paralysis	O	O
within	O	O
a	O	O
family	O	O
.	O	O
Hypokalaemic	O	O
periodic	O	O
paralysis	O	O
typically	O	O
presents	O	O
with	O	O
intermittent	O	O
mild	O	O
-	O	O
to	O	O
-	O	O
moderate	O	O
weakness	O	O
lasting	O	O
hours	O	O
to	O	O
days	O	O
.	O	O
We	O	O
report	O	O
a	O	O
case	O	O
with	O	O
an	O	O
uncommon	O	O
phenotype	O	O
of	O	O
late	O	O
-	O	O
onset	O	O
myopathy	O	O
without	O	O
episodic	O	O
paralytic	O	O
attacks	O	O
.	O	O
Initial	O	O
work	O	O
-	O	O
up	O	O
including	O	O
muscle	O	O
biopsy	O	O
was	O	O
inconclusive	O	O
.	O	O
A	O	O
subsequent	O	O
review	O	O
of	O	O
the	O	O
right	O	O
deltoid	O	O
biopsy	O	O
,	O	O
long	O	O
exercise	O	O
testing	O	O
and	O	O
repeated	O	O
family	O	O
history	O	O
was	O	O
helpful	O	O
,	O	O
followed	O	O
by	O	O
appropriate	O	O
genetic	O	O
testing	O	O
.	O	O
We	O	O
identified	O	O
a	O	O
heterozygous	O	O
pathogenic	O	O
mutation	O	O
in	O	O
calcium	O	O
ion	O	O
channel	O	O
(	B-Var	O
CACNA1S	I-Var	O
:	I-Var	O
c.1583G	I-Var	O
>	I-Var	O
A	I-Var	O
p	I-Var	O
.	I-Var	O
Arg528His	I-Var	O
)	I-Var	O
causing	B-Reg	O
hypokalaemic	B-Disease	O
periodic	I-Disease	O
paralysis	I-Disease	O
.	O	O
Myopathy	O	O
can	O	O
present	O	O
without	O	O
episodic	O	O
paralysis	O	O
and	O	O
the	O	O
frequency	O	O
of	O	O
paralytic	O	O
episodes	O	O
does	O	O
not	O	O
correlate	O	O
well	O	O
with	O	O
the	O	O
development	O	O
and	O	O
progression	O	O
of	O	O
a	O	O
fixed	O	O
myopathy	O	O
.	O	O
Our	O	O
report	O	O
also	O	O
highlights	O	O
the	O	O
intrafamilial	O	O
phenotypic	O	O
variation	O	O
of	O	O
hypokalaemic	B-Disease	O
periodic	I-Disease	O
paralysis	I-Disease	O
secondary	O	O
to	B-Reg	O
a	O	O
CACNA1S	B-Gene	O
gene	O	O
mutation	B-Var	O
.	O	O
Genetic	O	O
anticipation	O	O
in	O	O
Swedish	O	O
Lynch	O	O
syndrome	O	O
families	O	O
.	O	O
Among	O	O
hereditary	O	O
colorectal	O	O
cancer	O	O
predisposing	O	O
syndromes	O	O
,	O	O
Lynch	B-Disease	O
syndrome	I-Disease	O
(	O	O
LS	O	O
)	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
DNA	O	O
mismatch	O	O
repair	O	O
genes	O	O
MLH1	B-Gene	O
,	O	O
MSH2	B-Gene	O
,	O	O
MSH6	B-Gene	O
or	O	O
PMS2	B-Gene	O
is	O	O
the	O	O
most	O	O
common	O	O
.	O	O
Patients	O	O
with	O	O
LS	O	O
have	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
early	O	O
onset	O	O
colon	O	O
and	O	O
endometrial	O	O
cancer	O	O
,	O	O
but	O	O
also	O	O
other	O	O
tumors	O	O
that	O	O
generally	O	O
have	O	O
an	O	O
earlier	O	O
onset	O	O
compared	O	O
to	O	O
the	O	O
general	O	O
population	O	O
.	O	O
However	O	O
,	O	O
age	O	O
at	O	O
first	O	O
primary	O	O
cancer	O	O
varies	O	O
within	O	O
families	O	O
and	O	O
genetic	O	O
anticipation	O	O
,	O	O
i.e.	O	O
decreasing	O	O
age	O	O
at	O	O
onset	O	O
in	O	O
successive	O	O
generations	O	O
,	O	O
has	O	O
been	O	O
suggested	O	O
in	O	O
LS	O	O
.	O	O
Anticipation	O	O
is	O	O
a	O	O
well	O	O
-	O	O
known	O	O
phenomenon	O	O
in	O	O
e.g	O	O
neurodegenerative	O	O
diseases	O	O
and	O	O
several	O	O
reports	O	O
have	O	O
studied	O	O
anticipation	O	O
in	O	O
heritable	O	O
cancer	O	O
.	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
determine	O	O
whether	O	O
anticipation	O	O
can	O	O
be	O	O
shown	O	O
in	O	O
a	O	O
nationwide	O	O
cohort	O	O
of	O	O
Swedish	O	O
LS	O	O
families	O	O
referred	O	O
to	O	O
the	O	O
regional	O	O
departments	O	O
of	O	O
clinical	O	O
genetics	O	O
in	O	O
Lund	O	O
,	O	O
Stockholm	O	O
,	O	O
Linköping	O	O
,	O	O
Uppsala	O	O
and	O	O
Umeå	O	O
between	O	O
the	O	O
years	O	O
1990	O	O
-	O	O
2013	O	O
.	O	O
We	O	O
analyzed	O	O
a	O	O
homogenous	O	O
group	O	O
of	O	O
mutation	O	O
carriers	O	O
,	O	O
utilizing	O	O
information	O	O
from	O	O
both	O	O
affected	O	O
and	O	O
non	O	O
-	O	O
affected	O	O
family	O	O
members	O	O
.	O	O
In	O	O
total	O	O
,	O	O
239	O	O
families	O	O
with	O	O
a	O	O
mismatch	O	O
repair	O	O
gene	O	O
mutation	O	O
(	O	O
96	O	O
MLH1	O	O
families	O	O
,	O	O
90	O	O
MSH2	O	O
families	O	O
including	O	O
one	O	O
family	O	O
with	O	O
an	O	O
EPCAM	O	O
-	O	O
MSH2	O	O
deletion	O	O
,	O	O
39	O	O
MSH6	O	O
families	O	O
,	O	O
12	O	O
PMS2	O	O
families	O	O
,	O	O
and	O	O
2	O	O
MLH1+PMS2	O	O
families	O	O
)	O	O
comprising	O	O
1028	O	O
at	O	O
-	O	O
risk	O	O
carriers	O	O
were	O	O
identified	O	O
among	O	O
the	O	O
Swedish	O	O
LS	O	O
families	O	O
,	O	O
of	O	O
which	O	O
1003	O	O
mutation	O	O
carriers	O	O
had	O	O
available	O	O
follow	O	O
-	O	O
up	O	O
information	O	O
and	O	O
could	O	O
be	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O
Using	O	O
a	O	O
normal	O	O
random	O	O
effects	O	O
model	O	O
(	O	O
NREM	O	O
)	O	O
we	O	O
estimate	O	O
a	O	O
2.1	O	O
year	O	O
decrease	O	O
in	O	O
age	O	O
of	O	O
diagnosis	O	O
per	O	O
generation	O	O
.	O	O
An	O	O
alternative	O	O
analysis	O	O
using	O	O
a	O	O
mixed	O	O
-	O	O
effects	O	O
Cox	O	O
proportional	O	O
hazards	O	O
model	O	O
(	O	O
COX	O	O
-	O	O
R	O	O
)	O	O
estimates	O	O
a	O	O
hazard	O	O
ratio	O	O
of	O	O
exp(0.171	O	O
)	O	O
,	O	O
or	O	O
about	O	O
1.19	O	O
,	O	O
for	O	O
age	O	O
of	O	O
diagnosis	O	O
between	O	O
consecutive	O	O
generations	O	O
.	O	O
LS	O	O
-	O	O
associated	O	O
gene	O	O
-	O	O
specific	O	O
anticipation	O	O
effects	O	O
are	O	O
evident	O	O
for	O	O
MSH2	O	O
(	O	O
2.6	O	O
years	O	O
/	O	O
generation	O	O
for	O	O
NREM	O	O
and	O	O
hazard	O	O
ratio	O	O
of	O	O
1.33	O	O
for	O	O
COX	O	O
-	O	O
R	O	O
)	O	O
and	O	O
PMS2	O	O
(	O	O
7.3	O	O
years	O	O
/	O	O
generation	O	O
and	O	O
hazard	O	O
ratio	O	O
of	O	O
1.86	O	O
)	O	O
.	O	O
The	O	O
estimated	O	O
anticipation	O	O
effects	O	O
for	O	O
MLH1	O	O
and	O	O
MSH6	O	O
are	O	O
smaller	O	O
.	O	O
EYS	O	O
mutation	O	O
update	O	O
:	O	O
In	O	O
silico	O	O
assessment	O	O
of	O	O
271	O	O
reported	O	O
and	O	O
26	O	O
novel	O	O
variants	O	O
in	O	O
patients	O	O
with	O	O
retinitis	O	O
pigmentosa	O	O
.	O	O
Mutations	B-Var	O
in	O	O
Eyes	O	O
shut	O	O
homolog	O	O
(	B-Gene	O
EYS	I-Gene	O
)	I-Gene	O
are	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
causes	B-Reg	O
of	O	O
autosomal	B-Disease	O
recessive	I-Disease	O
(	I-Disease	O
ar	I-Disease	O
)	I-Disease	O
retinitis	I-Disease	O
pigmentosa	I-Disease	O
(	O	O
RP	O	O
)	O	O
,	O	O
a	O	O
progressive	O	O
blinding	O	O
disorder	O	O
.	O	O
The	O	O
exact	O	O
function	O	O
of	O	O
the	O	O
EYS	O	O
protein	O	O
and	O	O
the	O	O
pathogenic	O	O
mechanisms	O	O
underlying	O	O
EYS	O	O
-	O	O
associated	O	O
RP	O	O
are	O	O
still	O	O
poorly	O	O
understood	O	O
,	O	O
which	O	O
hampers	O	O
the	O	O
interpretation	O	O
of	O	O
the	O	O
causality	O	O
of	O	O
many	O	O
EYS	O	O
variants	O	O
discovered	O	O
to	O	O
date	O	O
.	O	O
We	O	O
collected	O	O
all	O	O
reported	O	O
EYS	O	O
variants	O	O
present	O	O
in	O	O
377	O	O
arRP	O	O
index	O	O
cases	O	O
published	O	O
before	O	O
June	O	O
2017	O	O
,	O	O
and	O	O
uploaded	O	O
them	O	O
in	O	O
the	O	O
Leiden	O	O
Open	O	O
Variation	O	O
Database	O	O
(	O	O
www.LOVD.nl/EYS	O	O
)	O	O
.	O	O
We	O	O
also	O	O
describe	O	O
36	O	O
additional	O	O
index	O	O
cases	O	O
,	O	O
carrying	O	O
26	O	O
novel	O	O
variants	O	O
.	O	O
Of	O	O
the	O	O
297	O	O
unique	O	O
EYS	O	O
variants	O	O
identified	O	O
,	O	O
almost	O	O
half	O	O
(	O	O
n	O	O
=	O	O
130	O	O
)	O	O
are	O	O
predicted	O	O
to	O	O
result	O	O
in	O	O
premature	O	O
truncation	O	O
of	O	O
the	O	O
EYS	O	O
protein	O	O
.	O	O
Classification	O	O
of	O	O
all	O	O
variants	O	O
using	O	O
the	O	O
American	O	O
College	O	O
of	O	O
Medical	O	O
Genetics	O	O
and	O	O
Genomics	O	O
guidelines	O	O
revealed	O	O
that	O	O
the	O	O
predicted	O	O
pathogenicity	O	O
of	O	O
these	O	O
variants	O	O
cover	O	O
the	O	O
complete	O	O
spectrum	O	O
ranging	O	O
from	O	O
likely	O	O
benign	O	O
to	O	O
pathogenic	O	O
,	O	O
although	O	O
especially	O	O
missense	O	O
variants	O	O
largely	O	O
fall	O	O
in	O	O
the	O	O
category	O	O
of	O	O
uncertain	O	O
significance	O	O
.	O	O
Besides	O	O
the	O	O
identification	O	O
of	O	O
likely	O	O
benign	O	O
alleles	O	O
previously	O	O
reported	O	O
as	O	O
being	O	O
probably	O	O
pathogenic	O	O
,	O	O
our	O	O
comprehensive	O	O
analysis	O	O
underscores	O	O
the	O	O
need	O	O
of	O	O
functional	O	O
assays	O	O
to	O	O
assess	O	O
the	O	O
causality	O	O
of	O	O
EYS	O	O
variants	O	O
,	O	O
in	O	O
order	O	O
to	O	O
improve	O	O
molecular	O	O
diagnostics	O	O
and	O	O
counseling	O	O
of	O	O
patients	O	O
with	O	O
EYS	O	O
-	O	O
associated	O	O
RP	O	O
.	O	O
Ciliopathy	O	O
-	O	O
associated	O	O
mutations	B-Var	O
of	O	O
IFT122	B-Gene	O
impair	B-NegReg	O
ciliary	B-Protein	O
protein	I-Protein	O
trafficking	B-MPA	O
but	O	O
not	O	O
ciliogenesis	O	O
.	O	O
The	O	O
intraflagellar	O	O
transport	O	O
(	O	O
IFT	O	O
)	O	O
machinery	O	O
containing	O	O
the	O	O
IFT	O	O
-	O	O
A	O	O
and	O	O
IFT	O	O
-	O	O
B	O	O
complexes	O	O
mediates	O	O
ciliary	O	O
protein	O	O
trafficking	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
genes	O	O
encoding	O	O
the	O	O
six	O	O
subunits	O	O
of	O	O
the	O	O
IFT	O	O
-	O	O
A	O	O
complex	O	O
(	B-Gene	O
IFT43	I-Gene	O
,	O	O
IFT121	B-Gene	O
,	O	O
IFT122	B-Gene	O
,	O	O
IFT139	B-Gene	O
,	O	O
IFT140	B-Gene	O
,	O	O
and	O	O
IFT144	B-Gene	O
)	I-Gene	O
are	O	O
known	O	O
to	O	O
cause	B-Reg	O
skeletal	O	O
ciliopathies	O	O
,	O	O
including	O	O
cranioectodermal	B-Disease	O
dysplasia	I-Disease	O
(	O	O
CED	O	O
)	O	O
.	O	O
As	O	O
the	O	O
IFT122	O	O
subunit	O	O
connects	O	O
the	O	O
core	O	O
and	O	O
peripheral	O	O
subcomplexes	O	O
of	O	O
the	O	O
IFT	O	O
-	O	O
A	O	O
complex	O	O
,	O	O
it	O	O
is	O	O
expected	O	O
to	O	O
play	O	O
a	O	O
pivotal	O	O
role	O	O
in	O	O
the	O	O
complex	O	O
.	O	O
Indeed	O	O
,	O	O
we	O	O
here	O	O
showed	O	O
that	O	O
knockout	O	O
(	O	O
KO	O	O
)	O	O
of	O	O
the	O	O
IFT122	O	O
gene	O	O
in	O	O
hTERT	O	O
-	O	O
RPE1	O	O
cells	O	O
using	O	O
the	O	O
CRISPR	O	O
/	O	O
Cas9	O	O
system	O	O
led	O	O
to	O	O
a	O	O
severe	O	O
ciliogenesis	O	O
defect	O	O
,	O	O
whereas	O	O
KO	O	O
of	O	O
other	O	O
IFT	O	O
-	O	O
A	O	O
genes	O	O
had	O	O
minor	O	O
effects	O	O
on	O	O
ciliogenesis	O	O
but	O	O
impaired	O	O
ciliary	O	O
protein	O	O
trafficking	O	O
.	O	O
Exogenous	O	O
expression	O	O
of	O	O
not	O	O
only	O	O
wild	O	O
-	O	O
type	O	O
IFT122	O	O
but	O	O
also	O	O
its	O	O
CED	O	O
-	O	O
associated	O	O
missense	O	O
mutants	O	O
,	O	O
which	O	O
fail	O	O
to	O	O
interact	O	O
with	O	O
other	O	O
IFT	O	O
-	O	O
A	O	O
subunits	O	O
,	O	O
rescued	O	O
the	O	O
ciliogenesis	O	O
defect	O	O
of	O	O
IFT122-KO	O	O
cells	O	O
.	O	O
However	O	O
,	O	O
IFT122-KO	O	O
cells	O	O
expressing	O	O
CED	O	O
-	O	O
type	O	O
IFT122	B-Gene	O
mutants	B-Var	O
showed	O	O
defects	B-NegReg	O
in	O	O
ciliary	B-Protein	O
protein	I-Protein	O
trafficking	B-MPA	O
,	O	O
such	O	O
as	O	O
ciliary	O	O
entry	O	O
of	O	O
Smoothened	O	O
in	O	O
response	O	O
to	O	O
Hedgehog	O	O
signaling	O	O
activation	O	O
.	O	O
The	O	O
trafficking	O	O
defects	O	O
partially	O	O
resembled	O	O
those	O	O
observed	O	O
in	O	O
IFT144-KO	O	O
cells	O	O
,	O	O
which	O	O
demonstrate	O	O
failed	O	O
assembly	O	O
of	O	O
the	O	O
functional	O	O
IFT	O	O
-	O	O
A	O	O
complex	O	O
at	O	O
the	O	O
base	O	O
of	O	O
cilia	O	O
.	O	O
These	O	O
observations	O	O
make	O	O
it	O	O
likely	O	O
that	O	O
,	O	O
although	O	O
IFT122	O	O
is	O	O
essential	O	O
for	O	O
ciliogenesis	O	O
,	O	O
CED	O	O
-	O	O
type	O	O
missense	O	O
mutations	O	O
underlie	O	O
a	O	O
skeletal	O	O
ciliopathy	O	O
phenotype	O	O
by	O	O
perturbing	O	O
ciliary	O	O
protein	O	O
trafficking	O	O
with	O	O
minor	O	O
effects	O	O
on	O	O
ciliogenesis	O	O
per	O	O
se	O	O
.	O	O
Association	O	O
of	O	O
the	O	O
AADAC	O	O
gene	O	O
and	O	O
Tourette	O	O
syndrome	O	O
in	O	O
a	O	O
Han	O	O
Chinese	O	O
cohort	O	O
.	O	O
Tourette	B-Disease	O
syndrome	I-Disease	O
(	O	O
TS	O	O
)	O	O
is	O	O
a	O	O
complex	O	O
neuropsychiatric	O	O
disorder	O	O
with	O	O
chronic	O	O
motor	O	O
and	O	O
vocal	O	O
tics	O	O
.	O	O
Though	O	O
the	O	O
etiology	O	O
is	O	O
elusive	O	O
,	O	O
strong	O	O
evidence	O	O
for	O	O
a	O	O
genetic	O	O
contribution	O	O
to	O	O
TS	O	O
has	O	O
been	O	O
established	O	O
.	O	O
To	O	O
date	O	O
,	O	O
various	O	O
chromosomal	O	O
or	O	O
genetic	O	O
alterations	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
its	O	O
pathogenesis	O	O
.	O	O
Recently	O	O
,	O	O
the	O	O
deletion	O	O
in	O	O
the	O	O
arylacetamide	O	O
deacetylase	O	O
gene	O	O
(	O	O
AADAC	O	O
)	O	O
was	O	O
reported	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
TS	O	O
.	O	O
To	O	O
investigate	O	O
the	O	O
association	O	O
between	O	O
the	O	O
AADAC	O	O
gene	O	O
variants	O	O
and	O	O
TS	O	O
,	O	O
we	O	O
conducted	O	O
genetic	O	O
analysis	O	O
of	O	O
the	O	O
AADAC	O	O
gene	O	O
in	O	O
200	O	O
Han	O	O
Chinese	O	O
patients	O	O
and	O	O
300	O	O
ethnicity	O	O
-	O	O
matched	O	O
normal	O	O
controls	O	O
.	O	O
Two	O	O
variants	O	O
,	O	O
including	O	O
a	O	O
heterozygous	O	O
splice	O	O
-	O	O
site	O	O
variant	O	O
,	O	O
c.361	O	O
+	O	O
1	O	O
G	O	O
>	O	O
A	O	O
(	O	O
rs762169706	O	O
)	O	O
,	O	O
and	O	O
a	O	O
missense	O	O
variant	O	O
,	O	O
c.744A	O	O
>	O	O
T	O	O
(	O	O
p	O	O
.	O	O
R248S	O	O
,	O	O
rs186388618	O	O
)	O	O
,	O	O
were	O	O
identified	O	O
in	O	O
two	O	O
unrelated	O	O
patients	O	O
.	O	O
The	O	O
c.361	B-Var	O
+	I-Var	O
1	I-Var	B-Var
G	I-Var	I-Var
>	I-Var	I-Var
A	I-Var	O
variant	O	O
,	O	O
absent	O	O
in	O	O
300	O	O
ethnicity	O	O
-	O	O
matched	O	O
controls	O	O
,	O	O
led	B-Reg	O
to	I-Reg	O
the	O	O
deletion	B-Var	O
of	O	O
exon	O	O
2	O	O
in	O	O
AADAC	O	O
mRNA	O	O
,	O	O
probably	O	O
associated	B-Reg	O
with	I-Reg	O
development	O	O
of	O	O
TS	B-Disease	O
.	O	O
The	O	O
c.744A	O	O
>	O	O
T	O	O
variant	O	O
,	O	O
predicted	O	O
to	O	O
be	O	O
damaging	O	O
,	O	O
was	O	O
identified	O	O
in	O	O
two	O	O
normal	O	O
controls	O	O
.	O	O
The	O	O
findings	O	O
indicate	O	O
that	O	O
the	O	O
AADAC	B-Gene	O
gene	O	O
c.361	B-Var	O
+	I-Var	O
1	I-Var	O
G	I-Var	O
>	I-Var	O
A	I-Var	O
variant	O	O
may	O	O
be	O	O
a	O	O
potential	O	O
candidate	B-Reg	O
factor	I-Reg	O
for	O	O
TS	B-Disease	O
development	O	O
,	O	O
though	O	O
further	O	O
investigations	O	O
are	O	O
warranted	O	O
.	O	O
MeCP2	O	O
as	O	O
an	O	O
Activator	O	O
of	O	O
Gene	O	O
Expression	O	O
.	O	O
Rett	B-Disease	O
syndrome	I-Disease	O
is	O	O
a	O	O
neurodevelopmental	O	O
disorder	O	O
that	O	O
primarily	O	O
affects	O	O
females	O	O
and	O	O
is	O	O
caused	B-Reg	B-Reg
by	I-Reg	O
mutations	B-Var	B-Var
in	O	O
the	O	O
methyl	O	O
-	O	O
CpG	O	O
-	O	O
binding	O	O
-	O	O
protein	O	O
2	O	O
(	B-Gene	B-Gene
MECP2	I-Gene	O
)	I-Gene	I-Gene
gene	O	O
.	O	O
Initially	O	O
,	O	O
MeCP2	O	O
had	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
a	O	O
repressor	O	O
of	O	O
gene	O	O
transcription	O	O
.	O	O
In	O	O
their	O	O
2008	O	O
paper	O	O
,	O	O
Chahrour	O	O
and	O	O
colleagues	O	O
(	O	O
DOI	O	O
:	O	O
10.1126	O	O
/	O	O
science.1153252	O	O
)	O	O
reported	O	O
that	O	O
MeCP2	O	O
could	O	O
also	O	O
function	O	O
as	O	O
a	O	O
transcriptional	O	O
activator	O	O
.	O	O
Molecular	O	O
Analysis	O	O
-	O	O
Based	O	O
Genetic	O	O
Characterization	O	O
of	O	O
a	O	O
Cohort	O	O
of	O	O
Patients	O	O
with	O	O
Duchenne	O	O
and	O	O
Becker	O	O
Muscular	O	O
Dystrophy	O	O
in	O	O
Eastern	O	O
China	O	O
.	O	O
Background	O	O
:	O	O
Duchenne	B-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
(	O	O
DMD	O	O
)	O	O
and	O	O
Becker	B-Disease	O
muscular	I-Disease	O
dystrophy	I-Disease	O
(	O	O
BMD	O	O
)	O	O
are	O	O
common	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
neuromuscular	O	O
disorders	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
dystrophin	B-Gene	O
gene	I-Gene	O
.	O	O
Multiplex	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
multiplex	O	O
PCR	O	O
)	O	O
and	O	O
multiplex	O	O
ligation	O	O
-	O	O
dependent	O	O
probe	O	O
amplification	O	O
(	O	O
MLPA	O	O
)	O	O
are	O	O
the	O	O
most	O	O
common	O	O
methods	O	O
for	O	O
detecting	O	O
dystrophin	O	O
gene	O	O
mutations	O	O
.	O	O
This	O	O
study	O	O
aimed	O	O
to	O	O
contrast	O	O
the	O	O
two	O	O
methods	O	O
and	O	O
discern	O	O
the	O	O
genetic	O	O
characterization	O	O
of	O	O
patients	O	O
with	O	O
DMD	O	O
/	O	O
BMD	O	O
in	O	O
Eastern	O	O
China	O	O
.	O	O
Methods	O	O
:	O	O
We	O	O
collected	O	O
121	O	O
probands	O	O
,	O	O
64	O	O
mothers	O	O
of	O	O
probands	O	O
,	O	O
and	O	O
15	O	O
fetuses	O	O
in	O	O
our	O	O
study	O	O
.	O	O
The	O	O
dystrophin	O	O
gene	O	O
was	O	O
detected	O	O
by	O	O
multiplex	O	O
PCR	O	O
primarily	O	O
in	O	O
28	O	O
probands	O	O
,	O	O
and	O	O
MLPA	O	O
was	O	O
used	O	O
in	O	O
multiplex	O	O
PCR	O	O
-	O	O
negative	O	O
cases	O	O
subsequently	O	O
.	O	O
The	O	O
dystrophin	O	O
gene	O	O
of	O	O
the	O	O
remaining	O	O
93	O	O
probands	O	O
and	O	O
62	O	O
female	O	O
potential	O	O
carriers	O	O
was	O	O
tested	O	O
by	O	O
MLPA	O	O
directly	O	O
.	O	O
In	O	O
fetuses	O	O
,	O	O
multiplex	O	O
PCR	O	O
and	O	O
MLPA	O	O
were	O	O
performed	O	O
on	O	O
4	O	O
fetuses	O	O
and	O	O
10	O	O
fetuses	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
sequencing	O	O
was	O	O
also	O	O
performed	O	O
in	O	O
4	O	O
probands	O	O
with	O	O
negative	O	O
MLPA	O	O
.	O	O
Results	O	O
:	O	O
We	O	O
found	O	O
that	O	O
61.98	O	O
%	O	O
of	O	O
the	O	O
subjects	O	O
had	O	O
genetic	O	O
mutations	O	O
including	O	O
deletions	O	O
(	O	O
50.41	O	O
%	O	O
)	O	O
and	O	O
duplications	O	O
(	O	O
11.57	O	O
%	O	O
)	O	O
.	O	O
There	O	O
were	O	O
43.75	O	O
%	O	O
of	O	O
mothers	O	O
as	O	O
carriers	O	O
of	O	O
the	O	O
mutation	O	O
.	O	O
In	O	O
15	O	O
fetuses	O	O
,	O	O
2	O	O
out	O	O
of	O	O
7	O	O
male	O	O
fetuses	O	O
were	O	O
found	O	O
to	O	O
be	O	O
unhealthy	O	O
and	O	O
2	O	O
out	O	O
of	O	O
8	O	O
female	O	O
fetuses	O	O
were	O	O
found	O	O
to	O	O
be	O	O
carriers	O	O
.	O	O
Exons	O	O
3	O	O
-	O	O
26	O	O
and	O	O
45	O	O
-	O	O
52	O	O
have	O	O
the	O	O
maximum	O	O
frequency	O	O
in	O	O
mutation	O	O
regions	O	O
.	O	O
In	O	O
the	O	O
frequency	O	O
of	O	O
exons	O	O
individually	O	O
,	O	O
exon	O	O
47	O	O
and	O	O
exon	O	O
50	O	O
were	O	O
the	O	O
most	O	O
common	O	O
in	O	O
deleted	O	O
regions	O	O
and	O	O
exons	O	O
5	O	O
,	O	O
6	O	O
,	O	O
and	O	O
7	O	O
were	O	O
found	O	O
most	O	O
frequently	O	O
in	O	O
duplicated	O	O
regions	O	O
.	O	O
Conclusions	O	O
:	O	O
MLPA	O	O
has	O	O
better	O	O
productivity	O	O
and	O	O
sensitivity	O	O
than	O	O
multiplex	O	O
PCR	O	O
.	O	O
Prenatal	O	O
diagnosis	O	O
should	O	O
be	O	O
applied	O	O
in	O	O
DMD	O	O
high	O	O
-	O	O
risk	O	O
fetuses	O	O
to	O	O
reduce	O	O
the	O	O
disease	O	O
incidence	O	O
.	O	O
Furthermore	O	O
,	O	O
it	O	O
is	O	O
the	O	O
responsibility	O	O
of	O	O
physicians	O	O
to	O	O
inform	O	O
female	O	O
carriers	O	O
the	O	O
importance	O	O
of	O	O
prenatal	O	O
diagnosis	O	O
.	O	O
A	O	O
novel	O	O
mutation	B-Var	O
in	O	O
RDH5	B-Gene	O
gene	O	O
causes	B-Reg	O
retinitis	B-Disease	O
pigmentosa	I-Disease	O
in	O	O
consanguineous	O	O
Pakistani	O	O
family	O	O
.	O	O
Retinitis	O	O
pigmentosa	O	O
(	O	O
RP	O	O
)	O	O
is	O	O
the	O	O
most	O	O
frequent	O	O
genetically	O	O
and	O	O
clinically	O	O
heterogeneous	O	O
inherited	O	O
retinal	O	O
degeneration	O	O
.	O	O
To	O	O
date	O	O
,	O	O
more	O	O
than	O	O
80	O	O
genes	O	O
have	O	O
been	O	O
identified	O	O
that	O	O
cause	O	O
autosomal	O	O
dominant	O	O
,	O	O
autosomal	O	O
recessive	O	O
and	O	O
X	O	O
linked	O	O
RP	O	O
.	O	O
However	O	O
,	O	O
locus	O	O
and	O	O
allelic	O	O
heterogeneity	O	O
of	O	O
RP	O	O
has	O	O
not	O	O
been	O	O
fully	O	O
captured	O	O
yet	O	O
.	O	O
This	O	O
heterogeneity	O	O
and	O	O
lack	O	O
of	O	O
an	O	O
accurate	O	O
genotype	O	O
phenotype	O	O
correlation	O	O
makes	O	O
molecular	O	O
dissection	O	O
of	O	O
the	O	O
disease	O	O
more	O	O
difficult	O	O
.	O	O
The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
characterize	O	O
the	O	O
underlying	O	O
pathogenic	O	O
variants	O	O
of	O	O
RP	O	O
in	O	O
Pakistan	O	O
.	O	O
For	O	O
this	O	O
purpose	O	O
,	O	O
a	O	O
large	O	O
consanguineous	O	O
family	O	O
with	O	O
RP	O	O
phenotype	O	O
showing	O	O
autosomal	O	O
recessive	O	O
mode	O	O
of	O	O
inheritance	O	O
was	O	O
selected	O	O
after	O	O
a	O	O
complete	O	O
ophthalmological	O	O
examination	O	O
.	O	O
Next	O	O
generation	O	O
sequencing	O	O
was	O	O
used	O	O
for	O	O
the	O	O
identification	O	O
of	O	O
molecular	O	O
determinant	O	O
followed	O	O
by	O	O
Sanger	O	O
-	O	O
sequencing	O	O
for	O	O
confirmation	O	O
.	O	O
After	O	O
sequence	O	O
analysis	O	O
a	O	O
novel	O	O
homozygous	O	O
missense	O	O
mutation	O	O
,	O	O
(	B-Var	O
c.602	I-Var	O
C	I-Var	O
>	I-Var	O
T	I-Var	O
)	I-Var	O
in	O	O
exon	O	O
4	O	O
of	O	O
the	O	O
RDH5	B-Gene	O
gene	O	O
(	O	O
MIM	O	O
:	O	O
601617	O	O
)	O	O
was	O	O
identified	O	O
.	O	O
This	O	O
mutation	O	O
resulted	B-Reg	O
in	I-Reg	O
substitution	O	O
of	O	O
phenyl	O	O
alanine	O	O
for	O	O
serine	O	O
at	O	O
amino	O	O
acid	O	O
201	O	O
(	B-Var	O
p	I-Var	O
.	I-Var	O
Ser201Phe	I-Var	O
)	I-Var	O
of	O	O
the	O	O
RDH5	B-Gene	O
gene	O	O
.	O	O
The	O	O
same	O	O
mutation	O	O
was	O	O
not	O	O
detected	O	O
in	O	O
the	O	O
200	O	O
ethnically	O	O
-	O	O
matched	O	O
control	O	O
samples	O	O
by	O	O
Sanger	O	O
sequencing	O	O
.	O	O
The	O	O
identified	O	O
mutant	O	O
allele	O	O
segregated	O	O
in	O	O
homozygous	O	O
fashion	O	O
in	O	O
all	O	O
the	O	O
affected	O	O
individuals	O	O
of	O	O
pedigree	O	O
.	O	O
Identification	O	O
of	O	O
this	O	O
mutation	O	O
reveals	O	O
the	O	O
allelic	O	O
heterogeneity	O	O
of	O	O
RDH5	O	O
in	O	O
patients	O	O
with	O	O
RP	O	O
phenotype	O	O
.	O	O
The	O	O
findings	O	O
of	O	O
this	O	O
study	O	O
demonstrate	O	O
the	O	O
clinical	O	O
significance	O	O
of	O	O
next	O	O
generation	O	O
sequencing	O	O
to	O	O
understand	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
diseases	O	O
and	O	O
would	O	O
help	O	O
to	O	O
reveal	O	O
new	O	O
proteins	O	O
and	O	O
their	O	O
function	O	O
in	O	O
visual	O	O
cycle	O	O
will	O	O
pave	O	O
the	O	O
way	O	O
for	O	O
early	O	O
diagnosis	O	O
,	O	O
genetic	O	O
counseling	O	O
and	O	O
better	O	O
therapeutic	O	O
inventions	O	O
.	O	O
Targeted	O	O
Next	O	O
Generation	O	O
Sequencing	O	O
Revealed	O	O
Novel	O	O
PRPF31	B-Gene	O
Mutations	B-Var	O
in	B-Reg	O
Autosomal	B-Disease	O
Dominant	I-Disease	O
Retinitis	I-Disease	O
Pigmentosa	I-Disease	O
.	O	O
BACKGROUND	O	O
:	O	O
Retinitis	O	O
pigmentosa	O	O
(	O	O
RP	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
type	O	O
of	O	O
inherited	O	O
retinal	O	O
dystrophy	O	O
that	O	O
can	O	O
result	O	O
in	O	O
progressive	O	O
vision	O	O
loss	O	O
.	O	O
Molecular	O	O
diagnosis	O	O
of	O	O
RP	O	O
is	O	O
challenging	O	O
due	O	O
to	O	O
phenotypic	O	O
and	O	O
genotypic	O	O
heterogeneities	O	O
.	O	O
AIMS	O	O
:	O	O
This	O	O
study	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
pathogenic	O	O
mutations	O	O
in	O	O
two	O	O
Chinese	O	O
families	O	O
with	O	O
autosomal	O	O
dominant	O	O
RP	O	O
(	O	O
adRP	O	O
)	O	O
and	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
sporadic	O	O
RP	O	O
.	O	O
MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Peripheral	O	O
blood	O	O
DNA	O	O
samples	O	O
were	O	O
obtained	O	O
from	O	O
the	O	O
participants	O	O
.	O	O
Targeted	O	O
next	O	O
generation	O	O
sequencing	O	O
(	O	O
NGS	O	O
)	O	O
was	O	O
applied	O	O
to	O	O
identify	O	O
mutations	O	O
in	O	O
these	O	O
patients	O	O
.	O	O
For	O	O
pathogenic	O	O
mutation	O	O
analyses	O	O
,	O	O
stringent	O	O
NGS	O	O
data	O	O
analyses	O	O
and	O	O
segregation	O	O
analyses	O	O
were	O	O
applied	O	O
.	O	O
Primers	O	O
were	O	O
designed	O	O
to	O	O
validate	O	O
the	O	O
identified	O	O
mutations	O	O
by	O	O
Sanger	O	O
sequencing	O	O
analyses	O	O
.	O	O
RESULTS	O	O
:	O	O
A	O	O
novel	O	O
heterozygous	O	O
insertion	O	O
frameshift	O	O
mutation	O	O
c.1226_1227insA	O	O
,	O	O
p	O	O
.	O	O
T410Dfs*65	O	O
,	O	O
and	O	O
a	O	O
novel	O	O
heterozygous	O	O
stopgain	O	O
mutation	O	O
c.1015C	O	O
>	O	O
T	O	O
,	O	O
p	O	O
.	O	O
Q339	O	O
*	O	O
were	O	O
identified	O	O
in	O	O
PRPF31	O	O
.	O	O
A	O	O
known	O	O
c.527	O	O
+	O	O
3A	O	O
>	O	O
G	O	O
splicing	O	O
mutation	O	O
was	O	O
identified	O	O
in	O	O
one	O	O
of	O	O
the	O	O
adRP-074	O	O
families	O	O
.	O	O
All	O	O
mutations	O	O
were	O	O
found	O	O
to	O	O
co	O	O
-	O	O
segregate	O	O
with	O	O
the	O	O
disease	O	O
,	O	O
and	O	O
none	O	O
of	O	O
these	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
500	O	O
control	O	O
samples	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Our	O	O
data	O	O
identified	O	O
two	O	O
new	O	O
autosomal	O	O
dominant	O	O
mutations	O	O
in	O	O
PRPF31	O	O
,	O	O
expanding	O	O
the	O	O
mutational	O	O
spectrum	O	O
of	O	O
this	O	O
gene	O	O
.	O	O
Identification	O	O
of	O	O
deletion	B-Var	O
-	I-Var	O
duplication	I-Var	O
in	O	O
HEXA	B-Gene	O
gene	O	O
in	O	O
five	O	O
children	O	O
with	B-Reg	O
Tay	B-Disease	O
-	I-Disease	O
Sachs	I-Disease	O
disease	I-Disease	O
from	O	O
India	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Tay	B-Disease	O
-	I-Disease	O
Sachs	I-Disease	O
disease	I-Disease	O
(	O	O
TSD	O	O
)	O	O
is	O	O
a	O	O
sphingolipid	O	O
storage	O	O
disorder	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	O
in	O	O
the	O	O
HEXA	B-Gene	O
gene	O	O
.	O	O
To	O	O
date	O	O
,	O	O
nearly	O	O
170	O	O
mutations	O	O
of	O	O
HEXA	O	O
have	O	O
been	O	O
described	O	O
,	O	O
including	O	O
only	O	O
one	O	O
7.6	O	O
kb	O	O
large	O	O
deletion	O	O
.	O	O
METHODS	O	O
:	O	O
Multiplex	O	O
Ligation	O	O
-	O	O
dependent	O	O
Probe	O	O
Amplification	O	O
(	O	O
MLPA	O	O
)	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
in	O	O
5	O	O
unrelated	O	O
patients	O	O
for	O	O
copy	O	O
number	O	O
changes	O	O
where	O	O
heterozygous	O	O
and/or	O	O
homozygous	O	O
disease	O	O
causing	O	O
mutation	O	O
/	O	O
s	O	O
could	O	O
not	O	O
be	O	O
identified	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
by	O	O
sequencing	O	O
of	O	O
HEXA	O	O
gene	O	O
.	O	O
RESULTS	O	O
:	O	O
The	O	O
study	O	O
has	O	O
identified	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
homozygous	O	O
deletion	O	O
of	O	O
exon-2	O	O
and	O	O
exon-3	O	O
in	O	O
two	O	O
patients	O	O
,	O	O
two	O	O
patient	O	O
showed	O	O
compound	O	O
heterozygosity	O	O
with	O	O
exon	O	O
1	O	O
deletion	O	O
combined	O	O
with	O	O
missense	O	O
mutation	O	O
p	O	O
.	O	O
E462V	O	O
and	O	O
one	O	O
patient	O	O
was	O	O
identified	O	O
with	O	O
duplication	O	O
of	O	O
exon-1	O	O
with	O	O
novel	O	O
variants	O	O
c.1527	O	O
-	O	O
2A	O	O
>	O	O
T	O	O
as	O	O
a	O	O
second	O	O
allele	O	O
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
deletion	O	O
/	O	O
duplication	O	O
in	O	O
HEXA	O	O
gene	O	O
providing	O	O
a	O	O
new	O	O
insight	O	O
into	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
TSD	O	O
and	O	O
use	O	O
of	O	O
MLPA	O	O
assay	O	O
for	O	O
detecting	O	O
large	O	O
copy	O	O
number	O	O
changes	O	O
in	O	O
the	O	O
HEXA	O	O
gene	O	O
.	O	O
Two	O	O
siblings	O	O
with	O	O
11qter	O	O
deletion	O	O
syndrome	O	O
that	O	O
had	O	O
been	O	O
rescued	O	O
in	O	O
their	O	O
mother	O	O
by	O	O
uniparental	O	O
disomy	O	O
.	O	O
Jacobsen	B-Disease	O
syndrome	I-Disease	O
refers	O	O
to	O	O
a	O	O
congenital	O	O
anomaly	O	O
caused	B-Reg	O
by	I-Reg	O
deletion	B-Var	O
at	O	O
11q23.3-qter	B-Gene	O
.	O	O
We	O	O
here	O	O
describe	O	O
two	O	O
siblings	O	O
with	O	O
the	O	O
same	O	O
11q23.3-qter	O	O
deletion	O	O
.	O	O
Both	O	O
parents	O	O
were	O	O
healthy	O	O
with	O	O
a	O	O
normal	O	O
karyotype	O	O
.	O	O
Cytogenetic	O	O
microarray	O	O
analysis	O	O
revealed	O	O
no	O	O
mosaicism	O	O
in	O	O
either	O	O
parent	O	O
but	O	O
the	O	O
mother	O	O
showed	O	O
uniparental	O	O
disomy	O	O
encompassing	O	O
the	O	O
deleted	O	O
region	O	O
found	O	O
in	O	O
the	O	O
two	O	O
siblings	O	O
.	O	O
The	O	O
pattern	O	O
of	O	O
X	O	O
chromosome	O	O
inactivation	O	O
was	O	O
almost	O	O
completely	O	O
skewed	O	O
in	O	O
the	O	O
mother	O	O
.	O	O
These	O	O
data	O	O
suggested	O	O
that	O	O
the	O	O
mother	O	O
was	O	O
a	O	O
carrier	O	O
of	O	O
the	O	O
11q23.3-qter	O	O
deletion	O	O
but	O	O
that	O	O
this	O	O
had	O	O
been	O	O
rescued	O	O
by	O	O
disomy	O	O
formation	O	O
during	O	O
early	O	O
embryogenesis	O	O
except	O	O
for	O	O
her	O	O
germinal	O	O
cells	O	O
.	O	O
Genotyping	O	O
of	O	O
five	O	O
Pakistani	O	O
patients	O	O
with	O	O
severe	O	O
inherited	O	O
factor	O	O
X	O	O
deficiency	O	O
:	O	O
identification	O	O
of	O	O
two	O	O
novel	O	O
mutations	O	O
.	O	O
:	O	O
Congenital	B-Disease	O
factor	I-Disease	O
X	I-Disease	O
deficiency	I-Disease	O
is	O	O
a	O	O
rare	O	O
coagulation	O	O
defect	O	O
characterized	O	O
by	O	O
variable	O	O
bleeding	O	O
tendency	O	O
.	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
give	O	O
a	O	O
first	O	O
insight	O	O
of	B-Reg	O
F10	B-Gene	O
gene	O	O
mutations	B-Var	O
in	O	O
Pakistani	O	O
probands	O	O
.	O	O
Direct	O	O
sequencing	O	O
and/or	O	O
next	O	O
-	O	O
generation	O	O
sequencing	O	O
was	O	O
performed	O	O
on	O	O
the	O	O
coding	O	O
regions	O	O
,	O	O
boundaries	O	O
and	O	O
5	O	O
'	O	O
and	O	O
3	O	O
'	O	O
untranslated	O	O
regions	O	O
of	O	O
the	O	O
F10	O	O
gene	O	O
in	O	O
five	O	O
severe	O	O
factor	O	O
X	O	O
-	O	O
deficient	O	O
patients	O	O
from	O	O
Pakistan	O	O
.	O	O
All	O	O
patients	O	O
were	O	O
born	O	O
from	O	O
consanguineous	O	O
marriages	O	O
and	O	O
displayed	O	O
FX	O	O
:	O	O
C	O	O
levels	O	O
below	O	O
2	O	O
%	O	O
.	O	O
Sequencing	O	O
revealed	O	O
five	O	O
different	O	O
substitutions	O	O
,	O	O
including	O	O
three	O	O
previously	O	O
reported	O	O
p	O	O
.	O	O
Ala15Asp	O	O
,	O	O
p	O	O
.	O	O
Gly406Ser	O	O
,	O	O
and	O	O
p	O	O
.	O	O
Gly420Arg	O	O
missense	O	O
variants	O	O
,	O	O
and	O	O
also	O	O
two	O	O
novel	O	O
variants	O	O
:	O	O
p	O	O
.	O	O
Cys57Arg	O	O
and	O	O
p	O	B-Var
.	O	I-Var
Gln175	O	O
*	O	O
.	O	O
Though	O	O
one	O	O
genotype	O	O
could	O	O
not	O	O
be	O	O
characterized	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
confirm	O	O
the	O	O
inherited	O	O
nature	O	O
of	O	O
the	O	O
defect	O	O
using	O	O
familial	O	O
studies	O	O
.	O	O
As	O	O
the	O	O
copy	O	O
number	O	O
variations	O	O
were	O	O
ruled	O	O
out	O	O
,	O	O
we	O	O
hypothesized	O	O
the	O	O
presence	O	O
of	O	O
deep	O	O
intronic	O	O
mutants	O	O
that	O	O
might	O	O
have	O	O
escaped	O	O
detection	O	O
from	O	O
sequencing	O	O
or	O	O
abnormalities	O	O
in	O	O
epigenetic	O	O
regulation	O	O
.	O	O
Three	O	O
patients	O	O
presented	O	O
with	O	O
severe	O	O
clinical	O	O
symptoms	O	O
,	O	O
in	O	O
the	O	O
early	O	O
days	O	O
of	O	O
life	O	O
,	O	O
whereas	O	O
two	O	O
presented	O	O
only	O	O
with	O	O
trauma	O	O
-	O	O
provoked	O	O
bleeds	O	O
and	O	O
bruises	O	O
later	O	O
in	O	O
life	O	O
.	O	O
Those	O	O
patients	O	O
with	O	O
milder	O	O
forms	O	O
bore	O	O
the	O	O
p	O	O
.	O	O
Gly406Ser	O	O
at	O	O
the	O	O
homozygous	O	O
state	O	O
and	O	O
F10	O	O
unknown	O	O
alleles	O	O
,	O	O
respectively	O	O
.	O	O
F10	O	O
mutation	O	O
spectrum	O	O
in	O	O
Pakistan	O	O
is	O	O
heterogeneous	O	O
as	O	O
seen	O	O
in	O	O
other	O	O
populations	O	O
.	O	O
Identification	O	O
of	O	O
the	O	O
F10	O	O
mutations	O	O
is	O	O
important	O	O
for	O	O
genetic	O	O
counseling	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
in	O	O
subsequent	O	O
pregnancies	O	O
.	O	O
Spectrum	O	O
of	O	O
MECP2	B-Gene	O
mutations	B-Var	O
in	O	O
Vietnamese	O	O
patients	O	O
with	B-Reg	O
RETT	B-Disease	O
syndrome	I-Disease	O
.	O	O
BACKGROUND	O	O
:	O	O
Rett	O	O
syndrome	O	O
(	O	O
RTT	O	O
)	O	O
is	O	O
a	O	O
severe	O	O
neurodevelopmental	O	O
disorder	O	O
in	O	O
children	O	O
characterized	O	O
by	O	O
a	O	O
normal	O	O
neurodevelopmental	O	O
process	O	O
in	O	O
the	O	O
first	O	O
6	O	O
-	O	O
18	O	O
months	O	O
followed	O	O
by	O	O
a	O	O
period	O	O
of	O	O
motor	O	O
and	O	O
vocal	O	O
deterioration	O	O
with	O	O
stereotypic	O	O
hand	O	O
movements	O	O
.	O	O
Incidence	O	O
of	O	O
RTT	B-Disease	O
is	O	O
mostly	O	O
due	B-Reg	O
to	I-Reg	O
de	O	O
novo	O	O
mutation	B-Var	O
in	O	O
the	O	O
MECP2	B-Gene	O
gene	O	O
(	O	O
methyl	O	O
-	O	O
CpG	O	O
-	O	O
binding	O	O
protein	O	O
2	O	O
)	O	O
.	O	O
METHODS	O	O
:	O	O
The	O	O
study	O	O
assessed	O	O
27	O	O
female	O	O
patients	O	O
presented	O	O
with	O	O
classical	O	O
RTT	O	O
phenotype	O	O
age	O	O
range	O	O
from	O	O
18	O	O
months	O	O
to	O	O
48	O	O
months	O	O
.	O	O
Specialist	O	O
carried	O	O
out	O	O
the	O	O
clinical	O	O
evaluation	O	O
and	O	O
diagnosis	O	O
according	O	O
to	O	O
RTT	O	O
diagnosis	O	O
criteria	O	O
.	O	O
Blood	O	O
samples	O	O
from	O	O
patients	O	O
were	O	O
then	O	O
collected	O	O
for	O	O
genomic	O	O
DNA	O	O
extraction	O	O
.	O	O
We	O	O
next	O	O
performed	O	O
MECP2	O	O
gene	O	O
amplification	O	O
and	O	O
sequencing	O	O
of	O	O
the	O	O
whole	O	O
coding	O	O
region	O	O
to	O	O
screen	O	O
for	O	O
mutations	O	O
.	O	O
RESULT	O	O
:	O	O
MECP2	O	O
mutation	O	O
was	O	O
found	O	O
in	O	O
20	O	O
patients	O	O
(	O	O
74	O	O
%	O	O
)	O	O
including	O	O
:	O	O
2	O	O
missense	O	O
,	O	O
4	O	O
nonsense	O	O
,	O	O
6	O	O
frameshift	O	O
and	O	O
2	O	O
deletion	O	O
mutation	O	O
.	O	O
The	O	O
study	O	O
identified	O	O
14	O	O
pathogenic	O	O
mutations	O	O
which	O	O
we	O	O
found	O	O
4	O	O
mutation	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
and	O	O
extensive	O	O
search	O	O
,	O	O
not	O	O
priory	O	O
reported	O	O
in	O	O
any	O	O
mutation	O	O
database	O	O
or	O	O
publication	O	O
:	O	O
c.1384	O	O
-	O	O
1385DelGT	O	O
,	O	O
c.1205insT	O	O
,	O	O
c.717delC	O	O
and	O	O
c.1132_1207del77	O	O
.	O	O
High	O	O
percentage	O	O
of	O	O
C	O	O
>	O	O
T	O	O
(	O	O
70	O	O
%	O	O
)	O	O
in	O	O
CpG	O	O
sites	O	O
mutation	O	O
was	O	O
found	O	O
.	O	O
CONCLUSION	O	O
:	O	O
Our	O	O
result	O	O
reveals	O	O
a	O	O
high	O	O
percentage	O	O
of	O	O
C	O	O
>	O	O
T	O	O
mutation	O	O
in	O	O
CpG	O	O
hot	O	O
spot	O	O
,	O	O
which	O	O
is	O	O
more	O	O
prone	O	O
to	O	O
modification	O	O
and	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
detected	O	O
in	O	O
RTT	O	O
as	O	O
a	O	O
disorder	O	O
is	O	O
strictly	O	O
due	O	O
to	O	O
de	O	O
novo	O	O
mutations	O	O
.	O	O
The	O	O
study	O	O
is	O	O
the	O	O
first	O	O
to	O	O
identify	O	O
the	O	O
mutation	O	O
spectrum	O	O
of	O	O
MECP2	O	O
gene	O	O
in	O	O
Vietnamese	O	O
patients	O	O
and	O	O
also	O	O
an	O	O
important	O	O
step	O	O
toward	O	O
better	O	O
diagnosis	O	O
and	O	O
care	O	O
for	O	O
RTT	O	O
patients	O	O
in	O	O
Vietnam	O	O
.	O	O
Clinical	O	O
presentation	O	O
and	O	O
natural	O	O
history	O	O
of	O	O
infantile	O	O
-	O	O
onset	O	O
ascending	O	O
spastic	O	O
paralysis	O	O
from	O	O
three	O	O
families	O	O
with	O	O
an	O	O
ALS2	O	O
founder	O	O
variant	O	O
.	O	O
Biallelic	B-Var	O
mutations	I-Var	O
of	O	O
the	O	O
alsin	O	O
Rho	O	O
guanine	O	O
nucleotide	O	O
exchange	O	O
factor	O	O
(	B-Gene	O
ALS2	I-Gene	O
)	I-Gene	O
gene	O	O
cause	B-Reg	O
a	O	O
group	O	O
of	O	O
overlapping	O	O
autosomal	O	O
recessive	O	O
neurodegenerative	O	O
disorders	O	O
including	O	O
infantile	B-Disease	O
-	I-Disease	O
onset	I-Disease	O
ascending	I-Disease	O
hereditary	I-Disease	O
spastic	I-Disease	O
paralysis	I-Disease	O
(	O	O
IAHSP	O	O
)	O	O
,	O	O
juvenile	B-Disease	O
primary	I-Disease	B-Disease
lateral	I-Disease	I-Disease
sclerosis	I-Disease	I-Disease
(	O	O
JPLS	O	O
)	O	O
,	O	O
and	O	O
juvenile	B-Disease	O
amyotrophic	I-Disease	B-Disease
lateral	I-Disease	B-Disease
sclerosis	I-Disease	I-Disease
(	O	O
JALS	O	O
/	O	O
ALS2	O	O
)	O	O
,	O	O
caused	B-Reg	O
by	I-Reg	O
retrograde	B-CPA	O
degeneration	I-CPA	B-MPA
of	I-CPA	O
the	I-CPA	O
upper	I-CPA	O
motor	I-CPA	O
neurons	I-CPA	O
of	I-CPA	O
the	I-CPA	O
pyramidal	I-CPA	O
tracts	I-CPA	O
.	O	O
Here	O	O
,	O	O
we	O	O
describe	O	O
11	O	O
individuals	O	O
with	O	O
IAHSP	O	O
,	O	O
aged	O	O
2	O	O
-	O	O
48	O	O
years	O	O
,	O	O
with	O	O
IAHSP	B-Disease	O
from	O	O
three	O	O
unrelated	O	O
consanguineous	O	O
Iranian	O	O
families	O	O
carrying	B-Reg	O
the	O	O
homozygous	O	O
c.1640	B-Var	O
+	I-Var	O
1G	I-Var	O
>	I-Var	O
A	I-Var	O
founder	O	O
mutation	O	O
in	O	O
ALS2	B-Gene	O
.	O	O
Three	O	O
affected	O	O
siblings	O	O
from	O	O
one	O	O
family	O	O
exhibit	O	O
generalized	O	O
dystonia	O	O
which	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
described	O	O
in	O	O
families	O	O
with	O	O
IAHSP	O	O
and	O	O
has	O	O
only	O	O
been	O	O
reported	O	O
in	O	O
three	O	O
unrelated	O	O
consanguineous	O	O
families	O	O
with	O	O
JALS	O	O
/	O	O
ALS2	O	O
.	O	O
We	O	O
report	O	O
the	O	O
oldest	O	O
individuals	O	O
with	O	O
IAHSP	O	O
to	O	O
date	O	O
and	O	O
provide	O	O
evidence	O	O
that	O	O
these	O	O
patients	O	O
survive	O	O
well	O	O
into	O	O
their	O	O
late	O	O
40s	O	O
with	O	O
preserved	O	O
cognition	O	O
and	O	O
normal	O	O
eye	O	O
movements	O	O
.	O	O
Our	O	O
study	O	O
delineates	O	O
the	O	O
phenotypic	O	O
spectrum	O	O
of	O	O
IAHSP	O	O
and	O	O
ALS2-related	O	O
disorders	O	O
and	O	O
provides	O	O
valuable	O	O
insights	O	O
into	O	O
the	O	O
natural	O	O
disease	O	O
course	O	O
.	O	O
A	O	O
novel	O	O
MFSD8	B-Gene	O
mutation	B-Var	O
in	O	O
a	O	O
Russian	O	O
patient	O	O
with	B-Reg	O
neuronal	B-Disease	O
ceroid	I-Disease	O
lipofuscinosis	I-Disease	O
type	O	O
7	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O
BACKGROUND	O	O
:	O	O
Neuronal	O	O
ceroid	O	O
lipofuscinoses	O	O
(	O	O
NCLs	O	O
)	O	O
are	O	O
the	O	O
most	O	O
common	O	O
autosomal	O	O
recessive	O	O
neurodegenerative	O	O
disorders	O	O
in	O	O
children	O	O
.	O	O
Clinical	O	O
manifestations	O	O
include	O	O
progressive	O	O
cognitive	O	O
decline	O	O
,	O	O
motor	O	O
impairment	O	O
,	O	O
ataxia	O	O
,	O	O
visual	O	O
loss	O	O
,	O	O
seizures	O	O
and	O	O
early	O	O
death	O	O
.	O	O
To	O	O
date	O	O
more	O	O
than	O	O
440	O	O
NCL	O	O
-	O	O
causing	O	O
mutations	O	O
in	O	O
13	O	O
genes	O	O
are	O	O
known	O	O
.	O	O
CASE	O	O
PRESENTATION	O	O
:	O	O
We	O	O
report	O	O
clinical	O	O
and	O	O
genetic	O	O
characteristics	O	O
of	O	O
a	O	O
5-year	O	O
-	O	O
old	O	O
girl	O	O
affected	O	O
by	O	O
ceroid	O	O
lipofuscinosis	O	O
type	O	O
7	O	O
(	O	O
NCL7	O	O
)	O	O
.	O	O
She	O	O
had	O	O
progressive	O	O
motor	O	O
and	O	O
mental	O	O
deterioration	O	O
since	O	O
the	O	O
age	O	O
of	O	O
2,5	O	O
years	O	O
.	O	O
Later	O	O
she	O	O
developed	O	O
progressive	O	O
vision	O	O
loss	O	O
,	O	O
stereotypies	O	O
,	O	O
action	O	O
myoclonus	O	O
and	O	O
epilepsy	O	O
.	O	O
By	O	O
the	O	O
age	O	O
of	O	O
5	O	O
years	O	O
she	O	O
stopped	O	O
walking	O	O
.	O	O
Based	O	O
on	O	O
symptoms	O	O
,	O	O
diagnosis	O	O
of	O	O
Rett	O	O
syndrome	O	O
was	O	O
suggested	O	O
,	O	O
but	O	O
no	O	O
abnormalities	O	O
were	O	O
detected	O	O
in	O	O
MeCP2	O	O
.	O	O
We	O	O
identified	O	O
a	O	O
novel	O	O
homozygous	O	O
mutation	O	O
in	O	O
MFSD8	O	O
gene	O	O
(	O	O
c.525	O	O
T	O	O
>	O	O
A	O	O
,	O	O
p	O	O
.	O	O
Cys175Ter	O	O
)	O	O
.	O	O
To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
MFSD8	O	O
gene	O	O
mutation	O	O
in	O	O
a	O	O
Russian	O	O
patient	O	O
with	O	O
variant	O	O
late	O	O
-	O	O
infantile	O	O
NCL	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Our	O	O
results	O	O
enlarge	O	O
mutational	O	O
spectrum	O	O
of	O	O
ceroid	O	O
lipofuscinosis	O	O
type	O	O
7	O	O
and	O	O
demonstrate	O	O
tremendous	O	O
diagnosis	O	O
value	O	O
of	O	O
exome	O	O
sequencing	O	O
for	O	O
pediatric	O	O
NCLs	O	O
.	O	O
Also	O	O
we	O	O
confirmed	O	O
that	O	O
NCL	O	O
should	O	O
be	O	O
suspected	O	O
in	O	O
patients	O	O
with	O	O
Rett	O	O
-	O	O
like	O	O
phenotype	O	O
at	O	O
onset	O	O
and	O	O
negative	O	O
MECP2	O	O
mutation	O	O
.	O	O
Molecular	O	O
genetics	O	O
of	O	O
the	O	O
POMT1-related	O	O
muscular	O	O
dystrophy	O	O
-	O	O
dystroglycanopathies	O	O
.	O	O
Protein	O	O
O	O	O
-	O	O
mannosyltransferase	O	O
1	O	O
(	O	O
POMT1	O	O
)	O	O
is	O	O
a	O	O
critical	O	O
enzyme	O	O
participating	O	O
in	O	O
the	O	O
first	O	O
step	O	O
of	O	O
protein	O	O
O	O	O
-	O	O
mannosylation	O	O
.	O	O
Mutations	B-Var	O
in	O	O
the	O	O
coding	O	O
gene	O	O
,	O	O
POMT1	B-Gene	O
,	O	O
have	O	O
been	O	O
described	O	O
to	O	O
be	O	O
related	O	O
to	O	O
a	O	O
series	O	O
of	O	O
autosomal	O	O
recessive	O	O
disorders	O	O
associated	O	O
with	O	O
defective	B-NegReg	O
alpha	B-MPA	O
-	I-MPA	O
dystroglycan	I-MPA	O
glycosylation	I-MPA	O
,	O	O
later	O	O
termed	O	O
muscular	B-Disease	O
dystrophy	I-Disease	O
-	I-Disease	O
dystroglycanopathies	I-Disease	O
(	O	O
MDDGs	O	O
)	O	O
.	O	O
MDDGs	O	O
are	O	O
characterized	O	O
by	O	O
a	O	O
broad	O	O
phenotypic	O	O
spectrum	O	O
of	O	O
congenital	O	O
muscular	O	O
dystrophy	O	O
or	O	O
later	O	O
-	O	O
onset	O	O
limb	O	O
-	O	O
girdle	O	O
muscular	O	O
dystrophy	O	O
,	O	O
accompanied	O	O
by	O	O
variable	O	O
degrees	O	O
of	O	O
intellectual	O	O
disability	O	O
,	O	O
brain	O	O
defects	O	O
,	O	O
and	O	O
ocular	O	O
abnormalities	O	O
.	O	O
To	O	O
date	O	O
,	O	O
at	O	O
least	O	O
76	O	O
disease	O	O
-	O	O
associated	O	O
mutations	O	O
in	O	O
the	O	O
POMT1	O	O
gene	O	O
,	O	O
including	O	O
missense	O	O
,	O	O
nonsense	O	O
,	O	O
splicing	O	O
,	O	O
deletion	O	O
,	O	O
insertion	O	O
/	O	O
duplication	O	O
,	O	O
and	O	O
insertion	O	O
-	O	O
deletion	O	O
mutations	O	O
,	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
.	O	O
In	O	O
this	O	O
review	O	O
,	O	O
we	O	O
highlight	O	O
the	O	O
present	O	O
knowledge	O	O
of	O	O
the	O	O
identified	O	O
disease	O	O
-	O	O
associated	O	O
POMT1	O	O
gene	O	O
mutations	O	O
and	O	O
genetic	O	O
animal	O	O
models	O	O
related	O	O
to	O	O
the	O	O
POMT1	O	O
gene	O	O
.	O	O
This	O	O
review	O	O
may	O	O
help	O	O
further	O	O
normative	O	O
classification	O	O
of	O	O
phenotypes	O	O
,	O	O
assist	O	O
in	O	O
definite	O	O
clinical	O	O
and	O	O
genetic	O	O
diagnoses	O	O
,	O	O
and	O	O
genetic	O	O
counseling	O	O
,	O	O
and	O	O
may	O	O
comprehensively	O	O
improve	O	O
our	O	O
understanding	O	O
of	O	O
the	O	O
basis	O	O
of	O	O
complex	O	O
phenotypes	O	O
and	O	O
possible	O	O
pathogenic	O	O
mechanisms	O	O
involved	O	O
.	O	O
Segmental	O	O
uniparental	O	O
disomy	O	O
as	O	O
a	O	O
rare	O	O
cause	O	O
of	O	O
congenital	O	O
severe	O	O
factor	O	O
XIII	O	O
deficiency	O	O
in	O	O
a	O	O
girl	O	O
with	O	O
only	O	O
one	O	O
heterozygous	O	O
carrier	O	O
parent	O	O
.	O	O
Uniparental	B-Disease	O
disomy	I-Disease	O
(	O	O
UPD	O	O
)	O	O
refers	O	O
to	O	O
a	O	O
situation	O	O
when	O	O
a	O	O
person	O	O
inherits	O	O
both	O	O
homologs	O	O
of	O	O
a	O	O
region	O	O
or	O	O
complete	O	O
part	O	O
of	O	O
a	O	O
chromosome	O	O
from	O	O
only	O	O
one	O	O
parent	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
present	O	O
an	O	O
unusual	O	O
case	O	O
of	O	O
UPD	O	O
in	O	O
congenital	O	O
severe	O	O
factor	O	O
(	O	O
F	O	O
)	O	O
XIII	O	O
deficiency	O	O
.	O	O
A	O	O
6-year	O	O
-	O	O
old	O	O
girl	O	O
experienced	O	O
cephalhematoma	O	O
and	O	O
umbilical	O	O
bleeding	O	O
after	O	O
birth	O	O
and	O	O
easy	O	O
bruising	O	O
,	O	O
and	O	O
postextraction	O	O
bleeding	O	O
since	O	O
early	O	O
infancy	O	O
.	O	O
FXIII	O	O
activity	O	O
was	O	O
0	O	O
%	O	O
[	O	O
mother	O	O
53.7	O	O
%	O	O
and	O	O
father	O	O
132.5	O	O
%	O	O
(	O	O
normal	O	O
70	O	O
-	O	O
140	O	O
%	O	O
)	O	O
]	O	O
and	O	O
the	O	O
FXIII	O	O
antigen	O	O
level	O	O
was	O	O
2.5	O	O
%	O	O
[	O	O
mother	O	O
38.9	O	O
%	O	O
and	O	O
father	O	O
151	O	O
%	O	O
(	O	O
normal	O	O
75	O	O
-	O	O
155	O	O
%	O	O
)	O	O
]	O	O
.	O	O
The	O	O
washed	O	O
platelet	O	O
FXIII	O	O
activity	O	O
was	O	O
0.1	O	O
%	O	O
in	O	O
the	O	O
patient	O	O
(	O	O
normal	O	O
64	O	O
-	O	O
144	O	O
%	O	O
)	O	O
,	O	O
suggesting	O	O
a	O	O
deficiency	O	O
of	O	O
FXIII	O	O
-	O	O
A	O	O
subunit	O	O
.	O	O
The	O	O
FXIII	O	O
-	O	O
A	O	O
subunit	O	O
genetic	O	O
analysis	O	O
detected	O	O
a	O	O
homozygous	O	O
p	O	O
.	O	O
Arg382Ser	O	O
mutation	O	O
.	O	O
A	O	O
similar	O	O
heterozygous	O	O
mutation	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
mother	O	O
but	O	O
surprisingly	O	O
,	O	O
not	O	O
in	O	O
the	O	O
father	O	O
.	O	O
Kinship	O	O
was	O	O
confirmed	O	O
by	O	O
a	O	O
paternity	O	O
test	O	O
.	O	O
To	O	O
confirm	O	O
the	O	O
possibility	O	O
of	O	O
UPD	O	O
,	O	O
a	O	O
test	O	O
using	O	O
four	O	O
markers	O	O
in	O	O
the	O	O
vicinity	O	O
of	O	O
the	O	O
F13A1	B-Gene	O
gene	O	O
revealed	O	O
that	O	O
she	O	O
inherited	O	O
duplicate	B-Var	O
mutations	I-Var	O
from	O	O
a	O	O
heterozygous	O	O
mutation	O	O
in	O	O
her	O	O
mother	O	O
,	O	O
presenting	O	O
a	O	O
unique	O	O
case	B-Reg	O
of	I-Reg	O
unusual	O	O
maternal	O	O
segmental	O	O
UPD	B-Disease	O
in	O	O
otherwise	O	O
unexplained	O	O
congenital	O	O
(	O	O
homozygous	O	O
)	O	O
severe	O	O
FXIII	B-Disease	O
deficiency	I-Disease	O
.	O	O
UPD	O	O
as	O	O
a	O	O
rare	O	O
cause	O	O
of	O	O
autosomal	O	O
recessive	O	O
bleeding	O	O
disorder	O	O
when	O	O
only	O	O
one	O	O
parent	O	O
is	O	O
affected	O	O
is	O	O
critical	O	O
for	O	O
genetic	O	O
counseling	O	O
.	O	O
